Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31100382,Zeta potential,"Results demonstrated that chitosomes possessed excellent nanosize of 137 nm, monodispersity (PDI < 0.2) and high Zeta potential of +36.8 mV.","Improved oral bioavailability of the anticancer drug catechin using chitosomes: Design, in-vitro appraisal and in-vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100382/),m,36.8,283,DB00898,Ethanol
,25531869,flow rate,"The U-HPLC separation was carried on a ZORBAX RRHD Eclipse Plus C18 column (2.1 mm × 50 mm, 1.8 μm) with gradient elution using a mobile phase composed of methanol and water (containing 0.3% formic acid) at a flow rate of 0.3 mL min(-1).",Simultaneous determination of ten active constituents of Yankening Capsule in rat plasma by ultra high performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25531869/),[ml] / [min],0.3,808,DB00898,Ethanol
,6115653,bioavailability,"Therefore, bioavailability is calculated as 75%.",[Pharmacokinetics of 3H-bamethan in humans]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115653/),%,75,936,DB00898,Ethanol
,6115653,biological half-life,The biological half-life is 2.5 h.,[Pharmacokinetics of 3H-bamethan in humans]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6115653/),h,2.5,937,DB00898,Ethanol
,22219221,half-life,Plasma concentration of GSK598809 was maximal 2-3 hours postdose and decreased with a half-life of roughly 20 hours.,Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22219221/),h,20,1119,DB00898,Ethanol
,11388702,encapsulation yield,An encapsulation yield ranging from 11-12% was obtained for ADH+ALDH-loaded erythrocytes.,"Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),%,11-12,1283,DB00898,Ethanol
,11388702,Carrier cell recovery,Carrier cell recovery was 52%.,"Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),%,52,1284,DB00898,Ethanol
,11388702,t1/2beta,"The values corresponding to in vivo survival rate during the elimination phase indicated that the survival rate of 51Cr-electroporated loaded-RBCs was slightly lower (t1/2beta, 4.5 days) than 51Cr-native RBCs (t1/2beta, 5.3 days).","Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),d,4.5,1285,DB00898,Ethanol
,11388702,t1/2beta,"The values corresponding to in vivo survival rate during the elimination phase indicated that the survival rate of 51Cr-electroporated loaded-RBCs was slightly lower (t1/2beta, 4.5 days) than 51Cr-native RBCs (t1/2beta, 5.3 days).","Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),d,5.3,1286,DB00898,Ethanol
,11388702,clearance,"The mean clearance values from blood of electroporated 51Cr-RBCs (unloaded and loaded) were higher (0.51 %51Cr/day and 0.54 %51Cr/day, respectively) than the obtained for native 51Cr-RBCs (0.18 %51Cr/day).","Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),%,0.51,1287,DB00898,Ethanol
,11388702,clearance,"The mean clearance values from blood of electroporated 51Cr-RBCs (unloaded and loaded) were higher (0.51 %51Cr/day and 0.54 %51Cr/day, respectively) than the obtained for native 51Cr-RBCs (0.18 %51Cr/day).","Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),%,0.54,1288,DB00898,Ethanol
,11388702,clearance,"The mean clearance values from blood of electroporated 51Cr-RBCs (unloaded and loaded) were higher (0.51 %51Cr/day and 0.54 %51Cr/day, respectively) than the obtained for native 51Cr-RBCs (0.18 %51Cr/day).","Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),%,0.18,1289,DB00898,Ethanol
,11388702,clearance,En consequence the clearance values of ethanol from blood in intoxicated mice treated with ADH+ALDH-RBCs (0.39 ml/min) were higher than the treated with native RBCs (0.20 ml/min).,"Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),[ml] / [min],0.39,1290,DB00898,Ethanol
,11388702,clearance,En consequence the clearance values of ethanol from blood in intoxicated mice treated with ADH+ALDH-RBCs (0.39 ml/min) were higher than the treated with native RBCs (0.20 ml/min).,"Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11388702/),[ml] / [min],0.20,1291,DB00898,Ethanol
,15716383,initial half-life,"In normal rats administered 5 mg/kg STAZN i.v. in Solutol HS 15/ethanol/saline vehicle, STAZN blood levels exhibited a biexponential decline, with an initial half-life of 28 min and a subsequent slow decay with half-life of approximately 7 h.","Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15716383/),min,28,1506,DB00898,Ethanol
,15716383,half-life,"In normal rats administered 5 mg/kg STAZN i.v. in Solutol HS 15/ethanol/saline vehicle, STAZN blood levels exhibited a biexponential decline, with an initial half-life of 28 min and a subsequent slow decay with half-life of approximately 7 h.","Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: neurobehavior, histopathology, and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15716383/),h,7,1507,DB00898,Ethanol
,32439308,T1/2,"Determination of the in vitro release kinetics showed a prolonged release when melatonin is solubilized in nanoparticles (T1/2: 81 min vs 50 min vs 26 min for melatonin-LP, melatonin-NE, and melatonin-EtOH respectively).",In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32439308/),min,81,2088,DB00898,Ethanol
,32439308,T1/2,"Determination of the in vitro release kinetics showed a prolonged release when melatonin is solubilized in nanoparticles (T1/2: 81 min vs 50 min vs 26 min for melatonin-LP, melatonin-NE, and melatonin-EtOH respectively).",In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32439308/),min,50,2089,DB00898,Ethanol
,32439308,T1/2,"Determination of the in vitro release kinetics showed a prolonged release when melatonin is solubilized in nanoparticles (T1/2: 81 min vs 50 min vs 26 min for melatonin-LP, melatonin-NE, and melatonin-EtOH respectively).",In vitro and in vivo evaluation of organic solvent-free injectable melatonin nanoformulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32439308/),min,26,2090,DB00898,Ethanol
,16696191,"constant of transport rate of speed, K10","The constant of transport rate of speed, K10 (0.55 h(-1)), was much smaller in the microemulsion group compared with the Taxol group (1.55 h(-l)).","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),1/[h],0.55,2213,DB00898,Ethanol
,16696191,"constant of transport rate of speed, K10","The constant of transport rate of speed, K10 (0.55 h(-1)), was much smaller in the microemulsion group compared with the Taxol group (1.55 h(-l)).","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),h(-l),1.55,2214,DB00898,Ethanol
,16696191,mean retention time,"The mean retention time was 3.89 h in microemulsion group and 2.52 h in the Taxol group, showing the elimination rate was much slower in the former than in the latter.","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),h,3.89,2215,DB00898,Ethanol
,16696191,mean retention time,"The mean retention time was 3.89 h in microemulsion group and 2.52 h in the Taxol group, showing the elimination rate was much slower in the former than in the latter.","An alternative paclitaxel self-emulsifying microemulsion formulation: preparation, pharmacokinetic profile, and hypersensitivity evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16696191/),h,2.52,2216,DB00898,Ethanol
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00898,Ethanol
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00898,Ethanol
,19913378,k(form),"The mean values (and standard deviations) obtained for k(form) and k(el) were 0.00052 h(-1) (0.00014) and 0.561 h(-1) (0.131), respectively.",Computer assisted modeling of ethyl sulfate pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19913378/),1/[h],0.00052,2605,DB00898,Ethanol
,19913378,k(el),"The mean values (and standard deviations) obtained for k(form) and k(el) were 0.00052 h(-1) (0.00014) and 0.561 h(-1) (0.131), respectively.",Computer assisted modeling of ethyl sulfate pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19913378/),1/[h],0.561,2606,DB00898,Ethanol
,17884739,flow rate,"The mobile phase consisting of a mixture of acetonitrile and 0.05 mM formic acid (50:50 v/v, pH 3.5) was delivered at a flow rate of 0.25 ml/min.",Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884739/),[ml] / [min],0.25,3007,DB00898,Ethanol
,28358225,solubility,"The formed optimal formulation of AP-M were provided with small size (178.5 nm) and spherical shape at ratio of 4:1 (Soluplus®:Pluronic F127), as well as increasing solubility of to 5.61 mg/mL in water which was about 3442-fold compared to that of free AP.",Improved solubility and oral bioavailability of apigenin via Soluplus/Pluronic F127 binary mixed micelles system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28358225/),[mg] / [ml],5.61,5764,DB00898,Ethanol
,28358225,entrapment efficiency,"The entrapment efficiency and drug loading of AP-M were 95.72 and 5.32%, respectively, and a sustained release of AP-M was obtained as in vitro release study indicated.",Improved solubility and oral bioavailability of apigenin via Soluplus/Pluronic F127 binary mixed micelles system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28358225/),%,95.72,5765,DB00898,Ethanol
,28358225,drug loading,"The entrapment efficiency and drug loading of AP-M were 95.72 and 5.32%, respectively, and a sustained release of AP-M was obtained as in vitro release study indicated.",Improved solubility and oral bioavailability of apigenin via Soluplus/Pluronic F127 binary mixed micelles system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28358225/),%,5.32,5766,DB00898,Ethanol
,10681341,population absorption half-life,The population absorption half-life of lumefantrine was 4.5 h.,Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),h,4.5,5829,DB00898,Ethanol
,10681341,peak plasma lumefantrine concentrations,"The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) microgram/ml after regimen A, 9. 0 (1.1 and 19.8) microgram/ml after regimen B, and 8 (1.4 and 17.4) microgram/ml after regimen C.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],6.2,5830,DB00898,Ethanol
,10681341,peak plasma lumefantrine concentrations,"The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) microgram/ml after regimen A, 9. 0 (1.1 and 19.8) microgram/ml after regimen B, and 8 (1.4 and 17.4) microgram/ml after regimen C.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],14.8,5831,DB00898,Ethanol
,10681341,peak plasma lumefantrine concentrations,"The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) microgram/ml after regimen A, 9. 0 (1.1 and 19.8) microgram/ml after regimen B, and 8 (1.4 and 17.4) microgram/ml after regimen C.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],9. 0,5832,DB00898,Ethanol
,10681341,peak plasma lumefantrine concentrations,"The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) microgram/ml after regimen A, 9. 0 (1.1 and 19.8) microgram/ml after regimen B, and 8 (1.4 and 17.4) microgram/ml after regimen C.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],19.8,5833,DB00898,Ethanol
,10681341,peak plasma lumefantrine concentrations,"The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) microgram/ml after regimen A, 9. 0 (1.1 and 19.8) microgram/ml after regimen B, and 8 (1.4 and 17.4) microgram/ml after regimen C.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],8,5834,DB00898,Ethanol
,10681341,peak plasma lumefantrine concentrations,"The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) microgram/ml after regimen A, 9. 0 (1.1 and 19.8) microgram/ml after regimen B, and 8 (1.4 and 17.4) microgram/ml after regimen C.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],17.4,5835,DB00898,Ethanol
,10681341,MIC,"The higher-dose regimens (B and C) gave 60 and 100% higher areas under the concentration-time curves (AUC), respectively, and thus longer durations for which plasma lumefantrine concentrations exceeded the putative in vivo MIC of 280 microgram/ml (median for regimen B, 252 h; that for regimen C, 298 h; that for regimen A, 204 h [P, 0.0001]) and higher cure rates.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),[μg] / [ml],280,5836,DB00898,Ethanol
,10681341,MIC,"The higher-dose regimens (B and C) gave 60 and 100% higher areas under the concentration-time curves (AUC), respectively, and thus longer durations for which plasma lumefantrine concentrations exceeded the putative in vivo MIC of 280 microgram/ml (median for regimen B, 252 h; that for regimen C, 298 h; that for regimen A, 204 h [P, 0.0001]) and higher cure rates.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),h,252,5837,DB00898,Ethanol
,10681341,MIC,"The higher-dose regimens (B and C) gave 60 and 100% higher areas under the concentration-time curves (AUC), respectively, and thus longer durations for which plasma lumefantrine concentrations exceeded the putative in vivo MIC of 280 microgram/ml (median for regimen B, 252 h; that for regimen C, 298 h; that for regimen A, 204 h [P, 0.0001]) and higher cure rates.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),h,298,5838,DB00898,Ethanol
,10681341,MIC,"The higher-dose regimens (B and C) gave 60 and 100% higher areas under the concentration-time curves (AUC), respectively, and thus longer durations for which plasma lumefantrine concentrations exceeded the putative in vivo MIC of 280 microgram/ml (median for regimen B, 252 h; that for regimen C, 298 h; that for regimen A, 204 h [P, 0.0001]) and higher cure rates.",Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681341/),h,204,5839,DB00898,Ethanol
,12485948,clearance,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [min],0.91,6083,DB00898,Ethanol
,12485948,clearance,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [min],0.79,6084,DB00898,Ethanol
,12485948,volumes of distribution,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [kg],2.6,6085,DB00898,Ethanol
,12485948,volumes of distribution,"The pharmacokinetic dispositions of cocaine and cocaethylene were similar with clearance values of 0.91 +/- 0.22 and 0.79 +/- 0.16 l/min, and volumes of distribution of 2.6 +/- 0.82 and 2.7 +/- 0.47 l/kg, respectively.",Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485948/),[l] / [kg],2.7,6086,DB00898,Ethanol
,34358122,retention time,"This formulation exhibited improved pharmacokinetics with a mean retention time of 123.7 min, half-life of 101.3 min, and clearance rate of 0.24 L/(kg*h).",Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34358122/),min,123.7,6127,DB00898,Ethanol
,34358122,half-life,"This formulation exhibited improved pharmacokinetics with a mean retention time of 123.7 min, half-life of 101.3 min, and clearance rate of 0.24 L/(kg*h).",Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34358122/),min,101.3,6128,DB00898,Ethanol
,34358122,clearance rate,"This formulation exhibited improved pharmacokinetics with a mean retention time of 123.7 min, half-life of 101.3 min, and clearance rate of 0.24 L/(kg*h).",Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34358122/),[l] / [h·kg],0.24,6129,DB00898,Ethanol
,6314055,dose giving maximum polarization,"The dose giving maximum polarization was found to be 0.65 mumole, and pharmacokinetic analysis revealed that the disappearance of this analog followed a two-compartment open model with an elimination half-life from the membrane fraction of 655 hr.",In vivo incorporation of a cholesterol-like fluorescent probe into rat brain membranes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6314055/),mumole,0.65,6130,DB00898,Ethanol
,6314055,elimination half-life from the membrane fraction,"The dose giving maximum polarization was found to be 0.65 mumole, and pharmacokinetic analysis revealed that the disappearance of this analog followed a two-compartment open model with an elimination half-life from the membrane fraction of 655 hr.",In vivo incorporation of a cholesterol-like fluorescent probe into rat brain membranes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6314055/),h,655,6131,DB00898,Ethanol
,19695390,maximum decreases,"Up to 4 hours after the administration of mirodenafil, alcohol, and mirodenafil + alcohol, the mean (SD) maximum decreases in SBP were 8.5 (3.5), 13.5 (7.8), and 15.1 (6.7) mm Hg, respectively, and the maximum decreases in DBP were 6.4 (4.8), 13.3 (7.4), and 13.8 (5.2) mm Hg.","Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),hg·mm,8.5,6604,DB00898,Ethanol
,19695390,maximum decreases,"Up to 4 hours after the administration of mirodenafil, alcohol, and mirodenafil + alcohol, the mean (SD) maximum decreases in SBP were 8.5 (3.5), 13.5 (7.8), and 15.1 (6.7) mm Hg, respectively, and the maximum decreases in DBP were 6.4 (4.8), 13.3 (7.4), and 13.8 (5.2) mm Hg.","Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),hg·mm,13.5,6605,DB00898,Ethanol
,19695390,maximum decreases,"Up to 4 hours after the administration of mirodenafil, alcohol, and mirodenafil + alcohol, the mean (SD) maximum decreases in SBP were 8.5 (3.5), 13.5 (7.8), and 15.1 (6.7) mm Hg, respectively, and the maximum decreases in DBP were 6.4 (4.8), 13.3 (7.4), and 13.8 (5.2) mm Hg.","Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),hg·mm,15.1,6606,DB00898,Ethanol
,19695390,maximum decreases,"Up to 4 hours after the administration of mirodenafil, alcohol, and mirodenafil + alcohol, the mean (SD) maximum decreases in SBP were 8.5 (3.5), 13.5 (7.8), and 15.1 (6.7) mm Hg, respectively, and the maximum decreases in DBP were 6.4 (4.8), 13.3 (7.4), and 13.8 (5.2) mm Hg.","Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),hg·mm,6.4,6607,DB00898,Ethanol
,19695390,maximum decreases,"Up to 4 hours after the administration of mirodenafil, alcohol, and mirodenafil + alcohol, the mean (SD) maximum decreases in SBP were 8.5 (3.5), 13.5 (7.8), and 15.1 (6.7) mm Hg, respectively, and the maximum decreases in DBP were 6.4 (4.8), 13.3 (7.4), and 13.8 (5.2) mm Hg.","Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),hg·mm,13.3,6608,DB00898,Ethanol
,19695390,maximum decreases,"Up to 4 hours after the administration of mirodenafil, alcohol, and mirodenafil + alcohol, the mean (SD) maximum decreases in SBP were 8.5 (3.5), 13.5 (7.8), and 15.1 (6.7) mm Hg, respectively, and the maximum decreases in DBP were 6.4 (4.8), 13.3 (7.4), and 13.8 (5.2) mm Hg.","Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),hg·mm,13.8,6609,DB00898,Ethanol
,19695390,AUC(0-t),The mean (SD) AUC(0-t) values were 842.0 (434.7) ng/mL/h with mirodenafil and 833.4 (398.2) ng/mL/h with mirodenafil + alcohol.,"Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),[ng] / [h·ml],842.0,6610,DB00898,Ethanol
,19695390,AUC(0-t),The mean (SD) AUC(0-t) values were 842.0 (434.7) ng/mL/h with mirodenafil and 833.4 (398.2) ng/mL/h with mirodenafil + alcohol.,"Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695390/),[ng] / [h·ml],833.4,6611,DB00898,Ethanol
,7870919,pseudo steady state levels,Breath alcohol reached pseudo steady state levels of 0.38 g/l (range: 0.24-0.57) after alcohol alone and 0.37 g/l (range: 0.27-0.52) in combination with diazepam.,Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870919/),[g] / [l],0.38,7352,DB00898,Ethanol
,7870919,pseudo steady state levels,Breath alcohol reached pseudo steady state levels of 0.38 g/l (range: 0.24-0.57) after alcohol alone and 0.37 g/l (range: 0.27-0.52) in combination with diazepam.,Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870919/),[g] / [l],0.37,7353,DB00898,Ethanol
,15627216,total urinary excretion,Application of either 5 mg (A) or 15 mg CPF (B) resulted in the total urinary excretion of 131.8 microg (A) or 115.6 microg (B) of TCP 120 h after dosing.,Dermal absorption of chlorpyrifos in human volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15627216/),μg,131.8,7363,DB00898,Ethanol
,15627216,total urinary excretion,Application of either 5 mg (A) or 15 mg CPF (B) resulted in the total urinary excretion of 131.8 microg (A) or 115.6 microg (B) of TCP 120 h after dosing.,Dermal absorption of chlorpyrifos in human volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15627216/),μg,115.6,7364,DB00898,Ethanol
,15627216,elimination half-life,A mean elimination half-life of 41 h was established.,Dermal absorption of chlorpyrifos in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15627216/),h,41,7365,DB00898,Ethanol
,495919,half-life (t0.5),Rats exposed to halothane (100 ppm) in a closed allglass-system eliminate halothane from the atmosphere of this system with a half-life (t0.5) of 0.99 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,0.99,8118,DB00898,Ethanol
,495919,t0.5,In 24 h-fasted rats t0.5 was prolonged to 1.24 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,1.24,8119,DB00898,Ethanol
,495919,t0.5,"On the other hand, ethanol (4.8 g/kg p.o.) applied 5 min before exposure to halothane markedly prolonged t0.5 to 3.79 h.","[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,3.79,8120,DB00898,Ethanol
,495919,t0.5,Pretreatment with phenobarbital (80 mg/kg i.p. for 4 days) shortened t0.5 significantly to 0.79 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,0.79,8121,DB00898,Ethanol
,495919,t0.5,Inhibition of the mixed-function oxidase system by dithiocarb (100 mg/kg i.p.) or diethyl maleate (1 ml/kg i.p.) markedly prolonged t0.5 to 7.53 and 1.57 h. respectively.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,7.53,8122,DB00898,Ethanol
,495919,t0.5,Inhibition of the mixed-function oxidase system by dithiocarb (100 mg/kg i.p.) or diethyl maleate (1 ml/kg i.p.) markedly prolonged t0.5 to 7.53 and 1.57 h. respectively.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,1.57,8123,DB00898,Ethanol
,18752263,critical micelle concentrations,"Dynamic light scattering revealed PEO-b-PDLLA (12:6 kDa) micelles with average sizes of 257 nm and critical micelle concentrations of 350 nM, solubilizing up to 1.5 mg/mL of 17-AAG.",A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18752263/),nM,350,8271,DB00898,Ethanol
,23818776,zeta potential,The particles had negative zeta potential values of -31 ± 0.1 mV and a single melting peak of 55.85°C.,"Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23818776/),mv,-31,8932,DB00898,Ethanol
,23818776,Tmax,"The Tmax, Cmax, and elimination half-life of TQ were found to be 3.96 ± 0.19 hours, 4811.33 ± 55.52 ng/mL, and 4.4933 ± 0.015 hours, respectively, indicating that TQ is suitable for extravascular administration.","Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23818776/),h,3.96,8933,DB00898,Ethanol
,23818776,Cmax,"The Tmax, Cmax, and elimination half-life of TQ were found to be 3.96 ± 0.19 hours, 4811.33 ± 55.52 ng/mL, and 4.4933 ± 0.015 hours, respectively, indicating that TQ is suitable for extravascular administration.","Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23818776/),[ng] / [ml],4811.33,8934,DB00898,Ethanol
,23818776,elimination half-life,"The Tmax, Cmax, and elimination half-life of TQ were found to be 3.96 ± 0.19 hours, 4811.33 ± 55.52 ng/mL, and 4.4933 ± 0.015 hours, respectively, indicating that TQ is suitable for extravascular administration.","Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23818776/),h,4.4933,8935,DB00898,Ethanol
,17051591,AUC0-300 min,The absorption of CBD (AUC0-300 min) decreased in the following order: sublingual ethanolic CBD solution (420+/-120 ngxmin/mL; mean+/-SD; n=4)>sublingual solid CBD/beta-CD complex (270+/-120 ngxmin/mL)>oral ethanolic CBD solution (concentrations in plasma below the quantitation limit).,Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051591/),[min·ng] / [ml],420,9156,DB00898,Ethanol
,17051591,AUC0-300 min,The absorption of CBD (AUC0-300 min) decreased in the following order: sublingual ethanolic CBD solution (420+/-120 ngxmin/mL; mean+/-SD; n=4)>sublingual solid CBD/beta-CD complex (270+/-120 ngxmin/mL)>oral ethanolic CBD solution (concentrations in plasma below the quantitation limit).,Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051591/),[min·ng] / [ml],270,9157,DB00898,Ethanol
,24123382,flow rate,"The separation of oxcarbazepine and the MHD enantiomers was obtained on a chiral phase Chiralcel OD-H column, using a mixture of hexane:ethanol:isopropanol (80:15:5, v/v/v) as mobile phase at a flow rate of 1.3 mL/min with a split ratio of 1:5, and quantification was performed by LC-MS/MS.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),[ml] / [min],1.3,9265,DB00898,Ethanol
,24123382,maximum plasma concentration,The maximum plasma concentration of oxcarbazepine was 1.2 µg/mL at 0.75 h.,Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),[μg] / [ml],1.2,9266,DB00898,Ethanol
,24123382,AUC(0-12),"The kinetic disposition of MHD is enantioselective, with a higher proportion of the S-(+)-MHD enantiomer compared to R-(-)-MHD and an AUC(0-12) S-(+)/R-(-) ratio of 5.44.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),,5.44,9267,DB00898,Ethanol
,24123382,ratio,"The kinetic disposition of MHD is enantioselective, with a higher proportion of the S-(+)-MHD enantiomer compared to R-(-)-MHD and an AUC(0-12) S-(+)/R-(-) ratio of 5.44.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),,5.44,9268,DB00898,Ethanol
,2861095,systemic availability,In extensive metabolizers the systemic availability of bufuralol was 43%.,Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861095/),%,43,9600,DB00898,Ethanol
,33081266,droplet,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),nm,173.77,9812,DB00898,Ethanol
,33081266,zeta potential,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),m,-,9813,DB00898,Ethanol
,33081266,encapsulation efficiency,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),m,-,9814,DB00898,Ethanol
,33081266,pH,"Mean droplet size, zeta potential, encapsulation efficiency, and pH of formulated nanoemulsion were 173.77 ± 5.76 nm, -35.63 ± 0.78 mV, 90.37 ± 0.96%, and 4.07 ± 0.03, respectively.",Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33081266/),,4.07,9815,DB00898,Ethanol
,15257069,gamma,The 2-compartment model gave a gamma of 1.75.,Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),,1.75,9835,DB00898,Ethanol
,15257069,ka,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],6.43,9836,DB00898,Ethanol
,15257069,ka,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],5.46,9837,DB00898,Ethanol
,15257069,ka,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],2.93,9838,DB00898,Ethanol
,15257069,ka,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],4.58,9839,DB00898,Ethanol
,15257069,Vmax,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [h],12.09,9840,DB00898,Ethanol
,15257069,Vmax,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [h],11.90,9841,DB00898,Ethanol
,15257069,Vmax,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [h],13.03,9842,DB00898,Ethanol
,15257069,Vmax,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [h],3.73,9843,DB00898,Ethanol
,15257069,Km,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [l],0.1273,9844,DB00898,Ethanol
,15257069,Km,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [l],0.1367,9845,DB00898,Ethanol
,15257069,Km,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [l],0.1991,9846,DB00898,Ethanol
,15257069,Km,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),[g] / [l],0.0528,9847,DB00898,Ethanol
,15257069,Vc (L),"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),,31.32,9848,DB00898,Ethanol
,15257069,Vc (L),"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),,29.30,9849,DB00898,Ethanol
,15257069,Vc (L),"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),,24.88,9850,DB00898,Ethanol
,15257069,Vc (L),"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),,10.52,9851,DB00898,Ethanol
,15257069,kcp,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],4.38,9852,DB00898,Ethanol
,15257069,kcp,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],1.30,9853,DB00898,Ethanol
,15257069,kcp,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],1.12,9854,DB00898,Ethanol
,15257069,kcp,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],6.16,9855,DB00898,Ethanol
,15257069,kpc,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],9.11,9856,DB00898,Ethanol
,15257069,kpc,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],2.47,9857,DB00898,Ethanol
,15257069,kpc,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],0.89,9858,DB00898,Ethanol
,15257069,kpc,"The NPAG program gave the following means, medians, modes, and standard deviations for the 2-compartment model: ka (h(-1)) = 6.43, 5.46, 2.93, 4.58; Vmax (g/h) = 12.09, 11.90, 13.03, 3.73; Km (g/L) = 0.1273, 0.1367, 0.1991, 0.0528; Vc (L) = 31.32, 29.30, 24.88, 10.52; kcp (h(-1)) = 4.38, 1.30, 1.12, 6.16; and kpc (h(-1)) = 9.11, 2.47, 0.89, 8.98.",Population pharmacokinetics of ethanol in drinking drivers using breath measures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257069/),1/[h],8.98,9859,DB00898,Ethanol
,17614267,C(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ng] / [ml],944.1,9969,DB00898,Ethanol
,17614267,C(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ng] / [ml],330.4,9970,DB00898,Ethanol
,17614267,T(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),h,2,9971,DB00898,Ethanol
,17614267,T(max),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),h,4.3,9972,DB00898,Ethanol
,17614267,area under the curve from day 0 to 2 (AUC(0-2day)),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ngh] / [ml],16294.8,9973,DB00898,Ethanol
,17614267,area under the curve from day 0 to 2 (AUC(0-2day)),"After a 12.5mg/kg IM injection of a 25mg/g RSP-SAIB in situ system, the C(max) was markedly reduced from 944.1+/-80.2 to 330.4+/-33.6ng/ml by increasing PLA from 1% to 10% (w/w), the T(max) were prolonged from 2 to 4.3+/-2.0h, and the area under the curve from day 0 to 2 (AUC(0-2day)) was reduced significantly from 16294.8+/-3946.4 to 7025.3+/-1979.2ngh/ml.",In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614267/),[ngh] / [ml],7025.3,9974,DB00898,Ethanol
up to,15081140,maximum solubility,"The optimal microemulsion formulation consisted of 8% Labrafil M 1944CS, 30% Cremophor RH 40/ethanol (3:1) and water, with a maximum solubility of NM up to 6.4 mg/ml, droplet size of 30.3 +/- 5.3 nm, and no ciliotoxicity.",Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081140/),[mg] / [ml],6.4,10186,DB00898,Ethanol
,15081140,absolute bioavailability,"After a single intranasal administration of this preparation at a dose of 2 mg/kg, the plasma concentration peaked at 1 h and the absolute bioavailability was about 32%.",Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081140/),%,32,10187,DB00898,Ethanol
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.75,10331,DB00898,Ethanol
,2316313,molar ratio of daily production rates,"Amiodarone, an iodine containing anti-arrhythmic drug, causes a significant decrease in molar ratio of daily production rates of T3 and T4 from 0.75 in controls to 0.36 in amiodarone-treated rabbits.",Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),,0.36,10332,DB00898,Ethanol
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.107,10333,DB00898,Ethanol
,2316313,metabolic clearance rates,Amiodarone treatment decreased metabolic clearance rates significantly from 0.107 +/- 0.008 in controls to 0.074 +/- 0.009 l/day in amiodarone-treated rabbits (p less than 0.05).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),[l] / [d],0.074,10334,DB00898,Ethanol
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,32.0,10335,DB00898,Ethanol
,2316313,terminal serum elimination half-life,The terminal serum elimination half-life in the two groups were similar (32.0 +/- 6.7 h in controls vs 49.2 +/- 12.4 h in amiodarone-treated).,Effect of amiodarone on non-deiodinative pathway of thyroid hormone metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316313/),h,49.2,10336,DB00898,Ethanol
,16419413,flow rate,The mobile phase consisted of 0.1% formic acid in deionized water (60%) and acetonitrile (40%) at a flow rate of 0.5 mL/min.,Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[ml] / [min],0.5,10347,DB00898,Ethanol
,16419413,Heart blood concentrations,"Heart blood concentrations for loperamide and its metabolite were 1.2 mg/L and 3.3 mg/L, respectively.",Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[mg] / [l],1.2,10348,DB00898,Ethanol
,16419413,Heart blood concentrations,"Heart blood concentrations for loperamide and its metabolite were 1.2 mg/L and 3.3 mg/L, respectively.",Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[mg] / [l],3.3,10349,DB00898,Ethanol
not exceed,16419413,peak plasma concentrations,"In contrast, reported peak plasma concentrations of loperamide after administration of recommended daily doses of 16 mg did not exceed 0.012 mg/L in controlled trials.",Tissue distribution of loperamide and N-desmethylloperamide following a fatal overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419413/),[mg] / [l],0.012,10350,DB00898,Ethanol
,9492336,elimination half-lives,"The sensitivity of the radioimmunoassay permitted the detection of a prolonged elimination phase for formononetin in both plasma and mammary glandular tissues, with mean elimination half-lives of 2 and 2.5 hr, respectively.",Radioimmunoassay determination of formononetin in murine plasma and mammary glandular tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9492336/),h,2,10411,DB00898,Ethanol
,9492336,elimination half-lives,"The sensitivity of the radioimmunoassay permitted the detection of a prolonged elimination phase for formononetin in both plasma and mammary glandular tissues, with mean elimination half-lives of 2 and 2.5 hr, respectively.",Radioimmunoassay determination of formononetin in murine plasma and mammary glandular tissue. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9492336/),h,2.5,10412,DB00898,Ethanol
,15358318,retention time,Glimepiride was eluted with retention time 34.9 min without interference of endogenous substance from plasma.,Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358318/),min,34.9,10648,DB00898,Ethanol
,15358318,limit of quantification (LOQ),The limit of quantification (LOQ) was 10 ng/ml for glimepiride.,Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358318/),[ng] / [ml],10,10649,DB00898,Ethanol
,22843108,urine concentration,"Median urine concentration, corrected for specific gravity, after the single-dose administration peaked during 0-4 h after inhalation at a maximum of 7.4 ng·mL(-1) in asthmatic subjects and 7.9 ng·mL(-1) in healthy subjects.",Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22843108/),[ng] / [ml],7.4,11050,DB00898,Ethanol
,22843108,urine concentration,"Median urine concentration, corrected for specific gravity, after the single-dose administration peaked during 0-4 h after inhalation at a maximum of 7.4 ng·mL(-1) in asthmatic subjects and 7.9 ng·mL(-1) in healthy subjects.",Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22843108/),[ng] / [ml],7.9,11051,DB00898,Ethanol
,22843108,maximum individual concentration,The maximum individual concentration of 25.6 ng·mL(-1) was found after inhalation of a total of 72 μg formoterol.,Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22843108/),[ng] / [ml],25.6,11052,DB00898,Ethanol
,22322984,V ( z )/F,"After intravenous administration, senkyunolide I was rapidly distributed (V ( z )/F 2.07 ± 0.43 L/kg) and eliminated from the plasma (CL( z ) 2.56 ± 0.29 L/h/kg and t (1/2z ) 0.56 ± 0.13 h).",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),[l] / [kg],2.07,11188,DB00898,Ethanol
,22322984,CL( z ),"After intravenous administration, senkyunolide I was rapidly distributed (V ( z )/F 2.07 ± 0.43 L/kg) and eliminated from the plasma (CL( z ) 2.56 ± 0.29 L/h/kg and t (1/2z ) 0.56 ± 0.13 h).",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),[l] / [h·kg],2.56,11189,DB00898,Ethanol
,22322984,t (1/2z ),"After intravenous administration, senkyunolide I was rapidly distributed (V ( z )/F 2.07 ± 0.43 L/kg) and eliminated from the plasma (CL( z ) 2.56 ± 0.29 L/h/kg and t (1/2z ) 0.56 ± 0.13 h).",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),h,0.56,11190,DB00898,Ethanol
,22322984,T (max),"After administration orally to normal rats at two dosages (20 and 72 mg/kg), the pharmacokinetic parameters of senkyunolide I were as follows: T (max) 0.25 ± 0.06 and 0.38 ± 0.11 h, C (max) 5,236.3 ± 802.8 and 22,071.9 ± 3,456.1 mg/L, Area under the curve(AUC)((0-t)) 5,217.5 ± 1,029.5 and 21,480.2 ± 3,003.1 μg h/L, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),h,0.25,11191,DB00898,Ethanol
,22322984,T (max),"After administration orally to normal rats at two dosages (20 and 72 mg/kg), the pharmacokinetic parameters of senkyunolide I were as follows: T (max) 0.25 ± 0.06 and 0.38 ± 0.11 h, C (max) 5,236.3 ± 802.8 and 22,071.9 ± 3,456.1 mg/L, Area under the curve(AUC)((0-t)) 5,217.5 ± 1,029.5 and 21,480.2 ± 3,003.1 μg h/L, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),h,0.38,11192,DB00898,Ethanol
,22322984,C (max),"After administration orally to normal rats at two dosages (20 and 72 mg/kg), the pharmacokinetic parameters of senkyunolide I were as follows: T (max) 0.25 ± 0.06 and 0.38 ± 0.11 h, C (max) 5,236.3 ± 802.8 and 22,071.9 ± 3,456.1 mg/L, Area under the curve(AUC)((0-t)) 5,217.5 ± 1,029.5 and 21,480.2 ± 3,003.1 μg h/L, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),[mg] / [l],"5,236.3",11193,DB00898,Ethanol
,22322984,C (max),"After administration orally to normal rats at two dosages (20 and 72 mg/kg), the pharmacokinetic parameters of senkyunolide I were as follows: T (max) 0.25 ± 0.06 and 0.38 ± 0.11 h, C (max) 5,236.3 ± 802.8 and 22,071.9 ± 3,456.1 mg/L, Area under the curve(AUC)((0-t)) 5,217.5 ± 1,029.5 and 21,480.2 ± 3,003.1 μg h/L, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),[mg] / [l],"22,071.9",11194,DB00898,Ethanol
,22322984,Area under the curve(AUC)((0-t)),"After administration orally to normal rats at two dosages (20 and 72 mg/kg), the pharmacokinetic parameters of senkyunolide I were as follows: T (max) 0.25 ± 0.06 and 0.38 ± 0.11 h, C (max) 5,236.3 ± 802.8 and 22,071.9 ± 3,456.1 mg/L, Area under the curve(AUC)((0-t)) 5,217.5 ± 1,029.5 and 21,480.2 ± 3,003.1 μg h/L, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),[h·μg] / [l],"5,217.5",11195,DB00898,Ethanol
,22322984,Area under the curve(AUC)((0-t)),"After administration orally to normal rats at two dosages (20 and 72 mg/kg), the pharmacokinetic parameters of senkyunolide I were as follows: T (max) 0.25 ± 0.06 and 0.38 ± 0.11 h, C (max) 5,236.3 ± 802.8 and 22,071.9 ± 3,456.1 mg/L, Area under the curve(AUC)((0-t)) 5,217.5 ± 1,029.5 and 21,480.2 ± 3,003.1 μg h/L, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),[h·μg] / [l],"21,480.2",11196,DB00898,Ethanol
,22322984,oral absolute bioavailability,"Its oral absolute bioavailability at the two dosages was 67.2 and 76.9%, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),%,67.2,11197,DB00898,Ethanol
,22322984,oral absolute bioavailability,"Its oral absolute bioavailability at the two dosages was 67.2 and 76.9%, respectively.",Comparative pharmacokinetics of senkyunolide I in a rat model of migraine versus normal controls. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22322984/),%,76.9,11198,DB00898,Ethanol
,26186460,AUC,"In normal rats, AUC of quercetin-glucuronide conjugates, isorhamnetin-glucuronide conjugates, quercetin-sulfate conjugates, and isorhamnetin-sulfate conjugates was 459.45 ± 192.70, 1153.01 ± 697.04, 417.81 ± 220.31, and 2475.19 ± 1085.22 μmol h/L, respectively.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],459.45,11216,DB00898,Ethanol
,26186460,AUC,"In normal rats, AUC of quercetin-glucuronide conjugates, isorhamnetin-glucuronide conjugates, quercetin-sulfate conjugates, and isorhamnetin-sulfate conjugates was 459.45 ± 192.70, 1153.01 ± 697.04, 417.81 ± 220.31, and 2475.19 ± 1085.22 μmol h/L, respectively.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],1153.01,11217,DB00898,Ethanol
,26186460,AUC,"In normal rats, AUC of quercetin-glucuronide conjugates, isorhamnetin-glucuronide conjugates, quercetin-sulfate conjugates, and isorhamnetin-sulfate conjugates was 459.45 ± 192.70, 1153.01 ± 697.04, 417.81 ± 220.31, and 2475.19 ± 1085.22 μmol h/L, respectively.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],417.81,11218,DB00898,Ethanol
,26186460,AUC,"In normal rats, AUC of quercetin-glucuronide conjugates, isorhamnetin-glucuronide conjugates, quercetin-sulfate conjugates, and isorhamnetin-sulfate conjugates was 459.45 ± 192.70, 1153.01 ± 697.04, 417.81 ± 220.31, and 2475.19 ± 1085.22 μmol h/L, respectively.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],2475.19,11219,DB00898,Ethanol
,26186460,AUC,While AUC of quercetin and isorhamnetin was 5.47 ± 2.54 and 30.73 ± 25.95 μmol h/L.,Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],5.47,11220,DB00898,Ethanol
,26186460,AUC,While AUC of quercetin and isorhamnetin was 5.47 ± 2.54 and 30.73 ± 25.95 μmol h/L.,Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],30.73,11221,DB00898,Ethanol
,26186460,AUC,"AUC of isorhamnetin-glucuronide conjugates and quercetin-sulfate conjugates was 719.65 ± 619.22 and 275.49 ± 1 60.95 μmol h/L, indicating that less conjugated metabolites were formed in CKD rats compared with normal rats.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],719.65,11222,DB00898,Ethanol
,26186460,AUC,"AUC of isorhamnetin-glucuronide conjugates and quercetin-sulfate conjugates was 719.65 ± 619.22 and 275.49 ± 1 60.95 μmol h/L, indicating that less conjugated metabolites were formed in CKD rats compared with normal rats.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),[h·μM] / [l],275.49,11223,DB00898,Ethanol
,26186460,ratio of AUCglucuronide/sulfate/AUCaglycone,"The ratio of AUCglucuronide/sulfate/AUCaglycone decreased from 125 to 104, which implied the impaired phase II metabolism ability in CKD rat.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),,125,11224,DB00898,Ethanol
,26186460,ratio of AUCglucuronide/sulfate/AUCaglycone,"The ratio of AUCglucuronide/sulfate/AUCaglycone decreased from 125 to 104, which implied the impaired phase II metabolism ability in CKD rat.",Conjugated metabolites represent the major circulating forms of Abelmoschus manihot in vivo and show an altered pharmacokinetic profile in renal pathology. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26186460/),,104,11225,DB00898,Ethanol
,15907602,pKa1,Piroxicam can be ionized as a zwitterion that has two pKa values (pKa1=1.86 and pKa2=5.46).,Enhanced bioavailability of piroxicam via salt formation with ethanolamines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907602/),,1.86,11357,DB00898,Ethanol
,15907602,pKa2,Piroxicam can be ionized as a zwitterion that has two pKa values (pKa1=1.86 and pKa2=5.46).,Enhanced bioavailability of piroxicam via salt formation with ethanolamines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907602/),,5.46,11358,DB00898,Ethanol
,25625345,areas under the concentration curves (AUCs),"The pharmacokinetic data demonstrate that the areas under the concentration curves (AUCs) of luteolin were 261 ± 33 and 611 ± 89 (min μg/mL) after luteolin administration (10 mg/kg, iv; and 100 mg/kg, po, respectively).",Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),[min·μg] / [ml],261,11433,DB00898,Ethanol
,25625345,areas under the concentration curves (AUCs),"The pharmacokinetic data demonstrate that the areas under the concentration curves (AUCs) of luteolin were 261 ± 33 and 611 ± 89 (min μg/mL) after luteolin administration (10 mg/kg, iv; and 100 mg/kg, po, respectively).",Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),[min·μg] / [ml],611,11434,DB00898,Ethanol
,25625345,oral bioavailability,The oral bioavailability of luteolin was 26 ± 6%.,Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),%,26,11435,DB00898,Ethanol
,25625345,AUCs,"The AUCs of luteolin-7-O-glucoside were 229 ± 15 and 2109 ± 350 (min μg/mL) after administration of luteolin-7-O-glucoside (10 mg/kg, iv; and 1 g/kg, po, respectively).",Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),[min·μg] / [ml],229,11436,DB00898,Ethanol
,25625345,AUCs,"The AUCs of luteolin-7-O-glucoside were 229 ± 15 and 2109 ± 350 (min μg/mL) after administration of luteolin-7-O-glucoside (10 mg/kg, iv; and 1 g/kg, po, respectively).",Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),[min·μg] / [ml],2109,11437,DB00898,Ethanol
,25625345,oral bioavailability,The oral bioavailability of luteolin-7-O-glucoside was approximately 10 ± 2%.,Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),%,10,11438,DB00898,Ethanol
,25625345,biotransformation ratio,The biotransformation ratio of luteolin to luteolin-7-O-glucoside (the AUC ratio of metabolite/parent compound) was approximately 48.78 ± 0.12%.,Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),%,48.78,11439,DB00898,Ethanol
,25625345,AUC ratio,The biotransformation ratio of luteolin to luteolin-7-O-glucoside (the AUC ratio of metabolite/parent compound) was approximately 48.78 ± 0.12%.,Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625345/),%,48.78,11440,DB00898,Ethanol
,11008783,recovery,"The recovery was approximately 100%, and the limit of detection was 37 ng/mL.",Determination of hydroxytyrosol in plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11008783/),%,100,11924,DB00898,Ethanol
,11008783,limit of detection,"The recovery was approximately 100%, and the limit of detection was 37 ng/mL.",Determination of hydroxytyrosol in plasma by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11008783/),[ng] / [ml],37,11925,DB00898,Ethanol
,10774810,Total recoveries,"Total recoveries of 97.17 +/- 4.18% and 99.80 +/- 2.41% were obtained from topical and intravenous experiments, respectively.",Dermatoxicokinetic modeling of p-nitrophenol and its conjugation metabolite in swine following topical and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774810/),%,97.17,11926,DB00898,Ethanol
,10774810,Total recoveries,"Total recoveries of 97.17 +/- 4.18% and 99.80 +/- 2.41% were obtained from topical and intravenous experiments, respectively.",Dermatoxicokinetic modeling of p-nitrophenol and its conjugation metabolite in swine following topical and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774810/),%,99.80,11927,DB00898,Ethanol
,6467149,bioavailability,"So after single intraperitoneal (IP) injection of 300 mg/kg P1 which caused a bioavailability of 36 mumol/ml-1/minute a 67% inhibition of tumor growth was achieved, whereas a tumor growth reduction of 83% was obtained after injection of the same dose in 6 fractions resulting in constant blood levels with a bioavailability of only 17 mumol/ml-1/minute.","Pharmacokinetics of ""activated"" cyclophosphamide and therapeutic efficacies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467149/),[μM] / [ml],36,12236,DB00898,Ethanol
,6467149,bioavailability,"So after single intraperitoneal (IP) injection of 300 mg/kg P1 which caused a bioavailability of 36 mumol/ml-1/minute a 67% inhibition of tumor growth was achieved, whereas a tumor growth reduction of 83% was obtained after injection of the same dose in 6 fractions resulting in constant blood levels with a bioavailability of only 17 mumol/ml-1/minute.","Pharmacokinetics of ""activated"" cyclophosphamide and therapeutic efficacies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467149/),[μM] / [ml],17,12237,DB00898,Ethanol
,6467149,bioavailability,"Therefore, the bioavailability of activated CP, which killed 50% of the animals, was determined to be approximately 89 mumol/ml-1/minute after adjustment of pharmacokinetics to yield constant levels and approximately 79 mumol/ml-1/minute after single bolus injection.","Pharmacokinetics of ""activated"" cyclophosphamide and therapeutic efficacies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467149/),[μM] / [ml],89,12238,DB00898,Ethanol
,6467149,bioavailability,"Therefore, the bioavailability of activated CP, which killed 50% of the animals, was determined to be approximately 89 mumol/ml-1/minute after adjustment of pharmacokinetics to yield constant levels and approximately 79 mumol/ml-1/minute after single bolus injection.","Pharmacokinetics of ""activated"" cyclophosphamide and therapeutic efficacies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467149/),[μM] / [ml],79,12239,DB00898,Ethanol
,23507629,Cmax,"The observed mean Cmax was 138.4±28.6 mg/dL (range 98.0-170.0 mg/dL), and the observed mean Tmax was 5.4±3.1 minutes (range 2-10 minutes) after alcohol consumption.",Blood alcohol concentrations rise rapidly and dramatically after Roux-en-Y gastric bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507629/),[mg] / [dl],138.4,12557,DB00898,Ethanol
,23507629,Tmax,"The observed mean Cmax was 138.4±28.6 mg/dL (range 98.0-170.0 mg/dL), and the observed mean Tmax was 5.4±3.1 minutes (range 2-10 minutes) after alcohol consumption.",Blood alcohol concentrations rise rapidly and dramatically after Roux-en-Y gastric bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507629/),min,5.4,12558,DB00898,Ethanol
,6437805,biological half-time,The biological half-time was 9.9 +/- 1.5 hr for the ethoxy-labeled compound and 12.5 +/- 1.9 hr for the ethanol label.,Metabolism and excretion of 2-ethoxyethanol in the adult male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437805/),h,9.9,13015,DB00898,Ethanol
,6437805,biological half-time,The biological half-time was 9.9 +/- 1.5 hr for the ethoxy-labeled compound and 12.5 +/- 1.9 hr for the ethanol label.,Metabolism and excretion of 2-ethoxyethanol in the adult male rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437805/),h,12.5,13016,DB00898,Ethanol
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14022,DB00898,Ethanol
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14023,DB00898,Ethanol
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14024,DB00898,Ethanol
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14025,DB00898,Ethanol
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14026,DB00898,Ethanol
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14027,DB00898,Ethanol
,11522481,C(max),"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[ng] / [ml],48.9,14048,DB00898,Ethanol
,11522481,C(max),"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[ng] / [ml],49.5,14049,DB00898,Ethanol
,11522481,area under the curve,"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[h·ng] / [ml],134.0,14050,DB00898,Ethanol
,11522481,area under the curve,"Besides very moderate prolongation of drug release, the submicron emulsion as a vehicle did not alter pharmacokinetics of diazepam when compared with the solution: the mean C(max) was 48.9+/-24.0 and 49.5+/-17.0 ng/ml, and area under the curve was 134.0+/-42.3 and 186.8+/-59.8 ng h/ml, for solution and emulsion, respectively.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),[h·ng] / [ml],186.8,14051,DB00898,Ethanol
,11522481,relative bioavailability,"The low relative bioavailability, 47% compared to the solution, was observed after administration of SLN.","Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522481/),%,47,14052,DB00898,Ethanol
,1457265,rate of decline of the plasma ethanol concentration (k0,"2. The rate of decline of the plasma ethanol concentration (k0; mean +/- s.d.), was 186 +/- 26 mg l-1 h-1.",Ethanol kinetics: extent of error in back extrapolation procedures. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457265/),[mg] / [h·l],186,14505,DB00898,Ethanol
,1457265,k0,5. When a k0 value of 150 mg l-1 h-1 (a value often cited as a population mean) was used for back extrapolation this resulted in significant under-estimation of actual values whereas the use of a k0 value of 238 mg l-1 h-1 (the highest value observed in the present study) resulted in significant over-estimation of actual values.,Ethanol kinetics: extent of error in back extrapolation procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457265/),[mg] / [h·l],150,14506,DB00898,Ethanol
,1457265,k0,5. When a k0 value of 150 mg l-1 h-1 (a value often cited as a population mean) was used for back extrapolation this resulted in significant under-estimation of actual values whereas the use of a k0 value of 238 mg l-1 h-1 (the highest value observed in the present study) resulted in significant over-estimation of actual values.,Ethanol kinetics: extent of error in back extrapolation procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457265/),[mg] / [h·l],238,14507,DB00898,Ethanol
,8424424,integrated 4-h plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[h·mg] / [dl],27.8,14560,DB00898,Ethanol
,8424424,integrated 4-h plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[h·mg] / [dl],32.4,14561,DB00898,Ethanol
,8424424,peak plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[mg] / [dl],18.0,14562,DB00898,Ethanol
,8424424,peak plasma ethanol concentration,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),[mg] / [dl],21.1,14563,DB00898,Ethanol
,8424424,time to peak,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),min,43,14564,DB00898,Ethanol
,8424424,time to peak,"Compared with placebo, dosing with ranitidine resulted in nonsignificant changes in either the mean integrated 4-h plasma ethanol concentration (27.8 vs. 32.4 mg.h/dl), the peak plasma ethanol concentration (18.0 vs. 21.1 mg/dl), or the time to peak (43 vs. 40 min).",Ranitidine has no effect on postbreakfast ethanol absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424424/),min,40,14565,DB00898,Ethanol
,29791112,blood alcohollevel,"Twelve subjects drank a volume of the grappa ""Vecchio di Prosecco"" (42 vol%) to reach a blood alcohollevel of 1.20 %o.",[Drinking study on the pharmacokinetics of the grappa congener 2-butanol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29791112/),,1.,14597,DB00898,Ethanol
,33748928,polydispersity index,The particle size of DMY-Ms was 13.97 ± 0.82 nm with an acceptable polydispersity index of 0.197 ± 0.015.,Self-Assembled Micelles Improve the Oral Bioavailability of Dihydromyricetin and Anti-Acute Alcoholism Activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33748928/),,0.197,15147,DB00898,Ethanol
,33748928,relative bioavailability,"The relative bioavailability of the DMY-Ms (AUC0-∞) was 205% compared with that of pure DMY (AUC0-∞), indicating potential for clinical application.",Self-Assembled Micelles Improve the Oral Bioavailability of Dihydromyricetin and Anti-Acute Alcoholism Activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33748928/),%,205,15148,DB00898,Ethanol
,9862244,absorption half-life,"The median absorption half-life of benflumetol was 5.3 h, with a tmax of 10 h and terminal elimination half-life of 4.5 days.",Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862244/),h,5.3,15458,DB00898,Ethanol
,9862244,tmax,"The median absorption half-life of benflumetol was 5.3 h, with a tmax of 10 h and terminal elimination half-life of 4.5 days.",Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862244/),h,10,15459,DB00898,Ethanol
,9862244,terminal elimination half-life,"The median absorption half-life of benflumetol was 5.3 h, with a tmax of 10 h and terminal elimination half-life of 4.5 days.",Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862244/),d,4.5,15460,DB00898,Ethanol
,3219663,Vmax,"In 18 cats, Vmax for ethanol was 93 +/- 7 mumol.min-1 per 100 g liver or 21 +/- 2 mumol.min-1.kg body weight-1 and Km was 144 +/- 19 microM in terms of logarithmic mean sinusoidal concentration.",Hepatic blood flow: estimation from clearances of very low dose infusions of ethanol in cats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219663/),[μM] / [min],93,15594,DB00898,Ethanol
,3219663,Vmax,"In 18 cats, Vmax for ethanol was 93 +/- 7 mumol.min-1 per 100 g liver or 21 +/- 2 mumol.min-1.kg body weight-1 and Km was 144 +/- 19 microM in terms of logarithmic mean sinusoidal concentration.",Hepatic blood flow: estimation from clearances of very low dose infusions of ethanol in cats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219663/),[body·kg·μM] / [min·weight],21,15595,DB00898,Ethanol
,3219663,Km,"In 18 cats, Vmax for ethanol was 93 +/- 7 mumol.min-1 per 100 g liver or 21 +/- 2 mumol.min-1.kg body weight-1 and Km was 144 +/- 19 microM in terms of logarithmic mean sinusoidal concentration.",Hepatic blood flow: estimation from clearances of very low dose infusions of ethanol in cats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219663/),μM,144,15596,DB00898,Ethanol
,3219663,extraction,"At the dose of 8 mumol.min-1.kg body weight-1 used for estimation of hepatic blood flow, extraction was 0.95 +/- 0.07 (mean +/- SD).",Hepatic blood flow: estimation from clearances of very low dose infusions of ethanol in cats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219663/),,0.95,15597,DB00898,Ethanol
,2178478,total body water,"The mean total body water was determined by desiccation in DBA/2J, CBA/J, and C57BL/6J mice to be 60.6, 65.6, and 68.6 percent of body weight, respectively.",Comparative pharmacokinetics of ethanol in inbred strains of mice using doses based on total body water. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178478/),%,60.6,15637,DB00898,Ethanol
,2178478,total body water,"The mean total body water was determined by desiccation in DBA/2J, CBA/J, and C57BL/6J mice to be 60.6, 65.6, and 68.6 percent of body weight, respectively.",Comparative pharmacokinetics of ethanol in inbred strains of mice using doses based on total body water. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178478/),%,65.6,15638,DB00898,Ethanol
,2178478,total body water,"The mean total body water was determined by desiccation in DBA/2J, CBA/J, and C57BL/6J mice to be 60.6, 65.6, and 68.6 percent of body weight, respectively.",Comparative pharmacokinetics of ethanol in inbred strains of mice using doses based on total body water. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178478/),%,68.6,15639,DB00898,Ethanol
,30399533,protein binding,Changes in bupivacaine plasma protein binding is of clinical relevance considering its high protein binding (approximately 95%) and its classification as an intermediate hepatic extraction ratio drug (E = 0.38).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,95,16533,DB00898,Ethanol
,30399533,flow rate,"The separation of bupivacaine enantiomers was obtained on a Chirex® 3020 chiral stationary phase column using as a mobile phase a mixture of 95% n-hexane:ethanol (80:20, v/v) at a flow rate of 0.8 mL/min.",Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[ml] / [min],0.8,16534,DB00898,Ethanol
,30399533,unbound concentration,The lower limit of quantification was 0.25 ng of each enantiomer/mL of plasma as the total concentration and 0.125 ng of each enantiomer/mL of plasma as the unbound concentration.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),ng,0.125,16535,DB00898,Ethanol
,30399533,AUC0-∞,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[h·ng] / [ml],25.42,16536,DB00898,Ethanol
,30399533,AUC0-∞,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[h·ng] / [ml],30.57,16537,DB00898,Ethanol
,30399533,volume of distribution,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),l,841.96,16538,DB00898,Ethanol
,30399533,volume of distribution,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),l,655.05,16539,DB00898,Ethanol
,30399533,total clearance,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[l] / [h],98.34,16540,DB00898,Ethanol
,30399533,total clearance,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[l] / [h],81.79,16541,DB00898,Ethanol
,30399533,AUC(R)/(S) ratio,The pharmacokinetics of bupivacaine were enantioselective displaying a lower plasma proportion of the enantiomer R-bupivacaine (AUC(R)/(S) ratio equal to 0.83).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),,0.83,16542,DB00898,Ethanol
,30399533,placental transfer,The placental transfer was approximately 60% for both bupivacaine enantiomers.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,60,16543,DB00898,Ethanol
,30399533,unbound fraction (Fu),The unbound fraction (Fu) for the R-bupivacaine enantiomer was higher (10.84%) than the eutomer S-bupivacaine (6.29%).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,10.84,16544,DB00898,Ethanol
,30399533,unbound fraction (Fu),The unbound fraction (Fu) for the R-bupivacaine enantiomer was higher (10.84%) than the eutomer S-bupivacaine (6.29%).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,6.29,16545,DB00898,Ethanol
>,17306943,ethanol-to-EtG ratios,"The ethanol-to-EtG ratios in blood (ethanol in g/L, EtG in mg/L) were >1 only for the first median 3.5 h (range 2.5-3.5) after drinking.",A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17306943/),,1,17505,DB00898,Ethanol
,17306943,half-life,"EtG elimination occurred with a median half-life of 2.2 h (range 1.7-3.1 h), and the renal clearance was 8.32 L/h (median, range 5.25-20.86).",A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17306943/),h,2.2,17506,DB00898,Ethanol
,17306943,renal clearance,"EtG elimination occurred with a median half-life of 2.2 h (range 1.7-3.1 h), and the renal clearance was 8.32 L/h (median, range 5.25-20.86).",A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17306943/),[l] / [h],8.32,17507,DB00898,Ethanol
,17306943,total amount of,"The total amount of EtG excreted in the urine was median 30 mg (range 21.5-39.7), representing 0.017% (median, range 0.013-0.022) of the ethanol given, on a molar basis.",A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17306943/),mg,30,17508,DB00898,Ethanol
,17306943,total amount of,"The total amount of EtG excreted in the urine was median 30 mg (range 21.5-39.7), representing 0.017% (median, range 0.013-0.022) of the ethanol given, on a molar basis.",A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17306943/),,0.017,17509,DB00898,Ethanol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],64,17873,DB00898,Ethanol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],56,17874,DB00898,Ethanol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],79,17875,DB00898,Ethanol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],72,17876,DB00898,Ethanol
,8276573,encapsulation efficiency,The mean diameter was 0.5 +/- 0.1 micron and the encapsulation efficiency ranged between 30% and 40%.,Characterization of iopromide liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276573/),%,30,17979,DB00898,Ethanol
,8276573,encapsulation efficiency,The mean diameter was 0.5 +/- 0.1 micron and the encapsulation efficiency ranged between 30% and 40%.,Characterization of iopromide liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276573/),%,40,17980,DB00898,Ethanol
,8276573,LD50,The LD50 in mouse and rat was approximately 3 g iodine/kg.,Characterization of iopromide liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276573/),g,3,17981,DB00898,Ethanol
,8269600,flow rate,O6-mG and the internal standard deoxyguanosine (dGuo) were eluted with a linear gradient of from 15% to 35% methanol in 0.5 M ammonium acetate (pH 6.5) at a flow rate of 1 ml/min.,Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[ml] / [min],1,18038,DB00898,Ethanol
,8269600,detection limit,The assay was linear over a 4-log concentration range with a detection limit of 0.1 microgram/ml.,Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[μg] / [ml],0.1,18039,DB00898,Ethanol
,8269600,terminal half-life (t1/2),"At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1.",Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),min,24,18040,DB00898,Ethanol
,8269600,total clearance (CLT),"At 20 mg/kg i.v., plasma O6-mG gave a biexponential profile with a terminal half-life (t1/2) of 24 min and a total clearance (CLT) of 23.7 ml min-1 kg-1.",Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8269600/),[ml] / [kg·min],23.7,18041,DB00898,Ethanol
,6495333,t1/2,The data indicate picloram was rapidly absorbed from the gastrointestinal tract (t1/2 = 20 min) and rapidly excreted unchanged in the urine.,Pharmacokinetics of picloram in male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495333/),min,20,18583,DB00898,Ethanol
,6495333,half-life,Over 90% of the po dose was recovered as unchanged picloram in the urine excreted through 72 hr; most of the dose (greater than 75%) was excreted within 6 hr and the remainder was excreted with an average half-life of 27 hr.,Pharmacokinetics of picloram in male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495333/),h,27,18584,DB00898,Ethanol
,6495333,t1/2,"By comparison picloram was slowly absorbed through the skin (t1/2 = 12 hr) and, based on the quantity of picloram excreted in the urine, only a small fraction (0.2%) of the picloram applied to the skin was absorbed.",Pharmacokinetics of picloram in male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495333/),h,12,18585,DB00898,Ethanol
,2815837,elimination half-lives,"1. 14C-Diethylene glycol (DEG), administered orally to rats at 1, 5, and 10 ml/kg, gave elimination half-lives of 6, 6, and 10 h, respectively, from urinary excretion data.",Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),h,6,19132,DB00898,Ethanol
,2815837,elimination half-lives,"1. 14C-Diethylene glycol (DEG), administered orally to rats at 1, 5, and 10 ml/kg, gave elimination half-lives of 6, 6, and 10 h, respectively, from urinary excretion data.",Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),h,10,19133,DB00898,Ethanol
,2815837,half-life,"14C-DEG urinary elimination kinetics changed into first-order 6, 9, and 18 h after oral doses of 1, 5, and 10 ml/kg, with a half-life of 3 h.",Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),h,3,19134,DB00898,Ethanol
,2815837,half-lives,"2. After oral doses of 3 and 5 ml ethylene glycol (EG)/kg, half-lives of 4.5 and 4.1 h were estimated from cumulative urinary excretion data for non-metabolized EG.",Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),h,4.5,19135,DB00898,Ethanol
,2815837,half-lives,"2. After oral doses of 3 and 5 ml ethylene glycol (EG)/kg, half-lives of 4.5 and 4.1 h were estimated from cumulative urinary excretion data for non-metabolized EG.",Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),h,4.1,19136,DB00898,Ethanol
,2815837,half-life,A half-life of 2 h was determined from half-logarithmic plots of urinary excretion rates of non-metabolized EG after the same oral doses of EG.,Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),h,2,19137,DB00898,Ethanol
,2815837,Ki,"DEG inhibited ethanol oxidation non-competitively, the Ki being 0.44 M.",Pharmacokinetics and biotransformation of diethylene glycol and ethylene glycol in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815837/),M,0.44,19138,DB00898,Ethanol
,9397551,ABAC,"When infusion of alcohol ended, ABAC, VBAC, and BrAC were 94.8 +/- 2.06 (+/- SE), 84.7 +/- 1.54, and 89.3 +/- 2.10 mg/dL, respectively.",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [dl],94.8,19447,DB00898,Ethanol
,9397551,VBAC,"When infusion of alcohol ended, ABAC, VBAC, and BrAC were 94.8 +/- 2.06 (+/- SE), 84.7 +/- 1.54, and 89.3 +/- 2.10 mg/dL, respectively.",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [dl],84.7,19448,DB00898,Ethanol
,9397551,VBAC,"When infusion of alcohol ended, ABAC, VBAC, and BrAC were 94.8 +/- 2.06 (+/- SE), 84.7 +/- 1.54, and 89.3 +/- 2.10 mg/dL, respectively.",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [dl],89.3,19449,DB00898,Ethanol
,9397551,BrAC,"When infusion of alcohol ended, ABAC, VBAC, and BrAC were 94.8 +/- 2.06 (+/- SE), 84.7 +/- 1.54, and 89.3 +/- 2.10 mg/dL, respectively.",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [dl],89.3,19450,DB00898,Ethanol
,9397551,apparent half-life,"The mean apparent half-life of the distribution plunge was 7 to 8 min, being about the same for ABAC, VBAC, and BrAC.",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),min,7 to 8,19451,DB00898,Ethanol
,9397551,disappearance rate of ethanol,"The disappearance rate of ethanol was 15.5 +/- 0.55 mg/ dL/h (mean +/- SE) for arterial blood, 15.2 +/- 0.49 mg/dL/h for venous blood, and 16.3 +/- 0.73 mg/230 L/h for breath; no significant differences were noted (p > 0.05).",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [dl·h],15.5,19452,DB00898,Ethanol
,9397551,disappearance rate of ethanol,"The disappearance rate of ethanol was 15.5 +/- 0.55 mg/ dL/h (mean +/- SE) for arterial blood, 15.2 +/- 0.49 mg/dL/h for venous blood, and 16.3 +/- 0.73 mg/230 L/h for breath; no significant differences were noted (p > 0.05).",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [dl·h],15.2,19453,DB00898,Ethanol
,9397551,disappearance rate of ethanol,"The disappearance rate of ethanol was 15.5 +/- 0.55 mg/ dL/h (mean +/- SE) for arterial blood, 15.2 +/- 0.49 mg/dL/h for venous blood, and 16.3 +/- 0.73 mg/230 L/h for breath; no significant differences were noted (p > 0.05).",Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397551/),[mg] / [230·h·l],16.3,19454,DB00898,Ethanol
,15850279,half-life elimination,"Formate half-life elimination during hemodialysis was 1.80+/-0.78 h, which was statistically different from the values observed before or in the absence of dialysis (6.04+/-3.26 h, P =0.004).",Formate kinetics in methanol poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850279/),h,1.80,20134,DB00898,Ethanol
,15850279,half-life elimination,"Formate half-life elimination during hemodialysis was 1.80+/-0.78 h, which was statistically different from the values observed before or in the absence of dialysis (6.04+/-3.26 h, P =0.004).",Formate kinetics in methanol poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850279/),h,6.04,20135,DB00898,Ethanol
,15850279,formate clearance rate,The mean hemodialysis formate clearance rate calculated in eight cases was 176+/-43 mL/min.,Formate kinetics in methanol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850279/),[ml] / [min],176,20136,DB00898,Ethanol
,9333902,biological half-life,The biological half-life of isopropanol calculated for the first 12 hours from admission to the Clinic was 6.9 hours.,[Acute oral poisoning with isopropyl alcohol in alcoholics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333902/),h,6.9,20727,DB00898,Ethanol
,9333902,biological half-life,"The biological half-life of acetone in the first 6 hours of hospitalisation was 5 hours, and then a considerable slowing down up to 29 hours was noted.",[Acute oral poisoning with isopropyl alcohol in alcoholics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333902/),h,5,20728,DB00898,Ethanol
,24010572,AUClast,"Adjusted geometric mean AUClast for artemether were 345 and 364 ng·h/mL (geometric mean ratio (GMR) 0.95; 90% CI 0.89-1.01) and for lumefantrine were 219 and 218 μg·h/mL (GMR 1.00; 90% CI 0.93-1.08) for 80/480 mg tablet versus four standard tablets, respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·ng] / [ml],345,21143,DB00898,Ethanol
,24010572,AUClast,"Adjusted geometric mean AUClast for artemether were 345 and 364 ng·h/mL (geometric mean ratio (GMR) 0.95; 90% CI 0.89-1.01) and for lumefantrine were 219 and 218 μg·h/mL (GMR 1.00; 90% CI 0.93-1.08) for 80/480 mg tablet versus four standard tablets, respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·ng] / [ml],364,21144,DB00898,Ethanol
,24010572,AUClast,"Adjusted geometric mean AUClast for artemether were 345 and 364 ng·h/mL (geometric mean ratio (GMR) 0.95; 90% CI 0.89-1.01) and for lumefantrine were 219 and 218 μg·h/mL (GMR 1.00; 90% CI 0.93-1.08) for 80/480 mg tablet versus four standard tablets, respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·μg] / [ml],219,21145,DB00898,Ethanol
,24010572,AUClast,"Adjusted geometric mean AUClast for artemether were 345 and 364 ng·h/mL (geometric mean ratio (GMR) 0.95; 90% CI 0.89-1.01) and for lumefantrine were 219 and 218 μg·h/mL (GMR 1.00; 90% CI 0.93-1.08) for 80/480 mg tablet versus four standard tablets, respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·μg] / [ml],218,21146,DB00898,Ethanol
,24010572,Cmax,Corresponding Cmax for artemether were 96.8 and 99.7 ng/mL (GMR 0.97; 90% CI 0.89-1.06) and for lumefantrine were 8.42 and 8.71 μg/mL (GMR 0.97; 90% CI 0.89-1.05).,"Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[ng] / [ml],96.8,21147,DB00898,Ethanol
,24010572,Cmax,Corresponding Cmax for artemether were 96.8 and 99.7 ng/mL (GMR 0.97; 90% CI 0.89-1.06) and for lumefantrine were 8.42 and 8.71 μg/mL (GMR 0.97; 90% CI 0.89-1.05).,"Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[ng] / [ml],99.7,21148,DB00898,Ethanol
,24010572,Cmax,Corresponding Cmax for artemether were 96.8 and 99.7 ng/mL (GMR 0.97; 90% CI 0.89-1.06) and for lumefantrine were 8.42 and 8.71 μg/mL (GMR 0.97; 90% CI 0.89-1.05).,"Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[μg] / [ml],8.42,21149,DB00898,Ethanol
,24010572,Cmax,Corresponding Cmax for artemether were 96.8 and 99.7 ng/mL (GMR 0.97; 90% CI 0.89-1.06) and for lumefantrine were 8.42 and 8.71 μg/mL (GMR 0.97; 90% CI 0.89-1.05).,"Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[μg] / [ml],8.71,21150,DB00898,Ethanol
,24010572,AUClast,"For the 60/360 mg tablet versus three standard tablets, adjusted geometric mean AUClast for artemether were 235 and 231 ng·h/mL (GMR 1.02; 90% CI 0.94-1.10), and for lumefantrine were 160 and 180 μg·h/mL (GMR 0.89; 90% CI 0.83-0.96), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·ng] / [ml],235,21151,DB00898,Ethanol
,24010572,AUClast,"For the 60/360 mg tablet versus three standard tablets, adjusted geometric mean AUClast for artemether were 235 and 231 ng·h/mL (GMR 1.02; 90% CI 0.94-1.10), and for lumefantrine were 160 and 180 μg·h/mL (GMR 0.89; 90% CI 0.83-0.96), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·ng] / [ml],231,21152,DB00898,Ethanol
,24010572,AUClast,"For the 60/360 mg tablet versus three standard tablets, adjusted geometric mean AUClast for artemether were 235 and 231 ng·h/mL (GMR 1.02; 90% CI 0.94-1.10), and for lumefantrine were 160 and 180 μg·h/mL (GMR 0.89; 90% CI 0.83-0.96), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·μg] / [ml],160,21153,DB00898,Ethanol
,24010572,AUClast,"For the 60/360 mg tablet versus three standard tablets, adjusted geometric mean AUClast for artemether were 235 and 231 ng·h/mL (GMR 1.02; 90% CI 0.94-1.10), and for lumefantrine were 160 and 180 μg·h/mL (GMR 0.89; 90% CI 0.83-0.96), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[h·μg] / [ml],180,21154,DB00898,Ethanol
,24010572,Cmax,"Corresponding Cmax for artemether were 75.5 and 71.5 ng/mL (GMR 1.06; 90% CI 0.95-1.18), and for lumefantrine were 6.64 and 7.61 μg/mL (GMR 0.87; 90% CI 0.81-0.94), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[ng] / [ml],75.5,21155,DB00898,Ethanol
,24010572,Cmax,"Corresponding Cmax for artemether were 75.5 and 71.5 ng/mL (GMR 1.06; 90% CI 0.95-1.18), and for lumefantrine were 6.64 and 7.61 μg/mL (GMR 0.87; 90% CI 0.81-0.94), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[ng] / [ml],71.5,21156,DB00898,Ethanol
,24010572,Cmax,"Corresponding Cmax for artemether were 75.5 and 71.5 ng/mL (GMR 1.06; 90% CI 0.95-1.18), and for lumefantrine were 6.64 and 7.61 μg/mL (GMR 0.87; 90% CI 0.81-0.94), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[μg] / [ml],6.64,21157,DB00898,Ethanol
,24010572,Cmax,"Corresponding Cmax for artemether were 75.5 and 71.5 ng/mL (GMR 1.06; 90% CI 0.95-1.18), and for lumefantrine were 6.64 and 7.61 μg/mL (GMR 0.87; 90% CI 0.81-0.94), respectively.","Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem) for bioequivalence in a randomized, open-label, two-period study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010572/),[μg] / [ml],7.61,21158,DB00898,Ethanol
,25978861,flow rate,"The plasma samples were prepared by methanol extraction from 200μL plasma, and then the baseline resolution was achieved on a Chiralpak ID column (250mm×4.6mm, 5μm) with mobile phase of hexane-ethanol-trifluoroacetic acid (78:22:0.1, v/v/v) at flow rate of 1.0mL/min.",Enantioselective HPLC determination of oxiracetam enantiomers and application to a pharmacokinetic study in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25978861/),[ml] / [min],1.0,21854,DB00898,Ethanol
,16995333,t(max),"The 90% non-parametric confidence interval for the median t(max) of almotriptan plus ethanol compared to almotriptan alone (0.61/2.72) was outside the acceptable range (0.70 - 1.30), demonstrating that concomitant ethanol administration slightly increases the variability of absorption of almotriptan 12.5 mg.","Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995333/),,0,21891,DB00898,Ethanol
,25246789,oral bioavailability,"Raloxifene hydrochloride, a highly effective drug for the treatment of invasive breast cancer and osteoporosis in post-menopausal women, shows poor oral bioavailability of 2%.",Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25246789/),%,2,22013,DB00898,Ethanol
,25246789,entrapment efficiency,"They had a particle size of 134±9 nM, with an entrapment efficiency of 91.00%±4.90%, and transdermal flux of 6.5±1.1 μg/cm(2)/hour.",Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25246789/),%,91.00,22014,DB00898,Ethanol
,25246789,transdermal flux,"They had a particle size of 134±9 nM, with an entrapment efficiency of 91.00%±4.90%, and transdermal flux of 6.5±1.1 μg/cm(2)/hour.",Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25246789/),[μg] / [cm(2)·h],6.5,22015,DB00898,Ethanol
,25246789,enhancement ratios,"Raloxifene hydrochloride-loaded transfersomes proved significantly superior in terms of amount of drug permeated and deposited in the skin, with enhancement ratios of 6.25±1.50 and 9.25±2.40, respectively, when compared with drug-loaded conventional liposomes, and an ethanolic phosphate buffer saline.",Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25246789/),,6.25,22016,DB00898,Ethanol
,25246789,enhancement ratios,"Raloxifene hydrochloride-loaded transfersomes proved significantly superior in terms of amount of drug permeated and deposited in the skin, with enhancement ratios of 6.25±1.50 and 9.25±2.40, respectively, when compared with drug-loaded conventional liposomes, and an ethanolic phosphate buffer saline.",Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25246789/),,9.25,22017,DB00898,Ethanol
,27670974,maximum plasma concentration (Cmax),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (3.14-4.96 μg/mL), area under the curve (AUC) (10.46-17.78 μg h/mL), half life (T1/2) (1.26-1.82 h) and significantly decreased elimination rate constant (Kel) (0.57-0.41 h - 1), apparent oral clearance (CL/F) (24.76-13.65 L/h) of CHZ when compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),[μg] / [ml],3.14-4.96,22384,DB00898,Ethanol
,27670974,area under the curve (AUC),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (3.14-4.96 μg/mL), area under the curve (AUC) (10.46-17.78 μg h/mL), half life (T1/2) (1.26-1.82 h) and significantly decreased elimination rate constant (Kel) (0.57-0.41 h - 1), apparent oral clearance (CL/F) (24.76-13.65 L/h) of CHZ when compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),[h·μg] / [ml],10.46-17.78,22385,DB00898,Ethanol
,27670974,half life (T1/2),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (3.14-4.96 μg/mL), area under the curve (AUC) (10.46-17.78 μg h/mL), half life (T1/2) (1.26-1.82 h) and significantly decreased elimination rate constant (Kel) (0.57-0.41 h - 1), apparent oral clearance (CL/F) (24.76-13.65 L/h) of CHZ when compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),h,1.26-1.82,22386,DB00898,Ethanol
,27670974,elimination rate constant (Kel),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (3.14-4.96 μg/mL), area under the curve (AUC) (10.46-17.78 μg h/mL), half life (T1/2) (1.26-1.82 h) and significantly decreased elimination rate constant (Kel) (0.57-0.41 h - 1), apparent oral clearance (CL/F) (24.76-13.65 L/h) of CHZ when compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),-·1·h,0.57-0.41,22387,DB00898,Ethanol
,27670974,apparent oral clearance (CL/F),"3. Treatment with PIP significantly enhanced maximum plasma concentration (Cmax) (3.14-4.96 μg/mL), area under the curve (AUC) (10.46-17.78 μg h/mL), half life (T1/2) (1.26-1.82 h) and significantly decreased elimination rate constant (Kel) (0.57-0.41 h - 1), apparent oral clearance (CL/F) (24.76-13.65 L/h) of CHZ when compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),[l] / [h],24.76-13.65,22388,DB00898,Ethanol
,27670974,Cmax,"In addition, treatment with PIP significantly decreased Cmax (0.22-0.15 μg/mL), AUC (0.94-0.68 μg h/mL), T1/2 (2.54-1.68 h) and significantly increased Kel (0.32-0.43 h - 1) of 6-hydroxychlorzoxazone (6-OHCHZ) as compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),[μg] / [ml],0.22-0.15,22389,DB00898,Ethanol
,27670974,AUC,"In addition, treatment with PIP significantly decreased Cmax (0.22-0.15 μg/mL), AUC (0.94-0.68 μg h/mL), T1/2 (2.54-1.68 h) and significantly increased Kel (0.32-0.43 h - 1) of 6-hydroxychlorzoxazone (6-OHCHZ) as compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),[h·μg] / [ml],0.94-0.68,22390,DB00898,Ethanol
,27670974,T1/2,"In addition, treatment with PIP significantly decreased Cmax (0.22-0.15 μg/mL), AUC (0.94-0.68 μg h/mL), T1/2 (2.54-1.68 h) and significantly increased Kel (0.32-0.43 h - 1) of 6-hydroxychlorzoxazone (6-OHCHZ) as compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),h,2.54-1.68,22391,DB00898,Ethanol
,27670974,Kel,"In addition, treatment with PIP significantly decreased Cmax (0.22-0.15 μg/mL), AUC (0.94-0.68 μg h/mL), T1/2 (2.54-1.68 h) and significantly increased Kel (0.32-0.43 h - 1) of 6-hydroxychlorzoxazone (6-OHCHZ) as compared to control.",Effect of piperine on CYP2E1 enzyme activity of chlorzoxazone in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27670974/),-·1·h,0.32-0.43,22392,DB00898,Ethanol
,2005658,peak acetone concentrations,Serum admission isopropanol and peak acetone concentrations ranged from 16.5 to 220 mg/dL and 141 to 585 mg/dL respectively.,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),[mg] / [dl],141 to 585,22519,DB00898,Ethanol
,2005658,apparent half-lives,The isopropanol and acetone apparent half-lives ranged from 2.9 to 16.2 hours (h) and 7.6 to 26.2 h respectively.,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),(h)·h,2.9 to 16.2,22520,DB00898,Ethanol
,2005658,apparent half-lives,The isopropanol and acetone apparent half-lives ranged from 2.9 to 16.2 hours (h) and 7.6 to 26.2 h respectively.,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),h,7.6 to 26.2,22521,DB00898,Ethanol
,2005658,terminal elimination rate constants,Isopropanol terminal elimination rate constants were 0.043 and 0.085 per hour (per h) with no marked difference in acetone terminal elimination rate constants (0.025 and 0.033 per h).,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),[h] / [h],0.043,22522,DB00898,Ethanol
,2005658,terminal elimination rate constants,Isopropanol terminal elimination rate constants were 0.043 and 0.085 per hour (per h) with no marked difference in acetone terminal elimination rate constants (0.025 and 0.033 per h).,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),[h] / [h],0.085,22523,DB00898,Ethanol
,2005658,terminal elimination rate constants,Isopropanol terminal elimination rate constants were 0.043 and 0.085 per hour (per h) with no marked difference in acetone terminal elimination rate constants (0.025 and 0.033 per h).,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),1/[h],0.025,22524,DB00898,Ethanol
,2005658,terminal elimination rate constants,Isopropanol terminal elimination rate constants were 0.043 and 0.085 per hour (per h) with no marked difference in acetone terminal elimination rate constants (0.025 and 0.033 per h).,Isopropanol ingestion: a report of six episodes with isopropanol and acetone serum concentration time data. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2005658/),1/[h],0.033,22525,DB00898,Ethanol
,26829518,association constant K(A),"The association constant K(A) (L mol(-1)) of the binding reaches 10(6) order of magnitude, which is significantly stronger than the other components of propolis.",Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829518/),order,10,22687,DB00898,Ethanol
,26829518,binding distance,"Based on the theory of fluorescence resonance energy transfer, the binding distance was calculated as 5.7 nm, which is longer than that of the other components of propolis.",Caffeic acid phenethyl ester exhibiting distinctive binding interaction with human serum albumin implies the pharmacokinetic basis of propolis bioactive components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829518/),nm,5.7,22688,DB00898,Ethanol
,34242946,flow rate,"Chromatographic separation was carried out on ACQUITY UPLC BEH - C18 column (2.1 mm × 50 mm, 1.7 μm) with a mobile phase composed of acetonitrile - water (containing 1.0 mmol/L ammonium acetate) using gradient elution at a flow rate of 0.2 mL/min.",An UPLC - Q - Orbitrap method for pharmacokinetics and tissue distribution of four triterpenoids in rats after oral administration of Poria cocos ethanol extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34242946/),[ml] / [min],0.2,22716,DB00898,Ethanol
,18608277,concentration,A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL).,Acute tacrolimus toxicity in a non-transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608277/),,96,22818,DB00898,Ethanol
,18608277,elimination half-life,"Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 +/- 7.7 hours.",Acute tacrolimus toxicity in a non-transplant patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608277/),h,16.5,22819,DB00898,Ethanol
,18608277,half-life,"Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 +/- 7.7 hours.",Acute tacrolimus toxicity in a non-transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608277/),h,34.2,22820,DB00898,Ethanol
,23376503,oral bioavailability,"Given its poor water solubility and low oral bioavailability (1-4%), there are limitations to the utilization of KP.",Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2-hydroxypropyl-β-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23376503/),%,1-4,23304,DB00898,Ethanol
,23376503,oral bioavailability,"The oral bioavailability values of KP-SMEDDS formulations were higher than those of KP (25.38-, 42.00-, and 26.01-fold for PMF, TMF, and DMF, respectively).",Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2-hydroxypropyl-β-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23376503/),,25,23305,DB00898,Ethanol
,24102672,dose-normalized AUC,"The dose-normalized AUC values were 7.3, 7.6 and 8.7 μg × h/ml (calculated based on the dose of 10 mg/kg) for intravenous doses of 10, 20 and 50 mg/kg, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),[h·μg] / [ml],7.3,23400,DB00898,Ethanol
,24102672,dose-normalized AUC,"The dose-normalized AUC values were 7.3, 7.6 and 8.7 μg × h/ml (calculated based on the dose of 10 mg/kg) for intravenous doses of 10, 20 and 50 mg/kg, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),[h·μg] / [ml],7.6,23401,DB00898,Ethanol
,24102672,dose-normalized AUC,"The dose-normalized AUC values were 7.3, 7.6 and 8.7 μg × h/ml (calculated based on the dose of 10 mg/kg) for intravenous doses of 10, 20 and 50 mg/kg, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),[h·μg] / [ml],8.7,23402,DB00898,Ethanol
,24102672,elimination half-lifes (t1/2λ),"The elimination half-lifes (t1/2λ) were 4.9, 4.6 and 4.8 h at 10, 20 and 50 mg/kg intravenous doses, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),h,4.9,23403,DB00898,Ethanol
,24102672,elimination half-lifes (t1/2λ),"The elimination half-lifes (t1/2λ) were 4.9, 4.6 and 4.8 h at 10, 20 and 50 mg/kg intravenous doses, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),h,4.6,23404,DB00898,Ethanol
,24102672,elimination half-lifes (t1/2λ),"The elimination half-lifes (t1/2λ) were 4.9, 4.6 and 4.8 h at 10, 20 and 50 mg/kg intravenous doses, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),h,4.8,23405,DB00898,Ethanol
,24102672,F,"The F values were 29.86, 22.70, 33.62% for oral doses of 20, 50 and 100 mg/kg, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),%,29.86,23406,DB00898,Ethanol
,24102672,F,"The F values were 29.86, 22.70, 33.62% for oral doses of 20, 50 and 100 mg/kg, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),%,22.70,23407,DB00898,Ethanol
,24102672,F,"The F values were 29.86, 22.70, 33.62% for oral doses of 20, 50 and 100 mg/kg, respectively.","Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),%,33.62,23408,DB00898,Ethanol
,24102672,plasma protein binding,The plasma protein binding of ISL in rats was 43.72%.,"Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24102672/),%,43.72,23409,DB00898,Ethanol
,28039091,transdermal flux,"In an in vitro permeation study, the paeonol transethosomes showed an enhanced transdermal flux of 95.7±8.8μg/cm2/h and a higher deposition quantity in porcine ear skin compared to the transfersomes.",Evaluation of paeonol-loaded transethosomes as transdermal delivery carriers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039091/),[μg] / [cm2·h],95.7,23462,DB00898,Ethanol
,22265667,V/V/,"A C18 cartridge was used in this method to extract the enantiomers in 200μL plasma followed by a chiral separation on a cellulose-based LC column with mobile phase consisted of hexane, methanol and ethanol (62:28:10, V/V/V).",Normal-phase liquid chromatography coupled with electrospray ionization mass spectrometry for chiral separation and quantification of clevudine and its enantiomer in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22265667/),,62,23484,DB00898,Ethanol
,22265667,m/,A transition of m/z 261.0 to m/z 126.8 was used for monitoring of clevudine and its enantiomer.,Normal-phase liquid chromatography coupled with electrospray ionization mass spectrometry for chiral separation and quantification of clevudine and its enantiomer in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22265667/),,261.0,23485,DB00898,Ethanol
,22265667,m/z,A transition of m/z 261.0 to m/z 126.8 was used for monitoring of clevudine and its enantiomer.,Normal-phase liquid chromatography coupled with electrospray ionization mass spectrometry for chiral separation and quantification of clevudine and its enantiomer in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22265667/),,126.8,23486,DB00898,Ethanol
,3307494,maximum BACs,"However, maximum BACs decreased with age from 155 mg/dl in 1-day-old rats to 111 mg/dl in 60-day-old rats.",Developmental changes in alcohol pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307494/),[mg] / [dl],155,23563,DB00898,Ethanol
,3307494,maximum BACs,"However, maximum BACs decreased with age from 155 mg/dl in 1-day-old rats to 111 mg/dl in 60-day-old rats.",Developmental changes in alcohol pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307494/),[mg] / [dl],111,23564,DB00898,Ethanol
,3307494,elimination rate,"By linear regression analysis, the elimination rate of alcohol in 1-day-old rats was estimated to be 7.5 mg/dl/hr which increased to 42.2 mg/dl/hr in 60-day-old-rats.",Developmental changes in alcohol pharmacokinetics in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307494/),[mg] / [dl·h],7.5,23565,DB00898,Ethanol
,3307494,elimination rate,"By linear regression analysis, the elimination rate of alcohol in 1-day-old rats was estimated to be 7.5 mg/dl/hr which increased to 42.2 mg/dl/hr in 60-day-old-rats.",Developmental changes in alcohol pharmacokinetics in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3307494/),[mg] / [dl·h],42.2,23566,DB00898,Ethanol
,10463813,peak BrACs,"Mean (+/-SD) peak BrACs actually achieved were 0.069+/-0.011 g/2101 after the low dose, and 0.105+/-0.014 g/2101 after the high dose.",Development of dosing guidelines for reaching selected target breath alcohol concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463813/),[g] / [2101],0.069,23621,DB00898,Ethanol
,10463813,peak BrACs,"Mean (+/-SD) peak BrACs actually achieved were 0.069+/-0.011 g/2101 after the low dose, and 0.105+/-0.014 g/2101 after the high dose.",Development of dosing guidelines for reaching selected target breath alcohol concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10463813/),[g] / [2101],0.105,23622,DB00898,Ethanol
,8798925,flow-rate,"The HPLC assay comprised a 25 cm-long Techopak C18 column and a mobile phase of (0.25 M sodium dihydrogen phosphate plus 0.25% heptane sulphonic acid, to pH 3.3 with orthophosphoric acid) containing 30% (v/v) methanol and 0.003% (w/v) EDTA, run at a flow-rate of 1.5 ml/min.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[ml] / [min],1.5,23681,DB00898,Ethanol
,8798925,initial half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,8.2,23682,DB00898,Ethanol
,8798925,initial half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,46.6,23683,DB00898,Ethanol
,8798925,elimination half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,76.4,23684,DB00898,Ethanol
,8798925,elimination half-lives,"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),min,166.5,23685,DB00898,Ethanol
,8798925,area under the plasma concentration-time curve (AUC),"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[h·ng] / [ml],236,23686,DB00898,Ethanol
,8798925,area under the plasma concentration-time curve (AUC),"Preliminary pharmacokinetic data from two patients given apomorphine by 12 h subcutaneous infusion (patient A dose = 35 mg and patient B dose = 141 mg) showed apomorphine elimination from plasma to fit a two-compartment model, with initial half-lives of 8.2 and 46.6 min, elimination half-lives of 76.4 and 166.5 min and area under the plasma concentration-time curve (AUC) values of 236 and 405 ng h/ml, respectively.",Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8798925/),[h·ng] / [ml],405,23687,DB00898,Ethanol
,2039683,flow rate,"The chromatographic separation was performed on a silica gel stationary phase (Zorbax Sil) using n-hexane-chloroform-ethanol (100:10:0.75, by vol) as mobile phase [flow rate, 2 ml/min; fluorescence detection, 305/355 nm; elution order of the derivatives, (-) before (+)].",Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039683/),[ml] / [min],2,23980,DB00898,Ethanol
,2039683,Limit of quantification,Limit of quantification was 20-25 ng/ml for plasma based on a sample volume of 0.2 ml.,Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039683/),[ng] / [ml],20-25,23981,DB00898,Ethanol
,7124461,methanol concentration,Their whole blood methanol concentration ranged from 137.2 mmol/l (4.39 g/l) to 7.4 mmol/l (0.24 g/l).,Studies on methanol poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[mM] / [l],137.2,24382,DB00898,Ethanol
,7124461,methanol concentration,Their whole blood methanol concentration ranged from 137.2 mmol/l (4.39 g/l) to 7.4 mmol/l (0.24 g/l).,Studies on methanol poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[mM] / [l],7.4,24383,DB00898,Ethanol
,7124461,clearance,"In two patients the average dialysator clearance of methanol was 157 and 176 ml/min at blood flows of 200 and 215 ml/min, respectively.",Studies on methanol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[ml] / [min],157,24384,DB00898,Ethanol
,7124461,clearance,"In two patients the average dialysator clearance of methanol was 157 and 176 ml/min at blood flows of 200 and 215 ml/min, respectively.",Studies on methanol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[ml] / [min],176,24385,DB00898,Ethanol
,7124461,blood flows,"In two patients the average dialysator clearance of methanol was 157 and 176 ml/min at blood flows of 200 and 215 ml/min, respectively.",Studies on methanol poisoning. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[ml] / [min],200,24386,DB00898,Ethanol
,7124461,blood flows,"In two patients the average dialysator clearance of methanol was 157 and 176 ml/min at blood flows of 200 and 215 ml/min, respectively.",Studies on methanol poisoning. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[ml] / [min],215,24387,DB00898,Ethanol
,7124461,clearance,In the same patients the average dialysator clearance of ethanol was 149 and 164 ml/min.,Studies on methanol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[ml] / [min],149,24388,DB00898,Ethanol
,7124461,clearance,In the same patients the average dialysator clearance of ethanol was 149 and 164 ml/min.,Studies on methanol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[ml] / [min],164,24389,DB00898,Ethanol
,7124461,volume of distribution,"Assuming a volume of distribution of methanol of 0.7 l/kg, the dialysator represented about 89 and 95%, respectively, of the total body clearance of methanol during ethanol therapy.",Studies on methanol poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124461/),[l] / [kg],0.7,24390,DB00898,Ethanol
,19650674,area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)],"Exposure to BDP was not significantly different between active treatment arms, but lower systemic exposure to B17MP was observed with the fixed combination than with the separate components (area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)] 5280 vs 8120 pg.h/mL; p = 0.001).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],5280,24541,DB00898,Ethanol
,19650674,area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)],"Exposure to BDP was not significantly different between active treatment arms, but lower systemic exposure to B17MP was observed with the fixed combination than with the separate components (area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)] 5280 vs 8120 pg.h/mL; p = 0.001).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],8120,24542,DB00898,Ethanol
,19650674,AUC from 0 to 30 minutes [AUC(30 min)],"Despite a lower total systemic exposure to B17MP with the fixed combination, B17MP plasma concentrations during the first 30 minutes after administration, indicative of pulmonary absorption, were 86% higher with BDP/F than with the separate components (AUC from 0 to 30 minutes [AUC(30 min)] 353 vs 190 pg x h/mL; p = 0.003).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],353,24543,DB00898,Ethanol
,19650674,AUC from 0 to 30 minutes [AUC(30 min)],"Despite a lower total systemic exposure to B17MP with the fixed combination, B17MP plasma concentrations during the first 30 minutes after administration, indicative of pulmonary absorption, were 86% higher with BDP/F than with the separate components (AUC from 0 to 30 minutes [AUC(30 min)] 353 vs 190 pg x h/mL; p = 0.003).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],190,24544,DB00898,Ethanol
,11862275,BACs,"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],15.2,24781,DB00898,Ethanol
,11862275,BACs,"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],27,24782,DB00898,Ethanol
,11862275,C(max),"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],13,24783,DB00898,Ethanol
,11862275,C(max),"Observed median peak BAC (C(max)) for 0.10- and 0.15-g/kg dose groups (median BACs 15.2 and 27 mg/dl, respectively) were very similar to the target C(max) (13 and 26 mg/dl).",Ethanol Pharmacodynamics at Low Blood Concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862275/),[mg] / [dl],26,24784,DB00898,Ethanol
,26318978,brain concentration,"Considering that the brain concentration at 24h was 1400±160.1ng/g (ABZ-SO) and 120±35.2ng/g (CUR), the in vitro efficacy seen at a 10 fold lower concentration of the drugs strongly supports the assumption of clinical efficacy.",Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26318978/),[ng] / [g],1400,25386,DB00898,Ethanol
,26318978,brain concentration,"Considering that the brain concentration at 24h was 1400±160.1ng/g (ABZ-SO) and 120±35.2ng/g (CUR), the in vitro efficacy seen at a 10 fold lower concentration of the drugs strongly supports the assumption of clinical efficacy.",Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26318978/),[ng] / [g],120,25387,DB00898,Ethanol
,33688872,Cmax,"After enzymatic hydrolysis, the Cmax values of artepillin C and drupanin, which were detected mainly in plasma after ingestion of BGP capsules, were 1255 ± 517 and 2893 ± 711 nM, respectively, of which 89.3% and 88.2% were found to be the phenolic glucuronide conjugate.",Pharmacokinetics and metabolism of cinnamic acid derivatives and flavonoids after oral administration of Brazilian green propolis in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33688872/),nM,1255,25734,DB00898,Ethanol
,33688872,Cmax,"After enzymatic hydrolysis, the Cmax values of artepillin C and drupanin, which were detected mainly in plasma after ingestion of BGP capsules, were 1255 ± 517 and 2893 ± 711 nM, respectively, of which 89.3% and 88.2% were found to be the phenolic glucuronide conjugate.",Pharmacokinetics and metabolism of cinnamic acid derivatives and flavonoids after oral administration of Brazilian green propolis in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33688872/),nM,2893,25735,DB00898,Ethanol
,33688872,Cmax,"After enzymatic hydrolysis, the Cmax values of artepillin C and drupanin, which were detected mainly in plasma after ingestion of BGP capsules, were 1255 ± 517 and 2893 ± 711 nM, respectively, of which 89.3% and 88.2% were found to be the phenolic glucuronide conjugate.",Pharmacokinetics and metabolism of cinnamic acid derivatives and flavonoids after oral administration of Brazilian green propolis in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33688872/),,89,25736,DB00898,Ethanol
,33688872,Cmax,"After enzymatic hydrolysis, the Cmax values of artepillin C and drupanin, which were detected mainly in plasma after ingestion of BGP capsules, were 1255 ± 517 and 2893 ± 711 nM, respectively, of which 89.3% and 88.2% were found to be the phenolic glucuronide conjugate.",Pharmacokinetics and metabolism of cinnamic acid derivatives and flavonoids after oral administration of Brazilian green propolis in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33688872/),,88,25737,DB00898,Ethanol
,33948896,liver terminal half life (t½),"The pharmacokinetic study revealed that the optimized galactosylated chitosan-coated spanlastics exhibited significantly higher liver peak concentration (Cmax) and area under liver concentration versus time curve (AUC0-72 h) and significant prolongation in the liver terminal half life (t½) and mean residence time (MRT) compared to the free ledipasvir dispersion with values of 6270 ng/g, 61,706.3 ng.h/g, 15.85 h, and 24.66 h, respectively.","Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948896/),[ng] / [g],6270,26265,DB00898,Ethanol
,33948896,liver terminal half life (t½),"The pharmacokinetic study revealed that the optimized galactosylated chitosan-coated spanlastics exhibited significantly higher liver peak concentration (Cmax) and area under liver concentration versus time curve (AUC0-72 h) and significant prolongation in the liver terminal half life (t½) and mean residence time (MRT) compared to the free ledipasvir dispersion with values of 6270 ng/g, 61,706.3 ng.h/g, 15.85 h, and 24.66 h, respectively.","Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948896/),[h·ng] / [g],"61,706.3",26266,DB00898,Ethanol
,33948896,mean residence time (MRT),"The pharmacokinetic study revealed that the optimized galactosylated chitosan-coated spanlastics exhibited significantly higher liver peak concentration (Cmax) and area under liver concentration versus time curve (AUC0-72 h) and significant prolongation in the liver terminal half life (t½) and mean residence time (MRT) compared to the free ledipasvir dispersion with values of 6270 ng/g, 61,706.3 ng.h/g, 15.85 h, and 24.66 h, respectively.","Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948896/),[h·ng] / [g],"61,706.3",26267,DB00898,Ethanol
,33948896,mean residence time (MRT),"The pharmacokinetic study revealed that the optimized galactosylated chitosan-coated spanlastics exhibited significantly higher liver peak concentration (Cmax) and area under liver concentration versus time curve (AUC0-72 h) and significant prolongation in the liver terminal half life (t½) and mean residence time (MRT) compared to the free ledipasvir dispersion with values of 6270 ng/g, 61,706.3 ng.h/g, 15.85 h, and 24.66 h, respectively.","Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948896/),h,15.85,26268,DB00898,Ethanol
,33948896,mean residence time (MRT),"The pharmacokinetic study revealed that the optimized galactosylated chitosan-coated spanlastics exhibited significantly higher liver peak concentration (Cmax) and area under liver concentration versus time curve (AUC0-72 h) and significant prolongation in the liver terminal half life (t½) and mean residence time (MRT) compared to the free ledipasvir dispersion with values of 6270 ng/g, 61,706.3 ng.h/g, 15.85 h, and 24.66 h, respectively.","Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948896/),h,24.66,26269,DB00898,Ethanol
,6641094,t 1/2 of the terminal decay phase,The t 1/2 of the terminal decay phase was 11.1 hr.,"Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),h,11.1,27628,DB00898,Ethanol
,6641094,apparent volume of distribution (aVD),"Mean apparent volume of distribution (aVD) was between 11.2 and 16.4 l/kg, and mean total body clearance (ClT) was between 0.73 and 0.99 l hr-1 kg-1.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),[l] / [kg],11.2 and 16.4,27629,DB00898,Ethanol
,6641094,total body clearance (ClT),"Mean apparent volume of distribution (aVD) was between 11.2 and 16.4 l/kg, and mean total body clearance (ClT) was between 0.73 and 0.99 l hr-1 kg-1.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),[l] / [h·kg],0.73 and 0.99,27630,DB00898,Ethanol
,6641094,urinary recovery,"Mean urinary recovery of parent drug within 48 hr was 2.3%, 3.9%, and 3.6% after the oral doses compared to 8.2% after the intravenous dose.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,2.3,27631,DB00898,Ethanol
,6641094,urinary recovery,"Mean urinary recovery of parent drug within 48 hr was 2.3%, 3.9%, and 3.6% after the oral doses compared to 8.2% after the intravenous dose.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,3.9,27632,DB00898,Ethanol
,6641094,urinary recovery,"Mean urinary recovery of parent drug within 48 hr was 2.3%, 3.9%, and 3.6% after the oral doses compared to 8.2% after the intravenous dose.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,3.6,27633,DB00898,Ethanol
,6641094,urinary recovery,"Mean urinary recovery of parent drug within 48 hr was 2.3%, 3.9%, and 3.6% after the oral doses compared to 8.2% after the intravenous dose.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,8.2,27634,DB00898,Ethanol
,6641094,Bioavailability,"Bioavailability estimated from AUC was 27.2% after 400 mg, 31.3% after 800 mg, and 37.4% after 1200 mg by mouth.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,27.2,27635,DB00898,Ethanol
,6641094,Bioavailability,"Bioavailability estimated from AUC was 27.2% after 400 mg, 31.3% after 800 mg, and 37.4% after 1200 mg by mouth.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,31.3,27636,DB00898,Ethanol
,6641094,Bioavailability,"Bioavailability estimated from AUC was 27.2% after 400 mg, 31.3% after 800 mg, and 37.4% after 1200 mg by mouth.","Kinetics of medroxalol, a beta- and alpha-adrenoceptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641094/),%,37.4,27637,DB00898,Ethanol
,8839215,half-lives,"Elimination of TCE and TCA from serum occurred biphasically, the estimated half-lives of each metabolites being about 52.6 and 50.4 h in an initial fast phase and 268.3 and 277.2 h in a subsequent slow phase, respectively.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,52.6,27682,DB00898,Ethanol
,8839215,half-lives,"Elimination of TCE and TCA from serum occurred biphasically, the estimated half-lives of each metabolites being about 52.6 and 50.4 h in an initial fast phase and 268.3 and 277.2 h in a subsequent slow phase, respectively.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,50.4,27683,DB00898,Ethanol
,8839215,half-lives,"Elimination of TCE and TCA from serum occurred biphasically, the estimated half-lives of each metabolites being about 52.6 and 50.4 h in an initial fast phase and 268.3 and 277.2 h in a subsequent slow phase, respectively.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,268.3,27684,DB00898,Ethanol
,8839215,half-lives,"Elimination of TCE and TCA from serum occurred biphasically, the estimated half-lives of each metabolites being about 52.6 and 50.4 h in an initial fast phase and 268.3 and 277.2 h in a subsequent slow phase, respectively.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,277.2,27685,DB00898,Ethanol
,8839215,t1/2,"The half-life of urinary TCE excretion (t1/2 25.7 h) was shorter than that of TCA (t1/2 52.1 h) in the fast phase but did no difference during the slow phase, with each half-time being about 166.3 h.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,25.7,27686,DB00898,Ethanol
,8839215,t1/2,"The half-life of urinary TCE excretion (t1/2 25.7 h) was shorter than that of TCA (t1/2 52.1 h) in the fast phase but did no difference during the slow phase, with each half-time being about 166.3 h.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,52.1,27687,DB00898,Ethanol
,8839215,half-time,"The half-life of urinary TCE excretion (t1/2 25.7 h) was shorter than that of TCA (t1/2 52.1 h) in the fast phase but did no difference during the slow phase, with each half-time being about 166.3 h.",Concentrations of trichloroethylene and its metabolites in blood and urine after acute poisoning by ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839215/),h,166.3,27688,DB00898,Ethanol
,3098270,steady state blood levels,Subsequently to an oral loading dose (0.54 g ethanol kg-1) ethanol was infused for 4 h (0.15 g ethanol kg-1 h-1) and steady state blood levels between 0.9 to 1.2 g l-1 were reached within 2 h.,Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098270/),[g] / [l],0.9 to 1.2,27696,DB00898,Ethanol
,3098270,t1/2,There was no pharmacokinetic interaction between both agents since elimination of Ro 15-1788 (t1/2 = 1.2 +/- 0.7 h) and of ethanol (0.17 +/- 0.02 g l-1 h-1) were in good agreement with control values.,Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098270/),h,1.2,27697,DB00898,Ethanol
,3098270,t1/2,There was no pharmacokinetic interaction between both agents since elimination of Ro 15-1788 (t1/2 = 1.2 +/- 0.7 h) and of ethanol (0.17 +/- 0.02 g l-1 h-1) were in good agreement with control values.,Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3098270/),[g] / [h·l],0.17,27698,DB00898,Ethanol
,19435095,terminal half lives,"The liposomal formulations showed much longer terminal half lives (4.92 h and 6.75 h for FR-targeted and non-targeted, respectively) than docetaxel in Tween 80/ethanol solution (1.09 h).","Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19435095/),h,4.92,28161,DB00898,Ethanol
,19435095,terminal half lives,"The liposomal formulations showed much longer terminal half lives (4.92 h and 6.75 h for FR-targeted and non-targeted, respectively) than docetaxel in Tween 80/ethanol solution (1.09 h).","Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19435095/),h,6.75,28162,DB00898,Ethanol
,19435095,terminal half lives,"The liposomal formulations showed much longer terminal half lives (4.92 h and 6.75 h for FR-targeted and non-targeted, respectively) than docetaxel in Tween 80/ethanol solution (1.09 h).","Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19435095/),h,1.09,28163,DB00898,Ethanol
,1491036,detection limit,"With an ultraviolet detector operated at 230 nm, a linear response was observed from 0.05 to 2.0 micrograms/ml with a detection limit of 5 ng/ml for cocaethylene, cocaine and norcocaine.","Determination of cocaethylene, cocaine and their metabolites in rat serum microsamples by high-performance liquid chromatography, and its application to pharmacokinetic studies in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491036/),[ng] / [ml],5,29066,DB00898,Ethanol
,1492851,flow rate,"The chromatographic separation was performed on a silica gel stationary phase (Zorbax Sil) using n-hexane-chloroform-ethanol (100:10:1, by vol.) as mobile phase (flow rate, 2 ml/min; fluorescence-detection, 305/355 nm; elution order of the derivatives, (-) before (+)).",Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492851/),[ml] / [min],2,29086,DB00898,Ethanol
,1492851,Limit of quantification,Limit of quantification was 1.0 ng/ml for plasma and 10 ng/ml for urine.,Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492851/),[ng] / [ml],1.0,29087,DB00898,Ethanol
,1492851,Limit of quantification,Limit of quantification was 1.0 ng/ml for plasma and 10 ng/ml for urine.,Studies on the metabolic clearance of ciclotropium to alpha-phenylciclopentylacetic acid using a new enantiospecific metabolite assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492851/),[ng] / [ml],10,29088,DB00898,Ethanol
,28178632,bioaccessibility,"The bioaccessibility indexes of phenolic compounds in EETg were 48.65 and 69.28% in the presence and absence of enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,48.65,30061,DB00898,Ethanol
,28178632,bioaccessibility,"The bioaccessibility indexes of phenolic compounds in EETg were 48.65 and 69.28% in the presence and absence of enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,69.28,30062,DB00898,Ethanol
,28178632,bioaccessible,"Among the identified phenolics classes, flavonoids, represented by galloylated procyanidins type B, proved to be more bioaccessible, 81.48 and 96.29% in the post-intestinal phase with and without enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,81.48,30063,DB00898,Ethanol
,28178632,bioaccessible,"Among the identified phenolics classes, flavonoids, represented by galloylated procyanidins type B, proved to be more bioaccessible, 81.48 and 96.29% in the post-intestinal phase with and without enzymes, respectively.",Impact of bioaccessibility and bioavailability of phenolic compounds in biological systems upon the antioxidant activity of the ethanolic extract of Triplaris gardneriana seeds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28178632/),%,96.29,30064,DB00898,Ethanol
,3783768,initial half-life for biliary elimination,"For rats with biliary cannulas, 36.6% of the radioactivity of an intravenous dose (4.46 mg/kg) appeared in the bile in 4 h; the initial half-life for biliary elimination was 40 min.","Disposition of 2-hydroxy-4-methoxybenzophenone in rats dosed orally, intravenously, or topically. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783768/),min,40,30573,DB00898,Ethanol
,12166812,UEG,Minimum UEG values of 0.5 mg/L could still be measured.,Excretion profiles of ethyl glucuronide in human urine after internal dilution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12166812/),[mg] / [l],0.5,30608,DB00898,Ethanol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],32.7,30659,DB00898,Ethanol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],42.2,30660,DB00898,Ethanol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],2.8,30661,DB00898,Ethanol
,26019183,maximum blood concentrations (Cmax),"Median (range) maximum blood concentrations (Cmax) for low and high THC doses (no alcohol) were 32.7 (11.4-66.2) and 42.2 (15.2-137) μg/L THC, respectively, and 2.8 (0-9.1) and 5.0 (0-14.2) μg/L 11-OH-THC.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],5.0,30662,DB00898,Ethanol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],35.3,30663,DB00898,Ethanol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],67.5,30664,DB00898,Ethanol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],3.7,30665,DB00898,Ethanol
,26019183,Cmax,"With alcohol, low and high dose Cmax values were 35.3 (13.0-71.4) and 67.5 (18.1-210) μg/L THC and 3.7 (1.4-6.0) and 6.0 (0-23.3) μg/L 11-OH-THC, significantly higher than without alcohol.",Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019183/),[μg] / [l],6.0,30666,DB00898,Ethanol
at,16165405,resolution factor (Rs),(+)-THP and (-)-THP were separated with a resolution factor (Rs) of at least 1.6 and a separation factor (alpha) greater than 1.29.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of tetrahydropalmatine enantiomers in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16165405/),,1.6,30824,DB00898,Ethanol
greater,16165405,separation factor (alpha),(+)-THP and (-)-THP were separated with a resolution factor (Rs) of at least 1.6 and a separation factor (alpha) greater than 1.29.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of tetrahydropalmatine enantiomers in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16165405/),,1,30825,DB00898,Ethanol
,16165405,limit of detection (LOD),Linear calibration curves were obtained over the range of 0.025-4 microg/ml in plasma for each of (+)-THP and (-)-THP (R2>0.999) with a limit of detection (LOD) of 0.005 microg/ml and the recovery was greater than 88% for each enantiomer.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of tetrahydropalmatine enantiomers in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16165405/),[μg] / [ml],0.005,30826,DB00898,Ethanol
greater,16165405,recovery,Linear calibration curves were obtained over the range of 0.025-4 microg/ml in plasma for each of (+)-THP and (-)-THP (R2>0.999) with a limit of detection (LOD) of 0.005 microg/ml and the recovery was greater than 88% for each enantiomer.,Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of tetrahydropalmatine enantiomers in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16165405/),%,88,30827,DB00898,Ethanol
,22116603,extraction efficiency,The extraction efficiency for decursin/DA (quantitated together) and decursinol was between 82-95 % in both mouse plasma and tumor homogenate.,"Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116603/),%,82-95,30983,DB00898,Ethanol
,22116603,Maximum plasma concentrations,"Maximum plasma concentrations for decursin/DA and decursinol were 11.2 and 79.7 µg/mL, respectively, when decursin/DA was administered via intraperitoneal injection, and 0.54 and 14.9 µg/mL via oral gavage.","Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116603/),[μg] / [ml],11.2,30984,DB00898,Ethanol
,22116603,Maximum plasma concentrations,"Maximum plasma concentrations for decursin/DA and decursinol were 11.2 and 79.7 µg/mL, respectively, when decursin/DA was administered via intraperitoneal injection, and 0.54 and 14.9 µg/mL via oral gavage.","Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116603/),[μg] / [ml],79.7,30985,DB00898,Ethanol
,22116603,Maximum plasma concentrations,"Maximum plasma concentrations for decursin/DA and decursinol were 11.2 and 79.7 µg/mL, respectively, when decursin/DA was administered via intraperitoneal injection, and 0.54 and 14.9 µg/mL via oral gavage.","Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116603/),[μg] / [ml],0.54,30986,DB00898,Ethanol
,22116603,Maximum plasma concentrations,"Maximum plasma concentrations for decursin/DA and decursinol were 11.2 and 79.7 µg/mL, respectively, when decursin/DA was administered via intraperitoneal injection, and 0.54 and 14.9 µg/mL via oral gavage.","Quantitative determination of decursin, decursinol angelate, and decursinol in mouse plasma and tumor tissue using liquid-liquid extraction and HPLC. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116603/),[μg] / [ml],14.9,30987,DB00898,Ethanol
,14552814,flow rate,"After extraction of the plasma samples with ethyl acetate, the separation was accomplished by an HPLC system consisting of a Chirex chiral column (250 mm x 4.6 mm i.d.) and a mobile phase of hexane:ethanol:tetrahydrofuran (280:20:40 (v/v)) containing trifluroacetic acid (0.3% (v/v)) and triethylamine (0.018% (v/v)) at a flow rate of 0.8 ml/min with UV detection.","Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of the enantiomers of a novel anticonvulsant, N-(4-chlorophenyl)-1-(4-pyridyl)ethylamine, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552814/),[ml] / [min],0.8,31345,DB00898,Ethanol
at,14552814,"resolution factor, Rs","(+)-AAP-Cl and (-)-AAP-Cl were separated with a resolution factor, Rs, of at least 1.4, and a separation factor, alpha, greater than 1.09.","Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of the enantiomers of a novel anticonvulsant, N-(4-chlorophenyl)-1-(4-pyridyl)ethylamine, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552814/),,1.4,31346,DB00898,Ethanol
greater,14552814,"separation factor, alpha","(+)-AAP-Cl and (-)-AAP-Cl were separated with a resolution factor, Rs, of at least 1.4, and a separation factor, alpha, greater than 1.09.","Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of the enantiomers of a novel anticonvulsant, N-(4-chlorophenyl)-1-(4-pyridyl)ethylamine, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552814/),,1.09,31347,DB00898,Ethanol
,14552814,terminal half-life,"The plasma concentration-time profiles of the enantiomers of AAP-Cl were best described by a two-compartment open model with a mean terminal half-life of about 5h, volume of distribution at steady state of 3 l/kg and clearance of about 0.6l/(hkg) in rats.","Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of the enantiomers of a novel anticonvulsant, N-(4-chlorophenyl)-1-(4-pyridyl)ethylamine, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552814/),h,5,31348,DB00898,Ethanol
,14552814,volume of distribution at steady state,"The plasma concentration-time profiles of the enantiomers of AAP-Cl were best described by a two-compartment open model with a mean terminal half-life of about 5h, volume of distribution at steady state of 3 l/kg and clearance of about 0.6l/(hkg) in rats.","Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of the enantiomers of a novel anticonvulsant, N-(4-chlorophenyl)-1-(4-pyridyl)ethylamine, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552814/),[l] / [kg],3,31349,DB00898,Ethanol
,14552814,clearance,"The plasma concentration-time profiles of the enantiomers of AAP-Cl were best described by a two-compartment open model with a mean terminal half-life of about 5h, volume of distribution at steady state of 3 l/kg and clearance of about 0.6l/(hkg) in rats.","Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of the enantiomers of a novel anticonvulsant, N-(4-chlorophenyl)-1-(4-pyridyl)ethylamine, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14552814/),[l] / [hkg],0.6,31350,DB00898,Ethanol
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·ng] / [ml],320 to 740,33690,DB00898,Ethanol
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·ng] / [ml],331 to 501,33691,DB00898,Ethanol
,12445027,"AUC(0, infinity )","AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole.",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),[h·μg] / [ml],207 to 333,33692,DB00898,Ethanol
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,2.5,33693,DB00898,Ethanol
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,1.9,33694,DB00898,Ethanol
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,3.1,33695,DB00898,Ethanol
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,2.1,33696,DB00898,Ethanol
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,88,33697,DB00898,Ethanol
,12445027,terminal elimination half-life,"The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04).",Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12445027/),h,95,33698,DB00898,Ethanol
,18062845,T(max),Median T(max) values were between 12 and 16 h and ranges were similar for all treatments.,Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062845/),h,12 and 16,34454,DB00898,Ethanol
,8794983,log octanol/water partition coefficient,"The log octanol/water partition coefficient and saturated aqueous solubility of 8-MOP at 32 degrees C were 1-98 and 55.8 micrograms mL-1 respectively, 8-MOP showed Fickian diffusion, with its flux being linearly related to the concentration of drug in the donor solution.",Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794983/),[μg] / [ml],1-98,34604,DB00898,Ethanol
,8794983,permeability coefficient,The permeability coefficient of 8-MOP through human skin from different concentrations of aqueous solutions and a 2.6 micrograms mL-1 bath lotion (as used in clinics) were statistically identical with mean values of 1.76 +/- 0.12 x 10(-2) and 1.70 +/- 0.32 x 10(-2) cm h-1 respectively (P > or = 0.05).,Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794983/),[cm] / [h],1.76,34605,DB00898,Ethanol
,8794983,permeability coefficient,The permeability coefficient of 8-MOP through human skin from different concentrations of aqueous solutions and a 2.6 micrograms mL-1 bath lotion (as used in clinics) were statistically identical with mean values of 1.76 +/- 0.12 x 10(-2) and 1.70 +/- 0.32 x 10(-2) cm h-1 respectively (P > or = 0.05).,Permeation characteristics of 8-methoxypsoralen through human skin; relevance to clinical treatment. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794983/),[cm] / [h],1.70,34606,DB00898,Ethanol
,7681466,initial,"An intravenous bolus of 12.5 micrograms hIGF-I, given to 12-h fasted rats, disappeared from the circulation in a double exponential fashion with an initial t1/2 of 1.2 +/- 0.2 min (n = 8), which increased to 5.3 +/- 0.9 min when 100 micrograms hIGFBP-1 was co-administered (n = 5; P < 0.001).",Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7681466/),min,1.2,34649,DB00898,Ethanol
,7681466,t1/2,"An intravenous bolus of 12.5 micrograms hIGF-I, given to 12-h fasted rats, disappeared from the circulation in a double exponential fashion with an initial t1/2 of 1.2 +/- 0.2 min (n = 8), which increased to 5.3 +/- 0.9 min when 100 micrograms hIGFBP-1 was co-administered (n = 5; P < 0.001).",Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7681466/),min,1.2,34650,DB00898,Ethanol
,7681466,t1/2,"An intravenous bolus of 12.5 micrograms hIGF-I, given to 12-h fasted rats, disappeared from the circulation in a double exponential fashion with an initial t1/2 of 1.2 +/- 0.2 min (n = 8), which increased to 5.3 +/- 0.9 min when 100 micrograms hIGFBP-1 was co-administered (n = 5; P < 0.001).",Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7681466/),min,5.3,34651,DB00898,Ethanol
,7681466,apparent t1/2,The second phase of disappearance of hIGF-I indicated an apparent t1/2 of 35.7 +/- 5.6 min which was not significantly altered by the co-infusion of hIGFBP-1.,Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7681466/),min,35.7,34652,DB00898,Ethanol
,7681466,t1/2,"Circulating hIGFBP-1, measured with a primate-specific radioimmunoassay, disappeared in a single exponential fashion with a t1/2 of 8.8 +/- 0.7 min.",Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7681466/),min,8.8,34653,DB00898,Ethanol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],7.76,35040,DB00898,Ethanol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],11.50,35041,DB00898,Ethanol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],73.0,35042,DB00898,Ethanol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],91.5,35043,DB00898,Ethanol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],101,35044,DB00898,Ethanol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],123,35045,DB00898,Ethanol
more,25759584,Accumulative drug release,Accumulative drug release was more than 56% within 24 hours.,"Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759584/),%,56,35222,DB00898,Ethanol
,33540783,IC50,"The crude extract displayed favorable antioxidant activity against both 2,2-diphenyl-1-picrylhydrazyl (DPPH) (IC50 = 231.6 μg/mL) and H2O2 (IC50 = 288.3 μg/mL) molecules.","Phytochemistry, Bioactivities, Pharmacokinetics and Toxicity Prediction of Selaginella repanda with Its Anticancer Potential against Human Lung, Breast and Colorectal Carcinoma Cell Lines. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540783/),[μg] / [ml],231.6,35528,DB00898,Ethanol
,33540783,IC50,"The crude extract displayed favorable antioxidant activity against both 2,2-diphenyl-1-picrylhydrazyl (DPPH) (IC50 = 231.6 μg/mL) and H2O2 (IC50 = 288.3 μg/mL) molecules.","Phytochemistry, Bioactivities, Pharmacokinetics and Toxicity Prediction of Selaginella repanda with Its Anticancer Potential against Human Lung, Breast and Colorectal Carcinoma Cell Lines. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540783/),[μg] / [ml],288.3,35529,DB00898,Ethanol
,33540783,IC50,"Higher activity was found against lung (A549) (IC50 = 341.1 μg/mL), followed by colon (HCT-116) (IC50 = 378.8 μg/mL) and breast (MCF-7) (IC50 = 428.3 μg/mL) cancer cells.","Phytochemistry, Bioactivities, Pharmacokinetics and Toxicity Prediction of Selaginella repanda with Its Anticancer Potential against Human Lung, Breast and Colorectal Carcinoma Cell Lines. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540783/),[μg] / [ml],341.1,35530,DB00898,Ethanol
,33540783,IC50,"Higher activity was found against lung (A549) (IC50 = 341.1 μg/mL), followed by colon (HCT-116) (IC50 = 378.8 μg/mL) and breast (MCF-7) (IC50 = 428.3 μg/mL) cancer cells.","Phytochemistry, Bioactivities, Pharmacokinetics and Toxicity Prediction of Selaginella repanda with Its Anticancer Potential against Human Lung, Breast and Colorectal Carcinoma Cell Lines. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540783/),[μg] / [ml],378.8,35531,DB00898,Ethanol
,33540783,IC50,"Higher activity was found against lung (A549) (IC50 = 341.1 μg/mL), followed by colon (HCT-116) (IC50 = 378.8 μg/mL) and breast (MCF-7) (IC50 = 428.3 μg/mL) cancer cells.","Phytochemistry, Bioactivities, Pharmacokinetics and Toxicity Prediction of Selaginella repanda with Its Anticancer Potential against Human Lung, Breast and Colorectal Carcinoma Cell Lines. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33540783/),[μg] / [ml],428.3,35532,DB00898,Ethanol
,8104122,KM,"The in vivo metabolic constants for HCFC-141b were: KM = 7.0 mg liter-1 (59.9 mumol liter-1), Vmax = 0.2 mg kg-1 hr-1 (1.71 mumol kg-1 hr-1), and k = 0.5 hr-1.","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),[mg] / [l],7.0,36531,DB00898,Ethanol
,8104122,KM,"The in vivo metabolic constants for HCFC-141b were: KM = 7.0 mg liter-1 (59.9 mumol liter-1), Vmax = 0.2 mg kg-1 hr-1 (1.71 mumol kg-1 hr-1), and k = 0.5 hr-1.","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),[μM] / [l],59.9,36532,DB00898,Ethanol
,8104122,Vmax,"The in vivo metabolic constants for HCFC-141b were: KM = 7.0 mg liter-1 (59.9 mumol liter-1), Vmax = 0.2 mg kg-1 hr-1 (1.71 mumol kg-1 hr-1), and k = 0.5 hr-1.","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),[mg] / [h·kg],0.2,36533,DB00898,Ethanol
,8104122,Vmax,"The in vivo metabolic constants for HCFC-141b were: KM = 7.0 mg liter-1 (59.9 mumol liter-1), Vmax = 0.2 mg kg-1 hr-1 (1.71 mumol kg-1 hr-1), and k = 0.5 hr-1.","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),[μM] / [h·kg],1.71,36534,DB00898,Ethanol
,8104122,k,"The in vivo metabolic constants for HCFC-141b were: KM = 7.0 mg liter-1 (59.9 mumol liter-1), Vmax = 0.2 mg kg-1 hr-1 (1.71 mumol kg-1 hr-1), and k = 0.5 hr-1.","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),1/[h],0.5,36535,DB00898,Ethanol
,8104122,KM,"The in vitro metabolic rate constants for the biotransformation of HCFC-141b to 2,2-dichloro-2-fluoroethanol were: KM = 0.39 +/- 0.11 mM and Vmax = 2.08 +/- 0.23 nmol mg protein-1 hr-1.(ABSTRACT TRUNCATED AT 250 WORDS)","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),mM,0.39,36536,DB00898,Ethanol
,8104122,Vmax,"The in vitro metabolic rate constants for the biotransformation of HCFC-141b to 2,2-dichloro-2-fluoroethanol were: KM = 0.39 +/- 0.11 mM and Vmax = 2.08 +/- 0.23 nmol mg protein-1 hr-1.(ABSTRACT TRUNCATED AT 250 WORDS)","Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104122/),[-1·mg·nM] / [h],2.08,36537,DB00898,Ethanol
,9692688,first pass metabolism,"Following food, and with ethanol taken in the form of beer, mean first pass metabolism of ethanol was 58% (range 34-78%).","Omeprazole, ranitidine, and cimetidine have no effect on peak blood ethanol concentrations, first pass metabolism or area under the time-ethanol curve under 'real-life' drinking conditions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692688/),%,58,37226,DB00898,Ethanol
,11005677,C0 concentrations,"Taking into account the endogenous blood methanol levels detectable before the administration of methanol, C0 concentrations of 11.1-15.9 mg/kg were reached.",Invasion and distribution of methanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11005677/),[mg] / [kg],11.1-15.9,37241,DB00898,Ethanol
,11005677,distribution volume,"This corresponds to a distribution volume of approximately 0.77 +/- 0.07 l/kg, which is comparable to the 0.78 +/- 0.09 l/kg obtained for ethanol.",Invasion and distribution of methanol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11005677/),[l] / [kg],0.77,37242,DB00898,Ethanol
,11005677,distribution volume,"This corresponds to a distribution volume of approximately 0.77 +/- 0.07 l/kg, which is comparable to the 0.78 +/- 0.09 l/kg obtained for ethanol.",Invasion and distribution of methanol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11005677/),[l] / [kg],0.78,37243,DB00898,Ethanol
,11005677,distribution half-life,"After parenterally administering methanol as a bolus, the distribution half-life was on average 8 min (range: 3.8-13.8 min).",Invasion and distribution of methanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11005677/),min,8,37244,DB00898,Ethanol
,11005677,half-life,"After oral administration of methanol diluted in 100 ml water on an empty stomach, invasion took place with a half-life of approximately 5 min (3.8-6.9 min).",Invasion and distribution of methanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11005677/),min,5,37245,DB00898,Ethanol
,11005677,invasion half-life,"In one case, however, due to vegetative disturbances the invasion half-life was 23.1 min.",Invasion and distribution of methanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11005677/),min,23.1,37246,DB00898,Ethanol
,24985105,total bioaccessibility,TNO intestinal model-1 experiments confirmed higher total bioaccessibility of DMC-2 in vitro when delivered in 5011-Nutrasorb (50.2%) or Gelucire-5011 (44.4%) compared with PMI-5011 (27.1%; P = 0.08).,Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985105/),%,50.2,37313,DB00898,Ethanol
,24985105,total bioaccessibility,TNO intestinal model-1 experiments confirmed higher total bioaccessibility of DMC-2 in vitro when delivered in 5011-Nutrasorb (50.2%) or Gelucire-5011 (44.4%) compared with PMI-5011 (27.1%; P = 0.08).,Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985105/),%,44.4,37314,DB00898,Ethanol
,24985105,total bioaccessibility,TNO intestinal model-1 experiments confirmed higher total bioaccessibility of DMC-2 in vitro when delivered in 5011-Nutrasorb (50.2%) or Gelucire-5011 (44.4%) compared with PMI-5011 (27.1%; P = 0.08).,Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985105/),%,27.1,37315,DB00898,Ethanol
,4079588,K alpha AAC,"The average first order absorption rate constant (K alpha) and pseudo-zero-order elimination rate constant (beta) for ten trials in a single subject were: K alpha AAC = 1.60 h-1 and 1.39 h-1, beta AAC = 0.154 g/l/h and 0.192 g/l/h.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),1/[h],1.60,37398,DB00898,Ethanol
,4079588,K alpha AAC,"The average first order absorption rate constant (K alpha) and pseudo-zero-order elimination rate constant (beta) for ten trials in a single subject were: K alpha AAC = 1.60 h-1 and 1.39 h-1, beta AAC = 0.154 g/l/h and 0.192 g/l/h.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),1/[h],1.39,37399,DB00898,Ethanol
,4079588,beta AAC,"The average first order absorption rate constant (K alpha) and pseudo-zero-order elimination rate constant (beta) for ten trials in a single subject were: K alpha AAC = 1.60 h-1 and 1.39 h-1, beta AAC = 0.154 g/l/h and 0.192 g/l/h.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),[g] / [h·l],0.154,37400,DB00898,Ethanol
,4079588,beta AAC,"The average first order absorption rate constant (K alpha) and pseudo-zero-order elimination rate constant (beta) for ten trials in a single subject were: K alpha AAC = 1.60 h-1 and 1.39 h-1, beta AAC = 0.154 g/l/h and 0.192 g/l/h.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),[g] / [h·l],0.192,37401,DB00898,Ethanol
,4079588,K alpha PAC,"K alpha PAC = 1.27 h-1 and 1.11 h-1, beta PAC = 0.109 g/l/h and 0.141 g/l/h for 0.5 g/kg and 0.75 g/kg ETOH, respectively.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),1/[h],1.27,37402,DB00898,Ethanol
,4079588,K alpha PAC,"K alpha PAC = 1.27 h-1 and 1.11 h-1, beta PAC = 0.109 g/l/h and 0.141 g/l/h for 0.5 g/kg and 0.75 g/kg ETOH, respectively.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),1/[h],1.11,37403,DB00898,Ethanol
,4079588,beta PAC,"K alpha PAC = 1.27 h-1 and 1.11 h-1, beta PAC = 0.109 g/l/h and 0.141 g/l/h for 0.5 g/kg and 0.75 g/kg ETOH, respectively.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),[g] / [h·l],0.109,37404,DB00898,Ethanol
,4079588,beta PAC,"K alpha PAC = 1.27 h-1 and 1.11 h-1, beta PAC = 0.109 g/l/h and 0.141 g/l/h for 0.5 g/kg and 0.75 g/kg ETOH, respectively.",The pharmacokinetics of alcohol excretion in human perspiration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4079588/),[g] / [h·l],0.141,37405,DB00898,Ethanol
,7288618,total systemic clearance,"Acute infusions of ethanol, 1.5 ml/kg/hr from -3 to 0 hr and 0.5 ml/kg/hr from 0 to +3 hr into the portal circulation, increased the total systemic clearance of propoxyphene from 64 to 95 ml/min/kg on the average (P less than .02), probably due to increased hepatic blood perfusion rate.",Acute effect of ethanol on hepatic first-pass elimination of propoxyphene in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7288618/),[ml] / [kg·min],64,37967,DB00898,Ethanol
,7288618,systemic availability,The same rate and route of ethanol administration caused an increase in the average systemic availability of propoxyphene from 28 to 56% (P less than .001) after injection of 8 mg/kg into the portal circulation.,Acute effect of ethanol on hepatic first-pass elimination of propoxyphene in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7288618/),,56,37968,DB00898,Ethanol
,7531285,Cmax,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[mg] / [ml],1.39,38345,DB00898,Ethanol
,7531285,Cmax,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[mg] / [ml],2.84,38346,DB00898,Ethanol
,7531285,Cmax,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[mg] / [ml],3.15,38347,DB00898,Ethanol
,7531285,Cmax,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[mg] / [ml],3.69,38348,DB00898,Ethanol
,7531285,Cmax,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[mg] / [ml],4.13,38349,DB00898,Ethanol
,7531285,Cmax,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[mg] / [ml],4.76,38350,DB00898,Ethanol
,7531285,AUCs,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[h·mg] / [ml],1.37,38351,DB00898,Ethanol
,7531285,AUCs,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[h·mg] / [ml],4.84,38352,DB00898,Ethanol
,7531285,AUCs,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[h·mg] / [ml],5.88,38353,DB00898,Ethanol
,7531285,AUCs,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[h·mg] / [ml],7.28,38354,DB00898,Ethanol
,7531285,AUCs,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[h·mg] / [ml],10.76,38355,DB00898,Ethanol
,7531285,AUCs,"The observed Cmax of ethanol at doses of 1250, 2000, 2250, 2500, 3000 and 3500 mg/kg were 1.39, 2.84, 3.15, 3.69, 4.13 and 4.76 mg/ml, with AUCs of 1.37, 4.84, 5.88, 7.28, 10.76 and 13.51 mg.h/ml, respectively.",A pharmacokinetic study of ethanol inhibition of micronuclei induction by urethane in mouse bone marrow erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531285/),[h·mg] / [ml],13.51,38356,DB00898,Ethanol
,10923995,FPM,Analysis of the IV and IG ethanol curves revealed a FPM of 94+/-11 mg/kg (31% of dose).,Contribution of gastric oxidation to ethanol first-pass metabolism in baboons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923995/),[mg] / [kg],94,39042,DB00898,Ethanol
>,22209996,solubility,Optimized microemulsion formulations with a mean diameter of 120-154 nm achieved enhanced solubility of udenafil (>10mg/ml) compared with its aqueous solubility (0.02 mg/ml).,Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),[mg] / [ml],10,39961,DB00898,Ethanol
,22209996,solubility,Optimized microemulsion formulations with a mean diameter of 120-154 nm achieved enhanced solubility of udenafil (>10mg/ml) compared with its aqueous solubility (0.02 mg/ml).,Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),[mg] / [ml],0.02,39962,DB00898,Ethanol
,22209996,T(max),"According to the results of an in vivo pharmacokinetic study in rats, intranasal administration of udenafil-loaded microemulsion had a shorter T(max) value (1 min) compared with oral administration and improved bioavailability (85.71%) compared with oral and intranasal (solution) administration.",Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),min,1,39963,DB00898,Ethanol
,22209996,bioavailability,"According to the results of an in vivo pharmacokinetic study in rats, intranasal administration of udenafil-loaded microemulsion had a shorter T(max) value (1 min) compared with oral administration and improved bioavailability (85.71%) compared with oral and intranasal (solution) administration.",Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),%,85.71,39964,DB00898,Ethanol
,1127587,T 1/2,"All semilogarithmic intravenous curves exhibited an irregular decay behavior in the first 3-hr period, followed by a linear disappearance phase (T 1/2 equals 1.0-2.4 hr).",Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127587/),h,1.0-2.4,40040,DB00898,Ethanol
,1127587,elimination half-life,"Oral studies also yielded a short elimination half-life (1.0-1.60 hr), which was confirmed by urinary excretion measurements.",Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1127587/),h,1.0-1.60,40041,DB00898,Ethanol
,25011261,Zeta potential,"The results showed that the mean diameter of Cur-LCL was 110 nm, the Zeta potential was -5.8 mV.",[Preparation of curcumin-loaded long-circulating liposomes and its pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25011261/),m,5.8,40471,DB00898,Ethanol
,25011261,entrapment efficiency,"The entrapment efficiency and drug loading of Cur-LCL was 80.25%, 2.06%, respectively.",[Preparation of curcumin-loaded long-circulating liposomes and its pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25011261/),%,80.25,40472,DB00898,Ethanol
,25011261,drug loading,"The entrapment efficiency and drug loading of Cur-LCL was 80.25%, 2.06%, respectively.",[Preparation of curcumin-loaded long-circulating liposomes and its pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25011261/),%,2.06,40473,DB00898,Ethanol
,25011261,t(1/2beta),"The pharmacokinetic parameters showed that compared with Cur and Cur-Lips, the t(1/2beta) of Cur-LCL was extended to 13 and 1.8-fold, respectively.",[Preparation of curcumin-loaded long-circulating liposomes and its pharmacokinetics in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25011261/),,13,40474,DB00898,Ethanol
,28591773,half-life,EtG disappeared from nails after ~2 months of abstinence and the median calculated EtG half-life in nail clippings was 13.3 days (range: 5.5-29.0).,Ethyl Glucuronide Elimination Kinetics in Fingernails and Comparison to Levels in Hair. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28591773/),d,13.3,40483,DB00898,Ethanol
,25943177,clearance rate,"Alcohol elimination in this patient followed zero-order kinetics with a clearance rate of 22.5 mg/kg/h, consistent with the limited pharmacokinetic information available for children who experience alcohol intoxication from more traditional sources.",Acute alcohol intoxication in a child following ingestion of an ethyl-alcohol-based hand sanitizer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943177/),[mg] / [h·kg],22.5,40576,DB00898,Ethanol
,3005541,clearance,The results showed that the clearance of alcohol was 0.0226 l/min/kg and the elimination rate constant of acetaldehyde from the liver compartment was very large and 35 min-1.,"Effects of diethyldithiocarbamate, a metabolite of disulfiram, on the pharmacokinetics of alcohol and acetaldehyde in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3005541/),[l] / [kg·min],0.0226,41252,DB00898,Ethanol
,3005541,elimination rate constant,The results showed that the clearance of alcohol was 0.0226 l/min/kg and the elimination rate constant of acetaldehyde from the liver compartment was very large and 35 min-1.,"Effects of diethyldithiocarbamate, a metabolite of disulfiram, on the pharmacokinetics of alcohol and acetaldehyde in the rat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3005541/),1/[min],35,41253,DB00898,Ethanol
,10993514,C.V.s,"Intra- and inter-day C.V.s did not exceed 15% for all concentrations except at 12.5 ng/ml for EII (+)-cisapride, which was approximately 20 and 19%, respectively.","Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993514/),[ng] / [ml],12.5,41954,DB00898,Ethanol
,10993514,C.V.s,"Intra- and inter-day C.V.s did not exceed 15% for all concentrations except at 12.5 ng/ml for EII (+)-cisapride, which was approximately 20 and 19%, respectively.","Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993514/),%,20,41955,DB00898,Ethanol
,10993514,C.V.s,"Intra- and inter-day C.V.s did not exceed 15% for all concentrations except at 12.5 ng/ml for EII (+)-cisapride, which was approximately 20 and 19%, respectively.","Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993514/),%,19,41956,DB00898,Ethanol
,33550391,clearance,"Typical population estimates for clearance, absorption rate constant, central volume, peripheral volume and mean absorption transit time were 0.713 L/h, 1.68 h-1, 13.2 L, 5.73 L and 1.18 h, respectively.",Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33550391/),[l] / [h],0.713,42067,DB00898,Ethanol
,33550391,IC90,Simulations showed that simulated trough concentrations of dolutegravir alone or in combination with artemether/lumefantrine or artesunate/amodiaquine are maintained above the dolutegravir protein-adjusted IC90 of 0.064 mg/L for more than 99% of the individuals.,Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33550391/),[mg] / [l],0.064,42068,DB00898,Ethanol
,27830982,elimination half-life,Pharmacokinetic parameters showed that 131I-SA had fast blood clearance with an elimination half-life of 6.7 h.,Excretion and toxicity evaluation of 131I-Sennoside A as a necrosis-avid agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27830982/),h,6.7,42081,DB00898,Ethanol
,20545189,drop size,The mean drop size of the system was 30.,[Self-microemulsifying drug delivery system of patchoulic alcohol to improve oral bioavailability in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545189/),,30,42187,DB00898,Ethanol
,20545189,self-microemulsifying time,The average self-microemulsifying time was 142 s.,[Self-microemulsifying drug delivery system of patchoulic alcohol to improve oral bioavailability in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545189/),s,142,42188,DB00898,Ethanol
,20545189,AUCs,"Patchoulic alcohol SMEDDS and patchoulic oil SMEDDS showed no signficant difference in Tmax compared with patchoulic alcohol with around 60 minutes, while the AUCs of both SMEDDSs (2001 745.6 +/- 329 663.6) and (1594 005.6 +/- 280 150.3) microg x min x L(-1) were significantly higher than that of patchoulic alcohol (1 163 153.3 +/- 232 324.3) microg x min x L(-1).",[Self-microemulsifying drug delivery system of patchoulic alcohol to improve oral bioavailability in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545189/),[min·μg] / [l],2001 745.6,42189,DB00898,Ethanol
,20545189,AUCs,"Patchoulic alcohol SMEDDS and patchoulic oil SMEDDS showed no signficant difference in Tmax compared with patchoulic alcohol with around 60 minutes, while the AUCs of both SMEDDSs (2001 745.6 +/- 329 663.6) and (1594 005.6 +/- 280 150.3) microg x min x L(-1) were significantly higher than that of patchoulic alcohol (1 163 153.3 +/- 232 324.3) microg x min x L(-1).",[Self-microemulsifying drug delivery system of patchoulic alcohol to improve oral bioavailability in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545189/),[min·μg] / [l],(,42190,DB00898,Ethanol
,20545189,AUCs,"Patchoulic alcohol SMEDDS and patchoulic oil SMEDDS showed no signficant difference in Tmax compared with patchoulic alcohol with around 60 minutes, while the AUCs of both SMEDDSs (2001 745.6 +/- 329 663.6) and (1594 005.6 +/- 280 150.3) microg x min x L(-1) were significantly higher than that of patchoulic alcohol (1 163 153.3 +/- 232 324.3) microg x min x L(-1).",[Self-microemulsifying drug delivery system of patchoulic alcohol to improve oral bioavailability in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545189/),[min·μg] / [l],1594 005.6,42191,DB00898,Ethanol
,20545189,AUCs,"Patchoulic alcohol SMEDDS and patchoulic oil SMEDDS showed no signficant difference in Tmax compared with patchoulic alcohol with around 60 minutes, while the AUCs of both SMEDDSs (2001 745.6 +/- 329 663.6) and (1594 005.6 +/- 280 150.3) microg x min x L(-1) were significantly higher than that of patchoulic alcohol (1 163 153.3 +/- 232 324.3) microg x min x L(-1).",[Self-microemulsifying drug delivery system of patchoulic alcohol to improve oral bioavailability in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545189/),[min·μg] / [l],1 163 153.3,42192,DB00898,Ethanol
,26257143,peak breath alcohol concentration [BrAC],"Healthy adult occasional-to-moderate cannabis smokers received a vaporized placebo or active cannabis (2.9% and 6.7% Δ(9) -tetrahydrocannabinol, THC) with or without oral low-dose alcohol (~0.065g/210L peak breath alcohol concentration [BrAC]) in a within-subjects design.","Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26257143/),,0.065,42234,DB00898,Ethanol
,21247718,recovery,Average recovery for both unconjugated and total S-equol was 85% with no observable matrix effects.,Development of chiral liquid chromatography-tandem mass spectrometry isotope dilution methods for the determination of unconjugated and total S-equol in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21247718/),%,85,42420,DB00898,Ethanol
,18520070,solubility,It had the piroxicam solubility of about 1.87 mg/ml and the amount of ethanol of about 4.37 microg/mg.,Preparation and in vivo evaluation of piroxicam-loaded gelatin microcapsule by spray drying technique. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520070/),[mg] / [ml],1.87,42891,DB00898,Ethanol
,25906774,AUC0-inf;,"Upon post hoc simulation of lumefantrine exposure, patients in the EFV-arm had lower exposure (median (IQR)) compared to that in the control-arm; AUC0-inf; was 303,130 (211,080-431,962) versus 784,830 (547,405-1,116,250); day-7 lumefantrine plasma concentrations was: 335.5 (215.8-519.5) versus 858.7 (562.3-1,333.8), respectively.",The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25906774/),,"303,130",43038,DB00898,Ethanol
,25906774,AUC0-inf;,"Upon post hoc simulation of lumefantrine exposure, patients in the EFV-arm had lower exposure (median (IQR)) compared to that in the control-arm; AUC0-inf; was 303,130 (211,080-431,962) versus 784,830 (547,405-1,116,250); day-7 lumefantrine plasma concentrations was: 335.5 (215.8-519.5) versus 858.7 (562.3-1,333.8), respectively.",The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25906774/),,"784,830",43039,DB00898,Ethanol
,25906774,plasma concentrations,"Upon post hoc simulation of lumefantrine exposure, patients in the EFV-arm had lower exposure (median (IQR)) compared to that in the control-arm; AUC0-inf; was 303,130 (211,080-431,962) versus 784,830 (547,405-1,116,250); day-7 lumefantrine plasma concentrations was: 335.5 (215.8-519.5) versus 858.7 (562.3-1,333.8), respectively.",The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25906774/),,335.5,43040,DB00898,Ethanol
,25906774,plasma concentrations,"Upon post hoc simulation of lumefantrine exposure, patients in the EFV-arm had lower exposure (median (IQR)) compared to that in the control-arm; AUC0-inf; was 303,130 (211,080-431,962) versus 784,830 (547,405-1,116,250); day-7 lumefantrine plasma concentrations was: 335.5 (215.8-519.5) versus 858.7 (562.3-1,333.8), respectively.",The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25906774/),,858.7,43041,DB00898,Ethanol
,16188728,overall drug targeting efficiency,"Moreover, the overall drug targeting efficiency of liver was enhanced from 3.66% to 6.10%.",An investigation on liver-targeting microemulsions of norcantharidin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16188728/),%,3.66,43133,DB00898,Ethanol
,16188728,overall drug targeting efficiency,"Moreover, the overall drug targeting efficiency of liver was enhanced from 3.66% to 6.10%.",An investigation on liver-targeting microemulsions of norcantharidin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16188728/),%,6.10,43134,DB00898,Ethanol
,31549442,AUC0-∞ ratio,"On the contrary, artemether-to-dihydroartemisinin AUC0-∞ ratio was 73% significantly higher (1.73 [1.27-2.37]).",CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31549442/),,1.73,43200,DB00898,Ethanol
,23246847,K(i),"LF-3-88 (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol) was identified as a highly selective α4β2-nAChRs partial agonist, with a K(i) value of 0.4nM and EC(50) value of 110nM.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),nM,0.4,43884,DB00898,Ethanol
,23246847,EC(50),"LF-3-88 (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol) was identified as a highly selective α4β2-nAChRs partial agonist, with a K(i) value of 0.4nM and EC(50) value of 110nM.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),nM,110,43885,DB00898,Ethanol
greater,23246847,recovery,"Protein precipitation with acetonitrile was used to prepare the plasma and brain samples, and the recovery was greater than 90%.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),%,90,43886,DB00898,Ethanol
,23246847,limit of detection,"The limit of detection and limit of quantitation were 0.5ng/mL (1.8nM) and 1ng/mL (3.6nM), respectively.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),[ng] / [ml],0.5,43887,DB00898,Ethanol
,23246847,limit of quantitation,"The limit of detection and limit of quantitation were 0.5ng/mL (1.8nM) and 1ng/mL (3.6nM), respectively.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),nM,1.8,43888,DB00898,Ethanol
,23246847,limit of quantitation,"The limit of detection and limit of quantitation were 0.5ng/mL (1.8nM) and 1ng/mL (3.6nM), respectively.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),[ng] / [ml],1,43889,DB00898,Ethanol
,23246847,limit of quantitation,"The limit of detection and limit of quantitation were 0.5ng/mL (1.8nM) and 1ng/mL (3.6nM), respectively.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),nM,3.6,43890,DB00898,Ethanol
,23246847,half-lives,"Plasma concentrations of LF-3-88 and brain levels were dose-dependent with half-lives of approximately 60min and 180min, respectively, indicating good oral bioavailability and penetration of the blood-brain barrier.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),min,60,43891,DB00898,Ethanol
,23246847,half-lives,"Plasma concentrations of LF-3-88 and brain levels were dose-dependent with half-lives of approximately 60min and 180min, respectively, indicating good oral bioavailability and penetration of the blood-brain barrier.","Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23246847/),min,180,43892,DB00898,Ethanol
,4009442,lag times,The lag times ranged from 2.5 to 23 min for preparation I and from 2.2 to 29 min for preparation II.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,2.5 to 23,44114,DB00898,Ethanol
,4009442,lag times,The lag times ranged from 2.5 to 23 min for preparation I and from 2.2 to 29 min for preparation II.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,2.2 to 29,44115,DB00898,Ethanol
,4009442,peak plasma concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),[μg] / [ml],12.38,44116,DB00898,Ethanol
,4009442,peak plasma concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),[μg] / [ml],9.14,44117,DB00898,Ethanol
,4009442,time-to-peak concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,26.57,44118,DB00898,Ethanol
,4009442,time-to-peak concentrations,The mean peak plasma concentrations (12.38 micrograms/mL for preparation I and 9.14 micrograms/mL for preparation II) and the mean time-to-peak concentrations (26.57 min for preparation I and 36.57 min for preparation II) were significantly different.,Impact of dilution on the pharmacokinetic behavior of acetaminophen in rabbits after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4009442/),min,36.57,44119,DB00898,Ethanol
,2818507,specific clearance,The n-propanol-specific clearance is approximately 10 ml/min.,[Reference values of n-propanol elimination]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818507/),[ml] / [min],10,44859,DB00898,Ethanol
,2818507,max. velocity of metabolizing,It is determined by a Michaelis-Menten-metabolism (max. velocity of metabolizing: approximately 2.5 mg/l min; Michaelis-Menten-constant: approximately 10 mg/l) and is inhibited in the presence of ethanol.,[Reference values of n-propanol elimination]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818507/),[mg] / [l·min],2.5,44860,DB00898,Ethanol
,2818507,Michaelis-Menten-constant,It is determined by a Michaelis-Menten-metabolism (max. velocity of metabolizing: approximately 2.5 mg/l min; Michaelis-Menten-constant: approximately 10 mg/l) and is inhibited in the presence of ethanol.,[Reference values of n-propanol elimination]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2818507/),[mg] / [l],10,44861,DB00898,Ethanol
,11092587,recoveries,The recoveries were around 90% for both T and ODT.,Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11092587/),%,90,46275,DB00898,Ethanol
,18655841,AUC(0-12),"Mean FEV(1) AUC(0-12) following FFIS treatment ranged from 1.3 to 3.0l/h in a dose-related manner, with equivalent values (2.3l/h) for FFIS 20microg and FA.",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),[l] / [h],1.3 to 3.0,46456,DB00898,Ethanol
,18655841,AUC(0-12),"Mean FEV(1) AUC(0-12) following FFIS treatment ranged from 1.3 to 3.0l/h in a dose-related manner, with equivalent values (2.3l/h) for FFIS 20microg and FA.",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),[l] / [h],2.3,46457,DB00898,Ethanol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),min,3.9,46458,DB00898,Ethanol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),min,2.2,46459,DB00898,Ethanol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),%,15,46460,DB00898,Ethanol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),%,12,46461,DB00898,Ethanol
,18655841,T(max),FFIS 244mug was rapidly absorbed with a T(max) of 12min and t(1/2) of 6.1h.,Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),min,12,46462,DB00898,Ethanol
,18655841,t(1/2),FFIS 244mug was rapidly absorbed with a T(max) of 12min and t(1/2) of 6.1h.,Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),h,6.1,46463,DB00898,Ethanol
,1036940,half-life,"DFV is hydrolysed in the skin of rats and guinea pigs with a half-life of about 30-60 min to diflucortolone 6alpha,9-difluoro-11bets,21-dihydroxy-16alpha-methyl-1,4-pregnadiene-3,20-dione) and valeric acid.","[Biotransformation of diflucortolone valerate in the skin of rat, guinea pig and man (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1036940/),min,30-60,47125,DB00898,Ethanol
,6618437,peak blood ethanol,"Mean peak blood ethanol values were significantly higher in females (88 +/- 3 mg per 100 ml) than in males (75 +/- 4 mg per 100 ml) (p less than 0.05), and the mean area under the ethanol concentration-time curve was significantly greater in females (241 +/- 12 mg X hr per 100 ml) than in males (177 +/- 11 mg X hr per 100 ml) (p less than 0.001).",Ethanol elimination in males and females: relationship to menstrual cycle and body composition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6618437/),[mg] / [100·ml],88,47391,DB00898,Ethanol
,6618437,peak blood ethanol,"Mean peak blood ethanol values were significantly higher in females (88 +/- 3 mg per 100 ml) than in males (75 +/- 4 mg per 100 ml) (p less than 0.05), and the mean area under the ethanol concentration-time curve was significantly greater in females (241 +/- 12 mg X hr per 100 ml) than in males (177 +/- 11 mg X hr per 100 ml) (p less than 0.001).",Ethanol elimination in males and females: relationship to menstrual cycle and body composition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6618437/),[mg] / [100·ml],75,47392,DB00898,Ethanol
,6618437,area under the ethanol concentration-time curve,"Mean peak blood ethanol values were significantly higher in females (88 +/- 3 mg per 100 ml) than in males (75 +/- 4 mg per 100 ml) (p less than 0.05), and the mean area under the ethanol concentration-time curve was significantly greater in females (241 +/- 12 mg X hr per 100 ml) than in males (177 +/- 11 mg X hr per 100 ml) (p less than 0.001).",Ethanol elimination in males and females: relationship to menstrual cycle and body composition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6618437/),[h·mg] / [100·ml],241,47393,DB00898,Ethanol
,6618437,area under the ethanol concentration-time curve,"Mean peak blood ethanol values were significantly higher in females (88 +/- 3 mg per 100 ml) than in males (75 +/- 4 mg per 100 ml) (p less than 0.05), and the mean area under the ethanol concentration-time curve was significantly greater in females (241 +/- 12 mg X hr per 100 ml) than in males (177 +/- 11 mg X hr per 100 ml) (p less than 0.001).",Ethanol elimination in males and females: relationship to menstrual cycle and body composition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6618437/),[h·mg] / [100·ml],177,47394,DB00898,Ethanol
,6618437,apparent volume of distribution,The mean apparent volume of distribution of ethanol in female (0.59 +/- 0.02 liter per kg) was less than in males (0.73 +/- 0.02 liter per kg) (p less than 0.001).,Ethanol elimination in males and females: relationship to menstrual cycle and body composition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6618437/),[l] / [kg],0.59,47395,DB00898,Ethanol
,6618437,apparent volume of distribution,The mean apparent volume of distribution of ethanol in female (0.59 +/- 0.02 liter per kg) was less than in males (0.73 +/- 0.02 liter per kg) (p less than 0.001).,Ethanol elimination in males and females: relationship to menstrual cycle and body composition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6618437/),[l] / [kg],0.73,47396,DB00898,Ethanol
,27701038,flow rate,"Chromatographic separation of the three analytes and N-(4-ethoxyphenyl)retinamide (4-EPR), an internal standard, was achieved on a Zorbax SB-C18 column (3.5μm, 50×2.1mm) using gradient elution with the mobile phase of 0.1% formic acid in water and acetonitrile (pH* 2.4) at a flow rate of 0.5mL/min.",Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27701038/),[ml] / [min],0.5,47590,DB00898,Ethanol
higher,27701038,extraction recoveries,The extraction recoveries were found to be higher than 90.39% and no matrix effect was observed.,Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27701038/),%,90.39,47591,DB00898,Ethanol
,19655405,area under the curve between 0-12 hours (AUC(0-12)),"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[min·ng] / [ml],102490.7,47595,DB00898,Ethanol
,19655405,area under the curve between 0-12 hours (AUC(0-12)),"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[min·ng] / [ml],49933.3,47596,DB00898,Ethanol
,19655405,Cmax,"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[ng] / [ml],1102.0,47597,DB00898,Ethanol
,19655405,Cmax,"In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05).",Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655405/),[ng] / [ml],274.3,47598,DB00898,Ethanol
,3824418,half-life,"The half-life of FG in serum was 10.8 +/- 0.7 h in the EG-only treatment group, 6.8 +/- 0.7 (P less than 0.05) in the EG + ethanol group and 9.8 +/- 0.9 h in the EG + 4MP group.",Comparison of the effects of ethanol and 4-methylpyrazole on the pharmacokinetics and toxicity of ethylene glycol in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824418/),h,10.8,47903,DB00898,Ethanol
,3824418,half-life,"The half-life of FG in serum was 10.8 +/- 0.7 h in the EG-only treatment group, 6.8 +/- 0.7 (P less than 0.05) in the EG + ethanol group and 9.8 +/- 0.9 h in the EG + 4MP group.",Comparison of the effects of ethanol and 4-methylpyrazole on the pharmacokinetics and toxicity of ethylene glycol in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824418/),h,6.8,47904,DB00898,Ethanol
,3824418,half-life,"The half-life of FG in serum was 10.8 +/- 0.7 h in the EG-only treatment group, 6.8 +/- 0.7 (P less than 0.05) in the EG + ethanol group and 9.8 +/- 0.9 h in the EG + 4MP group.",Comparison of the effects of ethanol and 4-methylpyrazole on the pharmacokinetics and toxicity of ethylene glycol in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3824418/),h,9.8,47905,DB00898,Ethanol
,33483021,zeta potential,"nm, with zeta potential and polydispersity index of 32.1 ± 0.57 mV and 0.173 ± 0.06, respectively.",Biodegradable nanoparticles from prosopisylated cellulose as a platform for enhanced oral bioavailability of poorly water-soluble drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33483021/),mv,32.1,47911,DB00898,Ethanol
,33483021,polydispersity index,"nm, with zeta potential and polydispersity index of 32.1 ± 0.57 mV and 0.173 ± 0.06, respectively.",Biodegradable nanoparticles from prosopisylated cellulose as a platform for enhanced oral bioavailability of poorly water-soluble drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33483021/),,0.173,47912,DB00898,Ethanol
,21463340,half-lives for clearance,Peak ethanol levels from the 3 doses of ethanol in the SCN occurred within 20 to 40 minutes postinjection with half-lives for clearance ranging from 0.6 to 1.8 hours.,Acute ethanol disrupts photic and serotonergic circadian clock phase-resetting in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21463340/),h,0.6 to 1.8,49039,DB00898,Ethanol
,24368338,recoveries,Enantiomer recoveries yielded 100.0 ± 15%.,HPLC method with solid-phase extraction for determination of (R)- and (S)-ketoprofen in plasma without caffeine interference: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368338/),%,100.0,49544,DB00898,Ethanol
,26660672,IC50,"The IC50 value of RM-133 was 0.8 μM and 0.3 μM for OVCAR-3 and PANC-1 cell lines in culture, respectively.",The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660672/),μM,0.8,51376,DB00898,Ethanol
,26660672,IC50,"The IC50 value of RM-133 was 0.8 μM and 0.3 μM for OVCAR-3 and PANC-1 cell lines in culture, respectively.",The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660672/),μM,0.3,51377,DB00898,Ethanol
,12180532,mass,The mass median aerodynamic diameter of the aerosol was 2.9 +/- 0.1 microm with a geometric standard deviation of 1.3 +/- 0.1 (n = 15).,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),μm,2.9,51570,DB00898,Ethanol
,12180532,aerodynamic diameter,The mass median aerodynamic diameter of the aerosol was 2.9 +/- 0.1 microm with a geometric standard deviation of 1.3 +/- 0.1 (n = 15).,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),μm,2.9,51571,DB00898,Ethanol
,12180532,Tmax,Tmax (mean +/- SD) after inhalation ranged from 0.9 +/- 0.6 to 11.5 +/- 2.5.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),,0.9,51572,DB00898,Ethanol
,12180532,Tmax,Tmax (mean +/- SD) after inhalation ranged from 0.9 +/- 0.6 to 11.5 +/- 2.5.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),,11.5,51573,DB00898,Ethanol
,12180532,absolute pulmonary bioavailibility,The mean absolute pulmonary bioavailibility (as A-86929) based on emitted dose ranged from 81.9% to 107.4%.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),%,81.9,51574,DB00898,Ethanol
,12180532,absolute pulmonary bioavailibility,The mean absolute pulmonary bioavailibility (as A-86929) based on emitted dose ranged from 81.9% to 107.4%.,"Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12180532/),%,107.4,51575,DB00898,Ethanol
,12520172,Flow rate,Flow rate was 1.5 ml/min and UV detection was carried out at 275 nm.,Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520172/),[ml] / [min],1.5,51708,DB00898,Ethanol
,9638309,absolute bioavailability (F),"The extent of the absolute bioavailability (F) of tramadol after oral administration of the drops, based on AUC data, was 66.3% (point estimate; n = 8) with a 95% confidence interval of 58.1-75.6% (ANOVAlog).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),%,66.3,51729,DB00898,Ethanol
,9638309,areas under the serum concentration curves,"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2390 +/- 712 h.ng/ml (p.o.) and 3490 +/- 510 h.ng/ml (i.v.) (mean +/- SD; n = 8).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[h·ng] / [ml],2390,51730,DB00898,Ethanol
,9638309,areas (AUC),"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2390 +/- 712 h.ng/ml (p.o.) and 3490 +/- 510 h.ng/ml (i.v.) (mean +/- SD; n = 8).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[h·ng] / [ml],2390,51731,DB00898,Ethanol
,9638309,areas (AUC),"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2390 +/- 712 h.ng/ml (p.o.) and 3490 +/- 510 h.ng/ml (i.v.) (mean +/- SD; n = 8).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[h·ng] / [ml],3490,51732,DB00898,Ethanol
,9638309,cmax,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[ng] / [ml],308,51733,DB00898,Ethanol
,9638309,tmax,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,1.20,51734,DB00898,Ethanol
,9638309,half-life of absorption,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.34,51735,DB00898,Ethanol
,9638309,"t1/2,ka","After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.34,51736,DB00898,Ethanol
,9638309,lag time,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.23,51737,DB00898,Ethanol
,9638309,t0,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.23,51738,DB00898,Ethanol
,9638309,"biological half-life in the terminal phase (t1/2,beta)","The biological half-life in the terminal phase (t1/2,beta) was 5.5 +/- 0.9 h and agreed well with the value of 5.2 +/- 0.8 h determined after i.v. injection.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,5.5,51739,DB00898,Ethanol
,9638309,"biological half-life in the terminal phase (t1/2,beta)","The biological half-life in the terminal phase (t1/2,beta) was 5.5 +/- 0.9 h and agreed well with the value of 5.2 +/- 0.8 h determined after i.v. injection.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,5.2,51740,DB00898,Ethanol
,9638309,"distribution half-life (t1/2,alpha)","For the slower distribution half-life (t1/2,alpha) mean values of 1.2 +/- 0.7 h (p.o.; n = 6) and 1.9 +/- 0.7 h (i.v.; n = 6) were obtained.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,1.2,51741,DB00898,Ethanol
,9638309,"distribution half-life (t1/2,alpha)","For the slower distribution half-life (t1/2,alpha) mean values of 1.2 +/- 0.7 h (p.o.; n = 6) and 1.9 +/- 0.7 h (i.v.; n = 6) were obtained.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,1.9,51742,DB00898,Ethanol
,9638309,total distribution volume,"The values determined after i.v. injection for the total distribution volume and the total and renal clearance were 216 +/- 21 l (Vd,beta), 487 +/- 71 ml/min (Cltot) and 77 +/- 20 ml/min (Clren), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),l,216,51743,DB00898,Ethanol
,9638309,Cltot,"The values determined after i.v. injection for the total distribution volume and the total and renal clearance were 216 +/- 21 l (Vd,beta), 487 +/- 71 ml/min (Cltot) and 77 +/- 20 ml/min (Clren), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[ml] / [min],487,51744,DB00898,Ethanol
,9638309,Clren,"The values determined after i.v. injection for the total distribution volume and the total and renal clearance were 216 +/- 21 l (Vd,beta), 487 +/- 71 ml/min (Cltot) and 77 +/- 20 ml/min (Clren), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[ml] / [min],77,51745,DB00898,Ethanol
,1608903,relative bioavailability,"The relative bioavailability of nifedipine, measured as AUC, was increased by 54% (533 vs 346 ng.hr/ml) after the dose of alcohol (P less than 0.0002).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),[h·ng] / [ml],533,52229,DB00898,Ethanol
,1608903,relative bioavailability,"The relative bioavailability of nifedipine, measured as AUC, was increased by 54% (533 vs 346 ng.hr/ml) after the dose of alcohol (P less than 0.0002).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),[h·ng] / [ml],346,52230,DB00898,Ethanol
,1608903,time to reach peak heart rate,"Although there was no difference in the systolic and diastolic blood pressure and pulse rate between the two treatment groups, the time to reach peak heart rate was significantly faster in the group treated with alcohol (1.4 vs 2.2 hr).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),h,1.4,52231,DB00898,Ethanol
,1608903,time to reach peak heart rate,"Although there was no difference in the systolic and diastolic blood pressure and pulse rate between the two treatment groups, the time to reach peak heart rate was significantly faster in the group treated with alcohol (1.4 vs 2.2 hr).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),h,2.2,52232,DB00898,Ethanol
,24998506,ED50,The GALA/MENDEtOH induced more efficient gene silencing in the pulmonary endothelium (ED50; approximately 0.17 mg siRNA/kg) compared to the GALA/MENDHyd.,Advantages of ethanol dilution method for preparing GALA-modified liposomal siRNA carriers on the in vivo gene knockdown efficiency in pulmonary endothelium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24998506/),[mg·sirna] / [kg],0.17,53375,DB00898,Ethanol
,2802168,accumulation time,A carbon paste electrode containing Nujol - Ultra Carbon Ultra Superior Purity graphite (25 + 75 m/m) gave the highest sensitivity with adsorptive stripping voltammetry; the optimum accumulation time was 15 min at an open circuit.,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),min,15,53457,DB00898,Ethanol
,2802168,recovery,A solvent extraction method using hexane and ethanol gave the best recovery (91%) and detection limits [180 ng ml-1 in the supporting electrolyte (450 ng ml-1 in plasma)].,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),%,91,53458,DB00898,Ethanol
,2802168,detection limits,A solvent extraction method using hexane and ethanol gave the best recovery (91%) and detection limits [180 ng ml-1 in the supporting electrolyte (450 ng ml-1 in plasma)].,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),[ng] / [ml],180,53459,DB00898,Ethanol
,2802168,detection limits,A solvent extraction method using hexane and ethanol gave the best recovery (91%) and detection limits [180 ng ml-1 in the supporting electrolyte (450 ng ml-1 in plasma)].,Pre-concentration of vitamin K1 (phylloquinone) at carbon paste electrodes and its determination in plasma by adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802168/),[ng] / [ml],450,53460,DB00898,Ethanol
<,15031566,onset of action,Formoterol demonstrated an onset of action of <3 min.,Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031566/),min,3,54161,DB00898,Ethanol
,1172599,bioavailability,"A mean bioavailability of 82% (sx = 1.8) was found for beta-acetyldigoxin tablets (Novodigal¿), PETN/beta-acetyldigoxin tablets (Nitro-Novodigal¿), oxyfedrin/beta-acetyldigoxin tablets (ildamen¿-Novodigal¿) and beta-acetyldigoxin liquid.",[Bioavailability of beta-acetyldigoxin and digoxin (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1172599/),%,82,54385,DB00898,Ethanol
,20815879,AUC0-tlast,"Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine.",Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815879/),[h·ng] / [ml],208,54633,DB00898,Ethanol
,20815879,AUC0-tlast,"Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine.",Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815879/),[h·ng] / [ml],195,54634,DB00898,Ethanol
,20815879,AUC0-tlast,"Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine.",Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815879/),[h·ng] / [ml],206,54635,DB00898,Ethanol
,20815879,AUC0-tlast,"Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine.",Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815879/),[h·ng] / [ml],199,54636,DB00898,Ethanol
,20815879,AUC0-tlast,"Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine.",Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815879/),[h·μg] / [ml],262,54637,DB00898,Ethanol
,20815879,AUC0-tlast,"Study 2 demonstrated that the dispersible and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.ng/ml for DHA and 262 ± 107 vs 291 ± 106 h x μg/ml for lumefantrine.",Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815879/),[h·μg] / [ml],291,54638,DB00898,Ethanol
,18446506,onset of loss of righting reflex (LRR),"At 6.34 mmol/kg IV, the onset of loss of righting reflex (LRR) for BD was significantly delayed vs. that produced by GHB (72.0 +/- 9.1 min vs. 6.7 +/- 0.6 min, respectively, p < 0.001), and the total duration of LRR was prolonged for BD vs. GHB (192 +/- 28 min vs. 117 +/- 2 min, respectively, p < 0.05).","Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446506/),min,72.0,54678,DB00898,Ethanol
,18446506,onset of loss of righting reflex (LRR),"At 6.34 mmol/kg IV, the onset of loss of righting reflex (LRR) for BD was significantly delayed vs. that produced by GHB (72.0 +/- 9.1 min vs. 6.7 +/- 0.6 min, respectively, p < 0.001), and the total duration of LRR was prolonged for BD vs. GHB (192 +/- 28 min vs. 117 +/- 2 min, respectively, p < 0.05).","Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446506/),min,6.7,54679,DB00898,Ethanol
,18446506,total duration of LRR,"At 6.34 mmol/kg IV, the onset of loss of righting reflex (LRR) for BD was significantly delayed vs. that produced by GHB (72.0 +/- 9.1 min vs. 6.7 +/- 0.6 min, respectively, p < 0.001), and the total duration of LRR was prolonged for BD vs. GHB (192 +/- 28 min vs. 117 +/- 2 min, respectively, p < 0.05).","Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446506/),min,192,54680,DB00898,Ethanol
,18446506,total duration of LRR,"At 6.34 mmol/kg IV, the onset of loss of righting reflex (LRR) for BD was significantly delayed vs. that produced by GHB (72.0 +/- 9.1 min vs. 6.7 +/- 0.6 min, respectively, p < 0.001), and the total duration of LRR was prolonged for BD vs. GHB (192 +/- 28 min vs. 117 +/- 2 min, respectively, p < 0.05).","Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18446506/),min,117,54681,DB00898,Ethanol
,16303295,minimum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),[mM] / [l],3.4,54760,DB00898,Ethanol
,16303295,minimum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),[mM] / [l],3.3,54761,DB00898,Ethanol
,16303295,maximum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),,9.0,54762,DB00898,Ethanol
,16303295,maximum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),,8.7,54763,DB00898,Ethanol
,16303295,maximum forced expiratory volume,"Both drugs improved lung function (mean maximum forced expiratory volume in 1s [FEV(1)] 2.6 l with both treatments; P=0.624), with the improvement being significantly greater with formoterol than with salbutamol on all 3 days of treatment (mean area under the curve [AUC](0-24 h) of FEV(1) formoterol vs. salbutamol on days 1-3, all P<0.05).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),l,2.6,54764,DB00898,Ethanol
,26580099,clearance,"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),[l] / [h],6.8,54824,DB00898,Ethanol
,26580099,apparent volume of distribution (V),"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),l,159,54825,DB00898,Ethanol
,26580099,duration of absorption (D1),"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),h,2,54826,DB00898,Ethanol
,26580099,elimination half-life,"The elimination half-life was 16 hours (range, 3-42 hours).",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),h,16,54827,DB00898,Ethanol
,7851052,Bioavailability,"Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism.",Sumatriptan clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),%,96,55552,DB00898,Ethanol
,7851052,Bioavailability,"Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism.",Sumatriptan clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),%,14,55553,DB00898,Ethanol
,7851052,elimination half-life,"Total plasma clearance is rapid, with an elimination half-life of around 2 hours.",Sumatriptan clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),h,2,55554,DB00898,Ethanol
,2085346,half-life,AcDH-overloaded mouse red blood cells from donor animals were also injected intraperitoneally into compatible recipients (Balb/C) and 80 to 85% of these were found to enter into circulation within 24 hr and to circulate with a half-life of 6-7.3 days (normal half-life 11 days).,In vivo accelerated acetaldehyde metabolism using acetaldehyde dehydrogenase-loaded erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085346/),d,6-7.3,55677,DB00898,Ethanol
,2085346,half-life,AcDH-overloaded mouse red blood cells from donor animals were also injected intraperitoneally into compatible recipients (Balb/C) and 80 to 85% of these were found to enter into circulation within 24 hr and to circulate with a half-life of 6-7.3 days (normal half-life 11 days).,In vivo accelerated acetaldehyde metabolism using acetaldehyde dehydrogenase-loaded erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085346/),d,11,55678,DB00898,Ethanol
,15930819,flow rate,"The mobile phase consisting of methanol and water (95:5, v/v) was delivered at a flow rate of 1.0 ml/min.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),[ml] / [min],1.0,55716,DB00898,Ethanol
,15930819,extraction recovery,"The method was shown to be reproducible and reliable with intraday precision below 7.8%, interday precision below 8.1%, accuracy within +/-4.3%, and mean extraction recovery excess of 83.6%, which were all calculated from the blank plasma sample spiked with ursolic acid at three concentrations of 20, 200, and 800 ng/ml.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),,83,55717,DB00898,Ethanol
,15930819,t(1/2),"The main pharmacokinetic parameters were: t(1/2), 4.3 h; K(e), 0.16 1/h; t(max), 1.0 h; C(max), 294.8 ng/ml; AUC(0-t) and AUC(0-infinity), 1007.1 ng.h/ml and 1175.3 ng.h/ml, respectively.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),h,4.3,55718,DB00898,Ethanol
,15930819,K(e),"The main pharmacokinetic parameters were: t(1/2), 4.3 h; K(e), 0.16 1/h; t(max), 1.0 h; C(max), 294.8 ng/ml; AUC(0-t) and AUC(0-infinity), 1007.1 ng.h/ml and 1175.3 ng.h/ml, respectively.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),[1] / [h],0.16,55719,DB00898,Ethanol
,15930819,t(max),"The main pharmacokinetic parameters were: t(1/2), 4.3 h; K(e), 0.16 1/h; t(max), 1.0 h; C(max), 294.8 ng/ml; AUC(0-t) and AUC(0-infinity), 1007.1 ng.h/ml and 1175.3 ng.h/ml, respectively.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),h,1.0,55720,DB00898,Ethanol
,15930819,C(max),"The main pharmacokinetic parameters were: t(1/2), 4.3 h; K(e), 0.16 1/h; t(max), 1.0 h; C(max), 294.8 ng/ml; AUC(0-t) and AUC(0-infinity), 1007.1 ng.h/ml and 1175.3 ng.h/ml, respectively.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),[ng] / [ml],294.8,55721,DB00898,Ethanol
,15930819,AUC(0-t),"The main pharmacokinetic parameters were: t(1/2), 4.3 h; K(e), 0.16 1/h; t(max), 1.0 h; C(max), 294.8 ng/ml; AUC(0-t) and AUC(0-infinity), 1007.1 ng.h/ml and 1175.3 ng.h/ml, respectively.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),[h·ng] / [ml],1007.1,55722,DB00898,Ethanol
,15930819,AUC(0-infinity),"The main pharmacokinetic parameters were: t(1/2), 4.3 h; K(e), 0.16 1/h; t(max), 1.0 h; C(max), 294.8 ng/ml; AUC(0-t) and AUC(0-infinity), 1007.1 ng.h/ml and 1175.3 ng.h/ml, respectively.",LC-MS determination and pharmacokinetic studies of ursolic acid in rat plasma after administration of the traditional chinese medicinal preparation Lu-Ying extract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930819/),[h·ng] / [ml],1175.3,55723,DB00898,Ethanol
,2440455,maximum concentration,"The mean maximum concentration in plasma for midodrin was ca. 10 ng/ml 20-30 min after oral administration, for ST 1059 ca. 5 ng/ml after 1 h.","[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),[ng] / [ml],10,55839,DB00898,Ethanol
,2440455,maximum concentration,"The mean maximum concentration in plasma for midodrin was ca. 10 ng/ml 20-30 min after oral administration, for ST 1059 ca. 5 ng/ml after 1 h.","[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),[ng] / [ml],5,55840,DB00898,Ethanol
,2440455,terminal half-life,Midodrin was eliminated with a terminal half-life of 0.5 h.,"[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),h,0.5,55841,DB00898,Ethanol
,2440455,half-life,The half-life of ST 1059 was determined to be 3 h.,"[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),h,3,55842,DB00898,Ethanol
,2440455,area under the plasma-level vs. time curve (AUC),"The mean area under the plasma-level vs. time curve (AUC) of ST 1059 after administration of 2.5 mg midodrin i.v. was 28.7 ng X h/ml, and as drinking solution or as tablet 25.7 and 25.6 ng X h/ml, respectively.","[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),[h·ng] / [ml],28.7,55843,DB00898,Ethanol
,2440455,area under the plasma-level vs. time curve (AUC),"The mean area under the plasma-level vs. time curve (AUC) of ST 1059 after administration of 2.5 mg midodrin i.v. was 28.7 ng X h/ml, and as drinking solution or as tablet 25.7 and 25.6 ng X h/ml, respectively.","[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),[h·ng] / [ml],25.7,55844,DB00898,Ethanol
,2440455,area under the plasma-level vs. time curve (AUC),"The mean area under the plasma-level vs. time curve (AUC) of ST 1059 after administration of 2.5 mg midodrin i.v. was 28.7 ng X h/ml, and as drinking solution or as tablet 25.7 and 25.6 ng X h/ml, respectively.","[The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2440455/),[h·ng] / [ml],25.6,55845,DB00898,Ethanol
,21801400,total MCD,The total MCD of tafenoquine required in combination regimens for radical cure was ten-fold lower (1.8 mg/kg versus 18 mg/kg) than for monotherapy.,Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),,1,55856,DB00898,Ethanol
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],20-84,55857,DB00898,Ethanol
,21801400,maximum observed plasma concentrations,"At its MCD in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical studies.",Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21801400/),[ng] / [ml],"550-1,100",55858,DB00898,Ethanol
,10820132,area under the concentration versus time curve,"The mean (+/-S.D.) area under the concentration versus time curve for ethylphenidate was 1.2 +/- 0.7 ng/ml/h, representing 2.3 +/- 1.3% that of methylphenidate (48 +/- 12 ng/ml/h).",Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820132/),[ng] / [h·ml],1.2,56485,DB00898,Ethanol
,10820132,area under the concentration versus time curve,"The mean (+/-S.D.) area under the concentration versus time curve for ethylphenidate was 1.2 +/- 0.7 ng/ml/h, representing 2.3 +/- 1.3% that of methylphenidate (48 +/- 12 ng/ml/h).",Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820132/),[ng] / [h·ml],48,56486,DB00898,Ethanol
,27691904,terminal half life,"After I/V administration in the two dogs the terminal half life was 5.30 and 6.06 hours, clearance was 444 and 476 mL/hours/kg, and volume of distribution was 3,642 and 3,883 mL/kg.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),h,5.30,57204,DB00898,Ethanol
,27691904,terminal half life,"After I/V administration in the two dogs the terminal half life was 5.30 and 6.06 hours, clearance was 444 and 476 mL/hours/kg, and volume of distribution was 3,642 and 3,883 mL/kg.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),h,6.06,57205,DB00898,Ethanol
,27691904,clearance,"After I/V administration in the two dogs the terminal half life was 5.30 and 6.06 hours, clearance was 444 and 476 mL/hours/kg, and volume of distribution was 3,642 and 3,883 mL/kg.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),[ml] / [h·kg],444,57206,DB00898,Ethanol
,27691904,clearance,"After I/V administration in the two dogs the terminal half life was 5.30 and 6.06 hours, clearance was 444 and 476 mL/hours/kg, and volume of distribution was 3,642 and 3,883 mL/kg.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),[ml] / [h·kg],476,57207,DB00898,Ethanol
,27691904,volume of distribution,"After I/V administration in the two dogs the terminal half life was 5.30 and 6.06 hours, clearance was 444 and 476 mL/hours/kg, and volume of distribution was 3,642 and 3,883 mL/kg.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),[ml] / [kg],"3,642",57208,DB00898,Ethanol
,27691904,volume of distribution,"After I/V administration in the two dogs the terminal half life was 5.30 and 6.06 hours, clearance was 444 and 476 mL/hours/kg, and volume of distribution was 3,642 and 3,883 mL/kg.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),[ml] / [kg],"3,883",57209,DB00898,Ethanol
,27691904,peak concentrations,"Compared with fasted dogs, oral administration in fed dogs resulted in reduced median peak concentrations in plasma (1,598 vs. 614 ng/mL) and delayed median time of peak concentration (1.0 vs. 3.0 hours).","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),[ng] / [ml],"1,598",57210,DB00898,Ethanol
,27691904,peak concentrations,"Compared with fasted dogs, oral administration in fed dogs resulted in reduced median peak concentrations in plasma (1,598 vs. 614 ng/mL) and delayed median time of peak concentration (1.0 vs. 3.0 hours).","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),[ng] / [ml],614,57211,DB00898,Ethanol
,27691904,time of peak concentration,"Compared with fasted dogs, oral administration in fed dogs resulted in reduced median peak concentrations in plasma (1,598 vs. 614 ng/mL) and delayed median time of peak concentration (1.0 vs. 3.0 hours).","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),h,1.0,57212,DB00898,Ethanol
,27691904,time of peak concentration,"Compared with fasted dogs, oral administration in fed dogs resulted in reduced median peak concentrations in plasma (1,598 vs. 614 ng/mL) and delayed median time of peak concentration (1.0 vs. 3.0 hours).","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),h,3.0,57213,DB00898,Ethanol
,27691904,bioavailability,"The estimated bioavailability in fasted and fed dogs was 111.9 and 59.1%, respectively.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),%,111.9,57214,DB00898,Ethanol
,27691904,bioavailability,"The estimated bioavailability in fasted and fed dogs was 111.9 and 59.1%, respectively.","Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691904/),%,59.1,57215,DB00898,Ethanol
,24619932,terminal half-life,LY2456302 displayed rapid oral absorption and a terminal half-life of approximately 30-40 hours.,"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24619932/),h,30-40,57236,DB00898,Ethanol
,20332028,solubility,High loading level was achieved for valspodar in PEO-b-PCL leading to an aqueous solubility of 2.8 mg/mL.,Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20332028/),[mg] / [ml],2.8,57356,DB00898,Ethanol
,20332028,plasma unbound fraction,The plasma unbound fraction of valspodar in the polymeric micellar formulation was significantly lower than control (8.27% versus 14.85%).,Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20332028/),%,8.27,57357,DB00898,Ethanol
,20332028,plasma unbound fraction,The plasma unbound fraction of valspodar in the polymeric micellar formulation was significantly lower than control (8.27% versus 14.85%).,Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20332028/),%,14.85,57358,DB00898,Ethanol
,8852049,limit of quantitation (LOQ),The limit of quantitation (LOQ) in human plasma is 2.5 ng ml-1 for both S-(-)- and R-(+)-amisulpride isomers with both detection methods.,"Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column. application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852049/),[ng] / [ml],2.5,57548,DB00898,Ethanol
,24700417,en,The obtained LNs were 150 nm in size with a high value of entrapment efficiency (99.95%).,"Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24700417/),%,99.95,57670,DB00898,Ethanol
,24700417,relative bioavailability,The pharmacokinetic results showed that LNs significantly enhanced the oral bioavailability of TRI with a relative bioavailability of 224.88% (TRI suspensions was used as a reference).,"Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24700417/),%,224.88,57671,DB00898,Ethanol
,24648310,run-time,GC was performed in isothermal mode with a GC run-time of 5.0 min.,Rapid and sensitive headspace gas chromatography-mass spectrometry method for the analysis of ethanol in the whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648310/),min,5.0,57785,DB00898,Ethanol
,24648310,limit of detection,"The method was linear (r(2) = 0.999, in the concentration range of 39.5-1,262.9 μg/ml), specific, sensitive (limit of quantification and limit of detection of 39.5 and 0.4 μg/ml, respectively), and robust.",Rapid and sensitive headspace gas chromatography-mass spectrometry method for the analysis of ethanol in the whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648310/),,0.4,57786,DB00898,Ethanol
,24648310,run-time,The method used an isothermal GC program with a run-time of 5.0 min.,Rapid and sensitive headspace gas chromatography-mass spectrometry method for the analysis of ethanol in the whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24648310/),min,5.0,57787,DB00898,Ethanol
,16652314,failure rates,"PCR-corrected failure rates at day 42 were 13% (95% confidence interval [CI], 9.6%-17%) for the 4-dose regimen and 3.2% (95% CI, 1.8%-4.6%) for the 6-dose regimen.",Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16652314/),%,13,58143,DB00898,Ethanol
,16652314,failure rates,"PCR-corrected failure rates at day 42 were 13% (95% confidence interval [CI], 9.6%-17%) for the 4-dose regimen and 3.2% (95% CI, 1.8%-4.6%) for the 6-dose regimen.",Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16652314/),%,3.,58144,DB00898,Ethanol
,15850630,cure rates,"Day-28 cure rates were 97.7% (296 of 303) and 98.0% (603 of 615) in the supervised and unsupervised groups, respectively.","Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850630/),%,97.7,58204,DB00898,Ethanol
,15850630,cure rates,"Day-28 cure rates were 97.7% (296 of 303) and 98.0% (603 of 615) in the supervised and unsupervised groups, respectively.","Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850630/),%,98.0,58205,DB00898,Ethanol
,17408901,flow rate,"The mobile phase, methanol-water-triethanol amine (45:55:0.05, v/v/v), was delivered at a flow rate of 1.0 ml/min.",Determination of Huperzine A in rat plasma by high-performance liquid chromatography with a fluorescence detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408901/),[ml] / [min],1.0,58249,DB00898,Ethanol
,17408901,method,"The method and extraction recovery of Huperzine A were 101.9-108.9% and 73.5-84.6%, respectively.",Determination of Huperzine A in rat plasma by high-performance liquid chromatography with a fluorescence detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408901/),%,101.9-108.9,58250,DB00898,Ethanol
,17408901,extraction recovery,"The method and extraction recovery of Huperzine A were 101.9-108.9% and 73.5-84.6%, respectively.",Determination of Huperzine A in rat plasma by high-performance liquid chromatography with a fluorescence detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408901/),%,73.5-84.6,58251,DB00898,Ethanol
,3132551,elimination half-life,"The model was tested with flumazenil (Ro 15-1788), a short-acting benzodiazepine antagonist with an elimination half-life of 1 h.",Experimental model for the investigation of kinetic and/or dynamic interactions between drugs and ethanol in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132551/),h,1,58606,DB00898,Ethanol
,3064641,peak blood alcohol level,"On one night, six asymptomatic nonalcoholic male snorers drank 2 ml/kg of 100 proof vodka mixed in orange juice (ethanol dose, 0.79 gm/kg, giving a peak blood alcohol level of 71.8 +/- 33.3 mg/dl).",Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3064641/),[mg] / [dl],71.8,59098,DB00898,Ethanol
,3064641,number of respiratory events per,The number of respiratory events per hour of sleep (apnea index) was 7.5 +/- 2.1 for ethanol nights versus 3.8 +/- 2.7 for placebo nights (p less than 0.0125).,Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3064641/),,7.5,59099,DB00898,Ethanol
,3064641,number of respiratory events per,The number of respiratory events per hour of sleep (apnea index) was 7.5 +/- 2.1 for ethanol nights versus 3.8 +/- 2.7 for placebo nights (p less than 0.0125).,Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3064641/),,3.8,59100,DB00898,Ethanol
greater,3064641,apnea index,An apnea index of greater than 5 is generally considered abnormal.,Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3064641/),,5,59101,DB00898,Ethanol
,3064641,minimum SaO2,"There was no significant difference in the number of desaturation events (declines of 4% or more in the SaO2) or in the mean SaO2, but the minimum SaO2 was significantly lower on the ethanol night (placebo 89.8% +/- 1.6, alcohol 86.8% +/- 2.7, p less than 0.05).",Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3064641/),%,89.8,59102,DB00898,Ethanol
,3064641,minimum SaO2,"There was no significant difference in the number of desaturation events (declines of 4% or more in the SaO2) or in the mean SaO2, but the minimum SaO2 was significantly lower on the ethanol night (placebo 89.8% +/- 1.6, alcohol 86.8% +/- 2.7, p less than 0.05).",Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3064641/),%,86.8,59103,DB00898,Ethanol
,25459927,flow rate,"After solid phase extraction of 50.0 μL rat plasma in 96 well plate, a baseline resolution of arotinolol enantiomers was achieved on a CHIRALPAK AD-H column using the mobile phase of n-hexane and ethanol in 0.02% diethylamine (20:80, v/v) at a flow rate of 0.550 mL/min within 11.0 min.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),[ml] / [min],0.550,59150,DB00898,Ethanol
,25459927,m/z,Acquisition of mass spectrometric data was performed on a triple-quadrupole mass spectrometer in multiple-reaction-monitoring (MRM) mode with an ESI source using the transition m/z 372.1 → 316.1 for (±)-arotinolol and m/z 376.1 → 165.1 for haloperidol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),,376.1,59151,DB00898,Ethanol
,25459927,m/z,Acquisition of mass spectrometric data was performed on a triple-quadrupole mass spectrometer in multiple-reaction-monitoring (MRM) mode with an ESI source using the transition m/z 372.1 → 316.1 for (±)-arotinolol and m/z 376.1 → 165.1 for haloperidol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),,165.1,59152,DB00898,Ethanol
,25459927,Accuracy,Accuracy varied from 0.0% to 7.0% for R-(-)-arotinolol and 5.0-10.0% for S-(+)-arotinolol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,0,59153,DB00898,Ethanol
,25459927,Accuracy,Accuracy varied from 0.0% to 7.0% for R-(-)-arotinolol and 5.0-10.0% for S-(+)-arotinolol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,7.0,59154,DB00898,Ethanol
,25459927,Accuracy,Accuracy varied from 0.0% to 7.0% for R-(-)-arotinolol and 5.0-10.0% for S-(+)-arotinolol.,Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,5.0-10.0,59155,DB00898,Ethanol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,87.2,59156,DB00898,Ethanol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,99.2,59157,DB00898,Ethanol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,88.0,59158,DB00898,Ethanol
,25459927,recovery,"For R-(-)-arotinolol, the recovery ranged from 87.2% to 99.2% and the matrix factor was 1.03-1.09; for S-(+)-arotinolol, the recovery ranged from 88.0% to 92.4% and the matrix factor was 0.84-0.95, both were not concentration dependent.",Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25459927/),%,92.4,59159,DB00898,Ethanol
,19022451,flow rate for,"Hydroxytyrosol in the microdialysis samples was separated by a reversed-phase C18 column and eluted with a mobile phase containing acetonitrile - 2% acetic acid (pH 2.6) (12:88, v/v), using a flow rate for the mobile phase of 1 mL/min.",Measurement of free hydroxytyrosol in microdialysates from blood and brain of anesthetized rats by liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19022451/),[ml] / [min],1,59223,DB00898,Ethanol
less,7601331,Excretion of,Excretion of radioactivity in the feces was less than 0.08% of the applied dose in both groups.,"Absorption, metabolism, and excretion of N,N-diethyl-m-toluamide following dermal application to human volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7601331/),%,0.08,59224,DB00898,Ethanol
,8070028,MTD,"Data from these trials show the rapid and complete conversion of EP to VP-16, a pharmacokinetic/pharmacodynamic relationship for myelosuppression and exposure to VP-16, and an MTD of 100 and 150 mg/m2 (molar equivalent to VP-16) when EP is given daily for 5 days and on days 1, 3, and 5, respectively.",Clinical and pharmacokinetic overview of parenteral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070028/),[mg] / [m2],100,59962,DB00898,Ethanol
,8070028,MTD,"Data from these trials show the rapid and complete conversion of EP to VP-16, a pharmacokinetic/pharmacodynamic relationship for myelosuppression and exposure to VP-16, and an MTD of 100 and 150 mg/m2 (molar equivalent to VP-16) when EP is given daily for 5 days and on days 1, 3, and 5, respectively.",Clinical and pharmacokinetic overview of parenteral etoposide phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070028/),[mg] / [m2],150,59963,DB00898,Ethanol
,15102073,V(d),"V(d) (mean +/- SEM) for male rhesus was 0.771 +/- 0.008 l/kg and for females was 0.730 +/- 0.008 l/kg, different at P < 0.00001.",Sex differences in total body water in adolescent rhesus macaques estimated by ethanol dilution. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102073/),[l] / [kg],0.771,59964,DB00898,Ethanol
,15102073,V(d),"V(d) (mean +/- SEM) for male rhesus was 0.771 +/- 0.008 l/kg and for females was 0.730 +/- 0.008 l/kg, different at P < 0.00001.",Sex differences in total body water in adolescent rhesus macaques estimated by ethanol dilution. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102073/),[l] / [kg],0.730,59965,DB00898,Ethanol
,15102073,rate of zero-order ethanol elimination,"There were no sex differences in the rate of zero-order ethanol elimination, estimated to be 0.0032 +/- 0.0004 g/kg/minute.",Sex differences in total body water in adolescent rhesus macaques estimated by ethanol dilution. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102073/),[g] / [kg·min],0.0032,59966,DB00898,Ethanol
,1575909,Vmax,Vmax and Km in fed animals were respectively 295 +/- 10 mg.h-1.l-1 (l = litre of body water) and 32.1 +/- 2.4 mg.,Kinetics of ethanol metabolism in sheep. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1575909/),[mg] / [h·l],295,59983,DB00898,Ethanol
,1575909,Km,Vmax and Km in fed animals were respectively 295 +/- 10 mg.h-1.l-1 (l = litre of body water) and 32.1 +/- 2.4 mg.,Kinetics of ethanol metabolism in sheep. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1575909/),mg,32.1,59984,DB00898,Ethanol
,1575909,Elimination half-life,Elimination half-life was 1.47 +/- 0.26 h.,Kinetics of ethanol metabolism in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1575909/),h,1.47,59985,DB00898,Ethanol
,26655109,flow rate,"The chromatographic separation was achieved using gradient elution with a mobile phase consisting of ethanol and 10mM ammonium acetate on a Synergi MAX-RP analytical column (150×2mm, 4μm) protected by a security guard cartridge (C12 4×2mm) at a flow rate of 300μL/min.",Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[μl] / [min],300,60351,DB00898,Ethanol
,26655109,limit of detection,The limit of detection was 30pg/mL for all analytes.,Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26655109/),[pg] / [ml],30,60352,DB00898,Ethanol
,20856831,p,"The elemene microemulsion as a clarified and isotropic system containing 1% elemene (w/v), 5% ethanol (v/v), 15% propylene glycol (v/v), 15% glycerol (v/v), and 5% polysorbate 80 (w/v), was characterized as (57.7 ± 2.8) nm in size, 0.485 ± 0.032 in polydispersity index, (3.2 ± 0.4) mv in zeta potential, (5.19 ± 0.08) in pH, 6 mpa·s in viscosity, (31.8 ± 0.3) mN·m(-1) in surface tension, (8.273 ± 0.018) mg·mL(-1) in content of β-elemene, and (99.81 ± 0.24)% in average entrapment efficiency.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),mv,0.485,60733,DB00898,Ethanol
,20856831,zeta potential,"The elemene microemulsion as a clarified and isotropic system containing 1% elemene (w/v), 5% ethanol (v/v), 15% propylene glycol (v/v), 15% glycerol (v/v), and 5% polysorbate 80 (w/v), was characterized as (57.7 ± 2.8) nm in size, 0.485 ± 0.032 in polydispersity index, (3.2 ± 0.4) mv in zeta potential, (5.19 ± 0.08) in pH, 6 mpa·s in viscosity, (31.8 ± 0.3) mN·m(-1) in surface tension, (8.273 ± 0.018) mg·mL(-1) in content of β-elemene, and (99.81 ± 0.24)% in average entrapment efficiency.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),mv,3.2,60734,DB00898,Ethanol
,20856831,surface tension,"The elemene microemulsion as a clarified and isotropic system containing 1% elemene (w/v), 5% ethanol (v/v), 15% propylene glycol (v/v), 15% glycerol (v/v), and 5% polysorbate 80 (w/v), was characterized as (57.7 ± 2.8) nm in size, 0.485 ± 0.032 in polydispersity index, (3.2 ± 0.4) mv in zeta potential, (5.19 ± 0.08) in pH, 6 mpa·s in viscosity, (31.8 ± 0.3) mN·m(-1) in surface tension, (8.273 ± 0.018) mg·mL(-1) in content of β-elemene, and (99.81 ± 0.24)% in average entrapment efficiency.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),[mn] / [m],31.8,60735,DB00898,Ethanol
,20856831,entrapment efficiency,"The elemene microemulsion as a clarified and isotropic system containing 1% elemene (w/v), 5% ethanol (v/v), 15% propylene glycol (v/v), 15% glycerol (v/v), and 5% polysorbate 80 (w/v), was characterized as (57.7 ± 2.8) nm in size, 0.485 ± 0.032 in polydispersity index, (3.2 ± 0.4) mv in zeta potential, (5.19 ± 0.08) in pH, 6 mpa·s in viscosity, (31.8 ± 0.3) mN·m(-1) in surface tension, (8.273 ± 0.018) mg·mL(-1) in content of β-elemene, and (99.81 ± 0.24)% in average entrapment efficiency.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),[mg] / [ml],8.273,60736,DB00898,Ethanol
,20856831,entrapment efficiency,"The elemene microemulsion as a clarified and isotropic system containing 1% elemene (w/v), 5% ethanol (v/v), 15% propylene glycol (v/v), 15% glycerol (v/v), and 5% polysorbate 80 (w/v), was characterized as (57.7 ± 2.8) nm in size, 0.485 ± 0.032 in polydispersity index, (3.2 ± 0.4) mv in zeta potential, (5.19 ± 0.08) in pH, 6 mpa·s in viscosity, (31.8 ± 0.3) mN·m(-1) in surface tension, (8.273 ± 0.018) mg·mL(-1) in content of β-elemene, and (99.81 ± 0.24)% in average entrapment efficiency.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),%,99.81,60737,DB00898,Ethanol
,20856831,area under the concentration-time curves from 0 h to 24 h (AUC(0→24h)),"The area under the concentration-time curves from 0 h to 24 h (AUC(0→24h)) of the elemene microemulsion and commercial elemene emulsion were integrated to be 3.092 mg·h·L(-1) and 1.896 mg·h·L(-1) respectively, yielding a relative bioavailability of 163.1%.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),[h·mg] / [l],3.092,60738,DB00898,Ethanol
,20856831,area under the concentration-time curves from 0 h to 24 h (AUC(0→24h)),"The area under the concentration-time curves from 0 h to 24 h (AUC(0→24h)) of the elemene microemulsion and commercial elemene emulsion were integrated to be 3.092 mg·h·L(-1) and 1.896 mg·h·L(-1) respectively, yielding a relative bioavailability of 163.1%.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),[h·mg] / [l],1.896,60739,DB00898,Ethanol
,20856831,relative bioavailability,"The area under the concentration-time curves from 0 h to 24 h (AUC(0→24h)) of the elemene microemulsion and commercial elemene emulsion were integrated to be 3.092 mg·h·L(-1) and 1.896 mg·h·L(-1) respectively, yielding a relative bioavailability of 163.1%.","Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856831/),%,163.1,60740,DB00898,Ethanol
,9776436,Ka,"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),1/[h],6.9,61263,DB00898,Ethanol
,9776436,t1/2,"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),h,8.5,61264,DB00898,Ethanol
,9776436,AUC,"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),[pg] / [h·l],741,61265,DB00898,Ethanol
,9776436,V(area/f),"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),l,1470,61266,DB00898,Ethanol
,23467076,steady-state,In vivo pharmacokinetic study of the bufalin patch in rat showed steady-state of bufalin from 3h to 12 h.,Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23467076/),h,3,61284,DB00898,Ethanol
,23467076,steady-state,In vivo pharmacokinetic study of the bufalin patch in rat showed steady-state of bufalin from 3h to 12 h.,Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23467076/),h,12,61285,DB00898,Ethanol
,23467076,MRT,The MRT increased from 1h of IV administration to 9h of transdermal administration.,Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23467076/),h,1,61286,DB00898,Ethanol
,23467076,MRT,The MRT increased from 1h of IV administration to 9h of transdermal administration.,Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23467076/),h,9,61287,DB00898,Ethanol
,21302040,flow rate,"After one-step protein precipitation with methanol, plasma samples were separated on an Ultimate AQ-C18 column (150 mm×4.6 mm, 5 μm) using acetonitrile-water (7:93, v/v) as mobile phase at a flow rate of 1.2 mL/min.",A rapid determination of drug candidate tyrosol galactoside in rat plasma by HPLC and its application to the pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302040/),[ml] / [min],1.2,61361,DB00898,Ethanol
,21302040,bioavailability,The bioavailability of TG in rats is 27.9%.,A rapid determination of drug candidate tyrosol galactoside in rat plasma by HPLC and its application to the pharmacokinetics study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302040/),%,27.9,61362,DB00898,Ethanol
,10701701,percutaneous absorption,Mean percutaneous absorption of [3H]tretinoin based on the cumulative recoveries of radioactivity in the urine and faeces was about 4.5% (median 2.18%).,Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),%,4.5,62171,DB00898,Ethanol
,10701701,percutaneous absorption,Mean percutaneous absorption of [3H]tretinoin based on the cumulative recoveries of radioactivity in the urine and faeces was about 4.5% (median 2.18%).,Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),%,2.18,62172,DB00898,Ethanol
,10701701,Cmax,"This was consistent with the concentrations of radioactivity in plasma, which showed an average Cmax of 91 pg-eq/mL (median 26 ng/mL).",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[pg-eq] / [ml],91,62173,DB00898,Ethanol
,10701701,Cmax,"This was consistent with the concentrations of radioactivity in plasma, which showed an average Cmax of 91 pg-eq/mL (median 26 ng/mL).",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[ng] / [ml],26,62174,DB00898,Ethanol
,10701701,Cmax,"Average Cmax and AUC(0-12 h) values for mequinol were 10 ng/mL and 33 ng h/mL, respectively.",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[ng] / [ml],10,62175,DB00898,Ethanol
,10701701,AUC(0-12 h),"Average Cmax and AUC(0-12 h) values for mequinol were 10 ng/mL and 33 ng h/mL, respectively.",Percutaneous absorption of [3H]tretinoin and systemic exposure to mequinol after dermal application of 2% mequinol/0.01% [3H]tretinoin (Solagé) solution in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701701/),[h·ng] / [ml],33,62176,DB00898,Ethanol
,11601748,forced expiratory volume in 1 sec (FEV1),"A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted].",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),l,1.38,62345,DB00898,Ethanol
,11601748,forced expiratory volume in 1 sec (FEV1),"A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted].",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),%,45.8,62346,DB00898,Ethanol
,11601748,area under the curve (AUC),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],5.89,62347,DB00898,Ethanol
,11601748,area under the curve (AUC),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],6.06,62348,DB00898,Ethanol
,11601748,AUC(0-30 min),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],5.89,62349,DB00898,Ethanol
,11601748,AUC(0-30 min),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],6.06,62350,DB00898,Ethanol
,33844326,K m,"The PD-ME was successfully prepared by the water titration method at K m = 2, to draw the pseudoternary phase diagrams.",In vitro and in vivo evaluation of a water-in-oil microemulsion of platycodin D. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33844326/),,2,62942,DB00898,Ethanol
,33844326,viscosity,"The average viscosity, pH, droplet size, PDI, and zeta potential of the PD-ME were 78.65 ± 0.13 cPa•s, 5.70 ± 0.05, 30.46 ± 0.20 nm, 0.33 ± 0.00, and -3.13 mV, respectively.",In vitro and in vivo evaluation of a water-in-oil microemulsion of platycodin D. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33844326/),cpa·s,78.65,62943,DB00898,Ethanol
,33844326,zeta potential,"The average viscosity, pH, droplet size, PDI, and zeta potential of the PD-ME were 78.65 ± 0.13 cPa•s, 5.70 ± 0.05, 30.46 ± 0.20 nm, 0.33 ± 0.00, and -3.13 mV, respectively.",In vitro and in vivo evaluation of a water-in-oil microemulsion of platycodin D. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33844326/),mv,-3.13,62944,DB00898,Ethanol
,20604833,maximum drug solubility,"The gelatin microcapsule at a weight ratio for itraconazole/gelatin/citric acid of 1 : 3 : 0.3 was spherical in shape with a smooth surface and inner hole, and gave a maximum drug solubility of about 700 microg/ml.",Development of an itraconazole-loaded gelatin microcapsule with enhanced oral bioavailability: physicochemical characterization and in-vivo evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20604833/),[μg] / [ml],700,63418,DB00898,Ethanol
,3672568,terminal elimination half-life,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),h,7.1,64445,DB00898,Ethanol
,3672568,terminal elimination half-life,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),h,6.3,64446,DB00898,Ethanol
,3672568,volume of distribution,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),[l] / [m2],105,64447,DB00898,Ethanol
,3672568,volume of distribution,"The mean terminal elimination half-life of AMSA-NCL and AMSA-lactate was 7.1 and 6.3 h, respectively, and the mean volume of distribution was 105 and 99 L/m2, respectively.",Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3672568/),[l] / [m2],99,64448,DB00898,Ethanol
,25261835,flow rate,"The CY and CEPM enantiomers were extracted from plasma using only ethyl acetate and separated on a Chiralpak(®) AD-RH column using a mixture of water:acetonitrile:ethanol (45:30:25, v/v/v) plus 0.1% trifluoroacetic acid as the mobile phase at a flow rate of 0.5mL/min.",Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25261835/),[ml] / [min],0.5,64596,DB00898,Ethanol
,25261835,S/R ratio,The pharmacokinetic parameters showed plasma accumulation of the (S)-(-)-CY enantiomer (S/R ratio=1.3) and lack of enantioselective exposure to the CEPM metabolite (S/R ratio=1.0).,Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25261835/),,1.3,64597,DB00898,Ethanol
,25261835,S/R ratio,The pharmacokinetic parameters showed plasma accumulation of the (S)-(-)-CY enantiomer (S/R ratio=1.3) and lack of enantioselective exposure to the CEPM metabolite (S/R ratio=1.0).,Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25261835/),,1.0,64598,DB00898,Ethanol
,29386159,flow rate,"This method was used a RP-18 Column (250 x 4.6 mm i.d, 5 µm), under isocratic elution and acetonitrile:water (50:50 v/v) was used as mobile phase with flow rate of 1.0ml/min.",Bioanalytical method development and validation for quantification of morachalcone A in rabbit plasma using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29386159/),[ml] / [min],1.0,64702,DB00898,Ethanol
,29386159,LOD,"LOD and LLOQ were 89.384 and 154.839ng/ml, respectively.",Bioanalytical method development and validation for quantification of morachalcone A in rabbit plasma using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29386159/),[ng] / [ml],89.384,64703,DB00898,Ethanol
,29386159,recovery,Intra and inter-day precision were ≤15% and recovery from this extraction method of morachalcone A and Internal Standard were 80-120%.,Bioanalytical method development and validation for quantification of morachalcone A in rabbit plasma using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29386159/),%,80-120,64704,DB00898,Ethanol
,23982887,Total clearance,Total clearance values for CAPA ranged from 45 to 156 mL/min and decreased with increasing dose of CAPA.,Development and validation of an LCMS method to determine the pharmacokinetic profiles of caffeic acid phenethyl amide and caffeic acid phenethyl ester in male Sprague-Dawley rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982887/),[ml] / [min],45 to 156,65433,DB00898,Ethanol
,23982887,volume of distribution,"The volume of distribution for CAPA ranged from 17,750 to 52,420 mL, decreasing with increasing dose.",Development and validation of an LCMS method to determine the pharmacokinetic profiles of caffeic acid phenethyl amide and caffeic acid phenethyl ester in male Sprague-Dawley rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982887/),ml,"17,750 to 52,420",65434,DB00898,Ethanol
,23982887,elimination half-life,The elimination half-life for CAPA ranged from 243.1 to 295.8 min and no statistically significant differences were observed between dose groups in the range of 5-20 mg/kg (p > 0.05).,Development and validation of an LCMS method to determine the pharmacokinetic profiles of caffeic acid phenethyl amide and caffeic acid phenethyl ester in male Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982887/),min,243.1 to 295.8,65435,DB00898,Ethanol
,23982887,elimination half-life,The elimination half-life for CAPE was found to be 92.26 min.,Development and validation of an LCMS method to determine the pharmacokinetic profiles of caffeic acid phenethyl amide and caffeic acid phenethyl ester in male Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982887/),min,92.26,65436,DB00898,Ethanol
,27667514,polydispersity index (PDI),"The mean droplet size was 19.12 nm, and the average polydispersity index (PDI) was 0.153.",A new biocompatible microemulsion increases extraction yield and bioavailability of Andrographis paniculata. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27667514/),,0.153,65532,DB00898,Ethanol
,27667514,AUC0-7,"The pharmacokinetic results of BMAP showed that the AUC0-7 and AUC0→∞ values of BMAP were 2.267 and 27.156 μg·mL(-1)·h(-1), respectively, and were about 1.41-fold and 6.30-fold greater than that of ethanol extraction, respectively.",A new biocompatible microemulsion increases extraction yield and bioavailability of Andrographis paniculata. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27667514/),[μg] / [h·ml],2.267,65533,DB00898,Ethanol
,27667514,AUC0→∞,"The pharmacokinetic results of BMAP showed that the AUC0-7 and AUC0→∞ values of BMAP were 2.267 and 27.156 μg·mL(-1)·h(-1), respectively, and were about 1.41-fold and 6.30-fold greater than that of ethanol extraction, respectively.",A new biocompatible microemulsion increases extraction yield and bioavailability of Andrographis paniculata. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27667514/),[μg] / [h·ml],27.156,65534,DB00898,Ethanol
,26883760,zeta potential,"These variables were also the major contributing variables for particle size (101.4 ± 6.1 nm), higher EE (90.28% ± 1.36%), zeta potential (-18.3 ± 2.6 mV) and PDI (0.122 ± 0.027).",Optimization of the process variables of tilianin-loaded composite phospholipid liposomes based on response surface-central composite design and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26883760/),m,-18.3,65688,DB00898,Ethanol
,3279863,peak blood ethanol concentrations (BEC),"During pregnancy, low and high doses produced peak blood ethanol concentrations (BEC) of 89 +/- 8 mg/dl (mean +/- SE) and 125 +/- 6 mg/dl, respectively.",Pharmacokinetics of ethanol in the guinea pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3279863/),[mg] / [dl],89,66050,DB00898,Ethanol
,3279863,peak blood ethanol concentrations (BEC),"During pregnancy, low and high doses produced peak blood ethanol concentrations (BEC) of 89 +/- 8 mg/dl (mean +/- SE) and 125 +/- 6 mg/dl, respectively.",Pharmacokinetics of ethanol in the guinea pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3279863/),[mg] / [dl],125,66051,DB00898,Ethanol
,4045696,maximum,"The plasma levels of clenbuterol reached the maximum value of 0.1, 0.2 and 0.35 ng/ml, respectively, in a dose-dependent manner within 2.5 h, which lasted for over 6 h after the administration.","Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),[ng] / [ml],0.1,66163,DB00898,Ethanol
,4045696,maximum,"The plasma levels of clenbuterol reached the maximum value of 0.1, 0.2 and 0.35 ng/ml, respectively, in a dose-dependent manner within 2.5 h, which lasted for over 6 h after the administration.","Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),[ng] / [ml],0.2,66164,DB00898,Ethanol
,4045696,maximum,"The plasma levels of clenbuterol reached the maximum value of 0.1, 0.2 and 0.35 ng/ml, respectively, in a dose-dependent manner within 2.5 h, which lasted for over 6 h after the administration.","Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),[ng] / [ml],0.35,66165,DB00898,Ethanol
,4045696,half-life,The half-life of clenbuterol in plasma was estimated to be about 35 h.,"Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),h,35,66166,DB00898,Ethanol
,4045696,bound ratio,The bound ratio of the drug to plasma protein was estimated to be 89-98% at a single administration of 80 micrograms of the drug.,"Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),%,89-98,66167,DB00898,Ethanol
,4045696,maximum,"In rabbits, the plasma concentrations reached the maximum value of about 0.2 and 0.8 ng/ml within 2 h following administration of clenbuterol hydrochloride at doses of 0.5 and 2 micrograms/kg, respectively.","Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),[ng] / [ml],0.2,66168,DB00898,Ethanol
,4045696,maximum,"In rabbits, the plasma concentrations reached the maximum value of about 0.2 and 0.8 ng/ml within 2 h following administration of clenbuterol hydrochloride at doses of 0.5 and 2 micrograms/kg, respectively.","Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),[ng] / [ml],0.8,66169,DB00898,Ethanol
,4045696,half-life,The half-life of clenbuterol in plasma was about 30 h in rats and about 9 h in rabbits.,"Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),h,30,66170,DB00898,Ethanol
,4045696,half-life,The half-life of clenbuterol in plasma was about 30 h in rats and about 9 h in rabbits.,"Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4045696/),h,9,66171,DB00898,Ethanol
up to,29501737,bioavailability,The major problem reported with raloxifene is its poor bioavailability which is only up to 2%.,"Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501737/),%,2,66291,DB00898,Ethanol
,29501737,Transdermal flux,Transdermal flux of the optimized ethosome formulation was 22.14 ± 0.83 µg/ml/cm2 which was 21 times higher when compared to the conventional liposomes.,"Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501737/),[μg] / [cm2·ml],22.14,66292,DB00898,Ethanol
,29501737,bioavailability,In-vivo studies on rats showed a higher bioavailability of RXL (157% times) for ethosomal formulation when compared with the oral formulation.,"Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501737/),%·times,157,66293,DB00898,Ethanol
,6634829,Peak blood ethanol,Peak blood ethanol values of about 10 mmol/l were attained after 1 hour both in alcoholics and normal controls irrespective of their ALDH type.,Blood ethanol and acetaldehyde levels in Japanese alcoholics and controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6634829/),[mM] / [l],10,66475,DB00898,Ethanol
,6634829,Peak blood acetaldehyde concentration,Peak blood acetaldehyde concentration was significantly higher in healthy controls and alcoholics deficient in ALDH isozyme I after alcohol drinking (about 30 micro-mmol/l) than in individuals with normal ALDH isozyme I (3 micro-mmol/l).,Blood ethanol and acetaldehyde levels in Japanese alcoholics and controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6634829/),[μ-mmol] / [l],30,66476,DB00898,Ethanol
,6634829,Peak blood acetaldehyde concentration,Peak blood acetaldehyde concentration was significantly higher in healthy controls and alcoholics deficient in ALDH isozyme I after alcohol drinking (about 30 micro-mmol/l) than in individuals with normal ALDH isozyme I (3 micro-mmol/l).,Blood ethanol and acetaldehyde levels in Japanese alcoholics and controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6634829/),[μ-mmol] / [l],3,66477,DB00898,Ethanol
,2991865,half-life,The long half-life previously reported in the literature (7 hours) is mainly the half-life of inactive fenoterol metabolites.,"Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991865/),h,7,66681,DB00898,Ethanol
,33628282,peak concentration (Cmax),"The pharmacokinetics of piperine following SHT remedy extract capsule administration demonstrated a mean peak concentration (Cmax) of piperine of 3.77 μg/mL and 6.59 μg/mL after dosing with 100 and 200 mg, respectively.",Pharmacokinetics of piperine after oral administration of Sahastara remedy capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628282/),[μg] / [ml],3.77,66908,DB00898,Ethanol
,33628282,peak concentration (Cmax),"The pharmacokinetics of piperine following SHT remedy extract capsule administration demonstrated a mean peak concentration (Cmax) of piperine of 3.77 μg/mL and 6.59 μg/mL after dosing with 100 and 200 mg, respectively.",Pharmacokinetics of piperine after oral administration of Sahastara remedy capsules in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628282/),[μg] / [ml],6.59,66909,DB00898,Ethanol
,19320632,peak BrAC,"In the first session, subjects ingested an oral dose of alcohol, based on total body water, to achieve a target peak BrAC of 80 mg%.",Intravenous ethanol infusions can mimic the time course of breath alcohol concentrations following oral alcohol administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19320632/),mg%,80,67249,DB00898,Ethanol
,27348457,AUC(0-t),The AUC(0-t) of CAPE-NO2 (3239.9 ± 352 ng × h/mL) was two-time greater than CAPE (1659.6 ± 152 ng × h/mL) in rats.,Absorption properties and effects of caffeic acid phenethyl ester and its p-nitro-derivative on P-glycoprotein in Caco-2 cells and rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27348457/),[h·ng] / [ml],3239.9,67670,DB00898,Ethanol
,27348457,AUC(0-t),The AUC(0-t) of CAPE-NO2 (3239.9 ± 352 ng × h/mL) was two-time greater than CAPE (1659.6 ± 152 ng × h/mL) in rats.,Absorption properties and effects of caffeic acid phenethyl ester and its p-nitro-derivative on P-glycoprotein in Caco-2 cells and rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27348457/),[h·ng] / [ml],1659.6,67671,DB00898,Ethanol
,27348457,Papp,"The Papp values of CAPE and CAPE-NO2 were (4.86 ± 0.90) × 10-6 cm/s and (12.34 ± 1.6) × 10-6 cm/s, respectively.",Absorption properties and effects of caffeic acid phenethyl ester and its p-nitro-derivative on P-glycoprotein in Caco-2 cells and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27348457/),[cm] / [s],4.86,67672,DB00898,Ethanol
,27348457,Papp,"The Papp values of CAPE and CAPE-NO2 were (4.86 ± 0.90) × 10-6 cm/s and (12.34 ± 1.6) × 10-6 cm/s, respectively.",Absorption properties and effects of caffeic acid phenethyl ester and its p-nitro-derivative on P-glycoprotein in Caco-2 cells and rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27348457/),[cm] / [s],12.34,67673,DB00898,Ethanol
,17613029,flow rate,"Ethylcellulose with di-n-butyl-phthalate in ethanol and methylene chloride mixture for the coating of drug resinate beads was performed in Glatt fluidized bed coater, where the coating solution flow rate was 8-12 g/min, the inlet air temperature was 50-60 degrees C, the outlet air temperature was 32-38 degrees C, the atomizing air pressure was 2.0 bar and the fluidized air pressure was adjusted as required.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),[g] / [min],8-12,68225,DB00898,Ethanol
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,103.6,68226,DB00898,Ethanol
,17613029,relative bioavailability,"The results showed that the CCSS had the longer value of Tmax and the lower value of Cmax, which meant an obviously sustained release effect, and its relative bioavailability of codeine and chlorpheniramine were (103.6 +/- 14.6)% and (98.1 +/- 10.3)%, respectively, compared with the reference preparation.",Preparation of codeine-resinate and chlorpheniramine-resinate sustained-release suspension and its pharmacokinetic evaluation in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17613029/),%,98.1,68227,DB00898,Ethanol
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],12 to 22,68577,DB00898,Ethanol
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00898,Ethanol
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00898,Ethanol
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kg·min],0.7 to 1.5,68580,DB00898,Ethanol
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00898,Ethanol
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],20 to 40,68582,DB00898,Ethanol
,15919096,maximal concentrations,The maximal concentrations for the sum of alkamides in human plasma were reached within 2.3 h post ingestion and averaged 336+/-131 ng eq/mL plasma.,Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919096/),[eq·ng] / [ml],336,68911,DB00898,Ethanol
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],547,69199,DB00898,Ethanol
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],531,69200,DB00898,Ethanol
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],563,69201,DB00898,Ethanol
,8018458,Cmax,"Mean Cmax (95% CI) results for ranitidine were 547 (516, 580), cimetidine 531 (501, 563), famotidine 563 (530, 598) and placebo 529 (499, 561) mg l-1.",Lack of effect of H2-receptor antagonists on the pharmacokinetics of alcohol consumed after food at lunchtime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018458/),[mg] / [l],529,69202,DB00898,Ethanol
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,29,69545,DB00898,Ethanol
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,20,69546,DB00898,Ethanol
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,45,69547,DB00898,Ethanol
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,46,69548,DB00898,Ethanol
,6360176,T50,"Average T50 amounted to 29 min in controls, was reduced to 20 min after enzyme induction by phenobarbital or 3-methylcholanthrene, and prolonged to 45, 46 and 66 min after bile duct ligation, portacaval shunt and a single dose of ethanol, respectively.",In vivo hydroxylation of 3H-acetanilide--evaluation of a new radiospirometric method in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6360176/),min,66,69549,DB00898,Ethanol
,6356898,elimination half life,"At steady state, the absorption, distribution, and elimination kinetics were similar for both dosage regimens with elimination half life of 7.65 and 7.92 hours for the 200 mg three times a day and 300 mg twice a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),h,7.65,69752,DB00898,Ethanol
,6356898,elimination half life,"At steady state, the absorption, distribution, and elimination kinetics were similar for both dosage regimens with elimination half life of 7.65 and 7.92 hours for the 200 mg three times a day and 300 mg twice a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),h,7.92,69753,DB00898,Ethanol
,6356898,steady-state plasma drug concentrations,"During the multiple dosing period average steady-state plasma drug concentrations were 0.149 mg/ml and 0.145 mg/ml for the 300 mg twice a day and 200 mg three times a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),[mg] / [ml],0.149,69754,DB00898,Ethanol
,6356898,steady-state plasma drug concentrations,"During the multiple dosing period average steady-state plasma drug concentrations were 0.149 mg/ml and 0.145 mg/ml for the 300 mg twice a day and 200 mg three times a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),[mg] / [ml],0.145,69755,DB00898,Ethanol
,2308588,re,"Though the generally accepted average of resorption deficit is 20%, which is calculated with in forensic practice, this value can occasionally be a lot higher.",[Variabilities of kinetics of alcohol catabolism]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308588/),,20,70217,DB00898,Ethanol
higher,2308588,Beta,"Beta value was found higher than 0.15%o/h, the generally accepted one, even below 1.5% blood alcohol content, above 2.5% the beta value was found to be as high as 0.33%o h.",[Variabilities of kinetics of alcohol catabolism]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308588/),[%o] / [h],0.15,70218,DB00898,Ethanol
high,2308588,beta,"Beta value was found higher than 0.15%o/h, the generally accepted one, even below 1.5% blood alcohol content, above 2.5% the beta value was found to be as high as 0.33%o h.",[Variabilities of kinetics of alcohol catabolism]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308588/),%o·h,0.33,70219,DB00898,Ethanol
,9253149,half-life of elimination,"The steady-state of bioaccumulation was approached only after several weeks of repeat oral dosing, and the half-life of elimination was approximately 1 week.","Diethanolamine absorption, metabolism and disposition in rat and mouse following oral, intravenous and dermal administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9253149/),week,1,71133,DB00898,Ethanol
,6441581,minimum concentration,"Not until after 13.1 h (20 mg/kg p.o.) and 18.5 h (40 mg/kg p.o.), respectively, concentration drops below the minimum concentration of 100 micrograms/ml presumed to be still reliably protective.",Bioavailability of orally administered mesna. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6441581/),[μg] / [ml],100,71365,DB00898,Ethanol
,7192119,absolute bioavailabiltiy,Based on these values an absolute bioavailabiltiy for the LCB-29-ointment could be estimated at 1% in an application on 200 cm2 skin.,[Pharmacokinetics and bioavailability of the myotonolytic N-(hydroxy-2-ethyl)-cinnamide (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192119/),%,1,71932,DB00898,Ethanol
,7192119,absolute bioavailability,This proved that the absorption of LCN-29 as ointment is very low compared to that in the oral application (absolute bioavailability 30%).,[Pharmacokinetics and bioavailability of the myotonolytic N-(hydroxy-2-ethyl)-cinnamide (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192119/),%,30,71933,DB00898,Ethanol
,7192119,half-life,The half-life was determined to be quite similar for all 3 routes of application: approximately 1 h.,[Pharmacokinetics and bioavailability of the myotonolytic N-(hydroxy-2-ethyl)-cinnamide (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7192119/),h,1,71934,DB00898,Ethanol
,12551760,steady state AACs,"Body weight was used to compute individualized infusion rate profiles that would achieve steady state AACs of 75, 150, and 250 mg%.",Maintaining steady state arterial alcohol levels in rats by using a physiologically based pharmacokinetic model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551760/),mg%,75,72235,DB00898,Ethanol
,12551760,steady state AACs,"Body weight was used to compute individualized infusion rate profiles that would achieve steady state AACs of 75, 150, and 250 mg%.",Maintaining steady state arterial alcohol levels in rats by using a physiologically based pharmacokinetic model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551760/),mg%,150,72236,DB00898,Ethanol
,12551760,steady state AACs,"Body weight was used to compute individualized infusion rate profiles that would achieve steady state AACs of 75, 150, and 250 mg%.",Maintaining steady state arterial alcohol levels in rats by using a physiologically based pharmacokinetic model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551760/),mg%,250,72237,DB00898,Ethanol
,18256423,times to parasite clearance,"Median times to parasite clearance and fever clearance were 41.5 and 36.8 hours, respectively.","Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256423/),h,41.5,72397,DB00898,Ethanol
,18256423,fever clearance,"Median times to parasite clearance and fever clearance were 41.5 and 36.8 hours, respectively.","Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18256423/),h,36.8,72398,DB00898,Ethanol
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,12,72602,DB00898,Ethanol
,25724154,time to maximum concentration,Median time to maximum concentration was 12 h postdose when ALO-02 was administered with water or 20 % ethanol and decreased to 8 h postdose with 40 % ethanol.,Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724154/),h,8,72603,DB00898,Ethanol
above,18076788,entrapment efficiency,The entrapment efficiency of DOC liposomes was above 75%.,[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),%,75,73588,DB00898,Ethanol
,18076788,half-life of distribution (T(1/2alpha)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),h,0.17,73589,DB00898,Ethanol
,18076788,half-life of distribution (T(1/2alpha)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),h,0.31,73590,DB00898,Ethanol
,18076788,half-life of distribution (T(1/2alpha)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),h,0.32,73591,DB00898,Ethanol
,18076788,half-life of clearance (T(1/2beta)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),h,8.54,73592,DB00898,Ethanol
,18076788,half-life of clearance (T(1/2beta)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),h,11.18,73593,DB00898,Ethanol
,18076788,half-life of clearance (T(1/2beta)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),h,10.51,73594,DB00898,Ethanol
,18076788,apparent volume of distribution (V(d)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),l,13.66,73595,DB00898,Ethanol
,18076788,apparent volume of distribution (V(d)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),l,8.65,73596,DB00898,Ethanol
,18076788,apparent volume of distribution (V(d)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),l,6.31,73597,DB00898,Ethanol
,18076788,area under the concentration-time curve from 0 to 24 h (AUC(0-->24)),"The half-life of distribution (T(1/2alpha)) were (0.17+/-0.04) h for market docetaxel injection (M-DOC), (0.31+/-0.11) h for common DOC liposome (L-DOC), and (0.32+/-0.06) h for PEG-2000-modified DOC long circulating liposome (PEG-DOC-LCL); the half-life of clearance (T(1/2beta)) were (8.54+/-1.05), (11.18+/-1.33), and (10.51+/-1.13) h, respectively; the apparent volume of distribution (V(d)) were (13.66+/-3.62), (8.65+/-1.11), and (6.31+/-0.55) L, respectively; the area under the concentration-time curve from 0 to 24 h (AUC(0-->24)) were (13.45+/-2.44), (22.83+/-3.57), and (29.31+/-5.96) mg x (h x L)(-1), respectively; the area under the concentration-time curve from 0 to infinity h (AUC(0-->infinity)) were (15.07+/-2.76), (28.70+/-4.95), and (36.95+/-9.13) mg x (h x L)(-1), respectively; the clearance (CL) were (1.10+/-0.18), (0.54+/-0.08), and (0.42+/-0.07) L/h, respectively.",[Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076788/),,13.45,73598,DB00898,Ethanol
,2609975,recovery,"The average recovery was 97.6 +/- 5.5%, the coefficient of variation was 5.64%.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),%,97.6,74331,DB00898,Ethanol
,2609975,T1/2 (alpha),"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),min,0.705,74332,DB00898,Ethanol
,2609975,T1/2 (beta),"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),min,17.869,74333,DB00898,Ethanol
,2609975,K21,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),1/[min],0.292,74334,DB00898,Ethanol
,2609975,K10,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),1/[min],0.145,74335,DB00898,Ethanol
,2609975,K12,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),1/[min],0.621,74336,DB00898,Ethanol
,2609975,Vc,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),[l] / [kg],0.152,74337,DB00898,Ethanol
,2609975,Vp,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),[l] / [kg],0.367,74338,DB00898,Ethanol
,2609975,Vd,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),[l] / [kg],0.518,74339,DB00898,Ethanol
,2609975,Clr,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),[ml] / [kg],0.021,74340,DB00898,Ethanol
,2609975,AUC,"The pharmacokinetic parameters (mean +/- SD) were T1/2 (alpha), 0.705 +/- 0.142 min; T1/2 (beta), 17.869 +/- 5.383 min; K21, 0.292 +/- 0.035 min-1; K10, 0.145 +/- 0.054 min-1; K12, 0.621 +/- 0.153 min-1; Vc, 0.152 +/- 0.029 L/kg; Vp, 0.367 +/- 0.045 L/kg; Vd, 0.518 +/- 0.062 L/kg; Clr, 0.021 +/- 0.004 ml/kg; AUC, 492.263 +/- 101.574 micrograms.min.ml-1.",[Pharmacokinetic studies on actinodaphine hydrochloride in rabbits by UV secondary derivative spectroscopy]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609975/),[min·μg] / [ml],492.263,74341,DB00898,Ethanol
,24122994,solubility,A co-solvent formulation with increased solubility of 20 mg/ml was developed and optimized.,Development and pharmacokinetic evaluation of a curcumin co-solvent formulation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122994/),[mg] / [ml],20,74401,DB00898,Ethanol
,24122994,absolute bioavailability,The intramuscular injection of formulation resulted in 30% absolute bioavailability and provided sustained release by maintaining plasma concentrations of curcumin above 240 ng/ml for up to 4 h.,Development and pharmacokinetic evaluation of a curcumin co-solvent formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122994/),%,30,74402,DB00898,Ethanol
,32691454,zeta-potential,The magnitude of negative zeta-potential increased from 3.1 to 31.0 mV at pH 2.0 to 7.4.,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),mv,3.1,74521,DB00898,Ethanol
,32691454,zeta-potential,The magnitude of negative zeta-potential increased from 3.1 to 31.0 mV at pH 2.0 to 7.4.,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),mv,31.0,74522,DB00898,Ethanol
,32691454,Bioaccessibility,Bioaccessibility of VD3 in capsules (95.76%) was significantly higher than the nonencapsulated VD3 (68.98%).,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),%,95.76,74523,DB00898,Ethanol
,32691454,Bioaccessibility,Bioaccessibility of VD3 in capsules (95.76%) was significantly higher than the nonencapsulated VD3 (68.98%).,Encapsulation of vitamin D3 in gum arabic to enhance bioavailability and stability for beverage applications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32691454/),%,68.98,74524,DB00898,Ethanol
,21787714,respirable fraction,In vitro and in vivo studies showed that drug nebulization resulted in a significant respirable fraction of 65 ± 0.6% with whole lung deposition of 13 ± 1%.,Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21787714/),%,65,74751,DB00898,Ethanol
,21787714,peak serum concentration (C(max)),"Human pharmacokinetic data was derived in 6 healthy human volunteers with peak serum concentration (C(max)) of 39 ± 3 μg/ml, while the area under curve (AUC) after inhalation was 376 ± 23 μg × h/ml indicating that the drug was rapidly and completely absorbed when targeted directly to lungs.",Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21787714/),[μg] / [ml],39,74752,DB00898,Ethanol
,21787714,area under curve (AUC),"Human pharmacokinetic data was derived in 6 healthy human volunteers with peak serum concentration (C(max)) of 39 ± 3 μg/ml, while the area under curve (AUC) after inhalation was 376 ± 23 μg × h/ml indicating that the drug was rapidly and completely absorbed when targeted directly to lungs.",Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21787714/),[h·μg] / [ml],376,74753,DB00898,Ethanol
,7600398,serum ethanol clearance rate,"Initial serum ethanol levels ranged from 13.7 to 84.2 mmol/L (63-388 mg/dL) and the mean serum ethanol clearance rate was 4.0 mmol/L/hr (18.6 mg/dL/hr), consistent with clearance rates previously reported for adults.",Serum ethanol clearance in intoxicated children and adolescents presenting to the ED. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7600398/),[mM] / [h·l],4.0,74781,DB00898,Ethanol
,8437133,peak-to-peak interval,"Both BACs and UACs increased from values below 10 mg/dl to greater than 500 mg/dl, and then decreased back to below 10 mg/dl with a mean peak-to-peak interval of 6 +/- 0.9 days.",Episodic excretion of ethanol during chronic intragastric ethanol infusion in the male rat: continuous vs. cyclic ethanol and nutrient infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437133/),d,6,75154,DB00898,Ethanol
,29055065,absolute bioavailabilities,"The pharmacokinetic results indicated that the absolute bioavailabilities of UA after oral administration of UA and UE reached 69.2 and 146.9%, respectively.","Simultaneous determination of usnic, diffractaic, evernic and barbatic acids in rat plasma by ultra-high-performance liquid chromatography-quadrupole exactive Orbitrap mass spectrometry and its application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055065/),%,69.2,75965,DB00898,Ethanol
,29055065,absolute bioavailabilities,"The pharmacokinetic results indicated that the absolute bioavailabilities of UA after oral administration of UA and UE reached 69.2 and 146.9%, respectively.","Simultaneous determination of usnic, diffractaic, evernic and barbatic acids in rat plasma by ultra-high-performance liquid chromatography-quadrupole exactive Orbitrap mass spectrometry and its application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055065/),%,146.9,75966,DB00898,Ethanol
,29055065,relative bioavailability,"Compared with UA in UE, the relative bioavailability of DA, BA and EA reached 103.7, 10.4 and 0.7% after oral administration of UE.","Simultaneous determination of usnic, diffractaic, evernic and barbatic acids in rat plasma by ultra-high-performance liquid chromatography-quadrupole exactive Orbitrap mass spectrometry and its application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055065/),%,103.7,75967,DB00898,Ethanol
,29055065,relative bioavailability,"Compared with UA in UE, the relative bioavailability of DA, BA and EA reached 103.7, 10.4 and 0.7% after oral administration of UE.","Simultaneous determination of usnic, diffractaic, evernic and barbatic acids in rat plasma by ultra-high-performance liquid chromatography-quadrupole exactive Orbitrap mass spectrometry and its application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055065/),%,10.4,75968,DB00898,Ethanol
,29055065,relative bioavailability,"Compared with UA in UE, the relative bioavailability of DA, BA and EA reached 103.7, 10.4 and 0.7% after oral administration of UE.","Simultaneous determination of usnic, diffractaic, evernic and barbatic acids in rat plasma by ultra-high-performance liquid chromatography-quadrupole exactive Orbitrap mass spectrometry and its application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055065/),%,0.7,75969,DB00898,Ethanol
,10372652,Km,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.53,77305,DB00898,Ethanol
,10372652,Km,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.97,77306,DB00898,Ethanol
,10372652,Km,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),[pM] / [mg·min],390,77307,DB00898,Ethanol
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.97,77308,DB00898,Ethanol
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),mM,0.56,77309,DB00898,Ethanol
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),[pM] / [mg·min],233,77310,DB00898,Ethanol
,10372652,Vmax,"The mean +/- standard deviation for Km and Vmax in the rat, dog and human were 0.53 +/- 0.04, 0.97 +/- 0.07, and 0.56 +/- 0.08 mM, and 390 +/- 9, 233 +/- 6, and 60 +/- 3 pmol/minute/mg protein, respectively.","Cocaethylene formation in rat, dog, and human hepatic microsomes. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372652/),[pM] / [mg·min],60,77311,DB00898,Ethanol
,10371410,maximum ethanol elimination rate,The maximum ethanol elimination rate was 0.31+/-0.20 g/h x kg.,Effect of acute ethanol administration on toloxatone pharmacokinetics in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371410/),[g] / [h·kg],0.31,77471,DB00898,Ethanol
,10371410,effective half-lives,"Toloxatone concentrations in plasma and cerebrospinal fluid were characterized by a multiexponential decay with effective half-lives of 0.39+/-0.06 and 0.56+/-0.07 hr, respectively.",Effect of acute ethanol administration on toloxatone pharmacokinetics in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371410/),h,0.39,77472,DB00898,Ethanol
,10371410,effective half-lives,"Toloxatone concentrations in plasma and cerebrospinal fluid were characterized by a multiexponential decay with effective half-lives of 0.39+/-0.06 and 0.56+/-0.07 hr, respectively.",Effect of acute ethanol administration on toloxatone pharmacokinetics in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10371410/),h,0.56,77473,DB00898,Ethanol
,1449411,peak level,"In the control group, blood ethanol concentrations in the portal vein increased rapidly, with a peak level of 9.8 +/- 1.9 mM 30 min after administration.",Effect of acetaldehyde on ethanol absorption in the canine jejunum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449411/),mM,9.8,77507,DB00898,Ethanol
,1449411,absorbed amount,"The absorbed amount of ethanol in the control and cyanamide-pretreated groups was 94.9 +/- 4.1% and 69.3 +/- 4.8%, respectively.",Effect of acetaldehyde on ethanol absorption in the canine jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449411/),%,94.9,77508,DB00898,Ethanol
,1449411,absorbed amount,"The absorbed amount of ethanol in the control and cyanamide-pretreated groups was 94.9 +/- 4.1% and 69.3 +/- 4.8%, respectively.",Effect of acetaldehyde on ethanol absorption in the canine jejunum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449411/),%,69.3,77509,DB00898,Ethanol
,22961680,maximal concentration,"After oral administration, concentrations of the three methoxyflavones quickly approached their maximal concentration, ranging from 0.55 to 0.88 μg/ml within 1 to 2 h after administration, and then were gradually excreted with half-lives of 3 to 6 h.","Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961680/),[μg] / [ml],0.55 to 0.88,78594,DB00898,Ethanol
,22961680,half-lives,"After oral administration, concentrations of the three methoxyflavones quickly approached their maximal concentration, ranging from 0.55 to 0.88 μg/ml within 1 to 2 h after administration, and then were gradually excreted with half-lives of 3 to 6 h.","Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961680/),h,3 to 6,78595,DB00898,Ethanol
,22961680,oral bioavailability,The methoxyflavones showed low oral bioavailability of 1 to 4%.,"Pharmacokinetics, bioavailability, tissue distribution, excretion, and metabolite identification of methoxyflavones in Kaempferia parviflora extract in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961680/),%,1 to 4,78596,DB00898,Ethanol
,34176378,oral bioavailability,FLB suffers from low oral bioavailability (33%) which might be due to hepatic first-pass metabolism in addition to its poor aqueous solubility.,"Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176378/),%,33,78988,DB00898,Ethanol
,34176378,saturated solubility,The optimized formula had a particle size of 443.12 ± 14.91 nm and a saturated solubility of 23.27 ± 4.62 mg/L which is five times the saturated solubility of FLB.,"Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176378/),[mg] / [l],23.27,78989,DB00898,Ethanol
,34176378,disintegration time,Sublingual tablet formulation with the shortest disintegration time (36 s) was selected for the in vivo study.,"Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176378/),s,36,78990,DB00898,Ethanol
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],140,79102,DB00898,Ethanol
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],14.7,79103,DB00898,Ethanol
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],130,79104,DB00898,Ethanol
,10187759,total body clearances,"The estimated total body clearances for cocaine, benzoylecgonine, norcocaine, and cocaethylene were 140 +/- 19, 14.7 +/- 1.2, 130 +/- 19, and 111 +/- 16 mL/min/kg, respectively.",Cocaine and alcohol interactions in the rat: contribution of cocaine metabolites to the pharmacological effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187759/),[ml] / [kg·min],111,79105,DB00898,Ethanol
,27989820,particle size distribution,"The particle size distribution, zeta potential and entrapment efficiency of optimized batch (LF-SLN7) was found to be 357.7±43.27nm, 25.29±1.15mV and 97.35±0.30%, respectively.",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),nm,357.7,79172,DB00898,Ethanol
,27989820,zeta potential,"The particle size distribution, zeta potential and entrapment efficiency of optimized batch (LF-SLN7) was found to be 357.7±43.27nm, 25.29±1.15mV and 97.35±0.30%, respectively.",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),mv,25.29,79173,DB00898,Ethanol
,27989820,entrapment efficiency,"The particle size distribution, zeta potential and entrapment efficiency of optimized batch (LF-SLN7) was found to be 357.7±43.27nm, 25.29±1.15mV and 97.35±0.30%, respectively.",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),%,97.35,79174,DB00898,Ethanol
,27989820,Cmax,"Pharmacokinetic study also showed significant increase in Cmax and area under curve (AUC0-∞) from LF-SLN7 (3860±521ng/mL and 43181±2557h×ng/mL, respectively) as compared to that of LF-control suspension (1425±563ng/mL and 19586±1537h×ng/mL, respectively).",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),[ng] / [ml],3860,79175,DB00898,Ethanol
,27989820,Cmax,"Pharmacokinetic study also showed significant increase in Cmax and area under curve (AUC0-∞) from LF-SLN7 (3860±521ng/mL and 43181±2557h×ng/mL, respectively) as compared to that of LF-control suspension (1425±563ng/mL and 19586±1537h×ng/mL, respectively).",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),[ng] / [ml],1425,79176,DB00898,Ethanol
,27989820,area under curve (AUC0-∞),"Pharmacokinetic study also showed significant increase in Cmax and area under curve (AUC0-∞) from LF-SLN7 (3860±521ng/mL and 43181±2557h×ng/mL, respectively) as compared to that of LF-control suspension (1425±563ng/mL and 19586±1537h×ng/mL, respectively).",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),[h·ng] / [ml],43181,79177,DB00898,Ethanol
,27989820,area under curve (AUC0-∞),"Pharmacokinetic study also showed significant increase in Cmax and area under curve (AUC0-∞) from LF-SLN7 (3860±521ng/mL and 43181±2557h×ng/mL, respectively) as compared to that of LF-control suspension (1425±563ng/mL and 19586±1537h×ng/mL, respectively).",In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27989820/),[h·ng] / [ml],19586,79178,DB00898,Ethanol
,21855624,AUC,"The pharmacokinetic results indicated that the AUC was 565±95.1 and 1163±273 min μg/mL and the t(1/2) of GPS was 71±9 and 106±17 min after intravenous and oral administration, respectively.",Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21855624/),[min·μg] / [ml],565,79501,DB00898,Ethanol
,21855624,AUC,"The pharmacokinetic results indicated that the AUC was 565±95.1 and 1163±273 min μg/mL and the t(1/2) of GPS was 71±9 and 106±17 min after intravenous and oral administration, respectively.",Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21855624/),[min·μg] / [ml],1163,79502,DB00898,Ethanol
,21855624,t(1/2),"The pharmacokinetic results indicated that the AUC was 565±95.1 and 1163±273 min μg/mL and the t(1/2) of GPS was 71±9 and 106±17 min after intravenous and oral administration, respectively.",Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21855624/),min,71,79503,DB00898,Ethanol
,21855624,t(1/2),"The pharmacokinetic results indicated that the AUC was 565±95.1 and 1163±273 min μg/mL and the t(1/2) of GPS was 71±9 and 106±17 min after intravenous and oral administration, respectively.",Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21855624/),min,106,79504,DB00898,Ethanol
,21855624,oral bioavailability,The oral bioavailability of GPS was 10.3±2.4% in the rats.,Isolation of gentiopicroside from Gentianae Radix and its pharmacokinetics on liver ischemia/reperfusion rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21855624/),%,10.3,79505,DB00898,Ethanol
,34410358,PCT,"All single or multiple cipargamin doses ≥50 mg were associated with rapid parasite clearance, with median PCT of 8 hours versus 24 hours for artemether-lumefantrine.","Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34410358/),h,8,79605,DB00898,Ethanol
,34410358,PCT,"All single or multiple cipargamin doses ≥50 mg were associated with rapid parasite clearance, with median PCT of 8 hours versus 24 hours for artemether-lumefantrine.","Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34410358/),h,24,79606,DB00898,Ethanol
,7199922,biological half-life,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),h,3.6,79912,DB00898,Ethanol
,7199922,body clearance,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),[l] / [h·kg],0.26,79913,DB00898,Ethanol
,7199922,volume of the reference compartment,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),[l] / [kg],0.47,79914,DB00898,Ethanol
,7199922,volume in the steady state,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),[l] / [kg],1.01,79915,DB00898,Ethanol
,7199922,absolute bioavailability,The absolute bioavailability is calculated at 10%.,"Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),%,10,79916,DB00898,Ethanol
,2229205,flow rate,"The mobile phase consisted of ethanol:water:glacial acetic acid (65:34:1, v/v) pumped isocratically at a flow rate of 1.3 ml/min.",High-performance liquid chromatographic analysis of indomethacin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229205/),[ml] / [min],1.3,80117,DB00898,Ethanol
,2229205,absolute recoveries,"Quantification was achieved by the measurement of the peak area ratio, and the absolute recoveries ranged from 94 to 97%.",High-performance liquid chromatographic analysis of indomethacin in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2229205/),%,94 to 97,80118,DB00898,Ethanol
,19506482,area under the curve (AUC) (AUC0-264,PK of lumefantrine was influenced by LPV/r resulting in 2- to 3-fold increases in area under the curve (AUC) (AUC0-264: 413 versus 931 h.microg.mL; AUC0-inf: 456 versus 1073 h.microg.mL).,Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·μg,413,80207,DB00898,Ethanol
,19506482,area under the curve (AUC) (AUC0-264,PK of lumefantrine was influenced by LPV/r resulting in 2- to 3-fold increases in area under the curve (AUC) (AUC0-264: 413 versus 931 h.microg.mL; AUC0-inf: 456 versus 1073 h.microg.mL).,Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·μg,931,80208,DB00898,Ethanol
,19506482,AUC0-inf,PK of lumefantrine was influenced by LPV/r resulting in 2- to 3-fold increases in area under the curve (AUC) (AUC0-264: 413 versus 931 h.microg.mL; AUC0-inf: 456 versus 1073 h.microg.mL).,Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·μg,456,80209,DB00898,Ethanol
,19506482,AUC0-inf,PK of lumefantrine was influenced by LPV/r resulting in 2- to 3-fold increases in area under the curve (AUC) (AUC0-264: 413 versus 931 h.microg.mL; AUC0-inf: 456 versus 1073 h.microg.mL).,Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·μg,1073,80210,DB00898,Ethanol
,19506482,Cmax,"For artemether, trends toward Cmax and AUC decreases (Cmax 14.3 versus 11.2 ng/mL and 42.7-62.0 versus 25.9-40.5 h.ng.mL for AUC) were noted during coadministration.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),[ng] / [ml],14.3,80211,DB00898,Ethanol
,19506482,Cmax,"For artemether, trends toward Cmax and AUC decreases (Cmax 14.3 versus 11.2 ng/mL and 42.7-62.0 versus 25.9-40.5 h.ng.mL for AUC) were noted during coadministration.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),[ng] / [ml],11.2,80212,DB00898,Ethanol
,19506482,AUC,"For artemether, trends toward Cmax and AUC decreases (Cmax 14.3 versus 11.2 ng/mL and 42.7-62.0 versus 25.9-40.5 h.ng.mL for AUC) were noted during coadministration.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),[ng] / [ml],11.2,80213,DB00898,Ethanol
,19506482,AUC,"For artemether, trends toward Cmax and AUC decreases (Cmax 14.3 versus 11.2 ng/mL and 42.7-62.0 versus 25.9-40.5 h.ng.mL for AUC) were noted during coadministration.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·ng,42.7-62.0,80214,DB00898,Ethanol
,19506482,AUC,"For artemether, trends toward Cmax and AUC decreases (Cmax 14.3 versus 11.2 ng/mL and 42.7-62.0 versus 25.9-40.5 h.ng.mL for AUC) were noted during coadministration.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·ng,25.9-40.5,80215,DB00898,Ethanol
,19506482,Cmax,"For DHA, decreases in Cmax (58.8 versus 37.3 ng/mL) and AUC (190-198 versus 104-109 h.ng.mL) were observed during coadministration without changes in DHA:artemether AUC ratios.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),[ng] / [ml],58.8,80216,DB00898,Ethanol
,19506482,Cmax,"For DHA, decreases in Cmax (58.8 versus 37.3 ng/mL) and AUC (190-198 versus 104-109 h.ng.mL) were observed during coadministration without changes in DHA:artemether AUC ratios.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),[ng] / [ml],37.3,80217,DB00898,Ethanol
,19506482,AUC,"For DHA, decreases in Cmax (58.8 versus 37.3 ng/mL) and AUC (190-198 versus 104-109 h.ng.mL) were observed during coadministration without changes in DHA:artemether AUC ratios.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·ng,190-198,80218,DB00898,Ethanol
,19506482,AUC,"For DHA, decreases in Cmax (58.8 versus 37.3 ng/mL) and AUC (190-198 versus 104-109 h.ng.mL) were observed during coadministration without changes in DHA:artemether AUC ratios.",Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19506482/),h·ml·ng,104-109,80219,DB00898,Ethanol
,11829132,half-life,"Results from data analysis showed non-linear pharmacokinetics of ABT-773, noted by the increases in half-life (3.1 to 27.2 h) and AUC/dose (23.7 to 149 mg h(-1) L(-1) mg(-1)), with doses from 25 to 200 mg kg(-1).","Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11829132/),h,3.1 to 27.2,80281,DB00898,Ethanol
,11829132,AUC/dose,"Results from data analysis showed non-linear pharmacokinetics of ABT-773, noted by the increases in half-life (3.1 to 27.2 h) and AUC/dose (23.7 to 149 mg h(-1) L(-1) mg(-1)), with doses from 25 to 200 mg kg(-1).","Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11829132/),[mg] / [h·l·mg],23.7 to 149,80282,DB00898,Ethanol
,11829132,total volume of distribution,The total volume of distribution was 0.316 L.,"Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11829132/),l,0.316,80283,DB00898,Ethanol
,11829132,clearance for the linear first-order elimination,The clearance for the linear first-order elimination was 0.0027 L h(-1).,"Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11829132/),[l] / [h],0.0027,80284,DB00898,Ethanol
,11829132,Vm,"The Vm and Km were 0.0385 L h(-1) and 0.141 mg L(-1), respectively, for the capacity-limited elimination.","Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11829132/),[l] / [h],0.0385,80285,DB00898,Ethanol
,11829132,Km,"The Vm and Km were 0.0385 L h(-1) and 0.141 mg L(-1), respectively, for the capacity-limited elimination.","Pharmacokinetics of ABT-773, a new semi-synthetic ketolide in neutropenic lung-infected mice: a population approach. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11829132/),[mg] / [l],0.141,80286,DB00898,Ethanol
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,1,80668,DB00898,Ethanol
,8120112,peak height,Linear relationships between the amount of drug and peak height were confirmed at 1-20 micrograms/ml in serum for carbamazepine and 5-40 micrograms/ml in serum for phenytoin and phenobarbital.,Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120112/),,5-40,80669,DB00898,Ethanol
,20542476,flow rate,"Separation of GAS was achieved on an AichromBond-AQ C18 column (5 microm, 150 mm x 4.6 mm) with the mobile phase of methanol-0.1% phosphoric acid solution (2:98, v/v) at a flow rate of 0.8 ml/min.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),[ml] / [min],0.8,80821,DB00898,Ethanol
over,20542476,extraction recoveries,The extraction recoveries were over 65% with RSDs less than 5.50%.,Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),%,65,80822,DB00898,Ethanol
,20542476,C(max),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),[ng] / [ml],1484.55,80823,DB00898,Ethanol
,20542476,T(max),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),h,0.81,80824,DB00898,Ethanol
,20542476,t(1/2alpha),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),h,3.78,80825,DB00898,Ethanol
,20542476,t(1/2beta),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),h,6.06,80826,DB00898,Ethanol
,20542476,t(1/2Ka),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),h,0.18,80827,DB00898,Ethanol
,20542476,K(12),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),1/[h],0.18,80828,DB00898,Ethanol
,20542476,K(21),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),1/[h],0.20,80829,DB00898,Ethanol
,20542476,K(10),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),1/[h],4.11,80830,DB00898,Ethanol
,20542476,V1/F,"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),l,180.35,80831,DB00898,Ethanol
,20542476,CL/F,"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),[l] / [h],62.50,80832,DB00898,Ethanol
,20542476,AUC(0-->t),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),h,5619.41,80833,DB00898,Ethanol
,20542476,AUC(0-->infinity),"The pharmacokinetic parameters of GAS in human plasma after an oral administration of 200 mg GAS capsule were described as: C(max), 1484.55+/-285.05 ng/ml; T(max), 0.81+/-0.16 h; t(1/2alpha), 3.78+/-2.33 h; t(1/2beta), 6.06+/-3.20 h; t(1/2Ka), 0.18+/-0.53 h; K(12), 0.18+/-0.41/h; K(21), 0.20+/-0.16/h; K(10), 4.11+/-15.81/h; V1/F, 180.35+/-89.44 L; CL/F, 62.50+/-140.03 l/h; AUC(0-->t), 5619.41+/-1972.88 (ng/ml) h; and AUC(0-->infinity), 7210.26+/-3472.74 (ng/ml) h, respectively.",Determination and pharmacokinetics of gastrodin in human plasma by HPLC coupled with photodiode array detector. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20542476/),,7210,80834,DB00898,Ethanol
over,34237365,Final reversibility,Final reversibility of the IgG microbeads with trehalose was over 99% at both low and high protein concentrations.,Protein microbeadification to achieve highly concentrated protein formulation with reversible properties and in vivo pharmacokinetics after reconstitution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34237365/),%,99,80864,DB00898,Ethanol
,33313887,limit of detection,The limit of detection was 3 pg/mL (S/N > 5) for A-F and B-F.,Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),[pg] / [ml],3,81016,DB00898,Ethanol
>,33313887,S/N,The limit of detection was 3 pg/mL (S/N > 5) for A-F and B-F.,Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),,5,81017,DB00898,Ethanol
,33313887,Extraction recoveries,"Extraction recoveries were 91.3%-97.6% with RSD ≤ 11.2% and 90.5%-94.3% with RSD ≤ 10.5% for A-F and B-F, respectively.",Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),%,91.,81018,DB00898,Ethanol
,33313887,Extraction recoveries,"Extraction recoveries were 91.3%-97.6% with RSD ≤ 11.2% and 90.5%-94.3% with RSD ≤ 10.5% for A-F and B-F, respectively.",Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),%,90.5,81019,DB00898,Ethanol
,33313887,LOD,"This assay, for which the LOD was 3 pg/mL for A-F and B-F may help the forensic science field to determine fentanyl analogue-related causes of death and identify illicit drug tampering.",Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),[pg] / [ml],3,81020,DB00898,Ethanol
,6149656,terminal half-lives,"After an i.v. dose (1 mg/kg), the plasma concentration-time curve fitted a two-compartment open model with terminal half-lives of 2.5 h in rats, 2.1 h in dogs and 1.8 h in monkeys.","Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149656/),h,2.5,81169,DB00898,Ethanol
,6149656,terminal half-lives,"After an i.v. dose (1 mg/kg), the plasma concentration-time curve fitted a two-compartment open model with terminal half-lives of 2.5 h in rats, 2.1 h in dogs and 1.8 h in monkeys.","Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149656/),h,2.1,81170,DB00898,Ethanol
,6149656,terminal half-lives,"After an i.v. dose (1 mg/kg), the plasma concentration-time curve fitted a two-compartment open model with terminal half-lives of 2.5 h in rats, 2.1 h in dogs and 1.8 h in monkeys.","Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149656/),h,1.8,81171,DB00898,Ethanol
,6149656,systemic availabilities,"The systemic availabilities of the drug in rats, dogs and monkeys were 22-31%, 51-59% and 57-66%, respectively.","Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149656/),%,22-31,81172,DB00898,Ethanol
,6149656,systemic availabilities,"The systemic availabilities of the drug in rats, dogs and monkeys were 22-31%, 51-59% and 57-66%, respectively.","Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149656/),%,51-59,81173,DB00898,Ethanol
,6149656,systemic availabilities,"The systemic availabilities of the drug in rats, dogs and monkeys were 22-31%, 51-59% and 57-66%, respectively.","Pharmacokinetics of amosulalol, an alpha, beta-adrenoceptor blocker, in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149656/),%,57-66,81174,DB00898,Ethanol
,2737224,steady-state plasma concentration,The plasma concentrations increased with increasing dose; at the highest dose a mean steady-state plasma concentration of 22.1 ng.,Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),ng,22.1,81328,DB00898,Ethanol
,2737224,plasma clearance,"ml-1 was obtained, and the mean plasma clearance was 1.41.kg-1.h-1.",Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),1/[h·kg],1.41,81329,DB00898,Ethanol
,2737224,steady-state plasma concentration,A mean steady-state plasma concentration of 17.6 ng.,Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),ng,17.6,81330,DB00898,Ethanol
,2737224,plasma clearance,ml-1 was obtained and the mean plasma clearance was 1.91.kg-1.h-1.,Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),,1.91.,81331,DB00898,Ethanol
,31614750,absolute oral bioavailability,"The pharmacokinetic study demonstrated that the absolute oral bioavailability for quercetin and kaempferol was determined to be 4.6% and 1.6%, respectively.",Pharmacokinetics and Novel Metabolite Identification of Tartary Buckwheat Extracts in Beagle Dogs Following Co-Administration with Ethanol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31614750/),%,4.6,81574,DB00898,Ethanol
,31614750,absolute oral bioavailability,"The pharmacokinetic study demonstrated that the absolute oral bioavailability for quercetin and kaempferol was determined to be 4.6% and 1.6%, respectively.",Pharmacokinetics and Novel Metabolite Identification of Tartary Buckwheat Extracts in Beagle Dogs Following Co-Administration with Ethanol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31614750/),%,1.6,81575,DB00898,Ethanol
,11129729,t 1/2,Pharmacokinetic analyses revealed a low elimination-rate of Cremophor EL (CI=37.8-134 ml/h/m2; t 1/2=34.4-61.5 h) and a volume of distribution similar to the volume of the central blood compartment (Vss=4.96-7.85 l).,Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129729/),h,34.4-61.5,82296,DB00898,Ethanol
,11129729,Vss,Pharmacokinetic analyses revealed a low elimination-rate of Cremophor EL (CI=37.8-134 ml/h/m2; t 1/2=34.4-61.5 h) and a volume of distribution similar to the volume of the central blood compartment (Vss=4.96-7.85 l).,Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129729/),l,4.96-7.85,82297,DB00898,Ethanol
,10595840,amount,The amount of ethanol recovered in urine was 681 mg (standard deviation [SD] 203 mg) corresponding to 1.5% (SD 0.46%) of the dose administered.,"Impact of water-induced diuresis on excretion profiles of ethanol, urinary creatinine, and urinary osmolality. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595840/),mg,681,82659,DB00898,Ethanol
,3900139,half life,The maximum level was achieved after 2-3 hrs with approximately 280 pg mabuterol /ml of plasma and the half life of mabuterol was estimated to be 19.5 hrs.,"Enzyme immunoassay for mabuterol, a selective beta 2-adrenergic stimulant in the trachea. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3900139/),h,19.5,83092,DB00898,Ethanol
,29128276,Total chromatographic run time,Total chromatographic run time was 10.5min.,"Simultaneous determination of saikosaponin a, paeonol, and imperatorin, components of DA-9805, in rat plasma by LC-MS/MS and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128276/),min,10.5,83905,DB00898,Ethanol
,29128276,m/,"Multiple reaction monitoring mode was used for mass spectrometry; the transitions were m/z 779.5→617.2 for saikosaponin a in negative-ion mode, m/z 167→149 for paeonol and m/z 271.1→203 for imperatorin in positive-ion mode.","Simultaneous determination of saikosaponin a, paeonol, and imperatorin, components of DA-9805, in rat plasma by LC-MS/MS and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128276/),,779.5,83906,DB00898,Ethanol
,29128276,m/,"Multiple reaction monitoring mode was used for mass spectrometry; the transitions were m/z 779.5→617.2 for saikosaponin a in negative-ion mode, m/z 167→149 for paeonol and m/z 271.1→203 for imperatorin in positive-ion mode.","Simultaneous determination of saikosaponin a, paeonol, and imperatorin, components of DA-9805, in rat plasma by LC-MS/MS and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128276/),,167,83907,DB00898,Ethanol
,29128276,m/z,"Multiple reaction monitoring mode was used for mass spectrometry; the transitions were m/z 779.5→617.2 for saikosaponin a in negative-ion mode, m/z 167→149 for paeonol and m/z 271.1→203 for imperatorin in positive-ion mode.","Simultaneous determination of saikosaponin a, paeonol, and imperatorin, components of DA-9805, in rat plasma by LC-MS/MS and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128276/),,271.1,83908,DB00898,Ethanol
,29128276,m/z,"Multiple reaction monitoring mode was used for mass spectrometry; the transitions were m/z 779.5→617.2 for saikosaponin a in negative-ion mode, m/z 167→149 for paeonol and m/z 271.1→203 for imperatorin in positive-ion mode.","Simultaneous determination of saikosaponin a, paeonol, and imperatorin, components of DA-9805, in rat plasma by LC-MS/MS and application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128276/),,203,83909,DB00898,Ethanol
,8838439,Km,Using the technique of simultaneous fitting across all doses the Km and Vmax constants were similar and close to literature value of 100 mg l-1 and 200-300 mg h l-1 respectively.,"Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838439/),[mg] / [l],100,84400,DB00898,Ethanol
,8838439,Vmax,Using the technique of simultaneous fitting across all doses the Km and Vmax constants were similar and close to literature value of 100 mg l-1 and 200-300 mg h l-1 respectively.,"Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1). ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838439/),[mg] / [l],100,84401,DB00898,Ethanol
,1516610,peak concentration,The peak concentration of ethanol in plasma was 120 mg.,Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516610/),mg,120,84733,DB00898,Ethanol
,1516610,disappearance rate,The disappearance rate of ethanol from plasma was 18.6 mg.,Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516610/),mg,18.6,84734,DB00898,Ethanol
,1516610,apparent volume of distribution of ethanol (Vz),The apparent volume of distribution of ethanol (Vz) was 0.54 l.kg-1 according to plasma kinetics compared to 0.59 l.kg-1 for the kinetics derived from whole blood.,Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516610/),[l] / [kg],0.54,84735,DB00898,Ethanol
,1516610,apparent volume of distribution of ethanol (Vz),The apparent volume of distribution of ethanol (Vz) was 0.54 l.kg-1 according to plasma kinetics compared to 0.59 l.kg-1 for the kinetics derived from whole blood.,Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516610/),[l] / [kg],0.59,84736,DB00898,Ethanol
,1516610,area under the curve (AUC),The mean area under the curve (AUC) was 294 mg.,Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516610/),mg,294,84737,DB00898,Ethanol
,1516610,TBW,The TBW was 40.9 l or 50.9% of body weight for the plasma concentration-time data.,Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516610/),l,40.9,84738,DB00898,Ethanol
<,31704259,half-lives,"Elimination of these metabolites was rapid, with half-lives <4 h for each one.",The urinary metabolic profile of diethylene glycol methyl ether and triethylene glycol methyl ether in Sprague-Dawley rats and the role of the metabolite methoxyacetic acid in their toxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704259/),h,4,85167,DB00898,Ethanol
,22326299,zeta potentials,Stable colloidal dispersions of the nanoparticles were formed with zeta potentials of the range of -24.9 to -38.4 mV.,"Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326299/),mv,24.9,85214,DB00898,Ethanol
,22326299,zeta potentials,Stable colloidal dispersions of the nanoparticles were formed with zeta potentials of the range of -24.9 to -38.4 mV.,"Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326299/),mv,38.4,85215,DB00898,Ethanol
,33948767,zeta potential,"API-ETHO2 was spherical with an average size of 145.1±12.3 nm, zeta potential of -20±4 mV, entrapment efficiency of 67.11%±3.26, and in vitro % release of 79.54%±4.1.","Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),mv,-20,85455,DB00898,Ethanol
,33948767,entrapment efficiency,"API-ETHO2 was spherical with an average size of 145.1±12.3 nm, zeta potential of -20±4 mV, entrapment efficiency of 67.11%±3.26, and in vitro % release of 79.54%±4.1.","Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),%,67.11,85456,DB00898,Ethanol
,33948767,% release,"API-ETHO2 was spherical with an average size of 145.1±12.3 nm, zeta potential of -20±4 mV, entrapment efficiency of 67.11%±3.26, and in vitro % release of 79.54%±4.1.","Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),%,79.54,85457,DB00898,Ethanol
,33948767,permeation,Apixaban ethosomal in situ gel evolved higher ex vivo permeation (1.499±0.11 μg/cm2h) through the nasal mucosa than pure apixaban gel.,"Intranasal In Situ Gel of Apixaban-Loaded Nanoethosomes: Preparation, Optimization, and In Vivo Evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33948767/),[μg] / [cm2h],1.499,85458,DB00898,Ethanol
,1377706,area under the total IGF-I concentration curve,"The area under the total IGF-I concentration curve was greater on day 5 than day 1 (311 +/- 99 min.g/L vs. 249 +/- 77, P = 0.0001).","Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1377706/),[g·min] / [l],311,85461,DB00898,Ethanol
,1377706,area under the total IGF-I concentration curve,"The area under the total IGF-I concentration curve was greater on day 5 than day 1 (311 +/- 99 min.g/L vs. 249 +/- 77, P = 0.0001).","Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1377706/),,249,85462,DB00898,Ethanol
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],1103.2,85610,DB00898,Ethanol
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85611,DB00898,Ethanol
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85612,DB00898,Ethanol
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],208.5,85613,DB00898,Ethanol
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],383.1,85614,DB00898,Ethanol
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],1.7,85615,DB00898,Ethanol
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],0.5,85616,DB00898,Ethanol
,24786480,en,"Due to the lipophilic nature of both antimalarial drugs, both single drugs-loaded and co-loaded NLCs have shown high encapsulation efficiency, which is 84% for artemether and 79% for lumefantrine.",Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786480/),%,84,86249,DB00898,Ethanol
,24786480,en,"Due to the lipophilic nature of both antimalarial drugs, both single drugs-loaded and co-loaded NLCs have shown high encapsulation efficiency, which is 84% for artemether and 79% for lumefantrine.",Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786480/),%,79,86250,DB00898,Ethanol
,19818171,terminal elimination half-life,"Lumefantrine is absorbed and cleared more slowly (terminal elimination half-life 3-4 days in malaria patients), and accumulates with successive doses, acting to prevent recrudescence by destroying any residual parasites that remain after artemether and DHA have been cleared from the body.",Understanding the pharmacokinetics of Coartem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19818171/),d,3-4,86574,DB00898,Ethanol
,6151170,serum half-life,It achieves peak serum concentrations within one hour and has a serum half-life of 2 to 5 hours.,"Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151170/),h,2 to 5,86750,DB00898,Ethanol
,31623262,viscosity,"The physicochemical properties of F7 (pH: 7.1 ± 0.15, viscosity: 8943 ± 116 centipoise, drug content: 98.81% ± 2.16%) seem ideal for transdermal application.",Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623262/),centipoise,8943,86770,DB00898,Ethanol
,31623262,transdermal flux,Greater transdermal flux (30.86 ± 4.08 µg/cm2/h) was observed in F7 as compared with other prepared gels.,Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623262/),[μg] / [cm2·h],30.86,86771,DB00898,Ethanol
,31623262,AUC0-α,Noticeable enhancement in AUC0-α value (986.52 ± 382.63 ng.h/ml; p < 0.01) of transdermal therapy (~2-fold higher compared with oral administration) established the potential of F7 to improve the rate and extent of nebivolol delivery.,Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623262/),[h·ng] / [ml],986.52,86772,DB00898,Ethanol
,17356822,oral bioavailability,(+/-)-Gossypol and (-)-gossypol showed comparable pharmacokinetic profile and oral bioavailability (12.2-17.6%) with some variations of clearance and V (ss) following oral and intravenous administration to mice.,"Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17356822/),%,12.2-17.6,87040,DB00898,Ethanol
,17356822,T (max),"At the same molar dose, apogossypol showed delayed T (max)(1 h), a slower clearance rate and less distribution after administration to mice.","Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17356822/),h,1,87041,DB00898,Ethanol
,21947399,concentrations,"Median (range) day 7 lumefantrine concentrations were 622 ng/ml (185 to 2,040 ng/ml) and 336 ng/ml (29 to 934 ng/ml) in the nevirapine and ART-naïve groups, respectively (P = 0.0002).",Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21947399/),[ng] / [ml],622,87361,DB00898,Ethanol
,21947399,concentrations,"Median (range) day 7 lumefantrine concentrations were 622 ng/ml (185 to 2,040 ng/ml) and 336 ng/ml (29 to 934 ng/ml) in the nevirapine and ART-naïve groups, respectively (P = 0.0002).",Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21947399/),[ng] / [ml],336,87362,DB00898,Ethanol
less,8314938,completion time,"The completion time for assay was less than 15 min, and the lower limit of quantitation was 10 ng/ml for a 100-microliters injection volume.",Determination of diltiazem hydrochloride in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314938/),min,15,87469,DB00898,Ethanol
,17322143,alpha half-life,Dapoxetine was rapidly absorbed and eliminated; peak concentrations were noted 1.47 hours after administration and decreased with an alpha half-life of 1.33 hours and a terminal half-life of 15.6 hours.,Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322143/),h,1.33,87855,DB00898,Ethanol
,17322143,terminal half-life,Dapoxetine was rapidly absorbed and eliminated; peak concentrations were noted 1.47 hours after administration and decreased with an alpha half-life of 1.33 hours and a terminal half-life of 15.6 hours.,Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322143/),h,15.6,87856,DB00898,Ethanol
,10640577,t(1/2) beta,"PEGylated liposomes were long-circulating liposomes, with an increased t(1/2) beta 48.6 h, against t(1/2) beta 9.27 h of conventional liposomes.","Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640577/),h,48.6,88076,DB00898,Ethanol
,10640577,t(1/2) beta,"PEGylated liposomes were long-circulating liposomes, with an increased t(1/2) beta 48.6 h, against t(1/2) beta 9.27 h of conventional liposomes.","Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640577/),h,9.27,88077,DB00898,Ethanol
,15500572,half-life,"Mean +/- SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 +/-0.6 h, 5.1 +/- 2.6 L/kg, and 33.8 +/- 16.5 mL/min/kg.",Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),h,2.0,88082,DB00898,Ethanol
,15500572,apparent volume of distribution,"Mean +/- SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 +/-0.6 h, 5.1 +/- 2.6 L/kg, and 33.8 +/- 16.5 mL/min/kg.",Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),[l] / [kg],5.1,88083,DB00898,Ethanol
,15500572,clearance,"Mean +/- SD values for half-life, apparent volume of distribution, and clearance after i.v. administration were 2.0 +/-0.6 h, 5.1 +/- 2.6 L/kg, and 33.8 +/- 16.5 mL/min/kg.",Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),[ml] / [kg·min],33.8,88084,DB00898,Ethanol
,15500572,Oral bioavailability,Oral bioavailability was 11% as calculated from naive pooled data.,Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15500572/),%,11,88085,DB00898,Ethanol
,22271601,flow rate,"The enantioseparation was carried out on a Chiral®-AD column using methanol:ethanol (80:20, v/v) as the mobile phase at the flow rate 0.4 ml/min.",Chiral HPLC determination and stereoselective pharmacokinetics of tetrahydroberberine enantiomers in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271601/),[ml] / [min],0.4,88388,DB00898,Ethanol
,22271601,ratio of AUC(0-∞),"The (-)/(+)-enantiomer ratio of AUC(0-∞) after oral and intravenous administration were 2.17 and 1.43, respectively.",Chiral HPLC determination and stereoselective pharmacokinetics of tetrahydroberberine enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271601/),,2.17,88389,DB00898,Ethanol
,22271601,ratio of AUC(0-∞),"The (-)/(+)-enantiomer ratio of AUC(0-∞) after oral and intravenous administration were 2.17 and 1.43, respectively.",Chiral HPLC determination and stereoselective pharmacokinetics of tetrahydroberberine enantiomers in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271601/),,1.43,88390,DB00898,Ethanol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],1·78,88983,DB00898,Ethanol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],4·24,88984,DB00898,Ethanol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],0·58,88985,DB00898,Ethanol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],0·79,88986,DB00898,Ethanol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,1·37,88987,DB00898,Ethanol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,3·11,88988,DB00898,Ethanol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,3·96,88989,DB00898,Ethanol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,7·33,88990,DB00898,Ethanol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],17·26,88991,DB00898,Ethanol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],106·20,88992,DB00898,Ethanol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],13·03,88993,DB00898,Ethanol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],74·56,88994,DB00898,Ethanol
,10628425,biologic potency,"The biologic potency of the synthesized cCT in rats is 24 IU/mg of peptide, which is low in comparison with the 4,000 IU/mg of the salmon CT standard.",Biological potency and radioimmunoassay of canine calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628425/),[iu] / [mg],24,89022,DB00898,Ethanol
,10628425,biologic potency,"The biologic potency of the synthesized cCT in rats is 24 IU/mg of peptide, which is low in comparison with the 4,000 IU/mg of the salmon CT standard.",Biological potency and radioimmunoassay of canine calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628425/),,4,89023,DB00898,Ethanol
,10628425,potency,"In the dog, an even lower potency of 4.4 IU/mg of cCT was found.",Biological potency and radioimmunoassay of canine calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628425/),[iu] / [mg],4.4,89024,DB00898,Ethanol
less,10628425,biologic half-life,"Measurement of the disappearance of iv-injected radioiodinated or nonradioiodinated cCT revealed a short biologic half-life of less than 3 min, followed by a long half-life of 20 min.",Biological potency and radioimmunoassay of canine calcitonin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628425/),min,3,89025,DB00898,Ethanol
,10628425,half-life,"Measurement of the disappearance of iv-injected radioiodinated or nonradioiodinated cCT revealed a short biologic half-life of less than 3 min, followed by a long half-life of 20 min.",Biological potency and radioimmunoassay of canine calcitonin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628425/),min,20,89026,DB00898,Ethanol
,10628425,detection limit,"Using a final antiserum dilution of 1:12,000 and 125I-labeled synthetic cCT, the RIA had a detection limit of 6.5 ng/l.",Biological potency and radioimmunoassay of canine calcitonin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10628425/),[ng] / [l],6.5,89027,DB00898,Ethanol
,6961762,elimination half-life,The elimination half-life was 1.6 to 8.5 h for the first 8 h.,Single-dose pharmacokinetics of labetalol in healthy young men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961762/),h,1.6 to 8.5,89168,DB00898,Ethanol
,6961762,oral bioavailability,The oral bioavailability ranged from 4 to 23%.,Single-dose pharmacokinetics of labetalol in healthy young men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961762/),%,4 to 23,89169,DB00898,Ethanol
,6478731,coefficients A,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),[μg] / [ml],0.85,90348,DB00898,Ethanol
,6478731,B,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),[μg] / [ml],0.22,90349,DB00898,Ethanol
,6478731,rate constants alpha,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),1/[h],2.78,90350,DB00898,Ethanol
,6478731,beta,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),1/[h],0.25,90351,DB00898,Ethanol
,6478731,"elimination rate constants, k12","Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),1/[h],1.36,90352,DB00898,Ethanol
,6478731,k21,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),1/[h],0.78,90353,DB00898,Ethanol
,6478731,kel,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),1/[h],0.88,90354,DB00898,Ethanol
,6478731,terminal phase volume of distribution,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),[l] / [kg],0.75,90355,DB00898,Ethanol
,6478731,clearance,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),[l] / [h],8.09,90356,DB00898,Ethanol
,6478731,AUC,"Kinetics were as follows: coefficients A = 0.85 +/- 0.09 microgram/ml and B = 0.22 +/- 0.01 microgram/ml; rate constants alpha = 2.78 +/- 0.24 hr-1 and beta = 0.25 +/- 0.01 hr-1; elimination rate constants, k12 = 1.36 +/- 0.17 hr-1, k21 = 0.78 +/- 0.06 hr-1, and kel = 0.88 +/- 0.06 hr-1; terminal phase volume of distribution = 0.75 +/- 0.06 l/kg; clearance = 8.09 +/- 0.54 l/hr; AUC = 1.22 +/- 0.09 microgram .","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),μg,1.22,90357,DB00898,Ethanol
,6478731,t1/2 alpha,hr/ml; and t1/2 alpha = 0.26 +/- 0.02 hr and t1/2 beta = 2.8 +/- 0.1 hr.,"Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),h,0.26,90358,DB00898,Ethanol
,6478731,t1/2 beta,hr/ml; and t1/2 alpha = 0.26 +/- 0.02 hr and t1/2 beta = 2.8 +/- 0.1 hr.,"Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),h,2.8,90359,DB00898,Ethanol
,6478731,t1/2,"Maximum plasma concentrations and AUC increased in a dose-dependent manner, whereas t1/2 were about 5 hr (range 4.4 to 5.7 hr) at each dose.","Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),h,5,90360,DB00898,Ethanol
,6478731,Systemic availability,Systemic availability of amosulalol was about 100% as determined by the ratio of AUC after oral and intravenous dosing.,"Amosulalol, a combined alpha and beta adrenoceptor antagonist: kinetics after intravenous and oral doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478731/),%,100,90361,DB00898,Ethanol
<,19564366,capillary plasma concentrations,"A high proportion of all women (40%, 41/103) had day 7 capillary plasma concentrations of <355 ng/ml (which corresponds to approximately <280 ng/ml in venous plasma), a threshold previously associated with an increased risk of therapeutic failure in nonpregnant patients in this area.",Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564366/),[ng] / [ml],355,90615,DB00898,Ethanol
<,19564366,capillary plasma concentrations,"A high proportion of all women (40%, 41/103) had day 7 capillary plasma concentrations of <355 ng/ml (which corresponds to approximately <280 ng/ml in venous plasma), a threshold previously associated with an increased risk of therapeutic failure in nonpregnant patients in this area.",Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564366/),ng,280,90616,DB00898,Ethanol
,7273603,total phenytoin clearance,The mean (+/- SD) total phenytoin clearance in 9 of 11 subjects was 0.023 +/- 0.006 l/kg/hr during the alcohol ingestion period.,Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273603/),[l] / [h·kg],0.023,90737,DB00898,Ethanol
,7273603,Clearance,Clearance rose to 0.033 +/- 0.013 l/kg/hr (P less than 0.05) during alcohol withdrawal.,Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273603/),[l] / [h·kg],0.033,90738,DB00898,Ethanol
,7273603,Total steady-state concentration,"Total steady-state concentration after 3 wk ranged from 3.4 to 29.9 mg/l, while the weight-corrected dose range was only 3.7 to 5.5 mg/kg/day.",Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273603/),[mg] / [l],3.4 to 29.9,90739,DB00898,Ethanol
,9448069,flow-rate,"The mobile phase consisted of methanol-acetonitrile-50 mM monobasic ammonium phosphate (5:7:63, v/v/v) and was maintained at a flow-rate of 0.4 ml/min.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ml] / [min],0.4,90866,DB00898,Ethanol
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,56.6,90867,DB00898,Ethanol
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,78.6,90868,DB00898,Ethanol
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,61.1,90869,DB00898,Ethanol
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,76.4,90870,DB00898,Ethanol
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,67.0,90871,DB00898,Ethanol
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],20,90872,DB00898,Ethanol
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],24,90873,DB00898,Ethanol
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],15,90874,DB00898,Ethanol
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],12.9,90875,DB00898,Ethanol
,23523547,aerodynamic,"By modifying the formulation parameters, including actuator orifice, HFA and metering volumes, it was possible to produce two formulations (glycerol-free and glycerol-containing) which had identical mass median aerodynamic diameters (2.4μm±0.1 and 2.5μm±0.2), fine particle dose (⩽5μm; 66μg±6 and 68μg±2) and fine particle fractions (28%±2% and 30%±1%), respectively.",Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523547/),μm,2.4,91196,DB00898,Ethanol
,23523547,aerodynamic,"By modifying the formulation parameters, including actuator orifice, HFA and metering volumes, it was possible to produce two formulations (glycerol-free and glycerol-containing) which had identical mass median aerodynamic diameters (2.4μm±0.1 and 2.5μm±0.2), fine particle dose (⩽5μm; 66μg±6 and 68μg±2) and fine particle fractions (28%±2% and 30%±1%), respectively.",Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523547/),μm,2.5,91197,DB00898,Ethanol
,17344409,ED50,"After oral administration to rats, MTIP inhibited 125I-sauvagine binding to rat cerebellar membranes ex vivo with an ED50 of approximately 1.3 mg/kg and an oral bioavailability of 91.1%.","3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344409/),[mg] / [kg],1.3,92788,DB00898,Ethanol
,17344409,oral bioavailability,"After oral administration to rats, MTIP inhibited 125I-sauvagine binding to rat cerebellar membranes ex vivo with an ED50 of approximately 1.3 mg/kg and an oral bioavailability of 91.1%.","3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344409/),%,91.1,92789,DB00898,Ethanol
,15282089,Nominal retention times,"Nominal retention times of R(+)-DRF 2725, S(-)-DRF 2725 and I.S. were 15.8, 17.7 and 22.4 min, respectively.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),min,15.8,92924,DB00898,Ethanol
,15282089,Nominal retention times,"Nominal retention times of R(+)-DRF 2725, S(-)-DRF 2725 and I.S. were 15.8, 17.7 and 22.4 min, respectively.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),min,17.7,92925,DB00898,Ethanol
,15282089,Nominal retention times,"Nominal retention times of R(+)-DRF 2725, S(-)-DRF 2725 and I.S. were 15.8, 17.7 and 22.4 min, respectively.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),min,22.4,92926,DB00898,Ethanol
,15282089,Absolute recovery,"Absolute recovery, when compared to neat standards, was 70-85% for DRF 2725 enantiomers and 96% for I.S. from rat plasma.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),%,70-85,92927,DB00898,Ethanol
,15282089,Absolute recovery,"Absolute recovery, when compared to neat standards, was 70-85% for DRF 2725 enantiomers and 96% for I.S. from rat plasma.","Development and validation of a chiral liquid chromatographic method, based on Chiralpak to quantify enantiomers of (+/-)-DRF 2725 in rat plasma: lack of inversion of ragaglitazar (S(-)-DRF 2725) to its antipode in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15282089/),%,96,92928,DB00898,Ethanol
,7199303,t1/2e,"The mean values of t1/2e, ke, 51/2a, ka and tmax were 1.98 h, 0.3455 h-1, 1.2357 h, 1.2357 h, 0.5653 h-1 and 2.2267 h, respectively.",Pharmacokinetics of diclofenac sodium using a developed HPLC method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199303/),h,1.98,93636,DB00898,Ethanol
,7199303,tmax,"The mean values of t1/2e, ke, 51/2a, ka and tmax were 1.98 h, 0.3455 h-1, 1.2357 h, 1.2357 h, 0.5653 h-1 and 2.2267 h, respectively.",Pharmacokinetics of diclofenac sodium using a developed HPLC method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199303/),h,2.2267,93637,DB00898,Ethanol
,10418761,Lag time,"Lag time = 0.48 h (mean), Cmax after first dose = 157 ng/ml, t(max) = 1.73 h and elimination half-life = 1.16 h.",Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418761/),h,0.48,93755,DB00898,Ethanol
,10418761,Cmax,"Lag time = 0.48 h (mean), Cmax after first dose = 157 ng/ml, t(max) = 1.73 h and elimination half-life = 1.16 h.",Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418761/),[ng] / [ml],157,93756,DB00898,Ethanol
,10418761,t(max),"Lag time = 0.48 h (mean), Cmax after first dose = 157 ng/ml, t(max) = 1.73 h and elimination half-life = 1.16 h.",Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418761/),h,1.73,93757,DB00898,Ethanol
,10418761,elimination half-life,"Lag time = 0.48 h (mean), Cmax after first dose = 157 ng/ml, t(max) = 1.73 h and elimination half-life = 1.16 h.",Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418761/),h,1.16,93758,DB00898,Ethanol
,2134710,area under the intravenous curve (AUCi.v.),"The results suggested a pharmacokinetic behavior related to a one open compartment model with the following values for the total drug: area under the intravenous curve (AUCi.v.): 443 +/- 24.0; AUCoral: 85.5 +/- 14.5 micrograms min.ml-1; elimination rate constant: 0.069 +/- 0.0055 min-1, biological half-life: 10.0 +/- 0.80 min; distribution volume 1.15 +/- 0.15 ml/g; biodisponibility: 0.19 +/- 0.02.",Pharmacokinetic profile of tert-butylaminoethanethiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2134710/),,443,93863,DB00898,Ethanol
,2134710,AUCoral,"The results suggested a pharmacokinetic behavior related to a one open compartment model with the following values for the total drug: area under the intravenous curve (AUCi.v.): 443 +/- 24.0; AUCoral: 85.5 +/- 14.5 micrograms min.ml-1; elimination rate constant: 0.069 +/- 0.0055 min-1, biological half-life: 10.0 +/- 0.80 min; distribution volume 1.15 +/- 0.15 ml/g; biodisponibility: 0.19 +/- 0.02.",Pharmacokinetic profile of tert-butylaminoethanethiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2134710/),[min·μg] / [ml],85.5,93864,DB00898,Ethanol
,2134710,elimination rate constant,"The results suggested a pharmacokinetic behavior related to a one open compartment model with the following values for the total drug: area under the intravenous curve (AUCi.v.): 443 +/- 24.0; AUCoral: 85.5 +/- 14.5 micrograms min.ml-1; elimination rate constant: 0.069 +/- 0.0055 min-1, biological half-life: 10.0 +/- 0.80 min; distribution volume 1.15 +/- 0.15 ml/g; biodisponibility: 0.19 +/- 0.02.",Pharmacokinetic profile of tert-butylaminoethanethiol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2134710/),1/[min],0.069,93865,DB00898,Ethanol
,2134710,biological half-life,"The results suggested a pharmacokinetic behavior related to a one open compartment model with the following values for the total drug: area under the intravenous curve (AUCi.v.): 443 +/- 24.0; AUCoral: 85.5 +/- 14.5 micrograms min.ml-1; elimination rate constant: 0.069 +/- 0.0055 min-1, biological half-life: 10.0 +/- 0.80 min; distribution volume 1.15 +/- 0.15 ml/g; biodisponibility: 0.19 +/- 0.02.",Pharmacokinetic profile of tert-butylaminoethanethiol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2134710/),min,10.0,93866,DB00898,Ethanol
,2134710,distribution volume,"The results suggested a pharmacokinetic behavior related to a one open compartment model with the following values for the total drug: area under the intravenous curve (AUCi.v.): 443 +/- 24.0; AUCoral: 85.5 +/- 14.5 micrograms min.ml-1; elimination rate constant: 0.069 +/- 0.0055 min-1, biological half-life: 10.0 +/- 0.80 min; distribution volume 1.15 +/- 0.15 ml/g; biodisponibility: 0.19 +/- 0.02.",Pharmacokinetic profile of tert-butylaminoethanethiol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2134710/),[ml] / [g],1.15,93867,DB00898,Ethanol
,2134710,biodisponibility,"The results suggested a pharmacokinetic behavior related to a one open compartment model with the following values for the total drug: area under the intravenous curve (AUCi.v.): 443 +/- 24.0; AUCoral: 85.5 +/- 14.5 micrograms min.ml-1; elimination rate constant: 0.069 +/- 0.0055 min-1, biological half-life: 10.0 +/- 0.80 min; distribution volume 1.15 +/- 0.15 ml/g; biodisponibility: 0.19 +/- 0.02.",Pharmacokinetic profile of tert-butylaminoethanethiol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2134710/),,0.19,93868,DB00898,Ethanol
,20627230,total run time,The total run time was 2.5 min.,Bioanalytics and pharmacokinetics of the nociceptin/orphanin FQ peptide receptor agonist RO0646198 in Wistar rats and Cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20627230/),min,2.5,93945,DB00898,Ethanol
above,20627230,recoveries,"The recoveries were above 90%, and no significant matrix effect was observed.",Bioanalytics and pharmacokinetics of the nociceptin/orphanin FQ peptide receptor agonist RO0646198 in Wistar rats and Cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20627230/),%,90,93946,DB00898,Ethanol
below,20627230,bioavailability,"The bioavailability after oral dosing was below 5% for rats and below 1% in Cynomolgus monkeys, limiting the application of RO0646198 in the clinic to parenteral routes.",Bioanalytics and pharmacokinetics of the nociceptin/orphanin FQ peptide receptor agonist RO0646198 in Wistar rats and Cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20627230/),%,5,93947,DB00898,Ethanol
below,20627230,bioavailability,"The bioavailability after oral dosing was below 5% for rats and below 1% in Cynomolgus monkeys, limiting the application of RO0646198 in the clinic to parenteral routes.",Bioanalytics and pharmacokinetics of the nociceptin/orphanin FQ peptide receptor agonist RO0646198 in Wistar rats and Cynomolgus monkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20627230/),%,1,93948,DB00898,Ethanol
,10669897,parasite clearance time,"All patients showed a rapid initial response with a median parasite clearance time of 40, 41 and 39.5 h and a fever clearance time of 27.8, 32 and 24.5 h for regimens A, B and C, respectively.",Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,40,93949,DB00898,Ethanol
,10669897,parasite clearance time,"All patients showed a rapid initial response with a median parasite clearance time of 40, 41 and 39.5 h and a fever clearance time of 27.8, 32 and 24.5 h for regimens A, B and C, respectively.",Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,41,93950,DB00898,Ethanol
,10669897,parasite clearance time,"All patients showed a rapid initial response with a median parasite clearance time of 40, 41 and 39.5 h and a fever clearance time of 27.8, 32 and 24.5 h for regimens A, B and C, respectively.",Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,39.5,93951,DB00898,Ethanol
,10669897,fever clearance time,"All patients showed a rapid initial response with a median parasite clearance time of 40, 41 and 39.5 h and a fever clearance time of 27.8, 32 and 24.5 h for regimens A, B and C, respectively.",Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,27.8,93952,DB00898,Ethanol
,10669897,fever clearance time,"All patients showed a rapid initial response with a median parasite clearance time of 40, 41 and 39.5 h and a fever clearance time of 27.8, 32 and 24.5 h for regimens A, B and C, respectively.",Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,32,93953,DB00898,Ethanol
,10669897,fever clearance time,"All patients showed a rapid initial response with a median parasite clearance time of 40, 41 and 39.5 h and a fever clearance time of 27.8, 32 and 24.5 h for regimens A, B and C, respectively.",Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,24.5,93954,DB00898,Ethanol
,10669897,Cmax per,Median Cmax per dose (first dose) was significantly higher in regimen B (6.29 ng/ml/mg dose) than in regimen A (2.6 ng/ml/mg dose) and regimen C (3.06 ng/ml/mg dose).,Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),[ng] / [mg·ml],6.29,93955,DB00898,Ethanol
,10669897,Cmax per,Median Cmax per dose (first dose) was significantly higher in regimen B (6.29 ng/ml/mg dose) than in regimen A (2.6 ng/ml/mg dose) and regimen C (3.06 ng/ml/mg dose).,Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),[ng] / [mg·ml],2.6,93956,DB00898,Ethanol
,10669897,Cmax per,Median Cmax per dose (first dose) was significantly higher in regimen B (6.29 ng/ml/mg dose) than in regimen A (2.6 ng/ml/mg dose) and regimen C (3.06 ng/ml/mg dose).,Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),[ng] / [mg·ml],3.06,93957,DB00898,Ethanol
,10669897,T1/2z,Mean T1/2z in regimen C (2.65 h) was significantly shorter than in regimen A (4.5 h) and regimen B (3.89 h).,Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,2.65,93958,DB00898,Ethanol
,10669897,T1/2z,Mean T1/2z in regimen C (2.65 h) was significantly shorter than in regimen A (4.5 h) and regimen B (3.89 h).,Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,4.5,93959,DB00898,Ethanol
,10669897,T1/2z,Mean T1/2z in regimen C (2.65 h) was significantly shorter than in regimen A (4.5 h) and regimen B (3.89 h).,Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10669897/),h,3.89,93960,DB00898,Ethanol
,19395207,EDI,The median EDI was 172 g (range 60-564).,Blood kinetics of ethyl glucuronide and ethyl sulphate in heavy drinkers during alcohol detoxification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395207/),g,172,94127,DB00898,Ethanol
,19395207,terminal elimination half lives,"This patient's initial value of EtG was 17.9 mg/L and of EtS 5.9 mg/L, with terminal elimination half lives of 11.9 h for EtG and 12.5 h for EtS.",Blood kinetics of ethyl glucuronide and ethyl sulphate in heavy drinkers during alcohol detoxification. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395207/),h,11.9,94128,DB00898,Ethanol
,19395207,terminal elimination half lives,"This patient's initial value of EtG was 17.9 mg/L and of EtS 5.9 mg/L, with terminal elimination half lives of 11.9 h for EtG and 12.5 h for EtS.",Blood kinetics of ethyl glucuronide and ethyl sulphate in heavy drinkers during alcohol detoxification. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395207/),h,12.5,94129,DB00898,Ethanol
,19395207,half-life,Elimination occurred with a median half-life of 3.3 h for EtG (range 2.6-4.3) and 3.6 h for EtS (range 2.7-5.4).,Blood kinetics of ethyl glucuronide and ethyl sulphate in heavy drinkers during alcohol detoxification. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395207/),h,3.3,94130,DB00898,Ethanol
,19395207,half-life,Elimination occurred with a median half-life of 3.3 h for EtG (range 2.6-4.3) and 3.6 h for EtS (range 2.7-5.4).,Blood kinetics of ethyl glucuronide and ethyl sulphate in heavy drinkers during alcohol detoxification. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395207/),h,3.6,94131,DB00898,Ethanol
,2971841,half-lives,"MPA was distributed very rapidly into three compartments after i.v. injections, revealing half-lives of 4-7 h.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),h,4-7,94522,DB00898,Ethanol
,2971841,metabolic clearance rates (MCR),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),[1] / [d],652,94523,DB00898,Ethanol
,2971841,metabolic clearance rates (MCR),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),[1] / [d],601,94524,DB00898,Ethanol
,2971841,distribution volumes (V0),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),,5.9,94525,DB00898,Ethanol
,2971841,distribution volumes (V0),"Using a nonlinear model fitting metabolic clearance rates (MCR) were found to be 652 1/day before and 601 1/day during MPA treatment, and distribution volumes (V0) 5.9 and 3.41 respectively.",Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971841/),,3.41,94526,DB00898,Ethanol
,17981422,total chromatographic run time,"Transitions 456>166 for VER enantiomers, 441>166 for NOR enantiomers and 330>193 for the internal standard were monitored and the method had a total chromatographic run time of 12 min.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),min,12,94549,DB00898,Ethanol
,17981422,AUC ratio (-)/(+),"The concentration of (-)-(S)-VER was three folds higher than (+)-(R)-VER, with an AUC ratio (-)/(+) of 2.66.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),,2.66,94550,DB00898,Ethanol
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],12.17,94551,DB00898,Ethanol
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],28.77,94552,DB00898,Ethanol
,8360849,relative bioavailability,"However, single-dose studies with a panel of fasting subjects showed that the tablets had a relative bioavailability of only 64.4%.",Use of hydroxypropyl methylcellulose acetate succinate in an enteric polymer matrix to design controlled-release tablets of amoxicillin trihydrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8360849/),%,64.4,94707,DB00898,Ethanol
,8590616,Plasma ritanserin concentration,Plasma ritanserin concentration was 143 ng/ml 1 h after alcohol administration and decayed to 53 ng/ml 6 h after alcohol consumption in the active treatment session.,Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590616/),[ng] / [ml],143,94784,DB00898,Ethanol
,8590616,Plasma ritanserin concentration,Plasma ritanserin concentration was 143 ng/ml 1 h after alcohol administration and decayed to 53 ng/ml 6 h after alcohol consumption in the active treatment session.,Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8590616/),[ng] / [ml],53,94785,DB00898,Ethanol
less,16548053,sample preparation time,"Because the proposed method combined a rapid water-phase derivatization with a fast, simple and solvent-free sample extraction and concentration technique of SPME, the sample preparation time was less than 25 min.",Development of water-phase derivatization followed by solid-phase microextraction and gas chromatography/mass spectrometry for fast determination of valproic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16548053/),min,25,94847,DB00898,Ethanol
,27749255,bioavailability,"Consequently, the bioavailability of kaempferol in oral control groups was 3.1 % (100 mg kg-1 bm) and 2.1 % (250 mg kg-1 bm).",Pharmacokinetic evaluation of the interaction between oral kaempferol and ethanol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749255/),%,3.1,94995,DB00898,Ethanol
,27749255,bioavailability,"Consequently, the bioavailability of kaempferol in oral control groups was 3.1 % (100 mg kg-1 bm) and 2.1 % (250 mg kg-1 bm).",Pharmacokinetic evaluation of the interaction between oral kaempferol and ethanol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27749255/),%,2.1,94996,DB00898,Ethanol
,15568892,peak concentration (Cmax),"The peak concentration (Cmax) of alcohol in arterial blood was 0.98 g/L (SD 0.209) compared with 0.84 g/L (SD 0.176) for venous blood (p < 0.001), whereas median time to reach Cmax (tmax) was the same (35 minutes).",Magnitude and time-course of arterio-venous differences in blood-alcohol concentration in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568892/),[g] / [l],0.98,95076,DB00898,Ethanol
,15568892,peak concentration (Cmax),"The peak concentration (Cmax) of alcohol in arterial blood was 0.98 g/L (SD 0.209) compared with 0.84 g/L (SD 0.176) for venous blood (p < 0.001), whereas median time to reach Cmax (tmax) was the same (35 minutes).",Magnitude and time-course of arterio-venous differences in blood-alcohol concentration in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568892/),[g] / [l],0.84,95077,DB00898,Ethanol
,15568892,time to reach Cmax (tmax),"The peak concentration (Cmax) of alcohol in arterial blood was 0.98 g/L (SD 0.209) compared with 0.84 g/L (SD 0.176) for venous blood (p < 0.001), whereas median time to reach Cmax (tmax) was the same (35 minutes).",Magnitude and time-course of arterio-venous differences in blood-alcohol concentration in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568892/),min,35,95078,DB00898,Ethanol
,15568892,time to reach zero BAC,The extrapolated time to reach zero BAC was 391 minutes (SD 34) for arterial blood and 420 minutes (SD 41) for venous blood; the difference of 29 minutes was statistically highly significant (p < 0.001).,Magnitude and time-course of arterio-venous differences in blood-alcohol concentration in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568892/),min,391,95079,DB00898,Ethanol
,15568892,time to reach zero BAC,The extrapolated time to reach zero BAC was 391 minutes (SD 34) for arterial blood and 420 minutes (SD 41) for venous blood; the difference of 29 minutes was statistically highly significant (p < 0.001).,Magnitude and time-course of arterio-venous differences in blood-alcohol concentration in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568892/),min,420,95080,DB00898,Ethanol
,11689265,dissolution,"Fluorescein's dissolution was increased in the amorphous form by 6.5-fold when compared to the crystalline material (83.9-87.2 vs. 13.5 microg/ml, respectively).",Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689265/),[μg] / [ml],83.9-87.2,95153,DB00898,Ethanol
,11689265,dissolution,"Fluorescein's dissolution was increased in the amorphous form by 6.5-fold when compared to the crystalline material (83.9-87.2 vs. 13.5 microg/ml, respectively).",Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689265/),[μg] / [ml],13.5,95154,DB00898,Ethanol
,11689265,T(max),"Poor dissolution for the 'control' crystalline fluorescein appeared to be rate-determined, which showed bi-phasic absorption profiles (T(max)=60 min), simultaneously competing with mucociliary clearance out of the lower airways.",Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689265/),min,60,95155,DB00898,Ethanol
,11689265,T(max),"While the crystalline/HPC microspheres prolonged absorption, the amorphous fluorescein/HPC microspheres showed rapid absorption with T(max)=0 min (immediately after the administration had terminated).",Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689265/),min,0,95156,DB00898,Ethanol
,11689265,bioavailability,"In contrast, the microspheres with the highly viscous HPC-H with ratios > or = 1:4 successfully enhanced absorption, achieving 88.0% bioavailability by virtue of HPC increasing the dissolution and retarding the mucociliary clearance.",Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689265/),%,88.0,95157,DB00898,Ethanol
,10803773,Vmax,"The Vmax and Km values of acetate elimination were 40.80 +/- 14.10 mM/hr and 0.47 +/- 0.19 mM, respectively.",Michaelis-Menten elimination kinetics of acetate during ethanol oxidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803773/),[mM] / [h],40.80,95185,DB00898,Ethanol
,10803773,Km,"The Vmax and Km values of acetate elimination were 40.80 +/- 14.10 mM/hr and 0.47 +/- 0.19 mM, respectively.",Michaelis-Menten elimination kinetics of acetate during ethanol oxidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803773/),mM,0.47,95186,DB00898,Ethanol
,10803773,fraction of a dose of ethanol converted to acetate (f(AcA)),The fraction of a dose of ethanol converted to acetate (f(AcA)) was calculated to be 0.54.,Michaelis-Menten elimination kinetics of acetate during ethanol oxidation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803773/),,0.54,95187,DB00898,Ethanol
,12236843,total urinary excretion,The median (range) of the total urinary excretion of formoterol was 37.8% (20.9-51.2%) of the dose.,Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,37.8,95229,DB00898,Ethanol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,2.1,95230,DB00898,Ethanol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,3.5,95231,DB00898,Ethanol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,21.0,95232,DB00898,Ethanol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,10.3,95233,DB00898,Ethanol
,18958430,yield,"The yield and drug loading amount of hollow microspheres were 83.21+/-0.28% and 20.71+/-0.32%, respectively.",In vitro and in vivo evaluation of ranitidine hydrochloride loaded hollow microspheres in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18958430/),%,83.21,95266,DB00898,Ethanol
,18958430,drug loading amount,"The yield and drug loading amount of hollow microspheres were 83.21+/-0.28% and 20.71+/-0.32%, respectively.",In vitro and in vivo evaluation of ranitidine hydrochloride loaded hollow microspheres in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18958430/),%,20.71,95267,DB00898,Ethanol
,32380748,residual drug,"Photostability increased significantly for both drugs in the liquid microemulsion and microemulsion-in-gel, compared to the ethanol solution and plain gel, reaching a residual drug of 97% and 98% for Nabumetone and analog in microemulsion-in-gel, respectively.",Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380748/),%,97,95291,DB00898,Ethanol
,32380748,residual drug,"Photostability increased significantly for both drugs in the liquid microemulsion and microemulsion-in-gel, compared to the ethanol solution and plain gel, reaching a residual drug of 97% and 98% for Nabumetone and analog in microemulsion-in-gel, respectively.",Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380748/),%,98,95292,DB00898,Ethanol
,10792196,Vmax,"The mean +/- total s.d. of the parameter estimates derived from blood data were Vmax 95 +/- 25 mg min-1, Km 27 +/- 19 mg l-1, CLd 809 +/- 232 ml min-1, VC 14.5 +/- 4.3 l, VT 21.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),[mg] / [min],95,95411,DB00898,Ethanol
,10792196,Km,"The mean +/- total s.d. of the parameter estimates derived from blood data were Vmax 95 +/- 25 mg min-1, Km 27 +/- 19 mg l-1, CLd 809 +/- 232 ml min-1, VC 14.5 +/- 4.3 l, VT 21.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),[mg] / [l],27,95412,DB00898,Ethanol
,10792196,CLd,"The mean +/- total s.d. of the parameter estimates derived from blood data were Vmax 95 +/- 25 mg min-1, Km 27 +/- 19 mg l-1, CLd 809 +/- 232 ml min-1, VC 14.5 +/- 4.3 l, VT 21.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),[ml] / [min],809,95413,DB00898,Ethanol
,10792196,VC,"The mean +/- total s.d. of the parameter estimates derived from blood data were Vmax 95 +/- 25 mg min-1, Km 27 +/- 19 mg l-1, CLd 809 +/- 232 ml min-1, VC 14.5 +/- 4.3 l, VT 21.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),l,14.5,95414,DB00898,Ethanol
,10792196,VT,"The mean +/- total s.d. of the parameter estimates derived from blood data were Vmax 95 +/- 25 mg min-1, Km 27 +/- 19 mg l-1, CLd 809 +/- 232 ml min-1, VC 14.5 +/- 4.3 l, VT 21.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),,21,95415,DB00898,Ethanol
,10792196,CLR,"2 +/- 4.4 l, CLR 3.6 +/- 2.0 ml min-1 and Vss 35.8 +/- 4.3 l.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),[ml] / [min],3.6,95416,DB00898,Ethanol
,10792196,Vss,"2 +/- 4.4 l, CLR 3.6 +/- 2.0 ml min-1 and Vss 35.8 +/- 4.3 l.","Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792196/),l,35.8,95417,DB00898,Ethanol
,10516540,reversibility,"In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3+/-5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV(1)) 19.3+/-3.1%] were evaluated after inhalation of 12 microg formoterol and 50 microg salmeterol.","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),%,19.3,95418,DB00898,Ethanol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.39,95419,DB00898,Ethanol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.40,95420,DB00898,Ethanol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.02,95421,DB00898,Ethanol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.12,95422,DB00898,Ethanol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.5,95423,DB00898,Ethanol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.2,95424,DB00898,Ethanol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,1.2,95425,DB00898,Ethanol
,32110832,flow rate,Chromatography separation was performed by a Waters BEH (ethylene-bridged hybrid) C18 column (2.1 × 50 mm; 1.7 μm) using a gradient elution from acetonitrile and water (containing 0.1% formic acid) and at a flow rate of 0.4 mL/min.,Simultaneous quantitation of glycyrrhetic acid and puerarin in plasma using ultra flow liquid chromatography tandem mass spectrometry and application in a pharmacokinetics study in healthy and alcoholic liver injury rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110832/),[ml] / [min],0.4,95573,DB00898,Ethanol
,4057346,total body clearance,The 35 mg/dl serum ethanol level reduced the total body clearance of EG from 93.9 to 50.0 ml/h/kg and increased the effective half-life from 5.78 to 11.4 h.,Low-dose ethanol in the treatment of ethylene glycol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057346/),[ml] / [h·kg],93.9 to 50.0,95584,DB00898,Ethanol
,4057346,effective half-life,The 35 mg/dl serum ethanol level reduced the total body clearance of EG from 93.9 to 50.0 ml/h/kg and increased the effective half-life from 5.78 to 11.4 h.,Low-dose ethanol in the treatment of ethylene glycol poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057346/),h,5.78 to 11.4,95585,DB00898,Ethanol
,21566203,half-life (t(1/2)),Mean half-life (t(1/2)) values were prolonged in the moderate impairment group (21 hours) relative to the normal group (11 hours).,Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21566203/),h,21,95727,DB00898,Ethanol
,21566203,half-life (t(1/2)),Mean half-life (t(1/2)) values were prolonged in the moderate impairment group (21 hours) relative to the normal group (11 hours).,Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21566203/),h,11,95728,DB00898,Ethanol
,20508296,biological half-life,"The average biological half-life of carbamazepine in non-addicted epileptics was 41.5 h, 43.5 h for alcohol-dependent patients during abstinency, and 38.6 in abused patients.",Carbamazepine intoxication in alcohol dependent epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508296/),h,41.5,96189,DB00898,Ethanol
,20508296,biological half-life,"The average biological half-life of carbamazepine in non-addicted epileptics was 41.5 h, 43.5 h for alcohol-dependent patients during abstinency, and 38.6 in abused patients.",Carbamazepine intoxication in alcohol dependent epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508296/),h,43.5,96190,DB00898,Ethanol
,20508296,biological half-life,"The average biological half-life of carbamazepine in non-addicted epileptics was 41.5 h, 43.5 h for alcohol-dependent patients during abstinency, and 38.6 in abused patients.",Carbamazepine intoxication in alcohol dependent epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508296/),,38.6,96191,DB00898,Ethanol
,11041263,systemic bioavailability,"The remaining FP in the gel 6 h after the application was 60% of the initial loading and the systemic bioavailability over the 6 h application was about 10%, suggesting that the rest (30%) had accumulated in the skin tissues.",Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041263/),%,10,96196,DB00898,Ethanol
,11041263,systemic bioavailability,"The remaining FP in the gel 6 h after the application was 60% of the initial loading and the systemic bioavailability over the 6 h application was about 10%, suggesting that the rest (30%) had accumulated in the skin tissues.",Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041263/),%,30,96197,DB00898,Ethanol
,25637266,time to maximum plasma concentration,"The time to maximum plasma concentration of EDX was 2h, and the half-life was 9h.","A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637266/),h,2,96348,DB00898,Ethanol
,25637266,half-life,"The time to maximum plasma concentration of EDX was 2h, and the half-life was 9h.","A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637266/),h,9,96349,DB00898,Ethanol
,17482416,maximum GGA plasma concentration (Cmax),"The maximum GGA plasma concentration (Cmax) was 246.9+/-85.4 ng/ml, the elimination half-life (t1/2) was 3.38+/-1.20 h, and the time to the Cmax was 5.35+/-1.39 h.",HPLC-APCI-MS for the determination of teprenone in human plasma: method and clinical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482416/),[ng] / [ml],246.9,96463,DB00898,Ethanol
,17482416,elimination half-life (t1/2),"The maximum GGA plasma concentration (Cmax) was 246.9+/-85.4 ng/ml, the elimination half-life (t1/2) was 3.38+/-1.20 h, and the time to the Cmax was 5.35+/-1.39 h.",HPLC-APCI-MS for the determination of teprenone in human plasma: method and clinical application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482416/),h,3.38,96464,DB00898,Ethanol
,17482416,time to the Cmax,"The maximum GGA plasma concentration (Cmax) was 246.9+/-85.4 ng/ml, the elimination half-life (t1/2) was 3.38+/-1.20 h, and the time to the Cmax was 5.35+/-1.39 h.",HPLC-APCI-MS for the determination of teprenone in human plasma: method and clinical application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17482416/),h,5.35,96465,DB00898,Ethanol
,6636256,Absolute recoveries,Absolute recoveries were 87-97%.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),%,87-97,96511,DB00898,Ethanol
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],2,96512,DB00898,Ethanol
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],4,96513,DB00898,Ethanol
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],10,96514,DB00898,Ethanol
less,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,10,96515,DB00898,Ethanol
,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,12,96516,DB00898,Ethanol
,10776683,peak,"Plasma endotoxin levels were not different between group 1 (9 +/- 2 pg/ml) and group 2 (14 +/-3 pg/ml), whereas they significantly increased in group 3 with a peak at 60 min (87 +/- 35 pg/ml).",Effect of acute ethanol administration on the intestinal absorption of endotoxin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10776683/),[pg] / [ml],87,96535,DB00898,Ethanol
,20528005,area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)),"The mean (SD) area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)) and maximum plasma concentration (C(max)) of trans-resveratrol were 3558 (2195) ng * h/mL and 1274 (790) ng/mL, respectively, after the standard breakfast.","Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528005/),[h·ng] / [ml],3558,96750,DB00898,Ethanol
,20528005,maximum plasma concentration (C(max)),"The mean (SD) area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)) and maximum plasma concentration (C(max)) of trans-resveratrol were 3558 (2195) ng * h/mL and 1274 (790) ng/mL, respectively, after the standard breakfast.","Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528005/),[ng] / [ml],1274,96751,DB00898,Ethanol
up to,23429905,Maximum concentrations,"Maximum concentrations of tetrahydrocannabinol (THC) immediately after smoking (up to 44,412 ng/g) were below 4,300 (median 377) ng/g 1 h after smoking and less than 312 (median 88) ng/g 3 h later with 5 of 49 samples negative, suggesting that recent cannabis use might occasionally not be detectable.",Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429905/),[ng] / [g],"44,412",96870,DB00898,Ethanol
below,23429905,Maximum concentrations,"Maximum concentrations of tetrahydrocannabinol (THC) immediately after smoking (up to 44,412 ng/g) were below 4,300 (median 377) ng/g 1 h after smoking and less than 312 (median 88) ng/g 3 h later with 5 of 49 samples negative, suggesting that recent cannabis use might occasionally not be detectable.",Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429905/),[ng] / [g],"4,300",96871,DB00898,Ethanol
less,23429905,Maximum concentrations,"Maximum concentrations of tetrahydrocannabinol (THC) immediately after smoking (up to 44,412 ng/g) were below 4,300 (median 377) ng/g 1 h after smoking and less than 312 (median 88) ng/g 3 h later with 5 of 49 samples negative, suggesting that recent cannabis use might occasionally not be detectable.",Influence of ethanol on the pharmacokinetic properties of Δ9-tetrahydrocannabinol in oral fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429905/),[ng] / [g],312,96872,DB00898,Ethanol
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,"0,63-1,00",97122,DB00898,Ethanol
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,"0,85",97123,DB00898,Ethanol
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,0.62-1.22,97124,DB00898,Ethanol
,28710938,concentrations (Cmax),"Ethanol concentrations (Cmax) were in the range of 0,63-1,00‰ (median 0,85‰) and 0.62-1.22‰ (median 0.84‰) in the placebo and ""Eezup!"" condition, respectively, and not statistically different.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),‰,0.84,97125,DB00898,Ethanol
,28710938,ethanol,"The ethanol elimination rates were 0.16‰/h (0.14-0.19‰/h) and 0.17‰/h (0.14-0.22 ‰/h) in the placebo and ""Eezup!"" condition without significant difference.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),[‰] / [h],0.16,97126,DB00898,Ethanol
,28710938,elimination rates,"The ethanol elimination rates were 0.16‰/h (0.14-0.19‰/h) and 0.17‰/h (0.14-0.22 ‰/h) in the placebo and ""Eezup!"" condition without significant difference.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),[‰] / [h],0.16,97127,DB00898,Ethanol
,28710938,elimination rates,"The ethanol elimination rates were 0.16‰/h (0.14-0.19‰/h) and 0.17‰/h (0.14-0.22 ‰/h) in the placebo and ""Eezup!"" condition without significant difference.","Lack of effects of a ""sobering"" product, ""Eezup!"", on the blood ethanol and congener alcohol concentration. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28710938/),[‰] / [h],0.17,97128,DB00898,Ethanol
,7267697,Peak plasma diazepam levels,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[ng] / [ml],166,97200,DB00898,Ethanol
,7267697,Peak plasma diazepam levels,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[ng] / [ml],140,97201,DB00898,Ethanol
,7267697,Peak plasma diazepam levels,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[ng] / [ml],145,97202,DB00898,Ethanol
,7267697,time of peak concentration,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,0.71,97203,DB00898,Ethanol
,7267697,time of peak concentration,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,2.1,97204,DB00898,Ethanol
,7267697,time of peak concentration,"Peak plasma diazepam levels averaged 166, 140 and 145 ng/ml in trials A, B and C, respectively; the time of peak concentration was 0.71, 2.1 and 1.5 h after the dose, respectively.",Alcohol does not enhance diazepam absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,1.5,97205,DB00898,Ethanol
,7267697,Total areas under the plasma concentration curve,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[μg] / [h·ml],2.7,97206,DB00898,Ethanol
,7267697,Total areas under the plasma concentration curve,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[μg] / [h·ml],2.8,97207,DB00898,Ethanol
,7267697,Total areas under the plasma concentration curve,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),[μg] / [h·ml],2.9,97208,DB00898,Ethanol
,7267697,elimination half-life,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,29,97209,DB00898,Ethanol
,7267697,elimination half-life,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,36,97210,DB00898,Ethanol
,7267697,elimination half-life,"Total areas under the plasma concentration curve were nearly identical (2.7, 2.8 and 2.9 micrograms/ml X h) among the 3 trials, as were values of diazepam elimination half-life (29, 36 and 35 h).",Alcohol does not enhance diazepam absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7267697/),h,35,97211,DB00898,Ethanol
,11049009,time to reach peak concentration (tmax),"In the single-dose study, time to reach peak concentration (tmax) ranged from 1.3 h to 4.0 h; peak concentration (Cmax) ranged from 15 ng/ml to 445 ng/ ml; and the estimated terminal elimination half-life (mean +/- SD; t1/2) was 24.8 +/- 7.0 h.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,1.3,97821,DB00898,Ethanol
,11049009,time to reach peak concentration (tmax),"In the single-dose study, time to reach peak concentration (tmax) ranged from 1.3 h to 4.0 h; peak concentration (Cmax) ranged from 15 ng/ml to 445 ng/ ml; and the estimated terminal elimination half-life (mean +/- SD; t1/2) was 24.8 +/- 7.0 h.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,4.0,97822,DB00898,Ethanol
,11049009,peak concentration (Cmax),"In the single-dose study, time to reach peak concentration (tmax) ranged from 1.3 h to 4.0 h; peak concentration (Cmax) ranged from 15 ng/ml to 445 ng/ ml; and the estimated terminal elimination half-life (mean +/- SD; t1/2) was 24.8 +/- 7.0 h.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),[ng] / [ml],15,97823,DB00898,Ethanol
,11049009,peak concentration (Cmax),"In the single-dose study, time to reach peak concentration (tmax) ranged from 1.3 h to 4.0 h; peak concentration (Cmax) ranged from 15 ng/ml to 445 ng/ ml; and the estimated terminal elimination half-life (mean +/- SD; t1/2) was 24.8 +/- 7.0 h.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),[ng] / [ml],445,97824,DB00898,Ethanol
,11049009,t1/2,"In the single-dose study, time to reach peak concentration (tmax) ranged from 1.3 h to 4.0 h; peak concentration (Cmax) ranged from 15 ng/ml to 445 ng/ ml; and the estimated terminal elimination half-life (mean +/- SD; t1/2) was 24.8 +/- 7.0 h.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,24.8,97825,DB00898,Ethanol
,11049009,tmax,"In the repeated-dose study, tmax ranged from 1.9 h to 2.6 h at 6 weeks and from 2.5 h to 2.9 h at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,1.9,97826,DB00898,Ethanol
,11049009,tmax,"In the repeated-dose study, tmax ranged from 1.9 h to 2.6 h at 6 weeks and from 2.5 h to 2.9 h at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,2.6,97827,DB00898,Ethanol
,11049009,tmax,"In the repeated-dose study, tmax ranged from 1.9 h to 2.6 h at 6 weeks and from 2.5 h to 2.9 h at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,2.5,97828,DB00898,Ethanol
,11049009,tmax,"In the repeated-dose study, tmax ranged from 1.9 h to 2.6 h at 6 weeks and from 2.5 h to 2.9 h at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,2.9,97829,DB00898,Ethanol
,11049009,Cmax,"Cmax ranged from 295 ng/ml to 1,043 ng/ml at 6 weeks and from 25 ng/ml to 1211 ng/ml at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),[ng] / [ml],295,97830,DB00898,Ethanol
,11049009,Cmax,"Cmax ranged from 295 ng/ml to 1,043 ng/ml at 6 weeks and from 25 ng/ml to 1211 ng/ml at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),[ng] / [ml],"1,043",97831,DB00898,Ethanol
,11049009,Cmax,"Cmax ranged from 295 ng/ml to 1,043 ng/ml at 6 weeks and from 25 ng/ml to 1211 ng/ml at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),[ng] / [ml],25,97832,DB00898,Ethanol
,11049009,Cmax,"Cmax ranged from 295 ng/ml to 1,043 ng/ml at 6 weeks and from 25 ng/ml to 1211 ng/ml at 12 weeks.","Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),[ng] / [ml],1211,97833,DB00898,Ethanol
,11049009,t1/2,The average t1/2 at all dose levels was 29.7 +/- 1.5 h (overall mean +/- SD).,"Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049009/),h,29.7,97834,DB00898,Ethanol
,10773839,rate of penetration,There was a significant difference (P=0.03) between the rate of penetration from the commercial concentrate (9.0 nmoles cm(-2) h(-1)) and that from the reference standard (4.9 nmoles cm(-2) h(-1)).,The in vitro percutaneous penetration of chlorpyrifos. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),[nmoles] / [(cm)^2·h],9.0,97843,DB00898,Ethanol
,10773839,rate of penetration,There was a significant difference (P=0.03) between the rate of penetration from the commercial concentrate (9.0 nmoles cm(-2) h(-1)) and that from the reference standard (4.9 nmoles cm(-2) h(-1)).,The in vitro percutaneous penetration of chlorpyrifos. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),[nmoles] / [(cm)^2·h],4.9,97844,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,91,97845,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,87,97846,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,15,97847,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,10,97848,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,56,97849,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,66,97850,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,20,97851,DB00898,Ethanol
,10773839,recoveries,"The recoveries from experiments where chlorpyrifos was applied to the skin as a commercial concentrate and as a reference standard dissolved in ethanol were, respectively, in total 91 and 87% of the applied dose of which 15 and 10% was recovered from the skin, 56 and 66% was recovered from the surface of the skin and 20 and 11% was recovered from the receptor fluid.",The in vitro percutaneous penetration of chlorpyrifos. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773839/),%,11,97852,DB00898,Ethanol
,31228805,t1/2α,"The t1/2α of SMH loaded ISH in the knee joints of AA rats, was longer (13.42 h) than that of healthy rats (1.34 h) (P < 0.05), most likely that in vivo drug release behavior of SMH loaded ISH was affected by the physiological environment of the joint.",In situ hexagonal liquid crystal for intra-articular delivery of sinomenine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31228805/),h,13.42,97964,DB00898,Ethanol
,31228805,t1/2α,"The t1/2α of SMH loaded ISH in the knee joints of AA rats, was longer (13.42 h) than that of healthy rats (1.34 h) (P < 0.05), most likely that in vivo drug release behavior of SMH loaded ISH was affected by the physiological environment of the joint.",In situ hexagonal liquid crystal for intra-articular delivery of sinomenine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31228805/),h,1.34,97965,DB00898,Ethanol
,23766098,Peak oleuropein concentrations,"Peak oleuropein concentrations in plasma were greater following ingestion of liquid than capsule preparations (0.47 versus 2.74 ng/mL; p = 0.004), but no such effect was observed for peak concentrations of conjugated (sulfated and glucuronidated) hydroxytyrosol (p = 0.94).",Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23766098/),[ng] / [ml],0.47,98027,DB00898,Ethanol
,23766098,Peak oleuropein concentrations,"Peak oleuropein concentrations in plasma were greater following ingestion of liquid than capsule preparations (0.47 versus 2.74 ng/mL; p = 0.004), but no such effect was observed for peak concentrations of conjugated (sulfated and glucuronidated) hydroxytyrosol (p = 0.94).",Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23766098/),[ng] / [ml],2.74,98028,DB00898,Ethanol
,23766098,plasma area under the curve,"There was a gender effect on the bioavailability of phenolic compounds, with males displaying greater plasma area under the curve for conjugated hydroxytyrosol (11,600 versus 2550 ng/mL; p = 0.048).",Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23766098/),[ng] / [ml],"11,600",98029,DB00898,Ethanol
,23766098,plasma area under the curve,"There was a gender effect on the bioavailability of phenolic compounds, with males displaying greater plasma area under the curve for conjugated hydroxytyrosol (11,600 versus 2550 ng/mL; p = 0.048).",Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23766098/),[ng] / [ml],2550,98030,DB00898,Ethanol
,8462123,distribution,"Plasma drug elimination was best described by a bi-exponential model, with short distribution and elimination half-lives of 4.15 +/- 2.57 and 28.8 +/- 12.1 min being observed, respectively.",Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462123/),min,4.15,99996,DB00898,Ethanol
,8462123,elimination half-lives,"Plasma drug elimination was best described by a bi-exponential model, with short distribution and elimination half-lives of 4.15 +/- 2.57 and 28.8 +/- 12.1 min being observed, respectively.",Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462123/),min,28.8,99997,DB00898,Ethanol
,8462123,area under the concentrationtime curve (AUC),"During dose escalation, the mean area under the concentrationtime curve (AUC) increased from 5.96 +/- 2.89 to 12.22 +/- 3.95 mg l-1 h.",Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462123/),[h·mg] / [l],5.96,99998,DB00898,Ethanol
,8462123,area under the concentrationtime curve (AUC),"During dose escalation, the mean area under the concentrationtime curve (AUC) increased from 5.96 +/- 2.89 to 12.22 +/- 3.95 mg l-1 h.",Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462123/),[h·mg] / [l],12.22,99999,DB00898,Ethanol
,8462123,clearance,"Drug clearance was independent of the dose given and equal to 109 +/- 65 l/h, indicating no possible saturation of metabolism and elimination mechanisms at these high-dose levels.",Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462123/),[l] / [h],109,100000,DB00898,Ethanol
,25481447,localization,Topical application of SP50 significantly increased the localization of CsA in the target skin (113.1±13.6(μg/g)/mg) compared to all other groups (p<0.01).,Topical delivery of Cyclosporine A into the skin using SPACE-peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25481447/),,113.1,100163,DB00898,Ethanol
,25481447,skin/blood ratio,"In addition, SP50 led to significantly higher skin/blood ratio (443.4±181.5) and skin/liver ratio (1059.5±110.8) of CsA compared to all other groups (p<0.01).",Topical delivery of Cyclosporine A into the skin using SPACE-peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25481447/),,443.4,100164,DB00898,Ethanol
,25481447,skin/liver ratio,"In addition, SP50 led to significantly higher skin/blood ratio (443.4±181.5) and skin/liver ratio (1059.5±110.8) of CsA compared to all other groups (p<0.01).",Topical delivery of Cyclosporine A into the skin using SPACE-peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25481447/),,1059.5,100165,DB00898,Ethanol
,18847571,bioavailability,After smoking THC bioavailability averages 30%.,[Delta-9-tetrahydrocannabinol pharmacokinetics]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18847571/),%,30,100625,DB00898,Ethanol
,18847571,peak plasma level,"With a 3.55% THC cigarette, a peak plasma level near 160 ng/mL occurs approximately 10 min after inhalation.",[Delta-9-tetrahydrocannabinol pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18847571/),[ng] / [ml],160,100626,DB00898,Ethanol
,23583861,plasma levels,"Maximum mean (±SD) plasma levels of ivermectin (67±49ngml(-1)) were reached within 2h in fasting patients, and had dropped to 26±20ngml(-1) after 30h.",The lack of influence of food and local alcoholic brew on the blood level of Mectizan(®) (ivermectin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23583861/),1/[ngml],67,100899,DB00898,Ethanol
,23583861,plasma levels,"Maximum mean (±SD) plasma levels of ivermectin (67±49ngml(-1)) were reached within 2h in fasting patients, and had dropped to 26±20ngml(-1) after 30h.",The lack of influence of food and local alcoholic brew on the blood level of Mectizan(®) (ivermectin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23583861/),1/[ngml],26,100900,DB00898,Ethanol
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],86.2,101172,DB00898,Ethanol
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],26.2,101173,DB00898,Ethanol
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],152,101174,DB00898,Ethanol
,33051517,Cmax,Male animals received a higher ivermectin dose adjusted by adipose weight and reached higher plasma concentrations than females in the same dosing group (mean Cmax 86.2 ng/ml vs. 26.2 ng/ml in the lower dose group and 152 ng/ml vs. 51.8 ng/ml in the higher dose group).,"Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33051517/),[ng] / [ml],51.8,101175,DB00898,Ethanol
,30448313,peak plasma concentration (Cmax),"The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug as 238.09 ± 25.96% and 219.78 ± 36.33%, respectively, after oral administration in rats.",A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30448313/),%,238.09,101782,DB00898,Ethanol
,30448313,relative bioavailability,"The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug as 238.09 ± 25.96% and 219.78 ± 36.33%, respectively, after oral administration in rats.",A novel composition of ticagrelor by solid dispersion technique for increasing solubility and intestinal permeability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30448313/),%,219.78,101783,DB00898,Ethanol
,24421229,entrapment efficiency (EE),The entrapment efficiency (EE) of long-circulation oridonin liposomes was about 65%.,[Preparation of freeze-dried long-circulation oridonin liposomes and their pharmacokinetics in rats]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24421229/),%,65,102243,DB00898,Ethanol
,9876518,maximal plasma concentration of ketoprofen (Cmax),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[μg] / [ml],24.6,102301,DB00898,Ethanol
,9876518,maximal plasma concentration of ketoprofen (Cmax),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[μg] / [ml],7.6,102302,DB00898,Ethanol
,9876518,area under the concentration-time curve from zero to 8 hr (AUC0-8 hr),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[μg] / [ml],7.6,102303,DB00898,Ethanol
,9876518,area under the concentration-time curve from zero to 8 hr (AUC0-8 hr),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[h·μg] / [ml],38.4,102304,DB00898,Ethanol
,9876518,area under the concentration-time curve from zero to 8 hr (AUC0-8 hr),The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC0-8 hr) after the oral administration of dry elixir increased about 3.2- (24.6 versus 7.6 micrograms/ml) and 2.2-(38.4 versus 17.3 micrograms hr/ml) fold compared with powder alone.,Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876518/),[h·μg] / [ml],17.3,102305,DB00898,Ethanol
,9347092,peak BACs,"Five men and seven women were administered single-blind intravenous infusions of ethyl alcohol in 5% dextrose/water to achieve peak BACs of 0, 10, 20, and 40 mg/dl.",Behavioral effects and pharmacokinetics of low-dose intravenous alcohol in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9347092/),[mg] / [dl],0,102426,DB00898,Ethanol
,9347092,peak BACs,"Five men and seven women were administered single-blind intravenous infusions of ethyl alcohol in 5% dextrose/water to achieve peak BACs of 0, 10, 20, and 40 mg/dl.",Behavioral effects and pharmacokinetics of low-dose intravenous alcohol in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9347092/),[mg] / [dl],10,102427,DB00898,Ethanol
,9347092,peak BACs,"Five men and seven women were administered single-blind intravenous infusions of ethyl alcohol in 5% dextrose/water to achieve peak BACs of 0, 10, 20, and 40 mg/dl.",Behavioral effects and pharmacokinetics of low-dose intravenous alcohol in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9347092/),[mg] / [dl],20,102428,DB00898,Ethanol
,9347092,peak BACs,"Five men and seven women were administered single-blind intravenous infusions of ethyl alcohol in 5% dextrose/water to achieve peak BACs of 0, 10, 20, and 40 mg/dl.",Behavioral effects and pharmacokinetics of low-dose intravenous alcohol in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9347092/),[mg] / [dl],40,102429,DB00898,Ethanol
,24931869,C0 breath alcohol concentrations,Specific individual doses were calculated individually from height and weight (according to the Forrest Method) to give target C0 breath alcohol concentrations of 35 μg/100 ml breath in males and 31 μg/100 ml breath in females.,Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),breath·ml,35,102466,DB00898,Ethanol
,24931869,C0 breath alcohol concentrations,Specific individual doses were calculated individually from height and weight (according to the Forrest Method) to give target C0 breath alcohol concentrations of 35 μg/100 ml breath in males and 31 μg/100 ml breath in females.,Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),breath·ml,31,102467,DB00898,Ethanol
,24931869,C0,"Values of C0 taken from the BrAC-time curves varied widely, from 21 to 47 μg/100 ml on visit 1 and from 22 to 45 μg/100 ml on visit 2.",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),[μg] / [100·ml],21 to 47,102468,DB00898,Ethanol
,24931869,C0,"Values of C0 taken from the BrAC-time curves varied widely, from 21 to 47 μg/100 ml on visit 1 and from 22 to 45 μg/100 ml on visit 2.",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),[μg] / [100·ml],22 to 45,102469,DB00898,Ethanol
,24931869,Elimination rate,Elimination rate was higher in the morning than evening in both males (7.4 versus 5.7 μg/100 ml/h) and females (6.9 versus 5.8 μg/100 ml/h).,Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),[μg] / [100·h·ml],7.4,102470,DB00898,Ethanol
,24931869,Elimination rate,Elimination rate was higher in the morning than evening in both males (7.4 versus 5.7 μg/100 ml/h) and females (6.9 versus 5.8 μg/100 ml/h).,Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),[μg] / [100·h·ml],5.7,102471,DB00898,Ethanol
,24931869,Elimination rate,Elimination rate was higher in the morning than evening in both males (7.4 versus 5.7 μg/100 ml/h) and females (6.9 versus 5.8 μg/100 ml/h).,Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),[μg] / [100·h·ml],6.9,102472,DB00898,Ethanol
,24931869,Elimination rate,Elimination rate was higher in the morning than evening in both males (7.4 versus 5.7 μg/100 ml/h) and females (6.9 versus 5.8 μg/100 ml/h).,Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),[μg] / [100·h·ml],5.8,102473,DB00898,Ethanol
,24931869,Total body water,"Total body water, measured by electronic scales, averaged 58.7% (range, 56.6-63%) in males and 48.3% (range, 40.9-57.6%) in females.",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),%,58.7,102474,DB00898,Ethanol
,24931869,Total body water,"Total body water, measured by electronic scales, averaged 58.7% (range, 56.6-63%) in males and 48.3% (range, 40.9-57.6%) in females.",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: the effect of short-term variation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24931869/),%,48.3,102475,DB00898,Ethanol
,26704541,total encapsulation efficiency,Results showed that the total encapsulation efficiency was 32.38 ± 2.76 %.,"Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26704541/),%,32.38,102616,DB00898,Ethanol
,26704541,Total drug loading,"Total drug loading was 12.01 ± 0.42 %, particle size was 91.70 ± 2.11 nm, polydispersity index was 0.22 ± 0.01, and zeta potential was -24.5 ± 1.16 mV for the optimized SH-NPs.","Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26704541/),%,12.01,102617,DB00898,Ethanol
,26704541,polydispersity index,"Total drug loading was 12.01 ± 0.42 %, particle size was 91.70 ± 2.11 nm, polydispersity index was 0.22 ± 0.01, and zeta potential was -24.5 ± 1.16 mV for the optimized SH-NPs.","Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26704541/),,0.22,102618,DB00898,Ethanol
,26704541,zeta potential,"Total drug loading was 12.01 ± 0.42 %, particle size was 91.70 ± 2.11 nm, polydispersity index was 0.22 ± 0.01, and zeta potential was -24.5 ± 1.16 mV for the optimized SH-NPs.","Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26704541/),mv,-24.5,102619,DB00898,Ethanol
<,15741775,onset of action,The onset of action of formoterol was <3 min for all active treatments.,Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15741775/),min,3,103271,DB00898,Ethanol
,2114376,t1/2,"The mean elimination half-life of diazepam fell within the range observed in healthy persons after the ingestion of therapeutic doses (5), or it was only moderately prolonged (t1/2 49.7 h).",Diazepam loading in alcohol withdrawal: clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114376/),h,49.7,103280,DB00898,Ethanol
,8496273,minimum measurable level,The minimum measurable level was 125 pg per 100 microliters of plasma.,Simultaneous determination of the enantiomers of pimobendan and its main metabolite in rat plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8496273/),[pg] / [100·μl],125,103519,DB00898,Ethanol
,1400792,recovery,"After a 100-mg oral dose of 14C-labelled girisopam to seven male subjects, the mean recovery of 14C radioactivity was 51% in urine and 33% in faeces.",Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400792/),%,51,103944,DB00898,Ethanol
,1400792,recovery,"After a 100-mg oral dose of 14C-labelled girisopam to seven male subjects, the mean recovery of 14C radioactivity was 51% in urine and 33% in faeces.",Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400792/),%,33,103945,DB00898,Ethanol
,1400792,recovery,"The recovery was 60% and the detection limit was 3 ng/ml, using 1 ml of serum.",Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400792/),%,60,103946,DB00898,Ethanol
,1400792,detection limit,"The recovery was 60% and the detection limit was 3 ng/ml, using 1 ml of serum.",Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400792/),[ng] / [ml],3,103947,DB00898,Ethanol
,1400792,elimination half-time,"After reaching a mean serum level of 178 ng/ml at a mean time of 2.0 h, the serum concentration of girisopam decreased with a mean elimination half-time of 22.2 h.",Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400792/),h,22.2,103948,DB00898,Ethanol
,25392942,flow rate,"The 5 bioactive constituents were separated by isocratic elution using a mobile phase consisting of acetonitrile, methanol, and 0.1% aqueous formic acid at a flow rate of 0.3 mL/min.",Validation of an LC-MS/MS method for quantitative analysis of the 5 bioactive components of Wuzhi capsule in human plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392942/),[ml] / [min],0.3,104210,DB00898,Ethanol
,25392942,total run time,The total run time was 3.5 minutes.,Validation of an LC-MS/MS method for quantitative analysis of the 5 bioactive components of Wuzhi capsule in human plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25392942/),min,3.5,104211,DB00898,Ethanol
,20032972,half-life,"Pharmacokinetic analyses of 23-epi-26-deoxyactein in sera indicated that the maximum concentration and area under the curve increased proportionately with dosage, and that the half-life was ~2 h for all dosages.",Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20032972/),h,2,104673,DB00898,Ethanol
,9836721,detection limit,"Urine samples with or without ethanol extraction and plasma samples without pretreatment were analyzed by the RIA, which had a detection limit of 10.5 ng/L, a linear measuring range between 10.5 and 1000 ng/L, and recoveries of 93-102% in urine and 90-104% in plasma.",Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9836721/),[ng] / [l],10.5,104726,DB00898,Ethanol
,9836721,recoveries,"Urine samples with or without ethanol extraction and plasma samples without pretreatment were analyzed by the RIA, which had a detection limit of 10.5 ng/L, a linear measuring range between 10.5 and 1000 ng/L, and recoveries of 93-102% in urine and 90-104% in plasma.",Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9836721/),%,93-102,104727,DB00898,Ethanol
,9836721,recoveries,"Urine samples with or without ethanol extraction and plasma samples without pretreatment were analyzed by the RIA, which had a detection limit of 10.5 ng/L, a linear measuring range between 10.5 and 1000 ng/L, and recoveries of 93-102% in urine and 90-104% in plasma.",Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9836721/),%,90-104,104728,DB00898,Ethanol
,19073899,half-life,Peak EtOH levels (approximately 50 mM) from a 2 g/kg injection occurred within 20-40 min with a half-life of approximately 3 h.,Acute ethanol impairs photic and nonphotic circadian phase resetting in the Syrian hamster. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19073899/),h,3,105071,DB00898,Ethanol
,7248481,apparent bioavailability,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),%,1,106343,DB00898,Ethanol
,7248481,apparent bioavailability,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),%,2,106344,DB00898,Ethanol
,7248481,half-life,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),h,1.0,106345,DB00898,Ethanol
,7248481,half-life,"The results confirm previous reports, based on urine data and on plasma data following intravenous administration, that the drug is poorly absorbed (apparent bioavailability of 1 and 2 per cent), rapidly eliminated (half-life of 1.0 and 2.4 h) and not converted to theophylline.",The assay and absorption kinetics of oral theophylline-7-acetic acid in the human. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248481/),h,2.4,106346,DB00898,Ethanol
≈,31150807,en,"Reconstitution of CXBPLs with gentle shaking by hand generated CXB-loaded liposomes with nano-sized mean diameter, negative zeta potential, vesicular-shaped morphology, and high CXB entrapment efficiency (≈84.7%).",Preparation and evaluation of celecoxib-loaded proliposomes with high lipid content. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150807/),,84.7,106572,DB00898,Ethanol
up to,6283699,max.,"The injection of free catecholestrogens resulted in bolus-like elevations of the serum and tissue concentrations of the respective compound (max. values up to 9 ng/ml, half-life below 1 h) whereas the injection of catecholestrogen benzoates gave lower (max. values about 1 ng/ml) but prolonged elevations (half-life approx.",Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283699/),[ng] / [ml],9,107151,DB00898,Ethanol
below,6283699,half-life,"The injection of free catecholestrogens resulted in bolus-like elevations of the serum and tissue concentrations of the respective compound (max. values up to 9 ng/ml, half-life below 1 h) whereas the injection of catecholestrogen benzoates gave lower (max. values about 1 ng/ml) but prolonged elevations (half-life approx.",Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283699/),h,1,107152,DB00898,Ethanol
,6283699,max.,"The injection of free catecholestrogens resulted in bolus-like elevations of the serum and tissue concentrations of the respective compound (max. values up to 9 ng/ml, half-life below 1 h) whereas the injection of catecholestrogen benzoates gave lower (max. values about 1 ng/ml) but prolonged elevations (half-life approx.",Pharmacokinetics of free catecholestrogens and catecholestrogen benzoates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283699/),[ng] / [ml],1,107153,DB00898,Ethanol
,3577707,Kel,"After ocular application of tracer labelled timolol, the radioactivity decreased slowly in the iris (Kel = 0.05 h-1) and ciliary body (Kel = 0.02 h-1).",The pharmacokinetics of ocularly applied timolol in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3577707/),1/[h],0.05,107966,DB00898,Ethanol
,3577707,Kel,"After ocular application of tracer labelled timolol, the radioactivity decreased slowly in the iris (Kel = 0.05 h-1) and ciliary body (Kel = 0.02 h-1).",The pharmacokinetics of ocularly applied timolol in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3577707/),1/[h],0.02,107967,DB00898,Ethanol
,3577707,Kel,In the aqueous humour the elimination rate was faster (Kel = 0.57 h-1).,The pharmacokinetics of ocularly applied timolol in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3577707/),1/[h],0.57,107968,DB00898,Ethanol
,9491787,plasma protein binding,The reported plasma protein binding of both compounds ranged from 76 to 97% in different animal species.,Preclinical pharmacokinetics of paclitaxel and docetaxel. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9491787/),%,76 to 97,108312,DB00898,Ethanol
,9923583,fecal fat excretion,The means of baseline-corrected fecal fat excretion values were comparable: 23.7 g for group A (orlistat) and 22.7 g for group B (orlistat and ethanol).,The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923583/),g,23.7,108485,DB00898,Ethanol
,9923583,fecal fat excretion,The means of baseline-corrected fecal fat excretion values were comparable: 23.7 g for group A (orlistat) and 22.7 g for group B (orlistat and ethanol).,The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923583/),g,22.7,108486,DB00898,Ethanol
,23698061,C(12),"For artemether, mean (±SD) C(12) was 0.5(±1.0) and 5.9(±2.5) ng/ml in phases 1 and 2, respectively.","Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698061/),[ng] / [ml],0.5,109045,DB00898,Ethanol
,23698061,C(12),"For artemether, mean (±SD) C(12) was 0.5(±1.0) and 5.9(±2.5) ng/ml in phases 1 and 2, respectively.","Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698061/),[ng] / [ml],5.9,109046,DB00898,Ethanol
,16713502,maximal alcohol concentration in blood,Mean maximal alcohol concentration in blood (30.2+/-5.0 mg/dl) was achieved at 23.5+/-7.6 min and in milk (31.6+/-10.3 mg/dl) at 31.7+/-12.7 min.,"Alcohol levels in Chinese lactating mothers after consumption of alcoholic diet during postpartum ""doing-the-month"" ritual. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713502/),[mg] / [dl],30.2,109425,DB00898,Ethanol
,16713502,maximal alcohol concentration in blood,Mean maximal alcohol concentration in blood (30.2+/-5.0 mg/dl) was achieved at 23.5+/-7.6 min and in milk (31.6+/-10.3 mg/dl) at 31.7+/-12.7 min.,"Alcohol levels in Chinese lactating mothers after consumption of alcoholic diet during postpartum ""doing-the-month"" ritual. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713502/),[mg] / [dl],31.6,109426,DB00898,Ethanol
,16713502,time required,"Potential infant doses were 3.0-58.8 mg (mean, 13.4 mg), and the predicted time required for milk alcohol level to return to zero level was 175 min.","Alcohol levels in Chinese lactating mothers after consumption of alcoholic diet during postpartum ""doing-the-month"" ritual. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713502/),min,175,109427,DB00898,Ethanol
<,16713502,hazard index,The acute health risks for infants exposed to alcohol through their mothers' milk under the current exposure scenario are low (hazard index<0.2).,"Alcohol levels in Chinese lactating mothers after consumption of alcoholic diet during postpartum ""doing-the-month"" ritual. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713502/),,0.2,109428,DB00898,Ethanol
,19841149,maximum concentration in plasma (C(max)),"AS achieved an estimated maximum concentration in plasma (C(max)) of 51 ng/ml and an area under the concentration-time curve from time zero to infinity (AUC(0-infinity)) of 113 ng.h/ml; and its active metabolite, dihydroartemisinin (DHA), achieved a geometric mean C(max) of 473 ng/ml and an AUC(0-infinity) of 1,404 ng.h/ml.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[ng] / [ml],51,110875,DB00898,Ethanol
,19841149,area under the concentration-time curve from time zero to infinity (AUC(0-infinity)),"AS achieved an estimated maximum concentration in plasma (C(max)) of 51 ng/ml and an area under the concentration-time curve from time zero to infinity (AUC(0-infinity)) of 113 ng.h/ml; and its active metabolite, dihydroartemisinin (DHA), achieved a geometric mean C(max) of 473 ng/ml and an AUC(0-infinity) of 1,404 ng.h/ml.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[h·ng] / [ml],113,110876,DB00898,Ethanol
,19841149,C(max),"AS achieved an estimated maximum concentration in plasma (C(max)) of 51 ng/ml and an area under the concentration-time curve from time zero to infinity (AUC(0-infinity)) of 113 ng.h/ml; and its active metabolite, dihydroartemisinin (DHA), achieved a geometric mean C(max) of 473 ng/ml and an AUC(0-infinity) of 1,404 ng.h/ml.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[ng] / [ml],473,110877,DB00898,Ethanol
,19841149,AUC(0-infinity),"AS achieved an estimated maximum concentration in plasma (C(max)) of 51 ng/ml and an area under the concentration-time curve from time zero to infinity (AUC(0-infinity)) of 113 ng.h/ml; and its active metabolite, dihydroartemisinin (DHA), achieved a geometric mean C(max) of 473 ng/ml and an AUC(0-infinity) of 1,404 ng.h/ml.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[h·ng] / [ml],"1,404",110878,DB00898,Ethanol
,19841149,C(max),"AR-DHA exhibited a C(max) of 34/119 ng/ml and an AUC(0-infinity) of 168/382 ng.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[ng] / [ml],34/119,110879,DB00898,Ethanol
,19841149,AUC(0-infinity),"AR-DHA exhibited a C(max) of 34/119 ng/ml and an AUC(0-infinity) of 168/382 ng.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[h·ng] / [ml],168/382,110880,DB00898,Ethanol
,19841149,C(max),"For LR, C(max) and AUC(0-infinity) were 6,757 ng/ml and 210 microg.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[ng] / [ml],"6,757",110881,DB00898,Ethanol
,19841149,AUC(0-infinity),"For LR, C(max) and AUC(0-infinity) were 6,757 ng/ml and 210 microg.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[h·μg] / [ml],210,110882,DB00898,Ethanol
,19841149,C(max)s,"For AQ and its active metabolite, desethylamodiaquine (DEAQ), the C(max)s were 5.2 ng/ml and 235 ng/ml, respectively, and the AUC(0-infinity)s were 39.3 ng.h/ml and 148 microg.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[ng] / [ml],5.2,110883,DB00898,Ethanol
,19841149,C(max)s,"For AQ and its active metabolite, desethylamodiaquine (DEAQ), the C(max)s were 5.2 ng/ml and 235 ng/ml, respectively, and the AUC(0-infinity)s were 39.3 ng.h/ml and 148 microg.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[ng] / [ml],235,110884,DB00898,Ethanol
,19841149,AUC(0-infinity)s,"For AQ and its active metabolite, desethylamodiaquine (DEAQ), the C(max)s were 5.2 ng/ml and 235 ng/ml, respectively, and the AUC(0-infinity)s were 39.3 ng.h/ml and 148 microg.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[h·ng] / [ml],39.3,110885,DB00898,Ethanol
,19841149,AUC(0-infinity)s,"For AQ and its active metabolite, desethylamodiaquine (DEAQ), the C(max)s were 5.2 ng/ml and 235 ng/ml, respectively, and the AUC(0-infinity)s were 39.3 ng.h/ml and 148 microg.h/ml, respectively.","Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841149/),[h·μg] / [ml],148,110886,DB00898,Ethanol
,26165665,elimination rates,"Average elimination rates in males (5.3 μg/100 ml breath/h, range 4-7.7) and females (5.6 μg/100 ml breath/h, range 4-7) were not significantly different.",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: Variation over three visits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26165665/),[μg] / [100·breath·h·ml],5.3,111089,DB00898,Ethanol
,26165665,elimination rates,"Average elimination rates in males (5.3 μg/100 ml breath/h, range 4-7.7) and females (5.6 μg/100 ml breath/h, range 4-7) were not significantly different.",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: Variation over three visits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26165665/),[μg] / [100·breath·h·ml],5.6,111090,DB00898,Ethanol
,2341111,total clearance,Following intravenous administration total clearance and volume of distribution of tianeptine were 230 +/- 59 ml.min-1 and 0.47 +/- 0.14 l.kg-1 respectively.,The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),[ml] / [min],230,111202,DB00898,Ethanol
,2341111,volume of distribution,Following intravenous administration total clearance and volume of distribution of tianeptine were 230 +/- 59 ml.min-1 and 0.47 +/- 0.14 l.kg-1 respectively.,The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),[l] / [kg],0.47,111203,DB00898,Ethanol
,2341111,tmax,"When given orally, tianeptine was absorbed rapidly (tmax = 0.94 +/- 0.47 h).",The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),h,0.94,111204,DB00898,Ethanol
,2341111,systemic availability,The mean systemic availability was estimated to be 99 +/- 29%.,The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),%,99,111205,DB00898,Ethanol
,2341111,half-life,"Tianeptine was eliminated from plasma with a half-life of 2.5 +/- 1.1 h, mainly via extrarenal route since its renal clearance averaged 0.38 +/- 0.47 ml.min-1.",The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),h,2.5,111206,DB00898,Ethanol
,2341111,renal clearance,"Tianeptine was eliminated from plasma with a half-life of 2.5 +/- 1.1 h, mainly via extrarenal route since its renal clearance averaged 0.38 +/- 0.47 ml.min-1.",The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),[ml] / [min],0.38,111207,DB00898,Ethanol
,2341111,half-life,Plasma levels of metabolite MC5 were lower than those of the parent drug but decreased with a longer half-life (7.2 +/- 5.7 h).,The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341111/),h,7.2,111208,DB00898,Ethanol
,7015871,half-life,Serial measurements of FDP levels in serum after thrombin-induced DIC showed peak levels to be found at 30 minutes; the FDPs were rapidly cleared from the circulation (half-life about one hour).,Immunoenzyme histochemical localization of fibrin degradation products in tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7015871/),h,one,111316,DB00898,Ethanol
,18755258,relative bioavailability,The relative bioavailability of ibuprofen gel compared to the two marketed products was 228.8% and 181.0%.,Optimization of ibuprofen gel formulations using experimental design technique for enhanced transdermal penetration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18755258/),%,228.8,111317,DB00898,Ethanol
,18755258,relative bioavailability,The relative bioavailability of ibuprofen gel compared to the two marketed products was 228.8% and 181.0%.,Optimization of ibuprofen gel formulations using experimental design technique for enhanced transdermal penetration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18755258/),%,181.0,111318,DB00898,Ethanol
less,6799188,chemical plasma half-life,The chemical plasma half-life of the drug was less than 5 min.,"Disposition and metabolism in 1-(2-chloroethyl)-3-(2',3',4'-tri-o-acetyl, ribopyranosyl)-1-nitrosourea in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6799188/),min,5,111881,DB00898,Ethanol
,8799523,steady target-blood concentration,"2. Bretazenil (0.5 mg), diazepam (10 mg) and matching placebos were given as single oral doses after intravenous infusion of alcohol to a steady target-blood concentration of 0.5 g l-1 or a control infusion of 5% w/v glucose at 1 week intervals.",Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799523/),[g] / [l],0.5,112400,DB00898,Ethanol
,31970527,Tmax,"In mice orally administered with DHA-dFdC-SLNs, plasma DHA-dFdC concentration vs. time curve has a Tmax of ~ 1.7 h and a Cmax of 17.01 μg/mL.","Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970527/),h,1.7,112495,DB00898,Ethanol
,31970527,Cmax,"In mice orally administered with DHA-dFdC-SLNs, plasma DHA-dFdC concentration vs. time curve has a Tmax of ~ 1.7 h and a Cmax of 17.01 μg/mL.","Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970527/),[μg] / [ml],17.01,112496,DB00898,Ethanol
,31970527,absolute oral bioavailability,"The absolute oral bioavailability of DHA-dFdC when given as DHA-dFdC-SLNs was ~ 68% (based on AUC0-24 h values), while the relative oral bioavailability DHA-dFdC (compared with DHA-dFdC in a Tween 80/ethanol-in-water solution) was 126%.","Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970527/),%,68,112497,DB00898,Ethanol
,31970527,relative oral bioavailability,"The absolute oral bioavailability of DHA-dFdC when given as DHA-dFdC-SLNs was ~ 68% (based on AUC0-24 h values), while the relative oral bioavailability DHA-dFdC (compared with DHA-dFdC in a Tween 80/ethanol-in-water solution) was 126%.","Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970527/),%,126,112498,DB00898,Ethanol
,9221833,Maximum BEC,Maximum BEC ranged from 71 microM in rats to 105 microM in mice.,"A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,71,112566,DB00898,Ethanol
,9221833,Maximum BEC,Maximum BEC ranged from 71 microM in rats to 105 microM in mice.,"A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,105,112567,DB00898,Ethanol
,9221833,peak BEC,Exposure to 200 ppm ethanol for 30 min resulted in peak BEC of approximately 25 microM in mice and approximately 15 microM in rats.,"A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,25,112568,DB00898,Ethanol
,9221833,peak BEC,Exposure to 200 ppm ethanol for 30 min resulted in peak BEC of approximately 25 microM in mice and approximately 15 microM in rats.,"A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,15,112569,DB00898,Ethanol
,9221833,Peak BEC,"Peak BEC of about 10 microM were measured following exposure to 50 ppm in female rats and male and female mice, while blood ethanol was undetectable in male rats.","A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,10,112570,DB00898,Ethanol
,9221833,peak BEC,"Simulated peak BEC in human males following exposure to 50 and 600 ppm ranged from 7 to 23 microM and 86 and 293 microM, respectively.","A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,7 to 23,112571,DB00898,Ethanol
,9221833,peak BEC,"Simulated peak BEC in human males following exposure to 50 and 600 ppm ranged from 7 to 23 microM and 86 and 293 microM, respectively.","A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,86,112572,DB00898,Ethanol
,9221833,peak BEC,"Simulated peak BEC in human males following exposure to 50 and 600 ppm ranged from 7 to 23 microM and 86 and 293 microM, respectively.","A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221833/),μM,293,112573,DB00898,Ethanol
,10235296,BECs,Mean BECs 60 min after 1.0 g/kg ethanol were: males = 86 mg/dl (+/- 2; n = 4) and females = 82 mg/dl (+/- 5; n = 4).,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl],86,112842,DB00898,Ethanol
,10235296,BECs,Mean BECs 60 min after 1.0 g/kg ethanol were: males = 86 mg/dl (+/- 2; n = 4) and females = 82 mg/dl (+/- 5; n = 4).,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl],82,112843,DB00898,Ethanol
,10235296,rates of ethanol elimination,Female monkeys did have faster average rates of ethanol elimination [34 +/- 2 (mg/dl)/hr] compared with males [23 +/- 1 (mg/dl)/hr].,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl)·h],34,112844,DB00898,Ethanol
,10235296,rates of ethanol elimination,Female monkeys did have faster average rates of ethanol elimination [34 +/- 2 (mg/dl)/hr] compared with males [23 +/- 1 (mg/dl)/hr].,Comparison of ethanol metabolism in male and female cynomolgus macaques (Macaca fascicularis). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235296/),[mg] / [dl],23,112845,DB00898,Ethanol
,26753818,zeta potential,The zeta potential of the particles was about -30 mV.,Using PG-Liposome-Based System to Enhance Puerarin Liver-Targeted Therapy for Alcohol-Induced Liver Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26753818/),mv,-30,113048,DB00898,Ethanol
above,26753818,entrapment efficiency,The entrapment efficiency of puerarin was above 90%.,Using PG-Liposome-Based System to Enhance Puerarin Liver-Targeted Therapy for Alcohol-Induced Liver Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26753818/),%,90,113049,DB00898,Ethanol
,26753818,AUC,"The results show that puerarin-PG-liposome prolonged drug retention time and decreased elimination of puerarin in mice (AUC of liposome system and solution was 9.5 and 4.0 mg h L-1, respectively).",Using PG-Liposome-Based System to Enhance Puerarin Liver-Targeted Therapy for Alcohol-Induced Liver Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26753818/),[h·mg] / [l],9.5,113050,DB00898,Ethanol
,26753818,AUC,"The results show that puerarin-PG-liposome prolonged drug retention time and decreased elimination of puerarin in mice (AUC of liposome system and solution was 9.5 and 4.0 mg h L-1, respectively).",Using PG-Liposome-Based System to Enhance Puerarin Liver-Targeted Therapy for Alcohol-Induced Liver Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26753818/),[h·mg] / [l],4.0,113051,DB00898,Ethanol
,6120804,apparent first-order half-lives,"The plasma decay curve for intact sulfinalol in the dog was biphasic, with apparent first-order half-lives of 0.55 and 6.2 hr.",Metabolism and disposition of sulfinalol in laboratory animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),h,0.55,113381,DB00898,Ethanol
,6120804,apparent first-order half-lives,"The plasma decay curve for intact sulfinalol in the dog was biphasic, with apparent first-order half-lives of 0.55 and 6.2 hr.",Metabolism and disposition of sulfinalol in laboratory animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),h,6.2,113382,DB00898,Ethanol
,6120804,Urinary,"Urinary and fecal recovery were 53.8% and 41.2%, respectively, after 10 days for dogs and 57.8% and 38.0%, respectively, after 9 days for monkeys.",Metabolism and disposition of sulfinalol in laboratory animals. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),%,53.8,113383,DB00898,Ethanol
,6120804,Urinary,"Urinary and fecal recovery were 53.8% and 41.2%, respectively, after 10 days for dogs and 57.8% and 38.0%, respectively, after 9 days for monkeys.",Metabolism and disposition of sulfinalol in laboratory animals. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),%,57.8,113384,DB00898,Ethanol
,6120804,fecal recovery,"Urinary and fecal recovery were 53.8% and 41.2%, respectively, after 10 days for dogs and 57.8% and 38.0%, respectively, after 9 days for monkeys.",Metabolism and disposition of sulfinalol in laboratory animals. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),%,41.2,113385,DB00898,Ethanol
,6120804,fecal recovery,"Urinary and fecal recovery were 53.8% and 41.2%, respectively, after 10 days for dogs and 57.8% and 38.0%, respectively, after 9 days for monkeys.",Metabolism and disposition of sulfinalol in laboratory animals. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),%,57.8,113386,DB00898,Ethanol
,6120804,fecal recovery,"Urinary and fecal recovery were 53.8% and 41.2%, respectively, after 10 days for dogs and 57.8% and 38.0%, respectively, after 9 days for monkeys.",Metabolism and disposition of sulfinalol in laboratory animals. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6120804/),%,38.0,113387,DB00898,Ethanol
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.57,114020,DB00898,Ethanol
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.38,114021,DB00898,Ethanol
,10187758,systemic bioavailability,Intragastric alcohol administration significantly increased cocaine systemic bioavailability after ip administration from 0.550 +/- 0.044 to 0. 754 +/- 0.071.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,0.550,114230,DB00898,Ethanol
,10187758,systemic bioavailability,Intragastric alcohol administration significantly increased cocaine systemic bioavailability after ip administration from 0.550 +/- 0.044 to 0. 754 +/- 0.071.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,0. 754,114231,DB00898,Ethanol
,10187758,absorption rate constant,"Also, the absorption rate constant increased from 0. 199 +/- 0.045 to 0.276 +/- 0.059 min-1 due to alcohol coadministration; however, this increase was not significant.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),1/[min],0. 199,114232,DB00898,Ethanol
,10187758,absorption rate constant,"Also, the absorption rate constant increased from 0. 199 +/- 0.045 to 0.276 +/- 0.059 min-1 due to alcohol coadministration; however, this increase was not significant.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),1/[min],0.276,114233,DB00898,Ethanol
,10187758,elimination half-life,Alcohol inhibition of cocaine metabolism caused an increase in cocaine elimination half-life from 26.3 +/- 3.6 to 40.0 +/- 8.1 min.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),min,26.3,114234,DB00898,Ethanol
,10187758,elimination half-life,Alcohol inhibition of cocaine metabolism caused an increase in cocaine elimination half-life from 26.3 +/- 3.6 to 40.0 +/- 8.1 min.,Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),min,40.0,114235,DB00898,Ethanol
,10187758,Emax,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,850,114236,DB00898,Ethanol
,10187758,Emax,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),,1550,114237,DB00898,Ethanol
,10187758,EC50,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),[ng] / [ml],3400,114238,DB00898,Ethanol
,10187758,EC50,"Analysis of the brain cocaine concentration-neurochemical effect relationship by the sigmoid-Emax pharmacodynamic model showed that Emax increased from 850 +/- 200 to 1550 +/- 640% of baseline due to alcohol coadministration, whereas EC50 decreased from 3400 +/- 580 to 2000 +/- 650 ng/mL, indicating higher cocaine potency in the presence of alcohol.",Cocaine and alcohol interactions in the rat: effect on cocaine pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10187758/),[ng] / [ml],2000,114239,DB00898,Ethanol
,27095388,EE%,"EE% of 92.2-97.3% and 30.2-84.7% and pH of 3.0 ± 0.02 to 4.9 ± 0.12 and 3.0 ± 0.02 to 5.8 ± 0.05 were obtained for artemether and lumefantrine SLMs, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,92.2-97.3,114823,DB00898,Ethanol
,27095388,EE%,"EE% of 92.2-97.3% and 30.2-84.7% and pH of 3.0 ± 0.02 to 4.9 ± 0.12 and 3.0 ± 0.02 to 5.8 ± 0.05 were obtained for artemether and lumefantrine SLMs, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,30.2-84.7,114824,DB00898,Ethanol
,27095388,EE%,"EE% of 92.2-97.3% and 30.2-84.7% and pH of 3.0 ± 0.02 to 4.9 ± 0.12 and 3.0 ± 0.02 to 5.8 ± 0.05 were obtained for artemether and lumefantrine SLMs, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),,3.0,114825,DB00898,Ethanol
,27095388,Release,"Release of 100, 88.28 and 75.49%, as well as 63.26, 34.31 and 56.17% were recorded for artemether and lumefantrine in alcoholic buffer, SGF and SIF, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,100,114826,DB00898,Ethanol
,27095388,Release,"Release of 100, 88.28 and 75.49%, as well as 63.26, 34.31 and 56.17% were recorded for artemether and lumefantrine in alcoholic buffer, SGF and SIF, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,88.28,114827,DB00898,Ethanol
,27095388,Release,"Release of 100, 88.28 and 75.49%, as well as 63.26, 34.31 and 56.17% were recorded for artemether and lumefantrine in alcoholic buffer, SGF and SIF, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,75.49,114828,DB00898,Ethanol
,27095388,Release,"Release of 100, 88.28 and 75.49%, as well as 63.26, 34.31 and 56.17% were recorded for artemether and lumefantrine in alcoholic buffer, SGF and SIF, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,63.26,114829,DB00898,Ethanol
,27095388,Release,"Release of 100, 88.28 and 75.49%, as well as 63.26, 34.31 and 56.17% were recorded for artemether and lumefantrine in alcoholic buffer, SGF and SIF, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,34.31,114830,DB00898,Ethanol
,27095388,Release,"Release of 100, 88.28 and 75.49%, as well as 63.26, 34.31 and 56.17% were recorded for artemether and lumefantrine in alcoholic buffer, SGF and SIF, respectively.","Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27095388/),%,56.17,114831,DB00898,Ethanol
,1520634,rate constant for the elimination phase,"The elimination of methanol administered alone was found to follow first-order kinetics with a rate constant for the elimination phase of 0.475-0.259 h-1, corresponding to an elimination half-life of 1.8-3.0 h.",The elimination kinetics of methanol and the influence of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1520634/),1/[h],0.475-0.259,115197,DB00898,Ethanol
,1520634,elimination half-life,"The elimination of methanol administered alone was found to follow first-order kinetics with a rate constant for the elimination phase of 0.475-0.259 h-1, corresponding to an elimination half-life of 1.8-3.0 h.",The elimination kinetics of methanol and the influence of ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1520634/),h,1.8-3.0,115198,DB00898,Ethanol
,1520634,k,"When the ethanol concentration had dropped to zero, methanol elimination followed exactly the same course as that observed in the experiment without prior administration of ethanol (k: 0.378-0.231 h-1; t1/2: 1.5-2.7 h).",The elimination kinetics of methanol and the influence of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1520634/),1/[h],0.378-0.231,115199,DB00898,Ethanol
,1520634,t1/2,"When the ethanol concentration had dropped to zero, methanol elimination followed exactly the same course as that observed in the experiment without prior administration of ethanol (k: 0.378-0.231 h-1; t1/2: 1.5-2.7 h).",The elimination kinetics of methanol and the influence of ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1520634/),h,1.5-2.7,115200,DB00898,Ethanol
,10419838,E max,The E max values+/-SD for the hypokalemic effects were 2.29+/-0.78 mmol/l for formoterol and 1.64+/-1.16 mmol/l for theophylline (P>0.05).,Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[mM] / [l],2.29,115359,DB00898,Ethanol
,10419838,E max,The E max values+/-SD for the hypokalemic effects were 2.29+/-0.78 mmol/l for formoterol and 1.64+/-1.16 mmol/l for theophylline (P>0.05).,Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[mM] / [l],1.64,115360,DB00898,Ethanol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[pg] / [ml],91.4,115361,DB00898,Ethanol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[pg] / [ml],128.4,115362,DB00898,Ethanol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[μg] / [ml],11. 9,115363,DB00898,Ethanol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[μg] / [ml],15.5,115364,DB00898,Ethanol
,18074336,C(max) ratio,"The C(max) ratio (-/+) of THP was 2.91, 1.38, and 1.19, and the AUC(0 approximately infinity) ratio (-/+) of THP was 2.84, 1.50, and 1.35 in rats after dosed with rac-THP, extracts of Rhizoma corydalis and YB, respectively.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),,2.91,116049,DB00898,Ethanol
,18074336,C(max) ratio,"The C(max) ratio (-/+) of THP was 2.91, 1.38, and 1.19, and the AUC(0 approximately infinity) ratio (-/+) of THP was 2.84, 1.50, and 1.35 in rats after dosed with rac-THP, extracts of Rhizoma corydalis and YB, respectively.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),,1.38,116050,DB00898,Ethanol
,18074336,C(max) ratio,"The C(max) ratio (-/+) of THP was 2.91, 1.38, and 1.19, and the AUC(0 approximately infinity) ratio (-/+) of THP was 2.84, 1.50, and 1.35 in rats after dosed with rac-THP, extracts of Rhizoma corydalis and YB, respectively.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),,1.19,116051,DB00898,Ethanol
,18074336,AUC(0 approximately infinity) ratio,"The C(max) ratio (-/+) of THP was 2.91, 1.38, and 1.19, and the AUC(0 approximately infinity) ratio (-/+) of THP was 2.84, 1.50, and 1.35 in rats after dosed with rac-THP, extracts of Rhizoma corydalis and YB, respectively.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),,2.84,116052,DB00898,Ethanol
,18074336,AUC(0 approximately infinity) ratio,"The C(max) ratio (-/+) of THP was 2.91, 1.38, and 1.19, and the AUC(0 approximately infinity) ratio (-/+) of THP was 2.84, 1.50, and 1.35 in rats after dosed with rac-THP, extracts of Rhizoma corydalis and YB, respectively.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),,1.50,116053,DB00898,Ethanol
,18074336,AUC(0 approximately infinity) ratio,"The C(max) ratio (-/+) of THP was 2.91, 1.38, and 1.19, and the AUC(0 approximately infinity) ratio (-/+) of THP was 2.84, 1.50, and 1.35 in rats after dosed with rac-THP, extracts of Rhizoma corydalis and YB, respectively.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),,1.35,116054,DB00898,Ethanol
,18074336,AUC(0 approximately infinity),"The mean AUC(0 approximately infinity) and C(max) of (+)-THP dosed with YB extracts were 0.652 +/- 0.30 microg h ml(-1) and 0.148 +/- 0.09 microg ml(-1), significantly higher (P < 0.05) than those dosed with rac-THP and Rhizoma corydalis extracts.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),[h·μg] / [ml],0.652,116055,DB00898,Ethanol
,18074336,C(max),"The mean AUC(0 approximately infinity) and C(max) of (+)-THP dosed with YB extracts were 0.652 +/- 0.30 microg h ml(-1) and 0.148 +/- 0.09 microg ml(-1), significantly higher (P < 0.05) than those dosed with rac-THP and Rhizoma corydalis extracts.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),[μg] / [ml],0.148,116056,DB00898,Ethanol
,18074336,AUC(0 approximately infinity),"The mean AUC(0 approximately infinity) and T(max) of rac-THP dosed with YB extracts were 1.500 +/- 0.56 microg h ml(-1) and 2.12 +/- 1.1 h, significantly higher (P < 0.05) than those dosed with rac-THP or Rhizoma corydalis extracts.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),[h·μg] / [ml],1.500,116057,DB00898,Ethanol
,18074336,T(max),"The mean AUC(0 approximately infinity) and T(max) of rac-THP dosed with YB extracts were 1.500 +/- 0.56 microg h ml(-1) and 2.12 +/- 1.1 h, significantly higher (P < 0.05) than those dosed with rac-THP or Rhizoma corydalis extracts.",Comparative studies on pharmacokinetic fates of tetrahydropalmatine enantiomers in different chemical environments in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074336/),h,2.12,116058,DB00898,Ethanol
,21499422,entrapment efficiency,Ligustrazine ethosomes were obtained with an average particle size of 78.71 ± 1.23 nm and an average entrapment efficiency of 86.42% ± 1.50%.,Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499422/),%,86.42,116160,DB00898,Ethanol
,21499422,relative bioavailability,The pharmacokinetic results revealed that the relative bioavailability was 209.45%.,Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499422/),%,209.45,116161,DB00898,Ethanol
,6719467,steady state benzene concentrations,"During the first benzene exposures, the mean steady state benzene concentrations in benzene/EtOH-treated mice and benzene/water-treated mice were 5.2 and 10.7 micrograms/ml, respectively.",The effects of ethanol ingestion and repeated benzene exposures on benzene pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6719467/),[μg] / [ml],5.2,116625,DB00898,Ethanol
,6719467,steady state benzene concentrations,"During the first benzene exposures, the mean steady state benzene concentrations in benzene/EtOH-treated mice and benzene/water-treated mice were 5.2 and 10.7 micrograms/ml, respectively.",The effects of ethanol ingestion and repeated benzene exposures on benzene pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6719467/),[μg] / [ml],10.7,116626,DB00898,Ethanol
,6719467,elimination rate constants,"The mean elimination rate constants for the benzene/EtOH- and benzene/water-treated groups were 0.124 and 0.042 min-1, respectively.",The effects of ethanol ingestion and repeated benzene exposures on benzene pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6719467/),1/[min],0.124,116627,DB00898,Ethanol
,6719467,elimination rate constants,"The mean elimination rate constants for the benzene/EtOH- and benzene/water-treated groups were 0.124 and 0.042 min-1, respectively.",The effects of ethanol ingestion and repeated benzene exposures on benzene pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6719467/),1/[min],0.042,116628,DB00898,Ethanol
,6719467,Css,"By 20 exposures, the benzene/EtOH group showed no change in mean blood steady state concentration (Css); however, the Css of the benzene/water group was reduced to 7.9 micrograms/ml.",The effects of ethanol ingestion and repeated benzene exposures on benzene pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6719467/),[μg] / [ml],7.9,116629,DB00898,Ethanol
,16405034,T1/2,"The drug is rapidly eliminated from rat organism, with T1/2 approximately 70 min.",[The main pharmacokinetic parameters of p-tyrosol upon intravenous injection in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16405034/),min,70,116748,DB00898,Ethanol
,1581022,Peak blood alcohol,Peak blood alcohol values between 0.5 and 1.1 per thousand are attained.,[Increased ethanol elimination after barium meal--human experimental study with parenteral alcohol administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1581022/),1/[thousand],0.5 and 1.1,117227,DB00898,Ethanol
,1581022,beta 60 min,The rate of increase up to 27 percent of the baseline value (beta 60 min. 0.108; beta 60 max. 0.15 g/kg) is attributed to the raised hepatic blood flow.,[Increased ethanol elimination after barium meal--human experimental study with parenteral alcohol administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1581022/),[g] / [kg],0.108,117228,DB00898,Ethanol
,1581022,beta 60 max,The rate of increase up to 27 percent of the baseline value (beta 60 min. 0.108; beta 60 max. 0.15 g/kg) is attributed to the raised hepatic blood flow.,[Increased ethanol elimination after barium meal--human experimental study with parenteral alcohol administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1581022/),[g] / [kg],0.15,117229,DB00898,Ethanol
,26658806,half-life,"Based on the exponential best fit line for the patient's methanol concentrations, his methanol half-life during fomepizole treatment was approximately 70 hours, significantly longer than the 30-50 hours typically reported.",Methanol Kinetics in Chronic Kidney Disease After Fomepizole: A Case Report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658806/),h,70,117374,DB00898,Ethanol
,26658806,half-life,"Based on the exponential best fit line for the patient's methanol concentrations, his methanol half-life during fomepizole treatment was approximately 70 hours, significantly longer than the 30-50 hours typically reported.",Methanol Kinetics in Chronic Kidney Disease After Fomepizole: A Case Report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658806/),h,30-50,117375,DB00898,Ethanol
,24170571,Absolute recoveries,Absolute recoveries ranged within 65.06-85.1% for plasma samples.,Ultra-fast LC-ESI-MS/MS method for the simultaneous determination of six highly toxic Aconitum alkaloids from Aconiti kusnezoffii radix in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24170571/),%,65.06-85.1,117393,DB00898,Ethanol
,12507057,elimination half-life,The elimination half-life was calculated to be 5.14 hours.,A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507057/),h,5.14,117772,DB00898,Ethanol
,1806626,elimination half-life,The elimination half-life is about 32 h; metabolism is by demethylation to an inactive metabolite.,Clinical implications of the pharmacology of sertraline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1806626/),h,32,117841,DB00898,Ethanol
,10442208,Maximum concentrations (Cmax),Maximum concentrations (Cmax) achieved were 22.28 ng/ml (tilidine) and 92.78 ng/ml (nortilidine) for the test preparation.,Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10442208/),[ng] / [ml],22.28,117845,DB00898,Ethanol
,10442208,Maximum concentrations (Cmax),Maximum concentrations (Cmax) achieved were 22.28 ng/ml (tilidine) and 92.78 ng/ml (nortilidine) for the test preparation.,Bioavailability investigation of a new tilidine/naloxone liquid formulation compared to a reference formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10442208/),[ng] / [ml],92.78,117846,DB00898,Ethanol
,6468479,first order absorption rate constant (ka),"The average values for the first order absorption rate constant (ka) ranged from 2.2 to 3.1, from 2.4 to 2.6 and from 1.0 to 1.7 h-1 for ACC, ABAC and VBAC, respectively.","The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468479/),1/[h],2.2 to 3.1,118298,DB00898,Ethanol
,6468479,first order absorption rate constant (ka),"The average values for the first order absorption rate constant (ka) ranged from 2.2 to 3.1, from 2.4 to 2.6 and from 1.0 to 1.7 h-1 for ACC, ABAC and VBAC, respectively.","The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468479/),1/[h],2.4 to 2.6,118299,DB00898,Ethanol
,6468479,first order absorption rate constant (ka),"The average values for the first order absorption rate constant (ka) ranged from 2.2 to 3.1, from 2.4 to 2.6 and from 1.0 to 1.7 h-1 for ACC, ABAC and VBAC, respectively.","The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468479/),1/[h],1.0 to 1.7,118300,DB00898,Ethanol
,6468479,pseudo-zero-order elimination rate constant (beta),"The pseudo-zero-order elimination rate constant (beta) was 0.17 to 0.18, 0.21 to 0.22 and 0.26 to 0.27 g X 1(-1) X h-1, respectively.","The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468479/),[g] / [1·h],0.17 to 0.18,118301,DB00898,Ethanol
,6468479,pseudo-zero-order elimination rate constant (beta),"The pseudo-zero-order elimination rate constant (beta) was 0.17 to 0.18, 0.21 to 0.22 and 0.26 to 0.27 g X 1(-1) X h-1, respectively.","The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468479/),[g] / [1·h],0.21 to 0.22,118302,DB00898,Ethanol
,6468479,pseudo-zero-order elimination rate constant (beta),"The pseudo-zero-order elimination rate constant (beta) was 0.17 to 0.18, 0.21 to 0.22 and 0.26 to 0.27 g X 1(-1) X h-1, respectively.","The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6468479/),[g] / [1·h],0.26 to 0.27,118303,DB00898,Ethanol
,6090354,total chromatography time,The assay uses 150 microL of plasma and requires a total chromatography time of about 50 minutes.,An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6090354/),min,50,118304,DB00898,Ethanol
,526397,elimination half-life,The mean elimination half-life was 3.25 hours.,Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/526397/),h,3.25,119188,DB00898,Ethanol
,526397,Systemic availability,Systemic availability varied from 11-86% (mean 33%).,Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526397/),%,33,119189,DB00898,Ethanol
,24021293,Plasma Tmax,"Plasma Tmax of clonazepam nanostructured carriers varied from 10-30 min., while their brain Tmax did not exceed 10 min, in comparison with 30 min for iv solution.","Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24021293/),min,10-30,119222,DB00898,Ethanol
not exceed,24021293,Tmax,"Plasma Tmax of clonazepam nanostructured carriers varied from 10-30 min., while their brain Tmax did not exceed 10 min, in comparison with 30 min for iv solution.","Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24021293/),min,10,119223,DB00898,Ethanol
,24021293,Tmax,"Plasma Tmax of clonazepam nanostructured carriers varied from 10-30 min., while their brain Tmax did not exceed 10 min, in comparison with 30 min for iv solution.","Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24021293/),min,30,119224,DB00898,Ethanol
,19653937,plasma elimination half-life (t(1/2)),The recreational drug gamma-hydroxybutyrate (GHB) has a short plasma elimination half-life (t(1/2)) reported to be about 30-50 min.,Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653937/),min,30-50,120952,DB00898,Ethanol
,19653937,half-life,"A back-calculation for 6 h, assuming a GHB half-life of 40 min, gives a very high concentration in blood of approximately 900 mg/L, which would probably have proven fatal.",Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653937/),min,40,120953,DB00898,Ethanol
,19653937,elimination rate,"Back-calculating using zero-order kinetics and a proposed elimination rate of 18 mg/L per hour leads to a GHB concentration of 208 mg/L, which is much more realistic.",Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653937/),[mg] / [h·l],18,120954,DB00898,Ethanol
,29349861,extraction recoveries,The extraction recoveries ranged from 74.65 to 107.45% with RSD ≤ 15.36%.,Validated UPLC-MS/MS method for quantification of seven compounds in rat plasma and tissues: Application to pharmacokinetic and tissue distribution studies in rats after oral administration of extract of Eclipta prostrata L. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29349861/),%,74.65 to 107.45,122001,DB00898,Ethanol
,31032954,flow rate,"The separation was achieved on Chiralpak IA (amylose-based immobilized chiral stationary phase), using a mobile phase consisting of n-hexane-ethanol-trifluoroacetic acid (70:30:0.2, v/v/v) at a flow rate of 1.0 mL/min.","Chiral separation and thermodynamic investigation of WCK 3023: A novel oxazolidinone antibacterial agent, application to pre-clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31032954/),[ml] / [min],1.0,122027,DB00898,Ethanol
,31032954,limit of,The limit of quantitation and limit of detection for RE were 0.11 and 0.04 μg/mL respectively.,"Chiral separation and thermodynamic investigation of WCK 3023: A novel oxazolidinone antibacterial agent, application to pre-clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31032954/),[μg] / [ml],0.11,122028,DB00898,Ethanol
,31032954,limit of detection,The limit of quantitation and limit of detection for RE were 0.11 and 0.04 μg/mL respectively.,"Chiral separation and thermodynamic investigation of WCK 3023: A novel oxazolidinone antibacterial agent, application to pre-clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31032954/),[μg] / [ml],0.04,122029,DB00898,Ethanol
,31032954,recovery,Average recovery of the RE was in the range of 98.11-99.55%.,"Chiral separation and thermodynamic investigation of WCK 3023: A novel oxazolidinone antibacterial agent, application to pre-clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31032954/),%,98.11-99.55,122030,DB00898,Ethanol
,8364260,Peak ethanol concentrations,"Peak ethanol concentrations (median values) were 153, 140, and 155 mg/L, respectively.",Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364260/),[mg] / [l],153,122115,DB00898,Ethanol
,8364260,Peak ethanol concentrations,"Peak ethanol concentrations (median values) were 153, 140, and 155 mg/L, respectively.",Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364260/),[mg] / [l],140,122116,DB00898,Ethanol
,8364260,Peak ethanol concentrations,"Peak ethanol concentrations (median values) were 153, 140, and 155 mg/L, respectively.",Comparative trial in volunteers to investigate possible ethanol-ranitidine interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364260/),[mg] / [l],155,122117,DB00898,Ethanol
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,5500,122118,DB00898,Ethanol
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,500,122119,DB00898,Ethanol
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,150,122120,DB00898,Ethanol
,12490375,50% inhibition (IC(50)),"The 50% inhibition (IC(50)) was calculated to be 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h, respectively.",A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12490375/),nM,100,122121,DB00898,Ethanol
,9788573,half-life,The half-life of Bu in the present formulation was determined to be 8.7 +/- 2.7 days at 4 degrees C.,Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),d,8.7,122394,DB00898,Ethanol
,9788573,distribution volume,"A higher distribution volume was observed for L-Bu as compared with D-Bu (1.39 versus 0.67 l/kg, respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),[l] / [kg],1.39,122395,DB00898,Ethanol
,9788573,distribution volume,"A higher distribution volume was observed for L-Bu as compared with D-Bu (1.39 versus 0.67 l/kg, respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),[l] / [kg],0.67,122396,DB00898,Ethanol
,9788573,elimination half-lives,"The elimination half-lives were significantly longer in both blood and marrow after the administration of L-Bu as compared with D-Bu (2.52 and 3.08 versus 1.53 and 1.75 h, respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),h,2.52,122397,DB00898,Ethanol
,9788573,elimination half-lives,"The elimination half-lives were significantly longer in both blood and marrow after the administration of L-Bu as compared with D-Bu (2.52 and 3.08 versus 1.53 and 1.75 h, respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),h,3.08,122398,DB00898,Ethanol
,9788573,elimination half-lives,"The elimination half-lives were significantly longer in both blood and marrow after the administration of L-Bu as compared with D-Bu (2.52 and 3.08 versus 1.53 and 1.75 h, respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),h,1.53,122399,DB00898,Ethanol
,9788573,elimination half-lives,"The elimination half-lives were significantly longer in both blood and marrow after the administration of L-Bu as compared with D-Bu (2.52 and 3.08 versus 1.53 and 1.75 h, respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),h,1.75,122400,DB00898,Ethanol
,9788573,AUC,"A slight difference was observed in systemic exposure to L-Bu as compared with D-Bu as expressed in AUC (9.93 and 11.82 microg h ml(-1), respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),[h·μg] / [ml],9.93,122401,DB00898,Ethanol
,9788573,AUC,"A slight difference was observed in systemic exposure to L-Bu as compared with D-Bu as expressed in AUC (9.93 and 11.82 microg h ml(-1), respectively).",Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788573/),[h·μg] / [ml],11.82,122402,DB00898,Ethanol
,728283,T1/2alpha,It is proposed that a two-compartment model adequately describes the disposition of the drug which is rapidly distributed (T1/2alpha = 4.9 +/- 1.1 min) and eliminated (T1/2beta = 165.7 +/- 20.2 min).,Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728283/),min,4.9,122408,DB00898,Ethanol
,728283,T1/2beta,It is proposed that a two-compartment model adequately describes the disposition of the drug which is rapidly distributed (T1/2alpha = 4.9 +/- 1.1 min) and eliminated (T1/2beta = 165.7 +/- 20.2 min).,Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/728283/),min,165.7,122409,DB00898,Ethanol
,728283,Total body plasma clearance,Total body plasma clearance of the drug is high (10.9 +/- 1.5 ml min-1 kg-1) and approximates to liver plasma flow.,Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/728283/),[ml] / [kg·min],10.9,122410,DB00898,Ethanol
,10817729,area under the concentration curve,The geometric least squares mean area under the concentration curve extrapolated to infinite time for abacavir increased 41% (from 11.07 to 15.62 microg.,Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817729/),μg,11.07,122471,DB00898,Ethanol
,10817729,area under the concentration curve,The geometric least squares mean area under the concentration curve extrapolated to infinite time for abacavir increased 41% (from 11.07 to 15.62 microg.,Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817729/),μg,15.62,122472,DB00898,Ethanol
,10817729,half-life,"h/ml), and the half-life increased 26% (from 1.42 to 1.79 h) in the presence of ethanol (mean ethanol maximum concentration in plasma of 498 microg/ml).",Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817729/),h,1.42,122473,DB00898,Ethanol
,10817729,half-life,"h/ml), and the half-life increased 26% (from 1.42 to 1.79 h) in the presence of ethanol (mean ethanol maximum concentration in plasma of 498 microg/ml).",Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817729/),h,1.79,122474,DB00898,Ethanol
,10817729,maximum concentration,"h/ml), and the half-life increased 26% (from 1.42 to 1.79 h) in the presence of ethanol (mean ethanol maximum concentration in plasma of 498 microg/ml).",Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10817729/),[μg] / [ml],498,122475,DB00898,Ethanol
,2423790,plasma half-life,Recent pharmacokinetic and biotransformation studies confirm earlier reports that the drug is well absorbed and extensively metabolized and has a plasma half-life of approximately 5 h.,Recent developments in the pharmacology and pharmacokinetics of indoramin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2423790/),h,5,122895,DB00898,Ethanol
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],2.24x10(-11),123149,DB00898,Ethanol
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],1.97x10(-11),123150,DB00898,Ethanol
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],0.51x10(-11),123151,DB00898,Ethanol
,30792745,analysis time,The single-run analysis time was 10.0 minutes.,Development of a MD-LC-MS/MS Method to Analyze 3 Bioactive Compounds in Huoxuezhitong Rubber Patch and Application to a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30792745/),min,10.0,123266,DB00898,Ethanol
,30792745,Tmax,"Pip's Tmax (488.00±150.73) min was greater than that of Pae (186.67±48.44) min and Eug (240.00±138.56) min, and the rank order of t1/2 was Pae > Pip > Eug.",Development of a MD-LC-MS/MS Method to Analyze 3 Bioactive Compounds in Huoxuezhitong Rubber Patch and Application to a Pharmacokinetic Study in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30792745/),min,488.00,123267,DB00898,Ethanol
,30792745,Tmax,"Pip's Tmax (488.00±150.73) min was greater than that of Pae (186.67±48.44) min and Eug (240.00±138.56) min, and the rank order of t1/2 was Pae > Pip > Eug.",Development of a MD-LC-MS/MS Method to Analyze 3 Bioactive Compounds in Huoxuezhitong Rubber Patch and Application to a Pharmacokinetic Study in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30792745/),min,186.67,123268,DB00898,Ethanol
,30792745,Tmax,"Pip's Tmax (488.00±150.73) min was greater than that of Pae (186.67±48.44) min and Eug (240.00±138.56) min, and the rank order of t1/2 was Pae > Pip > Eug.",Development of a MD-LC-MS/MS Method to Analyze 3 Bioactive Compounds in Huoxuezhitong Rubber Patch and Application to a Pharmacokinetic Study in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30792745/),min,240.00,123269,DB00898,Ethanol
,28971375,particle size,"In the end, we acquired the optimal formulation of ibuprofen cationic liposomes (Ibu-CL) by orthogonal test design, and the particle size and entrapment efficiency (EE%) were 121.0 ± 3.5 nm and 72.9 ± 3.4%, respectively.",In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971375/),nm,121.0,123423,DB00898,Ethanol
,28971375,entrapment efficiency (EE%),"In the end, we acquired the optimal formulation of ibuprofen cationic liposomes (Ibu-CL) by orthogonal test design, and the particle size and entrapment efficiency (EE%) were 121.0 ± 3.5 nm and 72.9 ± 3.4%, respectively.",In vitro and In vivo Studies on a Novel Bioadhesive Colloidal System: Cationic Liposomes of Ibuprofen. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28971375/),%,72.9,123424,DB00898,Ethanol
,7701044,elimination rate constant,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),[l] / [h],0.42,123689,DB00898,Ethanol
,7701044,elimination rate constant,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),[l] / [h],0.67,123690,DB00898,Ethanol
,7701044,elimination half-life,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),h,1.68,123691,DB00898,Ethanol
,7701044,elimination half-life,"The results indicate, that in comparison to cocaine, cocaethylene had a significant smaller elimination rate constant (0.42 versus 0.67 l/h), had a longer elimination half-life (1.68 versus 1.07 h), and induced ratings of ""high"" and changes in heart rate that were of lower magnitude (65%, and 43%, respectively).",Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7701044/),h,1.07,123692,DB00898,Ethanol
,27883269,AUC0-8 hr,"The AUC0-8 hr was comparable between A and B [geometric mean (95% CI): 6.01 (3.26-11.1) versus 6.26 (4.5-8.43) hr*μg/mL, p = 0.9].",Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883269/),[h·μg] / [ml],6.01,123851,DB00898,Ethanol
,27883269,AUC0-8 hr,"The AUC0-8 hr was comparable between A and B [geometric mean (95% CI): 6.01 (3.26-11.1) versus 6.26 (4.5-8.43) hr*μg/mL, p = 0.9].",Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883269/),[h·μg] / [ml],6.26,123852,DB00898,Ethanol
,27883269,d7LUM,"Children receiving two tablets had significantly higher exposure than those receiving one tablet [median d7LUM (505 versus 289 ng/mL, p = 0.02) and AUCd7-28 (108 versus 41 hr*μg/mL, p = 0.006)].",Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883269/),[ng] / [ml],505,123853,DB00898,Ethanol
,27883269,d7LUM,"Children receiving two tablets had significantly higher exposure than those receiving one tablet [median d7LUM (505 versus 289 ng/mL, p = 0.02) and AUCd7-28 (108 versus 41 hr*μg/mL, p = 0.006)].",Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883269/),[ng] / [ml],289,123854,DB00898,Ethanol
,27883269,AUCd7-28,"Children receiving two tablets had significantly higher exposure than those receiving one tablet [median d7LUM (505 versus 289 ng/mL, p = 0.02) and AUCd7-28 (108 versus 41 hr*μg/mL, p = 0.006)].",Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883269/),[h·μg] / [ml],108,123855,DB00898,Ethanol
,27883269,AUCd7-28,"Children receiving two tablets had significantly higher exposure than those receiving one tablet [median d7LUM (505 versus 289 ng/mL, p = 0.02) and AUCd7-28 (108 versus 41 hr*μg/mL, p = 0.006)].",Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27883269/),[h·μg] / [ml],41,123856,DB00898,Ethanol
,2769820,AUC,The AUC (mean 1184 mcg x hr/ml) and highest ethanol concentrations (mean 46.3 mg/dl) for the control group were not significantly greater than in the SAC group (mean AUC 1167 mcg x hr/ml and highest ethanol concentration of 49.0 mg/dl).,"The effect of ""superactive"" charcoal and magnesium citrate solution on blood ethanol concentrations and area under the curve in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769820/),[h·mcg] / [ml],1184,124284,DB00898,Ethanol
,2769820,AUC,The AUC (mean 1184 mcg x hr/ml) and highest ethanol concentrations (mean 46.3 mg/dl) for the control group were not significantly greater than in the SAC group (mean AUC 1167 mcg x hr/ml and highest ethanol concentration of 49.0 mg/dl).,"The effect of ""superactive"" charcoal and magnesium citrate solution on blood ethanol concentrations and area under the curve in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2769820/),[h·mcg] / [ml],1167,124285,DB00898,Ethanol
,10682405,time of withdrawal,The time of withdrawal in lactating cows after i.m. administration of DXM-AM was found to be 5 days.,"Albumin microsphere as a drug delivery system for dexamethasone: pharmacokinetics in sheep, residue amount in cows and distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682405/),d,5,124469,DB00898,Ethanol
,2590522,Maximal elimination velocity Vmax,"The analyses of ethanol infusion studies showed, that there are no sex differences in parameters of ethanol elimination: Maximal elimination velocity Vmax was 3.41 +/- 0.61 mmol/l.h in females and 3.98 +/- 0.69 mmol/l.h in males.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),[mM] / [h·l],3.41,124893,DB00898,Ethanol
,2590522,Maximal elimination velocity Vmax,"The analyses of ethanol infusion studies showed, that there are no sex differences in parameters of ethanol elimination: Maximal elimination velocity Vmax was 3.41 +/- 0.61 mmol/l.h in females and 3.98 +/- 0.69 mmol/l.h in males.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),[mM] / [h·l],3.98,124894,DB00898,Ethanol
,2590522,Michaelis-Menten-constant kM,"Michaelis-Menten-constant kM was 1.49 +/- 0.44 mmol/l and 1.69 +/- 0.88 mmol/l, respectively.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),[mM] / [l],1.49,124895,DB00898,Ethanol
,2590522,Michaelis-Menten-constant kM,"Michaelis-Menten-constant kM was 1.49 +/- 0.44 mmol/l and 1.69 +/- 0.88 mmol/l, respectively.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),[mM] / [l],1.69,124896,DB00898,Ethanol
,2590522,volume of distribution,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.0 l significant smaller than in males with 50.5 +/- 3.5 l.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),l,38.4,124897,DB00898,Ethanol
,2590522,volume of distribution,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.0 l significant smaller than in males with 50.5 +/- 3.5 l.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),l,50.5,124898,DB00898,Ethanol
,2590522,V1,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.0 l significant smaller than in males with 50.5 +/- 3.5 l.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),l,38.4,124899,DB00898,Ethanol
,2590522,V1,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.0 l significant smaller than in males with 50.5 +/- 3.5 l.",[New methods for pharmacokinetic assessment of alcohol and its metabolites in male and female probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2590522/),l,50.5,124900,DB00898,Ethanol
,31593810,Tmax,Absorption from oral tablet is slow with Tmax of approximately 1-1.5 h.,Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593810/),h,1-1.5,127007,DB00898,Ethanol
more,31593810,solubility,"Binary and ternary co-solvents using ethanol, water, propylene glycol and polyethylene glycol resulted rizatriptan equivalent base solubility more than 60 mg/mL.",Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593810/),[mg] / [ml],60,127008,DB00898,Ethanol
,31593810,Cmax,"Nasal spray formulation containing 20% w/w ethanol exhibited highest exposure, where Cmax (312 ng/mL) reached in 5 min and maintained higher concentration than oral dose for more than 30 min.",Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593810/),[ng] / [ml],312,127009,DB00898,Ethanol
,6834854,half lives (t 1/2 beta),The half lives (t 1/2 beta) for digoxin and SC4453 were 8.4 h and 4.2 h respectively.,"Comparison of the pharmacokinetic parameters of digoxin and SC4453 a digoxin analogue, following a single bolus i.v. dose and following an infusion preceeded by an i.v. loading dose in the guinea-pig. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834854/),h,8.4,127033,DB00898,Ethanol
,6834854,half lives (t 1/2 beta),The half lives (t 1/2 beta) for digoxin and SC4453 were 8.4 h and 4.2 h respectively.,"Comparison of the pharmacokinetic parameters of digoxin and SC4453 a digoxin analogue, following a single bolus i.v. dose and following an infusion preceeded by an i.v. loading dose in the guinea-pig. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834854/),h,4.2,127034,DB00898,Ethanol
,6834854,apparent volumes of distribution (V1),The apparent volumes of distribution (V1) were respectively 11.4 l/kg and 3.7 l/kg.,"Comparison of the pharmacokinetic parameters of digoxin and SC4453 a digoxin analogue, following a single bolus i.v. dose and following an infusion preceeded by an i.v. loading dose in the guinea-pig. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834854/),[l] / [kg],11.4,127035,DB00898,Ethanol
,6834854,apparent volumes of distribution (V1),The apparent volumes of distribution (V1) were respectively 11.4 l/kg and 3.7 l/kg.,"Comparison of the pharmacokinetic parameters of digoxin and SC4453 a digoxin analogue, following a single bolus i.v. dose and following an infusion preceeded by an i.v. loading dose in the guinea-pig. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834854/),[l] / [kg],3.7,127036,DB00898,Ethanol
,3438223,maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),μM,0.34,127614,DB00898,Ethanol
,3438223,maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),μM,6.3,127615,DB00898,Ethanol
,3438223,time to reach the maximum serum concentration,"The fraction of codeine glucuronized in serum (approximately 94%), the maximum serum concentration of free (0.34 microM) and total codeine (6.3 microM), the time to reach the maximum serum concentration values (approximately 65 min.) were also similar in the absence and presence of ethanol.",Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3438223/),min,65,127616,DB00898,Ethanol
,1868611,elimination half-life,"The elimination half-life of 2,3-butanediol was 3.9 days when ethanol was administered during therapy for suspected ethylene glycol poisoning.","2,3-Butanediol in plasma from an alcoholic mistakenly identified as ethylene glycol by gas-chromatographic analysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868611/),d,3.9,128508,DB00898,Ethanol
,33825087,globule size,"The globule size and average viscosity of the optimized MEs-Ap were 99.34 nm and 1.7 mPa·s, respectively, which was oil-in-water microemulsion without serious irritation or allergy for skin.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),nm,99.34,128651,DB00898,Ethanol
,33825087,viscosity,"The globule size and average viscosity of the optimized MEs-Ap were 99.34 nm and 1.7 mPa·s, respectively, which was oil-in-water microemulsion without serious irritation or allergy for skin.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),mpa·s,1.7,128652,DB00898,Ethanol
,33825087,Js,"The Js, Qn, and Qretention of MEs-Ap (0.81 ± 0.19 μg/cm2/h, 24.73 ± 4.24 μg/cm2, 2.08 ± 0.18 μg/cm2) were apparently higher than Differin® (0.022 ± 0.009 μg/cm2/h, 0.536 ± 0.103 μg/cm2, and 0.523 ± 0.130 μg/cm2) respectively.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2·h],0.81,128653,DB00898,Ethanol
,33825087,Qn,"The Js, Qn, and Qretention of MEs-Ap (0.81 ± 0.19 μg/cm2/h, 24.73 ± 4.24 μg/cm2, 2.08 ± 0.18 μg/cm2) were apparently higher than Differin® (0.022 ± 0.009 μg/cm2/h, 0.536 ± 0.103 μg/cm2, and 0.523 ± 0.130 μg/cm2) respectively.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2],24.73,128654,DB00898,Ethanol
,33825087,Qn,"The Js, Qn, and Qretention of MEs-Ap (0.81 ± 0.19 μg/cm2/h, 24.73 ± 4.24 μg/cm2, 2.08 ± 0.18 μg/cm2) were apparently higher than Differin® (0.022 ± 0.009 μg/cm2/h, 0.536 ± 0.103 μg/cm2, and 0.523 ± 0.130 μg/cm2) respectively.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2],0.536,128655,DB00898,Ethanol
,33825087,Qretention,"The Js, Qn, and Qretention of MEs-Ap (0.81 ± 0.19 μg/cm2/h, 24.73 ± 4.24 μg/cm2, 2.08 ± 0.18 μg/cm2) were apparently higher than Differin® (0.022 ± 0.009 μg/cm2/h, 0.536 ± 0.103 μg/cm2, and 0.523 ± 0.130 μg/cm2) respectively.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2],2.08,128656,DB00898,Ethanol
,33825087,Qretention,"The Js, Qn, and Qretention of MEs-Ap (0.81 ± 0.19 μg/cm2/h, 24.73 ± 4.24 μg/cm2, 2.08 ± 0.18 μg/cm2) were apparently higher than Differin® (0.022 ± 0.009 μg/cm2/h, 0.536 ± 0.103 μg/cm2, and 0.523 ± 0.130 μg/cm2) respectively.",Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2],0.523,128657,DB00898,Ethanol
,33825087,AUC0 → 36h,The local bioavailability study showed that the AUC0 → 36h of the MEs-Ap in the dermal (19.6 ± 1.22 μg/cm2) was significantly improved comparing to Differin® (13.9 ± 1.73 μg/cm2) (p < 0.01).,Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2],19.6,128658,DB00898,Ethanol
,33825087,AUC0 → 36h,The local bioavailability study showed that the AUC0 → 36h of the MEs-Ap in the dermal (19.6 ± 1.22 μg/cm2) was significantly improved comparing to Differin® (13.9 ± 1.73 μg/cm2) (p < 0.01).,Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33825087/),[μg] / [cm2],13.9,128659,DB00898,Ethanol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],2822.3,128799,DB00898,Ethanol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],5454.9,128800,DB00898,Ethanol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],771.6,128801,DB00898,Ethanol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],1138.9,128802,DB00898,Ethanol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],38.4,128803,DB00898,Ethanol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],54.7,128804,DB00898,Ethanol
,26628406,rmax,"Based on the pharmacokinetic (PK)-RO model, the rmax and IC50 of LY2456302 were estimated as 93% and 0.58 ng/ml to 0.65 ng/ml, respectively.",Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26628406/),%,93,128980,DB00898,Ethanol
,26628406,rmax,"Based on the pharmacokinetic (PK)-RO model, the rmax and IC50 of LY2456302 were estimated as 93% and 0.58 ng/ml to 0.65 ng/ml, respectively.",Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26628406/),[ng] / [ml],0.58,128981,DB00898,Ethanol
,26628406,IC50,"Based on the pharmacokinetic (PK)-RO model, the rmax and IC50 of LY2456302 were estimated as 93% and 0.58 ng/ml to 0.65 ng/ml, respectively.",Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26628406/),[ng] / [ml],0.58,128982,DB00898,Ethanol
,26628406,IC50,"Based on the pharmacokinetic (PK)-RO model, the rmax and IC50 of LY2456302 were estimated as 93% and 0.58 ng/ml to 0.65 ng/ml, respectively.",Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26628406/),[ng] / [ml],0.65,128983,DB00898,Ethanol
,26628406,IC50,"Assuming that rmax is 100%, IC50 was estimated as 0.83 ng/ml.",Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26628406/),[ng] / [ml],0.83,128984,DB00898,Ethanol
,2886315,t 1/2 alpha,"In blood, kidney, liver, and lymph nodes, t 1/2 alpha of cyclosporine ranged from 6-10 hr.","Tissue distribution, disposition, and metabolism of cyclosporine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886315/),h,6-10,129141,DB00898,Ethanol
,2886315,terminal half-life,"Elimination of radioactivity from the systemic circulation was multiphasic, with a terminal half-life of 20-30 hr.","Tissue distribution, disposition, and metabolism of cyclosporine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886315/),h,20-30,129142,DB00898,Ethanol
,3395458,Apparent availability,"Apparent availability of intragastric ethanol, computed by dividing the intragastric by the intravenous plasma ethanol concentration at zero time (both values extrapolated from the linear portion of the blood alcohol curve), was 0.739 +/- 0.125.",Ethanol elimination in the anesthetized dog: intragastric versus intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395458/),,0.739,129215,DB00898,Ethanol
,22849510,time to maximum concentration (t(max)),"The time to maximum concentration (t(max)) of edivoxetine was ∼2 hours, which was followed by a mono-exponential decline in plasma concentrations with a terminal elimination half-life (t(1/2)) of ∼6 hours.","Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849510/),h,∼2,129569,DB00898,Ethanol
,22849510,terminal elimination half-life (t(1/2)),"The time to maximum concentration (t(max)) of edivoxetine was ∼2 hours, which was followed by a mono-exponential decline in plasma concentrations with a terminal elimination half-life (t(1/2)) of ∼6 hours.","Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22849510/),h,∼6,129570,DB00898,Ethanol
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00898,Ethanol
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00898,Ethanol
,12579808,mean residence time (MRT),"With the same dosage (2 mg.kg-1) i.v. in rabbits, the mean residence time (MRT) of the long circulating mitoxantrone liposomes was 9.8 h, while that of the normal liposomes was 3.6 h, and the AUC of the former is 6.4 fold greater than of the latter.",[Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579808/),h,9.8,129725,DB00898,Ethanol
,12579808,mean residence time (MRT),"With the same dosage (2 mg.kg-1) i.v. in rabbits, the mean residence time (MRT) of the long circulating mitoxantrone liposomes was 9.8 h, while that of the normal liposomes was 3.6 h, and the AUC of the former is 6.4 fold greater than of the latter.",[Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579808/),h,3.6,129726,DB00898,Ethanol
,2310537,Maximal elimination velocity Vmax,"The analyses of ethanol infusion studies showed, that there are no sex differences in parameters of ethanol elimination: Maximal elimination velocity Vmax was 3.41 +/- 0.61 mmol/l.h in females and 3.98 +/- 0.69 mmol/l.h in males.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),[mM] / [h·l],3.41,130264,DB00898,Ethanol
,2310537,Maximal elimination velocity Vmax,"The analyses of ethanol infusion studies showed, that there are no sex differences in parameters of ethanol elimination: Maximal elimination velocity Vmax was 3.41 +/- 0.61 mmol/l.h in females and 3.98 +/- 0.69 mmol/l.h in males.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),[mM] / [h·l],3.98,130265,DB00898,Ethanol
,2310537,Michaelis-Menten-constant kM,"Michaelis-Menten-constant kM was 1.49 +/- 0.44 mmol/l and 1.69 +/- 0.88 mmol/l, respectively.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),[mM] / [l],1.49,130266,DB00898,Ethanol
,2310537,Michaelis-Menten-constant kM,"Michaelis-Menten-constant kM was 1.49 +/- 0.44 mmol/l and 1.69 +/- 0.88 mmol/l, respectively.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),[mM] / [l],1.69,130267,DB00898,Ethanol
,2310537,volume of distribution,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.01 significant smaller than in males with 50.5 +/- 3.51.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),,38.4,130268,DB00898,Ethanol
,2310537,volume of distribution,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.01 significant smaller than in males with 50.5 +/- 3.51.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),,50.5,130269,DB00898,Ethanol
,2310537,V1,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.01 significant smaller than in males with 50.5 +/- 3.51.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),,38.4,130270,DB00898,Ethanol
,2310537,V1,"In the female group, the volume of distribution of ethanol V1 was with 38.4 +/- 5.01 significant smaller than in males with 50.5 +/- 3.51.",[New methods of pharmacokinetic evaluation of alcohol and its metabolites in female and male probands]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310537/),,50.5,130271,DB00898,Ethanol
,24141040,AUC(0-∞),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[ng] / [h·ml],9.4,130306,DB00898,Ethanol
,24141040,AUC(0-∞),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[ng] / [h·ml],4.7,130307,DB00898,Ethanol
,24141040,apparent clearance (Cl/f),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[l] / [h],531.8,130308,DB00898,Ethanol
,24141040,apparent clearance (Cl/f),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[l] / [h],1304.4,130309,DB00898,Ethanol
,12492605,maximum blood-ethanol concentration (Cmax),"The maximum blood-ethanol concentration (Cmax) was 0.741 +/- 0.211 g l-1 (+/- s.d.) in the operated group compared with 0.577 +/- 0.112 g l-1 in the controls (mean difference 0.164 g l-1, 95% confidence interval (CI) 0.021, 0.307).",Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492605/),[g] / [l],0.741,130716,DB00898,Ethanol
,12492605,maximum blood-ethanol concentration (Cmax),"The maximum blood-ethanol concentration (Cmax) was 0.741 +/- 0.211 g l-1 (+/- s.d.) in the operated group compared with 0.577 +/- 0.112 g l-1 in the controls (mean difference 0.164 g l-1, 95% confidence interval (CI) 0.021, 0.307).",Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492605/),[g] / [l],0.577,130717,DB00898,Ethanol
,12492605,time to peak (tmax),"The median time to peak (tmax) was 10 min in the bypass patients compared with 30 min in controls (median difference -15 min (95% CI -10, -20 min).",Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492605/),min,10,130718,DB00898,Ethanol
,12492605,time to peak (tmax),"The median time to peak (tmax) was 10 min in the bypass patients compared with 30 min in controls (median difference -15 min (95% CI -10, -20 min).",Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492605/),min,30,130719,DB00898,Ethanol
,26004006,inhibitory rate of tumor (IRT),"And the inhibitory rate of tumor (IRT) values were determined to be 43.08%, 56.92%, 67.69% and 80.00% for 9-NC solution, inclusion complexes, P-9-NC-CL and Tf-9-NC-CL, respectively.",Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004006/),%,43.08,130909,DB00898,Ethanol
,26004006,inhibitory rate of tumor (IRT),"And the inhibitory rate of tumor (IRT) values were determined to be 43.08%, 56.92%, 67.69% and 80.00% for 9-NC solution, inclusion complexes, P-9-NC-CL and Tf-9-NC-CL, respectively.",Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004006/),%,56.92,130910,DB00898,Ethanol
,26004006,inhibitory rate of tumor (IRT),"And the inhibitory rate of tumor (IRT) values were determined to be 43.08%, 56.92%, 67.69% and 80.00% for 9-NC solution, inclusion complexes, P-9-NC-CL and Tf-9-NC-CL, respectively.",Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004006/),%,67.69,130911,DB00898,Ethanol
,26004006,inhibitory rate of tumor (IRT),"And the inhibitory rate of tumor (IRT) values were determined to be 43.08%, 56.92%, 67.69% and 80.00% for 9-NC solution, inclusion complexes, P-9-NC-CL and Tf-9-NC-CL, respectively.",Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004006/),%,80.00,130912,DB00898,Ethanol
,15454293,rate of penetration,The rate of penetration of ketoprofen through isolated skin was approximately 0.2 microg/cm2 h for both formulations.,Bioequivalence determination of topical ketoprofen using a dermatopharmacokinetic approach and excised skin penetration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454293/),[μg] / [cm2·h],0.2,131209,DB00898,Ethanol
,27568854,relative bioavailability,"Meanwhile, a relative bioavailability of 200% was achieved compared with pure PD.",Development of protocatechualdehyde proliposomes-based sustained-release pellets with improved bioavailability and desired pharmacokinetic behavior for angina chronotherapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568854/),%,200,131337,DB00898,Ethanol
,8223840,terminal half-life,After a mean period of treatment of 9.2 (range 3 to 26) days and a mean dose of 0.72 (range 0.29 to 2.37) mg per day of clonidine the mean terminal half-life was 15.8 (range 9.9 to 23) h (n = 7).,The pharmacokinetics of clonidine in high dosage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,15.8,131442,DB00898,Ethanol
,8223840,distribution half-life,"The pharmacokinetics of clonidine were described by two exponentials, with a distribution half-life of 1.2 h and a terminal half-life of 14.6 h.",The pharmacokinetics of clonidine in high dosage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,1.2,131443,DB00898,Ethanol
,8223840,terminal half-life,"The pharmacokinetics of clonidine were described by two exponentials, with a distribution half-life of 1.2 h and a terminal half-life of 14.6 h.",The pharmacokinetics of clonidine in high dosage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,14.6,131444,DB00898,Ethanol
,8223840,terminal half-life,After a mean period of 8.3 (range 2 to 15) days and a mean dose of 0.62 (range 0.15 to 1.82) mg per day the terminal half-life in these four patients was 15.6 (range 14.0 to 17.9) h.,The pharmacokinetics of clonidine in high dosage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,15.6,131445,DB00898,Ethanol
,21384434,AUC((+))/((-)) ratio,"The kinetic disposition of trans-T and M2 was enantioselective (AUC((+))/((-)) ratio=4.16 and 6.36, respectively).","Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21384434/),,4.16,131863,DB00898,Ethanol
,21384434,AUC((+))/((-)) ratio,"The kinetic disposition of trans-T and M2 was enantioselective (AUC((+))/((-)) ratio=4.16 and 6.36, respectively).","Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21384434/),,6.36,131864,DB00898,Ethanol
,11498270,Clearance,"Clearance of DEA from blood was calculated to be approximately 84 ml/h/kg at the low dose, increasing to approximately 242 ml/h/kg at the high dose.",The pharmacokinetics of diethanolamine in Sprague-Dawley rats following intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498270/),[ml] / [h·kg],84,131879,DB00898,Ethanol
,11498270,Clearance,"Clearance of DEA from blood was calculated to be approximately 84 ml/h/kg at the low dose, increasing to approximately 242 ml/h/kg at the high dose.",The pharmacokinetics of diethanolamine in Sprague-Dawley rats following intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498270/),[ml] / [h·kg],242,131880,DB00898,Ethanol
,8399519,relative recoveries,"Mean relative recoveries of GHB from plasma and urine are 75.5% (RSD% = 2.2) and 76.4% (RSD% = 2.4), respectively.",Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399519/),%,75.5,132116,DB00898,Ethanol
,8399519,relative recoveries,"Mean relative recoveries of GHB from plasma and urine are 75.5% (RSD% = 2.2) and 76.4% (RSD% = 2.4), respectively.",Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8399519/),%,76.4,132117,DB00898,Ethanol
,15930349,clearance,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[h·l] / [m(2],21.13,132203,DB00898,Ethanol
,15930349,clearance,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[h·l] / [m(2],14.76,132204,DB00898,Ethanol
,15930349,volume of distribution,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[l] / [m(2],663.8,132205,DB00898,Ethanol
,15930349,volume of distribution,"Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively].","Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15930349/),[l] / [m(2],433.4,132206,DB00898,Ethanol
,3230597,elimination rate,"At doses of 10 and 20 mg/kg, 4-MP elimination appeared to be saturated, with an elimination rate of 10 mumol/L/h.",Distribution of oral 4-methylpyrazole in the rat: inhibition of elimination by ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230597/),[μM] / [h·l],10,132758,DB00898,Ethanol
,3398647,half-lives,The pharmacokinetic study showed short half-lives (5 and 30 min for the distribution and elimination phases) and small distribution volumes.,"Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3398647/),min,5,132830,DB00898,Ethanol
,3398647,half-lives,The pharmacokinetic study showed short half-lives (5 and 30 min for the distribution and elimination phases) and small distribution volumes.,"Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3398647/),min,30,132831,DB00898,Ethanol
,4081309,half-life,"There were no observed differences in theophylline pharmacokinetics in rabbits administered in the cosolvent system when compared to theophylline administered as Aminophylline Injection USP, with the half-life being 4.5 hours and 4.3 hours respectively.",Ethyl lactate-ethanol-water cosolvent for intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081309/),h,4.5,133072,DB00898,Ethanol
,4081309,half-life,"There were no observed differences in theophylline pharmacokinetics in rabbits administered in the cosolvent system when compared to theophylline administered as Aminophylline Injection USP, with the half-life being 4.5 hours and 4.3 hours respectively.",Ethyl lactate-ethanol-water cosolvent for intravenous theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081309/),h,4.3,133073,DB00898,Ethanol
,22183131,flow rate,"The optimized process conditions were applied, those included temperature (65 °C), pressure (250 bar), CO(2) and drug solution flow rate (15 and 8 mL min(-1)), drug concentration in ethanol (20 mg mL(-1)).","Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22183131/),[ml] / [min],15,133191,DB00898,Ethanol
,22183131,flow rate,"The optimized process conditions were applied, those included temperature (65 °C), pressure (250 bar), CO(2) and drug solution flow rate (15 and 8 mL min(-1)), drug concentration in ethanol (20 mg mL(-1)).","Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22183131/),[ml] / [min],8,133192,DB00898,Ethanol
,23917320,concentrations,"Median day 7 lumefantrine concentrations were 488 (range, 30.7 to 3,550) ng/ml in pregnant women compared to 720 (339 to 2,150) ng/ml in nonpregnant women (P = 0.128).","Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23917320/),[ng] / [ml],488,133608,DB00898,Ethanol
,23917320,concentrations,"Median day 7 lumefantrine concentrations were 488 (range, 30.7 to 3,550) ng/ml in pregnant women compared to 720 (339 to 2,150) ng/ml in nonpregnant women (P = 0.128).","Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23917320/),[ng] / [ml],720,133609,DB00898,Ethanol
,31615669,Half-life (t1/2),"Half-life (t1/2) of the xylanase, cellulase and pectinase in free form remarkably enhance from 84.51, 29.36, and 25.29 min respectively to 533.07, 187.29 and 147.44 min in magnetic-combi CLEA respectively.",Preparation and characterization of reusable magnetic combi-CLEA of cellulase and hemicellulase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31615669/),min,84.51,133908,DB00898,Ethanol
,31615669,Half-life (t1/2),"Half-life (t1/2) of the xylanase, cellulase and pectinase in free form remarkably enhance from 84.51, 29.36, and 25.29 min respectively to 533.07, 187.29 and 147.44 min in magnetic-combi CLEA respectively.",Preparation and characterization of reusable magnetic combi-CLEA of cellulase and hemicellulase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31615669/),min,29.36,133909,DB00898,Ethanol
,31615669,Half-life (t1/2),"Half-life (t1/2) of the xylanase, cellulase and pectinase in free form remarkably enhance from 84.51, 29.36, and 25.29 min respectively to 533.07, 187.29 and 147.44 min in magnetic-combi CLEA respectively.",Preparation and characterization of reusable magnetic combi-CLEA of cellulase and hemicellulase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31615669/),min,25.29,133910,DB00898,Ethanol
,31615669,Half-life (t1/2),"Half-life (t1/2) of the xylanase, cellulase and pectinase in free form remarkably enhance from 84.51, 29.36, and 25.29 min respectively to 533.07, 187.29 and 147.44 min in magnetic-combi CLEA respectively.",Preparation and characterization of reusable magnetic combi-CLEA of cellulase and hemicellulase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31615669/),min,533.07,133911,DB00898,Ethanol
,31615669,Half-life (t1/2),"Half-life (t1/2) of the xylanase, cellulase and pectinase in free form remarkably enhance from 84.51, 29.36, and 25.29 min respectively to 533.07, 187.29 and 147.44 min in magnetic-combi CLEA respectively.",Preparation and characterization of reusable magnetic combi-CLEA of cellulase and hemicellulase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31615669/),min,187.29,133912,DB00898,Ethanol
,31615669,Half-life (t1/2),"Half-life (t1/2) of the xylanase, cellulase and pectinase in free form remarkably enhance from 84.51, 29.36, and 25.29 min respectively to 533.07, 187.29 and 147.44 min in magnetic-combi CLEA respectively.",Preparation and characterization of reusable magnetic combi-CLEA of cellulase and hemicellulase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31615669/),min,147.44,133913,DB00898,Ethanol
,15691159,peak BAL,"The mean peak BAL obtained for the male and female subjects (0.093% vs 0.096%) imply that the women were more intoxicated, though for a shorter time (314 minutes vs 280 minutes).",Oral fructose-induced changes in blood ethanol oxidokinetic data among healthy Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15691159/),%,0.093,134308,DB00898,Ethanol
,15691159,peak BAL,"The mean peak BAL obtained for the male and female subjects (0.093% vs 0.096%) imply that the women were more intoxicated, though for a shorter time (314 minutes vs 280 minutes).",Oral fructose-induced changes in blood ethanol oxidokinetic data among healthy Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15691159/),%,0.096,134309,DB00898,Ethanol
,15691159,peak BAL,"The mean peak BAL obtained for the male and female subjects (0.093% vs 0.096%) imply that the women were more intoxicated, though for a shorter time (314 minutes vs 280 minutes).",Oral fructose-induced changes in blood ethanol oxidokinetic data among healthy Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15691159/),min,314,134310,DB00898,Ethanol
,15691159,peak BAL,"The mean peak BAL obtained for the male and female subjects (0.093% vs 0.096%) imply that the women were more intoxicated, though for a shorter time (314 minutes vs 280 minutes).",Oral fructose-induced changes in blood ethanol oxidokinetic data among healthy Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15691159/),min,280,134311,DB00898,Ethanol
,11488519,AUC,"A total of 18 patients were treated with a dose of carboplatin determined by GFR, to attain a target AUC of 6 or 7 mg/ml x min.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[mg] / [min·ml],6,134506,DB00898,Ethanol
,11488519,AUC,"A total of 18 patients were treated with a dose of carboplatin determined by GFR, to attain a target AUC of 6 or 7 mg/ml x min.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[mg] / [min·ml],7,134507,DB00898,Ethanol
,11488519,peak concentration,"The peak concentration of paclitaxel obtained at the end of the infusion (9.1 vs 4.5 microg/ml), and the plasma ethanol concentration (40.0 vs 20.5 mg/dl) were higher following the shorter duration infusion.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[μg] / [ml],9.1,134508,DB00898,Ethanol
,11488519,peak concentration,"The peak concentration of paclitaxel obtained at the end of the infusion (9.1 vs 4.5 microg/ml), and the plasma ethanol concentration (40.0 vs 20.5 mg/dl) were higher following the shorter duration infusion.",Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[μg] / [ml],4.5,134509,DB00898,Ethanol
,11488519,AUC,The combination of paclitaxel at a dose of 175 mg/m2 and carboplatin at a target AUC of 6-7 mg/ml min can safely be administered every 3 weeks.,Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11488519/),[mg] / [min·ml],6-7,134510,DB00898,Ethanol
,7439248,Plasma clearance,Plasma clearance of chlordiazepoxide fell from 26.6 +/- 2.6 ml/min (mean +/- SD) without ethanol to 16.6 +/- 3.1 ml/min (P less than 0.05) after ethanol.,Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439248/),[ml] / [min],26.6,134514,DB00898,Ethanol
,7439248,Plasma clearance,Plasma clearance of chlordiazepoxide fell from 26.6 +/- 2.6 ml/min (mean +/- SD) without ethanol to 16.6 +/- 3.1 ml/min (P less than 0.05) after ethanol.,Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439248/),[ml] / [min],16.6,134515,DB00898,Ethanol
,7439248,elimination half-life,There was no change in the volume of distribution and therefore the elimination half-life was prolonged from 7.1 +/- 1.9 h to 11.8 +/- 6.0 h (P less than 0.05) after ethanol.,Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439248/),h,7.1,134516,DB00898,Ethanol
,7439248,elimination half-life,There was no change in the volume of distribution and therefore the elimination half-life was prolonged from 7.1 +/- 1.9 h to 11.8 +/- 6.0 h (P less than 0.05) after ethanol.,Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439248/),h,11.8,134517,DB00898,Ethanol
,7439248,plasma clearance of unbound,The plasma clearance of unbound chlordiazepoxide fell from 468 +/- 51 ml/min to 264 +/- 98 ml/min (P less than 0.05) after ethanol.,Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439248/),[ml] / [min],468,134518,DB00898,Ethanol
,7439248,plasma clearance of unbound,The plasma clearance of unbound chlordiazepoxide fell from 468 +/- 51 ml/min to 264 +/- 98 ml/min (P less than 0.05) after ethanol.,Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439248/),[ml] / [min],264,134519,DB00898,Ethanol
,17922078,Km,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),μM,12.3,134955,DB00898,Ethanol
,17922078,Vmax,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),[nM] / [mg·min],2.01,134956,DB00898,Ethanol
,26427296,bioavailability,This increase has important implications not only for the pharmacokinetics but also for the pharmacology of THC The mean bioavailability of THC in smoked cannabis is about 25%.,[Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26427296/),%,25,135037,DB00898,Ethanol
,26427296,peak plasma level,"In a cigarette containing 3.55% of THC, a peak plasma level of about 160 ng/mL occurs approximately 10 min after inhalation.",[Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26427296/),[ng] / [ml],160,135038,DB00898,Ethanol
,19026170,flow rate,"Separation was achieved using a C18 column (2 mm x 50 mm, 5 microm) at room temperature and a linear gradient elution with a mobile phase containing methanol (1.96% acetic acid) and 10% methanol in water (1.96% acetic acid and 10 mmol/L ammonium acetate) at a flow rate of 0.2 mL/min.",Quantitative determination of acetylshikonin in macaque monkey blood by LC-ESI-MS/MS after precolumn derivatization with 2-mercaptoethanol and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026170/),[ml] / [min],0.2,135257,DB00898,Ethanol
,19026170,area under the concentration-time curve to the last measurable concentration,"After the administration of acetylshikonin (80 mg/kg, po) in macaque monkeys, the pharmacokinetic parameters were obtained through the non-compartmental analysis, where the area under the concentration-time curve to the last measurable concentration, the terminal elimination halflife, and the mean residual time were 615.4+/-206.5 ng x dh/mL,12.3+/-1.6 h, and 10.2+/-0.7 h, respectively.",Quantitative determination of acetylshikonin in macaque monkey blood by LC-ESI-MS/MS after precolumn derivatization with 2-mercaptoethanol and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026170/),[dh·ng] / [ml],615.4,135258,DB00898,Ethanol
,19026170,terminal elimination halflife,"After the administration of acetylshikonin (80 mg/kg, po) in macaque monkeys, the pharmacokinetic parameters were obtained through the non-compartmental analysis, where the area under the concentration-time curve to the last measurable concentration, the terminal elimination halflife, and the mean residual time were 615.4+/-206.5 ng x dh/mL,12.3+/-1.6 h, and 10.2+/-0.7 h, respectively.",Quantitative determination of acetylshikonin in macaque monkey blood by LC-ESI-MS/MS after precolumn derivatization with 2-mercaptoethanol and its application in pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026170/),h,12.3,135259,DB00898,Ethanol
,19026170,mean residual time,"After the administration of acetylshikonin (80 mg/kg, po) in macaque monkeys, the pharmacokinetic parameters were obtained through the non-compartmental analysis, where the area under the concentration-time curve to the last measurable concentration, the terminal elimination halflife, and the mean residual time were 615.4+/-206.5 ng x dh/mL,12.3+/-1.6 h, and 10.2+/-0.7 h, respectively.",Quantitative determination of acetylshikonin in macaque monkey blood by LC-ESI-MS/MS after precolumn derivatization with 2-mercaptoethanol and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026170/),h,10.2,135260,DB00898,Ethanol
,26604700,entrapment efficiency,The results showed that the optimized formula produced nanoethosomes with an average size of 128 nm and an entrapment efficiency of 76.23%.,"Nanoethosomal transdermal delivery of vardenafil for treatment of erectile dysfunction: optimization, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26604700/),%,76.23,135483,DB00898,Ethanol
,6103881,relative bioavailability,"The relative bioavailability of the stearic acid ester of etilefrine, which was determined from the comparison of the areas under the plasma level and the renal excretion, amounts to 51% related to etilefrine.","Pharmacokinetic comparison of etilefrine to its prodrug, the stearic acid ester of etilefrine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103881/),%,51,136333,DB00898,Ethanol
,11440081,nasal bioavailability,"The nasal bioavailability of procyclidine in rats and dogs, based on the radioactivity, was calculated to be 81.1 and 98.6%, respectively.",Nasal absorption of procyclidine in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11440081/),%,81.1,136406,DB00898,Ethanol
,11440081,nasal bioavailability,"The nasal bioavailability of procyclidine in rats and dogs, based on the radioactivity, was calculated to be 81.1 and 98.6%, respectively.",Nasal absorption of procyclidine in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11440081/),%,98.6,136407,DB00898,Ethanol
,12182761,Tilde,For oral ethanol with a meal: absorption is slow (Tilde; 3 hours) and the fractional PKQuest FPM was 36% (0.15 gm/Kg dose) and 7% (0.3 gm/Kg).,PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182761/),h,3,136439,DB00898,Ethanol
,12182761,Tilde,"In contrast, fasting oral ethanol absorption is fast (Tilde; 50 minutes) and FPM is small.",PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182761/),min,50,136440,DB00898,Ethanol
,21907780,exposure,"There were no significant differences between the pharmacokinetic parameters of docetaxel after administration of docetaxel premix solution or ModraDoc001 15 mg capsules, although there was a trend towards a higher and more variable exposure to docetaxel after oral administration of docetaxel premix solution (513 ± 219 vs. 790 ± 669 ngh/mL).",Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21907780/),[ngh] / [ml],513,136558,DB00898,Ethanol
,21907780,exposure,"There were no significant differences between the pharmacokinetic parameters of docetaxel after administration of docetaxel premix solution or ModraDoc001 15 mg capsules, although there was a trend towards a higher and more variable exposure to docetaxel after oral administration of docetaxel premix solution (513 ± 219 vs. 790 ± 669 ngh/mL).",Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21907780/),[ngh] / [ml],790,136559,DB00898,Ethanol
,22525439,flow rate,"Samples were analyzed by LC-MS/MS on a reverse-phase xTerra MS C18 column which was equilibrated and eluted with an isocratic mixture of acetonitrile-water (1:9, v/v) at a flow rate of 0.3 mL/min.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),[ml] / [min],0.3,136640,DB00898,Ethanol
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,299.0,136641,DB00898,Ethanol
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,118.8,136642,DB00898,Ethanol
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,137.0,136643,DB00898,Ethanol
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,118.9,136644,DB00898,Ethanol
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,150.1,136645,DB00898,Ethanol
,22525439,precursor/product transitions (m/z),"The precursor/product transitions (m/z) were 299.0 → 118.8 for salidroside, 137.0 → 118.9 for p-tyrosol and 150.1 → 106.9 for the internal standard (IS), paracetamol, respectively.",Simultaneous determination of salidroside and its aglycone metabolite p-tyrosol in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22525439/),,106.9,136646,DB00898,Ethanol
,25864706,detected plasma concentration,"Furthermore, detected plasma concentration of boeravinone B was two times higher in RRF-PC (75 ng/mL) as compared with RRF (40 ng/mL).",Anti-inflammatory potential of a lipid-based formulation of a rotenoid-rich fraction prepared from Boerhavia diffusa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864706/),[ng] / [ml],75,136662,DB00898,Ethanol
,25864706,detected plasma concentration,"Furthermore, detected plasma concentration of boeravinone B was two times higher in RRF-PC (75 ng/mL) as compared with RRF (40 ng/mL).",Anti-inflammatory potential of a lipid-based formulation of a rotenoid-rich fraction prepared from Boerhavia diffusa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864706/),[ng] / [ml],40,136663,DB00898,Ethanol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,3.07,136756,DB00898,Ethanol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,6.21,136757,DB00898,Ethanol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,0.84,136758,DB00898,Ethanol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,1.50,136759,DB00898,Ethanol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136760,DB00898,Ethanol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136761,DB00898,Ethanol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136762,DB00898,Ethanol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136763,DB00898,Ethanol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,15.5,136764,DB00898,Ethanol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,50.8,136765,DB00898,Ethanol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,4.41,136766,DB00898,Ethanol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,12.78,136767,DB00898,Ethanol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,1.08,136768,DB00898,Ethanol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,0.09,136769,DB00898,Ethanol
,10595724,retention times,Observed retention times were 3.22 min for I and 2.32 min for II.,Assay method for the perfluorooctyl bromide (perflubron) in rat blood by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595724/),min,3.22,137908,DB00898,Ethanol
,10595724,retention times,Observed retention times were 3.22 min for I and 2.32 min for II.,Assay method for the perfluorooctyl bromide (perflubron) in rat blood by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595724/),min,2.32,137909,DB00898,Ethanol
,10595724,extraction efficiency,The extraction efficiency averaged 50% for I and 93% for II.,Assay method for the perfluorooctyl bromide (perflubron) in rat blood by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595724/),%,50,137910,DB00898,Ethanol
,10595724,extraction efficiency,The extraction efficiency averaged 50% for I and 93% for II.,Assay method for the perfluorooctyl bromide (perflubron) in rat blood by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595724/),%,93,137911,DB00898,Ethanol
,3723647,peak concentration,Six healthy young adults drank a dose of ethanol designed to give a peak concentration of 125 mg/dl on two different days after overnight fasting.,Activated charcoal in oral ethanol absorption: lack of effect in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723647/),[mg] / [dl],125,138226,DB00898,Ethanol
,22278951,flow rate,"Good separation was achieved at 20°C using cellulose tris-(4-methylbenzoate) as chiral stationary phase, a mixture of n-hexane and ethanol (90:10) as mobile phase at a flow rate of 0.8 ml/min.","Enantioselective determination of triazole fungice tetraconazole by chiral high-performance liquid chromatography and its application to pharmacokinetic study in cucumber, muskmelon, and soils. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278951/),[ml] / [min],0.8,138487,DB00898,Ethanol
more,22278951,recoveries,The assay method was linear over a range of concentrations (0.5-50 μg/ml) and the mean recoveries in all samples were more than 85% for the two enantiomers.,"Enantioselective determination of triazole fungice tetraconazole by chiral high-performance liquid chromatography and its application to pharmacokinetic study in cucumber, muskmelon, and soils. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278951/),%,85,138488,DB00898,Ethanol
,22278951,limits of detection,"The limits of detection for both enantiomers in plant and soil samples were 0.06 and 0.12 μg/g, respectively.","Enantioselective determination of triazole fungice tetraconazole by chiral high-performance liquid chromatography and its application to pharmacokinetic study in cucumber, muskmelon, and soils. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278951/),[μg] / [g],0.06,138489,DB00898,Ethanol
,22278951,limits of detection,"The limits of detection for both enantiomers in plant and soil samples were 0.06 and 0.12 μg/g, respectively.","Enantioselective determination of triazole fungice tetraconazole by chiral high-performance liquid chromatography and its application to pharmacokinetic study in cucumber, muskmelon, and soils. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22278951/),[μg] / [g],0.12,138490,DB00898,Ethanol
,18321744,minimum concentrations,"Formoterol caused a significantly greater decrease in serum potassium than BDP/formoterol or placebo (difference in mean minimum concentrations; 0.11 and -0.15 mmol/l, respectively, p<0.05 for both comparisons).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.11,138663,DB00898,Ethanol
,18321744,minimum concentrations,"Formoterol caused a significantly greater decrease in serum potassium than BDP/formoterol or placebo (difference in mean minimum concentrations; 0.11 and -0.15 mmol/l, respectively, p<0.05 for both comparisons).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],-0.15,138664,DB00898,Ethanol
,18321744,maximum increase,"For glucose, the mean maximum increase after formoterol treatment was 0.4 mmol/l (p<0.01 compared to placebo), while BDP/formoterol treatment caused a maximum increase of 0.7 mmol/l (p<0.01 compared to formoterol and placebo).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.4,138665,DB00898,Ethanol
,18321744,maximum increase,"For glucose, the mean maximum increase after formoterol treatment was 0.4 mmol/l (p<0.01 compared to placebo), while BDP/formoterol treatment caused a maximum increase of 0.7 mmol/l (p<0.01 compared to formoterol and placebo).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.7,138666,DB00898,Ethanol
,18321744,elimination half-life,"The active metabolite of BDP is beclomethasone-17-monopropriate (B17MP), which reached Cmax at 0.25 h, with an elimination half-life of 3.7 h.",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),h,3.7,138667,DB00898,Ethanol
,31015760,skin retention:permeation ratio,"Among various ME formulations developed, a formulation containing 2.9% ethyl oleate, 17.2% Cromophor EL35, 8.6% ethanol and 71.3% water showed the highest ex vivo skin retention:permeation ratio (1.98).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),,1.98,139635,DB00898,Ethanol
,31015760,skin retention:permeation ratio,"Of four chitosan-coated MEs prepared, carboxymethyl chitosan-coated MEs (CC-MEs) and hydroxypropyl chitosan-coated MEs (HC-MEs) showed higher ex vivo skin retention:permeation ratio (1.46 and 1.84).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),,1.46,139636,DB00898,Ethanol
,31015760,skin retention:permeation ratio,"Of four chitosan-coated MEs prepared, carboxymethyl chitosan-coated MEs (CC-MEs) and hydroxypropyl chitosan-coated MEs (HC-MEs) showed higher ex vivo skin retention:permeation ratio (1.46 and 1.84).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),,1.84,139637,DB00898,Ethanol
,31015760,AUCskin (0-12 h),"AUCskin (0-12 h) for 8-MOP MEs (4578.56 h·ng·mL-1) was higher than HC-MEs (3422.47 h·ng·mL-1), CC-MEs (2808.51 h·ng·mL-1) and tincture (1500.16 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],4578.56,139638,DB00898,Ethanol
,31015760,AUCskin (0-12 h),"AUCskin (0-12 h) for 8-MOP MEs (4578.56 h·ng·mL-1) was higher than HC-MEs (3422.47 h·ng·mL-1), CC-MEs (2808.51 h·ng·mL-1) and tincture (1500.16 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],3422.47,139639,DB00898,Ethanol
,31015760,AUCskin (0-12 h),"AUCskin (0-12 h) for 8-MOP MEs (4578.56 h·ng·mL-1) was higher than HC-MEs (3422.47 h·ng·mL-1), CC-MEs (2808.51 h·ng·mL-1) and tincture (1500.16 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],2808.51,139640,DB00898,Ethanol
,31015760,AUCskin (0-12 h),"AUCskin (0-12 h) for 8-MOP MEs (4578.56 h·ng·mL-1) was higher than HC-MEs (3422.47 h·ng·mL-1), CC-MEs (2808.51 h·ng·mL-1) and tincture (1500.16 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],1500.16,139641,DB00898,Ethanol
,31015760,AUCplasma (0-12 h),"Also, AUCplasma (0-12 h) for MEs (39.35±13.90 h·ng·mL-1) was significantly lower than HC-MEs (66.32 h·ng·mL-1), CC-MEs (59.70 h·ng·mL-1) and tincture (73.02 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],39.35,139642,DB00898,Ethanol
,31015760,AUCplasma (0-12 h),"Also, AUCplasma (0-12 h) for MEs (39.35±13.90 h·ng·mL-1) was significantly lower than HC-MEs (66.32 h·ng·mL-1), CC-MEs (59.70 h·ng·mL-1) and tincture (73.02 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],66.32,139643,DB00898,Ethanol
,31015760,AUCplasma (0-12 h),"Also, AUCplasma (0-12 h) for MEs (39.35±13.90 h·ng·mL-1) was significantly lower than HC-MEs (66.32 h·ng·mL-1), CC-MEs (59.70 h·ng·mL-1) and tincture (73.02 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],59.70,139644,DB00898,Ethanol
,31015760,AUCplasma (0-12 h),"Also, AUCplasma (0-12 h) for MEs (39.35±13.90 h·ng·mL-1) was significantly lower than HC-MEs (66.32 h·ng·mL-1), CC-MEs (59.70 h·ng·mL-1) and tincture (73.02 h·ng·mL-1).",Microemulsions vs chitosan derivative-coated microemulsions for dermal delivery of 8-methoxypsoralen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015760/),[h·ng] / [ml],73.02,139645,DB00898,Ethanol
,10681375,total percentage of administered radioactive dose recovered,"The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces.",Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681375/),%,84.8,140944,DB00898,Ethanol
,10681375,total percentage of administered radioactive dose recovered,"The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces.",Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681375/),%,27.1,140945,DB00898,Ethanol
,10681375,total percentage of administered radioactive dose recovered,"The total percentage of administered radioactive dose recovered was 84.8 +/- 4.9%, with 27.1 +/- 2.2% in the urine and 57.6 +/- 7.3% in the feces.",Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10681375/),%,57.6,140946,DB00898,Ethanol
,27356395,encapsulation efficiency,"The baicalein liposomes were spherical, the mean diameter was (93.1 ± 11.2) nm, PDI was 0.258, the encapsulation efficiency was (83.9 ± 0.4)%.",[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),%,83.9,140961,DB00898,Ethanol
,27356395,AUC(0 --> 24,The pharmacokinetic parameters of baicalein liposomes and solution were as follows: AUC(0 --> 24 (129.04 ± 12.73) μg/mL x h and (73.31 ± 9.34) μg/mL x h; C(max) (15.07 ± 3.13) μg/mL and (9.38 ± 2.42) μg/mL; T(max) 1 and 1.5 h.,[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),[μg] / [h·ml],129.04,140962,DB00898,Ethanol
,27356395,AUC(0 --> 24,The pharmacokinetic parameters of baicalein liposomes and solution were as follows: AUC(0 --> 24 (129.04 ± 12.73) μg/mL x h and (73.31 ± 9.34) μg/mL x h; C(max) (15.07 ± 3.13) μg/mL and (9.38 ± 2.42) μg/mL; T(max) 1 and 1.5 h.,[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),[μg] / [h·ml],73.31,140963,DB00898,Ethanol
,27356395,C(max),The pharmacokinetic parameters of baicalein liposomes and solution were as follows: AUC(0 --> 24 (129.04 ± 12.73) μg/mL x h and (73.31 ± 9.34) μg/mL x h; C(max) (15.07 ± 3.13) μg/mL and (9.38 ± 2.42) μg/mL; T(max) 1 and 1.5 h.,[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),[μg] / [ml],15.07,140964,DB00898,Ethanol
,27356395,C(max),The pharmacokinetic parameters of baicalein liposomes and solution were as follows: AUC(0 --> 24 (129.04 ± 12.73) μg/mL x h and (73.31 ± 9.34) μg/mL x h; C(max) (15.07 ± 3.13) μg/mL and (9.38 ± 2.42) μg/mL; T(max) 1 and 1.5 h.,[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),[μg] / [ml],9.38,140965,DB00898,Ethanol
,27356395,T(max),The pharmacokinetic parameters of baicalein liposomes and solution were as follows: AUC(0 --> 24 (129.04 ± 12.73) μg/mL x h and (73.31 ± 9.34) μg/mL x h; C(max) (15.07 ± 3.13) μg/mL and (9.38 ± 2.42) μg/mL; T(max) 1 and 1.5 h.,[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),h,1,140966,DB00898,Ethanol
,27356395,T(max),The pharmacokinetic parameters of baicalein liposomes and solution were as follows: AUC(0 --> 24 (129.04 ± 12.73) μg/mL x h and (73.31 ± 9.34) μg/mL x h; C(max) (15.07 ± 3.13) μg/mL and (9.38 ± 2.42) μg/mL; T(max) 1 and 1.5 h.,[Preparation of Baicalein Liposome-Lyophilized Powder and Its Pharmacokinetics Study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27356395/),h,1.5,140967,DB00898,Ethanol
,3319346,volume of distribution,The volume of distribution estimated from blood concentrations is about 37 L/70 kg.,Clinical pharmacokinetics of ethanol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[l] / [70·kg],37,141026,DB00898,Ethanol
,3319346,extraction ratio,"First-pass extraction of ethanol is predicted to be dependent on hepatic blood flow and ethanol absorption rate, with a typical extraction ratio of 0.2.",Clinical pharmacokinetics of ethanol. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),,0.2,141027,DB00898,Ethanol
,3319346,maximum rate of elimination of ethanol (elimination capacity or,The maximum rate of elimination of ethanol (elimination capacity or Vmax is 8.5 g/h/70 kg.,Clinical pharmacokinetics of ethanol. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[g] / [70·h·kg],8.5,141028,DB00898,Ethanol
,3319346,Vmax,The maximum rate of elimination of ethanol (elimination capacity or Vmax is 8.5 g/h/70 kg.,Clinical pharmacokinetics of ethanol. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[g] / [70·h·kg],8.5,141029,DB00898,Ethanol
,3319346,blood ethanol disappearance rate,This would be equivalent to a blood ethanol disappearance rate of 230 mg/L/h if metabolism took place at its maximum rate.,Clinical pharmacokinetics of ethanol. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[mg] / [h·l],230,141030,DB00898,Ethanol
,3319346,peripheral blood ethanol concentration (Km),The elimination rate is half of the elimination capacity at a peripheral blood ethanol concentration (Km) of about 80 mg/L.,Clinical pharmacokinetics of ethanol. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[mg] / [l],80,141031,DB00898,Ethanol
,3319346,blood:expired air ratio,The usual blood:expired air ratio is 2300:1 and breath clearance at rest is 0.16 L/h.,Clinical pharmacokinetics of ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),:1,2300,141032,DB00898,Ethanol
,3319346,breath clearance,The usual blood:expired air ratio is 2300:1 and breath clearance at rest is 0.16 L/h.,Clinical pharmacokinetics of ethanol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[l] / [h],0.16,141033,DB00898,Ethanol
,3319346,renal clearance,The renal clearance of ethanol is 0.06 L/h and sweat clearance is 0.02 L/h.,Clinical pharmacokinetics of ethanol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[l] / [h],0.06,141034,DB00898,Ethanol
,3319346,sweat clearance,The renal clearance of ethanol is 0.06 L/h and sweat clearance is 0.02 L/h.,Clinical pharmacokinetics of ethanol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3319346/),[l] / [h],0.02,141035,DB00898,Ethanol
,1523347,Clearance rates,Clearance rates between groups were different: ethanol concentration in milk at 60 min were 8.4 +/- 3.0 mg/dL for group A and 26.2 +/- 7.0 mg/dL for group B.,[Plasma clearance of ethanol and its excretion in the milk of rural women who consume pulque]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1523347/),[mg] / [dl],8.4,141538,DB00898,Ethanol
,1523347,Clearance rates,Clearance rates between groups were different: ethanol concentration in milk at 60 min were 8.4 +/- 3.0 mg/dL for group A and 26.2 +/- 7.0 mg/dL for group B.,[Plasma clearance of ethanol and its excretion in the milk of rural women who consume pulque]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1523347/),[mg] / [dl],26.2,141539,DB00898,Ethanol
,1523347,ethanol concentration in milk at,Clearance rates between groups were different: ethanol concentration in milk at 60 min were 8.4 +/- 3.0 mg/dL for group A and 26.2 +/- 7.0 mg/dL for group B.,[Plasma clearance of ethanol and its excretion in the milk of rural women who consume pulque]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1523347/),[mg] / [dl],8.4,141540,DB00898,Ethanol
,1523347,ethanol concentration in milk at,Clearance rates between groups were different: ethanol concentration in milk at 60 min were 8.4 +/- 3.0 mg/dL for group A and 26.2 +/- 7.0 mg/dL for group B.,[Plasma clearance of ethanol and its excretion in the milk of rural women who consume pulque]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1523347/),[mg] / [dl],26.2,141541,DB00898,Ethanol
,10604282,absolute oral bioavailability,The absolute oral bioavailability of PG (administered as an HPB complex) in rats was low (5%) suggesting extensive metabolism or incomplete absorption.,Influence of dosing vehicles on the preclinical pharmacokinetics of phenolic antioxidants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604282/),%,5,141620,DB00898,Ethanol
,3449205,metabolic rates,"After a dose of approximately 750 mg/kg, the metabolic rates of ethanol determined by gas chromatographic analysis of plasma (226 +/- 13 mg.kg-1.h-1) and by eye ethanol vapour analysis (210 +/- 8 mg.kg-1.h-1) were virtually identical.",Ethanol vapours above lacrimal fluid in the rabbit. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449205/),[mg] / [h·kg],226,142496,DB00898,Ethanol
,3449205,metabolic rates,"After a dose of approximately 750 mg/kg, the metabolic rates of ethanol determined by gas chromatographic analysis of plasma (226 +/- 13 mg.kg-1.h-1) and by eye ethanol vapour analysis (210 +/- 8 mg.kg-1.h-1) were virtually identical.",Ethanol vapours above lacrimal fluid in the rabbit. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3449205/),[mg] / [h·kg],210,142497,DB00898,Ethanol
,7170790,elimination half-life,The elimination half-life of formoterol was 4-6 h in dogs and 1.7 h in rats.,"Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),h,4-6,142695,DB00898,Ethanol
,7170790,elimination half-life,The elimination half-life of formoterol was 4-6 h in dogs and 1.7 h in rats.,"Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),h,1.7,142696,DB00898,Ethanol
,7170790,Biliary excretion,"Biliary excretion after oral dosage amounted to 65 and 31% in rats and dogs, respectively.","Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),%,65,142697,DB00898,Ethanol
,7170790,Biliary excretion,"Biliary excretion after oral dosage amounted to 65 and 31% in rats and dogs, respectively.","Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),%,31,142698,DB00898,Ethanol
,24867986,relative bioavailability,"The relative bioavailability of lumefantrine and its metabolism rate into desmethyl-lumefantrine were, respectively, 34% lower and 78% higher in pregnant women than in nonpregnant patients.",Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867986/),%,34,142761,DB00898,Ethanol
,24867986,relative bioavailability,"The relative bioavailability of lumefantrine and its metabolism rate into desmethyl-lumefantrine were, respectively, 34% lower and 78% higher in pregnant women than in nonpregnant patients.",Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24867986/),%,78,142762,DB00898,Ethanol
,6149657,half-lives,"After oral administration of [14C]amosulalol hydrochloride, the plasma concentration of radioactivity reached a maximum at 0.5 to 1 h in all species and declined with half-lives of about 2 h in both rats and monkeys, and of about 4 h in dogs.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),h,2,143081,DB00898,Ethanol
,6149657,half-lives,"After oral administration of [14C]amosulalol hydrochloride, the plasma concentration of radioactivity reached a maximum at 0.5 to 1 h in all species and declined with half-lives of about 2 h in both rats and monkeys, and of about 4 h in dogs.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),h,4,143082,DB00898,Ethanol
,6149657,urinary excretion,"Following oral dosage, the urinary excretion of radioactivity was 26-34% of the dose in rats, 45% in dogs and 46% in monkeys in 48 h.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),%,26-34,143083,DB00898,Ethanol
,6149657,urinary excretion,"Following oral dosage, the urinary excretion of radioactivity was 26-34% of the dose in rats, 45% in dogs and 46% in monkeys in 48 h.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),%,45,143084,DB00898,Ethanol
,6149657,urinary excretion,"Following oral dosage, the urinary excretion of radioactivity was 26-34% of the dose in rats, 45% in dogs and 46% in monkeys in 48 h.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),%,46,143085,DB00898,Ethanol
,6149657,biliary excretion,"The biliary excretion after oral dosage amounted to 66% and 41% in rats and dogs, respectively.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),%,66,143086,DB00898,Ethanol
,6149657,biliary excretion,"The biliary excretion after oral dosage amounted to 66% and 41% in rats and dogs, respectively.","Disposition and metabolism of amosulalol hydrochloride, a new combined alpha- and beta-adrenoceptor blocking agent, in rats, dogs and monkeys. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149657/),%,41,143087,DB00898,Ethanol
,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,10,143406,DB00898,Ethanol
over,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,80,143407,DB00898,Ethanol
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,30,143408,DB00898,Ethanol
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,65,143409,DB00898,Ethanol
,6370541,apparent volume of distribution at equilibrium,"The apparent volume of distribution at equilibrium varies from approximately 200 to over 800L, suggesting that concentration of labetalol occurs in extravascular sites.",Clinical pharmacokinetics of labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),l,200 to over 800,143410,DB00898,Ethanol
,6370541,half-life,The half-life of labetalol in plasma is 3 to 3.5 hours.,Clinical pharmacokinetics of labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),h,3 to 3.5,143411,DB00898,Ethanol
,6145441,"terminal elimination half-life (t 1/2,Z)","For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15.6 h, a peak level of 450 ng/ml and a time to peak of 2-3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,15.6,143493,DB00898,Ethanol
,6145441,peak level,"For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15.6 h, a peak level of 450 ng/ml and a time to peak of 2-3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ng] / [ml],450,143494,DB00898,Ethanol
,6145441,time to peak,"For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15.6 h, a peak level of 450 ng/ml and a time to peak of 2-3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,2-3,143495,DB00898,Ethanol
,6145441,bioavailability,"Following intravenous medroxalol the bioavailability was calculated as 64%, the plasma clearance was 948 ml/min and the t 1/2,Z was 7.3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),%,64,143496,DB00898,Ethanol
,6145441,plasma clearance,"Following intravenous medroxalol the bioavailability was calculated as 64%, the plasma clearance was 948 ml/min and the t 1/2,Z was 7.3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ml] / [min],948,143497,DB00898,Ethanol
,6145441,"t 1/2,Z","Following intravenous medroxalol the bioavailability was calculated as 64%, the plasma clearance was 948 ml/min and the t 1/2,Z was 7.3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,7.3,143498,DB00898,Ethanol
,6145441,time to peak,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,2.3,143499,DB00898,Ethanol
,6145441,time to peak,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,1.1,143500,DB00898,Ethanol
,6145441,oral t 1/2,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,15.6,143501,DB00898,Ethanol
,6145441,oral t 1/2,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,5.5,143502,DB00898,Ethanol
,6145441,clearance,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ml] / [min],948,143503,DB00898,Ethanol
,6145441,clearance,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ml] / [min],1560,143504,DB00898,Ethanol
,6145441,bioavailability,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),%,64,143505,DB00898,Ethanol
,6145441,bioavailability,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),%,20,143506,DB00898,Ethanol
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],19.9,143867,DB00898,Ethanol
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],6.2,143868,DB00898,Ethanol
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],22.5,143869,DB00898,Ethanol
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],21.0,143870,DB00898,Ethanol
,10496300,terminal half-lives,"The artemether component is absorbed rapidly and biotransformed to dihydroartemisinin, and both are eliminated with terminal half-lives of around 1 hour.",Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496300/),h,1,143903,DB00898,Ethanol
,10496300,half-life,"The lumefantrine component is absorbed variably in malaria, and is eliminated more slowly (half-life of 3 to 6 days).",Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496300/),d,3 to 6,143904,DB00898,Ethanol
,19224373,solubility,"The volume ratio of 5:4:1 in the DMSO/polyethoxylated castor oil/ethanol system resulted in a more suitable vehicle than other systems, with a high solubility (20.73 mg/ml) and low viscosity (10.0 Cp).",Improving tenoxicam solubility and bioavailability by cosolvent system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19224373/),[mg] / [ml],20.73,144017,DB00898,Ethanol
,18760341,t(max),"After i.n. administration, DZ was rapidly absorbed into the systemic circulation, and readily and homogeneously distributed into the different regions of brain tissues with a t(max) of 5 and 10 min in rats and rabbits, respectively.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),min,5,144291,DB00898,Ethanol
,18760341,t(max),"After i.n. administration, DZ was rapidly absorbed into the systemic circulation, and readily and homogeneously distributed into the different regions of brain tissues with a t(max) of 5 and 10 min in rats and rabbits, respectively.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),min,10,144292,DB00898,Ethanol
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,68.4,144293,DB00898,Ethanol
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,67.7,144294,DB00898,Ethanol
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,32-47,144295,DB00898,Ethanol
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,51.6,144296,DB00898,Ethanol
,18760341,bioavailability,The bioavailability of DZ in rat plasma (68.4%) and brain (67.7%) were 32-47% higher than those observed in rabbit plasma (51.6%) and brain (45.9%).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),%,45.9,144297,DB00898,Ethanol
,18760341,AUC(brain)/AUC(plasma) ratios,The AUC(brain)/AUC(plasma) ratios in rabbits after i.n. administration (3.77+/-0.17) were slightly lower than from i.v. administration (4.23+/-0.08).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,3.77,144298,DB00898,Ethanol
,18760341,AUC(brain)/AUC(plasma) ratios,The AUC(brain)/AUC(plasma) ratios in rabbits after i.n. administration (3.77+/-0.17) were slightly lower than from i.v. administration (4.23+/-0.08).,Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,4.23,144299,DB00898,Ethanol
,18760341,AUC(brain)/AUC(plasma) ratios,"However, in rats the AUC(brain)/AUC(plasma) ratios after i.v. (3.03+/-0.07) and i.n. (3.00+/-0.32) administration were nearly identical.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,3.03,144300,DB00898,Ethanol
,18760341,AUC(brain)/AUC(plasma) ratios,"However, in rats the AUC(brain)/AUC(plasma) ratios after i.v. (3.03+/-0.07) and i.n. (3.00+/-0.32) administration were nearly identical.",Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760341/),,3.00,144301,DB00898,Ethanol
,9112066,distribution volume at steady state (Vss),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),l,673,145242,DB00898,Ethanol
,9112066,volume corrected by real body weight (Vss.kg-1),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [kg],11.2,145243,DB00898,Ethanol
,9112066,total clearance (CL),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),1/[h],51.6,145244,DB00898,Ethanol
,9112066,terminal half-life (t1/2),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),h,10.3,145245,DB00898,Ethanol
,9112066,Vss,The Vss (898 l) and CL (71.6 l.h-1) were significantly higher in obese patients.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),l,898,145246,DB00898,Ethanol
,9112066,CL,The Vss (898 l) and CL (71.6 l.h-1) were significantly higher in obese patients.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [h],71.6,145247,DB00898,Ethanol
,9112066,Vss.kg-1,But Vss.kg-1 (9.4 l.kg-1) and t1/2 (10.0 h) were not significantly different from those in controls.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [kg],9.4,145248,DB00898,Ethanol
,9112066,t1/2,But Vss.kg-1 (9.4 l.kg-1) and t1/2 (10.0 h) were not significantly different from those in controls.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),h,10.0,145249,DB00898,Ethanol
,9112066,CL,"The CL was clearly reduced (15-18 l.h-1) and the t1/2 prolonged (32-34 h) in poor hydroxylators, in both control and obese subjects.",Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [h],15-18,145250,DB00898,Ethanol
,9112066,t1/2,"The CL was clearly reduced (15-18 l.h-1) and the t1/2 prolonged (32-34 h) in poor hydroxylators, in both control and obese subjects.",Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),h,32-34,145251,DB00898,Ethanol
,7389748,relative bioavailability,The relative bioavailability of dexamethasone was found to be 120% (urinary excretion data) or 146% (blood concentration data).,Effect of benzyl nicotinate on the percutaneous absorption of dexamethasone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389748/),%,120,147585,DB00898,Ethanol
,7389748,relative bioavailability,The relative bioavailability of dexamethasone was found to be 120% (urinary excretion data) or 146% (blood concentration data).,Effect of benzyl nicotinate on the percutaneous absorption of dexamethasone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389748/),%,146,147586,DB00898,Ethanol
,1361928,Recoveries,"Recoveries from spiked plasma and urine standards were 70 +/- 1.2% and 68 +/- 1.1%, respectively.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),%,70,148753,DB00898,Ethanol
,1361928,Recoveries,"Recoveries from spiked plasma and urine standards were 70 +/- 1.2% and 68 +/- 1.1%, respectively.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),%,68,148754,DB00898,Ethanol
,1361928,minimum detection level,The minimum detection level in plasma was 1 ng/mL and the average CV was 5.1% for concentrations that ranged from 1 to 30 ng/mL.,Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),[ng] / [ml],1,148755,DB00898,Ethanol
,1361928,half-lives,Plasma CIM levels declined in a biphasic manner with half-lives of 2.5 min for the distribution phase and 54 min for the elimination phase.,Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),min,2.5,148756,DB00898,Ethanol
,1361928,half-lives,Plasma CIM levels declined in a biphasic manner with half-lives of 2.5 min for the distribution phase and 54 min for the elimination phase.,Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),min,54,148757,DB00898,Ethanol
,1361928,central compartment volume (Vc),"A two-compartment open model was used to describe the disappearance of CIM and the following pharmacokinetic parameters were obtained: central compartment volume (Vc) = .76 L/kg, apparent volume of distribution (Vd) = 4.1 L/kg, and transfer rate constants from the central to peripheral compartment (k12) = .177/min, from the peripheral to central compartment (k21) = .054/min and elimination from the central compartment (kel) = .074/min.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),[l] / [kg],.76,148758,DB00898,Ethanol
,1361928,apparent volume of distribution (Vd),"A two-compartment open model was used to describe the disappearance of CIM and the following pharmacokinetic parameters were obtained: central compartment volume (Vc) = .76 L/kg, apparent volume of distribution (Vd) = 4.1 L/kg, and transfer rate constants from the central to peripheral compartment (k12) = .177/min, from the peripheral to central compartment (k21) = .054/min and elimination from the central compartment (kel) = .074/min.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),[l] / [kg],4.1,148759,DB00898,Ethanol
,1361928,transfer rate constants from the central to peripheral compartment (k12),"A two-compartment open model was used to describe the disappearance of CIM and the following pharmacokinetic parameters were obtained: central compartment volume (Vc) = .76 L/kg, apparent volume of distribution (Vd) = 4.1 L/kg, and transfer rate constants from the central to peripheral compartment (k12) = .177/min, from the peripheral to central compartment (k21) = .054/min and elimination from the central compartment (kel) = .074/min.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),1/[min],.177,148760,DB00898,Ethanol
,1361928,from the peripheral to central compartment (k21),"A two-compartment open model was used to describe the disappearance of CIM and the following pharmacokinetic parameters were obtained: central compartment volume (Vc) = .76 L/kg, apparent volume of distribution (Vd) = 4.1 L/kg, and transfer rate constants from the central to peripheral compartment (k12) = .177/min, from the peripheral to central compartment (k21) = .054/min and elimination from the central compartment (kel) = .074/min.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),1/[min],.054,148761,DB00898,Ethanol
,1361928,elimination from the central compartment (kel),"A two-compartment open model was used to describe the disappearance of CIM and the following pharmacokinetic parameters were obtained: central compartment volume (Vc) = .76 L/kg, apparent volume of distribution (Vd) = 4.1 L/kg, and transfer rate constants from the central to peripheral compartment (k12) = .177/min, from the peripheral to central compartment (k21) = .054/min and elimination from the central compartment (kel) = .074/min.",Analysis and pharmacokinetics of cimaterol in growing Holstein steers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361928/),1/[min],.074,148762,DB00898,Ethanol
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],68.4,148763,DB00898,Ethanol
,7497581,AUC (AUC,"Specifically, metoclopramide had little effect on the etoposide absorption profile and did not significantly alter the AUC (AUC with etoposide alone, 68.4 +/- 20.3 micrograms ml-1 h, versus 74.3 +/- 25.9 micrograms ml-1 h with metoclopramide), suggesting that in most patients the drug is already emptied rapidly from the stomach.",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],74.3,148764,DB00898,Ethanol
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,1.1,148765,DB00898,Ethanol
,7497581,time of maximal concentration tmax,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),h,3.5,148766,DB00898,Ethanol
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],78.3,148767,DB00898,Ethanol
,7497581,AUC,"In contrast, propantheline produced a dramatic effect on etoposide absorption, delaying the time of maximal concentration tmax from 1.1 to 3.5 h (P < 0.01), but again without a significant improvement in drug AUC or bioavailability across the 24-h study period (AUC with etoposide alone 78.3 +/- 19.1 micrograms ml-1 h, versus 88.1 +/- 23.6 micrograms ml-1 h with propantheline).",Pharmacological attempts to improve the bioavailability of oral etoposide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497581/),[h·μg] / [ml],88.1,148768,DB00898,Ethanol
above,1978486,bioavailability,After oral administration the drug is rapidly and almost completely absorbed with a bioavailability above 90%.,Clinical pharmacokinetics of remoxipride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),%,90,148873,DB00898,Ethanol
,1978486,systemic plasma clearance,"Thus remoxipride is a low clearance drug, with a systemic plasma clearance of about 120 ml/min, and without any first-pass metabolism.",Clinical pharmacokinetics of remoxipride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),[ml] / [min],120,148874,DB00898,Ethanol
,1978486,apparent volume of distribution,"The apparent volume of distribution is 0.7 1/kg, about 80% being bound to plasma proteins (mainly alpha 1-acid glycoprotein).",Clinical pharmacokinetics of remoxipride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),[1] / [kg],0.7,148875,DB00898,Ethanol
,1978486,plasma half-life,Remoxipride has a plasma half-life in the range of 4-7 h and is eliminated by both hepatic metabolism and renal excretion.,Clinical pharmacokinetics of remoxipride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978486/),h,4-7,148876,DB00898,Ethanol
,30831030,particle size (MPS),"Take advantage of the optimal conditions, UA nanoemulsion had mean particle size (MPS) of 69.7 ± 15.6 nm and polydispersity index value (PI) of 0.005.","Ursolic acid nanoparticles for oral delivery prepared by emulsion solvent evaporation method: characterization, in vitro evaluation of radical scavenging activity and bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831030/),nm,69.7,149009,DB00898,Ethanol
,30831030,MPS,"Finally, UANs possessing an MPS of 157.5 ± 28.0 nm (PI = 0.005) and zeta potential of 20.33 ± 1.67 mV were obtained after freeze-dried.","Ursolic acid nanoparticles for oral delivery prepared by emulsion solvent evaporation method: characterization, in vitro evaluation of radical scavenging activity and bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831030/),nm,157.5,149010,DB00898,Ethanol
,30831030,zeta potential,"Finally, UANs possessing an MPS of 157.5 ± 28.0 nm (PI = 0.005) and zeta potential of 20.33 ± 1.67 mV were obtained after freeze-dried.","Ursolic acid nanoparticles for oral delivery prepared by emulsion solvent evaporation method: characterization, in vitro evaluation of radical scavenging activity and bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831030/),mv,20.33,149011,DB00898,Ethanol
,31466218,elimination half-lives (t1/2),"Their elimination half-lives (t1/2) were different, ranging from 3.42 h to 8.99 h, although they shared similar molecular structures.",Simultaneous Quantification of Four Phenylethanoid Glycosides in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study of Acanthus Ilicifolius Herb. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31466218/),h,3.42,149193,DB00898,Ethanol
,31466218,elimination half-lives (t1/2),"Their elimination half-lives (t1/2) were different, ranging from 3.42 h to 8.99 h, although they shared similar molecular structures.",Simultaneous Quantification of Four Phenylethanoid Glycosides in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study of Acanthus Ilicifolius Herb. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31466218/),h,8.99,149194,DB00898,Ethanol
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,-,149414,DB00898,Ethanol
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,3.7,149415,DB00898,Ethanol
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,4.6,149416,DB00898,Ethanol
,29355620,zeta potential,"SEDDS containing the octreotide-deoxycholate, -decanoate and -docusate ion pair exhibited a mean droplet size of 152nm, 112nm and 191nm and a zeta potential of -3.7, -4.6 and -5.7mV, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),mv,5.7,149417,DB00898,Ethanol
,29355620,log DSEDDS/release medium,"They were completely stable towards degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),,1.7,149418,DB00898,Ethanol
,29355620,log DSEDDS/release medium,"They were completely stable towards degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),,1.8,149419,DB00898,Ethanol
,29355620,log DSEDDS/release medium,"They were completely stable towards degradation by lipase and showed a log DSEDDS/release medium of 1.7, 1.8 and 2.7, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),,2.7,149420,DB00898,Ethanol
,29355620,diffusion coefficient,"The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 and 0.17×10-9cm2/s, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),[cm2] / [s],0.03,149421,DB00898,Ethanol
,29355620,diffusion coefficient,"The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 and 0.17×10-9cm2/s, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),[cm2] / [s],0.11,149422,DB00898,Ethanol
,29355620,diffusion coefficient,"The diffusion coefficient of these SEDDS was in the range of 0.03, 0.11 and 0.17×10-9cm2/s, respectively.",Impact of different hydrophobic ion pairs of octreotide on its oral bioavailability in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29355620/),[cm2] / [s],0.17×10-9,149423,DB00898,Ethanol
,20734323,recovery,γ-T3 was extracted from rat and human plasma by liquid-liquid extraction with an average recovery of 60%.,Development and validation of a reversed-phase HPLC method for the determination of γ-tocotrienol in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20734323/),%,60,149554,DB00898,Ethanol
,11435519,Oral bioavailability,"Oral bioavailability estimates of hydroxytyrosol when administered in an olive oil solution and when dosed as an aqueous solution were 99% and 75%, respectively.","The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435519/),%,99,149689,DB00898,Ethanol
,11435519,Oral bioavailability,"Oral bioavailability estimates of hydroxytyrosol when administered in an olive oil solution and when dosed as an aqueous solution were 99% and 75%, respectively.","The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435519/),%,75,149690,DB00898,Ethanol
,11435519,Oral bioavailability,"Oral bioavailability estimates of tyrosol, when orally administered in an olive oil solution and when dosed as an aqueous solution were 98% and 71%, respectively.","The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435519/),%,98,149691,DB00898,Ethanol
,11435519,Oral bioavailability,"Oral bioavailability estimates of tyrosol, when orally administered in an olive oil solution and when dosed as an aqueous solution were 98% and 71%, respectively.","The in vivo fate of hydroxytyrosol and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled compounds to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435519/),%,71,149692,DB00898,Ethanol
,11596205,flow rate,"Chromatographic separation was achieved on a Spherisorb C8 column (200 mm x 4.6 mm, 5 microns), with ethanol--water--10% H3PO4--triethylamine (30:70:1.5:0.1) at a flow rate of 1.0 ml.min-1.",[Solid phase extraction and high performance liquid chromatographic determination of enalapril in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596205/),[ml] / [min],1.0,149874,DB00898,Ethanol
,11596205,detection limit,ml-1 with regression coefficient of 0.997 and detection limit of 1.5 ng.,[Solid phase extraction and high performance liquid chromatographic determination of enalapril in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596205/),ng,1.5,149875,DB00898,Ethanol
>,11596205,recovery,"The within-day RSD and between-day RSD were < 8.73%, the recovery of method > 91.6%.",[Solid phase extraction and high performance liquid chromatographic determination of enalapril in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596205/),%,91.6,149876,DB00898,Ethanol
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,0.048,150532,DB00898,Ethanol
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],9,150533,DB00898,Ethanol
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,64,150534,DB00898,Ethanol
,6356161,Km,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],560,150535,DB00898,Ethanol
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,0.048,150536,DB00898,Ethanol
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],9,150537,DB00898,Ethanol
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),mM,64,150538,DB00898,Ethanol
,6356161,Vmax,"At pH 7.5, Km values for ethanol and Vmax values range 0.048 mM and 9 min-1 for beta 1 beta 1 to 64 mM and 560 min-1 for beta ind beta ind, respectively.",Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356161/),1/[min],560,150539,DB00898,Ethanol
,32110819,Cmax,Mean Cmax values showed a significant (p value 0.035) decrease from 44.14±2.3 to 33.1±0.8 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],44.14,150635,DB00898,Ethanol
,32110819,Cmax,Mean Cmax values showed a significant (p value 0.035) decrease from 44.14±2.3 to 33.1±0.8 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],33.1,150636,DB00898,Ethanol
,32110819,AUC,AUC increased from 195.7±8.9 μg.hr/mL to 222.8±14.7 μg.hr/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[h·μg] / [ml],195.7,150637,DB00898,Ethanol
,32110819,AUC,AUC increased from 195.7±8.9 μg.hr/mL to 222.8±14.7 μg.hr/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[h·μg] / [ml],222.8,150638,DB00898,Ethanol
,32110819,t1/2,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),h,4.505,150639,DB00898,Ethanol
,32110819,t1/2,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),h,6.216,150640,DB00898,Ethanol
,32110819,Ke,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),1/[h],0.159,150641,DB00898,Ethanol
,32110819,Ke,t1/2 increased significantly from 4.505±0.19 hrs to 6.216±0.36 hrs whereas Ke reduced from 0.159±0.00 to 0.116±0.006 hrs-1.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),1/[h],0.116,150642,DB00898,Ethanol
,32110819,Cmax,Cmax increased from 44.877±2.263 to 51.721±0.096 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],44.877,150643,DB00898,Ethanol
,32110819,Cmax,Cmax increased from 44.877±2.263 to 51.721±0.096 μg/mL.,Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110819/),[μg] / [ml],51.721,150644,DB00898,Ethanol
,27567930,solubility,"The optimal PTX-M were provided with small size (164.8±2.0nm) and spherical shape at ratio of 1: 3 (Solutol(®)HS15: Soluplus(®)), thus increasing the solubility to 15.76±0.15mg/mL in water.",Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),[mg] / [ml],15.76,150995,DB00898,Ethanol
,27567930,entrapment efficiency,The entrapment efficiency and drug loading of PTX-M were 98.48±0.91% and 10.59±0.09% respectively.,Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),%,98.48,150996,DB00898,Ethanol
,27567930,drug loading,The entrapment efficiency and drug loading of PTX-M were 98.48±0.91% and 10.59±0.09% respectively.,Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),%,10.59,150997,DB00898,Ethanol
,27567930,IC50,"In addition, the MTT assay demonstrated that the IC50 value of PTX-M was reduced by 40.21% (PTX-M: 22.6±2.1μg/mL, PTX: 37.8±1.4μg/mL), and in vivo anti-tumor study (15days' therapy) showed PTX-M achieved higher anti-tumor efficacy (57.66%) compared with PTX (41.13%).",Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),μ,22.6,150998,DB00898,Ethanol
,27567930,IC50,"In addition, the MTT assay demonstrated that the IC50 value of PTX-M was reduced by 40.21% (PTX-M: 22.6±2.1μg/mL, PTX: 37.8±1.4μg/mL), and in vivo anti-tumor study (15days' therapy) showed PTX-M achieved higher anti-tumor efficacy (57.66%) compared with PTX (41.13%).",Improved oral bioavailability and anticancer efficacy on breast cancer of paclitaxel via Novel Soluplus(®)-Solutol(®) HS15 binary mixed micelles system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27567930/),μg,37.8,150999,DB00898,Ethanol
,6849783,Clearance,"Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61).",Labetalol disposition and concentration-effect relationships during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849783/),[1] / [min],2.16,151014,DB00898,Ethanol
,6849783,Clearance,"Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61).",Labetalol disposition and concentration-effect relationships during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849783/),[1] / [min],2.35,151015,DB00898,Ethanol
,6849783,Clearance,"Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61).",Labetalol disposition and concentration-effect relationships during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849783/),[1] / [min],1.96,151016,DB00898,Ethanol
,10541883,SA concentrations,"Microdialysates collected between 80 and 200 min showed mean SA concentrations of 3 microg/ml in unmodified and acetone-treated skin, whereas mean SA concentrations were 280 microg/ml in SLS-pretreated skin and 530 microg/ml in tape-stripped skin (P < 0.001).",Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541883/),[μg] / [ml],3,151017,DB00898,Ethanol
,10541883,SA concentrations,"Microdialysates collected between 80 and 200 min showed mean SA concentrations of 3 microg/ml in unmodified and acetone-treated skin, whereas mean SA concentrations were 280 microg/ml in SLS-pretreated skin and 530 microg/ml in tape-stripped skin (P < 0.001).",Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541883/),[μg] / [ml],280,151018,DB00898,Ethanol
,10541883,SA concentrations,"Microdialysates collected between 80 and 200 min showed mean SA concentrations of 3 microg/ml in unmodified and acetone-treated skin, whereas mean SA concentrations were 280 microg/ml in SLS-pretreated skin and 530 microg/ml in tape-stripped skin (P < 0.001).",Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541883/),[μg] / [ml],530,151019,DB00898,Ethanol
<,9379349,tmax,In the search for a nasal formulation leading to a peak plasma concentration of diazepam at a tmax < or = 5 min bioavailability in rabbits has been studied after intranasal administration of the drug in ten vehicles of different polarity.,Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379349/),min,5,151445,DB00898,Ethanol
,9379349,bioavailability,"The bioavailability, measured during the first 30 min, because periods after this are not relevant for acute treatment, was found to be between 49 and 62% for the four most promising vehicles, pure glycofurol 75, tetraethyleneglycol, poly(ethylene glycol) 200 and 30% glycofurol in tetraethyleneglycol.",Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379349/),%,49 and 62,151446,DB00898,Ethanol
,9379349,bioavailability,"The bioavailability, measured during the first 30 min, because periods after this are not relevant for acute treatment, was found to be between 49 and 62% for the four most promising vehicles, pure glycofurol 75, tetraethyleneglycol, poly(ethylene glycol) 200 and 30% glycofurol in tetraethyleneglycol.",Pharmacokinetic and pharmacodynamic response after intranasal administration of diazepam to rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9379349/),%,30,151447,DB00898,Ethanol
,7758252,time to achieve maximal systemic concentrations (tmax,"The pharmacokinetics of dipyrone are characterised by rapid hydrolysis to the active moiety 4-methyl-amino-antipyrine (MAA), which has 85% bioavailability after oral administration in tablet form, and takes a short time to achieve maximal systemic concentrations (tmax of 1.2 to 2.0 hours).",Clinical pharmacokinetics of dipyrone and its metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,1.2 to 2.0,151448,DB00898,Ethanol
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,87,151449,DB00898,Ethanol
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,54,151450,DB00898,Ethanol
,7758252,elimination half-life (t1/2),"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,2.6 to 3.5,151451,DB00898,Ethanol
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,3.8,151452,DB00898,Ethanol
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,5.5,151453,DB00898,Ethanol
less,7758252,Protein binding,Protein binding of the 4 main metabolites is less than 60%.,Clinical pharmacokinetics of dipyrone and its metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,60,151454,DB00898,Ethanol
,7758252,volume of distribution,The volume of distribution of MAA is about 1.15 L/kg of lean body mass.,Clinical pharmacokinetics of dipyrone and its metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),[l] / [kg],1.15,151455,DB00898,Ethanol
,26406153,particle size,The particle size of optimum formulation was 22.8 ± 4.0 nm.,Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406153/),,22.8,151552,DB00898,Ethanol
,10352591,45 minute-to-5 minute ratio,"The 45 minute-to-5 minute ratio was 0.18-0.67 (median value, 0.56) in the tumors.",Pharmacokinetic imaging of 11C ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous ethanol injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10352591/),,0.18-0.67,151553,DB00898,Ethanol
,10352591,45 minute-to-5 minute ratio,"The 45 minute-to-5 minute ratio was 0.18-0.67 (median value, 0.56) in the tumors.",Pharmacokinetic imaging of 11C ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous ethanol injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10352591/),,0.56,151554,DB00898,Ethanol
,19704025,C(max),"After a single oral administration of [(14)C]BmPy-Cl (50 mg/kg), BmPy-Cl in the blood decreased rapidly after C(max) of 89.1 min with a distribution half-life (t(1/2)(alpha)) of 21 min, an elimination half-life (t(1/2)(beta)) of 5.6 h, and a total body clearance of 7.6 ml/min.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),min,89.1,151792,DB00898,Ethanol
,19704025,distribution half-life (t(1/2)(alpha)),"After a single oral administration of [(14)C]BmPy-Cl (50 mg/kg), BmPy-Cl in the blood decreased rapidly after C(max) of 89.1 min with a distribution half-life (t(1/2)(alpha)) of 21 min, an elimination half-life (t(1/2)(beta)) of 5.6 h, and a total body clearance of 7.6 ml/min.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),min,21,151793,DB00898,Ethanol
,19704025,elimination half-life (t(1/2)(beta)),"After a single oral administration of [(14)C]BmPy-Cl (50 mg/kg), BmPy-Cl in the blood decreased rapidly after C(max) of 89.1 min with a distribution half-life (t(1/2)(alpha)) of 21 min, an elimination half-life (t(1/2)(beta)) of 5.6 h, and a total body clearance of 7.6 ml/min.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),h,5.6,151794,DB00898,Ethanol
,19704025,total body clearance,"After a single oral administration of [(14)C]BmPy-Cl (50 mg/kg), BmPy-Cl in the blood decreased rapidly after C(max) of 89.1 min with a distribution half-life (t(1/2)(alpha)) of 21 min, an elimination half-life (t(1/2)(beta)) of 5.6 h, and a total body clearance of 7.6 ml/min.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),[ml] / [min],7.6,151795,DB00898,Ethanol
,19704025,Oral systemic bioavailability,"Oral systemic bioavailability was 43.4%, approximately equal to the dose recovered in urine after oral administration (29-38%).",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),%,43.4,151796,DB00898,Ethanol
,19704025,Oral systemic bioavailability,"Oral systemic bioavailability was 43.4%, approximately equal to the dose recovered in urine after oral administration (29-38%).",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),%,29-38,151797,DB00898,Ethanol
,19704025,Total dermal absorption,"Total dermal absorption of [(14)C]BmPy-Cl (5 mg/kg) was moderate when it was applied in dimethylformamide-water (34 + or - 13%), variable in water (22 + or - 8%), or minimal in ethanol-water (13 + or - 1%) vehicles.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),%,34,151798,DB00898,Ethanol
,19704025,Total dermal absorption,"Total dermal absorption of [(14)C]BmPy-Cl (5 mg/kg) was moderate when it was applied in dimethylformamide-water (34 + or - 13%), variable in water (22 + or - 8%), or minimal in ethanol-water (13 + or - 1%) vehicles.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),%,22,151799,DB00898,Ethanol
,19704025,Total dermal absorption,"Total dermal absorption of [(14)C]BmPy-Cl (5 mg/kg) was moderate when it was applied in dimethylformamide-water (34 + or - 13%), variable in water (22 + or - 8%), or minimal in ethanol-water (13 + or - 1%) vehicles.",Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),%,13,151800,DB00898,Ethanol
,19704025,K(t),BmPy-Cl was found to be a substrate for (K(t) = 37 microM) and inhibitor of (IC(50/tetraethylammonium) = 0.5 microM) human organic cation transporter 2.,Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),μM,37,151801,DB00898,Ethanol
,19704025,IC(50/tetraeth,BmPy-Cl was found to be a substrate for (K(t) = 37 microM) and inhibitor of (IC(50/tetraethylammonium) = 0.5 microM) human organic cation transporter 2.,Effects of dose and route on the disposition and kinetics of 1-butyl-1-methylpyrrolidinium chloride in male F-344 rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19704025/),μM,0.5,151802,DB00898,Ethanol
,26486790,C max,"In the in vivo studies, the super-SNEDDS concept proved valid in a rat model with a significantly larger C max for the super-SNEDDS (964 ± 167 ng/mL) than for the SNEDDS (506 ± 112 ng/mL).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),[ng] / [ml],964,151932,DB00898,Ethanol
,26486790,C max,"In the in vivo studies, the super-SNEDDS concept proved valid in a rat model with a significantly larger C max for the super-SNEDDS (964 ± 167 ng/mL) than for the SNEDDS (506 ± 112 ng/mL).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),[ng] / [ml],506,151933,DB00898,Ethanol
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,32.9,151934,DB00898,Ethanol
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,22.5,151935,DB00898,Ethanol
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,45.5,151936,DB00898,Ethanol
,26486790,bioavailability,"The bioavailability of Hf dosed in super-SNEDDS (32.9 ± 3.6%) and SNEDDS (22.5 ± 6.3%) did not change significantly with co-administration of orlistat (45.5 ± 7.3% and 21.9 ± 6.5%, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),%,21.9,151937,DB00898,Ethanol
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,1.3,151938,DB00898,Ethanol
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,2.8,151939,DB00898,Ethanol
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,6.0,151940,DB00898,Ethanol
,26486790,t max,"However, the pharmacokinetic parameters changed; the t max of the super-SNEDDS (1.3 ± 0.1 h) and SNEDDS (2.8 ± 1.2 h) were significantly lower when dosed with orlistat (6.0 ± 1.3 and 6.3 ± 1.2 h, respectively).",The Effect of Digestion and Drug Load on Halofantrine Absorption from Self-nanoemulsifying Drug Delivery System (SNEDDS). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26486790/),h,6.3,151941,DB00898,Ethanol
,2916773,distribution volume,"This observation could be explained by both a significantly smaller distribution volume of ethanol during hypothermia (0.71 +/- 0.03 L/kg at 29 C and 0.84 +/- 0.05 L/kg at 37 C, P less than .02) and a significantly slower maximum velocity of metabolism of ethanol (Vm) during hypothermia (1.12 +/- 0.11 mg/kg.min vs. 1.83 +/- 0.21 mg/kg.min, P less than .01).",Effect of hypothermia on the pharmacokinetics of ethanol in piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916773/),[l] / [kg],0.71,152115,DB00898,Ethanol
,2916773,distribution volume,"This observation could be explained by both a significantly smaller distribution volume of ethanol during hypothermia (0.71 +/- 0.03 L/kg at 29 C and 0.84 +/- 0.05 L/kg at 37 C, P less than .02) and a significantly slower maximum velocity of metabolism of ethanol (Vm) during hypothermia (1.12 +/- 0.11 mg/kg.min vs. 1.83 +/- 0.21 mg/kg.min, P less than .01).",Effect of hypothermia on the pharmacokinetics of ethanol in piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916773/),[l] / [kg],0.84,152116,DB00898,Ethanol
,2916773,maximum velocity of metabolism of ethanol (Vm),"This observation could be explained by both a significantly smaller distribution volume of ethanol during hypothermia (0.71 +/- 0.03 L/kg at 29 C and 0.84 +/- 0.05 L/kg at 37 C, P less than .02) and a significantly slower maximum velocity of metabolism of ethanol (Vm) during hypothermia (1.12 +/- 0.11 mg/kg.min vs. 1.83 +/- 0.21 mg/kg.min, P less than .01).",Effect of hypothermia on the pharmacokinetics of ethanol in piglets. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916773/),[mg] / [kg·min],1.12,152117,DB00898,Ethanol
,2916773,maximum velocity of metabolism of ethanol (Vm),"This observation could be explained by both a significantly smaller distribution volume of ethanol during hypothermia (0.71 +/- 0.03 L/kg at 29 C and 0.84 +/- 0.05 L/kg at 37 C, P less than .02) and a significantly slower maximum velocity of metabolism of ethanol (Vm) during hypothermia (1.12 +/- 0.11 mg/kg.min vs. 1.83 +/- 0.21 mg/kg.min, P less than .01).",Effect of hypothermia on the pharmacokinetics of ethanol in piglets. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2916773/),[mg] / [kg·min],1.83,152118,DB00898,Ethanol
<,9314087,distribution half-life,"The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h).","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),min,5,152248,DB00898,Ethanol
,9314087,intermediate phase half-life,"The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h).","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),min,90,152249,DB00898,Ethanol
,9314087,terminal elimination half-life,"The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h).","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),h,9,152250,DB00898,Ethanol
,9314087,plasma clearance,"The plasma clearance of the drug was high (1,700 ml/min) and the volume of distribution approximately 15 l/kg.","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),[ml] / [min],"1,700",152251,DB00898,Ethanol
,9314087,volume of distribution,"The plasma clearance of the drug was high (1,700 ml/min) and the volume of distribution approximately 15 l/kg.","Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9314087/),[l] / [kg],15,152252,DB00898,Ethanol
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),min,45,152625,DB00898,Ethanol
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),h,4.3,152626,DB00898,Ethanol
,6193537,half-lives,"Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d.","Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),d,1.7,152627,DB00898,Ethanol
,6193537,half-life,The half-life of the unchanged drug was 13 min.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),min,13,152628,DB00898,Ethanol
,6193537,maximum plasma levels,Almost 10% of an oral dose of 200 microgram/kg were bioavailable exhibiting maximum plasma levels of 5.7 +/- 3.6 ng/ml.,"Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193537/),[ng] / [ml],5.7,152629,DB00898,Ethanol
,17869458,shelf-lives,"The shelf-lives of PAC at 25 degrees C in Taxol, LBMW and CMW, in an accelerated stability study, were 71, 57 and 31 days, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),d,71,152939,DB00898,Ethanol
,17869458,shelf-lives,"The shelf-lives of PAC at 25 degrees C in Taxol, LBMW and CMW, in an accelerated stability study, were 71, 57 and 31 days, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),d,57,152940,DB00898,Ethanol
,17869458,shelf-lives,"The shelf-lives of PAC at 25 degrees C in Taxol, LBMW and CMW, in an accelerated stability study, were 71, 57 and 31 days, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),d,31,152941,DB00898,Ethanol
,17869458,activation energy (Ea),"The activation energy (Ea) for PAC in Taxol, LBMW and CMW was 23, 16 and 14 kcal/mol, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),[kcal] / [mol],23,152942,DB00898,Ethanol
,17869458,activation energy (Ea),"The activation energy (Ea) for PAC in Taxol, LBMW and CMW was 23, 16 and 14 kcal/mol, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),[kcal] / [mol],16,152943,DB00898,Ethanol
,17869458,activation energy (Ea),"The activation energy (Ea) for PAC in Taxol, LBMW and CMW was 23, 16 and 14 kcal/mol, respectively.","Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869458/),[kcal] / [mol],14,152944,DB00898,Ethanol
>,28273367,extraction recoveries,The extraction recoveries of all analytes were >85%.,LC-MS/MS method for simultaneous determination of flavonoids and physalins in rat plasma: Application to pharmacokinetic study after oral administration of Physalis alkekengi var. franchetii (Chinese lantern) extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28273367/),%,85,153242,DB00898,Ethanol
less,18428980,water solubility,Antalarmin has a poor water solubility of less than 1 microg/mL and is weakly basic with an experimentally determined pK(a) of 5.0.,Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18428980/),[μg] / [ml],1,153543,DB00898,Ethanol
,18428980,pK(a),Antalarmin has a poor water solubility of less than 1 microg/mL and is weakly basic with an experimentally determined pK(a) of 5.0.,Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18428980/),,5.0,153544,DB00898,Ethanol
,18428980,drug loading capacity,"Four formulations, each with a targeted drug loading capacity of 100 mg/mL, show potential for oral administration.",Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18428980/),[mg] / [ml],100,153545,DB00898,Ethanol
,10335908,maximum concentration (Cmax),"Mean with (SD; n = 12) of maximum concentration (Cmax) and area under the curve (AUC) of formoterol in plasma were 266 (108) pmol x l(-1) and 1330 (398) pmol x l(-1), respectively.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),[pM] / [l],266,154250,DB00898,Ethanol
,10335908,area under the curve (AUC),"Mean with (SD; n = 12) of maximum concentration (Cmax) and area under the curve (AUC) of formoterol in plasma were 266 (108) pmol x l(-1) and 1330 (398) pmol x l(-1), respectively.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),[pM] / [l],1330,154251,DB00898,Ethanol
,10335908,half-life (t1/2),A predominant slow elimination of formoterol from plasma with a mean half-life (t1/2) of 10 h was demonstrated.,Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,10,154252,DB00898,Ethanol
,10335908,terminal half-lives,"The terminal half-lives calculated from the excretion rate-time curves, i.e., 13.9 h and 12.3 h for the (R,R)- and (S,S)-enantiomer, respectively, confirm the slow elimination of formoterol from plasma.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,13.9,154253,DB00898,Ethanol
,10335908,terminal half-lives,"The terminal half-lives calculated from the excretion rate-time curves, i.e., 13.9 h and 12.3 h for the (R,R)- and (S,S)-enantiomer, respectively, confirm the slow elimination of formoterol from plasma.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,12.3,154254,DB00898,Ethanol
,10335908,maximum QTc,The mean maximum QTc increase was 25 msec at 6 h.,Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),ms,25,154255,DB00898,Ethanol
,10335908,terminal elimination half-life,"Due to a terminal elimination half-life of about 10 h, sustained systemic concentrations of formoterol are predicted for a twice daily treatment regimen without noteworthy accumulation.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,10,154256,DB00898,Ethanol
,2863112,extraction ratios,"Presystemic intestinal (EGpre) and liver (EH) extraction ratios, EGpre = 0.93 +/- 0.01, EH = 0.67 +/- 0.04, were calculated from AUC values after intraduodenal, intraportal, and iv administration.",Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),,0.93,154433,DB00898,Ethanol
,2863112,extraction ratios,"Presystemic intestinal (EGpre) and liver (EH) extraction ratios, EGpre = 0.93 +/- 0.01, EH = 0.67 +/- 0.04, were calculated from AUC values after intraduodenal, intraportal, and iv administration.",Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),,0.67,154434,DB00898,Ethanol
,2863112,Total systemic availability,Total systemic availability after intraduodenal administration ranged from 0.8 (10 mg/kg) to 1.2% (40 mg/kg).,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),%,0.8,154435,DB00898,Ethanol
,2863112,Total systemic availability,Total systemic availability after intraduodenal administration ranged from 0.8 (10 mg/kg) to 1.2% (40 mg/kg).,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),%,1.2,154436,DB00898,Ethanol
,2863112,intestinal extraction ratio,"During iv infusion (30 micrograms fenoterol/min X kg), an intestinal extraction ratio of EG = 0.26 was observed.",Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),,0.26,154437,DB00898,Ethanol
,2863112,systemic clearance (Cl,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[ml] / [kg·min],53.8,154438,DB00898,Ethanol
,2863112,systemic clearance (Cl,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[ml] / [kg·min],74.4,154439,DB00898,Ethanol
,2863112,distribution volume (Vss,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[l] / [kg],0.95,154440,DB00898,Ethanol
,2863112,distribution volume (Vss,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[l] / [kg],1.21,154441,DB00898,Ethanol
,2863112,mean residence time,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,17.9,154442,DB00898,Ethanol
,2863112,mean residence time,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,16.3,154443,DB00898,Ethanol
,2863112,terminal half-life,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,45.8,154444,DB00898,Ethanol
,2863112,terminal half-life,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,46.8,154445,DB00898,Ethanol
,32922013,oral bioavailability,The oral bioavailability was significantly improved by the NNE (203.30%) and the LNE (205.89%) relative to the suspension group in rats.,"A Non-Lipolysis Nanoemulsion Improved Oral Bioavailability by Reducing the First-Pass Metabolism of Raloxifene, and Related Absorption Mechanisms Being Studied. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32922013/),%,203.30,154952,DB00898,Ethanol
,32922013,oral bioavailability,The oral bioavailability was significantly improved by the NNE (203.30%) and the LNE (205.89%) relative to the suspension group in rats.,"A Non-Lipolysis Nanoemulsion Improved Oral Bioavailability by Reducing the First-Pass Metabolism of Raloxifene, and Related Absorption Mechanisms Being Studied. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32922013/),%,205.89,154953,DB00898,Ethanol
,32922013,relative bioavailability,"However, 541.28% relative bioavailability was achieved in pigs after oral NNE intake compared to the suspension and had two-fold greater bioavailability than the LNE (p < 0.05).","A Non-Lipolysis Nanoemulsion Improved Oral Bioavailability by Reducing the First-Pass Metabolism of Raloxifene, and Related Absorption Mechanisms Being Studied. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32922013/),%,541.28,154954,DB00898,Ethanol
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],16.1,155061,DB00898,Ethanol
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.3,155062,DB00898,Ethanol
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],37.9,155063,DB00898,Ethanol
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.7,155064,DB00898,Ethanol
,16326435,area under the curve (AUC),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],63.0,155065,DB00898,Ethanol
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.3,155066,DB00898,Ethanol
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.7,155067,DB00898,Ethanol
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],63.0,155068,DB00898,Ethanol
,16326435,C(max),"After oral administration of 1-g/kg doses, mean area under the curve (AUC) and C(max) values were significantly reduced in BHR-treated rats (16.1 +/- 10.0 and 0.3 +/- 0.1 mg/ml, respectively) as compared with saline-treated (37.9 +/- 14.4 and 0.7 +/- 0.7 mg/ml, respectively) and placebo solution-treated (63.0 +/- 46.4 and 0.7 +/- 0.4 mg/ml, respectively) rats.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],0.7,155069,DB00898,Ethanol
,16326435,AUC,"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[)min·mg(] / [ml],188.1,155070,DB00898,Ethanol
,16326435,AUC,"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[)min·mg(] / [ml],571.4,155071,DB00898,Ethanol
,16326435,C(max),"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],1.0,155072,DB00898,Ethanol
,16326435,C(max),"Similarly, after administration of 3-g/kg doses, mean AUC and C(max) values in BHR-treated rats (188.1 +/- 119.7 mg(.)min/ml and 1.0 +/- 0.4 mg/ml) were significantly reduced over those in saline-treated rats (571.4 +/- 512.4 mg(.)min/ml and 1.8 +/- 0.9 mg/ml, respectively).",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),[mg] / [ml],1.8,155073,DB00898,Ethanol
,16326435,relative oral bioavailability,"The relative oral bioavailability of alcohol calculated as the ratio of AUC(BHR)/AUC(Saline) was 42.5% and 32.9% at 1- and 3-g/kg doses, respectively.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),%,42.5,155074,DB00898,Ethanol
,16326435,relative oral bioavailability,"The relative oral bioavailability of alcohol calculated as the ratio of AUC(BHR)/AUC(Saline) was 42.5% and 32.9% at 1- and 3-g/kg doses, respectively.",Altered oral absorption of alcohol by combined aqueous extracts of four herbal plants in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16326435/),%,32.9,155075,DB00898,Ethanol
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.22,155401,DB00898,Ethanol
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.30,155402,DB00898,Ethanol
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.85,155403,DB00898,Ethanol
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.58,155404,DB00898,Ethanol
,32013640,peak BACs,"Results and Discussion: The estimated peak BACs for these three user profiles were 0.22, 0.22, and 0.30 mg/L for first-generation devices, respectively, and 0.85, 0.58, and 0.34 mg/L for second-generation devices, respectively.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.34,155405,DB00898,Ethanol
,32013640,peak BACs,"Additionally, peak BACs for individual first-generation users with directly measured puffing parameters were estimated to range from 0.06 to 0.67 mg/L.",PBPK modeling characterization of potential acute impairment effects from inhalation of ethanol during e-cigarette use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32013640/),[mg] / [l],0.06 to 0.67,155406,DB00898,Ethanol
,26548758,drug loading,"TC-loaded nanoliposome (TNL1) and PE-conjugated TC-loaded nanoliposome (TNL-PE) showed 3.23±0.26% and 3.07±0.05% drug loading values, respectively.",Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548758/),%,3.23,155472,DB00898,Ethanol
,26548758,drug loading,"TC-loaded nanoliposome (TNL1) and PE-conjugated TC-loaded nanoliposome (TNL-PE) showed 3.23±0.26% and 3.07±0.05% drug loading values, respectively.",Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548758/),%,3.07,155473,DB00898,Ethanol
,26548758,diameters (z-average,"Average diameters (z-average) of the nanoliposomes were within 100 nm, with negative zeta potentials and cumulative percentages of drug release were 75.77±12.21% and 61.04±10.53% at 30 h for TNL1 and TNL-PE respectively.",Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26548758/),,100,155474,DB00898,Ethanol
,23091382,peak plasma concentration,"Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 ± 14.98 ng/mL versus 279.43 ± 7.21 ng/mL, P < 0.01), a shorter time taken to reach peak plasma concentration (0.5 ± 0.01 hour versus 1.0 ± 0.12 hour, P < 0.01), and a greater AUC(0-∞) (820.36 ± 25.11 mg × hour/L versus 344.11 ± 10.01 mg × hour/L, P < 0.05) compared with curcumin suspension.",In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091382/),[ng] / [ml],564.94,155599,DB00898,Ethanol
,23091382,peak plasma concentration,"Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 ± 14.98 ng/mL versus 279.43 ± 7.21 ng/mL, P < 0.01), a shorter time taken to reach peak plasma concentration (0.5 ± 0.01 hour versus 1.0 ± 0.12 hour, P < 0.01), and a greater AUC(0-∞) (820.36 ± 25.11 mg × hour/L versus 344.11 ± 10.01 mg × hour/L, P < 0.05) compared with curcumin suspension.",In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091382/),[ng] / [ml],279.43,155600,DB00898,Ethanol
,23091382,time taken to reach peak plasma concentration,"Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 ± 14.98 ng/mL versus 279.43 ± 7.21 ng/mL, P < 0.01), a shorter time taken to reach peak plasma concentration (0.5 ± 0.01 hour versus 1.0 ± 0.12 hour, P < 0.01), and a greater AUC(0-∞) (820.36 ± 25.11 mg × hour/L versus 344.11 ± 10.01 mg × hour/L, P < 0.05) compared with curcumin suspension.",In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091382/),h,0.5,155601,DB00898,Ethanol
,23091382,time taken to reach peak plasma concentration,"Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 ± 14.98 ng/mL versus 279.43 ± 7.21 ng/mL, P < 0.01), a shorter time taken to reach peak plasma concentration (0.5 ± 0.01 hour versus 1.0 ± 0.12 hour, P < 0.01), and a greater AUC(0-∞) (820.36 ± 25.11 mg × hour/L versus 344.11 ± 10.01 mg × hour/L, P < 0.05) compared with curcumin suspension.",In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091382/),h,1.0,155602,DB00898,Ethanol
,23091382,AUC(0-∞),"Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 ± 14.98 ng/mL versus 279.43 ± 7.21 ng/mL, P < 0.01), a shorter time taken to reach peak plasma concentration (0.5 ± 0.01 hour versus 1.0 ± 0.12 hour, P < 0.01), and a greater AUC(0-∞) (820.36 ± 25.11 mg × hour/L versus 344.11 ± 10.01 mg × hour/L, P < 0.05) compared with curcumin suspension.",In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091382/),[h·mg] / [l],820.36,155603,DB00898,Ethanol
,23091382,AUC(0-∞),"Nanostructured lipid curcumin carriers showed a significantly higher peak plasma concentration (564.94 ± 14.98 ng/mL versus 279.43 ± 7.21 ng/mL, P < 0.01), a shorter time taken to reach peak plasma concentration (0.5 ± 0.01 hour versus 1.0 ± 0.12 hour, P < 0.01), and a greater AUC(0-∞) (820.36 ± 25.11 mg × hour/L versus 344.11 ± 10.01 mg × hour/L, P < 0.05) compared with curcumin suspension.",In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23091382/),[h·mg] / [l],344.11,155604,DB00898,Ethanol
,9493333,fluid volume,"After removing a mean fluid volume of 2.46 +/- 0.48 liters (+/- SD), span 1.76-3.43 liters by hemodialysis, the same subjects received a second i.v. infusion of ethanol after they had eaten lunch.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),l,2.46,156279,DB00898,Ethanol
,9493333,plasma/whole blood ratio,Plasma always contained a higher concentration of ethanol than whole blood and the mean plasma/whole blood ratio in patients with renal failure was 1.07:1 (span 1.05-1.10).,Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),,1.07:1,156280,DB00898,Ethanol
,9493333,rate of ethanol disappearance from blood (beta-slope),"The rate of ethanol disappearance from blood (beta-slope) was faster (0.185 +/- 0.013 versus 0.157 +/- 0.022 g/l/h), the Co value was higher (0.79 +/- 0.08 versus 0.73 +/- 0.10 g/l) and the apparent volume of distribution (Vd) of ethanol was lower (0.507 +/- 0.049 versus 0.558 +/- 0.078 l/kg) after hemodialysis.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [h·l],0.185,156281,DB00898,Ethanol
,9493333,rate of ethanol disappearance from blood (beta-slope),"The rate of ethanol disappearance from blood (beta-slope) was faster (0.185 +/- 0.013 versus 0.157 +/- 0.022 g/l/h), the Co value was higher (0.79 +/- 0.08 versus 0.73 +/- 0.10 g/l) and the apparent volume of distribution (Vd) of ethanol was lower (0.507 +/- 0.049 versus 0.558 +/- 0.078 l/kg) after hemodialysis.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [h·l],0.157,156282,DB00898,Ethanol
,9493333,Co,"The rate of ethanol disappearance from blood (beta-slope) was faster (0.185 +/- 0.013 versus 0.157 +/- 0.022 g/l/h), the Co value was higher (0.79 +/- 0.08 versus 0.73 +/- 0.10 g/l) and the apparent volume of distribution (Vd) of ethanol was lower (0.507 +/- 0.049 versus 0.558 +/- 0.078 l/kg) after hemodialysis.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [l],0.79,156283,DB00898,Ethanol
,9493333,Co,"The rate of ethanol disappearance from blood (beta-slope) was faster (0.185 +/- 0.013 versus 0.157 +/- 0.022 g/l/h), the Co value was higher (0.79 +/- 0.08 versus 0.73 +/- 0.10 g/l) and the apparent volume of distribution (Vd) of ethanol was lower (0.507 +/- 0.049 versus 0.558 +/- 0.078 l/kg) after hemodialysis.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [l],0.73,156284,DB00898,Ethanol
,9493333,apparent volume of distribution (Vd),"The rate of ethanol disappearance from blood (beta-slope) was faster (0.185 +/- 0.013 versus 0.157 +/- 0.022 g/l/h), the Co value was higher (0.79 +/- 0.08 versus 0.73 +/- 0.10 g/l) and the apparent volume of distribution (Vd) of ethanol was lower (0.507 +/- 0.049 versus 0.558 +/- 0.078 l/kg) after hemodialysis.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[l] / [kg],0.507,156285,DB00898,Ethanol
,9493333,apparent volume of distribution (Vd),"The rate of ethanol disappearance from blood (beta-slope) was faster (0.185 +/- 0.013 versus 0.157 +/- 0.022 g/l/h), the Co value was higher (0.79 +/- 0.08 versus 0.73 +/- 0.10 g/l) and the apparent volume of distribution (Vd) of ethanol was lower (0.507 +/- 0.049 versus 0.558 +/- 0.078 l/kg) after hemodialysis.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[l] / [kg],0.558,156286,DB00898,Ethanol
,9493333,water content,The water content of whole blood was significantly higher (P < 0.001) before dialysis (88.6 +/- 1.97 g/100 ml) compared with after dialysis (87.4 +/- 2.01 g/100 ml).,Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [100·ml],88.6,156287,DB00898,Ethanol
,9493333,water content,The water content of whole blood was significantly higher (P < 0.001) before dialysis (88.6 +/- 1.97 g/100 ml) compared with after dialysis (87.4 +/- 2.01 g/100 ml).,Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [100·ml],87.4,156288,DB00898,Ethanol
,9493333,rate of elimination,"Nevertheless, the rate of elimination of ethanol from blood in patients with renal failure agreed reasonably well with values expected for healthy subjects, namely mean 0.15 g/l/h spanning from 0.10 to 0.20 g/l/h.",Pharmacokinetics of ethanol in patients with renal failure before and after hemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493333/),[g] / [h·l],0.15,156289,DB00898,Ethanol
,10594809,Kt/V,The mean Kt/V(EtOH) was 2.31 (SD 0. 50) compared with 2.46 (SD 0.52) using Watson.,Measuring total body water in peritoneal dialysis patients using an ethanol dilution technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594809/),,2.31,156834,DB00898,Ethanol
,10594809,Kt/V,The mean Kt/V(EtOH) was 2.31 (SD 0. 50) compared with 2.46 (SD 0.52) using Watson.,Measuring total body water in peritoneal dialysis patients using an ethanol dilution technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594809/),,2.46,156835,DB00898,Ethanol
,3426682,volume of distribution,A smaller volume of distribution of ethanol was evident after pretreatment with CC; 0.636 L/kg compared with 0.675 L/kg after placebo.,Elimination kinetics of ethanol and acetaldehyde in healthy men during the calcium carbimide-alcohol flush reaction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426682/),[l] / [kg],0.636,157412,DB00898,Ethanol
,3426682,volume of distribution,A smaller volume of distribution of ethanol was evident after pretreatment with CC; 0.636 L/kg compared with 0.675 L/kg after placebo.,Elimination kinetics of ethanol and acetaldehyde in healthy men during the calcium carbimide-alcohol flush reaction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426682/),[l] / [kg],0.675,157413,DB00898,Ethanol
,3426682,maximum blood-levels,The maximum blood-levels of acetaldehyde ranged from 40-242 microM compared with 1.7-6.5 microM in the placebo control experiments.,Elimination kinetics of ethanol and acetaldehyde in healthy men during the calcium carbimide-alcohol flush reaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426682/),μM,40-242,157414,DB00898,Ethanol
,3426682,maximum blood-levels,The maximum blood-levels of acetaldehyde ranged from 40-242 microM compared with 1.7-6.5 microM in the placebo control experiments.,Elimination kinetics of ethanol and acetaldehyde in healthy men during the calcium carbimide-alcohol flush reaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426682/),μM,1.7-6.5,157415,DB00898,Ethanol
,3426682,elimination half-life,The elimination half-life of acetaldehyde after CC treatment ranged from 18-31 min.,Elimination kinetics of ethanol and acetaldehyde in healthy men during the calcium carbimide-alcohol flush reaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426682/),min,18-31,157416,DB00898,Ethanol
,26858556,T max,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),h,0.25,157534,DB00898,Ethanol
,26858556,C max,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),[ng] / [ml],474.96,157535,DB00898,Ethanol
,26858556,AUC0-∞,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),[ng] / [h·ml],733.32,157536,DB00898,Ethanol
,26858556,T max,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),h,0.31,157537,DB00898,Ethanol
,26858556,C max,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),[ng] / [ml],533.94,157538,DB00898,Ethanol
,26858556,AUC0-∞,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),[ng] / [h·ml],1151.38,157539,DB00898,Ethanol
,26858556,T max,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),h,0.5,157540,DB00898,Ethanol
,26858556,C max,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),[ng] / [ml],680.62,157541,DB00898,Ethanol
,26858556,AUC0-∞,"The pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as follows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC0-∞ 733.32 ± 113.82 ng/ml h for GFS; T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC0-∞ 1151.38 ± 198.29 ng/ml h for Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC0-∞ 2082.49 ± 408.33 ng/ml h for the P-GFS.",Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),[ng] / [h·ml],2082.49,157542,DB00898,Ethanol
,26858556,bioavailability,The bioavailability of P-GFS was nearly 284% and 181% of the GFS and Zhengyuan tablets respectively.,Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),%,284,157543,DB00898,Ethanol
,26858556,bioavailability,The bioavailability of P-GFS was nearly 284% and 181% of the GFS and Zhengyuan tablets respectively.,Improvement of oral availability of ginseng fruit saponins by a proliposome delivery system containing sodium deoxycholate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26858556/),%,181,157544,DB00898,Ethanol
,23387090,polydispersity index,"The mean diameter of CU-SE was (478.5 +/- 80.3) nm and the polydispersity index was 0.285 +/- 0.042, while the mean value of apparent drug entrapment efficiency was 80.77%.",[Silica-coated ethosome as a novel oral delivery system for enhanced oral bioavailability of curcumin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387090/),,0.285,157660,DB00898,Ethanol
,23387090,apparent drug entrapment efficiency,"The mean diameter of CU-SE was (478.5 +/- 80.3) nm and the polydispersity index was 0.285 +/- 0.042, while the mean value of apparent drug entrapment efficiency was 80.77%.",[Silica-coated ethosome as a novel oral delivery system for enhanced oral bioavailability of curcumin]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23387090/),%,80.77,157661,DB00898,Ethanol
,11038241,half-life for dermal absorption,The half-life for dermal absorption of radioactivity was estimated to be 1.3 hours.,"Absorption, distribution, metabolism and excretion of intravenously and dermally administered triethanolamine in mice. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038241/),h,1.3,158480,DB00898,Ethanol
,11038241,half-life,Intravenously administered radioactivity was eliminated in a biphasic manner with a prominent initial phase (half-life of 0.3 hr) followed by a slower terminal phase (half-life of 10 hr).,"Absorption, distribution, metabolism and excretion of intravenously and dermally administered triethanolamine in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038241/),h,0.3,158481,DB00898,Ethanol
,11038241,half-life,Intravenously administered radioactivity was eliminated in a biphasic manner with a prominent initial phase (half-life of 0.3 hr) followed by a slower terminal phase (half-life of 10 hr).,"Absorption, distribution, metabolism and excretion of intravenously and dermally administered triethanolamine in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038241/),h,10,158482,DB00898,Ethanol
,11038241,Fecal excretion,Fecal excretion of radioactivity comprised 16-28% of dose administered.,"Absorption, distribution, metabolism and excretion of intravenously and dermally administered triethanolamine in mice. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038241/),%,16-28,158483,DB00898,Ethanol
,9789873,AUC0-24 h,AUC0-24 h was 245.2 +/- 337.2 h.ng/ml.,Development and in vivo assessment of a transdermal system for physostigmine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[h·ng] / [ml],245.2,158496,DB00898,Ethanol
,9789873,flux,"The mean pad flux reached 4.6 +/- 6.3 micrograms/cm2 from 0 to 24 h and, 24 h after the application of the pad, 110 micrograms/cm2 of PHY had been passed through the skin.",Development and in vivo assessment of a transdermal system for physostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[μg] / [cm2],4.6,158497,DB00898,Ethanol
,9789873,plasma concentrations,"After removed of the patch, plasma concentrations first increased from 15.8 +/- 28.6 ng/ml (at 24 h) to 21.4 +/- 36.7 ng/ml, then decreased with an elimination half-life of 0.7 +/- 0.2 h.",Development and in vivo assessment of a transdermal system for physostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[ng] / [ml],15.8,158498,DB00898,Ethanol
,9789873,plasma concentrations,"After removed of the patch, plasma concentrations first increased from 15.8 +/- 28.6 ng/ml (at 24 h) to 21.4 +/- 36.7 ng/ml, then decreased with an elimination half-life of 0.7 +/- 0.2 h.",Development and in vivo assessment of a transdermal system for physostigmine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),[ng] / [ml],21.4,158499,DB00898,Ethanol
,9789873,elimination half-life,"After removed of the patch, plasma concentrations first increased from 15.8 +/- 28.6 ng/ml (at 24 h) to 21.4 +/- 36.7 ng/ml, then decreased with an elimination half-life of 0.7 +/- 0.2 h.",Development and in vivo assessment of a transdermal system for physostigmine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),h,0.7,158500,DB00898,Ethanol
,9789873,inhibition percentages,AChE inhibition percentages increased from 6.5 +/- 2.3% to 16.0 +/- 27.7%.,Development and in vivo assessment of a transdermal system for physostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),%,6.5,158501,DB00898,Ethanol
,9789873,inhibition percentages,AChE inhibition percentages increased from 6.5 +/- 2.3% to 16.0 +/- 27.7%.,Development and in vivo assessment of a transdermal system for physostigmine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9789873/),%,16.0,158502,DB00898,Ethanol
,23362155,AUC,"In animals exposed to gasoline, we observed an increase in AUC(0-∞) for both enantiomers, with a sharper increase seen for the (-)-(R)-fluoxetine enantiomer (enantiomeric ratio AUC((+)-(S)/(-)-(R)) = 1.07), resulting in a loss of enantioselectivity.",Influence of gasoline inhalation on the enantioselective pharmacokinetics of fluoxetine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23362155/),,1.07,158762,DB00898,Ethanol
,31366828,relative bioavailability,"The plasma concentration curve showed that compared with LEF group, the peak concentration of TEF microemulsion group was decreased, the half-life (t1/2) was prolonged, and the relative bioavailability of TEF microemulsion was 75.35%.",Development and Evaluation of a Water-in-oil Microemulsion Formulation for the Transdermal Drug Delivery of Teriflunomide (A771726). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31366828/),%,75.35,158954,DB00898,Ethanol
,17289362,T(max),"T(max) increased from 20 min for the liquid to 30 min for the tablet, which is not unexpected as the tablet required time for disintegration before absorption could occur.",Comparison of Echinacea alkylamide pharmacokinetics between liquid and tablet preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17289362/),min,20,159220,DB00898,Ethanol
,17289362,T(max),"T(max) increased from 20 min for the liquid to 30 min for the tablet, which is not unexpected as the tablet required time for disintegration before absorption could occur.",Comparison of Echinacea alkylamide pharmacokinetics between liquid and tablet preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17289362/),min,30,159221,DB00898,Ethanol
,507092,dialysance,Methanol dialysance was 98 ml/min.,Severe methanol poisoning. Application of a pharmacokinetic model for ethanol therapy and hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/507092/),[ml] / [min],98,159553,DB00898,Ethanol
,28589492,half-life,The effective half-life was ∼12 h.,"A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28589492/),h,∼12,159570,DB00898,Ethanol
,3718588,time to attain the peak,"After oral administration to rats, rabbits and dogs, the time to attain the peak and the maximum concentration of the plasma levels of radioactivity were about 15 min, 4 micrograms eq./ml in rats, 15-45 min, 8 micrograms eq./ml in rabbits and 2-4 h, 2 micrograms eq./ml in dogs, respectively.","Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718588/),min,15,159626,DB00898,Ethanol
,3718588,time to attain the peak,"After oral administration to rats, rabbits and dogs, the time to attain the peak and the maximum concentration of the plasma levels of radioactivity were about 15 min, 4 micrograms eq./ml in rats, 15-45 min, 8 micrograms eq./ml in rabbits and 2-4 h, 2 micrograms eq./ml in dogs, respectively.","Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718588/),min,15-45,159627,DB00898,Ethanol
,3718588,maximum concentration,"After oral administration to rats, rabbits and dogs, the time to attain the peak and the maximum concentration of the plasma levels of radioactivity were about 15 min, 4 micrograms eq./ml in rats, 15-45 min, 8 micrograms eq./ml in rabbits and 2-4 h, 2 micrograms eq./ml in dogs, respectively.","Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718588/),h,2-4,159628,DB00898,Ethanol
,3718588,half-lives,"The plasma denopamine levels in dogs reached the peak (0.34 microgram/ml) at 0.5-3 h after administration, and thereafter gradually decreased with half-lives of 1.6-3.1 h.","Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718588/),h,1.6-3.1,159629,DB00898,Ethanol
,3718588,cumulative excretion,"When 3H-denopamine was orally administered to rats, cumulative excretion of radioactivity in the urine and feces within 24 h were about 60 and 32% of the dose, respectively.","Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718588/),%,60,159630,DB00898,Ethanol
,3718588,cumulative excretion,"When 3H-denopamine was orally administered to rats, cumulative excretion of radioactivity in the urine and feces within 24 h were about 60 and 32% of the dose, respectively.","Metabolic fate of the new cardiotonic denopamine in animals. 1st communication: absorption, distribution and excretion in the rat, rabbit and dog. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718588/),%,32,159631,DB00898,Ethanol
,9504434,maximum concentration,"When tranilast at a dose of 1.5 mg was applied topically as an ethanol solution containing 5% polyvinylpyrrolidone on a dorsal skin surface (2.25 cm2), the maximum concentration of tranilast in skin dialysate was approximately 2 microM.","Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504434/),μM,2,159723,DB00898,Ethanol
,9504434,maximum concentration,"When 10 or 20% oleic acid was added to the same ethanol solution the maximum concentration of tranilast in the dialysate increased to 10-20 microM, and this value was further increased to 60 microM by the addition of a combination of oleic acid (10 or 20%) and propylene glycol (10%) to the solution.","Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504434/),μM,10-20,159724,DB00898,Ethanol
,9504434,maximum concentration,"When 10 or 20% oleic acid was added to the same ethanol solution the maximum concentration of tranilast in the dialysate increased to 10-20 microM, and this value was further increased to 60 microM by the addition of a combination of oleic acid (10 or 20%) and propylene glycol (10%) to the solution.","Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504434/),μM,60,159725,DB00898,Ethanol
,9504434,transdermal bioavailability,"The transdermal bioavailability of tranilast as assessed by the AUC0-4 of tranilast in plasma, was 0.2% of the dose applied in the ethanol solution, 3-5% of that applied in the ethanol solution containing oleic acid, and 14-16% of that applied in the ethanol solution containing both oleic acid and propylene glycol.","Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504434/),%,0.2,159726,DB00898,Ethanol
,9504434,transdermal bioavailability,"The transdermal bioavailability of tranilast as assessed by the AUC0-4 of tranilast in plasma, was 0.2% of the dose applied in the ethanol solution, 3-5% of that applied in the ethanol solution containing oleic acid, and 14-16% of that applied in the ethanol solution containing both oleic acid and propylene glycol.","Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504434/),%,3-5,159727,DB00898,Ethanol
,9504434,transdermal bioavailability,"The transdermal bioavailability of tranilast as assessed by the AUC0-4 of tranilast in plasma, was 0.2% of the dose applied in the ethanol solution, 3-5% of that applied in the ethanol solution containing oleic acid, and 14-16% of that applied in the ethanol solution containing both oleic acid and propylene glycol.","Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504434/),%,14-16,159728,DB00898,Ethanol
,3358883,distribution volume of ethanol (V),3. The distribution volume of ethanol (V) was 0.64 +/- 0.023 1 kg-1 after CC and 0.68 +/- 0.026 l kg-1 after placebo treatment (P greater than 0.05).,"Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358883/),[1] / [kg],0.64,159960,DB00898,Ethanol
,3358883,distribution volume of ethanol (V),3. The distribution volume of ethanol (V) was 0.64 +/- 0.023 1 kg-1 after CC and 0.68 +/- 0.026 l kg-1 after placebo treatment (P greater than 0.05).,"Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358883/),[l] / [kg],0.68,159961,DB00898,Ethanol
,3358883,elimination of ethanol from the body (V X ko),The elimination of ethanol from the body (V X ko) was 1.9 +/- 0.051 mmol kg-1 h-1 after CC compared with 2.11 +/- 0.056 mmol kg-1 h-1 in placebo control experiments (P less than 0.001).,"Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358883/),[mM] / [h·kg],1.9,159962,DB00898,Ethanol
,3358883,elimination of ethanol from the body (V X ko),The elimination of ethanol from the body (V X ko) was 1.9 +/- 0.051 mmol kg-1 h-1 after CC compared with 2.11 +/- 0.056 mmol kg-1 h-1 in placebo control experiments (P less than 0.001).,"Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358883/),[mM] / [h·kg],2.11,159963,DB00898,Ethanol
,3358883,peak blood-concentrations,"The peak blood-concentrations, estimated by analysis of breath, ranged from 40-242 mumol l-1 compared with 1.7-6.5 mumol l-1 after placebo.","Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358883/),[μM] / [l],40-242,159964,DB00898,Ethanol
,3358883,peak blood-concentrations,"The peak blood-concentrations, estimated by analysis of breath, ranged from 40-242 mumol l-1 compared with 1.7-6.5 mumol l-1 after placebo.","Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358883/),[μM] / [l],1.7-6.5,159965,DB00898,Ethanol
,7124456,clearance,"The average dialysator clearance of ethylene glycol at a blood flow of 200 ml/min was 145 and 148 ml/min, respectively.",Studies on ethylene glycol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124456/),[ml] / [min],145,160416,DB00898,Ethanol
,7124456,clearance,"The average dialysator clearance of ethylene glycol at a blood flow of 200 ml/min was 145 and 148 ml/min, respectively.",Studies on ethylene glycol poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124456/),[ml] / [min],148,160417,DB00898,Ethanol
,7124456,blood flow,"The average dialysator clearance of ethylene glycol at a blood flow of 200 ml/min was 145 and 148 ml/min, respectively.",Studies on ethylene glycol poisoning. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124456/),[ml] / [min],145,160418,DB00898,Ethanol
,7124456,blood flow,"The average dialysator clearance of ethylene glycol at a blood flow of 200 ml/min was 145 and 148 ml/min, respectively.",Studies on ethylene glycol poisoning. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124456/),[ml] / [min],148,160419,DB00898,Ethanol
,7124456,volume of distribution,"Assuming a volume of distribution of ethylene glycol of 0.7 l/kg, the dialysator represented about 92 and 95%, respectively, of the total body clearance of ethylene glycol during ethanol treatment.",Studies on ethylene glycol poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124456/),[l] / [kg],0.7,160420,DB00898,Ethanol
,29505133,half-life,"(i) Nonzero PEth levels were observed before alcohol dosing for most participants, despite 7 days of alcohol use monitoring; (ii) 0.4 and 0.8 g/kg doses of alcohol produced proportional increases in PEth levels in all but 1 participant; (iii) the initial rate of synthesis of both PEth homologues did not differ between the 2 doses, but was greater for PEth 16:0/18:2 than PEth 16:0/18:1 at both doses; (iv) the mean AUC of both PEth homologues was higher at 0.8 g/kg than at 0.4 g/kg; (v) the mean AUC of 16:0/18:2 was greater than that of PEth 16:0/18:1 at both alcohol doses; (vi) the mean half-life of PEth 16:0/18:1 was longer than that of PEth 16:0/18:2 (7.8 ± 3.3 [SD] days and 6.4 ± 5.0 [SD] days, respectively); and (vii) there were no sex differences in PEth 16:0/18:1 or 16:0/18:2 pharmacokinetics.",Differences in the Synthesis and Elimination of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 After Acute Doses of Alcohol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505133/),d,7.8,161234,DB00898,Ethanol
,29505133,half-life,"(i) Nonzero PEth levels were observed before alcohol dosing for most participants, despite 7 days of alcohol use monitoring; (ii) 0.4 and 0.8 g/kg doses of alcohol produced proportional increases in PEth levels in all but 1 participant; (iii) the initial rate of synthesis of both PEth homologues did not differ between the 2 doses, but was greater for PEth 16:0/18:2 than PEth 16:0/18:1 at both doses; (iv) the mean AUC of both PEth homologues was higher at 0.8 g/kg than at 0.4 g/kg; (v) the mean AUC of 16:0/18:2 was greater than that of PEth 16:0/18:1 at both alcohol doses; (vi) the mean half-life of PEth 16:0/18:1 was longer than that of PEth 16:0/18:2 (7.8 ± 3.3 [SD] days and 6.4 ± 5.0 [SD] days, respectively); and (vii) there were no sex differences in PEth 16:0/18:1 or 16:0/18:2 pharmacokinetics.",Differences in the Synthesis and Elimination of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 After Acute Doses of Alcohol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29505133/),d,6.4,161235,DB00898,Ethanol
,19453703,oral clearance,"Carisbamate was well tolerated, and its mean oral clearance and half-life were similar in both groups, ranging from 35.1-41.4 ml/h/kg and 11.5-12.8 h.",Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19453703/),[ml] / [h·kg],35.1-41.4,161491,DB00898,Ethanol
,19453703,half-life,"Carisbamate was well tolerated, and its mean oral clearance and half-life were similar in both groups, ranging from 35.1-41.4 ml/h/kg and 11.5-12.8 h.",Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19453703/),h,11.5-12.8,161492,DB00898,Ethanol
,16300915,Tmax,"Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively.",The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300915/),min,10,161522,DB00898,Ethanol
,16300915,Tmax,"Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively.",The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300915/),min,5,161523,DB00898,Ethanol
,16300915,Cmax,"Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively.",The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300915/),[ng] / [ml],126.72,161524,DB00898,Ethanol
,16300915,Cmax,"Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively.",The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300915/),[ng] / [ml],104.29,161525,DB00898,Ethanol
,16300915,AUC(0-infinity),"Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively.",The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300915/),[ng] / [ml],1020.33,161526,DB00898,Ethanol
,16300915,AUC(0-infinity),"Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively.",The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16300915/),[ng] / [ml],235.81,161527,DB00898,Ethanol
,22481061,maximum solubility,The maximum solubility of aPPD in ethanol was 68.4 mg/ml.,A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22481061/),[mg] / [ml],68.4,161610,DB00898,Ethanol
,22481061,T(max),"aPPD administered at a dose of 70 mg/kg yielded a T(max) of approximately 40 min and a C(max) value of 3.9 ± 1.4 μg/ml, and no toxicity was observed.",A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22481061/),min,40,161611,DB00898,Ethanol
,22481061,C(max),"aPPD administered at a dose of 70 mg/kg yielded a T(max) of approximately 40 min and a C(max) value of 3.9 ± 1.4 μg/ml, and no toxicity was observed.",A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22481061/),[μg] / [ml],3.9,161612,DB00898,Ethanol
,20970943,extraction efficiency,The extraction efficiency for PGG at 1 μg/mL in mouse plasma was 70.0±1.3% (n=5).,Preparation of penta-O-galloyl-β-D-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970943/),%,70.0,162786,DB00898,Ethanol
,20970943,limit of detection (LOD),The limit of detection (LOD) for PGG was approximately 0.2 μg/mL.,Preparation of penta-O-galloyl-β-D-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970943/),[μg] / [ml],0.2,162787,DB00898,Ethanol
,20970943,peak plasma PGG concentrations (C(max)),The peak plasma PGG concentrations (C(max)) were approximately 3-4 μM at a dose of 0.5 mg per mouse (∼20 mg/kg) at 2 h post-injection (T(max)).,Preparation of penta-O-galloyl-β-D-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970943/),μM,3-4,162788,DB00898,Ethanol
,8382069,BEC,"On admission, the BEC ranged from 0.21 g/kg to 3.26 g/kg and the SMC ranged from 5 mg/kg to 44 mg/kg.",[Methanol level and methanol elimination in alcoholic patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382069/),,0.21,163135,DB00898,Ethanol
,8382069,BEC,"On admission, the BEC ranged from 0.21 g/kg to 3.26 g/kg and the SMC ranged from 5 mg/kg to 44 mg/kg.",[Methanol level and methanol elimination in alcoholic patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382069/),g,3.26,163136,DB00898,Ethanol
,8382069,elimination constants,"After the ethanol concentration had fallen to zero, methanol elimination was found to follow first order kinetics; the elimination constants ranged from 0.592 h-1 to 0.209 h-1, corresponding to elimination half-life values of 1.2 h to 3.3 h.",[Methanol level and methanol elimination in alcoholic patients]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382069/),1/[h],0.592,163137,DB00898,Ethanol
,8382069,elimination constants,"After the ethanol concentration had fallen to zero, methanol elimination was found to follow first order kinetics; the elimination constants ranged from 0.592 h-1 to 0.209 h-1, corresponding to elimination half-life values of 1.2 h to 3.3 h.",[Methanol level and methanol elimination in alcoholic patients]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382069/),1/[h],0.209,163138,DB00898,Ethanol
,8382069,elimination half-life,"After the ethanol concentration had fallen to zero, methanol elimination was found to follow first order kinetics; the elimination constants ranged from 0.592 h-1 to 0.209 h-1, corresponding to elimination half-life values of 1.2 h to 3.3 h.",[Methanol level and methanol elimination in alcoholic patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382069/),h,1.2,163139,DB00898,Ethanol
,8382069,elimination half-life,"After the ethanol concentration had fallen to zero, methanol elimination was found to follow first order kinetics; the elimination constants ranged from 0.592 h-1 to 0.209 h-1, corresponding to elimination half-life values of 1.2 h to 3.3 h.",[Methanol level and methanol elimination in alcoholic patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382069/),h,3.3,163140,DB00898,Ethanol
,25586675,z,"Optimized formulation had molar ratio of 60:30:8:2 (HSPC:Chol:DSPG:mPEG-DSPE) with entrapment efficiency ∼83%, particle size below 200 nm and zeta potential about -20 mV.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),,20,163179,DB00898,Ethanol
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.675,163180,DB00898,Ethanol
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.532,163181,DB00898,Ethanol
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.192,163182,DB00898,Ethanol
,10530655,SCs,All initial EtOH SCs were 0. EtOH SCs were higher after IV administration.,A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),,0,163301,DB00898,Ethanol
,10530655,peak SC,Mean peak SC was 103.6 mg/dL after IV administration and 71.3 mg/dL after PO administration (p<0.0001).,A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),[mg] / [dl],103.6,163302,DB00898,Ethanol
,10530655,peak SC,Mean peak SC was 103.6 mg/dL after IV administration and 71.3 mg/dL after PO administration (p<0.0001).,A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),[mg] / [dl],71.3,163303,DB00898,Ethanol
,10530655,time to peak,Mean time to peak was 46.5 minutes after IV administration and 103.5 minutes after PO administration (p<0.0001).,A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),min,46.5,163304,DB00898,Ethanol
,10530655,time to peak,Mean time to peak was 46.5 minutes after IV administration and 103.5 minutes after PO administration (p<0.0001).,A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),min,103.5,163305,DB00898,Ethanol
,10530655,Total area under the curve,"Total area under the curve was 17,440 min-mg/dL after IV administration and 13,875 min-mg/dL after PO administration (p<0.003).",A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),[min-mg] / [dl],"17,440",163306,DB00898,Ethanol
,10530655,Total area under the curve,"Total area under the curve was 17,440 min-mg/dL after IV administration and 13,875 min-mg/dL after PO administration (p<0.003).",A comparison of the bioavailabilities of oral and intravenous ethanol in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530655/),[min-mg] / [dl],"13,875",163307,DB00898,Ethanol
,24474574,diameter,Median diameter and original volume were 39.5 mm (range 2.7-21.8) and 14.79 mL (3.42-343.30).,Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),mm,39.5,163390,DB00898,Ethanol
,24474574,CEA,"Median cyst fluid CEA and amylase values were 17.10 ng/mL (0.5-14127.5) and 73.50 U/L (3.1-91,590).",Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),[ng] / [ml],17.10,163391,DB00898,Ethanol
,24474574,Peak plasma paclitaxel concentration,"Peak plasma paclitaxel concentration values were observed between 2 and 7 h, ranging from 0.45 to 14.73 ng/mL.",Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),[ng] / [ml],0.45 to 14.73,163392,DB00898,Ethanol
,24474574,concentration,The highest concentration (17.10 ng/mL at 0 h) was observed in a patient who had intracystic bleeding.,Systemic effect of endoscopic ultrasonography-guided pancreatic cyst ablation with ethanol and paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24474574/),[ng] / [ml],17.10,163393,DB00898,Ethanol
,20738181,relative oral bioavailability,"The developed SMEDDS formulation improved the oral bioavailability of curcumin significantly, and the relative oral bioavailability of SMEDDS compared with curcumin suspension was 1213%.",Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20738181/),%,1213,163752,DB00898,Ethanol
>,19333762,solubility,"The targeted solubility (>20 mg/ml) of sildenafil citrate was achieved with cosolvent systems S1, S3, and S5 and with microemulsion systems ME3-ME6.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],20,163937,DB00898,Ethanol
,19333762,saturated solubility,"The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],22.98,163938,DB00898,Ethanol
,19333762,saturated solubility,"The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],23.79,163939,DB00898,Ethanol
,19333762,t (max),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),h,0.75,163940,DB00898,Ethanol
,19333762,AUC((0-infinity)),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[h·ng] / [ml],"1,412.42",163941,DB00898,Ethanol
,19333762,t (max),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),h,1.25,163942,DB00898,Ethanol
,19333762,AUC((0-infinity)),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[h·ng] / [ml],"1,251.14",163943,DB00898,Ethanol
,19333762,relative bioavailability,The relative bioavailability was 112.89%.,Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),%,112.89,163944,DB00898,Ethanol
,18059045,flow-rate,The flow-rate was set at 1 mL/min and the eluent was detected at 350 nm for both quercitrin and isoquercitrin.,HPLC analysis and pharmacokinetic study of quercitrin and isoquercitrin in rat plasma after administration of Hypericum japonicum thunb. extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059045/),[ml] / [min],1,164162,DB00898,Ethanol
,18059045,extraction recoveries,"The mean extraction recoveries were 73 and 61% for quercitrin and isoquercitrin, respectively.",HPLC analysis and pharmacokinetic study of quercitrin and isoquercitrin in rat plasma after administration of Hypericum japonicum thunb. extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059045/),%,73,164163,DB00898,Ethanol
,18059045,extraction recoveries,"The mean extraction recoveries were 73 and 61% for quercitrin and isoquercitrin, respectively.",HPLC analysis and pharmacokinetic study of quercitrin and isoquercitrin in rat plasma after administration of Hypericum japonicum thunb. extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059045/),%,61,164164,DB00898,Ethanol
,24316521,flow rate,"The method showed adequate separation for lumefantrine and desbutyl lumefantrine and best resolution was achieved with Supelco Discovery HS C18 RP (150mm×4.6mm, 5μm) column using acetonitrile and 0.05% trifluroacetic acid (70:30, v/v) as a mobile phase pumped at a flow rate of 1.0ml/min and wavelength of 335nm.","Method development and validation for simultaneous determination of lumefantrine and its major metabolite, desbutyl lumefantrine in human plasma using RP-HPLC/UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316521/),[ml] / [min],1.0,164328,DB00898,Ethanol
,7168619,Half-life,Half-life of alcohol was shown to be 17 hours in this child.,[Poisoning by externally-administered ethanol in an infant]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7168619/),h,17,164449,DB00898,Ethanol
,2112344,clearance rates from blood,Alcohol clearance rates from blood for the two groups were: 130 +/- 3 mg/kg/hr for the 1.0-g/kg body weight group and 151 +/- 3 mg/kg/hr for the 2.0-g/kg body weight group.,Acute alcohol infusion does not alter plasma gonadotropins or prolactin in ovariectomized rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2112344/),[mg] / [h·kg],130,165395,DB00898,Ethanol
,2112344,clearance rates from blood,Alcohol clearance rates from blood for the two groups were: 130 +/- 3 mg/kg/hr for the 1.0-g/kg body weight group and 151 +/- 3 mg/kg/hr for the 2.0-g/kg body weight group.,Acute alcohol infusion does not alter plasma gonadotropins or prolactin in ovariectomized rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2112344/),[mg] / [h·kg],151,165396,DB00898,Ethanol
,28437888,oral bioavailability,"The oral bioavailability of TL in TNBS-treated rats was calculated to be as low as ca. 6.5%, and the poor oral absorption of TL may be a limitation of the treatment for IBD.",Protective effects of tranilast on experimental colitis in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28437888/),%,6.5,165515,DB00898,Ethanol
,23305849,V(max),"Population pharmacokinetic estimates of V(max) and K(m) were 3.256 mmol min(-1) and 0.8183 mmol L(-1), respectively.",Population pharmacokinetics of multiple alcohol intake in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305849/),[mM] / [min],3.256,165889,DB00898,Ethanol
,23305849,K(m),"Population pharmacokinetic estimates of V(max) and K(m) were 3.256 mmol min(-1) and 0.8183 mmol L(-1), respectively.",Population pharmacokinetics of multiple alcohol intake in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305849/),[mM] / [l],0.8183,165890,DB00898,Ethanol
,23305849,V(d)/F,"V(d)/F was estimated to be 77.0 L, and K(a) was 0.0767 min(-1).",Population pharmacokinetics of multiple alcohol intake in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305849/),l,77.0,165891,DB00898,Ethanol
,23305849,K(a),"V(d)/F was estimated to be 77.0 L, and K(a) was 0.0767 min(-1).",Population pharmacokinetics of multiple alcohol intake in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23305849/),1/[min],0.0767,165892,DB00898,Ethanol
,3621059,renal clearance,The renal clearance of ethanol by the fetus was 0.43 +/- 0.06 mL/min.,The role of fetal urinary excretion in the transfer of ethanol into amniotic fluid after maternal administration of ethanol to the near-term pregnant ewe. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621059/),[ml] / [min],0.43,166049,DB00898,Ethanol
,16781900,flow rate,The flow rate was 0.8 ml min(-1).,A rapid reversed phase high-performance liquid chromatographic method for determination of sophoridine in rat plasma and its application to pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16781900/),[ml] / [min],0.8,166098,DB00898,Ethanol
,8674157,flow rate,"Optimal separation was achieved isocratically with a mobile phase consisting of n-hexane/anhydrous ethanol (65/35, v/v) at a flow rate of 0.9 ml/min, with the column being thermostated at +35 degrees C (UV detection at 257 nm).",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),[ml] / [min],0.9,167227,DB00898,Ethanol
,8674157,retention times,"Under these conditions, retention times were approximately 17, 28, 31 and 76 min for R-Rog, S-Rog, R-Nox and S-Nox, respectively.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),min,17,167228,DB00898,Ethanol
,8674157,retention times,"Under these conditions, retention times were approximately 17, 28, 31 and 76 min for R-Rog, S-Rog, R-Nox and S-Nox, respectively.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),min,28,167229,DB00898,Ethanol
,8674157,retention times,"Under these conditions, retention times were approximately 17, 28, 31 and 76 min for R-Rog, S-Rog, R-Nox and S-Nox, respectively.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),min,31,167230,DB00898,Ethanol
,8674157,retention times,"Under these conditions, retention times were approximately 17, 28, 31 and 76 min for R-Rog, S-Rog, R-Nox and S-Nox, respectively.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),min,76,167231,DB00898,Ethanol
,8674157,retention time,S-aminoglutethimide (S-Ag) served as the internal standard (retention time 70 min).,Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),min,70,167232,DB00898,Ethanol
,8674157,detection limit,"The detection limit was 2.5 microM for R-Rog, 0.5 microM for S-Rog, 0.25 microM for R-Nox and 0.5 microM for S-Nox.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),μM,2.5,167233,DB00898,Ethanol
,8674157,detection limit,"The detection limit was 2.5 microM for R-Rog, 0.5 microM for S-Rog, 0.25 microM for R-Nox and 0.5 microM for S-Nox.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),μM,0.5,167234,DB00898,Ethanol
,8674157,detection limit,"The detection limit was 2.5 microM for R-Rog, 0.5 microM for S-Rog, 0.25 microM for R-Nox and 0.5 microM for S-Nox.",Development and validation of a chiral high-performance liquid chromatography assay for rogletimide and rogletimide-N-oxide isomers in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8674157/),μM,0.25,167235,DB00898,Ethanol
,2712894,half-life,The calculated half-life of isopropanol was 7.3 hours.,Isopropanol ingestion: case report with pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712894/),h,7.3,167270,DB00898,Ethanol
,12449497,constant plasma concentrations,Ethanol was administered as a constant rate infusion resulting in constant plasma concentrations of 0.5 g/l.,"Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[g] / [l],0.5,167442,DB00898,Ethanol
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],76,167443,DB00898,Ethanol
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],12,167444,DB00898,Ethanol
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],512,167445,DB00898,Ethanol
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],113,167446,DB00898,Ethanol
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],44,167447,DB00898,Ethanol
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],175,167448,DB00898,Ethanol
,7191273,half-life,"After oral administration, 3H-fenoterol was absorbed quickly, reaching a maximum concentration level within 0.5 h after administration, and decreased thereafter with a half-life of about 2 h.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),h,2,167846,DB00898,Ethanol
,7191273,rates of excretion,"The rates of excretion in urine and in feces in 72 h were ca. 81% and 16%, respectively, with i.v. administration and ca. 45% and 45%, respectively, with oral administration.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,81,167847,DB00898,Ethanol
,7191273,rates of excretion,"The rates of excretion in urine and in feces in 72 h were ca. 81% and 16%, respectively, with i.v. administration and ca. 45% and 45%, respectively, with oral administration.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,16,167848,DB00898,Ethanol
,7191273,rates of excretion,"The rates of excretion in urine and in feces in 72 h were ca. 81% and 16%, respectively, with i.v. administration and ca. 45% and 45%, respectively, with oral administration.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,45,167849,DB00898,Ethanol
,7191273,binding rate,"As a result, the binding rate with serum protein was 3--5%.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,3,167850,DB00898,Ethanol
,17936510,maximum blood ethanol concentration,The maximum blood ethanol concentration was 0.0819+/-0.0184 g/dl for women and 0.0841+/-0.0155 g/dl for men.,Ethanol elimination rates in men and women in consideration of the calculated liver weight. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17936510/),[g] / [dl],0.0819,168309,DB00898,Ethanol
,17936510,maximum blood ethanol concentration,The maximum blood ethanol concentration was 0.0819+/-0.0184 g/dl for women and 0.0841+/-0.0155 g/dl for men.,Ethanol elimination rates in men and women in consideration of the calculated liver weight. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17936510/),[g] / [dl],0.0841,168310,DB00898,Ethanol
,17936510,hourly elimination rates,"In relation to the liver weight, the hourly elimination rates were 5.008+/-0.678 g/kg liver/h for women and 4.854+/-0.659 g/kg liver/h for men, and were not statistically significant.",Ethanol elimination rates in men and women in consideration of the calculated liver weight. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17936510/),[g] / [h·kg·liver],5.008,168311,DB00898,Ethanol
,17936510,hourly elimination rates,"In relation to the liver weight, the hourly elimination rates were 5.008+/-0.678 g/kg liver/h for women and 4.854+/-0.659 g/kg liver/h for men, and were not statistically significant.",Ethanol elimination rates in men and women in consideration of the calculated liver weight. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17936510/),[g] / [h·kg·liver],4.854,168312,DB00898,Ethanol
,15135856,k(12),"The k(12) (0.20 =/- 0.26 h(-1)) was almost twice faster than k(21) (0, h(-1)).",Elimination kinetics of ethanol in pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15135856/),1/[h],0.20,169046,DB00898,Ethanol
,15135856,k(21),"The k(12) (0.20 =/- 0.26 h(-1)) was almost twice faster than k(21) (0, h(-1)).",Elimination kinetics of ethanol in pregnant women. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15135856/),1/[h],0,169047,DB00898,Ethanol
,15135856,V(max),The V(max)(EtOH) was 237.6 +/- 71.5 microgml(-1)h(-1) and K(m)(EtOH) was 3.7 +/- 4.7 microgml(-1).,Elimination kinetics of ethanol in pregnant women. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15135856/),1/[μgml],237.6,169048,DB00898,Ethanol
,15135856,K(m),The V(max)(EtOH) was 237.6 +/- 71.5 microgml(-1)h(-1) and K(m)(EtOH) was 3.7 +/- 4.7 microgml(-1).,Elimination kinetics of ethanol in pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15135856/),1/[μgml],3.7,169049,DB00898,Ethanol
,21425954,solubility,"Sildenafil displayed a high solubility of 124 mg/mL in the microemulsion consisting of 40% oleic acid, 10% H(2)O, and 50% Tween 80:ethanol (EA) (at a 1:4 weight ratio).",Rapid-onset sildenafil nasal spray carried by microemulsion systems: in vitro evaluation and in vivo pharmacokinetic studies in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425954/),[mg] / [ml],124,169246,DB00898,Ethanol
,12700396,steady-state ethanol concentrations,"Pharmacokinetic analysis of GHB concentrations with a two-compartment model with Michaelis-Menten (M-M) elimination in rats receiving a bolus of GHB (400 mg/kg, i.v.) in addition to steady-state ethanol concentrations (300-3000 microg/ml) (n = 12) or saline (n = 15) showed no marked differences in the area under the curve.",Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12700396/),[μg] / [ml],300-3000,169369,DB00898,Ethanol
,12700396,steady state concentrations,The nature of the pharmacodynamic interaction was studied using isobolographs and an interaction model for the loss of the startle and righting reflex and a reaction to a painful tail clamp in rats receiving combinations of steady state concentrations of ethanol (1000-3000 microg/ml) and GHB (200-1400 microg/ml).,Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12700396/),[μg] / [ml],1000-3000,169370,DB00898,Ethanol
,12700396,steady state concentrations,The nature of the pharmacodynamic interaction was studied using isobolographs and an interaction model for the loss of the startle and righting reflex and a reaction to a painful tail clamp in rats receiving combinations of steady state concentrations of ethanol (1000-3000 microg/ml) and GHB (200-1400 microg/ml).,Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12700396/),[μg] / [ml],200-1400,169371,DB00898,Ethanol
,19874116,t(1/2),"According to the HPLC results, t(1/2) = 2.36 +/- 0.18 h and K(e) = 0.32 +/- 0.02 h(-1) for BR-AEA in rabbit plasma.",Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874116/),h,2.36,169620,DB00898,Ethanol
,19874116,K(e),"According to the HPLC results, t(1/2) = 2.36 +/- 0.18 h and K(e) = 0.32 +/- 0.02 h(-1) for BR-AEA in rabbit plasma.",Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874116/),1/[h],0.32,169621,DB00898,Ethanol
,19874116,t(1/2),"Thus, BR-AEA has a greater half-life compared with salbutamol (t(1/2) = 0.66 +/- 0.08 h).",Pharmacokinetic parameters and a theoretical study about metabolism of BR-AEA (a salbutamol derivative) in rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874116/),h,0.66,169622,DB00898,Ethanol
,17339864,maximum d-MPH plasma concentration (C(max),"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ng] / [ml],15.3,169815,DB00898,Ethanol
,17339864,maximum d-MPH plasma concentration (C(max),"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ng] / [ml],21.5,169816,DB00898,Ethanol
,17339864,maximum d-MPH plasma concentration (C(max),"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ng] / [ml],21.4,169817,DB00898,Ethanol
,17339864,area under the concentration-time curve,"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ml·ng] / [h],82.9,169818,DB00898,Ethanol
,17339864,area under the concentration-time curve,"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),,105.2,169819,DB00898,Ethanol
,17339864,area under the concentration-time curve,"Ethanol after or before MPH significantly (P<0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C(max) (+/-SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2).",Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339864/),[ml·ng] / [h],102.9,169820,DB00898,Ethanol
greater,3890594,peak blood alcohol levels,"Select doses of ethanol (25%, W/V) were administered to female ferrets (Mustela putorius) by gastric intubation to determine dosage corresponding to peak blood alcohol levels (BAL) greater than 100 mg/100 ml of blood (mg%) for an extended duration.",Pharmacokinetics of ethanol in the ferret. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3890594/),mg,100,170302,DB00898,Ethanol
,3890594,peak BAL,Low doses (6 ml/kg) resulted in peak BAL of 202 mg% in 1.5 hr and 50 mg% after 12 hr.,Pharmacokinetics of ethanol in the ferret. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3890594/),mg%,202,170303,DB00898,Ethanol
,3890594,peak BAL,Low doses (6 ml/kg) resulted in peak BAL of 202 mg% in 1.5 hr and 50 mg% after 12 hr.,Pharmacokinetics of ethanol in the ferret. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3890594/),mg%,50,170304,DB00898,Ethanol
,3890594,peak BAL,Intermediate doses (8 ml/kg) resulted in peak BAL of 253 mg% in 1.4 hr and 89 mg% after 12 hr.,Pharmacokinetics of ethanol in the ferret. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3890594/),mg%,253,170305,DB00898,Ethanol
,3890594,peak BAL,Intermediate doses (8 ml/kg) resulted in peak BAL of 253 mg% in 1.4 hr and 89 mg% after 12 hr.,Pharmacokinetics of ethanol in the ferret. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3890594/),mg%,89,170306,DB00898,Ethanol
,7205625,peak blood ethanol concentration,The mean peak blood ethanol concentration was 3.36 +/- 0.14 mg/ml.,Ethanol and functional tolerance: interactions with pimozide and clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205625/),[mg] / [ml],3.36,170430,DB00898,Ethanol
,7205625,rate of clearance,The rate of clearance of ethanol from blood was found to be 0.34 +/- 0.01 mg/ml/hr in ethanol vapor-treated and control animals when ethanol was administered acutely 48 hr after the inhalation period.,Ethanol and functional tolerance: interactions with pimozide and clonidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205625/),[mg] / [h·ml],0.34,170431,DB00898,Ethanol
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,62.9,170668,DB00898,Ethanol
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,61.3,170669,DB00898,Ethanol
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,57.6,170670,DB00898,Ethanol
,10704025,absolute recoveries,"The extraction procedure resulted in absolute recoveries of 62.9 and 61.3% for (R)- and (S)-PPF, respectively, and of 57.6 and 56.5% for (R)- and (S)-PPF-5OH, respectively.",Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704025/),%,56.5,170671,DB00898,Ethanol
,1905732,run times,The chromatographic procedures allow run times ranging from 2.1-7.3 min using different reversed-phase materials as supports and eluents based on acetonitrile or isopropanol-diethanolamine-EDTA.,High-performance liquid chromatographic procedures for the quantitative analysis of 15 tetracycline derivatives in small blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905732/),min,2.1-7.3,170772,DB00898,Ethanol
,1905732,Detection limits,Detection limits are estimated at 10-500 ng/mL according to the derivative analyzed.,High-performance liquid chromatographic procedures for the quantitative analysis of 15 tetracycline derivatives in small blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905732/),[ng] / [ml],10-500,170773,DB00898,Ethanol
,1905732,recovery,The recovery of 13 derivatives from spiked plasma samples (100 micrograms/mL) reached 85-94% (n = 5).,High-performance liquid chromatographic procedures for the quantitative analysis of 15 tetracycline derivatives in small blood samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905732/),%,85-94,170774,DB00898,Ethanol
,11755750,Limit of quantification (LOQ),Limit of quantification (LOQ) was set at 0.25 nmol/l (0.10 microg/l).,Enantioselective determination of felodipine in human plasma by chiral normal-phase liquid chromatography and electrospray ionisation mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11755750/),[nM] / [l],0.25,170807,DB00898,Ethanol
,11755750,Limit of quantification (LOQ),Limit of quantification (LOQ) was set at 0.25 nmol/l (0.10 microg/l).,Enantioselective determination of felodipine in human plasma by chiral normal-phase liquid chromatography and electrospray ionisation mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11755750/),μ,0.10,170808,DB00898,Ethanol
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μM,28.,171538,DB00898,Ethanol
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μ,1,171539,DB00898,Ethanol
,3067620,area under the curve (AUC),"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),%·delta·min·t,5142,171540,DB00898,Ethanol
,3067620,AUC,"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),bpm·min,1622,171541,DB00898,Ethanol
,7624263,time to peak ethanol plasma concentrations,"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),h,1.1,171875,DB00898,Ethanol
,7624263,time to peak ethanol plasma concentrations,"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),h,1.3,171876,DB00898,Ethanol
,7624263,peak ethanol concentrations,"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[mg] / [dl],118,171877,DB00898,Ethanol
,7624263,peak ethanol concentrations,"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[mg] / [dl],114,171878,DB00898,Ethanol
,7624263,ethanol oral clearance (CL/F),"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[ml] / [kg·min],2.9,171879,DB00898,Ethanol
,7624263,ethanol oral clearance (CL/F),"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[ml] / [kg·min],3.4,171880,DB00898,Ethanol
,7624263,area under the curve,"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[h·mg] / [dl],481,171881,DB00898,Ethanol
,7624263,area under the curve,"Mean +/- SD ethanol pharmacokinetics for erythromycin versus placebo were time to peak ethanol plasma concentrations 1.1 +/- 0.4 hours versus 1.3 +/- 0.3 hours, peak ethanol concentrations 118 +/- 18 mg/dl versus 114 +/- 27 mg/dl, ethanol oral clearance (CL/F) 2.9 +/- 0.8 ml/min/kg versus 3.4 +/- 2.2 ml/min/kg, and area under the curve 481 +/- 104 mg.hour/dl versus 465 +/- 132 mg.hour/dl (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[h·mg] / [dl],465,171882,DB00898,Ethanol
,7624263,areas under the effect versus time curve,"Mean +/- SD areas under the effect versus time curve were 35.1 +/- 20.7 cm/hour and 31.5 +/- 18.2 cm/hour for erythromycin and placebo, respectively (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[cm] / [h],35.1,171883,DB00898,Ethanol
,7624263,areas under the effect versus time curve,"Mean +/- SD areas under the effect versus time curve were 35.1 +/- 20.7 cm/hour and 31.5 +/- 18.2 cm/hour for erythromycin and placebo, respectively (p > 0.05).",Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624263/),[cm] / [h],31.5,171884,DB00898,Ethanol
,4006376,peak serum lithium level,"Alcohol did, however, increase the peak serum lithium level in nine of 10 subjects, from a mean of 0.62 mEq/L in the placebo condition to 0.70 mEq/L in the alcohol condition.",Effect of acute alcohol consumption on lithium kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006376/),[meq] / [l],0.62,173523,DB00898,Ethanol
,4006376,peak serum lithium level,"Alcohol did, however, increase the peak serum lithium level in nine of 10 subjects, from a mean of 0.62 mEq/L in the placebo condition to 0.70 mEq/L in the alcohol condition.",Effect of acute alcohol consumption on lithium kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006376/),[meq] / [l],0.70,173524,DB00898,Ethanol
,32062561,relative elimination half-life (T1/2re),"The relative elimination half-life (T1/2re) calculated by compound concentration of 7:3 FTCA and PFOA was longest in kidney tissue (8.60 and 23.9 d, respectively), while their absolute elimination half-life (T1/2ab) of 7:3 FTCA and PFOA calculated by compound amount was longest in kidney tissue (10.41 and 64.1 d, respectively).",Tissue distribution and bioaccumulation of 8:2 fluorotelomer alcohol and its metabolites in pigs after oral exposure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062561/),d,8.60,173550,DB00898,Ethanol
,32062561,relative elimination half-life (T1/2re),"The relative elimination half-life (T1/2re) calculated by compound concentration of 7:3 FTCA and PFOA was longest in kidney tissue (8.60 and 23.9 d, respectively), while their absolute elimination half-life (T1/2ab) of 7:3 FTCA and PFOA calculated by compound amount was longest in kidney tissue (10.41 and 64.1 d, respectively).",Tissue distribution and bioaccumulation of 8:2 fluorotelomer alcohol and its metabolites in pigs after oral exposure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062561/),d,23.9,173551,DB00898,Ethanol
,32062561,absolute elimination half-life (T1/2ab),"The relative elimination half-life (T1/2re) calculated by compound concentration of 7:3 FTCA and PFOA was longest in kidney tissue (8.60 and 23.9 d, respectively), while their absolute elimination half-life (T1/2ab) of 7:3 FTCA and PFOA calculated by compound amount was longest in kidney tissue (10.41 and 64.1 d, respectively).",Tissue distribution and bioaccumulation of 8:2 fluorotelomer alcohol and its metabolites in pigs after oral exposure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062561/),d,10.41,173552,DB00898,Ethanol
,32062561,absolute elimination half-life (T1/2ab),"The relative elimination half-life (T1/2re) calculated by compound concentration of 7:3 FTCA and PFOA was longest in kidney tissue (8.60 and 23.9 d, respectively), while their absolute elimination half-life (T1/2ab) of 7:3 FTCA and PFOA calculated by compound amount was longest in kidney tissue (10.41 and 64.1 d, respectively).",Tissue distribution and bioaccumulation of 8:2 fluorotelomer alcohol and its metabolites in pigs after oral exposure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062561/),d,64.1,173553,DB00898,Ethanol
,32062561,T1/2re,"The T1/2re and T1/2ab for PFHpA was longest in heart tissue (19.3 d and 30.26 d, respectively).",Tissue distribution and bioaccumulation of 8:2 fluorotelomer alcohol and its metabolites in pigs after oral exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062561/),d,19.3,173554,DB00898,Ethanol
,32062561,T1/2ab,"The T1/2re and T1/2ab for PFHpA was longest in heart tissue (19.3 d and 30.26 d, respectively).",Tissue distribution and bioaccumulation of 8:2 fluorotelomer alcohol and its metabolites in pigs after oral exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062561/),d,30.26,173555,DB00898,Ethanol
,6487367,hepatic blood flow rate,"In each of the infusion periods the hepatic blood flow rate was varied experimentally (10 and 17 ml/min, respectively).",Current models of hepatic pharmacokinetics: flow effects on kinetic constants of ethanol elimination in perfused rat liver. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487367/),[ml] / [min],10,174473,DB00898,Ethanol
,6487367,hepatic blood flow rate,"In each of the infusion periods the hepatic blood flow rate was varied experimentally (10 and 17 ml/min, respectively).",Current models of hepatic pharmacokinetics: flow effects on kinetic constants of ethanol elimination in perfused rat liver. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487367/),[ml] / [min],17,174474,DB00898,Ethanol
,1280178,EC50,Nebulized RP 58802B produced a rapid onset and long lasting inhibition of histamine-induced bronchospasm in the anaesthetized guinea-pig (EC50 = 3.2 +/- 0.9 micrograms/ml; duration greater than 90 min).,"RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),[μg] / [ml],3.2,174504,DB00898,Ethanol
,1280178,time to severe dyspnoea,"In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug.","RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),s,170,174505,DB00898,Ethanol
,1280178,time to severe dyspnoea,"In conscious guinea-pigs, RP 58802B (5 or 25 mg/kg, p.o. 60 min before challenge) significantly attenuated antigen-induced dyspnoea with the time to severe dyspnoea increasing from 170 +/- 32 to 325 +/- 32 s at the higher dose of drug.","RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1280178/),s,325,174506,DB00898,Ethanol
,1623692,peak blood ethanol concentration,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[mg] / [dl],106.45,174685,DB00898,Ethanol
,1623692,peak blood ethanol concentration,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[mg] / [dl],124.24,174686,DB00898,Ethanol
,1623692,area under the ethanol concentration versus time curve,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[h·mg] / [dl],365.67,174687,DB00898,Ethanol
,1623692,area under the ethanol concentration versus time curve,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[h·mg] / [dl],475.07,174688,DB00898,Ethanol
,1623692,area under the effect versus time curve,"Compared with placebo, verapamil significantly increased area under the effect versus time curve (10.19 +/- 7.6 to 13.83 +/- 7.81 cm.hr, p less than 0.002) but did not change the peak effect or time to peak effect.",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),cm·h,10.19,174689,DB00898,Ethanol
,1623692,area under the effect versus time curve,"Compared with placebo, verapamil significantly increased area under the effect versus time curve (10.19 +/- 7.6 to 13.83 +/- 7.81 cm.hr, p less than 0.002) but did not change the peak effect or time to peak effect.",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),cm·h,13.83,174690,DB00898,Ethanol
,8569424,time to 50% emptying,"With ranitidine, we found an acceleration of gastric emptying in 7 of 8 subjects, with 20% shortening of the time to 50% emptying (51.8 +/- 4.1 min vs 64.3 +/- 3.4, without ranitidine; P < .001 by paired t test).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),min,51.8,174842,DB00898,Ethanol
,8569424,time to 50% emptying,"With ranitidine, we found an acceleration of gastric emptying in 7 of 8 subjects, with 20% shortening of the time to 50% emptying (51.8 +/- 4.1 min vs 64.3 +/- 3.4, without ranitidine; P < .001 by paired t test).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),,64.3,174843,DB00898,Ethanol
,8569424,first pass metabolism,"As a result, after oral but not intravenous alcohol administration, ranitidine increased blood alcohol concentrations (29 +/- 4 mg/dl vs 22 +/- 3, without ranitidine; P < .02), with a corresponding decrease in first pass metabolism of ethanol from 107 +/- 16 mg/kg to 47 +/- 16 (P < .01).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),[mg] / [kg],107,174844,DB00898,Ethanol
,8569424,first pass metabolism,"As a result, after oral but not intravenous alcohol administration, ranitidine increased blood alcohol concentrations (29 +/- 4 mg/dl vs 22 +/- 3, without ranitidine; P < .02), with a corresponding decrease in first pass metabolism of ethanol from 107 +/- 16 mg/kg to 47 +/- 16 (P < .01).",Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8569424/),,47,174845,DB00898,Ethanol
,2293339,plasma:whole blood ratio,"The mean plasma:whole blood ratio of ethanol was 1.10:1, range 1.03:1 to 1.24:1 (n = 159).",Distribution of ethanol and water between plasma and whole blood; inter- and intra-individual variations after administration of ethanol by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293339/),,1.10,174887,DB00898,Ethanol
,2293339,water content,The average water content in plasma and whole blood were 91.8% w/w (SD 0.49) and 80.1% w/w (SD 1.03) respectively.,Distribution of ethanol and water between plasma and whole blood; inter- and intra-individual variations after administration of ethanol by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293339/),[%·w] / [w],91.8,174888,DB00898,Ethanol
,2293339,water content,The average water content in plasma and whole blood were 91.8% w/w (SD 0.49) and 80.1% w/w (SD 1.03) respectively.,Distribution of ethanol and water between plasma and whole blood; inter- and intra-individual variations after administration of ethanol by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293339/),[%·w] / [w],80.1,174889,DB00898,Ethanol
,32821096,Q12h,"The optimized invasomal system (ETH9-INV8) was characterized with spherical vesicles (159.9 nm) possessing negative zeta potential (-20.3 mV), promising EE% (81.3%), low Q0.5h (25.4%), high Q12h (85.3%) and the largest steady-state flux (6.4 µg.cm-2h-1).","Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32821096/),%,85.3,174989,DB00898,Ethanol
,32821096,steady-state flux,"The optimized invasomal system (ETH9-INV8) was characterized with spherical vesicles (159.9 nm) possessing negative zeta potential (-20.3 mV), promising EE% (81.3%), low Q0.5h (25.4%), high Q12h (85.3%) and the largest steady-state flux (6.4 µg.cm-2h-1).","Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32821096/),[μg] / [(cm)^2],6.4,174990,DB00898,Ethanol
,32821096,AUC0-24h,"Lower Cmax values, delayed Tmax estimates and greater AUC0-24h folds in adults and geriatrics (≈ 2.18 and 1.69, respectively) were estimated following the transdermal application of ETH9-INV8 system.","Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32821096/),,2,174991,DB00898,Ethanol
>,18826299,water solubility,The LMWC-PTX conjugate contained approximately 12 wt % PTX and showed greatly enhanced water solubility (>1 mg/mL) as compared to native PTX.,Conjugated chitosan as a novel platform for oral delivery of paclitaxel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18826299/),[mg] / [ml],1,175184,DB00898,Ethanol
,18826299,bioavailability,The pharmacokinetic data revealed approximately 42% of bioavailability after oral administration of 5 mg PTX/kg of the conjugate.,Conjugated chitosan as a novel platform for oral delivery of paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18826299/),%,42,175185,DB00898,Ethanol
,11169171,tmax,"The peak of maximum 8-MOP concentration in blood was sharp, rapid and reproducible: tmax of 8-MOP in blood averaged 23+/-3 min, independent of the particular formulation.",Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11169171/),min,23,175366,DB00898,Ethanol
,11169171,Cmax,"Cmax was higher when 8-MOP was presented in dissolved form (solution and capsule formulations, 85+/-29 and 85+/-35 ng/ml, respectively) and lowest with the suspension (42+/-15 ng/ml).",Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11169171/),[ng] / [ml],85,175367,DB00898,Ethanol
,11169171,Cmax,"Cmax was higher when 8-MOP was presented in dissolved form (solution and capsule formulations, 85+/-29 and 85+/-35 ng/ml, respectively) and lowest with the suspension (42+/-15 ng/ml).",Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11169171/),[ng] / [ml],85,175368,DB00898,Ethanol
,11169171,Cmax,"Cmax was higher when 8-MOP was presented in dissolved form (solution and capsule formulations, 85+/-29 and 85+/-35 ng/ml, respectively) and lowest with the suspension (42+/-15 ng/ml).",Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11169171/),[ng] / [ml],42,175369,DB00898,Ethanol
,8341815,clearance,Antipyrine clearance (5.5 +/- 2 l/h) is increased significatively in chronic alcoholics respect to the control group value (3.4 +/- 1 l/h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),[l] / [h],5.5,175858,DB00898,Ethanol
,8341815,clearance,Antipyrine clearance (5.5 +/- 2 l/h) is increased significatively in chronic alcoholics respect to the control group value (3.4 +/- 1 l/h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),[l] / [h],3.4,175859,DB00898,Ethanol
,8341815,Elimination half-life,Elimination half-life of antipyrine in chronic alcoholic groups (7.6 +/- 3 h) is decreased significatively respect to the control group value (11.2 +/- 2 h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),h,7.6,175860,DB00898,Ethanol
,8341815,Elimination half-life,Elimination half-life of antipyrine in chronic alcoholic groups (7.6 +/- 3 h) is decreased significatively respect to the control group value (11.2 +/- 2 h) (p < 0.01).,[Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8341815/),h,11.2,175861,DB00898,Ethanol
,12065226,bioavailability,DMEE was readily absorbed through the skin (bioavailability=72-80%).,Toxicity and pharmacokinetics of 2-(2-dimethylaminoethoxy)ethanol following cutaneous dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065226/),%,72-80,175873,DB00898,Ethanol
,10191953,recovery,The recovery of ferrocene-A from serum using a hexaneisoamyl alcohol mixture was 90%.,Determination of ferrocene-A in the blood serum of rabbits using reversed-phase microcolumn HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10191953/),%,90,176066,DB00898,Ethanol
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,34.08,176657,DB00898,Ethanol
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,30.86,176658,DB00898,Ethanol
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,33.10,176659,DB00898,Ethanol
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,53.48,176660,DB00898,Ethanol
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,57.64,176661,DB00898,Ethanol
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,54.98,176662,DB00898,Ethanol
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.42,176663,DB00898,Ethanol
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.96,176664,DB00898,Ethanol
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.94,176665,DB00898,Ethanol
,12642963,peak concentrations,The peak concentrations of opipramol were 13-15 ng ml-1 (study I) and 28 ng ml-1 (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[ng] / [ml],13-15,176755,DB00898,Ethanol
,12642963,peak concentrations,The peak concentrations of opipramol were 13-15 ng ml-1 (study I) and 28 ng ml-1 (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[ng] / [ml],28,176756,DB00898,Ethanol
,12642963,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was about 170 ng ml-1 h (study I) and about 320 ng ml-1 h (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[h·ng] / [ml],170,176757,DB00898,Ethanol
,12642963,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was about 170 ng ml-1 h (study I) and about 320 ng ml-1 h (study II).,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),[h·ng] / [ml],320,176758,DB00898,Ethanol
,12642963,terminal plasma half-life,The terminal plasma half-life was 11 h.,"Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642963/),h,11,176759,DB00898,Ethanol
,33113433,half-life,Bornestiol reached peak plasma concentration within approximately 60 min after oral administration with a half-life ranging from 72.15 min to 123.69 min.,"Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33113433/),min,72.15,177211,DB00898,Ethanol
,33113433,half-life,Bornestiol reached peak plasma concentration within approximately 60 min after oral administration with a half-life ranging from 72.15 min to 123.69 min.,"Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33113433/),min,123.69,177212,DB00898,Ethanol
,33113433,oral bioavailability,"The peak concentration and area under the concentration-time curve of bornesitol did not rise proportionally with the increasing doses, suggesting a non-linear pharmacokinetics in rats and the oral bioavailability ranged from 28.5%-59.3%.","Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33113433/),%,28.5,177213,DB00898,Ethanol
,33113433,oral bioavailability,"The peak concentration and area under the concentration-time curve of bornesitol did not rise proportionally with the increasing doses, suggesting a non-linear pharmacokinetics in rats and the oral bioavailability ranged from 28.5%-59.3%.","Determination of l-(+)-bornesitol, the hypotensive constituent of Hancornia speciosa, in rat plasma by LC-MS/MS and its application on a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33113433/),%,59.3,177214,DB00898,Ethanol
,25695490,time to peak concentration (Tmax),"Analyses of plasma samples using UHPLC-MS/MS showed mean time to peak concentration (Tmax) of 2.1, 2.4 and 3.3 h and mean peak concentration (Cmax) of 5.3, 48.1 and 2,480 nmol/L for D, DA and DOH, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),h,2.1,178748,DB00898,Ethanol
,25695490,time to peak concentration (Tmax),"Analyses of plasma samples using UHPLC-MS/MS showed mean time to peak concentration (Tmax) of 2.1, 2.4 and 3.3 h and mean peak concentration (Cmax) of 5.3, 48.1 and 2,480 nmol/L for D, DA and DOH, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),h,2.4,178749,DB00898,Ethanol
,25695490,time to peak concentration (Tmax),"Analyses of plasma samples using UHPLC-MS/MS showed mean time to peak concentration (Tmax) of 2.1, 2.4 and 3.3 h and mean peak concentration (Cmax) of 5.3, 48.1 and 2,480 nmol/L for D, DA and DOH, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),h,3.3,178750,DB00898,Ethanol
,25695490,peak concentration (Cmax),"Analyses of plasma samples using UHPLC-MS/MS showed mean time to peak concentration (Tmax) of 2.1, 2.4 and 3.3 h and mean peak concentration (Cmax) of 5.3, 48.1 and 2,480 nmol/L for D, DA and DOH, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),[nM] / [l],5.3,178751,DB00898,Ethanol
,25695490,peak concentration (Cmax),"Analyses of plasma samples using UHPLC-MS/MS showed mean time to peak concentration (Tmax) of 2.1, 2.4 and 3.3 h and mean peak concentration (Cmax) of 5.3, 48.1 and 2,480 nmol/L for D, DA and DOH, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),[nM] / [l],48.1,178752,DB00898,Ethanol
,25695490,peak concentration (Cmax),"Analyses of plasma samples using UHPLC-MS/MS showed mean time to peak concentration (Tmax) of 2.1, 2.4 and 3.3 h and mean peak concentration (Cmax) of 5.3, 48.1 and 2,480 nmol/L for D, DA and DOH, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),[nM] / [l],"2,480",178753,DB00898,Ethanol
,25695490,terminal elimination half-life (t1/2),The terminal elimination half-life (t1/2) for D and DA was similar (17.4 and 19.3 h) and each was much longer than that of DOH (7.4 h).,Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),h,17.4,178754,DB00898,Ethanol
,25695490,terminal elimination half-life (t1/2),The terminal elimination half-life (t1/2) for D and DA was similar (17.4 and 19.3 h) and each was much longer than that of DOH (7.4 h).,Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),h,19.3,178755,DB00898,Ethanol
,25695490,terminal elimination half-life (t1/2),The terminal elimination half-life (t1/2) for D and DA was similar (17.4 and 19.3 h) and each was much longer than that of DOH (7.4 h).,Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),h,7.4,178756,DB00898,Ethanol
,25695490,area under the curve (AUC0-48h),"The mean area under the curve (AUC0-48h) for D, DA and DOH was estimated as 37, 335 and 27,579 h∙nmol/L, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),[h∙nmol] / [l],"37, 335",178757,DB00898,Ethanol
,25695490,area under the curve (AUC0-48h),"The mean area under the curve (AUC0-48h) for D, DA and DOH was estimated as 37, 335 and 27,579 h∙nmol/L, respectively.",Single oral dose pharmacokinetics of decursin and decursinol angelate in healthy adult men and women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25695490/),[h∙nmol] / [l],"27,579",178758,DB00898,Ethanol
,28733244,bioavailability,Risperidone bioavailability is 66% in extensive metabolizers and 82% in slow metabolizers.,"Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28733244/),%,66,179348,DB00898,Ethanol
,28733244,bioavailability,Risperidone bioavailability is 66% in extensive metabolizers and 82% in slow metabolizers.,"Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28733244/),%,82,179349,DB00898,Ethanol
,12489977,Michaelis-Menten constant (Km),"The rate-limiting step in oxidation is conversion of ethanol into acetaldehyde by cytosolic alcohol dehydrogenase (ADH), which has a low Michaelis-Menten constant (Km) of 0.05-0.1 g/L.",Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489977/),[g] / [l],0.05-0.1,179630,DB00898,Ethanol
,12489977,Km,"Another ethanol-metabolising enzyme, cytochrome P450 2E1, has a higher Km (0.5-0.8 g/L) and is also inducible, so that the clearance of ethanol is increased in heavy drinkers.",Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12489977/),[g] / [l],0.5-0.8,179631,DB00898,Ethanol
,8312842,time to reach maximal blood levels,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),min,48.0,180075,DB00898,Ethanol
,8312842,time to reach maximal blood levels,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),min,31.2,180076,DB00898,Ethanol
,8312842,area under the curve,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),mg%·min,3821.5,180077,DB00898,Ethanol
,8312842,area under the curve,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),mg%·min,5154.8,180078,DB00898,Ethanol
,8312842,area under the curve,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),,18.7,180079,DB00898,Ethanol
,8312842,area under the curve,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),,3.9,180080,DB00898,Ethanol
,8312842,area under the curve,"Results indicated that: time to reach maximal blood levels was significantly longer in the L group (L: 48.0 +/- 10.9, C: 31.2 +/- 16.4 min, means +/- SD), area under the curve was smaller when group L was compared to group C (L: 3821.5 +/- 1240.5, C: 5154.8 +/- 1313.7 mg% x min, means +/- SD), ethanol blood levels (mg/dl) at 150 and 180 min were significantly lower in the L group (150: L, 10.5 +/- 5.6; C, 18.7 +/- 6.8; 180: L, 3.9 +/- 2.8; C, 13.2 +/- 6.4, means +/- SD).",Ethanol pharmacokinetics in lactating women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8312842/),,13.2,180081,DB00898,Ethanol
,21612571,fluxes,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],12.89,181642,DB00898,Ethanol
,21612571,fluxes,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],5.88,181643,DB00898,Ethanol
,21612571,plasma concentrations,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [ml],1.4,181644,DB00898,Ethanol
,21612571,plasma concentrations,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[ng] / [ml],200,181645,DB00898,Ethanol
,21612571,fluxes,"However, in the second study, the fluxes of AT and PR increased to 50.92 ± 20.8 and 12.01 ± 1.5 µg cm(-2) h(-1) respectively, and pharmacokinetic calculations indicated that therapeutic plasma concentrations are attainable for pediatric application.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],50.92,181646,DB00898,Ethanol
,21612571,fluxes,"However, in the second study, the fluxes of AT and PR increased to 50.92 ± 20.8 and 12.01 ± 1.5 µg cm(-2) h(-1) respectively, and pharmacokinetic calculations indicated that therapeutic plasma concentrations are attainable for pediatric application.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],12.01,181647,DB00898,Ethanol
,11696661,TBW,"Mean TBW, determined by deuterium oxide dilution, was 44.1 +/- 3.9 liters (+/-SD) for men, corresponding to 0.61 liters/kg, and 37.4 +/- 3.2 liters for women, or 0.54 liters/kg.",Do ethanol and deuterium oxide distribute into the same water space in healthy volunteers? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696661/),l,44.1,181876,DB00898,Ethanol
,11696661,TBW,"Mean TBW, determined by deuterium oxide dilution, was 44.1 +/- 3.9 liters (+/-SD) for men, corresponding to 0.61 liters/kg, and 37.4 +/- 3.2 liters for women, or 0.54 liters/kg.",Do ethanol and deuterium oxide distribute into the same water space in healthy volunteers? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696661/),l,37.4,181877,DB00898,Ethanol
,11696661,Vss,The precision of the estimates of Vss and TBW was between +/-1.56 and +/-2.19 liters (95% confidence interval).,Do ethanol and deuterium oxide distribute into the same water space in healthy volunteers? ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696661/),l,1.56,181878,DB00898,Ethanol
,11948138,clearance,"In the presence of CrEL, i.v. paclitaxel clearance was 10.2 +/- 3.76 liters/h/m(2) (mean +/- SD), consistent with previous findings.",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),[h·l] / [m(2],10.2,182062,DB00898,Ethanol
,11948138,terminal disposition half-life,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,17.0,182063,DB00898,Ethanol
,11948138,terminal disposition half-life,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,28.7,182064,DB00898,Ethanol
,11948138,mean residence time,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,7.28,182065,DB00898,Ethanol
,11948138,mean residence time,"The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 +/- 11.3 versus 28.7 +/- 8.72 h), as was the mean residence time (7.28 +/- 2.76 versus 40.7 +/- 13.8 h).",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),h,40.7,182066,DB00898,Ethanol
,11948138,bioavailability,"The bioavailability of paclitaxel was 31.4 +/- 5.18%, indicating insignificant systemic concentrations after i.p. treatment.",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),%,31.4,182067,DB00898,Ethanol
,11948138,clearance,"CrEL levels were undetectable after i.p. dosing (<0.05 microl/ml), whereas after i.v. dosing, the mean clearance was 159 +/- 58.4 ml/h/m(2), in line with earlier observations.",Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11948138/),[h·ml] / [m(2],159,182068,DB00898,Ethanol
,9215969,Limits of detection (LOD),"Limits of detection (LOD) were 1.0 and 2.0 ng ml-1 for cocaine and cocaethylene, respectively.",Quantitation of cocaine and cocaethylene in small volumes of rat whole blood using gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215969/),[ng] / [ml],1.0,182632,DB00898,Ethanol
,9215969,Limits of detection (LOD),"Limits of detection (LOD) were 1.0 and 2.0 ng ml-1 for cocaine and cocaethylene, respectively.",Quantitation of cocaine and cocaethylene in small volumes of rat whole blood using gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215969/),[ng] / [ml],2.0,182633,DB00898,Ethanol
,624775,plasma half-life,"The pre- and post-plasma half-life values were 35 hours, while on dialysis the half-life was only 6 hours.",Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/624775/),h,35,183604,DB00898,Ethanol
,624775,half-life,"The pre- and post-plasma half-life values were 35 hours, while on dialysis the half-life was only 6 hours.",Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/624775/),h,6,183605,DB00898,Ethanol
,624775,clearance,"The average dialysis clearance was 120 ml/minute, and the amount of chloral hydrate removed by dialysis was 5.79 Gm.",Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/624775/),[ml] / [min],120,183606,DB00898,Ethanol
,31237691,Peak BECs,"Peak BECs were 34 and 87 mg/dl for 0.5 and 1.0 g/kg doses, respectively, and occurred at 66 and 87 minutes following gavage.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [dl],34,183696,DB00898,Ethanol
,31237691,Peak BECs,"Peak BECs were 34 and 87 mg/dl for 0.5 and 1.0 g/kg doses, respectively, and occurred at 66 and 87 minutes following gavage.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [dl],87,183697,DB00898,Ethanol
,31237691,ED50,"All GABAA and NMDA ligands tested resulted in responding on the EtOH-appropriate lever with the potency ranking of MK-801 (ED50 : 0.017 mg/kg) > midazolam (ED50 : 1.6 mg/kg) > pentobarbital (ED50 : 3.7 mg/kg) > EtOH (ED50 : 700 mg/kg, or 0.7 g/kg) in these subjects.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [kg],0.017,183698,DB00898,Ethanol
,32505794,Bioavailability,Bioavailability of RIF (F5 gel) was improved by transdermal absorption as evidenced with AUC0→24 of transdermal F5 gel (56.23±2.7 µg.hr/mL) and oral drug suspension (41.71±5.2 µg.hr/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[h·μg] / [ml],56.23,183716,DB00898,Ethanol
,32505794,AUC0→24,Bioavailability of RIF (F5 gel) was improved by transdermal absorption as evidenced with AUC0→24 of transdermal F5 gel (56.23±2.7 µg.hr/mL) and oral drug suspension (41.71±5.2 µg.hr/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[h·μg] / [ml],56.23,183717,DB00898,Ethanol
,32505794,AUC0→24,Bioavailability of RIF (F5 gel) was improved by transdermal absorption as evidenced with AUC0→24 of transdermal F5 gel (56.23±2.7 µg.hr/mL) and oral drug suspension (41.71±5.2 µg.hr/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[h·μg] / [ml],41.71,183718,DB00898,Ethanol
,32505794,transdermal Cmax,A lower value of transdermal Cmax (6.9 ± 0.8 µg/mL) validated sustained delivery for improved tuberculosis management than oral delivery (10.5 ± 1.46.9 ± 0.8 µg/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[μg] / [ml],6.9,183719,DB00898,Ethanol
,32505794,transdermal Cmax,A lower value of transdermal Cmax (6.9 ± 0.8 µg/mL) validated sustained delivery for improved tuberculosis management than oral delivery (10.5 ± 1.46.9 ± 0.8 µg/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[μg] / [ml],10.5,183720,DB00898,Ethanol
,30144114,peak concentration (Cmax ),"This was reflected in a peak concentration (Cmax ) of 808 ± 70 parts-per-billion (ppb) versus 1,715 ± 223 ppb, respectively (p = 0.001), and area under the curve values of 3,528 ± 1,399 ppb minutes versus 8,637 ± 1,293 ppb minutes, respectively (p = 0.002).",Effect of Alcohol Sensitivity in Healthy Young Adults on Breath Pharmacokinetics of Acetaldehyde After Mouth Washing with Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30144114/),(ppb)·parts-per-billion,808,184055,DB00898,Ethanol
,30144114,peak concentration (Cmax ),"This was reflected in a peak concentration (Cmax ) of 808 ± 70 parts-per-billion (ppb) versus 1,715 ± 223 ppb, respectively (p = 0.001), and area under the curve values of 3,528 ± 1,399 ppb minutes versus 8,637 ± 1,293 ppb minutes, respectively (p = 0.002).",Effect of Alcohol Sensitivity in Healthy Young Adults on Breath Pharmacokinetics of Acetaldehyde After Mouth Washing with Alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30144114/),ppb,"1,715",184056,DB00898,Ethanol
,30144114,area under the curve,"This was reflected in a peak concentration (Cmax ) of 808 ± 70 parts-per-billion (ppb) versus 1,715 ± 223 ppb, respectively (p = 0.001), and area under the curve values of 3,528 ± 1,399 ppb minutes versus 8,637 ± 1,293 ppb minutes, respectively (p = 0.002).",Effect of Alcohol Sensitivity in Healthy Young Adults on Breath Pharmacokinetics of Acetaldehyde After Mouth Washing with Alcohol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30144114/),min·ppb,"3,528",184057,DB00898,Ethanol
,30144114,area under the curve,"This was reflected in a peak concentration (Cmax ) of 808 ± 70 parts-per-billion (ppb) versus 1,715 ± 223 ppb, respectively (p = 0.001), and area under the curve values of 3,528 ± 1,399 ppb minutes versus 8,637 ± 1,293 ppb minutes, respectively (p = 0.002).",Effect of Alcohol Sensitivity in Healthy Young Adults on Breath Pharmacokinetics of Acetaldehyde After Mouth Washing with Alcohol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30144114/),min·ppb,"8,637",184058,DB00898,Ethanol
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,346.3,184532,DB00898,Ethanol
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,198.0,184533,DB00898,Ethanol
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,369.98,184534,DB00898,Ethanol
,33531903,m/z,OME enantiomers were determined utilizing a triple quadrupole tandem mass spectrometer in positive ion mode (ESI+) monitoring mass transitions: m/z 346.3 ⟶ 198.0 for OME and m/z 369.98 ⟶ 252.0 for internal standard.,Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),⟶,252.0,184535,DB00898,Ethanol
,33531903,limits of detection,"The limits of detection and quantification of the present method for both enantiomers were 0.1 and 0.4 ng/mL, respectively.",Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),[ng] / [ml],0.1,184536,DB00898,Ethanol
,33531903,limits of detection,"The limits of detection and quantification of the present method for both enantiomers were 0.1 and 0.4 ng/mL, respectively.",Determination and Pharmacokinetics of Omeprazole Enantiomers in Human Plasma and Oral Fluid Utilizing Microextraction by Packed Sorbent and Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33531903/),[ng] / [ml],0,184537,DB00898,Ethanol
,30059244,loading capacity,"CUR was successfully encapsulated in HP-β-CD with a loading capacity of about 1:7 of CUR to HP-β-CD mole ratio, which remarkably enhanced drug water solubility and maintained well the antitumour activity of CUR.",Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30059244/),,1:7,185043,DB00898,Ethanol
,29404053,flow rate,"n-Hexane (containing 0.1% acetic acid) and ethanol (75:25, v/v) were used as mobile phase at a flow rate of 0.6 mL/min.",Separation and determination of acetyl-glutamine enantiomers by HPLC-MS and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404053/),[ml] / [min],0.6,186144,DB00898,Ethanol
higher,29404053,extraction recovery,The average extraction recovery was higher than 85% for both enantiomers at QC levels.,Separation and determination of acetyl-glutamine enantiomers by HPLC-MS and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29404053/),%,85,186145,DB00898,Ethanol
,9153784,Elimination constants,Elimination constants of 0.406-0.267 h-1 with corresponding half-lives of 1.71-2.60 h were established for methanol not influenced by ethanol.,Methanol elimination in non-alcoholics: inter- and intraindividual variation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9153784/),1/[h],0.406-0.267,186180,DB00898,Ethanol
,9153784,half-lives,Elimination constants of 0.406-0.267 h-1 with corresponding half-lives of 1.71-2.60 h were established for methanol not influenced by ethanol.,Methanol elimination in non-alcoholics: inter- and intraindividual variation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9153784/),h,1.71-2.60,186181,DB00898,Ethanol
,9153784,elimination constant,"When data from a previous study using an identical protocol for parenteral administration were included, making the total number of subjects nine, the mean elimination constant was found to be 0.298 +/- 0.470 h-1 and the mean half-life 2.37 +/- 0.357 h, distribution being normal.",Methanol elimination in non-alcoholics: inter- and intraindividual variation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9153784/),1/[h],0.298,186182,DB00898,Ethanol
,9153784,half-life,"When data from a previous study using an identical protocol for parenteral administration were included, making the total number of subjects nine, the mean elimination constant was found to be 0.298 +/- 0.470 h-1 and the mean half-life 2.37 +/- 0.357 h, distribution being normal.",Methanol elimination in non-alcoholics: inter- and intraindividual variation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9153784/),h,2.37,186183,DB00898,Ethanol
,26621370,entrapment efficiency,"Optimized transfersomes with drug:SPC:SDC weight ratio of 5:75:10 were spherical with an average size of 126.0 nm, PDI of 0.232, ZP of -43.7 mV, and entrapment efficiency of 54.96%.",Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621370/),%,54.96,186585,DB00898,Ethanol
,26621370,permeated,"The cumulative amount of ASPM permeated after 24 h (Q24) by individual effect of ethanol and transfersome, and in combination was found to be 160.0, 132.9, and 309.3 μg, respectively, indicating beneficial synergistic effect of combined approach.",Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621370/),μg,160.0,186586,DB00898,Ethanol
,26621370,permeated,"The cumulative amount of ASPM permeated after 24 h (Q24) by individual effect of ethanol and transfersome, and in combination was found to be 160.0, 132.9, and 309.3 μg, respectively, indicating beneficial synergistic effect of combined approach.",Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621370/),μg,132.9,186587,DB00898,Ethanol
,26621370,permeated,"The cumulative amount of ASPM permeated after 24 h (Q24) by individual effect of ethanol and transfersome, and in combination was found to be 160.0, 132.9, and 309.3 μg, respectively, indicating beneficial synergistic effect of combined approach.",Nano-transfersomal formulations for transdermal delivery of asenapine maleate: in vitro and in vivo performance evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621370/),μg,309.3,186588,DB00898,Ethanol
,8995499,bioavailability,"Halomon bioavailability was 45%, 47%, and 4% after i.p., s.c., and enteral dosing, respectively.","Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995499/),%,45,187000,DB00898,Ethanol
,8995499,bioavailability,"Halomon bioavailability was 45%, 47%, and 4% after i.p., s.c., and enteral dosing, respectively.","Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995499/),%,47,187001,DB00898,Ethanol
,8995499,bioavailability,"Halomon bioavailability was 45%, 47%, and 4% after i.p., s.c., and enteral dosing, respectively.","Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995499/),%,4,187002,DB00898,Ethanol
,17344014,flow-rate,"Chromatographic separation was performed on a C(18) column (200 mm x 4.6mm, 5 microm) with the mobile phase acetonitrile-methanol-water-acetic acid (20:15:65:2, v/v/v/v) at a flow-rate of 1.0 ml/min.",High-performance liquid chromatographic method for the determination and pharmacokinetic study of oxypeucedanin hydrate and byak-angelicin after oral administration of Angelica dahurica extracts in mongrel dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344014/),[ml] / [min],1.0,187611,DB00898,Ethanol
,17344014,absolute recoveries,"The lowest absolute recoveries of oxypeucedanin hydrate and byak-angelicin were 85.7% and 87.0%, respectively.",High-performance liquid chromatographic method for the determination and pharmacokinetic study of oxypeucedanin hydrate and byak-angelicin after oral administration of Angelica dahurica extracts in mongrel dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344014/),%,85.7,187612,DB00898,Ethanol
,17344014,absolute recoveries,"The lowest absolute recoveries of oxypeucedanin hydrate and byak-angelicin were 85.7% and 87.0%, respectively.",High-performance liquid chromatographic method for the determination and pharmacokinetic study of oxypeucedanin hydrate and byak-angelicin after oral administration of Angelica dahurica extracts in mongrel dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17344014/),%,87.0,187613,DB00898,Ethanol
below,7948182,flow rates,Microdialysis probes used in this configuration provide very high concentration recoveries and good precision at flow rates below 2 microliters min-1.,Pharmacokinetic studies using microdialysis probes in subcutaneous tissue: effects of the co-administration of ethanol and acetaminophen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7948182/),[μl] / [min],2,188101,DB00898,Ethanol
,18479171,absolute bioavailability,The absolute bioavailability of abacavir is approximately 83%.,A review of the pharmacokinetics of abacavir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),%,83,188444,DB00898,Ethanol
,18479171,peak concentration,"To date, one study has assessed the steady-state pharmacokinetics of abacavir following a 600-mg once-daily regimen, and reported a geometric mean steady-state abacavir peak concentration of 3.85 microg/mL.",A review of the pharmacokinetics of abacavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[μg] / [ml],3.85,188445,DB00898,Ethanol
,18479171,peak concentration,"Although this concentration is higher than the steady-state abacavir peak concentration reported following a 300-mg twice-daily regimen (0.88-3.19 microg/mL, depending on the study), the geometric mean steady-state abacavir exposure over 24 hours was similar following these regimens.",A review of the pharmacokinetics of abacavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[μg] / [ml],0.88-3.19,188446,DB00898,Ethanol
,18479171,apparent volume of distribution,"The apparent volume of distribution of abacavir after intravenous administration is approximately 0.86 +/- 0.15 L/kg, suggesting that abacavir is distributed to extravascular spaces.",A review of the pharmacokinetics of abacavir. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),[l] / [kg],0.86,188447,DB00898,Ethanol
,18479171,Binding,Binding to plasma proteins is about 50% and is independent of the plasma abacavir concentration.,A review of the pharmacokinetics of abacavir. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),%,50,188448,DB00898,Ethanol
,18479171,terminal elimination half-life,The terminal elimination half-life of abacavir is approximately 1.5 hours.,A review of the pharmacokinetics of abacavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),h,1.5,188449,DB00898,Ethanol
>,18479171,elimination half-life,"When assessed by validated high-performance liquid chromatography electrospray ionization tandem mass spectrometry, CBV-TP has been shown to have a long elimination half-life (>20 hours), supporting once-daily dosing.",A review of the pharmacokinetics of abacavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18479171/),h,20,188450,DB00898,Ethanol
,3795962,Peak BALs,Peak BALs of 83 +/- 2 mg/d1 were obtained.,The effect of menstrual cycle on blood alcohol levels and behavior. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795962/),[mg] / [d1],83,188902,DB00898,Ethanol
,19560537,relative oral bioavailability (F(r)),"The relative oral bioavailability (F(r)) of DHA-ME in comparison to Neoral was determined to be 114%, while the F(r) of VE-ME was only 60%.",Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560537/),%,114,189010,DB00898,Ethanol
,19560537,F(r),"The relative oral bioavailability (F(r)) of DHA-ME in comparison to Neoral was determined to be 114%, while the F(r) of VE-ME was only 60%.",Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560537/),%,60,189011,DB00898,Ethanol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,12.1,189647,DB00898,Ethanol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,4.0,189648,DB00898,Ethanol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,3.8,189649,DB00898,Ethanol
,15955678,F,The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12.1+/-1.4%; mean+/-S.D.; n = 4) > oral THC/RM-beta-CD solution (F = 4.0+/-6.0%) > or = sublingual ethanolic THC solution (F = 3.8+/-2.8%) > oral ethanolic THC solution (F = 1.3+/-1.4%).,Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15955678/),%,1.3,189650,DB00898,Ethanol
,27789373,absolute bioavailability,The absolute bioavailability of 5-HMT hydrogels was 20.7% showed in pharmacokinetic study.,"Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789373/),%,20.7,189720,DB00898,Ethanol
,19770264,maximum plasma concentration (C(max)),"Pellitorine exhibited maximum plasma concentration (C(max)) 34.77 ng mL(-1) ± 1.040, time to achieve C(max) (T(max)) 8 h, mean resident time (MRT) 26.00 ± 0.149 h and half life (t(1/2)) 18.64 ± 1.65 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),[ng] / [ml],34.77,189763,DB00898,Ethanol
,19770264,time to achieve C(max) (T(max)),"Pellitorine exhibited maximum plasma concentration (C(max)) 34.77 ng mL(-1) ± 1.040, time to achieve C(max) (T(max)) 8 h, mean resident time (MRT) 26.00 ± 0.149 h and half life (t(1/2)) 18.64 ± 1.65 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),h,8,189764,DB00898,Ethanol
,19770264,resident time (MRT),"Pellitorine exhibited maximum plasma concentration (C(max)) 34.77 ng mL(-1) ± 1.040, time to achieve C(max) (T(max)) 8 h, mean resident time (MRT) 26.00 ± 0.149 h and half life (t(1/2)) 18.64 ± 1.65 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),h,26.00,189765,DB00898,Ethanol
,19770264,half life (t(1/2)),"Pellitorine exhibited maximum plasma concentration (C(max)) 34.77 ng mL(-1) ± 1.040, time to achieve C(max) (T(max)) 8 h, mean resident time (MRT) 26.00 ± 0.149 h and half life (t(1/2)) 18.64 ± 1.65 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),h,18.64,189766,DB00898,Ethanol
,19770264,C(max),"Sarmentine showed C(max) 191.50 ± 12.69 ng mL(-1), T(max) 6 h, MRT 11.12 ± 0.44 h and t(1/2) 10.30 ± 1.98 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),[ng] / [ml],191.50,189767,DB00898,Ethanol
,19770264,T(max),"Sarmentine showed C(max) 191.50 ± 12.69 ng mL(-1), T(max) 6 h, MRT 11.12 ± 0.44 h and t(1/2) 10.30 ± 1.98 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),h,6,189768,DB00898,Ethanol
,19770264,MRT,"Sarmentine showed C(max) 191.50 ± 12.69 ng mL(-1), T(max) 6 h, MRT 11.12 ± 0.44 h and t(1/2) 10.30 ± 1.98 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),h,11.12,189769,DB00898,Ethanol
,19770264,t(1/2),"Sarmentine showed C(max) 191.50 ± 12.69 ng mL(-1), T(max) 6 h, MRT 11.12 ± 0.44 h and t(1/2) 10.30 ± 1.98 h.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),h,10.30,189770,DB00898,Ethanol
,19770264,cumulative excretion,"The cumulative excretion of pellitorine, sarmentine and sarmentosine in feces in 72 h was 0.0773, 0.976, and 0.438 μg, respectively.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),μg,0.0773,189771,DB00898,Ethanol
,19770264,cumulative excretion,"The cumulative excretion of pellitorine, sarmentine and sarmentosine in feces in 72 h was 0.0773, 0.976, and 0.438 μg, respectively.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),μg,0.976,189772,DB00898,Ethanol
,19770264,cumulative excretion,"The cumulative excretion of pellitorine, sarmentine and sarmentosine in feces in 72 h was 0.0773, 0.976, and 0.438 μg, respectively.","Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770264/),μg,0.438,189773,DB00898,Ethanol
,29440893,visco,The optimized AG-NE had a droplet size of 122±11 nm confirmed using transmission electron microscopy and a viscosity of 28 centipoise (cps).,Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29440893/),centipoise,28,190025,DB00898,Ethanol
,29440893,relative bioavailability,"The pharmacokinetic results indicate that the absorption of AG from AG-NE was significantly enhanced in comparison with that from the AG suspension, with a relative bioavailability of 594.3%.",Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29440893/),%,594.3,190026,DB00898,Ethanol
,26081678,recoveries,The hematocrit effect on extraction recovery was evaluated and the mean recoveries of (-) and (+) enantiomers of darunavir from dried blood spots were found to be 85.76 and 88.91% respectively.,"Dried blood spot analysis of (+) and (-) darunavir enantiomers on immobilized amylose tris-(3, 5-dimethylphenylcarbamate) LC and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26081678/),%,85.76,190060,DB00898,Ethanol
,26081678,recoveries,The hematocrit effect on extraction recovery was evaluated and the mean recoveries of (-) and (+) enantiomers of darunavir from dried blood spots were found to be 85.76 and 88.91% respectively.,"Dried blood spot analysis of (+) and (-) darunavir enantiomers on immobilized amylose tris-(3, 5-dimethylphenylcarbamate) LC and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26081678/),%,88.91,190061,DB00898,Ethanol
,7093102,steady-state levels,2 Mean steady-state levels varied from 36 to 183 ng/ml on a chronic dose of 200 mg twice daily.,Labetalol steady-state pharmacokinetics in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093102/),[ng] / [ml],36 to 183,190307,DB00898,Ethanol
,8616858,clearance,"The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.37,191553,DB00898,Ethanol
,8616858,clearance,"The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],0.33,191554,DB00898,Ethanol
,8616858,clearance,"The clearance of 2.37 L/h/kg at 2 mg/kg was reduced to 0.33 and 0.15 L/h/kg at 10 and 20 mg/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],0.15,191555,DB00898,Ethanol
,8616858,clearance,"When 2 mg/kg were given with an amount of Cremophor EL-ethanol matching that of the 10-mg/kg dose level, the clearance was 0.56 L/h/kg.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],0.56,191556,DB00898,Ethanol
,8616858,clearances,"If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.66,191557,DB00898,Ethanol
,8616858,clearances,"If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.57,191558,DB00898,Ethanol
,8616858,clearances,"If administered at 10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, the clearances were 2.66, 2.57, and 2.62 L/h/kg, respectively.",Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616858/),[l] / [h·kg],2.62,191559,DB00898,Ethanol
,8556227,Cmax,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [ml],9.317,191953,DB00898,Ethanol
,8556227,Cmax,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [ml],12.362,191954,DB00898,Ethanol
,8556227,AUC,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [h·ml],62.65,191955,DB00898,Ethanol
,8556227,AUC,"In the present study, ingestion of alcohol caused significant increase of Cmax (from 9.317 to 12.362 micrograms/ml), and increase of AUC (from 62.65 to 94.28 micrograms/ml*h).",Influence of ethanol ingestion on tetracycline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8556227/),[μg] / [h·ml],94.28,191956,DB00898,Ethanol
,24655007,time to Cmax,The time to Cmax occurred significantly earlier (p < 0.01) after vodka/tonic (36 ± 10 minutes) compared to wine (54 ± 14 minutes) or beer (62 ± 23 minutes).,"Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655007/),min,36,192102,DB00898,Ethanol
,24655007,time to Cmax,The time to Cmax occurred significantly earlier (p < 0.01) after vodka/tonic (36 ± 10 minutes) compared to wine (54 ± 14 minutes) or beer (62 ± 23 minutes).,"Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655007/),min,54,192103,DB00898,Ethanol
,24655007,time to Cmax,The time to Cmax occurred significantly earlier (p < 0.01) after vodka/tonic (36 ± 10 minutes) compared to wine (54 ± 14 minutes) or beer (62 ± 23 minutes).,"Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655007/),min,62,192104,DB00898,Ethanol
,24655007,Cmax,"Six subjects exceeded a Cmax of 80 mg/dl after vodka/tonic, but none exceeded this limit after beer or wine.","Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24655007/),[mg] / [dl],80,192105,DB00898,Ethanol
,2515160,tmax (h),"Mean pharmacokinetic data of the new liquid formulation of Isocillin syrup were: tmax (h) = 0.81, Cmax (mg/l) = 9.92, AUC0-8h (mgh/l) = 13.67, lambda z (h) = 0.68, Cltot/f (ml/min) = 964.",Bioavailability of a new liquid formulation of penicillin V (Isocillin syrup) and the influence of ethanol on bioavailability of penicillin V. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515160/),,0.81,192124,DB00898,Ethanol
,2515160,Cmax,"Mean pharmacokinetic data of the new liquid formulation of Isocillin syrup were: tmax (h) = 0.81, Cmax (mg/l) = 9.92, AUC0-8h (mgh/l) = 13.67, lambda z (h) = 0.68, Cltot/f (ml/min) = 964.",Bioavailability of a new liquid formulation of penicillin V (Isocillin syrup) and the influence of ethanol on bioavailability of penicillin V. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515160/),[mg] / [l],9.92,192125,DB00898,Ethanol
,2515160,AUC0-8h,"Mean pharmacokinetic data of the new liquid formulation of Isocillin syrup were: tmax (h) = 0.81, Cmax (mg/l) = 9.92, AUC0-8h (mgh/l) = 13.67, lambda z (h) = 0.68, Cltot/f (ml/min) = 964.",Bioavailability of a new liquid formulation of penicillin V (Isocillin syrup) and the influence of ethanol on bioavailability of penicillin V. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515160/),[mgh] / [l],13.67,192126,DB00898,Ethanol
,2515160,lambda z,"Mean pharmacokinetic data of the new liquid formulation of Isocillin syrup were: tmax (h) = 0.81, Cmax (mg/l) = 9.92, AUC0-8h (mgh/l) = 13.67, lambda z (h) = 0.68, Cltot/f (ml/min) = 964.",Bioavailability of a new liquid formulation of penicillin V (Isocillin syrup) and the influence of ethanol on bioavailability of penicillin V. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515160/),h,0.68,192127,DB00898,Ethanol
,2515160,Cltot/f,"Mean pharmacokinetic data of the new liquid formulation of Isocillin syrup were: tmax (h) = 0.81, Cmax (mg/l) = 9.92, AUC0-8h (mgh/l) = 13.67, lambda z (h) = 0.68, Cltot/f (ml/min) = 964.",Bioavailability of a new liquid formulation of penicillin V (Isocillin syrup) and the influence of ethanol on bioavailability of penicillin V. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515160/),[ml] / [min],964,192128,DB00898,Ethanol
,16006083,runtime,"The chromatographic runtime was 2 min and the weighted (1/x2) calibration curves were linear over the range 50-10,000 pg/mL.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),min,2,192244,DB00898,Ethanol
,16006083,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 10 and 50 pg/mL, respectively.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),[pg] / [ml],10,192245,DB00898,Ethanol
,16006083,absolute recoveries,"The average absolute recoveries of nebivolol and tamsulosin, used as an internal standard, from spiked plasma samples were 73.4+/-3.7 and 72.1+/-2.0%, respectively.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),%,73.4,192246,DB00898,Ethanol
,16006083,absolute recoveries,"The average absolute recoveries of nebivolol and tamsulosin, used as an internal standard, from spiked plasma samples were 73.4+/-3.7 and 72.1+/-2.0%, respectively.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),%,72.1,192247,DB00898,Ethanol
,2145908,half-lives,"Plasma levels of radioactivity increased to a maximum of 4.1 and 5.5 micrograms equivalents per g when the infusion stopped then declined triexponentially with mean half-lives of about 1/2, 10 and 80 h for the initial, mid and terminal phases, respectively.","Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),h,1/2,192407,DB00898,Ethanol
,2145908,half-lives,"Plasma levels of radioactivity increased to a maximum of 4.1 and 5.5 micrograms equivalents per g when the infusion stopped then declined triexponentially with mean half-lives of about 1/2, 10 and 80 h for the initial, mid and terminal phases, respectively.","Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),h,10,192408,DB00898,Ethanol
,2145908,half-lives,"Plasma levels of radioactivity increased to a maximum of 4.1 and 5.5 micrograms equivalents per g when the infusion stopped then declined triexponentially with mean half-lives of about 1/2, 10 and 80 h for the initial, mid and terminal phases, respectively.","Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),h,80,192409,DB00898,Ethanol
,2145908,maximum levels,"Plasma levels of intact drug were lower, with maximum levels of 1.1 and 2.8 micrograms/ml, and declined monophasically with a half-life of about 24 min.","Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),[μg] / [ml],1.1,192410,DB00898,Ethanol
,2145908,maximum levels,"Plasma levels of intact drug were lower, with maximum levels of 1.1 and 2.8 micrograms/ml, and declined monophasically with a half-life of about 24 min.","Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),[μg] / [ml],2.8,192411,DB00898,Ethanol
,2145908,half-life,"Plasma levels of intact drug were lower, with maximum levels of 1.1 and 2.8 micrograms/ml, and declined monophasically with a half-life of about 24 min.","Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),min,24,192412,DB00898,Ethanol
,2145908,Plasma clearance,Plasma clearance was high (1426 and 764 ml/min) with the volume of distribution based on areas of 47.7 and 26.4 l.,"Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),[ml] / [min],1426,192413,DB00898,Ethanol
,2145908,Plasma clearance,Plasma clearance was high (1426 and 764 ml/min) with the volume of distribution based on areas of 47.7 and 26.4 l.,"Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),[ml] / [min],764,192414,DB00898,Ethanol
,2145908,volume of distribution based on areas,Plasma clearance was high (1426 and 764 ml/min) with the volume of distribution based on areas of 47.7 and 26.4 l.,"Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),l,47.7,192415,DB00898,Ethanol
,2145908,volume of distribution based on areas,Plasma clearance was high (1426 and 764 ml/min) with the volume of distribution based on areas of 47.7 and 26.4 l.,"Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2145908/),l,26.4,192416,DB00898,Ethanol
,9450505,clearance,Cocaine clearance was dose-dependent with clearance decreasing from 1.53 +/- 0.31 to 1.09 +/- 0.11 l/min as the dose was increased from 1 to 5 mg/kg (p<0.05).,Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [min],1.53,192600,DB00898,Ethanol
,9450505,clearance,Cocaine clearance was dose-dependent with clearance decreasing from 1.53 +/- 0.31 to 1.09 +/- 0.11 l/min as the dose was increased from 1 to 5 mg/kg (p<0.05).,Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [min],1.09,192601,DB00898,Ethanol
,9450505,Vmax x Vss,"Vmax x Vss and Km for cocaine were 0.95 +/- 0.40 l/min/kg and 11.2 +/- 6.2 mg/kg, respectively.",Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[l] / [kg·min],0.95,192602,DB00898,Ethanol
,9450505,Km,"Vmax x Vss and Km for cocaine were 0.95 +/- 0.40 l/min/kg and 11.2 +/- 6.2 mg/kg, respectively.",Evaluation of dose-dependent pharmacokinetics of cocaethylene and cocaine in conscious dogs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450505/),[mg] / [kg],11.2,192603,DB00898,Ethanol
,23311652,half-life,A transdermal delivery system is warranted for repaglinide (RPG) which possesses half-life of 1 h and oral bioavailability of 56%.,A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311652/),h,1,192741,DB00898,Ethanol
,23311652,oral bioavailability,A transdermal delivery system is warranted for repaglinide (RPG) which possesses half-life of 1 h and oral bioavailability of 56%.,A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311652/),%,56,192742,DB00898,Ethanol
,23311652,entrapment efficiency,RPG ethosomes possessing the size of 0.171-1.727 µm and entrapment efficiency of 75-92% were obtained.,A study on ethosomes as mode for transdermal delivery of an antidiabetic drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311652/),%,75-92,192743,DB00898,Ethanol
,15315787,flow rate,"The chromatographic separation of the (+)-(S)- and (-)-(R)-enantiomers of mirtazapine was achieved on a Chiralpak AD column (250 mm x 4.6 mm, 10 microm particle size) protected with a CN guard column, using hexane-ethanol (98:2, v/v) plus 0.1% diethylamine as the isocratic mobile phase, at a flow rate of 1.2 ml/min.",New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),[ml] / [min],1.2,192825,DB00898,Ethanol
less,15315787,total analysis time,The total analysis time was less than 12 min per sample.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),-1·min,12,192826,DB00898,Ethanol
,15315787,recoveries,The recoveries of (+)-(S)- and (-)-(R)-mirtazapine were in the 88-111% range with a linear response over the 6.25-625 ng/ml concentration range for both enantiomers.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),%,88-111,192827,DB00898,Ethanol
,15315787,quantification limit (LOQ),The quantification limit (LOQ) was 5 ng/ml.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),[ng] / [ml],5,192828,DB00898,Ethanol
,7892416,relative systemic bioavailability,Comparison of dose corrected areas under the curve of the two routes of administration for each drug indicated that relative systemic bioavailability of cocaethylene following intraperitoneal administration is only 58% that of cocaine.,Differences in bioavailability between cocaine and cocaethylene and their implications for drug-reward studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7892416/),%,58,193589,DB00898,Ethanol
,21927013,bioadhesive strength,The bioadhesive strength was as high as 0.98±0.06 N/cm(2).,Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21927013/),[n] / [cm(2],0.98,193825,DB00898,Ethanol
,21927013,relative bioavailability,"Compared with the commercially available capsules of tacrolimus, the relative bioavailability of the SME gastroretentive sustained-release tablets was 553.4%±353.8%.",Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21927013/),%,553.4,193826,DB00898,Ethanol
,22019193,Maximum concentrations,"Maximum concentrations were blood ethanol, 213±20 mg/dL; urine ethanol, 308±34 mg/dL; BEtG, 2,683±145 ng equivalents/mL; UEtG, 1.2±0.06 mg equivalents/mL (X±S.E.M.).",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[mg] / [dl],213,193930,DB00898,Ethanol
,22019193,Maximum concentrations,"Maximum concentrations were blood ethanol, 213±20 mg/dL; urine ethanol, 308±34 mg/dL; BEtG, 2,683±145 ng equivalents/mL; UEtG, 1.2±0.06 mg equivalents/mL (X±S.E.M.).",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[equivalents·ng] / [ml],"2,683",193931,DB00898,Ethanol
,22019193,Maximum concentrations,"Maximum concentrations were blood ethanol, 213±20 mg/dL; urine ethanol, 308±34 mg/dL; BEtG, 2,683±145 ng equivalents/mL; UEtG, 1.2±0.06 mg equivalents/mL (X±S.E.M.).",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[equivalents·mg] / [ml],1.2,193932,DB00898,Ethanol
,22019193,Areas under the concentration-time curve,"Areas under the concentration-time curve were blood ethanol, 1,578 h*mg/dL; urine ethanol, 3,096 h*mg/dL; BEtG, 18,284 h*ng equivalents/mL; and UEtG, 850 h*mg equivalents/dL.",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[h·mg] / [dl],"1,578",193933,DB00898,Ethanol
,22019193,Areas under the concentration-time curve,"Areas under the concentration-time curve were blood ethanol, 1,578 h*mg/dL; urine ethanol, 3,096 h*mg/dL; BEtG, 18,284 h*ng equivalents/mL; and UEtG, 850 h*mg equivalents/dL.",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[h·mg] / [dl],"3,096",193934,DB00898,Ethanol
,22019193,Areas under the concentration-time curve,"Areas under the concentration-time curve were blood ethanol, 1,578 h*mg/dL; urine ethanol, 3,096 h*mg/dL; BEtG, 18,284 h*ng equivalents/mL; and UEtG, 850 h*mg equivalents/dL.",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[equivalents·h·ng] / [ml],"18,284",193935,DB00898,Ethanol
,22019193,Areas under the concentration-time curve,"Areas under the concentration-time curve were blood ethanol, 1,578 h*mg/dL; urine ethanol, 3,096 h*mg/dL; BEtG, 18,284 h*ng equivalents/mL; and UEtG, 850 h*mg equivalents/dL.",Biotransformation of ethanol to ethyl glucuronide in a rat model after a single high oral dosage. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019193/),[equivalents·h·mg] / [dl],850,193936,DB00898,Ethanol
,20932349,maximum concentrations,"Observed maximum concentrations (mean ± SD) of artemether and dihydroartemisinin were 184 ± 100 ng/mL and 126 ± 46 ng/mL, respectively.",Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20932349/),[ng] / [ml],184,194053,DB00898,Ethanol
,20932349,maximum concentrations,"Observed maximum concentrations (mean ± SD) of artemether and dihydroartemisinin were 184 ± 100 ng/mL and 126 ± 46 ng/mL, respectively.",Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20932349/),[ng] / [ml],126,194054,DB00898,Ethanol
,20932349,terminal elimination half-life,"The terminal elimination half-life of artemether and dihydroartemisinin were 2.00 ± 0.71 hr and 1.80 ± 0.31 hr, respectively.",Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20932349/),h,2.00,194055,DB00898,Ethanol
,20932349,terminal elimination half-life,"The terminal elimination half-life of artemether and dihydroartemisinin were 2.00 ± 0.71 hr and 1.80 ± 0.31 hr, respectively.",Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20932349/),h,1.80,194056,DB00898,Ethanol
,20932349,Apparent volume of distribution,Apparent volume of distribution and oral clearance for artemether were estimated to 666 ± 220 L and 257 ± 140 L/hr.,Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20932349/),l,666,194057,DB00898,Ethanol
,20932349,oral clearance,Apparent volume of distribution and oral clearance for artemether were estimated to 666 ± 220 L and 257 ± 140 L/hr.,Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20932349/),[l] / [h],257,194058,DB00898,Ethanol
,1742848,peak plasma concentrations,An i.p. dose of 190 mg kg-1 (0.5 mmol kg-1) RB 6145 produced peak plasma concentrations of about 50 micrograms ml-1 of the pharmacologically active target molecule RSU 1069 as compared with levels of around twice this value that were obtained using an equimolar i.p. dose of RSU 1069 itself.,Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),[μg] / [ml],50,194149,DB00898,Ethanol
,1742848,plasma AUC0-infinity,The plasma AUC0-infinity value for administered RSU 1069 was ca. 47 micrograms ml-1 h and that for the analogue RSU 1069 was ca. 84 micrograms ml-1 h.,Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),[h·μg] / [ml],47,194150,DB00898,Ethanol
,1742848,plasma AUC0-infinity,The plasma AUC0-infinity value for administered RSU 1069 was ca. 47 micrograms ml-1 h and that for the analogue RSU 1069 was ca. 84 micrograms ml-1 h.,Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),[h·μg] / [ml],84,194151,DB00898,Ethanol
,1742848,elimination t1/2,"Post-peak plasma concentrations of both RB 6145 metabolites declined exponentially, displaying an elimination t1/2 of ca. 25 min, very similar to the 30-min value observed for injected RSU 1069.",Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),min,25,194152,DB00898,Ethanol
,1742848,elimination t1/2,"Post-peak plasma concentrations of both RB 6145 metabolites declined exponentially, displaying an elimination t1/2 of ca. 25 min, very similar to the 30-min value observed for injected RSU 1069.",Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),min,30,194153,DB00898,Ethanol
,1742848,peak level,The peak level of metabolite RSU 1069 was ca. 6 micrograms g-1 as compared with 10 micrograms g-1 following an equimolar dose of RSU 1069 itself; the tumour AUC0-infinity value for the metabolite RSU 1069 was some 35% lower.,Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),[μg] / [g],6,194154,DB00898,Ethanol
,1742848,peak level,The peak level of metabolite RSU 1069 was ca. 6 micrograms g-1 as compared with 10 micrograms g-1 following an equimolar dose of RSU 1069 itself; the tumour AUC0-infinity value for the metabolite RSU 1069 was some 35% lower.,Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742848/),[μg] / [g],10,194155,DB00898,Ethanol
,27130527,half-life,"(i) Single doses of 0.25 and 0.50 g EtOH/kg produced proportional increases in BrAC and combined PEth levels of all participants; (ii) the areas under the curve (AUCs) for each participant's BrAC levels during the 6-hour period after EtOH administration were correlated with AUCs of cPEth (calculated as the AUC of the increase above baseline for combined PEth); (iii) the mean half-life of combined PEth, determined during the 14-day period after EtOH consumption, was 4.6 ± 3.5 (SD) days (range: 1.0 to 13.1 days).",Characterization of the Pharmacokinetics of Phosphatidylethanol 16:0/18:1 and 16:0/18:2 in Human Whole Blood After Alcohol Consumption in a Clinical Laboratory Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27130527/),d,4.6,194700,DB00898,Ethanol
below,16854236,C [lum]day7,Re-infections occurred only among patients with C [lum]day7 below 400 ng/mL (p < 0.001).,Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854236/),[ng] / [ml],400,195032,DB00898,Ethanol
,1981634,bioavailability,"The alpha 1-adrenoceptor antagonist indoramin is rapidly and extensively absorbed after oral administration, but with only low to moderate bioavailability (8-24% median) from the tablet (Baratol).",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),%,8-24,195139,DB00898,Ethanol
,1981634,plasma protein binding,"Although plasma protein binding is high (72-86%), the drug is widely distributed into tissues (with median Vz 6.3-7.7 l/kg after i.v. dosage).",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),%,72-86,195140,DB00898,Ethanol
,1981634,Vz,"Although plasma protein binding is high (72-86%), the drug is widely distributed into tissues (with median Vz 6.3-7.7 l/kg after i.v. dosage).",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),[l] / [kg],6.3-7.7,195141,DB00898,Ethanol
,1981634,plasma clearances,"2. Elimination of indoramin is rapid in most healthy volunteers, with median plasma clearances of 18-26 ml/min per kg, after i.v. dosage.",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),[ml] / [kg·min],18-26,195142,DB00898,Ethanol
,9387042,terminal t1/2,Plasma concentration-time profiles were found to follow a biexponential decline with a mean terminal t1/2 of 97 min and mean total clearance (CLt) of 425.3 ml/min/kg following i.v. dosing at 10 mg/kg.,"Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387042/),min,97,195251,DB00898,Ethanol
,9387042,total clearance (CLt),Plasma concentration-time profiles were found to follow a biexponential decline with a mean terminal t1/2 of 97 min and mean total clearance (CLt) of 425.3 ml/min/kg following i.v. dosing at 10 mg/kg.,"Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387042/),[ml] / [kg·min],425.3,195252,DB00898,Ethanol
,9387042,bioavailability,"Following oral dosing at 50 mg/kg, the peptide was absorbed but produced erratic drug levels also with a bioavailability of 15.6%.","Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387042/),%,15.6,195253,DB00898,Ethanol
,23049254,half-maximal inhibitory concentration [IC(50)],"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],11.99,196170,DB00898,Ethanol
,23049254,IC(50),"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],0.88,196171,DB00898,Ethanol
>,23049254,IC(50),"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],30.0,196172,DB00898,Ethanol
>,23049254,IC(50),"After 72 hours of treatment, both the FVS (half-maximal inhibitory concentration [IC(50)] = 11.99 μg · mL(-1)) and the standard anticancer drug, 5-fluorouracil (IC(50) = 0.88 μg · mL(-1)) exhibited strong in vitro antiproliferative activity against SGC cells, with IC(50) > 30.0 μg · mL(-1); but the FVS performed poorly against LoVo cells (IC(50) > 40.0 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],40.0,196173,DB00898,Ethanol
,23049254,solubility,"The optimal FVSMs prescription consisted of 3.0% medium chain triglycerides, 5.0% ethanol, 21.0% Cremophor EL and 71.0% water (w/w) with associated solubility of FVS being 0.680 mg · mL(-1) as compared to free FVS (0.67 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[mg] / [ml],0.680,196174,DB00898,Ethanol
,23049254,solubility,"The optimal FVSMs prescription consisted of 3.0% medium chain triglycerides, 5.0% ethanol, 21.0% Cremophor EL and 71.0% water (w/w) with associated solubility of FVS being 0.680 mg · mL(-1) as compared to free FVS (0.67 μg · mL(-1)).","Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23049254/),[μg] / [ml],0.67,196175,DB00898,Ethanol
,3104347,LD50,Administration of 2 X molar cysteine i.v. or i.p. to mafosfamide-treated animals was even more effective against its lethal toxicity (LD50 i.p. 1800 mg/kg and i.v. 1130 mg/kg).,Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104347/),[mg] / [kg],1800,196810,DB00898,Ethanol
,3104347,LD50,Administration of 2 X molar cysteine i.v. or i.p. to mafosfamide-treated animals was even more effective against its lethal toxicity (LD50 i.p. 1800 mg/kg and i.v. 1130 mg/kg).,Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104347/),[mg] / [kg],1130,196811,DB00898,Ethanol
,3104347,t1/2,Compared with mesna the higher detoxification effect of cysteine is attributed to its longer half-life (t1/2 20 min vs 12 min of mesna) and presumably an accumulation of cysteine in some cell systems (distribution coefficient 1.20 ml/g vs 0.68 ml/g of mesna).,Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104347/),min,20,196812,DB00898,Ethanol
,3104347,t1/2,Compared with mesna the higher detoxification effect of cysteine is attributed to its longer half-life (t1/2 20 min vs 12 min of mesna) and presumably an accumulation of cysteine in some cell systems (distribution coefficient 1.20 ml/g vs 0.68 ml/g of mesna).,Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104347/),min,12,196813,DB00898,Ethanol
,3104347,distribution coefficient,Compared with mesna the higher detoxification effect of cysteine is attributed to its longer half-life (t1/2 20 min vs 12 min of mesna) and presumably an accumulation of cysteine in some cell systems (distribution coefficient 1.20 ml/g vs 0.68 ml/g of mesna).,Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104347/),[ml] / [g],1.20,196814,DB00898,Ethanol
,3104347,distribution coefficient,Compared with mesna the higher detoxification effect of cysteine is attributed to its longer half-life (t1/2 20 min vs 12 min of mesna) and presumably an accumulation of cysteine in some cell systems (distribution coefficient 1.20 ml/g vs 0.68 ml/g of mesna).,Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104347/),[ml] / [g],0.68,196815,DB00898,Ethanol
,12765992,Analytical recoveries,Analytical recoveries were 42-60%.,Hydroxytyrosol disposition in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765992/),%,42-60,197818,DB00898,Ethanol
,12765992,elimination half-life,The estimated hydroxytyrosol elimination half-life was 2.43 h.,Hydroxytyrosol disposition in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12765992/),h,2.43,197819,DB00898,Ethanol
,8461051,Km,"The Km (22 microM) and Vmax (10.2 and 13.4 nmol/g liver/min) for the metabolism of NDMA by slices from two human livers, the inhibition of that metabolism by ethanol (Ki 0.5 microM), and the rate of N-7 methylation of DNA when slices are incubated with NDMA, were measured.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,22,198126,DB00898,Ethanol
,8461051,Vmax,"The Km (22 microM) and Vmax (10.2 and 13.4 nmol/g liver/min) for the metabolism of NDMA by slices from two human livers, the inhibition of that metabolism by ethanol (Ki 0.5 microM), and the rate of N-7 methylation of DNA when slices are incubated with NDMA, were measured.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),[nM] / [g·liver·min],10.2,198127,DB00898,Ethanol
,8461051,Vmax,"The Km (22 microM) and Vmax (10.2 and 13.4 nmol/g liver/min) for the metabolism of NDMA by slices from two human livers, the inhibition of that metabolism by ethanol (Ki 0.5 microM), and the rate of N-7 methylation of DNA when slices are incubated with NDMA, were measured.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),[nM] / [g·liver·min],13.4,198128,DB00898,Ethanol
,8461051,Ki,"The Km (22 microM) and Vmax (10.2 and 13.4 nmol/g liver/min) for the metabolism of NDMA by slices from two human livers, the inhibition of that metabolism by ethanol (Ki 0.5 microM), and the rate of N-7 methylation of DNA when slices are incubated with NDMA, were measured.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,0.5,198129,DB00898,Ethanol
,8461051,Km,The Km (27 microM) for the metabolism of NDEA by rat liver slices and the inhibition of that metabolism by ethanol (Ki 1 microM) were estimated from the rate of ethylation of the DNA of the slices.,Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,27,198130,DB00898,Ethanol
,8461051,Ki,The Km (27 microM) for the metabolism of NDEA by rat liver slices and the inhibition of that metabolism by ethanol (Ki 1 microM) were estimated from the rate of ethylation of the DNA of the slices.,Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,1,198131,DB00898,Ethanol
,8461051,maximal rate of clearance,"The maximal rate of clearance of NDMA was 11.2 nmol/g liver/min and of NDEA 8.9 nmol/g liver/min, similar to the Vmax for metabolism of NDMA by liver slices and to the estimated maximal rate of liver metabolism of both nitrosamines in the living rat.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),[nM] / [g·liver·min],11.2,198132,DB00898,Ethanol
,8461051,maximal rate of clearance,"The maximal rate of clearance of NDMA was 11.2 nmol/g liver/min and of NDEA 8.9 nmol/g liver/min, similar to the Vmax for metabolism of NDMA by liver slices and to the estimated maximal rate of liver metabolism of both nitrosamines in the living rat.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),[nM] / [g·liver·min],8.9,198133,DB00898,Ethanol
,8461051,Km,"However, although the Km for metabolism of these two nitrosamines by liver slices is similar (about 25 microM), the logarithmic mean sinusoidal concentration [see Bass and Keiding, Biochem Pharmacol 37: 1425-1431, 1988] giving half maximal clearance during perfusion (the equivalent to Km) was 2.3 microM for NDMA and 10.6 microM for NDEA.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,25,198134,DB00898,Ethanol
,8461051,half maximal clearance,"However, although the Km for metabolism of these two nitrosamines by liver slices is similar (about 25 microM), the logarithmic mean sinusoidal concentration [see Bass and Keiding, Biochem Pharmacol 37: 1425-1431, 1988] giving half maximal clearance during perfusion (the equivalent to Km) was 2.3 microM for NDMA and 10.6 microM for NDEA.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,2.3,198135,DB00898,Ethanol
,8461051,half maximal clearance,"However, although the Km for metabolism of these two nitrosamines by liver slices is similar (about 25 microM), the logarithmic mean sinusoidal concentration [see Bass and Keiding, Biochem Pharmacol 37: 1425-1431, 1988] giving half maximal clearance during perfusion (the equivalent to Km) was 2.3 microM for NDMA and 10.6 microM for NDEA.",Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461051/),μM,10.6,198136,DB00898,Ethanol
,33866677,absolute recoveries,"Mean absolute recoveries of all analytes were between 73.31% and 94.76%, and the relative standard deviations of matrix effects were not higher than 15%.",Pharmacokinetic studies of six major 2-(2-phenylethyl) chromones in rat plasma using ultra high performance liquid chromatography with tandem mass spectrometry after oral administration of agarwood ethanol extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33866677/),%,73.31,198223,DB00898,Ethanol
,33866677,absolute recoveries,"Mean absolute recoveries of all analytes were between 73.31% and 94.76%, and the relative standard deviations of matrix effects were not higher than 15%.",Pharmacokinetic studies of six major 2-(2-phenylethyl) chromones in rat plasma using ultra high performance liquid chromatography with tandem mass spectrometry after oral administration of agarwood ethanol extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33866677/),%,94.76,198224,DB00898,Ethanol
not higher,33866677,absolute recoveries,"Mean absolute recoveries of all analytes were between 73.31% and 94.76%, and the relative standard deviations of matrix effects were not higher than 15%.",Pharmacokinetic studies of six major 2-(2-phenylethyl) chromones in rat plasma using ultra high performance liquid chromatography with tandem mass spectrometry after oral administration of agarwood ethanol extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33866677/),%,15,198225,DB00898,Ethanol
,10719611,absolute bioavailability (F),"The extent of the absolute bioavailability (F) of tramadol in the drops, based on AUC data, was 70.6 (1.13)% with a 90% confidence interval of 65.9-75.6% (ANOVAlog).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),%,70.6,198629,DB00898,Ethanol
,10719611,tmax,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),h,1.2,198630,DB00898,Ethanol
,10719611,Cmax,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),[ng] / [ml],136,198631,DB00898,Ethanol
,10719611,ka,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),h,0.23,198632,DB00898,Ethanol
,10719611,lag time t0,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),h,0.23,198633,DB00898,Ethanol
,26231237,Michaelis constant (km),"This enzyme was purified and characterized in the early 1950s and shown to have a low Michaelis constant (km), being about ~0.1 g/L.",Pharmacokinetics of Ethanol - Issues of Forensic Importance. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26231237/),[g] / [l],0.1,198905,DB00898,Ethanol
,26231237,elimination rates,"Owing to the combined influences of genetic and environmental factors, one expects a roughly threefold difference in elimination rates of ethanol from blood (0.1-0.3 g/L/h) between individuals.",Pharmacokinetics of Ethanol - Issues of Forensic Importance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26231237/),[g] / [h·l],0.1-0.3,198906,DB00898,Ethanol
,11447235,t(1/2),PGE(2)-G was rapidly hydrolyzed in rat plasma to generate PGE(2) (t(1/2) = 14 s) but was only slowly metabolized in human plasma (t(1/2) > 10 min).,Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),s,14,198936,DB00898,Ethanol
>,11447235,t(1/2),PGE(2)-G was rapidly hydrolyzed in rat plasma to generate PGE(2) (t(1/2) = 14 s) but was only slowly metabolized in human plasma (t(1/2) > 10 min).,Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),min,10,198937,DB00898,Ethanol
,11447235,t(1/2),An intermediate extent of metabolism of PGE(2)-G was observed in human whole blood (t(1/2) approximately 7 min).,Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),min,7,198938,DB00898,Ethanol
over,11447235,half-life,"However, PGE(2)-EA was detectable up to 2 h following an identical dose, displaying a large apparent volume of distribution and a half-life of over 6 min.",Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11447235/),min,6,198939,DB00898,Ethanol
,16941160,detection limits,"The detection limits for FAA in water, blood plasma, and organ homogenates are 0.001 microg mL(-1), 0.01 microg mL(-1), and 0.01 microg g(-1), respectively.",Determination of fluoroacetic acid in water and biological samples by GC-FID and GC-MS in combination with solid-phase microextraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941160/),[μg] / [ml],0.001,199673,DB00898,Ethanol
,16941160,detection limits,"The detection limits for FAA in water, blood plasma, and organ homogenates are 0.001 microg mL(-1), 0.01 microg mL(-1), and 0.01 microg g(-1), respectively.",Determination of fluoroacetic acid in water and biological samples by GC-FID and GC-MS in combination with solid-phase microextraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941160/),[μg] / [ml],0.01,199674,DB00898,Ethanol
,16941160,detection limits,"The detection limits for FAA in water, blood plasma, and organ homogenates are 0.001 microg mL(-1), 0.01 microg mL(-1), and 0.01 microg g(-1), respectively.",Determination of fluoroacetic acid in water and biological samples by GC-FID and GC-MS in combination with solid-phase microextraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941160/),[μg] / [g],0.01,199675,DB00898,Ethanol
,12959253,t 1/2,"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),min,4.92-17.5,202013,DB00898,Ethanol
,12959253,t 1/2,"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),min,55.72-74.52,202014,DB00898,Ethanol
,12959253,C(max),"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),[μg] / [cm3],11-13,202015,DB00898,Ethanol
,12959253,AUC,"We found that tryptamide undergoes fast absorption (t 1/2 = 4.92-17.5 min) and elimination (t 1/2 = 55.72-74.52 min), can reach C(max) values (11-13 microg/cm3) after 30 min, and gives AUC values in the range of 21.40-27.30 (microg x h/cm3).",Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959253/),[h·μg] / [cm3],21.40-27.30,202016,DB00898,Ethanol
,9526829,area under the ethanol concentration-time curve (AUC),Median area under the ethanol concentration-time curve (AUC) was lower during P1 (215.33 mg.h dl(-1)) than during P2 (231.33 mg.h dl(-1))(P = 0.8253).,Effect of the menstrual cycle in ethanol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9526829/),[h·mg] / [dl],215.33,202325,DB00898,Ethanol
,9526829,area under the ethanol concentration-time curve (AUC),Median area under the ethanol concentration-time curve (AUC) was lower during P1 (215.33 mg.h dl(-1)) than during P2 (231.33 mg.h dl(-1))(P = 0.8253).,Effect of the menstrual cycle in ethanol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9526829/),[h·mg] / [dl],231.33,202326,DB00898,Ethanol
,14628452,Tmax,"The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.",Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628452/),h,2.1,202488,DB00898,Ethanol
,14628452,CLs,"The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.",Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628452/),[h·μg] / [l],0.30,202489,DB00898,Ethanol
,8149868,time-to-peak plasma concentrations,The time-to-peak plasma concentrations following dermal treatments was 37.5 +/- 8.7 min.,"Pharmacokinetic assessment of the dermal absorption of N,N-diethyl-m-toluamide (DEET) in cattle. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149868/),min,37.5,202536,DB00898,Ethanol
,8149868,steady-state plasma levels,Linear pharmacokinetics was demonstrated with four additional cattle by comparing systemic clearance after intravenous infusion to steady-state plasma levels of approximately 0.5 and 2.5 micrograms/ml.,"Pharmacokinetic assessment of the dermal absorption of N,N-diethyl-m-toluamide (DEET) in cattle. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149868/),[μg] / [ml],0.5,202537,DB00898,Ethanol
,8149868,steady-state plasma levels,Linear pharmacokinetics was demonstrated with four additional cattle by comparing systemic clearance after intravenous infusion to steady-state plasma levels of approximately 0.5 and 2.5 micrograms/ml.,"Pharmacokinetic assessment of the dermal absorption of N,N-diethyl-m-toluamide (DEET) in cattle. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8149868/),[μg] / [ml],2.5,202538,DB00898,Ethanol
,9581607,half-life,A rapid washout with a half-life between 25.9 +/- 5.6 min for the lower dose and 34.3 +/- 4.2 min for the higher dose of Glc-IPM was observed in the tumor.,Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9581607/),min,25.9,202815,DB00898,Ethanol
,9581607,half-life,A rapid washout with a half-life between 25.9 +/- 5.6 min for the lower dose and 34.3 +/- 4.2 min for the higher dose of Glc-IPM was observed in the tumor.,Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9581607/),min,34.3,202816,DB00898,Ethanol
,29424805,AUC0-24h,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],3178,203142,DB00898,Ethanol
,29424805,AUC0-∞,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],3879,203143,DB00898,Ethanol
,29424805,AUC0-∞,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],1932,203144,DB00898,Ethanol
,29424805,AUC0-∞,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [h·l],4208,203145,DB00898,Ethanol
,29424805,Cmax,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [l],492,203146,DB00898,Ethanol
,29424805,Cmax,"In treatment A, average values of AUC0-24h, AUC0-∞, and Cmax were 3178 ng/h/L, 3879 ng/h/L, and 492 ng/L for blonanserin, and 1932 ng/h/L, 4208 ng/h/L, and 137 ng/L for N-deethylated blonanserin, respectively.",Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29424805/),[ng] / [l],137,203147,DB00898,Ethanol
<,7625572,half-life,Fitting of the experimental data to a two-compartmental mammillary model revealed that the labeled compounds are eliminated from the plasma with a half-life of < 1 min during the early time following the intravenous injection and that a large portion of the EthLin is hydrolyzed instantly to linoleic acid and ethanol.,Turnover of ethyl-linoleate in rat plasma and its distribution in various organs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625572/),min,1,203401,DB00898,Ethanol
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,9,203445,DB00898,Ethanol
,21593282,t(max),Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water.,Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21593282/),h,4,203446,DB00898,Ethanol
,2510294,t1/2,The dose-limiting urotoxicity of the oxazaphosphorines (t1/2 = 4-15 h) is due to renal elimination of metabolites such as acrolein.,"[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510294/),h,4-15,203755,DB00898,Ethanol
,2510294,bioavailability,The bioavailability of oral MESNA is in the range of 20-50% and its unpleasant taste severely limits patient compliance.,"[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510294/),%,20-50,203756,DB00898,Ethanol
,2510294,half-life,Due to the short half-life of MESNA (approx. 40 min) a regular fractionated or continuous administration is mandatory.,"[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510294/),min,40,203757,DB00898,Ethanol
,2510294,Total elimination,Total elimination of i.v. MESNA was 83.2 +/- 3.4% of the dose administered.,"[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510294/),%,83.2,203758,DB00898,Ethanol
,15917657,Surface tension,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mn] / [m],37.0,205106,DB00898,Ethanol
,15917657,Surface tension,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mn] / [m],38.1,205107,DB00898,Ethanol
,15917657,critical micellar concentration,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mn] / [m],38.1,205108,DB00898,Ethanol
,15917657,critical micellar concentration,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mg] / [ml],0.0387,205109,DB00898,Ethanol
,15917657,critical micellar concentration,"Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively.",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[mg] / [ml],0.0307,205110,DB00898,Ethanol
,15917657,clearance,"Over the tested dose range, the mean clearance of paclitaxel decreased from 45.1 to 16.9 L/h for Taxol, and from 50.7 to 16.4 L/h for Paxene (p > 0.05).",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[l] / [h],45.1 to 16.9,205111,DB00898,Ethanol
,15917657,clearance,"Over the tested dose range, the mean clearance of paclitaxel decreased from 45.1 to 16.9 L/h for Taxol, and from 50.7 to 16.4 L/h for Paxene (p > 0.05).",Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917657/),[l] / [h],50.7 to 16.4,205112,DB00898,Ethanol
,2551696,plasma half-life,The mean peak plasma concentration of Me-DDC occurred at 1.8 h and its plasma half-life was 6.3 h.,Inhibition of erythrocyte aldehyde dehydrogenase activity and elimination kinetics of diethyldithiocarbamic acid methyl ester and its monothio analogue after administration of single and repeated doses of disulfiram to man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2551696/),h,6.3,205580,DB00898,Ethanol
,2551696,peak plasma concentration,"In alcoholics with a rapid decrease in erythrocyte ALDH activity (in less than 5 days), the mean peak plasma concentration of Me-DTC was 278 nmol.l-1, whereas the peak concentration was below the detection limit in subjects with a prolonged inactivation time (7-20 days).",Inhibition of erythrocyte aldehyde dehydrogenase activity and elimination kinetics of diethyldithiocarbamic acid methyl ester and its monothio analogue after administration of single and repeated doses of disulfiram to man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2551696/),[nM] / [l],278,205581,DB00898,Ethanol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),[100·ml·tissue] / [ml],5.88,205656,DB00898,Ethanol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),[100·ml·tissue] / [ml],5.17,205657,DB00898,Ethanol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),100·ml,5.53,205658,DB00898,Ethanol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),[tissue] / [ml],5.97,205659,DB00898,Ethanol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,617,205660,DB00898,Ethanol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,548,205661,DB00898,Ethanol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,483,205662,DB00898,Ethanol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,593,205663,DB00898,Ethanol
,28516478,flow rate,"After curcuminoid extraction using 99.5% ethanol, bisdemethoxycurcumin (BDMC), demethoxycurcumin (DMC) and curcumin were separated within 10 min by high-performance liquid chromatography using an Eclipse XDB-C18 column (Agilent, Palo Alto, CA, USA) and a gradient mobile phase of 0.1% aqueous formic acid and acetonitrile, with a flow rate of 1 mL min-1 , column temperature of 35 °C and detection wavelength of 425 nm.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),[ml] / [min],1,205906,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,34.39,205907,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,4.65,205908,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,39.93,205909,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,5.49,205910,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,47.82,205911,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,9.38,205912,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,46,205913,DB00898,Ethanol
,28516478,oral bioavailabilities,"The oral bioavailabilities of BDMC, DMC, curcumin and total curcuminoids in nanoemulsion and dispersion were 34.39 and 4.65%, 39.93 and 5.49%, 47.82 and 9.38%, and 46 and 8.7%, respectively.",Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28516478/),%,8.7,205914,DB00898,Ethanol
,9397553,terminal half-life,EtG was eliminated with a terminal half-life of 2 to 3 h.,"Ethyl glucuronide concentration in serum of human volunteers, teetotalers, and suspected drinking drivers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9397553/),h,2 to 3,205984,DB00898,Ethanol
,33069713,% transmittance,"L-CAP-3 comprising of 15% isopropyl myristate, 33.75% Labrafil, & 11.25% ethanol exhibited higher % transmittance (98.90 ± 1.24%) & lower self-emulsification time (18.19 ± 0.46 s).","Capsaicin Loaded Solid SNEDDS for Enhanced Bioavailability and Anticancer Activity: In-Vitro, In-Silico, and In-Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33069713/),%,98.90,206235,DB00898,Ethanol
,33069713,self-emulsification time,"L-CAP-3 comprising of 15% isopropyl myristate, 33.75% Labrafil, & 11.25% ethanol exhibited higher % transmittance (98.90 ± 1.24%) & lower self-emulsification time (18.19 ± 0.46 s).","Capsaicin Loaded Solid SNEDDS for Enhanced Bioavailability and Anticancer Activity: In-Vitro, In-Silico, and In-Vivo Characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33069713/),s,18.19,206236,DB00898,Ethanol
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),min,20-90,206677,DB00898,Ethanol
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.3,206678,DB00898,Ethanol
,2842128,bio-availability,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,16,206679,DB00898,Ethanol
,2842128,half-life,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.7-1.3,206680,DB00898,Ethanol
,2842128,plasma,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206681,DB00898,Ethanol
,2842128,blood clearance,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206682,DB00898,Ethanol
,2842128,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,40,206683,DB00898,Ethanol
,2842128,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),kg,0.6-1,206684,DB00898,Ethanol
,9431825,peak blood-alcohol concentrations (BAC),"The peak blood-alcohol concentrations (BAC) were 16.6 +/- 4.0, 17.7 +/- 7.1, and 13.3 +/- 4.0 mg dl-1 (mean +/- s.d.) after fat, CHO, and protein-rich meals and 30.8 +/- 4.3 and 54.3 +/- 6.4 mg dl-1 after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg] / [dl],16.6,207043,DB00898,Ethanol
,9431825,peak blood-alcohol concentrations (BAC),"The peak blood-alcohol concentrations (BAC) were 16.6 +/- 4.0, 17.7 +/- 7.1, and 13.3 +/- 4.0 mg dl-1 (mean +/- s.d.) after fat, CHO, and protein-rich meals and 30.8 +/- 4.3 and 54.3 +/- 6.4 mg dl-1 after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg] / [dl],17.7,207044,DB00898,Ethanol
,9431825,peak blood-alcohol concentrations (BAC),"The peak blood-alcohol concentrations (BAC) were 16.6 +/- 4.0, 17.7 +/- 7.1, and 13.3 +/- 4.0 mg dl-1 (mean +/- s.d.) after fat, CHO, and protein-rich meals and 30.8 +/- 4.3 and 54.3 +/- 6.4 mg dl-1 after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg] / [dl],13.3,207045,DB00898,Ethanol
,9431825,peak blood-alcohol concentrations (BAC),"The peak blood-alcohol concentrations (BAC) were 16.6 +/- 4.0, 17.7 +/- 7.1, and 13.3 +/- 4.0 mg dl-1 (mean +/- s.d.) after fat, CHO, and protein-rich meals and 30.8 +/- 4.3 and 54.3 +/- 6.4 mg dl-1 after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg] / [dl],30.8,207046,DB00898,Ethanol
,9431825,peak blood-alcohol concentrations (BAC),"The peak blood-alcohol concentrations (BAC) were 16.6 +/- 4.0, 17.7 +/- 7.1, and 13.3 +/- 4.0 mg dl-1 (mean +/- s.d.) after fat, CHO, and protein-rich meals and 30.8 +/- 4.3 and 54.3 +/- 6.4 mg dl-1 after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg] / [dl],54.3,207047,DB00898,Ethanol
,9431825,areas under the concentration-time profiles (AUC),"The corresponding areas under the concentration-time profiles (AUC) were 1767 +/ -549, 1619 +/- 760 1270 +/- 406 mg dl-1 min after fat, CHO, and protein-rich meals compared with 3210 +/- 527 and 4786 +/- 446 mg dl-1 min after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg·min] / [dl],1767,207048,DB00898,Ethanol
,9431825,areas under the concentration-time profiles (AUC),"The corresponding areas under the concentration-time profiles (AUC) were 1767 +/ -549, 1619 +/- 760 1270 +/- 406 mg dl-1 min after fat, CHO, and protein-rich meals compared with 3210 +/- 527 and 4786 +/- 446 mg dl-1 min after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg·min] / [dl],1619,207049,DB00898,Ethanol
,9431825,areas under the concentration-time profiles (AUC),"The corresponding areas under the concentration-time profiles (AUC) were 1767 +/ -549, 1619 +/- 760 1270 +/- 406 mg dl-1 min after fat, CHO, and protein-rich meals compared with 3210 +/- 527 and 4786 +/- 446 mg dl-1 min after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg·min] / [dl],1270,207050,DB00898,Ethanol
,9431825,areas under the concentration-time profiles (AUC),"The corresponding areas under the concentration-time profiles (AUC) were 1767 +/ -549, 1619 +/- 760 1270 +/- 406 mg dl-1 min after fat, CHO, and protein-rich meals compared with 3210 +/- 527 and 4786 +/- 446 mg dl-1 min after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg·min] / [dl],3210,207051,DB00898,Ethanol
,9431825,areas under the concentration-time profiles (AUC),"The corresponding areas under the concentration-time profiles (AUC) were 1767 +/ -549, 1619 +/- 760 1270 +/- 406 mg dl-1 min after fat, CHO, and protein-rich meals compared with 3210 +/- 527 and 4786 +/- 446 mg dl-1 min after fasting and i.v. infusion, respectively.","Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431825/),[mg·min] / [dl],4786,207052,DB00898,Ethanol
,11849919,t(1/2)(beta),"The core of deramciclane, carrying the ring label, was almost completely eliminated during 24 h, while the elimination of the side chain was very slow (t(1/2)(beta): 99 h).",Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11849919/),h,99,207057,DB00898,Ethanol
,21719363,extraction efficiency,"The method involves a single ethanol extraction of mitotane, DDE, DDA, and an internal standard (int std) p,p'-DDD (1,1-dichloro-2,2-bis(p-chlorophenyl)ethane) with an extraction efficiency of 77-88%.",A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21719363/),%,77-88,207677,DB00898,Ethanol
,21719363,flow rate,All compounds are measured simultaneously using a reversed-phase phenyl HPLC column with an isocratic elution of mobile phase at a flow rate of 0.6 ml/min followed by UV detection at λ 226 nm.,A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21719363/),[ml] / [min],0.6,207678,DB00898,Ethanol
,21719363,Limits of quantitation,"Limits of quantitation are 0.2 μg/ml for mitotane and DDE, and 0.5 μg/ml for DDA.",A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21719363/),[μg] / [ml],0.2,207679,DB00898,Ethanol
,21719363,Limits of quantitation,"Limits of quantitation are 0.2 μg/ml for mitotane and DDE, and 0.5 μg/ml for DDA.",A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21719363/),[μg] / [ml],0.5,207680,DB00898,Ethanol
,31625026,oral bioavailability,Lercanidipine HCl (LER) is a vasoselective calcium-channel blocker that has a poor oral bioavailability of 10% due to its hepatic metabolism and low solubility.,"A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625026/),%,10,207690,DB00898,Ethanol
,31625026,vesicle size,Nanoethosomes showed a mean vesicle size between 210.87 and 400.57 nm and EE% ranging from 49.26 to 97.22%.,"A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625026/),nm,210.87 and 400.57,207691,DB00898,Ethanol
,31625026,EE%,Nanoethosomes showed a mean vesicle size between 210.87 and 400.57 nm and EE% ranging from 49.26 to 97.22%.,"A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625026/),%,49.26 to 97.22,207692,DB00898,Ethanol
,30393218,PDI,"The EE of C-CA-R-CPLs of CA and R was 91.3±2.13% and 92.6±2.44%, particle size of C-CA-R-CPLs was 176.7±2.3 nm, PDI was 0.207±0.014 and zeta potential of 12.61±1.33 mV.","Chitosan coated chlorogenic acid and rutincomposite phospholipid liposomes: Preparation, characterizations, permeability and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393218/),,0.207,208502,DB00898,Ethanol
,30393218,zeta potential,"The EE of C-CA-R-CPLs of CA and R was 91.3±2.13% and 92.6±2.44%, particle size of C-CA-R-CPLs was 176.7±2.3 nm, PDI was 0.207±0.014 and zeta potential of 12.61±1.33 mV.","Chitosan coated chlorogenic acid and rutincomposite phospholipid liposomes: Preparation, characterizations, permeability and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393218/),mv,12.61,208503,DB00898,Ethanol
,21876056,areas under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)s),"Although artemether bioavailability was variable and its clearance increased by 67.8% with each dose, the median areas under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)s) for artemether and dihydroartemisinin (3,063 and 2,839 μg · h/liter, respectively) were similar to those reported previously in adults with malaria.","Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21876056/),[h·μg] / [l],"3,063",208685,DB00898,Ethanol
,21876056,areas under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)s),"Although artemether bioavailability was variable and its clearance increased by 67.8% with each dose, the median areas under the plasma concentration-time curve from 0 h to infinity (AUC(0-∞)s) for artemether and dihydroartemisinin (3,063 and 2,839 μg · h/liter, respectively) were similar to those reported previously in adults with malaria.","Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21876056/),[h·μg] / [l],"2,839",208686,DB00898,Ethanol
,21876056,AUC(0-∞),"For lumefantrine, the median AUC(0-∞) (459,980 μg · h/liter) was also similar to that in adults with malaria.","Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21876056/),[h·μg] / [l],"459,980",208687,DB00898,Ethanol
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.973,209164,DB00898,Ethanol
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.136,209165,DB00898,Ethanol
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.041,209166,DB00898,Ethanol
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,38,209167,DB00898,Ethanol
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,53,209168,DB00898,Ethanol
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,75,209169,DB00898,Ethanol
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,2.72,209170,DB00898,Ethanol
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,1.22,209171,DB00898,Ethanol
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.794,209172,DB00898,Ethanol
,8421321,time to maximum plasma concentration (Tmax),"When CHN alone was administered orally, the time to maximum plasma concentration (Tmax) of CHN was as short as 15 min, but that of CHL was 120 min.",Metabolic interaction of ethanol and cyclohexanone in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8421321/),min,15,209236,DB00898,Ethanol
,8421321,time to maximum plasma concentration (Tmax),"When CHN alone was administered orally, the time to maximum plasma concentration (Tmax) of CHN was as short as 15 min, but that of CHL was 120 min.",Metabolic interaction of ethanol and cyclohexanone in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8421321/),min,120,209237,DB00898,Ethanol
,6152164,Peak concentrations,Peak concentrations of 96-160 pg/ml were reached between 1.5 and 3.2 h and drug concentrations declined thereafter in a biphasic pattern.,Single dose pharmacokinetics of mabuterol in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6152164/),[pg] / [ml],96-160,209267,DB00898,Ethanol
,6152164,t 1/2 beta,Elimination of unchanged drug was slow (t 1/2 beta 20-30 h) due to a low clearance (CL/F 3.0 ml/min/kg) and a large volume of distribution (V beta/F 5.8 l/kg).,Single dose pharmacokinetics of mabuterol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6152164/),h,20-30,209268,DB00898,Ethanol
,6152164,clearance (CL/F,Elimination of unchanged drug was slow (t 1/2 beta 20-30 h) due to a low clearance (CL/F 3.0 ml/min/kg) and a large volume of distribution (V beta/F 5.8 l/kg).,Single dose pharmacokinetics of mabuterol in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6152164/),[ml] / [kg·min],3.0,209269,DB00898,Ethanol
,6152164,volume of distribution (V beta/F,Elimination of unchanged drug was slow (t 1/2 beta 20-30 h) due to a low clearance (CL/F 3.0 ml/min/kg) and a large volume of distribution (V beta/F 5.8 l/kg).,Single dose pharmacokinetics of mabuterol in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6152164/),[l] / [kg],5.8,209270,DB00898,Ethanol
greater,6152164,F,Absorption of the drug from the gastrointestinal tract was complete and availability of unchanged drug to the systemic circulation could be estimated (F greater than 0.91) using flow model concepts.,Single dose pharmacokinetics of mabuterol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6152164/),,0.91,209271,DB00898,Ethanol
,6152164,cumulative amount,Fecal excretion was low with a cumulative amount recovered over the entire study period of 3%.,Single dose pharmacokinetics of mabuterol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6152164/),%,3,209272,DB00898,Ethanol
,10665129,peak FEV1 change,"Mean peak FEV1 change (primary endpoint) was maximum with the administration of the combination of ipratropium and formoterol (335.2 ml, SE 24.6), and it differed significantly from the observed peak changes following single administration of the two tested doses of ipratropium (p < 0.05 and p < 0.05 respectively).","Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10665129/),ml,335.2,209358,DB00898,Ethanol
,20058846,(beta60),"The value of (beta60) in experiment 1 was estimated at 0.17 +/- 0.04 per thousand/hour in young men aged between 18-26 years, 0.22 per thousand/hour in adult men of 32-48 years, and 0.21 per thousand/hour in women aged between 19-41 years.","[Ethanol elimination rate (beta60, beta-slope) in different age groups after intake of a moderate or high dose of alcohol]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058846/),1/[h·thousand],0.17,209383,DB00898,Ethanol
,20058846,(beta60),"The value of (beta60) in experiment 1 was estimated at 0.17 +/- 0.04 per thousand/hour in young men aged between 18-26 years, 0.22 per thousand/hour in adult men of 32-48 years, and 0.21 per thousand/hour in women aged between 19-41 years.","[Ethanol elimination rate (beta60, beta-slope) in different age groups after intake of a moderate or high dose of alcohol]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058846/),1/[h·thousand],0.22,209384,DB00898,Ethanol
,20058846,(beta60),"The value of (beta60) in experiment 1 was estimated at 0.17 +/- 0.04 per thousand/hour in young men aged between 18-26 years, 0.22 per thousand/hour in adult men of 32-48 years, and 0.21 per thousand/hour in women aged between 19-41 years.","[Ethanol elimination rate (beta60, beta-slope) in different age groups after intake of a moderate or high dose of alcohol]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058846/),1/[h·thousand],0.21,209385,DB00898,Ethanol
,20058846,elimination rate,"In the second experiment, ethanol elimination rate was practically identical in men of the above age groups (0.16 +/- 0. 02 per thousand/hour) and significantly higher than in 64-66 year-old men (0.14 +/- 0.03 per thousand/hour).","[Ethanol elimination rate (beta60, beta-slope) in different age groups after intake of a moderate or high dose of alcohol]. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058846/),1/[h·thousand],0.16,209386,DB00898,Ethanol
,20058846,elimination rate,"In the second experiment, ethanol elimination rate was practically identical in men of the above age groups (0.16 +/- 0. 02 per thousand/hour) and significantly higher than in 64-66 year-old men (0.14 +/- 0.03 per thousand/hour).","[Ethanol elimination rate (beta60, beta-slope) in different age groups after intake of a moderate or high dose of alcohol]. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20058846/),1/[h·thousand],0.14,209387,DB00898,Ethanol
,2612087,total peripheral resistance,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[mmhg] / [l·min],13,209446,DB00898,Ethanol
,2612087,total peripheral resistance,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[mmhg] / [l·min],17,209447,DB00898,Ethanol
,2612087,heart rate,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,72,209448,DB00898,Ethanol
,2612087,heart rate,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,67,209449,DB00898,Ethanol
,2612087,cardiac index,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[l] / [m2·min],3.7,209450,DB00898,Ethanol
,2612087,cardiac index,"Felodipine plus ethanol decreased mean (+/- SE) supine total peripheral resistance (13 +/- 2 vs 17 +/- 2 mmHg/L/min, p = 0.05) and diastolic blood pressure (68 +/- 3 vs 75 +/- 2 mmHg, p less than 0.05) associated with increased heart rate (72 +/- 3 vs 67 +/- 2 bpm, p less than 0.05) and cardiac index (3.7 +/- 0.4 vs 3.0 +/- 0.3 L/min/m2, p less than 0.05) more than felodipine alone.",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),[l] / [m2·min],3.0,209451,DB00898,Ethanol
,2612087,heart rate,"Co-administration of ethanol decreased standing systolic (113 +/- 8 vs 126 +/- 5 mmHg, p less than 0.01) and diastolic (69 +/- 5 vs 82 +/- 3 mmHg, p less than 0.01) blood pressure to a greater degree, but heart rate was not altered (87 +/- 6 vs 84 +/- 3 bpm).",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,87,209452,DB00898,Ethanol
,2612087,heart rate,"Co-administration of ethanol decreased standing systolic (113 +/- 8 vs 126 +/- 5 mmHg, p less than 0.01) and diastolic (69 +/- 5 vs 82 +/- 3 mmHg, p less than 0.01) blood pressure to a greater degree, but heart rate was not altered (87 +/- 6 vs 84 +/- 3 bpm).",Ethanol enhances the hemodynamic effects of felodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612087/),bpm,84,209453,DB00898,Ethanol
,1800701,Cmax,"After the buccal treatment, mean Cmax and Tmax values were 0.751 micrograms/mL and 41 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[μg] / [ml],0.751,209523,DB00898,Ethanol
,1800701,Tmax,"After the buccal treatment, mean Cmax and Tmax values were 0.751 micrograms/mL and 41 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),min,41,209524,DB00898,Ethanol
,1800701,Cmax,"Average Cmax and Tmax values after the oral treatment were 10.8 micrograms/mL and 32 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[μg] / [ml],10.8,209525,DB00898,Ethanol
,1800701,Tmax,"Average Cmax and Tmax values after the oral treatment were 10.8 micrograms/mL and 32 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),min,32,209526,DB00898,Ethanol
,1800701,dose-corrected AUCs,"Mean dose-corrected AUCs were 0.0854 and 0.811 (micrograms.h/mL)/mg for the buccal and the oral treatments, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[h·μgrams] / [mg·ml)],0.0854,209527,DB00898,Ethanol
,1800701,dose-corrected AUCs,"Mean dose-corrected AUCs were 0.0854 and 0.811 (micrograms.h/mL)/mg for the buccal and the oral treatments, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[h·μgrams] / [mg·ml)],0.811,209528,DB00898,Ethanol
,1800701,ka,"Analysis, by ELRM, of the plasma concentration-time data obtained after the buccal treatment indicated first-order absorption, with a mean ka value of 3.9 +/- 2.2 h-1.",Absorption of flurbiprofen through human buccal mucosa. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),1/[h],3.9,209529,DB00898,Ethanol
,1800701,ka,"This value was significantly different (0.05 greater than p greater than 0.02) from the ka after oral treatment (7.89 +/- 5.2 h-1), obtained from the triexponential fitting of the oral plasma data.",Absorption of flurbiprofen through human buccal mucosa. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),1/[h],7.89,209530,DB00898,Ethanol
,14502365,total counts,"There was no difference in total counts between the two types of radioaerosol at any time (mean of approximately 188,000 cpm for male and female subjects at time zero in both aerosols).",Evaluation of two 99mTc-DTPA radioaerosols with different characteristics in lung ventilation studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14502365/),cpm,"188,000",209978,DB00898,Ethanol
,14502365,clearance half-life,The clearance half-life did not differ between aerosols (mean of ~80-88 min for male and female subjects for both aerosols).,Evaluation of two 99mTc-DTPA radioaerosols with different characteristics in lung ventilation studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14502365/),min,80-88,209979,DB00898,Ethanol
,9073601,Vmax,Mice showed a higher whole-body metabolic capacity compared to rats (Vmax = 0.3 vs 0.1 mg/hr-kg).,Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[mg] / [hr-kg],0.3,210092,DB00898,Ethanol
,9073601,Vmax,Mice showed a higher whole-body metabolic capacity compared to rats (Vmax = 0.3 vs 0.1 mg/hr-kg).,Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[mg] / [hr-kg],0.1,210093,DB00898,Ethanol
<,9073601,Km,Both species had an estimated Km of < or = 0.02 mg/liter.,Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[mg] / [l],0.02,210094,DB00898,Ethanol
,9073601,Vmax,"Consistent with the in vivo data, VF was metabolized faster by mouse microsomes than by rat microsomes (Vmax = 3.5 and 1.1 nmol/hr-mg protein, respectively).",Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[nM] / [hr-mg],3.5,210095,DB00898,Ethanol
,9073601,Vmax,"Consistent with the in vivo data, VF was metabolized faster by mouse microsomes than by rat microsomes (Vmax = 3.5 and 1.1 nmol/hr-mg protein, respectively).",Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[nM] / [hr-mg],1.1,210096,DB00898,Ethanol
,9073601,Vmax,"The rates of metabolism by human liver microsomes were generally in the same range as those found with rat liver microsomes (Vmax = 0.5-1.3 nmol/hr-mg protein), but one sample was similar to mice (Vmax = 3.3 nmol/ hr-mg protein).",Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[nM] / [hr-mg],0.5-1.3,210097,DB00898,Ethanol
,9073601,Vmax,"The rates of metabolism by human liver microsomes were generally in the same range as those found with rat liver microsomes (Vmax = 0.5-1.3 nmol/hr-mg protein), but one sample was similar to mice (Vmax = 3.3 nmol/ hr-mg protein).",Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9073601/),[nM] / [hr-mg],3.3,210098,DB00898,Ethanol
,18434109,zeta potential,"Following 1:10 aqueous dilution of optimal 9-NC SMEDDS, the droplet sizes of resulting microemulsions were (30.8+/-4.6)nm and (39.8+/-8.2)nm for SMEDDS T-form and C-form, respectively, and the zeta potential values were -(4.3+/-0.5)mV and -(5.7+/-0.5)mV, respectively.",Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),mv,4.3,210878,DB00898,Ethanol
,18434109,zeta potential,"Following 1:10 aqueous dilution of optimal 9-NC SMEDDS, the droplet sizes of resulting microemulsions were (30.8+/-4.6)nm and (39.8+/-8.2)nm for SMEDDS T-form and C-form, respectively, and the zeta potential values were -(4.3+/-0.5)mV and -(5.7+/-0.5)mV, respectively.",Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),mv,5.7,210879,DB00898,Ethanol
,18434109,growth inhibition (IC50),"In SKOV-3 cells, the growth inhibition (IC50) of various 9-NC formulations was greatest with SMEDDS T-form (3.5+/-0.7 nM) followed by SMEDDS C-form (4.6+/-0.4 nM), 9-NC solution (6.6+/-1.4 nM) and 9-NC suspension (26.0+/-2.9 nM) (P<0.01).",Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),nM,3.5,210880,DB00898,Ethanol
,18434109,growth inhibition (IC50),"In SKOV-3 cells, the growth inhibition (IC50) of various 9-NC formulations was greatest with SMEDDS T-form (3.5+/-0.7 nM) followed by SMEDDS C-form (4.6+/-0.4 nM), 9-NC solution (6.6+/-1.4 nM) and 9-NC suspension (26.0+/-2.9 nM) (P<0.01).",Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),nM,4.6,210881,DB00898,Ethanol
,18434109,growth inhibition (IC50),"In SKOV-3 cells, the growth inhibition (IC50) of various 9-NC formulations was greatest with SMEDDS T-form (3.5+/-0.7 nM) followed by SMEDDS C-form (4.6+/-0.4 nM), 9-NC solution (6.6+/-1.4 nM) and 9-NC suspension (26.0+/-2.9 nM) (P<0.01).",Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),nM,6.6,210882,DB00898,Ethanol
,18434109,growth inhibition (IC50),"In SKOV-3 cells, the growth inhibition (IC50) of various 9-NC formulations was greatest with SMEDDS T-form (3.5+/-0.7 nM) followed by SMEDDS C-form (4.6+/-0.4 nM), 9-NC solution (6.6+/-1.4 nM) and 9-NC suspension (26.0+/-2.9 nM) (P<0.01).",Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),nM,26.0,210883,DB00898,Ethanol
,18434109,area under the plasma concentration-time curve (AUC0-->8h),It was indicated that the area under the plasma concentration-time curve (AUC0-->8h) values of various formulations of 9-NC after oral administration ranked as the following sequence: SMEDDS T-form (360.12+/-19.44 ngh/ml) approximately SMEDDS C-form (351.71+/-33.66 ngh/ml) >9-NC solution (241.21+/-24.67 ngh/ml)>9-NC suspension (161.24+/-24.31 ngh/ml).,Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),[ngh] / [ml],360.12,210884,DB00898,Ethanol
,18434109,area under the plasma concentration-time curve (AUC0-->8h),It was indicated that the area under the plasma concentration-time curve (AUC0-->8h) values of various formulations of 9-NC after oral administration ranked as the following sequence: SMEDDS T-form (360.12+/-19.44 ngh/ml) approximately SMEDDS C-form (351.71+/-33.66 ngh/ml) >9-NC solution (241.21+/-24.67 ngh/ml)>9-NC suspension (161.24+/-24.31 ngh/ml).,Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),[ngh] / [ml],351.71,210885,DB00898,Ethanol
,18434109,area under the plasma concentration-time curve (AUC0-->8h),It was indicated that the area under the plasma concentration-time curve (AUC0-->8h) values of various formulations of 9-NC after oral administration ranked as the following sequence: SMEDDS T-form (360.12+/-19.44 ngh/ml) approximately SMEDDS C-form (351.71+/-33.66 ngh/ml) >9-NC solution (241.21+/-24.67 ngh/ml)>9-NC suspension (161.24+/-24.31 ngh/ml).,Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),[ngh] / [ml],241.21,210886,DB00898,Ethanol
,18434109,area under the plasma concentration-time curve (AUC0-->8h),It was indicated that the area under the plasma concentration-time curve (AUC0-->8h) values of various formulations of 9-NC after oral administration ranked as the following sequence: SMEDDS T-form (360.12+/-19.44 ngh/ml) approximately SMEDDS C-form (351.71+/-33.66 ngh/ml) >9-NC solution (241.21+/-24.67 ngh/ml)>9-NC suspension (161.24+/-24.31 ngh/ml).,Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18434109/),[ngh] / [ml],161.24,210887,DB00898,Ethanol
less,3435591,detection limit,The sensitivity of the procedure (detection limit less than 1 ng/ml) permits the performance of pharmacokinetic studies after therapeutic doses.,Fluorimetric determination of levoprotiline in human plasma after thin-layer chromatographic or high performance liquid chromatographic separation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435591/),[ng] / [ml],1,211374,DB00898,Ethanol
exceeding,28189361,maximum ethanol concentrations,"Single doses of 20 mg intranasal BMT, administered with or without 0.6 g/kg ethanol, were found to be safe and generally well tolerated with mean maximum ethanol concentrations exceeding 80 mg/dL in women.","Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189361/),[mg] / [dl],80,211518,DB00898,Ethanol
,23500380,absolute bioavailability,The absolute bioavailability of brucine was determined to be 40.83%.,Evaluation of the pharmacodynamics and pharmacokinetics of brucine following transdermal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23500380/),%,40.83,211687,DB00898,Ethanol
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [kcal·mol·mol],-7.6,212013,DB00898,Ethanol
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],-,212014,DB00898,Ethanol
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],8.8,212015,DB00898,Ethanol
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],8.0,212016,DB00898,Ethanol
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),k,7.7,212017,DB00898,Ethanol
,21985153,clearance (Cl),"After intravenous administration the clearance (Cl) and volume of distribution (Vd) of lumefantrine in rats were 0.03 (± 0.02) L/h/kg and 2.40 (± 0.67) L/kg, respectively.","Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985153/),[l] / [h·kg],0.03,212058,DB00898,Ethanol
,21985153,volume of distribution (Vd),"After intravenous administration the clearance (Cl) and volume of distribution (Vd) of lumefantrine in rats were 0.03 (± 0.02) L/h/kg and 2.40 (± 0.67) L/kg, respectively.","Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985153/),[l] / [kg],2.40,212059,DB00898,Ethanol
,21985153,Absolute oral bioavailability,Absolute oral bioavailability of lumefantrine across the tested doses ranged between 4.97% and 11.98%.,"Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985153/),%,4.97,212060,DB00898,Ethanol
,21985153,Absolute oral bioavailability,Absolute oral bioavailability of lumefantrine across the tested doses ranged between 4.97% and 11.98%.,"Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985153/),%,11.98,212061,DB00898,Ethanol
,21985153,permeability,Lumefantrine showed high permeability (4.37 × 10(-5) cm/s) in permeability study.,"Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985153/),[cm] / [s],4.37 × 10(-5),212062,DB00898,Ethanol
,24830648,flux,"The optimized valsartan gel formulation (VGF-OPT) yielded flux of 143.27 ± 7.11 µg/cm(2)/h and 27.55 ± 2.51 µg/cm(2)/h across rat and human cadaver skin, respectively.","Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24830648/),[μg] / [cm(2)·h],143.27,213473,DB00898,Ethanol
,24830648,flux,"The optimized valsartan gel formulation (VGF-OPT) yielded flux of 143.27 ± 7.11 µg/cm(2)/h and 27.55 ± 2.51 µg/cm(2)/h across rat and human cadaver skin, respectively.","Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24830648/),[μg] / [cm(2)·h],27.55,213474,DB00898,Ethanol
,3109461,maximum mesna concentration,The mean maximum mesna concentration after i.v. administration was 111 (s.d. +/- 28.3) nmol ml-1 and the mean maximum dimesna concentration was 183 (s.d. +/- 41.6) nmol ml-1.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[nM] / [ml],111,213935,DB00898,Ethanol
,3109461,maximum dimesna concentration,The mean maximum mesna concentration after i.v. administration was 111 (s.d. +/- 28.3) nmol ml-1 and the mean maximum dimesna concentration was 183 (s.d. +/- 41.6) nmol ml-1.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[nM] / [ml],183,213936,DB00898,Ethanol
,3109461,peak mesna concentration,Following oral mesna dosing the mean peak mesna concentration was 19.6 (s.d. +/- 10.2) nmol ml-1 but mesna was only found in the plasma of five of the six subjects.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[nM] / [ml],19.6,213937,DB00898,Ethanol
,3109461,peak dimesna concentration,The mean peak dimesna concentration was 22.5 (s.d. +/- 12.4) nmol ml-1.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[nM] / [ml],22.5,213938,DB00898,Ethanol
,3109461,half-life,"Following i.v. mesna administration, the mean half-life of mesna was 21.8 (s.d. +/- 3.1) min and total body clearance 1.23 (s.d. +/- 0.31) l kg-1 h-1.",Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),min,21.8,213939,DB00898,Ethanol
,3109461,total body clearance,"Following i.v. mesna administration, the mean half-life of mesna was 21.8 (s.d. +/- 3.1) min and total body clearance 1.23 (s.d. +/- 0.31) l kg-1 h-1.",Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[l] / [h·kg],1.23,213940,DB00898,Ethanol
,3109461,half-life,The mean half-life of dimesna was 1.17 (s.d. +/- 0.32) h.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),h,1.17,213941,DB00898,Ethanol
,3109461,concentration,The mean mesna concentration in the 0-4 h urine collection was 9.6 (s.d. +/- 10.7; range 1.4-28.7) nmol ml-1 following i.v. mesna injection.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),,9,213942,DB00898,Ethanol
,3109461,peak mesna concentration,The mean peak mesna concentration was 2.5 (s.d. +/- 1.7) mumol ml-1 (c.f. estimated uroprotective concentration of 1.7 mumol ml-1).,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[μM] / [ml],2.5,213943,DB00898,Ethanol
,3109461,uroprotective concentration,The mean peak mesna concentration was 2.5 (s.d. +/- 1.7) mumol ml-1 (c.f. estimated uroprotective concentration of 1.7 mumol ml-1).,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),mum,1.7,213944,DB00898,Ethanol
,3109461,urinary clearance,The mean 4 h urinary clearance of the uroprotective species mesna was 0.413 (s.d. +/- 0.136) l kg-1 h-1.,Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3109461/),[l] / [h·kg],0.413,213945,DB00898,Ethanol
,10582871,peak concentration,"The peak concentration of abacavir in CSF ranged from 0.6 to 1.4 microg/ml, which is 8 to 20 times the mean 50% inhibitory concentration for HIV clinical isolates in vitro (0.07 microg/ml).","Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582871/),[μg] / [ml],0.6 to 1.4,214998,DB00898,Ethanol
,10582871,50% inhibitory concentration,"The peak concentration of abacavir in CSF ranged from 0.6 to 1.4 microg/ml, which is 8 to 20 times the mean 50% inhibitory concentration for HIV clinical isolates in vitro (0.07 microg/ml).","Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582871/),[μg] / [ml],0.07,214999,DB00898,Ethanol
,7203731,T 1/2,"After intravenous injections (n = 4) of 1.5 mg/kg, the drug was rapidly distributed (mean T 1/2 = 4.9 min) and quite rapidly eliminated (mean T 1/2 = 4.9 hrs).",Pharmacokinetics of labetalol in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),min,4.9,215137,DB00898,Ethanol
,7203731,T 1/2,"After intravenous injections (n = 4) of 1.5 mg/kg, the drug was rapidly distributed (mean T 1/2 = 4.9 min) and quite rapidly eliminated (mean T 1/2 = 4.9 hrs).",Pharmacokinetics of labetalol in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),h,4.9,215138,DB00898,Ethanol
,7203731,total plasma clearance,The mean total plasma clearance value was 24.80 ml/min/kg.,Pharmacokinetics of labetalol in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),[ml] / [kg·min],24.80,215139,DB00898,Ethanol
,7203731,Vdc,The values for Vdc (mean 1.1 l/kg) and Vdss (mean 9.41 l/kg) indicate extensive extravascular distribution of labetalol.,Pharmacokinetics of labetalol in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),[l] / [kg],1.1,215140,DB00898,Ethanol
,7203731,Vdss,The values for Vdc (mean 1.1 l/kg) and Vdss (mean 9.41 l/kg) indicate extensive extravascular distribution of labetalol.,Pharmacokinetics of labetalol in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),[l] / [kg],9.41,215141,DB00898,Ethanol
,7203731,systemic availability,The systemic availability was about 18%.,Pharmacokinetics of labetalol in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),%,18,215142,DB00898,Ethanol
,11955827,rate constant,"The means+/-standard deviation of the rate constant for the first-order formation of EG from serum ethanol was 0.0011+/-0.0006 h(-1), the transfer constant for an obstructed transfer of EG from the FS into the CC was 0.43+/-0.1996 h(-1) and the exponential elimination constant was 3.0+/-1.45 h(-1).",A kinetic model describing the pharmacokinetics of ethyl glucuronide in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955827/),1/[h],0.0011,215249,DB00898,Ethanol
,11955827,transfer constant,"The means+/-standard deviation of the rate constant for the first-order formation of EG from serum ethanol was 0.0011+/-0.0006 h(-1), the transfer constant for an obstructed transfer of EG from the FS into the CC was 0.43+/-0.1996 h(-1) and the exponential elimination constant was 3.0+/-1.45 h(-1).",A kinetic model describing the pharmacokinetics of ethyl glucuronide in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955827/),1/[h],0.43,215250,DB00898,Ethanol
,11955827,elimination constant,"The means+/-standard deviation of the rate constant for the first-order formation of EG from serum ethanol was 0.0011+/-0.0006 h(-1), the transfer constant for an obstructed transfer of EG from the FS into the CC was 0.43+/-0.1996 h(-1) and the exponential elimination constant was 3.0+/-1.45 h(-1).",A kinetic model describing the pharmacokinetics of ethyl glucuronide in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955827/),1/[h],3.0,215251,DB00898,Ethanol
up to,1743171,bioavailability,"Storage of carbamazepine (CBZ) and phenytoin (PHT) formulations in hot, humid conditions alters the dosage form and reduces bioavailability up to 50%.",Pharmacokinetic pitfalls of present antiepileptic medications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743171/),%,50,215613,DB00898,Ethanol
,15198520,infusion time,"The dose was 40 mg/kg, and the infusion time was 8 to 9 minutes.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),min,8 to 9,215661,DB00898,Ethanol
,15198520,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1 +/- 3.32 microg-h/mL; Cre-pac: 34.5 +/- 0.994 microg-h/mL), however, the AUC for various tissues was formulation-dependent.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),[μg-h] / [ml],38.1,215662,DB00898,Ethanol
,15198520,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1 +/- 3.32 microg-h/mL; Cre-pac: 34.5 +/- 0.994 microg-h/mL), however, the AUC for various tissues was formulation-dependent.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),[μg-h] / [ml],34.5,215663,DB00898,Ethanol
,15198520,Cre,"The area under the concentration vs time curve (AUC) for blood was similar for the 2 formulations (L-pac: 38.1 +/- 3.32 microg-h/mL; Cre-pac: 34.5 +/- 0.994 microg-h/mL), however, the AUC for various tissues was formulation-dependent.",Pharmacokinetics of paclitaxel-containing liposomes in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15198520/),[μg-h] / [ml],34.5,215664,DB00898,Ethanol
,1761689,half-life,"Injected intravenously, 20 mg of Candida mannan antigen was cleared from the serum with a half-life of approximately 2 h.",Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761689/),h,2,215670,DB00898,Ethanol
,1761689,half-life,"In contrast, 20 micrograms of Cryptococcus glucuronoxylomannan antigen had a half-life in serum of approximately 24 h.",Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761689/),h,24,215671,DB00898,Ethanol
,21894765,distribution constant,"The maximum concentration ofp-tyrosol in these organs was determined in 1 minute after administration, and the mean distribution constant was within 0.8-1.11.",[Main pharmacokinetic parameters of p-tyrosol after intravenous injection in rats. Part III: Distribution of p-tyrosol in rat]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21894765/),,0.8-1.11,215738,DB00898,Ethanol
,21894765,albumin bound fraction,The albumin bound fraction ofp-tyrozol amounted to 0.26-0.30.,[Main pharmacokinetic parameters of p-tyrosol after intravenous injection in rats. Part III: Distribution of p-tyrosol in rat]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21894765/),,0.26-0.30,215739,DB00898,Ethanol
,34126240,oral bioavailability,"Noopept (NPT), a potent neuroprotective agent, suffers the problem of poor oral bioavailability (~10%) and thus demands exploration of ways of bioavailability improvement.","QbD-driven development of dissolving microneedle patch loaded with ultradeformable liposomes encapsulated Noopept: Exploring a patient friendly, once-daily option to manage dementia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34126240/),%,10,215858,DB00898,Ethanol
,34126240,viability,In vitro viability of HaCaT cells after exposure to NPT UDL MNP matrix was found to be 89.74% supporting the formulation as safe for transdermal application.,"QbD-driven development of dissolving microneedle patch loaded with ultradeformable liposomes encapsulated Noopept: Exploring a patient friendly, once-daily option to manage dementia. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34126240/),%,89.74,215859,DB00898,Ethanol
,11510627,time (tmax) to peak concentration (Cmax),"In young healthy volunteers, absorption of mizolastine is rapid with time (tmax) to peak concentration (Cmax) of about 1 hour.",Clinical pharmacokinetics of mizolastine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1,215900,DB00898,Ethanol
,11510627,absolute bioavailability,The absolute bioavailability of mizolastine 10mg tablets is about 65%.,Clinical pharmacokinetics of mizolastine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),%,65,215901,DB00898,Ethanol
,11510627,distribution half-life,Distribution is rapid with a mean distribution half-life of 1.5 to 1.9 hours.,Clinical pharmacokinetics of mizolastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1.5 to 1.9,215902,DB00898,Ethanol
,11510627,apparent volume of distribution,Mizolastine is >98% bound to serum albumin and the apparent volume of distribution is between I and 1.4 L/kg.,Clinical pharmacokinetics of mizolastine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [kg],I and 1.4,215903,DB00898,Ethanol
,11510627,terminal elimination half-life (t1/2beta),The terminal elimination half-life (t1/2beta) is 7.3 to 17.1 hours.,Clinical pharmacokinetics of mizolastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,7.3 to 17.1,215904,DB00898,Ethanol
,11510627,apparent oral clearance,"The apparent oral clearance after a repeated oral dose of 10mg is 6.02 L/h, with steady state reached from day 3 and no accumulation between days 1 and 7.",Clinical pharmacokinetics of mizolastine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [h],6.02,215905,DB00898,Ethanol
,23628674,maximum plasma concentration (C(max)),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],18.87,216308,DB00898,Ethanol
,23628674,area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],40.98,216309,DB00898,Ethanol
,23628674,C(max),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],59.42,216310,DB00898,Ethanol
,23628674,AUC(0→t),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],239.71,216311,DB00898,Ethanol
,23628674,AUC(0→t),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],40.98,216312,DB00898,Ethanol
,23628674,AUC(0→t),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],89.21,216313,DB00898,Ethanol
,23628674,C(max),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],18.87,216314,DB00898,Ethanol
,23628674,C(max),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],43.16,216315,DB00898,Ethanol
,23628674,AUC(0→t),"The effect of WZC on tacrolimus AUC(0→t) also increased with dose, with a maximal effect observed at 450 mg/kg (825.34 ng h/ml).",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],825.34,216316,DB00898,Ethanol
,24956461,relative bioavailability,The oral absorption of stiripentol was also enhanced to a great extent with a relative bioavailability of 157% and 444% to the commercial formulation (Diacomit®) and in-house suspensions.,Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956461/),%,157,216940,DB00898,Ethanol
,24956461,relative bioavailability,The oral absorption of stiripentol was also enhanced to a great extent with a relative bioavailability of 157% and 444% to the commercial formulation (Diacomit®) and in-house suspensions.,Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24956461/),%,444,216941,DB00898,Ethanol
,6537224,apparent volume of distribution (Vd),The blood concentration of ethanol extrapolated to zero-time was 0.98 +/- 0.009 mg/ml (CV = 6.5%) and the apparent volume of distribution (Vd) was 0.695 +/- 0.0064 L/kg (CV = 6.4%).,Interindividual variations in the disposition and metabolism of ethanol in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6537224/),[l] / [kg],0.695,217299,DB00898,Ethanol
,6537224,rate of ethanol elimination from blood,The rate of ethanol elimination from blood was 0.126 +/- 0.0018 mg/ml/hr (CV = 9.9%) and the body clearance was 87.5 +/- 1.1 mg/kg/hr (CV = 8.7%).,Interindividual variations in the disposition and metabolism of ethanol in healthy men. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6537224/),[mg] / [h·ml],0.126,217300,DB00898,Ethanol
,6537224,body clearance,The rate of ethanol elimination from blood was 0.126 +/- 0.0018 mg/ml/hr (CV = 9.9%) and the body clearance was 87.5 +/- 1.1 mg/kg/hr (CV = 8.7%).,Interindividual variations in the disposition and metabolism of ethanol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6537224/),[mg] / [h·kg],87.5,217301,DB00898,Ethanol
,11267709,Total absorption,Total absorption was 72% of the applied dose with rats and 60% with humans.,The in vivo dermal absorption and metabolism of [4-14C] coumarin by rats and by human volunteers under simulated conditions of use in fragrances. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11267709/),%,72,217642,DB00898,Ethanol
,11267709,Total absorption,Total absorption was 72% of the applied dose with rats and 60% with humans.,The in vivo dermal absorption and metabolism of [4-14C] coumarin by rats and by human volunteers under simulated conditions of use in fragrances. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11267709/),%,60,217643,DB00898,Ethanol
,11267709,Peak plasma radioactivity,Peak plasma radioactivity in both was at 1 h.,The in vivo dermal absorption and metabolism of [4-14C] coumarin by rats and by human volunteers under simulated conditions of use in fragrances. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11267709/),h,1,217644,DB00898,Ethanol
,11267709,plasma half-life,The mean plasma half-life of coumarin and metabolites was approximately 1.7 h for humans and 5 h for rats.,The in vivo dermal absorption and metabolism of [4-14C] coumarin by rats and by human volunteers under simulated conditions of use in fragrances. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11267709/),h,1.7,217645,DB00898,Ethanol
,11267709,plasma half-life,The mean plasma half-life of coumarin and metabolites was approximately 1.7 h for humans and 5 h for rats.,The in vivo dermal absorption and metabolism of [4-14C] coumarin by rats and by human volunteers under simulated conditions of use in fragrances. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11267709/),h,5,217646,DB00898,Ethanol
,27042001,"area under curve, [AUC](0-t)","Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),[mg] / [)h·l(],12.53,217760,DB00898,Ethanol
,27042001,"area under curve, [AUC](0-t)","Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),[mg] / [)h·l(],7.80,217761,DB00898,Ethanol
,27042001,"area under curve, [AUC](0-t)","Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),[mg] / [)h·l(],5.82,217762,DB00898,Ethanol
,27042001,elimination half-life (t1/2),"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,15.43,217763,DB00898,Ethanol
,27042001,elimination half-life (t1/2),"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,2.25,217764,DB00898,Ethanol
,27042001,elimination half-life (t1/2),"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,1.43,217765,DB00898,Ethanol
,27042001,mean residence time,"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,7.65,217766,DB00898,Ethanol
,27042001,mean residence time,"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,3.61,217767,DB00898,Ethanol
,27042001,mean residence time,"Pharmacokinetic studies demonstrated that 5-FU hollow microspheres significantly enhanced oral bioavailability (area under curve, [AUC](0-t): 12.53±1.65 mg/L(*)h vs 7.80±0.83 and 5.82±0.83 mg/L(*)h) with longer elimination half-life (t1/2) (15.43±2.12 hours vs 2.25±0.22 and 1.43±0.18 hours) and mean residence time (7.65±0.97 hours vs 3.61±0.41 and 2.34±0.35 hours), in comparison with its solid microspheres and powder.","A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042001/),h,2.34,217768,DB00898,Ethanol
,30272138,flow rate,"Chromatographic analysis was achieved firstly by HPLC method on C18 column (150 × 4.6 mm2 i.d., 5 μm) and a mobile phase composed of ethanol:water (containing 0.1% acetic acid) (70:30, v/v) at the flow rate of 0.6 mL min-1.",Simultaneous Determination of Thalidomide and Dexamethasone in Rat Plasma by Validated HPLC and HPTLC With Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30272138/),[ml] / [min],0.6,217803,DB00898,Ethanol
,1940231,rate of clearance,The rate of clearance was found to be 20.43 mg/dL/h with a standard deviation of 6.86 mg/dL/h.,Rate of clearance of ethanol from the blood of intoxicated patients in the emergency department. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940231/),[mg] / [dl·h],20.43,218049,DB00898,Ethanol
,1940231,clearance rates,"We conclude that although the average patient presenting to the emergency department will clear ethanol at about 20 mg/dL/h, a standard deviation of 6 mg/dL/h means that only 83% of these patients will have clearance rates between 8 and 32 mg/dL/h, and that if accurate estimates are necessary, serial determinations of two or more levels are needed.",Rate of clearance of ethanol from the blood of intoxicated patients in the emergency department. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940231/),[mg] / [dl·h],8 and 32,218050,DB00898,Ethanol
,30091144,half-life,"(i) The increase in PEth 16:0/20:4 from baseline to maximum concentration was less than that of PEth 16:0/18:1 or PEth 16:0/18:2 homologs during the 6-hour period after EtOH administration; (ii) the mean half-life of PEth 16:0/20:4 was 2.1 ± 3 (SD) days, which was shorter than the mean half-life of either PEth 16:0/18:1 or PEth 16:0/18:2, 7.6 ± 3 (SD) or 6.8 ± 4 (SD) days, respectively.",Pharmacokinetics of Phosphatidylethanol 16:0/20:4 in Human Blood After Alcohol Intake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30091144/),d,2.1,218135,DB00898,Ethanol
,30091144,half-life,"(i) The increase in PEth 16:0/20:4 from baseline to maximum concentration was less than that of PEth 16:0/18:1 or PEth 16:0/18:2 homologs during the 6-hour period after EtOH administration; (ii) the mean half-life of PEth 16:0/20:4 was 2.1 ± 3 (SD) days, which was shorter than the mean half-life of either PEth 16:0/18:1 or PEth 16:0/18:2, 7.6 ± 3 (SD) or 6.8 ± 4 (SD) days, respectively.",Pharmacokinetics of Phosphatidylethanol 16:0/20:4 in Human Blood After Alcohol Intake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30091144/),d,7.6,218136,DB00898,Ethanol
,30091144,half-life,"(i) The increase in PEth 16:0/20:4 from baseline to maximum concentration was less than that of PEth 16:0/18:1 or PEth 16:0/18:2 homologs during the 6-hour period after EtOH administration; (ii) the mean half-life of PEth 16:0/20:4 was 2.1 ± 3 (SD) days, which was shorter than the mean half-life of either PEth 16:0/18:1 or PEth 16:0/18:2, 7.6 ± 3 (SD) or 6.8 ± 4 (SD) days, respectively.",Pharmacokinetics of Phosphatidylethanol 16:0/20:4 in Human Blood After Alcohol Intake. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30091144/),d,6.8,218137,DB00898,Ethanol
,31542420,flow rate,"A SBC18 column (2.1 mm × 100 mm, 1.8 μm) was used in this experiment at a flow rate of 0.3 mL/min at 30 °C with linear gradient elution using acetonitrile and water containing 0.1% formic acid.",Comparative pharmacokinetic study of the components in Alpinia oxyphylla Miq.-Schisandra chinensis (Turcz.) Baill. herb pair and its single herb between normal and Alzheimer's disease rats by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542420/),[ml] / [min],0.3,218201,DB00898,Ethanol
,25895956,flow rate,"Lumefantrine and 97-63 were separated on a Waters Atlantis C18 (4.6×50 mm, 5.0 μm) column under isocratic condition with mobile phase consisting of acetonitrile: methanol (50:50, v/v) and ammonium formate buffer (10 mM, pH 4.5) in the ratio of 95:5 (v/v) at a flow rate of 0.65 mL/min.",Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25895956/),[ml] / [min],0.65,218559,DB00898,Ethanol
,25895956,relative bioavailability,"Upon coadministration of 97-78, the relative bioavailability of lumefantrine significantly decreased to 64.41%.",Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25895956/),%,64.41,218560,DB00898,Ethanol
,21670177,maximum concentrations in plasma (C(max)),"Dispersible and crushed tablets showed similar artemether and DHA maximum concentrations in plasma (C(max)) for the different body weight groups, with overall means of 175 ± 168 and 190 ± 168 ng/ml, respectively, for artemether and 64.7 ± 58.1 and 63.7 ± 65.0 ng/ml, respectively, for DHA.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[ng] / [ml],175,218624,DB00898,Ethanol
,21670177,maximum concentrations in plasma (C(max)),"Dispersible and crushed tablets showed similar artemether and DHA maximum concentrations in plasma (C(max)) for the different body weight groups, with overall means of 175 ± 168 and 190 ± 168 ng/ml, respectively, for artemether and 64.7 ± 58.1 and 63.7 ± 65.0 ng/ml, respectively, for DHA.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[ng] / [ml],190,218625,DB00898,Ethanol
,21670177,maximum concentrations in plasma (C(max)),"Dispersible and crushed tablets showed similar artemether and DHA maximum concentrations in plasma (C(max)) for the different body weight groups, with overall means of 175 ± 168 and 190 ± 168 ng/ml, respectively, for artemether and 64.7 ± 58.1 and 63.7 ± 65.0 ng/ml, respectively, for DHA.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[ng] / [ml],64.7,218626,DB00898,Ethanol
,21670177,maximum concentrations in plasma (C(max)),"Dispersible and crushed tablets showed similar artemether and DHA maximum concentrations in plasma (C(max)) for the different body weight groups, with overall means of 175 ± 168 and 190 ± 168 ng/ml, respectively, for artemether and 64.7 ± 58.1 and 63.7 ± 65.0 ng/ml, respectively, for DHA.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[ng] / [ml],63.7,218627,DB00898,Ethanol
,21670177,C(max),"For lumefantrine, the population C(max) were 6.3 μg/ml (dispersible tablet) and 7.7 μg/ml (crushed tablet), whereas the areas under the concentration-time curves from time zero to the time of the last quantifiable plasma concentration measured were 574 and 636 μg · h/ml, respectively.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[μg] / [ml],6.3,218628,DB00898,Ethanol
,21670177,C(max),"For lumefantrine, the population C(max) were 6.3 μg/ml (dispersible tablet) and 7.7 μg/ml (crushed tablet), whereas the areas under the concentration-time curves from time zero to the time of the last quantifiable plasma concentration measured were 574 and 636 μg · h/ml, respectively.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[μg] / [ml],7.7,218629,DB00898,Ethanol
,21670177,areas under the concentration-time curves from time zero to the time of the last,"For lumefantrine, the population C(max) were 6.3 μg/ml (dispersible tablet) and 7.7 μg/ml (crushed tablet), whereas the areas under the concentration-time curves from time zero to the time of the last quantifiable plasma concentration measured were 574 and 636 μg · h/ml, respectively.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[h·μg] / [ml],574,218630,DB00898,Ethanol
,21670177,areas under the concentration-time curves from time zero to the time of the last,"For lumefantrine, the population C(max) were 6.3 μg/ml (dispersible tablet) and 7.7 μg/ml (crushed tablet), whereas the areas under the concentration-time curves from time zero to the time of the last quantifiable plasma concentration measured were 574 and 636 μg · h/ml, respectively.",Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21670177/),[h·μg] / [ml],636,218631,DB00898,Ethanol
,10594475,maximum blood-ethanol concentration (Cmax ),The maximum blood-ethanol concentration (Cmax ) increased from 3.8+/-1.7 to 5.6+/-2.3 mmol l-1 (+/-s.d.) after treatment with cisapride (95% confidence interval CI on mean difference 0.28-3.28 mmol l-1 ).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],3.8,219529,DB00898,Ethanol
,10594475,maximum blood-ethanol concentration (Cmax ),The maximum blood-ethanol concentration (Cmax ) increased from 3.8+/-1.7 to 5.6+/-2.3 mmol l-1 (+/-s.d.) after treatment with cisapride (95% confidence interval CI on mean difference 0.28-3.28 mmol l-1 ).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],5.6,219530,DB00898,Ethanol
,10594475,area under the blood-ethanol curve (AUC),The area under the blood-ethanol curve (AUC) increased from 6.3+/-3.5 to 7.9+/-2.6 mmol l-1 h after cisapride (95% CI -0. 74-3.9 mmol l-1 h).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],6.3,219531,DB00898,Ethanol
,10594475,area under the blood-ethanol curve (AUC),The area under the blood-ethanol curve (AUC) increased from 6.3+/-3.5 to 7.9+/-2.6 mmol l-1 h after cisapride (95% CI -0. 74-3.9 mmol l-1 h).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],7.9,219532,DB00898,Ethanol
,10594475,Cmax,"Both Cmax and AUC were highest when the ethanol was ingested on an empty stomach (Cmax 9.5+/-1.7 mmol l-1 and AUC 14. 6+/-1.9 mmol l-1 h), compared with drinking 1 h after a meal and regardless of pretreatment with cisapride.",Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],9.5,219533,DB00898,Ethanol
,10594475,AUC,"Both Cmax and AUC were highest when the ethanol was ingested on an empty stomach (Cmax 9.5+/-1.7 mmol l-1 and AUC 14. 6+/-1.9 mmol l-1 h), compared with drinking 1 h after a meal and regardless of pretreatment with cisapride.",Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],14. 6,219534,DB00898,Ethanol
,15901750,maximum concentration,"The maximum concentration of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides, the main alkamides in the roots of E. angustifolia, appeared already after 30 minutes and was 10.88 ng/mL for the 2.5-mL dose.",Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901750/),[ng] / [ml],10.88,219951,DB00898,Ethanol
,15167624,peak concentration,The mean peak concentration observed in the 4 adult patients was 18.5 +/- 2.6 microg/mL and in the child was 18.9 +/- 2.2 microg/mL.,Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167624/),[μg] / [ml],18.5,219967,DB00898,Ethanol
,15167624,peak concentration,The mean peak concentration observed in the 4 adult patients was 18.5 +/- 2.6 microg/mL and in the child was 18.9 +/- 2.2 microg/mL.,Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167624/),[μg] / [ml],18.9,219968,DB00898,Ethanol
,15167624,apparent elimination half-life,"At steady state and without any concomitant therapies, the mean apparent elimination half-life was 14.5 +/- 3 hours.",Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167624/),h,14.5,219969,DB00898,Ethanol
below,15167624,t(1/2),"A trend toward a progessive enhancement of the 4-MP elimination rate is suggested in the pediatric case, with the duration of the treatment resulting in a t(1/2) below 5 hours after 48 hours.",Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167624/),h,5,219970,DB00898,Ethanol
,26165244,relative bioavailability,"The W/O microemulsion can significantly promote the intestinal absorption of troxerutin in rats in vivo, and the relative bioavailability of the microemulsion was about 205.55% compared to control solution.",Development and in vitro-in vivo evaluation of a water-in-oil microemulsion formulation for the oral delivery of troxerutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26165244/),%,205.55,220469,DB00898,Ethanol
,4030982,void volume (Vo),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,1.4,221234,DB00898,Ethanol
,4030982,retention times (tR),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,3.5,221235,DB00898,Ethanol
,4030982,retention times (tR),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,ca,221236,DB00898,Ethanol
,4030982,retention times (tR),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,4.2,221237,DB00898,Ethanol
,4030982,retention times (tR),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,5,221238,DB00898,Ethanol
,4030982,retention times (tR),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,6,221239,DB00898,Ethanol
,4030982,retention times (tR),"The void volume (Vo) is approximately 1.4 min and the retention times (tR) of the respective isoquinolium derivatives of diclofensine (I) are ca. 3.5 min, internal standard (II) ca. 4.2 min, nordiclofensine (I-A) ca. 5 min, while the phenolic metabolites I-B and I-C give peaks at 6.4 min and 10.4 min, respectively.","Determination of diclofensine, an antidepressant agent, and its major metabolites in human plasma by high-performance liquid chromatography with fluorometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030982/),min,10,221240,DB00898,Ethanol
,22910790,polydispersity index,"The prepared PTX micelles have a mean particle size of 38.06 ± 2.30 nm, a polydispersity index of 0.168 ± 0.014, a drug loading of 14.89 ± 0.06% and an encapsulation efficiency of 99.25 ± 0.38%.",Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22910790/),,0.168,221438,DB00898,Ethanol
,22910790,drug loading,"The prepared PTX micelles have a mean particle size of 38.06 ± 2.30 nm, a polydispersity index of 0.168 ± 0.014, a drug loading of 14.89 ± 0.06% and an encapsulation efficiency of 99.25 ± 0.38%.",Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22910790/),,14.89,221439,DB00898,Ethanol
,22910790,encapsulation efficiency,"The prepared PTX micelles have a mean particle size of 38.06 ± 2.30 nm, a polydispersity index of 0.168 ± 0.014, a drug loading of 14.89 ± 0.06% and an encapsulation efficiency of 99.25 ± 0.38%.",Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22910790/),%,99.25,221440,DB00898,Ethanol
,2878678,plasma elimination half-life,In six subjects the plasma elimination half-life of bufuralol was 2.61 +/- 0.18 h and in the other three subjects 4.85 +/- 0.35 h.,Pharmacodynamic and pharmacokinetic studies on bufuralol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878678/),h,2.61,221444,DB00898,Ethanol
,2878678,plasma elimination half-life,In six subjects the plasma elimination half-life of bufuralol was 2.61 +/- 0.18 h and in the other three subjects 4.85 +/- 0.35 h.,Pharmacodynamic and pharmacokinetic studies on bufuralol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878678/),h,4.85,221445,DB00898,Ethanol
,10497139,plasma elimination half-life,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),h,1.72,221539,DB00898,Ethanol
,10497139,clearance,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),[ml] / [kg·min],18.2,221540,DB00898,Ethanol
,10497139,clearance,The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs.,"Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497139/),[ml] / [kg·min],7.15,221541,DB00898,Ethanol
>,16640337,oral bioavailability,The dog pharmacokinetic profile of some of these analogues showed >25% oral bioavailability and po half-lives of at least 1.5 h.,Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640337/),%,25,221875,DB00898,Ethanol
at,16640337,half-lives,The dog pharmacokinetic profile of some of these analogues showed >25% oral bioavailability and po half-lives of at least 1.5 h.,Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640337/),h,1.5,221876,DB00898,Ethanol
,27521532,flow rate,"The plasma samples were prepared by liquid-liquid extraction with ethyl acetate and the baseline chromatographic separation was achieved on a Chiralcel OJ-H column with a mobile phase consisting n-hexane/ethanol/methanol/diethylamine (85:5:10:0.4, v/v/v/v) at the flow rate of 1.0mL/min.","Development and validation of a chiral liquid chromatography method for the determination of MP 3950 enantiomers, a high selective 5-HT4 receptor agonist, in rat plasma and its application to stereoselective pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27521532/),[ml] / [min],1.0,221919,DB00898,Ethanol
,8637393,half-life,"kg-1, is rapidly eliminated with a half-life of 29 min and a total body clearance of 77 ml.",In vivo pharmacokinetics and in vitro production of cocaethylene in pregnant guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8637393/),min,29,223430,DB00898,Ethanol
,8637393,total body clearance,"kg-1, is rapidly eliminated with a half-life of 29 min and a total body clearance of 77 ml.",In vivo pharmacokinetics and in vitro production of cocaethylene in pregnant guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8637393/),ml,77,223431,DB00898,Ethanol
,8637393,apparent Vmax,"The rapid elimination of cocaethylene, coupled with the slow rate of formation (apparent Vmax of 140 pmol.min-1.mg microsomal protein-1) and the small amount of plasma analyzed most likely explains the inability to detect coacethylene in vivo after concomitant cocaine and ethanol administration.",In vivo pharmacokinetics and in vitro production of cocaethylene in pregnant guinea pigs. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8637393/),[mg·pM] / [min],140,223432,DB00898,Ethanol
,1600045,peak plasma alcohol concentration,"h/dL, respectively, P = 0.07), and a statistically significant increase in mean peak plasma alcohol concentration after dosing with ranitidine (4.92 and 6.47 mg/dL, respectively, P = 0.05).",Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600045/),[mg] / [dl],4.92,223750,DB00898,Ethanol
,1600045,peak plasma alcohol concentration,"h/dL, respectively, P = 0.07), and a statistically significant increase in mean peak plasma alcohol concentration after dosing with ranitidine (4.92 and 6.47 mg/dL, respectively, P = 0.05).",Short report: the effect of ranitidine on the post-prandial absorption of a low dose of alcohol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600045/),[mg] / [dl],6.47,223751,DB00898,Ethanol
,18623040,AUC ratios,Study II: AUC ratios were 97.9% (budesonide) and 82.2% (formoterol) (budesonide/formoterol pMDI versus budesonide pMDI+formoterol DPI).,"Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18623040/),%,97.9,224437,DB00898,Ethanol
,18623040,AUC ratios,Study II: AUC ratios were 97.9% (budesonide) and 82.2% (formoterol) (budesonide/formoterol pMDI versus budesonide pMDI+formoterol DPI).,"Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18623040/),%,82.2,224438,DB00898,Ethanol
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,10.6,224594,DB00898,Ethanol
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,170,224595,DB00898,Ethanol
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,0.180,224596,DB00898,Ethanol
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,371.35,225426,DB00898,Ethanol
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,270.20,225427,DB00898,Ethanol
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,360.00,225428,DB00898,Ethanol
,11589462,AUC(0-24) (+)/(-) ratio,The enantioselective pilot study on the kinetic disposition of nisoldipine administered in the racemic form to a hypertensive patient using a multiple dose regimen revealed the accumulation of the (+)-enantiomer with an AUC(0-24) (+)/(-) ratio of approximately 8.,Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,8,225429,DB00898,Ethanol
,6498049,plasma clearance,The plasma clearance of thiopentone was significantly increased from 3.7 +/- 0.9 ml min-1 kg-1 in the controls to 5.4 +/- 2.2 ml min-1 kg-1 in the patients with chronic alcoholism.,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),[ml] / [kg·min],3.7,225524,DB00898,Ethanol
,6498049,plasma clearance,The plasma clearance of thiopentone was significantly increased from 3.7 +/- 0.9 ml min-1 kg-1 in the controls to 5.4 +/- 2.2 ml min-1 kg-1 in the patients with chronic alcoholism.,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),[ml] / [kg·min],5.4,225525,DB00898,Ethanol
,6498049,terminal elimination half-life,The terminal elimination half-life was of 684 +/- 168 min in the alcoholics and did not differ significantly from the value found in the controls (750 +/- 212 min).,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),min,684,225526,DB00898,Ethanol
,6498049,terminal elimination half-life,The terminal elimination half-life was of 684 +/- 168 min in the alcoholics and did not differ significantly from the value found in the controls (750 +/- 212 min).,Thiopentone pharmacokinetics in patients with chronic alcoholism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498049/),min,750,225527,DB00898,Ethanol
,2724140,apparent ethanol Vmax,"The apparent ethanol Vmax and volume of distribution were 1.85 +/- 0.25 mg/min and 723 +/- 91 ml/kg (mean +/- S.D.), respectively.",Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724140/),[mg] / [min],1.85,225684,DB00898,Ethanol
,2724140,volume of distribution,"The apparent ethanol Vmax and volume of distribution were 1.85 +/- 0.25 mg/min and 723 +/- 91 ml/kg (mean +/- S.D.), respectively.",Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724140/),[ml] / [kg],723,225685,DB00898,Ethanol
,2729007,clearance,The clearance of acetanilide was significantly lower (p less than 0.05) in the elderly subjects at 27 +/- 3 l/h compared to 38 +/- 2 l/h in young subjects.,The relation of age to the acute effects of ethanol on acetanilide disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729007/),[l] / [h],27,225946,DB00898,Ethanol
,2729007,clearance,The clearance of acetanilide was significantly lower (p less than 0.05) in the elderly subjects at 27 +/- 3 l/h compared to 38 +/- 2 l/h in young subjects.,The relation of age to the acute effects of ethanol on acetanilide disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729007/),[l] / [h],38,225947,DB00898,Ethanol
,2729007,clearance,"After ethanol, acetanilide clearance fell 18% to 31 +/- 3 l/h in young subjects (p = 0.05) and by 15% to 23 +/- 2 l/h in elderly subjects (p = 0.08).",The relation of age to the acute effects of ethanol on acetanilide disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729007/),[l] / [h],31,225948,DB00898,Ethanol
,2729007,clearance,"After ethanol, acetanilide clearance fell 18% to 31 +/- 3 l/h in young subjects (p = 0.05) and by 15% to 23 +/- 2 l/h in elderly subjects (p = 0.08).",The relation of age to the acute effects of ethanol on acetanilide disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729007/),[l] / [h],23,225949,DB00898,Ethanol
,3703884,Volume of distribution,"Volume of distribution was 0.802 +/- 0.054 L/kg (mean +/- SD), Km (the apparent in vivo Michaelis constant) was 0.063 +/- 0.022 micrograms/ml, and Vmax was 0.199 +/- 0.039 g/kg/hr.",Pharmacokinetics of ethanol in pigtailed macaques: intersubject variability and effect of subchronic administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3703884/),[l] / [kg],0.802,226593,DB00898,Ethanol
,3703884,Km (the apparent in vivo Michaelis constant),"Volume of distribution was 0.802 +/- 0.054 L/kg (mean +/- SD), Km (the apparent in vivo Michaelis constant) was 0.063 +/- 0.022 micrograms/ml, and Vmax was 0.199 +/- 0.039 g/kg/hr.",Pharmacokinetics of ethanol in pigtailed macaques: intersubject variability and effect of subchronic administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3703884/),[μg] / [ml],0.063,226594,DB00898,Ethanol
,3703884,Vmax,"Volume of distribution was 0.802 +/- 0.054 L/kg (mean +/- SD), Km (the apparent in vivo Michaelis constant) was 0.063 +/- 0.022 micrograms/ml, and Vmax was 0.199 +/- 0.039 g/kg/hr.",Pharmacokinetics of ethanol in pigtailed macaques: intersubject variability and effect of subchronic administration. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3703884/),[g] / [h·kg],0.199,226595,DB00898,Ethanol
,24368917,elimination rate,The elimination rate of ethanol was calculated to be in a range from 17.1 to 21.2 mg/dL/hr and appeared to follow zero-order elimination kinetics with a R (2) = 0.9787.,Elimination kinetics of ethanol in a 5-week-old infant and a literature review of infant ethanol pharmacokinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368917/),[mg] / [dl·h],17.1 to 21.2,227408,DB00898,Ethanol
<,8894966,oral bioavailability,"Because of its low (< 1%) oral bioavailability, studies were performed to assess the feasibility of delivery of A-71623 by pulmonary, sublingual, and transdermal routes of administration.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),%,1,228516,DB00898,Ethanol
,8894966,pKa,The pKa was determined to be 4.2 by spectrophotometric titration; aqueous solubility is increased by increasing pH and by increasing ethanol content.,"Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),,4.2,228517,DB00898,Ethanol
,8894966,solubility,"The solubility of A-71623 in ethanol/propellant mixtures was investigated; solubility ranged from 1.0 to 2.5 mg/mL in mixtures of ethanol, propellant 11 (trichlorofluoromethane), and propellant 12 (dichlorodifluoromethane).","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),[mg] / [ml],1.0 to 2.5,228518,DB00898,Ethanol
,8894966,log apparent octanol/water partition coefficient,The log apparent octanol/water partition coefficient was 2.8 at pH 5 and 1.0 at pH 8.,"Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),,2.8,228519,DB00898,Ethanol
,8894966,log apparent octanol/water partition coefficient,The log apparent octanol/water partition coefficient was 2.8 at pH 5 and 1.0 at pH 8.,"Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),,1.0,228520,DB00898,Ethanol
,8894966,t90,Increasing ethanol content increases the stability; Arrhenius analysis indicated a t90 of 150 days under ambient conditions in 25% ethanol.,"Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),d,150,228521,DB00898,Ethanol
,8894966,Cmax,"Intratracheal delivery of 3 mumol/kg A-71623 in 50% ethanol to rats showed rapid and efficient absorption of drug from the lungs, with a Cmax of 2.7 microM and an AUC of 85 microM*min.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),μM,2.7,228522,DB00898,Ethanol
,8894966,AUC,"Intratracheal delivery of 3 mumol/kg A-71623 in 50% ethanol to rats showed rapid and efficient absorption of drug from the lungs, with a Cmax of 2.7 microM and an AUC of 85 microM*min.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),min·μM,85,228523,DB00898,Ethanol
,8894966,bioavailabilities,"Similar studies in dogs showed bioavailabilities of 59% and 46% for 2 and 3 mumol/kg intratracheal doses, respectively, relative to intravenous administration.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),%,59,228524,DB00898,Ethanol
,8894966,bioavailabilities,"Similar studies in dogs showed bioavailabilities of 59% and 46% for 2 and 3 mumol/kg intratracheal doses, respectively, relative to intravenous administration.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),%,46,228525,DB00898,Ethanol
,8894966,Cmax,"Sublingual administration of 1 mumol/kg A-71623 in a vehicle of 80% ethanol/2% Klucel/2.5% peppermint oil gave high prolonged plasma levels of A-71623, with a Cmax of 0.37 microM, indicating high bioavailability and favorable partitioning and distribution effects from the sublingual cavity for this formulation.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),μM,0.37,228526,DB00898,Ethanol
,8894966,permeability coefficient,"Transdermal delivery was examined by in vitro diffusion through human skin; the permeability coefficient of A-71623 in 40% ethanol was 2.6 x 10(-5) cm/hr, suggesting that transdermal delivery of up to 2 mg/day may be feasible.","Alternate drug delivery routes for A-71623, a potent cholecystokinin-A receptor agonist tetrapeptide. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894966/),[cm] / [h],2.6 x 10(-5),228527,DB00898,Ethanol
,7445577,half life,"2. The elimination of caffeine from the serum and tissues examined (liver, kidney, brain, muscle) showed an exponential course with a half life of 40-60 minutes and was completed after 4 to 5 hours.",[Pharmacokinetics of caffeine in mice and its modification by ethanol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445577/),min,40-60,228555,DB00898,Ethanol
,7445577,half life,3. By giving ethanol the elimination of caffeine was significantly decreased and its half life increased to 160-240 minutes.,[Pharmacokinetics of caffeine in mice and its modification by ethanol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445577/),min,160-240,228556,DB00898,Ethanol
,20429848,drug payload,The drug payload of paclitaxel was 500 +/- 0.27 mg/g of lyophilized powder.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),[mg] / [g],500,229185,DB00898,Ethanol
,20429848,encapsulation efficiency,"The encapsulation efficiency was 99.1 +/- 1.0%, and 1.7 +/- 0.2% of paclitaxel was crystallized after 48 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),%,99.1,229186,DB00898,Ethanol
,20429848,encapsulation efficiency,"The encapsulation efficiency was 99.1 +/- 1.0%, and 1.7 +/- 0.2% of paclitaxel was crystallized after 48 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),%,1.7,229187,DB00898,Ethanol
,20429848,relative oral bioavailability,The relative oral bioavailability of paclitaxel-loaded nanosponges was 256.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429848/),,256,229188,DB00898,Ethanol
,3742940,t1/2,The t1/2 of ornidazole was 14.1 +/- 0.5 hours for normal subjects and 21.9 +/- 2.9 hours for patients with cirrhosis.,Pharmacokinetics of ornidazole in patients with severe liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742940/),h,14.1,229235,DB00898,Ethanol
,3742940,t1/2,The t1/2 of ornidazole was 14.1 +/- 0.5 hours for normal subjects and 21.9 +/- 2.9 hours for patients with cirrhosis.,Pharmacokinetics of ornidazole in patients with severe liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742940/),h,21.9,229236,DB00898,Ethanol
,3742940,plasma clearance,"Mean plasma clearance was 50.6 +/- 2.1 ml/min in control subjects and 34.9 +/- 4.9 ml/min in patients, whereas apparent V SS was not modified in hepatic insufficiency.",Pharmacokinetics of ornidazole in patients with severe liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742940/),[ml] / [min],50.6,229237,DB00898,Ethanol
,3742940,plasma clearance,"Mean plasma clearance was 50.6 +/- 2.1 ml/min in control subjects and 34.9 +/- 4.9 ml/min in patients, whereas apparent V SS was not modified in hepatic insufficiency.",Pharmacokinetics of ornidazole in patients with severe liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3742940/),[ml] / [min],34.9,229238,DB00898,Ethanol
,9839087,distribution volume,"At steady-state, acamprosate has a moderate distribution volume of about 20L.",Clinical pharmacokinetics of acamprosate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),l,20,229746,DB00898,Ethanol
,9839087,terminal,The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion.,Clinical pharmacokinetics of acamprosate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),h,3,229747,DB00898,Ethanol
,9839087,accumulation ratio,"The pharmacokinetics of acamprosate administered as an enteric-coated tablets are time- and dose-independent, and its accumulation ratio is about 2.4 at steady-state.",Clinical pharmacokinetics of acamprosate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),,2.4,229748,DB00898,Ethanol
,21796250,area under the concentration curve (AUC)(0-∞),"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[h·μg] / [ml],20.343,230028,DB00898,Ethanol
,21796250,area under the concentration curve (AUC)(0-∞),"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[h·μg] / [ml],5.196,230029,DB00898,Ethanol
,21796250,clearance,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[l] / [h·kg],2.050,230030,DB00898,Ethanol
,21796250,clearance,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),[l] / [h·kg],0.556,230031,DB00898,Ethanol
,21796250,elimination half-life,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),h,5.646,230032,DB00898,Ethanol
,21796250,elimination half-life,"In rat plasma, paclitaxel nanosuspension exhibited a significantly (P < 0.01) reduced area under the concentration curve (AUC)(0-∞) (20.343 ± 9.119 μg · h · mL(-1) vs 5.196 ± 1.426 μg · h · mL(-1)), greater clearance (2.050 ± 0.616 L · kg(-1) · h(-1) vs 0.556 ± 0.190 L · kg(-1) · h(-1)), and shorter elimination half-life (5.646 ± 2.941 vs 3.774 ± 1.352 hours) compared with the paclitaxel solution.",Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796250/),h,3.774,230033,DB00898,Ethanol
,23385160,specific activities,"Absorption, distribution, metabolism, and excretion were compared following topical application of ¹⁴C-labeled PEA to rats, rabbits, and humans (specific activities of dosing solutions: 58-580, 164, and 50 µCi/mL, respectively).","The pharmacokinetics of phenylethyl alcohol (PEA): safety evaluation comparisons in rats, rabbits, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385160/),[µci] / [ml],58-580,230252,DB00898,Ethanol
,23385160,specific activities,"Absorption, distribution, metabolism, and excretion were compared following topical application of ¹⁴C-labeled PEA to rats, rabbits, and humans (specific activities of dosing solutions: 58-580, 164, and 50 µCi/mL, respectively).","The pharmacokinetics of phenylethyl alcohol (PEA): safety evaluation comparisons in rats, rabbits, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385160/),[µci] / [ml],164,230253,DB00898,Ethanol
,23385160,specific activities,"Absorption, distribution, metabolism, and excretion were compared following topical application of ¹⁴C-labeled PEA to rats, rabbits, and humans (specific activities of dosing solutions: 58-580, 164, and 50 µCi/mL, respectively).","The pharmacokinetics of phenylethyl alcohol (PEA): safety evaluation comparisons in rats, rabbits, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385160/),[µci] / [ml],50,230254,DB00898,Ethanol
,25666025,elimination half-life,"PVS has a short elimination half-life (1-3 h), suffers from instability at gastric pH, extensive hepatic first-pass metabolism and low absolute bioavailability (18%).","Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666025/),h,1-3,230470,DB00898,Ethanol
,25666025,absolute bioavailability,"PVS has a short elimination half-life (1-3 h), suffers from instability at gastric pH, extensive hepatic first-pass metabolism and low absolute bioavailability (18%).","Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666025/),%,18,230471,DB00898,Ethanol
,25666025,EE%,"The best achieved enteric surface-coated spanlastic dispersion (E-S6) displayed spherical nanosized vesicles (647.60 nm) possessing negative zeta potential (-6.93 mV), promising EE% (63.22%) and a biphasic drug-release pattern characterized by a retarded-release phase (0.1 N HCl, 2 h) and a controlled-release phase (pH 6.8, 10 h).","Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25666025/),%,63.22,230472,DB00898,Ethanol
,21238561,polydispersity index,The droplet size of the microemulsion was about 26 nm in diameter with narrow distribution (polydispersity index: 0.14).,An oil-free microemulsion for intravenous delivery of diallyl trisulfide: formulation and evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21238561/),,0.,230751,DB00898,Ethanol
,29020247,parasite clearance time,The median parasite clearance time was 24 hours in both the arms.,"Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29020247/),h,24,231103,DB00898,Ethanol
,29020247,fever clearance time,The median fever clearance time was 6 hours in AM-PQP and 12 hours in the AL arm.,"Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29020247/),h,6,231104,DB00898,Ethanol
,29020247,fever clearance time,The median fever clearance time was 6 hours in AM-PQP and 12 hours in the AL arm.,"Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29020247/),h,12,231105,DB00898,Ethanol
∼,25019201,tmax,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,2,231162,DB00898,Ethanol
,25019201,plasma t1/2,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,4 - 6,231163,DB00898,Ethanol
,27349691,encapsulation efficiency,"The encapsulation efficiency of osthole in ethosome and transfersome was measured to be 83.3±4.8% and 80.9±3.6%, respectively.","Preparation of osthole-loaded nano-vesicles for skin delivery: Characterization, in vitro skin permeation and preliminary in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349691/),%,83.3,231210,DB00898,Ethanol
,27349691,encapsulation efficiency,"The encapsulation efficiency of osthole in ethosome and transfersome was measured to be 83.3±4.8% and 80.9±3.6%, respectively.","Preparation of osthole-loaded nano-vesicles for skin delivery: Characterization, in vitro skin permeation and preliminary in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349691/),%,80.9,231211,DB00898,Ethanol
,27349691,transdermal flux,In vitro studies showed that osthole ethosome provided an enhanced transdermal flux of 6.98±1.6μg/cm(2)/h and a decreased lag time of 2.45h across porcine ear skin.,"Preparation of osthole-loaded nano-vesicles for skin delivery: Characterization, in vitro skin permeation and preliminary in vivo pharmacokinetic studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349691/),[μg] / [cm(2)·h],6.98,231212,DB00898,Ethanol
,27349691,lag time,In vitro studies showed that osthole ethosome provided an enhanced transdermal flux of 6.98±1.6μg/cm(2)/h and a decreased lag time of 2.45h across porcine ear skin.,"Preparation of osthole-loaded nano-vesicles for skin delivery: Characterization, in vitro skin permeation and preliminary in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27349691/),h,2.45,231213,DB00898,Ethanol
,17340562,energies of activation,"The energies of activation of CAPE and FCAPE were found to be 17.9 and 20.1 kcal/mol, respectively.",Stability of caffeic acid phenethyl ester and its fluorinated derivative in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17340562/),[kcal] / [mol],17.9,231574,DB00898,Ethanol
,17340562,energies of activation,"The energies of activation of CAPE and FCAPE were found to be 17.9 and 20.1 kcal/mol, respectively.",Stability of caffeic acid phenethyl ester and its fluorinated derivative in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17340562/),[kcal] / [mol],20.1,231575,DB00898,Ethanol
,21594724,half-life,The half-life of OA was 87.6 minutes.,"An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21594724/),min,87.6,232337,DB00898,Ethanol
,17481975,flow-rate,"Separation is achieved on a reversed-phase cellulose-based chiral column (Chiralcel-ODR, 250 mm x 4.6 mm i.d.) using 0.05 M potassium hexafluorophosphate (pH 4.5)/acetonitrile/ethanol (50:40:10 vol/vol/vol) as mobile phase at a flow-rate of 0.9 mL/min.",Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17481975/),[ml] / [min],0.9,232447,DB00898,Ethanol
,7616186,bioavailability,"The bioavailability of deet from 10% ethanol solution was 45%, whereas the bioavailability of deet from lipospheres was 16%, a 3-fold reduction in the amount of deet absorbed.","Insect repellent formulations of N,N-diethyl-m-toluamide (deet) in a liposphere system: efficacy and skin uptake. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616186/),%,45,232633,DB00898,Ethanol
,7616186,bioavailability,"The bioavailability of deet from 10% ethanol solution was 45%, whereas the bioavailability of deet from lipospheres was 16%, a 3-fold reduction in the amount of deet absorbed.","Insect repellent formulations of N,N-diethyl-m-toluamide (deet) in a liposphere system: efficacy and skin uptake. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616186/),%,16,232634,DB00898,Ethanol
,26664117,polydispersion index,"The particle size, polydispersion index, drug encapsulation efficiency, and drug loading were 187.20±10.55 nm, 0.51±0.017, 90.14%, and 7.51%, respectively, and the solubility was increased from 0.001 to 5 mg/mL.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),%,0.51,232951,DB00898,Ethanol
,26664117,drug loading,"The particle size, polydispersion index, drug encapsulation efficiency, and drug loading were 187.20±10.55 nm, 0.51±0.017, 90.14%, and 7.51%, respectively, and the solubility was increased from 0.001 to 5 mg/mL.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),%,90.14,232952,DB00898,Ethanol
,26664117,drug loading,"The particle size, polydispersion index, drug encapsulation efficiency, and drug loading were 187.20±10.55 nm, 0.51±0.017, 90.14%, and 7.51%, respectively, and the solubility was increased from 0.001 to 5 mg/mL.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),%,7.51,232953,DB00898,Ethanol
,26664117,solubility,"The particle size, polydispersion index, drug encapsulation efficiency, and drug loading were 187.20±10.55 nm, 0.51±0.017, 90.14%, and 7.51%, respectively, and the solubility was increased from 0.001 to 5 mg/mL.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),[mg] / [ml],0.001,232954,DB00898,Ethanol
,26664117,solubility,"The particle size, polydispersion index, drug encapsulation efficiency, and drug loading were 187.20±10.55 nm, 0.51±0.017, 90.14%, and 7.51%, respectively, and the solubility was increased from 0.001 to 5 mg/mL.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),[mg] / [ml],5,232955,DB00898,Ethanol
,26664117,50% inhibitory concentration,"With pretreatment of 50 μg/mL ethanolic extract of Taiwanofungus camphoratus followed by AmB to HT29 colon cancer cells, the 50% inhibitory concentration of AmB solution was 12 μg/mL, whereas that of Ambicelles was 1 μg/mL, indicating that Ambicelles exerted a greater synergistic anticancer effect.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),[μg] / [ml],12,232956,DB00898,Ethanol
,26664117,50% inhibitory concentration,"With pretreatment of 50 μg/mL ethanolic extract of Taiwanofungus camphoratus followed by AmB to HT29 colon cancer cells, the 50% inhibitory concentration of AmB solution was 12 μg/mL, whereas that of Ambicelles was 1 μg/mL, indicating that Ambicelles exerted a greater synergistic anticancer effect.",Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26664117/),[μg] / [ml],1,232957,DB00898,Ethanol
,22429777,peak serum concentration,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[ng] / [ml],24 100,232989,DB00898,Ethanol
,22429777,peak serum concentration,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[ng] / [ml],108,232990,DB00898,Ethanol
,22429777,area under the concentration-time curve from 0 to 48 h,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[h·ng] / [ml],191 000,232991,DB00898,Ethanol
,22429777,area under the concentration-time curve from 0 to 48 h,"Furthermore, the peak serum concentration was higher in the NK105 than PTX-Cre group (24 100 ± 3560 vs 108 ± 25 ng/mL, respectively; P < 0.001), as was the area under the concentration-time curve from 0 to 48 h (191 000 ± 32 100 vs 1500 ± 108 ng·h/mL, respectively; P < 0.001).","Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22429777/),[h·ng] / [ml],1500,232992,DB00898,Ethanol
,7988363,plasma half-life,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),min,10,233054,DB00898,Ethanol
,7988363,plasma half-life,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),min,18.7,233055,DB00898,Ethanol
,7988363,apparent volume of distribution,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),,73,233056,DB00898,Ethanol
,7988363,apparent volume of distribution,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),,51,233057,DB00898,Ethanol
,7988363,clearance,"Significant decrease in plasma half-life (10 +/- 1.2 vs. 18.7 +/- 1.4 min), and significant increases in apparent volume of distribution (73 +/- 6 vs. 51 +/- 31) and clearance (5.37 +/- 0.6 vs.",Alcohol pretreatment alters the metabolic pattern and accelerates cocaine metabolism in pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988363/),,5.37,233058,DB00898,Ethanol
,32296587,area under the concentration-time curves (AUCs),"Compared to elemene injection, PEG-Lipo-β-E demonstrated a 1.75-fold decrease in clearance, a 1.62-fold increase in half-life, and a 1.76-fold increase in area under the concentration-time curves (AUCs) from 0 hour to 1.5 hours (P < 0.05).","Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32296587/),h,0,233620,DB00898,Ethanol
,32296587,area under the concentration-time curves (AUCs),"Compared to elemene injection, PEG-Lipo-β-E demonstrated a 1.75-fold decrease in clearance, a 1.62-fold increase in half-life, and a 1.76-fold increase in area under the concentration-time curves (AUCs) from 0 hour to 1.5 hours (P < 0.05).","Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32296587/),h,1.5,233621,DB00898,Ethanol
,14595702,area under the concentration vs time curves (AUC),"After oral administration of SQV alone (20 mg/kg) in rats prepared by free access to 15% ethanol solution for 14 days (day 14 rats), the area under the concentration vs time curves (AUC) showed a significant decrease (p<0.01) in comparison with control rats from 0.78+/-0.10 to 0.38+/-0.03 microg h/ml.","Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595702/),[h·μg] / [ml],0.78,233688,DB00898,Ethanol
,14595702,area under the concentration vs time curves (AUC),"After oral administration of SQV alone (20 mg/kg) in rats prepared by free access to 15% ethanol solution for 14 days (day 14 rats), the area under the concentration vs time curves (AUC) showed a significant decrease (p<0.01) in comparison with control rats from 0.78+/-0.10 to 0.38+/-0.03 microg h/ml.","Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595702/),[h·μg] / [ml],0.38,233689,DB00898,Ethanol
,14595702,AUC,"With RTV, which has the strongest inhibitory effect on the CYP3A enzyme of the current HIV protease inhibitors, the AUC values of SQV at RTV doses of 2 and 20 mg/kg in day 14 rats also decreased significantly (p<0.01) from 1.30+/-0.06 to 0.57+/-0.05 microg h/ml and from 17.63+/-1.66 to 4.18+/-0.94 microg h/ml, respectively, indicating that the degree of the decrease of AUC values after oral administration with RTV after ethanol intake was larger than the mono-therapy with SQV.","Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595702/),[h·μg] / [ml],1.30,233690,DB00898,Ethanol
,14595702,AUC,"With RTV, which has the strongest inhibitory effect on the CYP3A enzyme of the current HIV protease inhibitors, the AUC values of SQV at RTV doses of 2 and 20 mg/kg in day 14 rats also decreased significantly (p<0.01) from 1.30+/-0.06 to 0.57+/-0.05 microg h/ml and from 17.63+/-1.66 to 4.18+/-0.94 microg h/ml, respectively, indicating that the degree of the decrease of AUC values after oral administration with RTV after ethanol intake was larger than the mono-therapy with SQV.","Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595702/),[h·μg] / [ml],0.57,233691,DB00898,Ethanol
,14595702,AUC,"With RTV, which has the strongest inhibitory effect on the CYP3A enzyme of the current HIV protease inhibitors, the AUC values of SQV at RTV doses of 2 and 20 mg/kg in day 14 rats also decreased significantly (p<0.01) from 1.30+/-0.06 to 0.57+/-0.05 microg h/ml and from 17.63+/-1.66 to 4.18+/-0.94 microg h/ml, respectively, indicating that the degree of the decrease of AUC values after oral administration with RTV after ethanol intake was larger than the mono-therapy with SQV.","Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595702/),[h·μg] / [ml],17.63,233692,DB00898,Ethanol
,14595702,AUC,"With RTV, which has the strongest inhibitory effect on the CYP3A enzyme of the current HIV protease inhibitors, the AUC values of SQV at RTV doses of 2 and 20 mg/kg in day 14 rats also decreased significantly (p<0.01) from 1.30+/-0.06 to 0.57+/-0.05 microg h/ml and from 17.63+/-1.66 to 4.18+/-0.94 microg h/ml, respectively, indicating that the degree of the decrease of AUC values after oral administration with RTV after ethanol intake was larger than the mono-therapy with SQV.","Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14595702/),[h·μg] / [ml],4.18,233693,DB00898,Ethanol
,23399782,concentration,"The median Day 7 lumefantrine concentration was 404, (range, 189-894 ng/ml).","Exploration of in vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in under fives in Tabora region, Tanzania. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23399782/),[ng] / [ml],404,234074,DB00898,Ethanol
,6121708,t 1/2,"Peak plasma concentrations were higher for the parent drug but due to a longer elimination half-life, the metabolite concentrations became higher after a few hours (bufuralol t 1/2 = 2.7 +/- 0.9 h, metabolite t 1/2 = 6.1 +/- 1.5h).",The genetic control of bufuralol metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),h,2.7,234409,DB00898,Ethanol
,6121708,t 1/2,"Peak plasma concentrations were higher for the parent drug but due to a longer elimination half-life, the metabolite concentrations became higher after a few hours (bufuralol t 1/2 = 2.7 +/- 0.9 h, metabolite t 1/2 = 6.1 +/- 1.5h).",The genetic control of bufuralol metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),h,6.1,234410,DB00898,Ethanol
,6121708,bioavailability,The bioavailability of the tablet tested was 46 +/- 15%.,The genetic control of bufuralol metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),%,46,234411,DB00898,Ethanol
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],180,234456,DB00898,Ethanol
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],177,234457,DB00898,Ethanol
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],14,234458,DB00898,Ethanol
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],1.265,234459,DB00898,Ethanol
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.696,234460,DB00898,Ethanol
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.092,234461,DB00898,Ethanol
,582950,bioavailability,The resulting bioavailability has to be calculated to 22% only.,[Pharmacokinetics and metabolism of 3H-synephrine (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582950/),%,22,234566,DB00898,Ethanol
,582950,biological half-life,The biological half-life was about 2 h.,[Pharmacokinetics and metabolism of 3H-synephrine (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582950/),h,2,234567,DB00898,Ethanol
,21471809,half-life,"Noscapine, the tubulin-binding anticancer agent, when administered orally, requires high ED(50) (300-600 mg/kg), whereas intravenous administration (10 mg/kg) results in rapid elimination of the drug with a half-life of 0.39 h.","Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21471809/),h,0.39,234725,DB00898,Ethanol
,21471809,maximum entrapment efficiency,Data indicate that smooth and spherical shaped nanoparticles of 127 ± 15 nm were engineered with maximum entrapment efficiency of 65.32 ± 3.81%.,"Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21471809/),%,65.32,234726,DB00898,Ethanol
,21471809,release rate constant,In-vitro release kinetic data suggest a first-order release of noscapine (85.1%) from gelatin nanoparticles with a release rate constant of 7.611×10(-3).,"Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21471809/),,7.611×10(-3),234727,DB00898,Ethanol
,21471809,IC(50),"Cytotoxicity analysis of the MCF-7 cell line indicated that the IC(50) value of the noscapine-loaded poly(ethylene glycol)-grafted gelatin nanoparticles was equivalent to 20.8 μmol/l, which was significantly (P<0.05) lower than the IC(50) value of the noscapine-loaded gelatin nanoparticles (26.3 μmol/l) and noscapine (40.5 μmol/l).","Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21471809/),[μM] / [l],20.8,234728,DB00898,Ethanol
,21471809,IC(50),"Cytotoxicity analysis of the MCF-7 cell line indicated that the IC(50) value of the noscapine-loaded poly(ethylene glycol)-grafted gelatin nanoparticles was equivalent to 20.8 μmol/l, which was significantly (P<0.05) lower than the IC(50) value of the noscapine-loaded gelatin nanoparticles (26.3 μmol/l) and noscapine (40.5 μmol/l).","Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21471809/),[μM] / [l],26.3,234729,DB00898,Ethanol
,21471809,IC(50),"Cytotoxicity analysis of the MCF-7 cell line indicated that the IC(50) value of the noscapine-loaded poly(ethylene glycol)-grafted gelatin nanoparticles was equivalent to 20.8 μmol/l, which was significantly (P<0.05) lower than the IC(50) value of the noscapine-loaded gelatin nanoparticles (26.3 μmol/l) and noscapine (40.5 μmol/l).","Long-circulating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21471809/),[μM] / [l],40.5,234730,DB00898,Ethanol
,10702883,t1/2z,The t1/2z of cilostazol decreased from 15.5 hours after a tablet to 2.5 hours after an ethanolic solution.,Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702883/),h,15.5,235205,DB00898,Ethanol
,10702883,t1/2z,The t1/2z of cilostazol decreased from 15.5 hours after a tablet to 2.5 hours after an ethanolic solution.,Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702883/),h,2.5,235206,DB00898,Ethanol
,10702883,t1/2z,The t1/2z decreased from 15.1 +/- 14.5 hours (mean +/- SD) in the fasted state to 5.4 +/- 2.0 hours in the fed state.,Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702883/),h,15.1,235207,DB00898,Ethanol
,10702883,t1/2z,The t1/2z decreased from 15.1 +/- 14.5 hours (mean +/- SD) in the fasted state to 5.4 +/- 2.0 hours in the fed state.,Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702883/),h,5.4,235208,DB00898,Ethanol
,10702883,relative bioavailability,The relative bioavailability of the 100 mg cilostazol tablet versus an oral 100 mg cilostazol suspension is 100%.,Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702883/),%,100,235209,DB00898,Ethanol
,15747778,Concentrations,"Concentrations of plasma corticosterone before gavage of the corticosterone-drinking rats (47.61 +/- 1.13 ng/mL) were lower than the water (418.47 +/- 1.13 ng/mL) or the ethanol rats (383.71 +/- 1.13 ng/mL, P < 0.0001).","Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747778/),[ng] / [ml],47.61,235784,DB00898,Ethanol
,15747778,Concentrations,"Concentrations of plasma corticosterone before gavage of the corticosterone-drinking rats (47.61 +/- 1.13 ng/mL) were lower than the water (418.47 +/- 1.13 ng/mL) or the ethanol rats (383.71 +/- 1.13 ng/mL, P < 0.0001).","Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747778/),[ng] / [ml],418.47,235785,DB00898,Ethanol
,15747778,Concentrations,"Concentrations of plasma corticosterone before gavage of the corticosterone-drinking rats (47.61 +/- 1.13 ng/mL) were lower than the water (418.47 +/- 1.13 ng/mL) or the ethanol rats (383.71 +/- 1.13 ng/mL, P < 0.0001).","Corticosterone in drinking water: altered kinetics of a single oral dose of corticosterone and concentrations of plasma sodium, albumin, globulin, and total protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747778/),[ng] / [ml],383.71,235786,DB00898,Ethanol
,18079079,concentration,"In the high progesterone group (n=11), the mean concentration was 11.1+/-3.5ng/ml and in the low progesterone group (n=50) the mean was 0.6+/-0.3ng/ml.",The influence of sex hormones on the elimination kinetics of ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[ng] / [ml],11.1,236249,DB00898,Ethanol
,18079079,concentration,"In the high progesterone group (n=11), the mean concentration was 11.1+/-3.5ng/ml and in the low progesterone group (n=50) the mean was 0.6+/-0.3ng/ml.",The influence of sex hormones on the elimination kinetics of ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[ng] / [ml],0.6,236250,DB00898,Ethanol
,18079079,hourly elimination rate (beta60),The mean hourly elimination rate (beta60) was 0.1677+/-0.0311g/kg/h in men.,The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.1677,236251,DB00898,Ethanol
,18079079,hourly elimination rate,"In women, the mean hourly elimination rate was 0.2044+/-0.0414g/kg/h in the high progesterone group and 0.1850+/-0.0276g/kg/h in the low progesterone group (p<0.05).",The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.2044,236252,DB00898,Ethanol
,18079079,hourly elimination rate,"In women, the mean hourly elimination rate was 0.2044+/-0.0414g/kg/h in the high progesterone group and 0.1850+/-0.0276g/kg/h in the low progesterone group (p<0.05).",The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.1850,236253,DB00898,Ethanol
,3663880,elimination half-life,"The elimination half-life of 14C was 105 h in the dog and 83 h in the rat, while that of 3H was approximately 32 h in both species.","Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663880/),h,105,236304,DB00898,Ethanol
,3663880,elimination half-life,"The elimination half-life of 14C was 105 h in the dog and 83 h in the rat, while that of 3H was approximately 32 h in both species.","Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663880/),h,83,236305,DB00898,Ethanol
,3663880,elimination half-life,"The elimination half-life of 14C was 105 h in the dog and 83 h in the rat, while that of 3H was approximately 32 h in both species.","Disposition of a silicon-containing amide, an inhibitor of acyl-CoA: cholesterol acyltransferase, in dog and rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663880/),h,32,236306,DB00898,Ethanol
,18828806,"rate of absorption, K(a)","Results show a slower mean rate of absorption, K(a), (0.12 vs. 0.15 min(-1), p = 0.03) and a longer time to reach maximum concentration, T(max), (28 vs. 23 minute, p < 0.01) for the ML compared with DS-Etoh beverage.",Alterations in ethyl alcohol pharmacokinetics during oral consumption of malt liquor beverages in African Americans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828806/),1/[min],0.12,236625,DB00898,Ethanol
,18828806,"rate of absorption, K(a)","Results show a slower mean rate of absorption, K(a), (0.12 vs. 0.15 min(-1), p = 0.03) and a longer time to reach maximum concentration, T(max), (28 vs. 23 minute, p < 0.01) for the ML compared with DS-Etoh beverage.",Alterations in ethyl alcohol pharmacokinetics during oral consumption of malt liquor beverages in African Americans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828806/),1/[min],0.15,236626,DB00898,Ethanol
,18828806,"time to reach maximum concentration, T(max)","Results show a slower mean rate of absorption, K(a), (0.12 vs. 0.15 min(-1), p = 0.03) and a longer time to reach maximum concentration, T(max), (28 vs. 23 minute, p < 0.01) for the ML compared with DS-Etoh beverage.",Alterations in ethyl alcohol pharmacokinetics during oral consumption of malt liquor beverages in African Americans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828806/),min,28,236627,DB00898,Ethanol
,18828806,"time to reach maximum concentration, T(max)","Results show a slower mean rate of absorption, K(a), (0.12 vs. 0.15 min(-1), p = 0.03) and a longer time to reach maximum concentration, T(max), (28 vs. 23 minute, p < 0.01) for the ML compared with DS-Etoh beverage.",Alterations in ethyl alcohol pharmacokinetics during oral consumption of malt liquor beverages in African Americans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828806/),min,23,236628,DB00898,Ethanol
,18828806,area under the BrAC-time curve,"The ML beverage resulted in a larger area under the BrAC-time curve compared with DS-Etoh beverage (8.4 vs. 6.8 min g/dl, p = 0.02).",Alterations in ethyl alcohol pharmacokinetics during oral consumption of malt liquor beverages in African Americans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828806/),[g·min] / [dl],8.4,236629,DB00898,Ethanol
,18828806,area under the BrAC-time curve,"The ML beverage resulted in a larger area under the BrAC-time curve compared with DS-Etoh beverage (8.4 vs. 6.8 min g/dl, p = 0.02).",Alterations in ethyl alcohol pharmacokinetics during oral consumption of malt liquor beverages in African Americans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18828806/),[g·min] / [dl],6.8,236630,DB00898,Ethanol
,11474778,volume of distribution,"Subsequent to tail-vein injection to FL-immunized mice, FL-LC showed approximately 4-fold smaller volume of distribution than mock-immunized mice: 0.041 +/- 0.005 vs. 0.16 +/- 0.02 mL/g.",Antibodies as drug carriers. For proteins. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474778/),[ml] / [g],0.041,236889,DB00898,Ethanol
,11474778,volume of distribution,"Subsequent to tail-vein injection to FL-immunized mice, FL-LC showed approximately 4-fold smaller volume of distribution than mock-immunized mice: 0.041 +/- 0.005 vs. 0.16 +/- 0.02 mL/g.",Antibodies as drug carriers. For proteins. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474778/),[ml] / [g],0.16,236890,DB00898,Ethanol
,11474778,FL-(LC)1/2,"Corresponding values for FL-(LC)1/2, were significantly larger: 0.070 +/-0.013 and 0.30 +/- 0.02 mL/g, respectively.",Antibodies as drug carriers. For proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474778/),[ml] / [g],0.070,236891,DB00898,Ethanol
,11474778,FL-(LC)1/2,"Corresponding values for FL-(LC)1/2, were significantly larger: 0.070 +/-0.013 and 0.30 +/- 0.02 mL/g, respectively.",Antibodies as drug carriers. For proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474778/),[ml] / [g],0.30,236892,DB00898,Ethanol
,11474778,half-life,"In mock-immunized mice, the radioactivity disappeared very rapidly after administration, followed by an extremely slow decline with half-life close to 60 h.",Antibodies as drug carriers. For proteins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474778/),h,60,236893,DB00898,Ethanol
,19555267,entrapment efficiency,The entrapment efficiency measured by reverse dialysis method was 77.89 +/- 0.28%.,"Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19555267/),%,77.89,237971,DB00898,Ethanol
,19555267,particle,"The particle size, polydispersity index, and zeta potential of breviscapine liposomes were 504.83 +/- 52.88 nm (by intensity), 0.17 +/- 0.02, and -(20.31 +/- 1.03) mV, respectively (mean +/- SD, n = 3).","Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19555267/),nm,504.83,237972,DB00898,Ethanol
,19555267,polydispersity index,"The particle size, polydispersity index, and zeta potential of breviscapine liposomes were 504.83 +/- 52.88 nm (by intensity), 0.17 +/- 0.02, and -(20.31 +/- 1.03) mV, respectively (mean +/- SD, n = 3).","Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19555267/),mv,0.17,237973,DB00898,Ethanol
,19555267,zeta potential,"The particle size, polydispersity index, and zeta potential of breviscapine liposomes were 504.83 +/- 52.88 nm (by intensity), 0.17 +/- 0.02, and -(20.31 +/- 1.03) mV, respectively (mean +/- SD, n = 3).","Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19555267/),mv,20.31,237974,DB00898,Ethanol
,19555267,t(1/2(beta)),"After bolus administration, the elimination phase (t(1/2(beta)) = 66.386) of liposomal formulation in plasma was 4.8 times longer than that of solution formulation (t(1/2(beta)) = 13.695).","Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19555267/),,13.695,237975,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),nm,331,238331,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],3400,238332,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],2956,238333,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1625,238334,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1500,238335,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1110,238336,DB00898,Ethanol
,24794908,λmax,"UV spectroscopy of gefitinib showed a λmax of approximately 331nm, whereas IR spectroscopy principal peaks were observed at 3400cm(-1) (NH), 2956cm(-1) (CH2, CH, alkyl), 1625cm(-1) (CC, CN), 1500cm(-1) (HCCH, aryl), 1110cm(-1) (CO), 1028cm(-1) (CF).",Gefitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),1/[cm],1028,238337,DB00898,Ethanol
,24794908,bioavailability,"Pharmacokinetically, after oral administration, gefitinib is slowly absorbed with bioavailability of approximately 60% in human.",Gefitinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),%,60,238338,DB00898,Ethanol
,24794908,total plasma clearance,Gefitinib is eliminated mainly hepatically with total plasma clearance of 595mL/min after intravenous administration.,Gefitinib. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24794908/),[ml] / [min],595,238339,DB00898,Ethanol
,23883364,AUC0-7,The results of the pharmacokinetic evaluation show that the AUC0-7 of the WCAM was 4510.66 and was about 4.41-fold compared to that of danggui concentrated pills (an existing Chinese angelica pharmaceutical preparation).,"""Whole Chinese angelica"" microemulsion: its preparation and in vivo and in vitro evaluations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883364/),,4510.66,238940,DB00898,Ethanol
,18513900,maximal plasma concentrations,"The maximal plasma concentrations of paclitaxel after an oral dose were 1.77+/-0.17 and 3.39+/-0.49microg/ml for Cremophor/ethanol and TPGS 400/ethanol formulations, respectively, with a similar time at 40-47min to reach the maximal plasma concentrations.",Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),[μg] / [ml],1.77,238991,DB00898,Ethanol
,18513900,maximal plasma concentrations,"The maximal plasma concentrations of paclitaxel after an oral dose were 1.77+/-0.17 and 3.39+/-0.49microg/ml for Cremophor/ethanol and TPGS 400/ethanol formulations, respectively, with a similar time at 40-47min to reach the maximal plasma concentrations.",Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),[μg] / [ml],3.39,238992,DB00898,Ethanol
,18513900,oral bioavailability,The oral bioavailability of paclitaxel in TPGS 400/ethanol (7.8%) was 3-fold higher than that in Cremophor/ethanol (2.5%).,Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),%,7.8,238993,DB00898,Ethanol
,18513900,oral bioavailability,The oral bioavailability of paclitaxel in TPGS 400/ethanol (7.8%) was 3-fold higher than that in Cremophor/ethanol (2.5%).,Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),%,2.5,238994,DB00898,Ethanol
,10617953,area under the curve,"Pooled mean (+/-SEM) values for the ARW and DRW were as follows: area under the curve, 306.1 +/- 29.5 nmol*h/L; c(max), 76.7 +/- 7.5 nmol/L; and t(max), 1.44 +/- 0.13 h.",(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10617953/),[h·nM] / [l],306.1,239746,DB00898,Ethanol
,10617953,c(max),"Pooled mean (+/-SEM) values for the ARW and DRW were as follows: area under the curve, 306.1 +/- 29.5 nmol*h/L; c(max), 76.7 +/- 7.5 nmol/L; and t(max), 1.44 +/- 0.13 h.",(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10617953/),[nM] / [l],76.7,239747,DB00898,Ethanol
,10617953,t(max),"Pooled mean (+/-SEM) values for the ARW and DRW were as follows: area under the curve, 306.1 +/- 29.5 nmol*h/L; c(max), 76.7 +/- 7.5 nmol/L; and t(max), 1.44 +/- 0.13 h.",(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10617953/),h,1.44,239748,DB00898,Ethanol
,10617953,half-life,The half-life of (+)-catechin in plasma was significantly less (P = 0.038) after ingestion of the ARW (3.17 h) than after ingestion of the DRW (4.08 h).,(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10617953/),h,3.17,239749,DB00898,Ethanol
,10617953,half-life,The half-life of (+)-catechin in plasma was significantly less (P = 0.038) after ingestion of the ARW (3.17 h) than after ingestion of the DRW (4.08 h).,(+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10617953/),h,4.08,239750,DB00898,Ethanol
,17300626,AUC((0-->infinity)),"The AUC((0-->infinity)) of the once-daily regimen was 30% lower than that in the conventional regimen (P = 0.011) with a median (range) value of 306 (114-5781) microg/ml h, compared with 432 (308-992) microg/ml h.",Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17300626/),[μg] / [h·ml],306,240095,DB00898,Ethanol
,17300626,AUC((0-->infinity)),"The AUC((0-->infinity)) of the once-daily regimen was 30% lower than that in the conventional regimen (P = 0.011) with a median (range) value of 306 (114-5781) microg/ml h, compared with 432 (308-992) microg/ml h.",Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17300626/),[μg] / [h·ml],432,240096,DB00898,Ethanol
,32154587,AUC,"In the alcohol pharmacokinetics parameters, the AUC was 44.5 mM∙h in the alcohol group.","Effect of Single-Dose, Oral Enzymatic Porcine Placental Extract on Pharmacokinetics of Alcohol and Liver Function in Rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154587/),mM∙h,44.5,240576,DB00898,Ethanol
,3871765,half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,1-3,240991,DB00898,Ethanol
,3871765,plasma half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,7-15,240992,DB00898,Ethanol
,17014999,T(max),"WIN55,212-2 was absorbed more rapidly (T(max)=0.2-0.3h) than Delta(9)-THC (T(max)=1.5-1.6h) and to a higher extent than Delta(9)-THC.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),h,0.2-0.3,241047,DB00898,Ethanol
,17014999,T(max),"WIN55,212-2 was absorbed more rapidly (T(max)=0.2-0.3h) than Delta(9)-THC (T(max)=1.5-1.6h) and to a higher extent than Delta(9)-THC.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),h,1.5-1.6,241048,DB00898,Ethanol
,17014999,absolute bioavailability (F(abs)),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,6.4,241049,DB00898,Ethanol
,17014999,F(abs),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,6.4,241050,DB00898,Ethanol
,17014999,F(abs),"Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6.4+/-2.4% and 9.1+/-3.0% for Delta(9)-THC in propylene glycol, with and without ethanol, respectively.","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,9.1,241051,DB00898,Ethanol
,17014999,F(abs),"For WIN55,212-2, F(abs)=49.9+/-6.9% (propylene glycol alone) and 56.6+/-14.1% (propylene glycol with 10% ethanol).","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,49.9,241052,DB00898,Ethanol
,17014999,F(abs),"For WIN55,212-2, F(abs)=49.9+/-6.9% (propylene glycol alone) and 56.6+/-14.1% (propylene glycol with 10% ethanol).","Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014999/),%,56.6,241053,DB00898,Ethanol
,33316031,Cmax,"We showed that liver is exposed to the highest EtOH concentration, faster than other organs (Cmax = 839.50 mg/L and Tmax = 0.53 h), while brain exposure of EtOH (AUC = 1139.43 mg·h/L) is the highest among all other organs.",Development of a Physiologically Based Pharmacokinetic Model for Prediction of Ethanol Concentration-Time Profile in Different Organs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316031/),[mg] / [l],839.50,241084,DB00898,Ethanol
,33316031,Tmax,"We showed that liver is exposed to the highest EtOH concentration, faster than other organs (Cmax = 839.50 mg/L and Tmax = 0.53 h), while brain exposure of EtOH (AUC = 1139.43 mg·h/L) is the highest among all other organs.",Development of a Physiologically Based Pharmacokinetic Model for Prediction of Ethanol Concentration-Time Profile in Different Organs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316031/),h,0.53,241085,DB00898,Ethanol
,33316031,AUC,"We showed that liver is exposed to the highest EtOH concentration, faster than other organs (Cmax = 839.50 mg/L and Tmax = 0.53 h), while brain exposure of EtOH (AUC = 1139.43 mg·h/L) is the highest among all other organs.",Development of a Physiologically Based Pharmacokinetic Model for Prediction of Ethanol Concentration-Time Profile in Different Organs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33316031/),[h·mg] / [l],1139.43,241086,DB00898,Ethanol
,30037041,run time,Chromatographic separation was performed on HPLC by using a biphenyl column with a gradient elution using 2 mM ammonium formate (pH 6) in water and 2 mM ammonium formate (pH 6) in methanol within a run time of 13 min.,A Simple and Sensitive Liquid Chromatography with Tandem Mass Spectrometric Method for the Simultaneous Determination of Anthraquinone Glycosides and Their Aglycones in Rat Plasma: Application to a Pharmacokinetic Study of Rumex acetosa Extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30037041/),min,13,241472,DB00898,Ethanol
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00898,Ethanol
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00898,Ethanol
,24071566,ED₅₀,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (ED₅₀ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00898,Ethanol
,23313344,transdermal flux,Optimized nanoethosomal formulation with mean particle size is 103 ± 5.0 nm showed 89.34 ± 2.54% entrapment efficiency and achieved mean transdermal flux 801.36 ± 21.45 μg/cm(2)/h.,"Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313344/),[μg] / [cm(2)·h],801.36,241726,DB00898,Ethanol
,23313344,enhancement ratio,"Nanoethosomes proved significantly superior in terms of, amount of drug permeated in the skin, with an enhancement ratio of 43.38 ± 1.37 when compared to rigid liposomes.","Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23313344/),,43.38,241727,DB00898,Ethanol
,19032175,pseudo-steady state breath alcohol concentration (BrAC),"Individual infusion regimens were calculated afterwards, based on a pseudo-steady state breath alcohol concentration (BrAC) of 0.65 g l(-1) and applied on a separate occasion.",A comparative study of two methods for attaining constant alcohol levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032175/),[g] / [l],0.65,242261,DB00898,Ethanol
,19032175,BrAC,"The mean BrAC during clamping [0.61 g l(-1), 95% confidence interval (CI) 0.58, 0.63] did not differ from its intended level of 0.6 g l(-1) (1.0% on average).",A comparative study of two methods for attaining constant alcohol levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032175/),[g] / [l],0.61,242262,DB00898,Ethanol
,19032175,BrAC,"The mean BrAC during clamping [0.61 g l(-1), 95% confidence interval (CI) 0.58, 0.63] did not differ from its intended level of 0.6 g l(-1) (1.0% on average).",A comparative study of two methods for attaining constant alcohol levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032175/),[g] / [l],0.6,242263,DB00898,Ethanol
,19032175,BrAC,"In contrast, the mean BrAC during the prekinetic procedure was significantly lower than the 0.65 g l(-1) set-point (0.59 g l(-1), 95% CI 0.54, 0.63) and deviated from this target by 9.7% on average.",A comparative study of two methods for attaining constant alcohol levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032175/),,0,242264,DB00898,Ethanol
,19032175,BrAC,"In contrast, the mean BrAC during the prekinetic procedure was significantly lower than the 0.65 g l(-1) set-point (0.59 g l(-1), 95% CI 0.54, 0.63) and deviated from this target by 9.7% on average.",A comparative study of two methods for attaining constant alcohol levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032175/),[g] / [l],0.59,242265,DB00898,Ethanol
,23364885,Tmax,"Our results show that gavage of decursinol led to a faster attainment of plasma decursinol peak (Tmax ~ 0.7 h) and much higher peak levels than an equal molar amount administered as decursin/decursinol angelate mixture or as Angelica gigas ethanol extract, resulting in 2-3 fold higher bioavailability as estimated by the area under the curve of the respective regimens (65 012 vs. 27 033 h · ng/mL for decursinol and decursin/decursinol angelate treatment groups, respectively).","Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364885/),h,0.7,242412,DB00898,Ethanol
,23364885,bioavailability,"Our results show that gavage of decursinol led to a faster attainment of plasma decursinol peak (Tmax ~ 0.7 h) and much higher peak levels than an equal molar amount administered as decursin/decursinol angelate mixture or as Angelica gigas ethanol extract, resulting in 2-3 fold higher bioavailability as estimated by the area under the curve of the respective regimens (65 012 vs. 27 033 h · ng/mL for decursinol and decursin/decursinol angelate treatment groups, respectively).","Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364885/),[h·ng] / [ml],65 012,242413,DB00898,Ethanol
,23364885,bioavailability,"Our results show that gavage of decursinol led to a faster attainment of plasma decursinol peak (Tmax ~ 0.7 h) and much higher peak levels than an equal molar amount administered as decursin/decursinol angelate mixture or as Angelica gigas ethanol extract, resulting in 2-3 fold higher bioavailability as estimated by the area under the curve of the respective regimens (65 012 vs. 27 033 h · ng/mL for decursinol and decursin/decursinol angelate treatment groups, respectively).","Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364885/),[h·ng] / [ml],27 033,242414,DB00898,Ethanol
,23364885,area under the curve,"Our results show that gavage of decursinol led to a faster attainment of plasma decursinol peak (Tmax ~ 0.7 h) and much higher peak levels than an equal molar amount administered as decursin/decursinol angelate mixture or as Angelica gigas ethanol extract, resulting in 2-3 fold higher bioavailability as estimated by the area under the curve of the respective regimens (65 012 vs. 27 033 h · ng/mL for decursinol and decursin/decursinol angelate treatment groups, respectively).","Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364885/),[h·ng] / [ml],65 012,242415,DB00898,Ethanol
,23364885,area under the curve,"Our results show that gavage of decursinol led to a faster attainment of plasma decursinol peak (Tmax ~ 0.7 h) and much higher peak levels than an equal molar amount administered as decursin/decursinol angelate mixture or as Angelica gigas ethanol extract, resulting in 2-3 fold higher bioavailability as estimated by the area under the curve of the respective regimens (65 012 vs. 27 033 h · ng/mL for decursinol and decursin/decursinol angelate treatment groups, respectively).","Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364885/),[h·ng] / [ml],27 033,242416,DB00898,Ethanol
,23364885,Tmax,"In addition, we detected peak levels of decursin and decursinol angelate in the plasma of rats administered with decursin/decursinol angelate or Angelica gigas extract in the nM range (Tmax ~ 0.5 h) with a newly established sensitive UHPLC-MS/MS method.","Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364885/),h,0.5,242417,DB00898,Ethanol
>,8598097,Analytical recovery,Analytical recovery was >90%.,Simultaneous measurement of ethanol and ethyl-d5 alcohol by stable isotope gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8598097/),%,90,242536,DB00898,Ethanol
,8186347,area under the plasma ethanol concentration-time curve (AUC0-t),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[h·mg] / [dl],7.1,242598,DB00898,Ethanol
,8186347,area under the plasma ethanol concentration-time curve (AUC0-t),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[h·mg] / [dl],5.5,242599,DB00898,Ethanol
,8186347,maximal plasma concentration (Cmax),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[mg] / [dl],9.2,242600,DB00898,Ethanol
,8186347,maximal plasma concentration (Cmax),"Famotidine increased the area under the plasma ethanol concentration-time curve (AUC0-t) by 29% (7.1 vs 5.5 mg.h/dL, P = 0.006) and maximal plasma concentration (Cmax) by 23% (9.2 vs 7.5 mg/dL, P = 0.013).",Famotidine increases plasma alcohol concentration in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186347/),[mg] / [dl],7.5,242601,DB00898,Ethanol
,20713675,oral clearance,"The pharmacokinetics of artemether was time dependent, with typical oral clearance increasing from 2.6 liters/h/kg on day 1 to 10 liters/h/kg on day 3.",Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20713675/),[l] / [h·kg],2.6,242653,DB00898,Ethanol
,20713675,oral clearance,"The pharmacokinetics of artemether was time dependent, with typical oral clearance increasing from 2.6 liters/h/kg on day 1 to 10 liters/h/kg on day 3.",Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20713675/),[l] / [h·kg],10,242654,DB00898,Ethanol
,20713675,oral clearance,The typical value of oral clearance was estimated to 77 ml/h/kg.,Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20713675/),[ml] / [h·kg],77,242655,DB00898,Ethanol
,9421115,total run time,"Chromatographic conditions comprise a C18 column, a mobile phase with 30% methanol and 70% 0.25N sodium acetate buffer (pH 5.0), a total run time of 10 minutes, and ultraviolet absorbance detection at 254 nm.",Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421115/),min,10,242688,DB00898,Ethanol
,9421115,CL(CR),The assay shows to be suitable for pharmacokinetics and drug metabolism studies after administration of a single oral dose of 500 mg of antipyrine to a patient with hypertension and chronic renal failure (CL(CR) = 34.17 ml/min(-1); 1.73 m(-2)).,Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421115/),[ml] / [min],34.17,242689,DB00898,Ethanol
,9421115,CL(CR),The assay shows to be suitable for pharmacokinetics and drug metabolism studies after administration of a single oral dose of 500 mg of antipyrine to a patient with hypertension and chronic renal failure (CL(CR) = 34.17 ml/min(-1); 1.73 m(-2)).,Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421115/),1/[(m)^2],1.73,242690,DB00898,Ethanol
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[g%] / [h],0.0194,243003,DB00898,Ethanol
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[mg] / [h·l],0.0975,243004,DB00898,Ethanol
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[g%] / [h],0.0193,243005,DB00898,Ethanol
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[mg] / [h·l],0.1026,243006,DB00898,Ethanol
,15846465,t(1/2beta),"Pharmacokinetic studies showed that encapsulation of paclitaxel in magnetoliposomes produced marked difference over the drug in Cremophor EL/ethanol pharmacokinetics, with an increased t(1/2beta) 19.37 h against 4.11 h.",Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846465/),h,19.37,243042,DB00898,Ethanol
,15846465,t(1/2beta),"Pharmacokinetic studies showed that encapsulation of paclitaxel in magnetoliposomes produced marked difference over the drug in Cremophor EL/ethanol pharmacokinetics, with an increased t(1/2beta) 19.37 h against 4.11 h.",Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846465/),h,4.11,243043,DB00898,Ethanol
,19353685,flow rate,The separation was accomplished on a normal-phase polysaccharide stationary phase Chiralcel OJ-H using n-hexane-ethanol (62:38 v/v) as a mobile phase at a flow rate of 1.0 mL/min.,Enantioselective separation and determination of adrafinil and modafinil on Chiralcel OJ-H column in rat serum and urine using solid-phase extraction followed by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353685/),[ml] / [min],1.0,243377,DB00898,Ethanol
>or=,19353685,recoveries,ADL and its metabolite were recovered from rat serum and urine by solid phase extraction using Oasis HLB cartridges and the mean recoveries were >or=80%.,Enantioselective separation and determination of adrafinil and modafinil on Chiralcel OJ-H column in rat serum and urine using solid-phase extraction followed by HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353685/),%,80,243378,DB00898,Ethanol
,6146413,t 1/2,"During S-14 infusions, plasma SLI rose rapidly, reached a plateau from 15-150 min and declined rapidly on cessation of the infusions with a mean t 1/2 of 2.72 +/- 0.45 min.",Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146413/),min,2.72,243807,DB00898,Ethanol
,6146413,plateau SLI levels,"Mean plateau SLI levels were: 149 +/- 3 pg/ml (25 micrograms/h), 465 +/- 35 pg/ml (50 micrograms/h), and 1244 +/- 71 pg/ml (75 micrograms/h).",Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146413/),[pg] / [ml],149,243808,DB00898,Ethanol
,6146413,plateau SLI levels,"Mean plateau SLI levels were: 149 +/- 3 pg/ml (25 micrograms/h), 465 +/- 35 pg/ml (50 micrograms/h), and 1244 +/- 71 pg/ml (75 micrograms/h).",Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146413/),[pg] / [ml],465,243809,DB00898,Ethanol
,6146413,plateau SLI levels,"Mean plateau SLI levels were: 149 +/- 3 pg/ml (25 micrograms/h), 465 +/- 35 pg/ml (50 micrograms/h), and 1244 +/- 71 pg/ml (75 micrograms/h).",Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146413/),[pg] / [ml],1244,243810,DB00898,Ethanol
,6146413,MCR,SLI was cleared rapidly but the MCR exhibited a dose-dependent decrease from 3225 +/- 699 ml/min for the 25 micrograms infusion to 1249 +/- 241 ml/min for the 75 micrograms/h infusion (P less than 0.05).,Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146413/),[ml] / [min],3225,243811,DB00898,Ethanol
,6146413,MCR,SLI was cleared rapidly but the MCR exhibited a dose-dependent decrease from 3225 +/- 699 ml/min for the 25 micrograms infusion to 1249 +/- 241 ml/min for the 75 micrograms/h infusion (P less than 0.05).,Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146413/),[ml] / [min],1249,243812,DB00898,Ethanol
,8633056,EC50,"EC50 values estimated from the graded dose-response curves for pure daidzin and RP extract daidzin are 23 and 2.3 mg per hamster per day, respectively.",Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633056/),[mg] / [d·hamster],23,244325,DB00898,Ethanol
,8633056,EC50,"EC50 values estimated from the graded dose-response curves for pure daidzin and RP extract daidzin are 23 and 2.3 mg per hamster per day, respectively.",Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633056/),[mg] / [d·hamster],2.3,244326,DB00898,Ethanol
,18243606,solubility,"Furthermore, the formula of ibuprofen-loaded gelatin microcapsule at the ratio of gelatin/ibuprofen/sodium lauryl sulfate/water/ethanol of 4/0.5/0.6/30/70 showed ibuprofen solubility of about 290microg/ml and ethanol content of about 160microg/mg.",Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18243606/),[μg] / [ml],290,244597,DB00898,Ethanol
,33388525,MRM,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,179.125,244845,DB00898,Ethanol
,33388525,MRM,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,105.049,244846,DB00898,Ethanol
,33388525,MRM,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,195.085,244847,DB00898,Ethanol
,33388525,m/z,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,179.125,244848,DB00898,Ethanol
,33388525,m/z,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,105.049,244849,DB00898,Ethanol
,33388525,m/,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,195.085,244850,DB00898,Ethanol
,33388525,m/,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,109.031,244851,DB00898,Ethanol
,33388525,linearity,The method linearity ranges was 5-200 ng/mL.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[ng] / [ml],5-200,244852,DB00898,Ethanol
,33388525,maximum plasma concentration (Cmax),"After intragastric (50 mg/kg) administration of D-pinitol to the rats, the maximum plasma concentration (Cmax) was 77.8 ± 19.5 ng/mL.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[ng] / [ml],77.8,244853,DB00898,Ethanol
,33388525,time to reach the maximum plasma concentration (Tmax),The time to reach the maximum plasma concentration (Tmax) was 2.2 ± 0.98 h.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),h,2.2,244854,DB00898,Ethanol
,33388525,Apparent distribution volume (Vz),Apparent distribution volume (Vz) was 1557.5 ± 1329.1 L/kg and the plasma centration time curve (AUC0-t) was 1265.5 ± 479.3 µg/L*h.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[l] / [kg],1557.5,244855,DB00898,Ethanol
,33388525,plasma centration time curve (AUC0-t),Apparent distribution volume (Vz) was 1557.5 ± 1329.1 L/kg and the plasma centration time curve (AUC0-t) was 1265.5 ± 479.3 µg/L*h.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[μg] / [h·l],1265.5,244856,DB00898,Ethanol
,33388525,Vz,"After intravenous (5.0 mg/kg) administration, Vz was 325.2 ± 107.8 L/kg and AUC(0-t) was 693.0 ± 89.9 µg/L*h.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[l] / [kg],325.2,244857,DB00898,Ethanol
,33388525,AUC(0-t),"After intravenous (5.0 mg/kg) administration, Vz was 325.2 ± 107.8 L/kg and AUC(0-t) was 693.0 ± 89.9 µg/L*h.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[μg] / [h·l],693.0,244858,DB00898,Ethanol
,16723584,times to maximum concentration,BCV was readily absorbed following oral administration with mean times to maximum concentration from >1 h to 2.5 h in part 1 and from 1.5 h to 3 h in part 2.,"Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723584/),h,>,245243,DB00898,Ethanol
,16723584,times to maximum concentration,BCV was readily absorbed following oral administration with mean times to maximum concentration from >1 h to 2.5 h in part 1 and from 1.5 h to 3 h in part 2.,"Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723584/),h,1,245244,DB00898,Ethanol
,16723584,times to maximum concentration,BCV was readily absorbed following oral administration with mean times to maximum concentration from >1 h to 2.5 h in part 1 and from 1.5 h to 3 h in part 2.,"Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723584/),h,2.5,245245,DB00898,Ethanol
,16723584,times to maximum concentration,BCV was readily absorbed following oral administration with mean times to maximum concentration from >1 h to 2.5 h in part 1 and from 1.5 h to 3 h in part 2.,"Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723584/),h,1.5,245246,DB00898,Ethanol
,16723584,times to maximum concentration,BCV was readily absorbed following oral administration with mean times to maximum concentration from >1 h to 2.5 h in part 1 and from 1.5 h to 3 h in part 2.,"Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723584/),h,3,245247,DB00898,Ethanol
,8376494,analytical recoveries,"The analytical recoveries of AMF at concentrations of 0.5, 2 and 10 micrograms/ml in plasma were ca. 92.1, 95.4 and 94.6%, respectively.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,ca,245375,DB00898,Ethanol
,8376494,analytical recoveries,"The analytical recoveries of AMF at concentrations of 0.5, 2 and 10 micrograms/ml in plasma were ca. 92.1, 95.4 and 94.6%, respectively.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,92.1,245376,DB00898,Ethanol
,8376494,analytical recoveries,"The analytical recoveries of AMF at concentrations of 0.5, 2 and 10 micrograms/ml in plasma were ca. 92.1, 95.4 and 94.6%, respectively.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,95.4,245377,DB00898,Ethanol
,8376494,analytical recoveries,"The analytical recoveries of AMF at concentrations of 0.5, 2 and 10 micrograms/ml in plasma were ca. 92.1, 95.4 and 94.6%, respectively.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,94.6,245378,DB00898,Ethanol
,8376494,S1 recoveries,"The S1 recoveries at the concentrations of 40, 200 and 400.ng/ml were ca. 93.4, 98.7 and 95.3%, and the coefficients of variation were below 6.0%.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,93.4,245379,DB00898,Ethanol
,8376494,S1 recoveries,"The S1 recoveries at the concentrations of 40, 200 and 400.ng/ml were ca. 93.4, 98.7 and 95.3%, and the coefficients of variation were below 6.0%.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,98.7,245380,DB00898,Ethanol
,8376494,S1 recoveries,"The S1 recoveries at the concentrations of 40, 200 and 400.ng/ml were ca. 93.4, 98.7 and 95.3%, and the coefficients of variation were below 6.0%.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),%,95.3,245381,DB00898,Ethanol
below,8376494,S1 recoveries,"The S1 recoveries at the concentrations of 40, 200 and 400.ng/ml were ca. 93.4, 98.7 and 95.3%, and the coefficients of variation were below 6.0%.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),,6,245382,DB00898,Ethanol
,8376494,detection limits,"The detection limits of AMF and S1 in plasma were as low as 0.1 microgram/ml and 20 ng/ml, and the coefficients of variation were 4.0 and 4.4%, respectively.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),[μg] / [ml],0.1,245383,DB00898,Ethanol
,8376494,detection limits,"The detection limits of AMF and S1 in plasma were as low as 0.1 microgram/ml and 20 ng/ml, and the coefficients of variation were 4.0 and 4.4%, respectively.",Simultaneous determination of amfenac sodium and its metabolite (7-benzoyl-2-oxindole) in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8376494/),,20,245384,DB00898,Ethanol
,32852060,flow rate,The chromatographic separation was performed on an Agilent ZORBAX RRHD Eclipse Plus C18 column with gradient elution using a mobile phase composed of methanol and water (containing 0.2% acetic acid) at a flow rate of 0.3 mL min-1 .,Pharmacokinetics and tissue distribution study of 15 ingredients of Polygonum chinense Linn extract in rats by UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32852060/),[ml] / [min],0.3,245907,DB00898,Ethanol
,32852060,extraction recovery,The mean extraction recovery and matrix effect of analytes and ISs ranged from 83.65% to 109.20%.,Pharmacokinetics and tissue distribution study of 15 ingredients of Polygonum chinense Linn extract in rats by UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32852060/),%,83.65,245908,DB00898,Ethanol
,32852060,matrix effect,The mean extraction recovery and matrix effect of analytes and ISs ranged from 83.65% to 109.20%.,Pharmacokinetics and tissue distribution study of 15 ingredients of Polygonum chinense Linn extract in rats by UHPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32852060/),%,109.20,245909,DB00898,Ethanol
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,7.9,246096,DB00898,Ethanol
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,9.6,246097,DB00898,Ethanol
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,16.9,246098,DB00898,Ethanol
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,20.8,246099,DB00898,Ethanol
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.26,246100,DB00898,Ethanol
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.23,246101,DB00898,Ethanol
,9722047,anion gap,"The initial serum EG concentration was 1.34 g/l (21.6 mmol/l), the anion gap 14.5, and the osmolal gap 24.",Ethylene glycol poisoning treated by intravenous 4-methylpyrazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9722047/),,14.5,246449,DB00898,Ethanol
,9722047,osmolal gap,"The initial serum EG concentration was 1.34 g/l (21.6 mmol/l), the anion gap 14.5, and the osmolal gap 24.",Ethylene glycol poisoning treated by intravenous 4-methylpyrazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9722047/),,24,246450,DB00898,Ethanol
,9722047,half-life,"The half-life of EG during 4-MP therapy was 11 h, with a mean EG renal clearance of 26.9 ml/min, and a total of 65.3 g EG was eliminated unchanged in the urine.",Ethylene glycol poisoning treated by intravenous 4-methylpyrazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9722047/),h,11,246451,DB00898,Ethanol
,9722047,renal clearance,"The half-life of EG during 4-MP therapy was 11 h, with a mean EG renal clearance of 26.9 ml/min, and a total of 65.3 g EG was eliminated unchanged in the urine.",Ethylene glycol poisoning treated by intravenous 4-methylpyrazole. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9722047/),[ml] / [min],26.9,246452,DB00898,Ethanol
,21612741,Cmax,"Mean Cmax was 4,120 ng/ml at tmax of 2.8 h, and mean AUCinf was 19,800 ng·h/ml.",Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),[ng] / [ml],"4,120",246732,DB00898,Ethanol
,21612741,tmax,"Mean Cmax was 4,120 ng/ml at tmax of 2.8 h, and mean AUCinf was 19,800 ng·h/ml.",Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),h,2.8,246733,DB00898,Ethanol
,21612741,AUCinf,"Mean Cmax was 4,120 ng/ml at tmax of 2.8 h, and mean AUCinf was 19,800 ng·h/ml.",Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),[h·ng] / [ml],"19,800",246734,DB00898,Ethanol
,21612741,t1/2,The t1/2 of pamapimod was 7.2 h.,Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),h,7.2,246735,DB00898,Ethanol
,21612741,drug recovery,"Mean drug recovery was 100 ± 2% by 120 h, of which 76.5% was recovered in urine and 23.9% in feces.",Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),%,100,246736,DB00898,Ethanol
,21612741,drug recovery,"Mean drug recovery was 100 ± 2% by 120 h, of which 76.5% was recovered in urine and 23.9% in feces.",Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),%,76.5,246737,DB00898,Ethanol
,21612741,drug recovery,"Mean drug recovery was 100 ± 2% by 120 h, of which 76.5% was recovered in urine and 23.9% in feces.",Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612741/),%,23.9,246738,DB00898,Ethanol
,9872349,sleep time,"Ethanol at a dose of 4 g/kg, i.p. induced sleep in rats (sleep time: 117.2+/-30.7 min).",The effects of the nitric oxide synthase inhibitor 7-nitroindazole on ethanol pharmacokinetics in rats after acute and chronic ethanol administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872349/),min,117.2,246861,DB00898,Ethanol
,30291986,half-life,Cobalt isotopes are good candidates for NP labelling since 55Co has half-life of 17.5 h and positron energy of 570 keV while 57Co (t1/2 271.6 d) is an isotope suited for preclinical single photon emission tomography (SPECT) to visualize biodistribution and pharmacokinetics of NPs.,"Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),h,17.5,247001,DB00898,Ethanol
,30291986,t1/2,Cobalt isotopes are good candidates for NP labelling since 55Co has half-life of 17.5 h and positron energy of 570 keV while 57Co (t1/2 271.6 d) is an isotope suited for preclinical single photon emission tomography (SPECT) to visualize biodistribution and pharmacokinetics of NPs.,"Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),d,271.6,247002,DB00898,Ethanol
,30291986,association constant,The association constant of cobalt to OEP was 2.49 × 105 M-1 and the formation of the hexacoordinate complex OEP-Co-4OA was measured by spectroscopy.,"Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),1/[M],2.49 × 105,247003,DB00898,Ethanol
,30291986,loading capacity,Encapsulation of OEP-Co-OA: The loading capacity of OEP-Co-OA in LNP was 5 mol%.,"Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),mol%,5,247004,DB00898,Ethanol
,30291986,half-life for retention,"4. Retention of OEP-57Co-4OA complex in the LNPs: the positive effect of the OA ligands was demonstrated on the stability of the OEP-57Co-4OA complex, providing a half-life for retention in PBS of 170 h (7 days) while in the absence of the axial OA ligands was only 22 h.","Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),h,170,247005,DB00898,Ethanol
,30291986,half-life for retention,"4. Retention of OEP-57Co-4OA complex in the LNPs: the positive effect of the OA ligands was demonstrated on the stability of the OEP-57Co-4OA complex, providing a half-life for retention in PBS of 170 h (7 days) while in the absence of the axial OA ligands was only 22 h.","Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),h,22,247006,DB00898,Ethanol
,30291986,half-life,The estimated half-life of LNPs in blood was about 7.2 h.,"Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),h,7.2,247007,DB00898,Ethanol
,30291986,doubling time for tumor accumulation,"Remarkably, the accumulation of LNPs in the tumor was as high as 9.4% ID/g 24 h after injection with a doubling time for tumor accumulation of 3.22 h.","Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with 57Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30291986/),h,3.22,247008,DB00898,Ethanol
,7093103,apparent volume of distribution,"3 Labetalol has a relatively large apparent volume of distribution (3.3-7.9 l/kg, two-compartment open model) and a relatively high plasma clearance (0.3-1.6 1 h-1 kg-1).",Elimination kinetics of labetalol in severe renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093103/),[l] / [kg],3.3-7.9,247014,DB00898,Ethanol
,7093103,plasma clearance,"3 Labetalol has a relatively large apparent volume of distribution (3.3-7.9 l/kg, two-compartment open model) and a relatively high plasma clearance (0.3-1.6 1 h-1 kg-1).",Elimination kinetics of labetalol in severe renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093103/),[1] / [h·kg],0.3-1.6,247015,DB00898,Ethanol
,15947923,time of maximal urinary excretion rate,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),h,12.3,247284,DB00898,Ethanol
,15947923,time of maximal urinary excretion rate,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),h,20.0,247285,DB00898,Ethanol
,15947923,time of maximal urinary excretion rate,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),h,14.6,247286,DB00898,Ethanol
,15947923,terminal elimination half-life,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),h,32.7,247287,DB00898,Ethanol
,15947923,terminal elimination half-life,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),h,28.8,247288,DB00898,Ethanol
,15947923,terminal elimination half-life,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),h,37.8,247289,DB00898,Ethanol
,15947923,urinary recovery,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),%·M,0.35,247290,DB00898,Ethanol
,15947923,urinary recovery,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),%·M,0.47,247291,DB00898,Ethanol
,15947923,urinary recovery,"The time of maximal urinary excretion rate was 12.3, 20.0 and 14.6 h, terminal elimination half-life was 32.7, 28.8 and 37.8 h and urinary recovery of the metabolite reached 0.35, 0.47 and 0.52 M percent of the permethrin dose, respectively, in parts 1, 2 and 3 (means).",Dermal absorption of permethrin following topical administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15947923/),%·M,0.52,247292,DB00898,Ethanol
,3354353,blood flow rate,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],200,247316,DB00898,Ethanol
,3354353,blood flow rate,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],188,247317,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],200,247318,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],188,247319,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],156,247320,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],184,247321,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],181,247322,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],142,247323,DB00898,Ethanol
,3354353,clearances,"At a blood flow rate of 200 ml/min clearances by hemodialysis and hemoperfusion, respectively, in ml/min were estimated to be 188 and 156 for TCE, 184 and 181 for TCE-Glu, 142 and 91 for TCA.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),[ml] / [min],91,247324,DB00898,Ethanol
,3354353,half-lives,The half-lives of TCE and TCA were 3.2 and 4.3 hours during combined hemodialysis and hemoperfusion.,Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),h,3.2,247325,DB00898,Ethanol
,3354353,half-lives,The half-lives of TCE and TCA were 3.2 and 4.3 hours during combined hemodialysis and hemoperfusion.,Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),h,4.3,247326,DB00898,Ethanol
,3354353,half-life,"After termination of treatment the half-life of TCE was 12.8 hours, whereas TCA was metabolized so slowly, that no reliable calculation could be performed.",Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354353/),h,12.8,247327,DB00898,Ethanol
,17666826,terminal half-life,"After intravenous administration (10 mg/kg), the plasma concentration of the unchanged drug declined biphasically, with a terminal half-life of 1.1 h.","Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666826/),h,1.1,247978,DB00898,Ethanol
,17666826,apparent half-lives,"The maximum plasma concentrations were reached at 0.25 h after oral administration, and then declined with apparent half-lives of 0.8-1.3 h.","Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666826/),h,0.8-1.3,247979,DB00898,Ethanol
,17666826,systemic bioavailability,The systemic bioavailability of a 10-mg/kg dose was 38.7%.,"Pharmacokinetics and metabolism of an alpha,beta-blocker, amosulalol hydrochloride, in mice: biliary excretion of carbamoyl glucuronide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17666826/),%,38.7,247980,DB00898,Ethanol
,23711150,recovery,The recovery ranged from 60.2 to 77.9%.,UHPLC-MS simultaneous determination and pharmacokinetic study of three aromatic acids and one monoterpene in rat plasma after oral administration of Shaofu Zhuyu decoction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23711150/),%,60.2 to 77.9,248934,DB00898,Ethanol
,2614668,recovery,The average recovery was 84.6 +/- 2.7%.,[Development of a simple analytical method to determine the serum concentration of denopamine by high performance liquid chromatography with electrochemical detection and its clinical application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614668/),%,84.6,248984,DB00898,Ethanol
,2614668,flow rate,"The mobile phase consisted of 0.1 M potassium phosphate buffer (pH 6.0) and acetonitrile (83: 17, v/v), and the flow rate was 1.0 ml/min.",[Development of a simple analytical method to determine the serum concentration of denopamine by high performance liquid chromatography with electrochemical detection and its clinical application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614668/),[ml] / [min],1.0,248985,DB00898,Ethanol
,2614668,lowest detectable concentration,The lowest detectable concentration was 1.0 ng/ml in the serum.,[Development of a simple analytical method to determine the serum concentration of denopamine by high performance liquid chromatography with electrochemical detection and its clinical application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614668/),[ng] / [ml],1.0,248986,DB00898,Ethanol
,8535330,t1/2,"The prospective therapeutic, propionyl-L-carnitine, was labelled in the N-methyl position with the positron-emitter, carbon-11 (t1/2 = 20.4 min), with a view to studying its pharmacokinetics in humans using PET.",Propionyl-L-carnitine: labelling in the N-methyl position with carbon-11 and pharmacokinetic studies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8535330/),min,20.4,249084,DB00898,Ethanol
,3337119,maximal ethylene glycol/glycolate concentrations,"Ethylene glycol and glycolate kinetics were studied in two cases of ethylene glycol intoxication with maximal ethylene glycol/glycolate concentrations of 40.9/26.8 and 56.4/22.4 mmol/liter, respectively.",Ethylene glycol intoxication: evaluation of kinetics and crystalluria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337119/),[mM] / [l],40.9,249520,DB00898,Ethanol
,3337119,maximal ethylene glycol/glycolate concentrations,"Ethylene glycol and glycolate kinetics were studied in two cases of ethylene glycol intoxication with maximal ethylene glycol/glycolate concentrations of 40.9/26.8 and 56.4/22.4 mmol/liter, respectively.",Ethylene glycol intoxication: evaluation of kinetics and crystalluria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337119/),[mM] / [l],56.4,249521,DB00898,Ethanol
,3337119,plasma half-lives,"Kinetic calculations showed that both ethylene glycol and glycolate were distributed in total body water with plasma half-lives of 8.4 and 7.0 hours, respectively.",Ethylene glycol intoxication: evaluation of kinetics and crystalluria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337119/),h,8.4,249522,DB00898,Ethanol
,3337119,plasma half-lives,"Kinetic calculations showed that both ethylene glycol and glycolate were distributed in total body water with plasma half-lives of 8.4 and 7.0 hours, respectively.",Ethylene glycol intoxication: evaluation of kinetics and crystalluria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337119/),h,7.0,249523,DB00898,Ethanol
,17132204,entrapment efficacy,"The particle size distribution, zeta potential, entrapment efficacy and assay of the NM-loaded LMs were found to be 188.2+/-5.4 nm, -31.6 mV, 94.2% and 1.04 mg mL(-1), respectively.",Formulation and evaluation of nimodipine-loaded lipid microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132204/),[mg] / [ml],1.04,249776,DB00898,Ethanol
,8360839,Michaelis constant,"These increases were due to the presence of a considerable amount of the beta 3 beta 3-alcohol dehydrogenase (ADH) isoenzyme, with a Michaelis constant of 34 mM in the black American population.",Simulation studies on ethanol metabolism in different human populations with a physiological pharmacokinetic model. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8360839/),mM,34,249823,DB00898,Ethanol
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.94,250000,DB00898,Ethanol
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.62,250001,DB00898,Ethanol
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.26,250002,DB00898,Ethanol
,11003200,ka,"Fitting this model to the individual BrAC data yielded mean ka = 0.062 hr(-1), Vd = 0.457 L x kg(-1), ke = 0.011 hr(-1), Vmax = 0.136 g x L(-1) x hr(-1), and Km = 0.096 g x L(-1).",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),1/[hr],0.062,250252,DB00898,Ethanol
,11003200,Vd,"Fitting this model to the individual BrAC data yielded mean ka = 0.062 hr(-1), Vd = 0.457 L x kg(-1), ke = 0.011 hr(-1), Vmax = 0.136 g x L(-1) x hr(-1), and Km = 0.096 g x L(-1).",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),[l] / [kg],0.457,250253,DB00898,Ethanol
,11003200,ke,"Fitting this model to the individual BrAC data yielded mean ka = 0.062 hr(-1), Vd = 0.457 L x kg(-1), ke = 0.011 hr(-1), Vmax = 0.136 g x L(-1) x hr(-1), and Km = 0.096 g x L(-1).",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),1/[hr],0.011,250254,DB00898,Ethanol
,11003200,Vmax,"Fitting this model to the individual BrAC data yielded mean ka = 0.062 hr(-1), Vd = 0.457 L x kg(-1), ke = 0.011 hr(-1), Vmax = 0.136 g x L(-1) x hr(-1), and Km = 0.096 g x L(-1).",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),[g] / [hr·l],0.136,250255,DB00898,Ethanol
,11003200,Km,"Fitting this model to the individual BrAC data yielded mean ka = 0.062 hr(-1), Vd = 0.457 L x kg(-1), ke = 0.011 hr(-1), Vmax = 0.136 g x L(-1) x hr(-1), and Km = 0.096 g x L(-1).",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),[g] / [l],0.096,250256,DB00898,Ethanol
,11003200,time to peak BrAC,"For the classical analyses, mean time to peak BrAC = 1.83 hr, disappearance rate = 0.179 g x L(-1) x hr(-1), and area under the blood ethanol-time curve (AUC) = 2.884 g x L(-1) x hr.",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),h,1.83,250257,DB00898,Ethanol
,11003200,disappearance rate,"For the classical analyses, mean time to peak BrAC = 1.83 hr, disappearance rate = 0.179 g x L(-1) x hr(-1), and area under the blood ethanol-time curve (AUC) = 2.884 g x L(-1) x hr.",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),[g] / [hr·l],0.179,250258,DB00898,Ethanol
,11003200,area under the blood ethanol-time curve (AUC),"For the classical analyses, mean time to peak BrAC = 1.83 hr, disappearance rate = 0.179 g x L(-1) x hr(-1), and area under the blood ethanol-time curve (AUC) = 2.884 g x L(-1) x hr.",Ethanol pharmacokinetics in white women: nonlinear model fitting versus zero-order elimination analyses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11003200/),[g·h] / [l],2.884,250259,DB00898,Ethanol
,6129834,alpha-,"The mean values for the alpha- and beta-phase constants were 33.3 hr-1 and 0.52 hr-1, respectively.",The pharmacokinetics and pharmacodynamics of sulfinalol hydrochloride in dogs after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129834/),1/[h],33.3,250448,DB00898,Ethanol
,6129834,beta-phase constants,"The mean values for the alpha- and beta-phase constants were 33.3 hr-1 and 0.52 hr-1, respectively.",The pharmacokinetics and pharmacodynamics of sulfinalol hydrochloride in dogs after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129834/),1/[h],0.52,250449,DB00898,Ethanol
,6129834,plasma clearance,The mean plasma clearance was 2.30 L/kg X hr.,The pharmacokinetics and pharmacodynamics of sulfinalol hydrochloride in dogs after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129834/),[l] / [h·kg],2.30,250450,DB00898,Ethanol
,15734149,flow rate,"acetonitrile (73:27, v/v) at a flow rate of 1.5 mL/min.",Determination of amosulalol in human plasma using solid-phase extraction combined with liquid chromatography and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734149/),[ml] / [min],1.5,250739,DB00898,Ethanol
>,15734149,Recovery,Recovery of amosulalol from human plasma was >95.6%.,Determination of amosulalol in human plasma using solid-phase extraction combined with liquid chromatography and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734149/),%,95.6,250740,DB00898,Ethanol
,27005906,vesicles size,"The optimum nano-invasomes formulation showed vesicles size of 83.35±3.25nm, entrapment efficiency of 65.21±2.25% and transdermal flux of 32.78±0.703 (μg/cm(2)/h) which were found in agreement with the predicted value generated by Box-Behnken design.","Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27005906/),nm,83.35,251556,DB00898,Ethanol
,27005906,entrapment efficiency,"The optimum nano-invasomes formulation showed vesicles size of 83.35±3.25nm, entrapment efficiency of 65.21±2.25% and transdermal flux of 32.78±0.703 (μg/cm(2)/h) which were found in agreement with the predicted value generated by Box-Behnken design.","Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27005906/),%,65.21,251557,DB00898,Ethanol
,27005906,transdermal flux,"The optimum nano-invasomes formulation showed vesicles size of 83.35±3.25nm, entrapment efficiency of 65.21±2.25% and transdermal flux of 32.78±0.703 (μg/cm(2)/h) which were found in agreement with the predicted value generated by Box-Behnken design.","Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27005906/),[μg] / [cm(2)·h],32.78,251558,DB00898,Ethanol
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],0. 06,252345,DB00898,Ethanol
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],1.14,252346,DB00898,Ethanol
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],32.8,252347,DB00898,Ethanol
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],1. 55,252348,DB00898,Ethanol
,9356303,fecal excretion rate constant,A fecal excretion rate constant value for TCOG was 4.61/hr/kg.,"A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],4.61,252349,DB00898,Ethanol
,16872565,urine concentrations,Peak GHB urine concentrations averaged 150-200 mg/L and occurred in the 0-3 h urine collection.,GHB urine concentrations after single-dose administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16872565/),[mg] / [l],150-200,252359,DB00898,Ethanol
,3237745,half lives,"Isometronidazole was absorbed rapidly, distributed slowly into peripheral compartments and eliminated with half lives of about 12 h.",[The pharmacokinetics of 2-methyl-4-nitroimidazole-1-ethanol (isometronidazole) in man]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3237745/),h,12,252410,DB00898,Ethanol
,15373928,PD20,"Geometric mean PD20 values were 0.51 mg with HFA, 0.62 mg with DPI, 0.62 mg with CFC and 0.2 mg with placebo.","Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373928/),mg,0.51,252557,DB00898,Ethanol
,15373928,PD20,"Geometric mean PD20 values were 0.51 mg with HFA, 0.62 mg with DPI, 0.62 mg with CFC and 0.2 mg with placebo.","Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373928/),mg,0.62,252558,DB00898,Ethanol
,15373928,PD20,"Geometric mean PD20 values were 0.51 mg with HFA, 0.62 mg with DPI, 0.62 mg with CFC and 0.2 mg with placebo.","Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373928/),mg,0.2,252559,DB00898,Ethanol
,6661511,terminal half-lives,"Mean terminal half-lives of 12.4, 13.4, and 11.3 h were observed for the intravenous, solution and tablet formulation, respectively.",Bioavailability of medroxalol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),h,12.4,253031,DB00898,Ethanol
,6661511,terminal half-lives,"Mean terminal half-lives of 12.4, 13.4, and 11.3 h were observed for the intravenous, solution and tablet formulation, respectively.",Bioavailability of medroxalol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),h,13.4,253032,DB00898,Ethanol
,6661511,terminal half-lives,"Mean terminal half-lives of 12.4, 13.4, and 11.3 h were observed for the intravenous, solution and tablet formulation, respectively.",Bioavailability of medroxalol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),h,11.3,253033,DB00898,Ethanol
,6661511,urinary recovery,"Mean urinary recovery of parent drug at 48 h was 8.9 per cent, 3.9 per cent, and 3.2 per cent.",Bioavailability of medroxalol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),%,8.9,253034,DB00898,Ethanol
,6661511,urinary recovery,"Mean urinary recovery of parent drug at 48 h was 8.9 per cent, 3.9 per cent, and 3.2 per cent.",Bioavailability of medroxalol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),%,3.9,253035,DB00898,Ethanol
,6661511,urinary recovery,"Mean urinary recovery of parent drug at 48 h was 8.9 per cent, 3.9 per cent, and 3.2 per cent.",Bioavailability of medroxalol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),%,3.2,253036,DB00898,Ethanol
,6661511,Absolute bioavailability,"Absolute bioavailability estimated from plasma AUC was 54 per cent for the solution and 38 per cent for the tablet, and the relative bioavailability from the tablet was 71 per cent.",Bioavailability of medroxalol in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),%,54,253037,DB00898,Ethanol
,6661511,Absolute bioavailability,"Absolute bioavailability estimated from plasma AUC was 54 per cent for the solution and 38 per cent for the tablet, and the relative bioavailability from the tablet was 71 per cent.",Bioavailability of medroxalol in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),%,38,253038,DB00898,Ethanol
,6661511,relative bioavailability,"Absolute bioavailability estimated from plasma AUC was 54 per cent for the solution and 38 per cent for the tablet, and the relative bioavailability from the tablet was 71 per cent.",Bioavailability of medroxalol in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661511/),%,71,253039,DB00898,Ethanol
,17942285,fraction of metabolism,"Tanshinone II(A) was also found after the administration of cryptotanshinone alone, and the fraction of metabolism of tanshinone II(A) was 21.0+/-4.1%.",Effects of the coexisting diterpenoid tanshinones on the pharmacokinetics of cryptotanshinone and tanshinone IIA in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17942285/),%,21.0,253188,DB00898,Ethanol
,27483391,total body clearance,"Following i.v. administration, [14 C]pimasertib exhibited a geometric mean total body clearance of 45.7 l h-1 (geometric coefficient of variation [geometric CV]: 47.2%) and a volume of distribution of 229 l (geometric CV: 42.0%).","Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27483391/),[l] / [h],45.7,253380,DB00898,Ethanol
,27483391,volume of distribution,"Following i.v. administration, [14 C]pimasertib exhibited a geometric mean total body clearance of 45.7 l h-1 (geometric coefficient of variation [geometric CV]: 47.2%) and a volume of distribution of 229 l (geometric CV: 42.0%).","Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27483391/),l,229,253381,DB00898,Ethanol
,27483391,Absolute bioavailability,Absolute bioavailability was 73%.,"Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27483391/),%,73,253382,DB00898,Ethanol
,21401341,relative bioavailability,The pharmacokinetics and biodistribution studies of the optimized radiolabeled formulation (99mTc-labeled) in mice (p.o.) demonstrated a relative bioavailability of 475% against AB suspension.,Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401341/),%,475,253646,DB00898,Ethanol
,21401341,drug targeting index,"In almost all the tested organs, the uptake of AB from NE was significantly higher (p < 0.05) than AB suspension especially in heart with a drug targeting index of 44.1%, also confirming the efficacy of nanosized formulation at therapeutic site.",Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21401341/),%,44.1,253647,DB00898,Ethanol
,8876934,plasma concentration,The mean plasma concentration of NZ-105 at the time was 14.5 ng/ml.,Effects of the new calcium antagonist efonidipine hydrochloride on resting and exercise hemodynamics in patients with stable effort angina. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876934/),[ng] / [ml],14.5,253696,DB00898,Ethanol
,7988628,AUC,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[h·mg] / [l],736,253766,DB00898,Ethanol
,7988628,AUC,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[h·mg] / [l],734,253767,DB00898,Ethanol
,7988628,Cmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [l],466,253768,DB00898,Ethanol
,7988628,Cmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [l],483,253769,DB00898,Ethanol
,7988628,tmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),h,0.6,253770,DB00898,Ethanol
,7988628,tmax,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),h,0.5,253771,DB00898,Ethanol
,7988628,elimination rate,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [h·l],134,253772,DB00898,Ethanol
,7988628,elimination rate,"Pretreatment with ciprofloxacin was shown to have no significant effect on ethanol AUC (736 mg.l-1 h placebo; 734 mg.l-1 h ciprofloxacin), Cmax (466 mg.l-1 placebo; 483 mg.l-1 ciprofloxacin) tmax (0.6 h placebo; 0.5 h ciprofloxacin) or the elimination rate (134 mg.l-1 h-1 placebo; 133 mg.l-1 h-1 ciprofloxacin).",No influence of ciprofloxacin on ethanol disposition. A pharmacokinetic-pharmacodynamic interaction study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988628/),[mg] / [h·l],133,253773,DB00898,Ethanol
,6487478,AUC,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"40,596",253780,DB00898,Ethanol
,6487478,AUC,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"22,057",253781,DB00898,Ethanol
,6487478,systemic bioavailability,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,30.3,253782,DB00898,Ethanol
,6487478,systemic bioavailability,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,17.0,253783,DB00898,Ethanol
,6487478,volume of distribution,"After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),1,520,253784,DB00898,Ethanol
,6487478,volume of distribution,"After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),1,445,253785,DB00898,Ethanol
,6487478,AUC,"The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"51,029",253786,DB00898,Ethanol
,6487478,AUC,"The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"84,772",253787,DB00898,Ethanol
,6487478,systemic bioavailability,The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06).,The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,25.1,253788,DB00898,Ethanol
,6487478,systemic bioavailability,The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06).,The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,39.0,253789,DB00898,Ethanol
,10235297,RST,"Compared with the oral/i.v. method, quick clamping produced a comparable precision in the control of BrACs during the clamped interval, and provided a much earlier RST (mean +/- SE for quick-clamp: 17 +/- 4 min; for oral/i.v. clamp: 45 +/- 7 min).",A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235297/),min,17,254108,DB00898,Ethanol
,10235297,RST,"Compared with the oral/i.v. method, quick clamping produced a comparable precision in the control of BrACs during the clamped interval, and provided a much earlier RST (mean +/- SE for quick-clamp: 17 +/- 4 min; for oral/i.v. clamp: 45 +/- 7 min).",A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235297/),min,45,254109,DB00898,Ethanol
,10512309,Km,The Km value (1.5 mM) was almost the same as that of ethanol and corresponded to blood acetate levels during ethanol oxidation that had been reported to be approximately 2 mM.,Michaelis-Menten elimination kinetics of acetate in rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10512309/),mM,1.5,254251,DB00898,Ethanol
,9931286,Peak blood TCE concentrations,"Peak blood TCE concentrations were 0.86 and 7.32 microgram/mL, respectively, in mice exposed to 100 and 600 ppm TCE.",Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931286/),[μg] / [ml],0.86,255053,DB00898,Ethanol
,9931286,Peak blood TCE concentrations,"Peak blood TCE concentrations were 0.86 and 7.32 microgram/mL, respectively, in mice exposed to 100 and 600 ppm TCE.",Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931286/),[μg] / [ml],7.32,255054,DB00898,Ethanol
,9931286,fractional absorption,"When fractional absorption (53%) of inhaled TCE was incorporated into the model, a comprehensive description of the uptake, distribution, and clearance of TCE in the blood was obtained.",Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931286/),%,53,255055,DB00898,Ethanol
,1618254,peak blood ethanol concentration,The peak blood ethanol concentration of 21.9 to 22.8 mmol.l-1 occurred at 64 to 70 min after the end of drinking.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [l],21.9 to 22.8,255086,DB00898,Ethanol
,1618254,rate of disappearance,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[mM] / [h·l],3.0 to 3.3,255087,DB00898,Ethanol
,1618254,rate of removal,The rate of disappearance of ethanol from the blood ranged from 3.0 to 3.3 mmol.l-1.h-1 and the rate of removal from the whole body ranged from 8.0 to 8.5 g.h-1.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[g] / [h],8.0 to 8.5,255088,DB00898,Ethanol
,1618254,apparent volume of distribution,"The apparent volume of distribution of ethanol was almost the same for all four treatments: mean 0.68 l.kg-1, corresponding to a mean total body water of 44 l (59% body weight).","Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[l] / [kg],0.68,255089,DB00898,Ethanol
,1618254,areas under the concentration-time profiles,Mean areas under the concentration-time profiles of ethanol ranged from 83 to 87 mmol.l-1.h for the four treatments.,"Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618254/),[h·mM] / [l],83 to 87,255090,DB00898,Ethanol
,12845448,BrAC,"During the elimination phase, BAC and BrAC of each volunteer were measured between 18 and 34 times in a BrAC range between 0.65 mg/l and 0.12 mg/l.",Concentration dependency of the BAC/BrAC (blood alcohol concentration/breath alcohol concentration) conversion factor during the linear elimination phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845448/),,0.65,255683,DB00898,Ethanol
,12845448,1/kappa,The values of 1/kappa of the hyperbolic functions varied between 1.808 and 2.165 and those of (CT) between 0.004 and 0.127.,Concentration dependency of the BAC/BrAC (blood alcohol concentration/breath alcohol concentration) conversion factor during the linear elimination phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845448/),,1.808 and 2.165,255684,DB00898,Ethanol
,12845448,1/kappa,The values of 1/kappa of the hyperbolic functions varied between 1.808 and 2.165 and those of (CT) between 0.004 and 0.127.,Concentration dependency of the BAC/BrAC (blood alcohol concentration/breath alcohol concentration) conversion factor during the linear elimination phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845448/),,0.004 and 0.127,255685,DB00898,Ethanol
,12845448,Q(0.40),"On average, the value of Q(0.40) amounted to 2.207+/-0.048 and that of Q(0.55) to 2.160+/-0.056.",Concentration dependency of the BAC/BrAC (blood alcohol concentration/breath alcohol concentration) conversion factor during the linear elimination phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845448/),,2.207,255686,DB00898,Ethanol
,12845448,Q(0.55),"On average, the value of Q(0.40) amounted to 2.207+/-0.048 and that of Q(0.55) to 2.160+/-0.056.",Concentration dependency of the BAC/BrAC (blood alcohol concentration/breath alcohol concentration) conversion factor during the linear elimination phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845448/),,2.160,255687,DB00898,Ethanol
less,10794928,T(max)'s,Both DZ and CZ were absorbed very rapidly from 1% SGC/60% PG-30% EtOH-10% Water after IN single application; the T(max)'s were less than 2 min.,Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),min,2,255791,DB00898,Ethanol
,10794928,peak time,The absorption rate of MCA was relatively slower with the peak time of 13-32 min.,Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),min,13-32,255792,DB00898,Ethanol
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,77,255793,DB00898,Ethanol
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,45,255794,DB00898,Ethanol
,10794928,bioavailability,"The bioavailability of single IN administration for DZ, CZ, and MCA determined over the first 2 or 4 h was found to be 77, 45, and 79%, respectively.",Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10794928/),%,79,255795,DB00898,Ethanol
,12563,apparent half-life of elimination,"In one subject, the apparent half-life of elimination was increased from 2.5 h (normal subjects) to 5 h for both drugs.",[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563/),h,2.5,256009,DB00898,Ethanol
,12563,apparent half-life of elimination,"In one subject, the apparent half-life of elimination was increased from 2.5 h (normal subjects) to 5 h for both drugs.",[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563/),h,5,256010,DB00898,Ethanol
,12932719,t(1/2)beta,"The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes.","Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932719/),min,52.3,256719,DB00898,Ethanol
,12932719,t(1/2)beta,"The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes.","Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932719/),min,260,256720,DB00898,Ethanol
,12932719,t(1/2)beta,"The t(1/2)beta, which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes.","Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932719/),min,665,256721,DB00898,Ethanol
,2150173,cis/trans ratio,"When etretinate and acitretin dissolved in ethanol were irradiated with UVB (280-320 nm; 10-336 mJ/cm2) or UVA (320-400 nm; 1-5 J/cm2), extensive and reproducible cis-isomerizations occurred at the 13-position (cis/trans ratio approximately 1.6 in all experiments) but there was no progressive photodegradation of the molecules.",UV-induced isomerization of oral retinoids in vitro and in vivo in hairless mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150173/),,1.6,257152,DB00898,Ethanol
,15568141,peak blood ethanol concentrations,The ethanol dosage regimen used resulted in peak blood ethanol concentrations between 78 mg/l and 103 mg/l.,The effects of acute ethanol intake on isoniazid pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568141/),[mg] / [l],78,257191,DB00898,Ethanol
,15568141,peak blood ethanol concentrations,The ethanol dosage regimen used resulted in peak blood ethanol concentrations between 78 mg/l and 103 mg/l.,The effects of acute ethanol intake on isoniazid pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568141/),[mg] / [l],103,257192,DB00898,Ethanol
,15568141,half-life,"Acute ethanol intake at this dose is unlikely to affect results of acetylation studies in which isoniazid is used as a substrate, whether the half-life of isoniazid or the AcINH /INH ratio at 3 h is used to phenotype patients.",The effects of acute ethanol intake on isoniazid pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568141/),h,3,257193,DB00898,Ethanol
,12774293,AUC(0-24),We observed stereo-selectivity in the alpha-hydroxymetoprolol formation favoring the new 1'R chiral center from both metoprolol enantiomers (AUC(0-24) (1'R1'S) = 3.02).,Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12774293/),,3.02,257405,DB00898,Ethanol
,12774293,AUC(0-24),"(-)-(S)-metoprolol was slightly more alpha-hydroxylated than its antipode (AUC(0-24) (2S/2R) = 1.19), suggesting that this pathway is not responsible for plasma accumulation of this enantiomer in humans.",Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12774293/),,1.19,257406,DB00898,Ethanol
,7391154,recovery of,"The recovery of the extraction was found to be 88% and 77% for indomethacin and salicylic acid, respectively.",Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),%,88,257472,DB00898,Ethanol
,7391154,recovery of,"The recovery of the extraction was found to be 88% and 77% for indomethacin and salicylic acid, respectively.",Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),%,77,257473,DB00898,Ethanol
,7391154,detection limits,The detection limits for indomethacin and salicylic acid were 2 ng.,Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),ng,2,257474,DB00898,Ethanol
,8872236,peak alcohol concentration,Each subject fasted for at least 10 h and then received an oral dose of alcohol (0.9 g per kilogram of lead body weight) calculated to yield a peak alcohol concentration of 0.100 g/210-L breath.,Determination of volume of distribution for ethanol in male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),[g] / [210-l·breath],0.100,258343,DB00898,Ethanol
,8872236,peak alcohol concentration,"Female subjects on average reached a lower peak alcohol concentration (mean, 0.086; range, 0.074-0.091 g/210 L) than male subjects (mean, 0.096; range, 0.093-0.101 g/210 L).",Determination of volume of distribution for ethanol in male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),[g] / [210·l],0.086,258344,DB00898,Ethanol
,8872236,peak alcohol concentration,"Female subjects on average reached a lower peak alcohol concentration (mean, 0.086; range, 0.074-0.091 g/210 L) than male subjects (mean, 0.096; range, 0.093-0.101 g/210 L).",Determination of volume of distribution for ethanol in male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),[g] / [210·l],0.096,258345,DB00898,Ethanol
,8872236,rate of elimination,"Females demonstrated a higher average rate of elimination (mean, 0.017; range, 0.014-0.021 g/210 L) than males (mean, 0.015; range, 0.013-0.017 g/210 L).",Determination of volume of distribution for ethanol in male and female subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),[g] / [210·l],0.017,258346,DB00898,Ethanol
,8872236,rate of elimination,"Females demonstrated a higher average rate of elimination (mean, 0.017; range, 0.014-0.021 g/210 L) than males (mean, 0.015; range, 0.013-0.017 g/210 L).",Determination of volume of distribution for ethanol in male and female subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),[g] / [210·l],0.015,258347,DB00898,Ethanol
,8872236,volume of distribution (Vd),"The average volume of distribution (Vd), as calculated from percentage of body fat, for the women (mean, 0.63; range, 0.54-0.71) was less than for the men (mean, 0.69; range, 0.63-0.76).",Determination of volume of distribution for ethanol in male and female subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),,0.63,258348,DB00898,Ethanol
,8872236,volume of distribution (Vd),"The average volume of distribution (Vd), as calculated from percentage of body fat, for the women (mean, 0.63; range, 0.54-0.71) was less than for the men (mean, 0.69; range, 0.63-0.76).",Determination of volume of distribution for ethanol in male and female subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),,0.69,258349,DB00898,Ethanol
,8872236,Vd,"The average Vd as calculated from linear regression of the alcohol concentration curve, for the women (mean 0.64, range, 0.56-0.71) was also less than for the men (mean, 0.72; range, 0.67-0.77).",Determination of volume of distribution for ethanol in male and female subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),,0.64,258350,DB00898,Ethanol
,8872236,Vd,"The average Vd as calculated from linear regression of the alcohol concentration curve, for the women (mean 0.64, range, 0.56-0.71) was also less than for the men (mean, 0.72; range, 0.67-0.77).",Determination of volume of distribution for ethanol in male and female subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8872236/),,0.72,258351,DB00898,Ethanol
,32376439,solubility,"A formulation consisting of 10% (w/v) of pluronic® F-127 and polyvinylpyrrolidone/vinyl acetate (PVP/VA), and 57% (v/v) ethanol enhanced etoposide's solubility approximately 100 times (16 mg mL-1) compared to its aqueous solubility.","High-dose etoposide formulations do not saturate intestinal P-glycoprotein: Development, stability, and pharmacokinetics in Sprague-Dawley rats. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32376439/),[mg] / [ml],16,258479,DB00898,Ethanol
,17967929,Clearance rates,"Clearance rates from the blood after i.v. and oral administration were similar (7.4 and 11.9 ml/min, respectively).",The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967929/),[ml] / [min],7.4,258569,DB00898,Ethanol
,17967929,Clearance rates,"Clearance rates from the blood after i.v. and oral administration were similar (7.4 and 11.9 ml/min, respectively).",The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967929/),[ml] / [min],11.9,258570,DB00898,Ethanol
,17967929,Systemic bioavailability,Systemic bioavailability was determined to be 62.1% of a 50 mg/kg dose in rats.,The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967929/),%,62.1,258571,DB00898,Ethanol
,17967929,Urinary excretion,Urinary excretion of the parent compound by rats was the major route of elimination (i.v.: 91% in 24 h; oral: 55-74% in 24 h).,The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967929/),%,91,258572,DB00898,Ethanol
,17967929,Urinary excretion,Urinary excretion of the parent compound by rats was the major route of elimination (i.v.: 91% in 24 h; oral: 55-74% in 24 h).,The effects of dose and route on the toxicokinetics and disposition of 1-butyl-3-methylimidazolium chloride in male F-344 rats and female B6C3F1 mice. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17967929/),%,55-74,258573,DB00898,Ethanol
,7161831,rate constant,Plasma concentration of ethylene oxide was found to decline exponentially with a mean rate constant of 0.024 +/- 0.008 min-1 (mean +/- SD) and total body clearance of 20.0 +/- 5.2 ml/kg X min.,"Disposition kinetics of ethylene oxide, ethylene glycol, and 2-chlorethanol in the dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161831/),1/[min],0.024,258614,DB00898,Ethanol
,7161831,total body clearance,Plasma concentration of ethylene oxide was found to decline exponentially with a mean rate constant of 0.024 +/- 0.008 min-1 (mean +/- SD) and total body clearance of 20.0 +/- 5.2 ml/kg X min.,"Disposition kinetics of ethylene oxide, ethylene glycol, and 2-chlorethanol in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161831/),[ml] / [kg·min],20.0,258615,DB00898,Ethanol
,7161831,plasma half-life,"Ethylene oxide was found to be metabolized mainly to ethylene glycol, which had a mean plasma half-life of 221.0 +/- 77.7 min and a total body clearance of 2.13 +/- 0.58 ml/kg X min.","Disposition kinetics of ethylene oxide, ethylene glycol, and 2-chlorethanol in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161831/),min,221.0,258616,DB00898,Ethanol
,7161831,total body clearance,"Ethylene oxide was found to be metabolized mainly to ethylene glycol, which had a mean plasma half-life of 221.0 +/- 77.7 min and a total body clearance of 2.13 +/- 0.58 ml/kg X min.","Disposition kinetics of ethylene oxide, ethylene glycol, and 2-chlorethanol in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161831/),[ml] / [kg·min],2.13,258617,DB00898,Ethanol
,7161831,elimination half-life,"The elimination half-life and clearance values for 2-chlorethanol were 40.8 +/- 5.7 min and 10.3 +/- 1.7 ml/kg X min, respectively.","Disposition kinetics of ethylene oxide, ethylene glycol, and 2-chlorethanol in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161831/),min,40.8,258618,DB00898,Ethanol
,7161831,clearance,"The elimination half-life and clearance values for 2-chlorethanol were 40.8 +/- 5.7 min and 10.3 +/- 1.7 ml/kg X min, respectively.","Disposition kinetics of ethylene oxide, ethylene glycol, and 2-chlorethanol in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7161831/),[ml] / [kg·min],10.3,258619,DB00898,Ethanol
,7603305,constant plasma alcohol concentration,Ethanol infusion resulted in a constant plasma alcohol concentration of 0.44 +/- 0.04 g/l (Mean +/- SE) and had no effect on the baseline value of the EEG effect parameter.,Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7603305/),[g] / [l],0.44,259444,DB00898,Ethanol
,29093350,peak concentration (Cmax),"Based on in vivo microdialysis experiments, the drug concentration in local deep skin of rat increased rapidly and reached a peak concentration (Cmax) of 319.35±23.72 µg/mL at 180 min, and decreased slowly thereafter.",In Vivo Microdialysis for Dynamic Monitoring of the Effectiveness of Nano-liposomes as Vehicles for Topical Psoralen Application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29093350/),[μg] / [ml],319.35,259518,DB00898,Ethanol
,19164498,pseudo-steady state levels,MDMA (100 mg) was given orally while blood alcohol concentration was maintained at pseudo-steady state levels of approximately 0.6 per thousand for 3 h by a 10% intravenous ethanol clamp.,Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164498/),1/[thousand],0.6,259565,DB00898,Ethanol
,29128828,half-life,The half-life of betamethasone was 8.5days.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),d,8.5,259718,DB00898,Ethanol
,29128828,elimination rate constant,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),1/[h],2.49,259719,DB00898,Ethanol
,29128828,clearance,The elimination rate constant was 2.49h-1; the mean clearance was 4.72L/d.,Quantitative assessment of betamethasone dual-acting formulation in urine of patients with rheumatoid arthritis and ankylosing spondylitis after single-dose intramuscular administration and its application to long-term pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128828/),[l] / [d],4.72,259720,DB00898,Ethanol
,11853233,t 1/2,"Histamine was absorbed with equal efficiency to all tissues (t 1/2 AB 3.9-7.7 minutes) but maximum concentration (Cmax; nmol/l) of histamine was higher in liver (2,388 +/- 357) than in subcutis (951 +/- 125) (p < 0.01) and subcutaneous tumor (523 +/- 140) (p = 0.01) and, moreover, Cmax in liver tumor (1,752 +/- 326) was higher than in subcutaneous tumor (p = 0.01).",Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),min,3.9-7.7,260072,DB00898,Ethanol
,11853233,maximum concentration (Cmax,"Histamine was absorbed with equal efficiency to all tissues (t 1/2 AB 3.9-7.7 minutes) but maximum concentration (Cmax; nmol/l) of histamine was higher in liver (2,388 +/- 357) than in subcutis (951 +/- 125) (p < 0.01) and subcutaneous tumor (523 +/- 140) (p = 0.01) and, moreover, Cmax in liver tumor (1,752 +/- 326) was higher than in subcutaneous tumor (p = 0.01).",Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),[nM] / [l],"2,388",260073,DB00898,Ethanol
,11853233,maximum concentration (Cmax,"Histamine was absorbed with equal efficiency to all tissues (t 1/2 AB 3.9-7.7 minutes) but maximum concentration (Cmax; nmol/l) of histamine was higher in liver (2,388 +/- 357) than in subcutis (951 +/- 125) (p < 0.01) and subcutaneous tumor (523 +/- 140) (p = 0.01) and, moreover, Cmax in liver tumor (1,752 +/- 326) was higher than in subcutaneous tumor (p = 0.01).",Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),[nM] / [l],951,260074,DB00898,Ethanol
,11853233,maximum concentration (Cmax,"Histamine was absorbed with equal efficiency to all tissues (t 1/2 AB 3.9-7.7 minutes) but maximum concentration (Cmax; nmol/l) of histamine was higher in liver (2,388 +/- 357) than in subcutis (951 +/- 125) (p < 0.01) and subcutaneous tumor (523 +/- 140) (p = 0.01) and, moreover, Cmax in liver tumor (1,752 +/- 326) was higher than in subcutaneous tumor (p = 0.01).",Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),[nM] / [l],523,260075,DB00898,Ethanol
,11853233,Cmax,"Histamine was absorbed with equal efficiency to all tissues (t 1/2 AB 3.9-7.7 minutes) but maximum concentration (Cmax; nmol/l) of histamine was higher in liver (2,388 +/- 357) than in subcutis (951 +/- 125) (p < 0.01) and subcutaneous tumor (523 +/- 140) (p = 0.01) and, moreover, Cmax in liver tumor (1,752 +/- 326) was higher than in subcutaneous tumor (p = 0.01).",Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),,"1,752",260076,DB00898,Ethanol
,11853233,Area under the curve (AUC,Area under the curve (AUC; mmol-min/l) for histamine was significantly lower in subcutaneous tumor (9.8 +/- 2.3) than in liver (17.6 +/- 1.9) (p = 0.03) and liver tumor (15.8 +/- 1.8) (p = 0.03).,Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),[mmol-min] / [l],9.8,260077,DB00898,Ethanol
,11853233,Area under the curve (AUC,Area under the curve (AUC; mmol-min/l) for histamine was significantly lower in subcutaneous tumor (9.8 +/- 2.3) than in liver (17.6 +/- 1.9) (p = 0.03) and liver tumor (15.8 +/- 1.8) (p = 0.03).,Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),[mmol-min] / [l],17.6,260078,DB00898,Ethanol
,11853233,Area under the curve (AUC,Area under the curve (AUC; mmol-min/l) for histamine was significantly lower in subcutaneous tumor (9.8 +/- 2.3) than in liver (17.6 +/- 1.9) (p = 0.03) and liver tumor (15.8 +/- 1.8) (p = 0.03).,Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853233/),[mmol-min] / [l],15.8,260079,DB00898,Ethanol
,10755373,recoveries,Average recoveries ranged from 96 to 101% in spiked liver samples and from 91 to 94% in spiked plasma samples.,Determination of lycopene in tissues and plasma of rats by normal-phase high-performance liquid chromatography with photometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755373/),%,96 to 101,260372,DB00898,Ethanol
,10755373,recoveries,Average recoveries ranged from 96 to 101% in spiked liver samples and from 91 to 94% in spiked plasma samples.,Determination of lycopene in tissues and plasma of rats by normal-phase high-performance liquid chromatography with photometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755373/),%,91 to 94,260373,DB00898,Ethanol
,19404864,K(m),To address the question of whether increased ethanol elimination in alcoholics can be ascribed to increased metabolism via alcohol dehydrogenase (ADH; K(m) around 0.2 mM) or the microsomal ethanol-oxidizing system (MEOS; K(m) 10 mM) by kinetic analysis of hepatic ethanol elimination in recently drinking patients with alcoholic cirrhosis and healthy subjects.,Hepatic ethanol elimination kinetics in patients with cirrhosis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19404864/),mM,0.2,260771,DB00898,Ethanol
,19404864,K(m),To address the question of whether increased ethanol elimination in alcoholics can be ascribed to increased metabolism via alcohol dehydrogenase (ADH; K(m) around 0.2 mM) or the microsomal ethanol-oxidizing system (MEOS; K(m) 10 mM) by kinetic analysis of hepatic ethanol elimination in recently drinking patients with alcoholic cirrhosis and healthy subjects.,Hepatic ethanol elimination kinetics in patients with cirrhosis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19404864/),mM,10,260772,DB00898,Ethanol
,19404864,hepatic K(m),"Mean hepatic K(m) for ethanol was 0.16 mM (range 0.09-0.36) in healthy subjects and 0.36 mM (range 0.16-0.69) in patients with cirrhosis (p>0.3), both compatible with the K(m) for ADH.",Hepatic ethanol elimination kinetics in patients with cirrhosis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19404864/),mM,0.16,260773,DB00898,Ethanol
,19404864,hepatic K(m),"Mean hepatic K(m) for ethanol was 0.16 mM (range 0.09-0.36) in healthy subjects and 0.36 mM (range 0.16-0.69) in patients with cirrhosis (p>0.3), both compatible with the K(m) for ADH.",Hepatic ethanol elimination kinetics in patients with cirrhosis. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19404864/),mM,0.36,260774,DB00898,Ethanol
,21098644,apparent,"Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903.",Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,10,260897,DB00898,Ethanol
,21098644,apparent,"Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903.",Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,6.6,260898,DB00898,Ethanol
,21098644,t(1/2),"Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903.",Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,10,260899,DB00898,Ethanol
,21098644,t(1/2),"Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903.",Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,12,260900,DB00898,Ethanol
,21098644,t(1/2),"Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903.",Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,6.6,260901,DB00898,Ethanol
,21098644,t(1/2),"Of more importance, the simulated plasma concentration-time profiles of PF02341066 and PF04217903 by PBPK modeling seemed to be consistent with the observed profiles showing multiexponential declines, resulting in more accurate prediction of the apparent half-lives (t(1/2)): the observed and predicted t(1/2) values were, respectively, 10 and 12 h for PF02341066 and 6.6 and 6.3 h for PF04217903.",Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,6.3,260902,DB00898,Ethanol
,21098644,t(1/2),The predicted t(1/2) values by the one-compartment PK model were 17 h for PF02341066 and 1.9 h for PF04217903.,Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,17,260903,DB00898,Ethanol
,21098644,t(1/2),The predicted t(1/2) values by the one-compartment PK model were 17 h for PF02341066 and 1.9 h for PF04217903.,Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098644/),h,1.9,260904,DB00898,Ethanol
,7104169,systemic bioavailability,2 Food caused a 38% increase in the mean systemic bioavailability of labetalol: from 0.26 +/- 0.03 (mean +/- s.e. mean) to 0.36 +/- 0.05 (P less than 0.05).,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),,0.26,260940,DB00898,Ethanol
,7104169,systemic bioavailability,2 Food caused a 38% increase in the mean systemic bioavailability of labetalol: from 0.26 +/- 0.03 (mean +/- s.e. mean) to 0.36 +/- 0.05 (P less than 0.05).,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),,0.36,260941,DB00898,Ethanol
,7104169,volume of distribution,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),,567,260942,DB00898,Ethanol
,7104169,volume of distribution,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),[ml] / [min],685,260943,DB00898,Ethanol
,7104169,plasma clearance,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),[ml] / [min],1923,260944,DB00898,Ethanol
,7104169,plasma clearance,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),[ml] / [min],2344,260945,DB00898,Ethanol
,1743317,extension,The mean extension was 50 hours.,Effects of vehicle supplementation on total estradiol absorption from a transdermal estradiol delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1743317/),h,50,261114,DB00898,Ethanol
,30182503,limits of detection,"The limits of detection of salidroside, neonuezhenide, and nuezhenide were 3.9, 25.4, and 24.2 ng/mL respectively.",Determination of three phenylethanoid glycosides in Osmanthus fragrans fruits by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182503/),[ng] / [ml],3.9,261246,DB00898,Ethanol
,30182503,limits of detection,"The limits of detection of salidroside, neonuezhenide, and nuezhenide were 3.9, 25.4, and 24.2 ng/mL respectively.",Determination of three phenylethanoid glycosides in Osmanthus fragrans fruits by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182503/),[ng] / [ml],25.4,261247,DB00898,Ethanol
,30182503,limits of detection,"The limits of detection of salidroside, neonuezhenide, and nuezhenide were 3.9, 25.4, and 24.2 ng/mL respectively.",Determination of three phenylethanoid glycosides in Osmanthus fragrans fruits by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182503/),[ng] / [ml],24.2,261248,DB00898,Ethanol
,7117351,concentrations,"The mean concentrations of clenbuterol in maternal plasma, fetus and placenta were 0.37 (range 0.22-0.56), 0.32 (0.14-0.48) and 0.91 (0.12-1.73) ng equivalents per ml or per gram of tissue wet weight.",Placental transfer of clenbuterol early in human pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117351/),[equivalents·ng] / [ml],0.37,261549,DB00898,Ethanol
,7117351,concentrations,"The mean concentrations of clenbuterol in maternal plasma, fetus and placenta were 0.37 (range 0.22-0.56), 0.32 (0.14-0.48) and 0.91 (0.12-1.73) ng equivalents per ml or per gram of tissue wet weight.",Placental transfer of clenbuterol early in human pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117351/),[equivalents·ng] / [ml],0.32,261550,DB00898,Ethanol
,7117351,concentrations,"The mean concentrations of clenbuterol in maternal plasma, fetus and placenta were 0.37 (range 0.22-0.56), 0.32 (0.14-0.48) and 0.91 (0.12-1.73) ng equivalents per ml or per gram of tissue wet weight.",Placental transfer of clenbuterol early in human pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117351/),[equivalents·ng] / [ml],0.91,261551,DB00898,Ethanol
,1981728,Ka2,Ka2 increased in groups IIa and IIb compared with the control group (35.79 hr-1 and 36.61 hr-1 vs. 28.18 hr-1).,Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],35.79,262175,DB00898,Ethanol
,1981728,Ka2,Ka2 increased in groups IIa and IIb compared with the control group (35.79 hr-1 and 36.61 hr-1 vs. 28.18 hr-1).,Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],36.61,262176,DB00898,Ethanol
,1981728,Ka2,Ka2 increased in groups IIa and IIb compared with the control group (35.79 hr-1 and 36.61 hr-1 vs. 28.18 hr-1).,Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],28.18,262177,DB00898,Ethanol
,1981728,Ka1,"However, Ka1 decreased in group IIb as compared with the control rats (2.34 hr-1 vs. 4.18 hr-1), whereas no modifications were seen in group IIa (4.35 hr-1).",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],2.34,262178,DB00898,Ethanol
,1981728,Ka1,"However, Ka1 decreased in group IIb as compared with the control rats (2.34 hr-1 vs. 4.18 hr-1), whereas no modifications were seen in group IIa (4.35 hr-1).",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],4.18,262179,DB00898,Ethanol
,1981728,Ka1,"However, Ka1 decreased in group IIb as compared with the control rats (2.34 hr-1 vs. 4.18 hr-1), whereas no modifications were seen in group IIa (4.35 hr-1).",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],4.35,262180,DB00898,Ethanol
,1981728,t1/2 beta,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),h,8.77,262181,DB00898,Ethanol
,1981728,t1/2 beta,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),h,7.78,262182,DB00898,Ethanol
,1981728,t1/2 beta,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),h,4.55,262183,DB00898,Ethanol
,1981728,Ke,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],0.86,262184,DB00898,Ethanol
,1981728,Ke,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],0.48,262185,DB00898,Ethanol
,1981728,Ke,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],0.98,262186,DB00898,Ethanol
,8742102,recovery,The recovery of paclitaxel in the feces (0-96 h) was reduced from 58% at the 2 mg/kg dose level to 44% at the 20 mg/kg dose level.,"Tissue distribution, metabolism and excretion of paclitaxel in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742102/),%,58,263286,DB00898,Ethanol
,8742102,recovery,The recovery of paclitaxel in the feces (0-96 h) was reduced from 58% at the 2 mg/kg dose level to 44% at the 20 mg/kg dose level.,"Tissue distribution, metabolism and excretion of paclitaxel in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8742102/),%,44,263287,DB00898,Ethanol
,32291553,viscosity,"pH of this nanogels was found within the range of 6.1-7.2, whereas the viscosity was found 310.13 to 6361 cps.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),cps,310.13 to 6361,263521,DB00898,Ethanol
,32291553,permeation flux,"The ex vivo skin permeation gels showed permeation flux range, 5.9 ± 0.80 to 17.92 ± 1.13 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],5.9,263522,DB00898,Ethanol
,32291553,permeation flux,"The ex vivo skin permeation gels showed permeation flux range, 5.9 ± 0.80 to 17.92 ± 1.13 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],17.92,263523,DB00898,Ethanol
,32291553,permeation flux,"The highest permeation flux (17.92 ± 1.13 μg/cm2 h) was observed, which was 3.14-folds higher than that of the plain DH gel (10.72 ± 0.84 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],17.92,263524,DB00898,Ethanol
,32291553,permeation flux,"The highest permeation flux (17.92 ± 1.13 μg/cm2 h) was observed, which was 3.14-folds higher than that of the plain DH gel (10.72 ± 0.84 μg/cm2 h.",Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32291553/),[μg] / [cm2·h],10.72,263525,DB00898,Ethanol
,7750592,half-life,"After ethanol ingestion and patch removal the half-life of E2 was calculated to be 378 minutes, and after carbohydrate punch and patch removal 245 minutes.",The effects of ethanol on the clearance of estradiol in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7750592/),min,378,263649,DB00898,Ethanol
,7750592,half-life,"After ethanol ingestion and patch removal the half-life of E2 was calculated to be 378 minutes, and after carbohydrate punch and patch removal 245 minutes.",The effects of ethanol on the clearance of estradiol in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7750592/),min,245,263650,DB00898,Ethanol
,6126917,MCR,"MCR was 27-38 ml/kg per min, independent of infusion rate (6.1 or 13 pmol/kg per min), extraction procedure or tracer.",On the accuracy of radioimmunological determination of somatostatin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126917/),[ml] / [kg·min],27-38,263990,DB00898,Ethanol
,6126917,T-1/2,T-1/2 was 1.9 min.,On the accuracy of radioimmunological determination of somatostatin in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126917/),min,1.9,263991,DB00898,Ethanol
,15803448,retention times,"The retention times of AMA and RIM derivatives were 12.6 and 22.2 min and the lower limits of detection were 0.025 and 0.016 microg/mL, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),min,12.6,264017,DB00898,Ethanol
,15803448,retention times,"The retention times of AMA and RIM derivatives were 12.6 and 22.2 min and the lower limits of detection were 0.025 and 0.016 microg/mL, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),min,22.2,264018,DB00898,Ethanol
,15803448,Bioavailability,"Bioavailability of AMA and RIM was 34.9 and 37.2%, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),%,34.9,264019,DB00898,Ethanol
,15803448,Bioavailability,"Bioavailability of AMA and RIM was 34.9 and 37.2%, respectively.",Simultaneous determination of amantadine and rimantadine by HPLC in rat plasma with pre-column derivatization and fluorescence detection for pharmacokinetic studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803448/),%,37.2,264020,DB00898,Ethanol
,6142906,peak serum triazolam level,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),[ng] / [ml],5.4,264068,DB00898,Ethanol
,6142906,time of peak level,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,1.5,264069,DB00898,Ethanol
,6142906,time of peak level,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,1.6,264070,DB00898,Ethanol
,6142906,elimination half-life,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,2.8,264071,DB00898,Ethanol
,6142906,elimination half-life,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),h,2.6,264072,DB00898,Ethanol
,6142906,apparent oral clearance,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),[ml] / [kg·min],6.6,264073,DB00898,Ethanol
,6142906,apparent oral clearance,"There were no significant differences between control and ethanol-coadministration trials in peak serum triazolam level (5.4 vs. 5.4 ng/ml), time of peak level (1.5 vs. 1.6 hours), elimination half-life (2.8 vs. 2.6 hours), or apparent oral clearance (6.6 vs. 7.9 ml/min/kg).",Pharmacokinetic noninteraction of triazolam and ethanol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6142906/),[ml] / [kg·min],7.9,264074,DB00898,Ethanol
,19544289,Total body clearance,Total body clearance values for CAPE ranged from 42.1 to 172 ml/min/kg (NCA) and decreased with the increasing dose of CAPE.,Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544289/),[ml] / [kg·min],42.1 to 172,264818,DB00898,Ethanol
,19544289,volume of distribution,"Similarly, the volume of distribution values for CAPE ranged from 1555 to 5209 ml/kg, decreasing with increasing dose.",Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544289/),[ml] / [kg],1555 to 5209,264819,DB00898,Ethanol
,19544289,elimination half-life,The elimination half-life for CAPE ranged from 21.2 to 26.7 min and was independent of dose.,Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19544289/),min,21.2 to 26.7,264820,DB00898,Ethanol
less,27750194,time of analysis,HPLC separations were run on a reversed-phase microcolumn; the time of analysis was less than 2min.,Development and validation of ultrafast LC-MS/MS method for quantification of anti-influenza agent camphecene in whole rat blood using dried blood spots and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27750194/),min,2,264999,DB00898,Ethanol
less,27750194,extraction recovery,"Despite low extraction recovery (less than 2%), the sensitivity of the method was enough to detect the analyte in the concentration range 50-2500ng/mL.",Development and validation of ultrafast LC-MS/MS method for quantification of anti-influenza agent camphecene in whole rat blood using dried blood spots and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27750194/),%,2,265000,DB00898,Ethanol
,7813995,beta-slope,"The rate of disappearance of ethanol from the blood (beta-slope) and the apparent volume of distribution of ethanol (Widmark's rho factor, rho) were calculated for each subject; the mean beta-slope was 13.3 mg/dl/h (SD = 2.0), and the mean rho factor was 0.689 l/kg (SD = 0.061).",Guidelines for estimating the amount of alcohol consumed from a single measurement of blood alcohol concentration: re-evaluation of Widmark's equation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813995/),[mg] / [dl·h],13.3,265093,DB00898,Ethanol
,7813995,rho factor,"The rate of disappearance of ethanol from the blood (beta-slope) and the apparent volume of distribution of ethanol (Widmark's rho factor, rho) were calculated for each subject; the mean beta-slope was 13.3 mg/dl/h (SD = 2.0), and the mean rho factor was 0.689 l/kg (SD = 0.061).",Guidelines for estimating the amount of alcohol consumed from a single measurement of blood alcohol concentration: re-evaluation of Widmark's equation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813995/),[l] / [kg],0.689,265094,DB00898,Ethanol
,21796700,AUC(0-24h),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],280.8,265395,DB00898,Ethanol
,21796700,AUC(0-24h),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],543.5,265396,DB00898,Ethanol
,21796700,C(max),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[ng] / [ml],44.6,265397,DB00898,Ethanol
,21796700,C(max),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[ng] / [ml],86.8,265398,DB00898,Ethanol
,21796700,AUC(0-24h),The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],163.6,265399,DB00898,Ethanol
,21796700,AUC(0-24h),The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],212.7,265400,DB00898,Ethanol
,21796700,clearance,The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[l] / [h·kg],3.2,265401,DB00898,Ethanol
,21796700,clearance,The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[l] / [h·kg],2.2,265402,DB00898,Ethanol
,3718591,areas under the plasma concentration curve,No significant differences were also found between the areas under the plasma concentration curve (110 vs.,Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),,110,266181,DB00898,Ethanol
,3718591,peak plasma concentrations,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),[ng] / [ml],32.4,266182,DB00898,Ethanol
,3718591,peak plasma concentrations,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),[ng] / [ml],39.6,266183,DB00898,Ethanol
,3718591,times to peak concentration,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,1.2,266184,DB00898,Ethanol
,3718591,times to peak concentration,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,1.0,266185,DB00898,Ethanol
,3718591,plasma half-lives,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,2.2,266186,DB00898,Ethanol
,3718591,plasma half-lives,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,2.0,266187,DB00898,Ethanol
,8811915,detection limits,"The detection limits of DS and oversulfated DS were 10 and 20 ng, respectively.",Simultaneous determination of dermatan sulfate and oversulfated dermatan sulfate in plasma by high-performance liquid chromatography with postcolumn fluorescence derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8811915/),ng,10,266302,DB00898,Ethanol
,8811915,detection limits,"The detection limits of DS and oversulfated DS were 10 and 20 ng, respectively.",Simultaneous determination of dermatan sulfate and oversulfated dermatan sulfate in plasma by high-performance liquid chromatography with postcolumn fluorescence derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8811915/),ng,20,266303,DB00898,Ethanol
,9853003,Metabolic capacity (Vmaxc),Metabolic capacity (Vmaxc) for oxidation of trichloroethylene was estimated to be 4 mg/kg/h in males and 5 mg/kg/h in females.,"A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853003/),[mg] / [h·kg],4,266879,DB00898,Ethanol
,9853003,Metabolic capacity (Vmaxc),Metabolic capacity (Vmaxc) for oxidation of trichloroethylene was estimated to be 4 mg/kg/h in males and 5 mg/kg/h in females.,"A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853003/),[mg] / [h·kg],5,266880,DB00898,Ethanol
up to,18465300,encapsulation efficiencies,The formulated microspheres were free flowing with good packability and encapsulation efficiencies were up to 96%.,In vitro and in vivo evaluation of ranitidine hydrochloride ethyl cellulose floating microparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18465300/),%,96,266881,DB00898,Ethanol
,21334574,C(max),"C(max) was highest in fasting subjects (mean 30.5, range 22.5-42μg/100ml) and lowest after a meal (mean 21.4, range 13.5-32μg/100ml).",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: The effect of food on absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21334574/),[μg] / [100],30.5,267413,DB00898,Ethanol
,21334574,C(max),"C(max) was highest in fasting subjects (mean 30.5, range 22.5-42μg/100ml) and lowest after a meal (mean 21.4, range 13.5-32μg/100ml).",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: The effect of food on absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21334574/),[μg] / [100],21.4,267414,DB00898,Ethanol
,21334574,T(max),"T(max) was shortest after a meal and also remarkably consistent (mean 22, range 17-50min).",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: The effect of food on absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21334574/),min,22,267415,DB00898,Ethanol
,21334574,Elimination of alcohol from breath,"Elimination of alcohol from breath was slightly lower after a meal (mean 5.4, range 3.9-8.5μg/100ml/h) than after either fasting (mean 6, range 4.7-7.3μg/100ml/h) or a snack (mean 6, range 4.4-8.8μg/100ml/h).",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: The effect of food on absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21334574/),[μg] / [100ml·h],5.4,267416,DB00898,Ethanol
,21334574,Elimination of alcohol from breath,"Elimination of alcohol from breath was slightly lower after a meal (mean 5.4, range 3.9-8.5μg/100ml/h) than after either fasting (mean 6, range 4.7-7.3μg/100ml/h) or a snack (mean 6, range 4.4-8.8μg/100ml/h).",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: The effect of food on absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21334574/),[μg] / [100],6,267417,DB00898,Ethanol
,21334574,Elimination of alcohol from breath,"Elimination of alcohol from breath was slightly lower after a meal (mean 5.4, range 3.9-8.5μg/100ml/h) than after either fasting (mean 6, range 4.7-7.3μg/100ml/h) or a snack (mean 6, range 4.4-8.8μg/100ml/h).",Intra-individual and inter-individual variation in breath alcohol pharmacokinetics: The effect of food on absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21334574/),[μg] / [100],6,267418,DB00898,Ethanol
,17763831,T 50% clearance,"Scintigraphic imaging revealed that clearance of the formulation from the oral cavity was rapid, with a mean T 50% clearance of 0.86 +/- 0.46 min, and T 80% clearance of 2.75 +/- 1.52 min.",Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763831/),min,0.86,267429,DB00898,Ethanol
,17763831,T 80% clearance,"Scintigraphic imaging revealed that clearance of the formulation from the oral cavity was rapid, with a mean T 50% clearance of 0.86 +/- 0.46 min, and T 80% clearance of 2.75 +/- 1.52 min.",Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763831/),min,2.75,267430,DB00898,Ethanol
,17763831,T max,"In comparison, absorption of buprenorphine was relatively slow, with a T max of 0.56 +/- 0.13 h.",Evaluation of the clearance of a sublingual buprenorphine spray in the beagle dog using gamma scintigraphy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763831/),h,0.56,267431,DB00898,Ethanol
,17408229,peak plasma concentration C(max),The in vivo study of the SA patch exhibited a peak plasma concentration C(max) of 126 microg/mL at T(max) 4 hours.,Formulation development and in vitro and in vivo evaluation of membrane-moderated transdermal systems of ampicillin sodium in ethanol: pH 4.7 buffer solvent system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408229/),[μg] / [ml],126,267824,DB00898,Ethanol
,17408229,T(max),The in vivo study of the SA patch exhibited a peak plasma concentration C(max) of 126 microg/mL at T(max) 4 hours.,Formulation development and in vitro and in vivo evaluation of membrane-moderated transdermal systems of ampicillin sodium in ethanol: pH 4.7 buffer solvent system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408229/),h,4,267825,DB00898,Ethanol
,34296469,areas under the concentration-time curve (AUC0-∞ ),"The areas under the concentration-time curve (AUC0-∞ ) for artemether, dihydroartemisinin and lumefantrine (medians 1626, 1881 and 625 098 μg.h/L, respectively) were similar to those reported in previous pharmacokinetic studies in adults and children.",The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34296469/),[h·μg] / [l],1626,267863,DB00898,Ethanol
,34296469,areas under the concentration-time curve (AUC0-∞ ),"The areas under the concentration-time curve (AUC0-∞ ) for artemether, dihydroartemisinin and lumefantrine (medians 1626, 1881 and 625 098 μg.h/L, respectively) were similar to those reported in previous pharmacokinetic studies in adults and children.",The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34296469/),[h·μg] / [l],1881,267864,DB00898,Ethanol
,34296469,areas under the concentration-time curve (AUC0-∞ ),"The areas under the concentration-time curve (AUC0-∞ ) for artemether, dihydroartemisinin and lumefantrine (medians 1626, 1881 and 625 098 μg.h/L, respectively) were similar to those reported in previous pharmacokinetic studies in adults and children.",The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34296469/),[h·μg] / [l],625 098,267865,DB00898,Ethanol
,34296469,terminal elimination half-life,The lumefantrine terminal elimination half-life (median 9.5 days) was longer than reported in healthy volunteers and adults with falciparum malaria.,The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34296469/),d,9.5,267866,DB00898,Ethanol
,17987360,concentrations of schi,"The geometric mean cut-off concentrations of schizont maturation (GMCOC) were 943.2 nM for lumefantrine, 146.3 nM for DBB and 182.2 nM for the 999:1 combination of lumefantrine and DBB.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,943.2,268249,DB00898,Ethanol
,17987360,concentrations of schi,"The geometric mean cut-off concentrations of schizont maturation (GMCOC) were 943.2 nM for lumefantrine, 146.3 nM for DBB and 182.2 nM for the 999:1 combination of lumefantrine and DBB.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,146.3,268250,DB00898,Ethanol
,17987360,concentrations of schi,"The geometric mean cut-off concentrations of schizont maturation (GMCOC) were 943.2 nM for lumefantrine, 146.3 nM for DBB and 182.2 nM for the 999:1 combination of lumefantrine and DBB.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,182.2,268251,DB00898,Ethanol
,17987360,EC(50),"The EC(50) values were 27.3 nM for lumefantrine, 5.7 nM for DBB, and 16.5 nM for the combination, and the EC(90) values 163.1 nM for lumefantrine, 44.1 nM for DBB, and 78.3 nM for the combination.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,27.3,268252,DB00898,Ethanol
,17987360,EC(50),"The EC(50) values were 27.3 nM for lumefantrine, 5.7 nM for DBB, and 16.5 nM for the combination, and the EC(90) values 163.1 nM for lumefantrine, 44.1 nM for DBB, and 78.3 nM for the combination.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,5.7,268253,DB00898,Ethanol
,17987360,EC(50),"The EC(50) values were 27.3 nM for lumefantrine, 5.7 nM for DBB, and 16.5 nM for the combination, and the EC(90) values 163.1 nM for lumefantrine, 44.1 nM for DBB, and 78.3 nM for the combination.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,16.5,268254,DB00898,Ethanol
,17987360,EC(90),"The EC(50) values were 27.3 nM for lumefantrine, 5.7 nM for DBB, and 16.5 nM for the combination, and the EC(90) values 163.1 nM for lumefantrine, 44.1 nM for DBB, and 78.3 nM for the combination.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,163.1,268255,DB00898,Ethanol
,17987360,EC(90),"The EC(50) values were 27.3 nM for lumefantrine, 5.7 nM for DBB, and 16.5 nM for the combination, and the EC(90) values 163.1 nM for lumefantrine, 44.1 nM for DBB, and 78.3 nM for the combination.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,44.1,268256,DB00898,Ethanol
,17987360,EC(90),"The EC(50) values were 27.3 nM for lumefantrine, 5.7 nM for DBB, and 16.5 nM for the combination, and the EC(90) values 163.1 nM for lumefantrine, 44.1 nM for DBB, and 78.3 nM for the combination.",Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17987360/),nM,78.3,268257,DB00898,Ethanol
,25886392,Cmax,The Cmax of (S)-ORC decreased from 21.3 ± 5.0 μg/ml to 13.2 ± 4.2 when (R)-ORC was co-administrated at the dose of 200mg/kg.,Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25886392/),[μg] / [ml],21.3,269090,DB00898,Ethanol
,25886392,Cmax,The Cmax of (S)-ORC decreased from 21.3 ± 5.0 μg/ml to 13.2 ± 4.2 when (R)-ORC was co-administrated at the dose of 200mg/kg.,Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25886392/),,13.2,269091,DB00898,Ethanol
,25886392,AUC0-t,AUC0-t values of (S)-ORC were different after oral administration of 200 mg/kg (S)-ORC and 400 mg/kg racemic ORC (96.7 ± 15.5 and 50.1 ± 16.3 μg h/ml).,Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25886392/),[h·μg] / [ml],96.7,269092,DB00898,Ethanol
,25886392,AUC0-t,AUC0-t values of (S)-ORC were different after oral administration of 200 mg/kg (S)-ORC and 400 mg/kg racemic ORC (96.7 ± 15.5 and 50.1 ± 16.3 μg h/ml).,Comparative pharmacokinetic studies of racemic oxiracetam and its pure enantiomers after oral administration in rats by a stereoselective HPLC method. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25886392/),[h·μg] / [ml],50.1,269093,DB00898,Ethanol
,27257769,absolute bioavailability,The absolute bioavailability of voacangine was determined to be 11-13 %.,Pharmacokinetics of hERG Channel Blocking Voacangine in Wistar Rats Applying a Validated LC-ESI-MS/MS Method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27257769/),%,11-13,269127,DB00898,Ethanol
,10918102,half-life,"In 19 patients analyzed (EG concentrations of 3.5 to 211 mg/dL), elimination was first order during fomepizole monotherapy (half-life of 19.7+/-1.3 hours) and was not affected by the presence of ethanol.",Toxicokinetics of ethylene glycol during fomepizole therapy: implications for management. For the Methylpyrazole for Toxic Alcohols Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10918102/),h,19.7,269284,DB00898,Ethanol
<,10918102,half-life,"The elimination rate was significantly faster (half-life of <8.6+/-1.1 hours, P <.001) in the absence of fomepizole and ethanol.",Toxicokinetics of ethylene glycol during fomepizole therapy: implications for management. For the Methylpyrazole for Toxic Alcohols Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10918102/),h,8.6,269285,DB00898,Ethanol
,10918102,fractional excretion,"EG elimination by the kidneys was directly proportional to remaining renal function as estimated by creatinine clearance, with a fractional excretion of 25.5%+/-9.4%.",Toxicokinetics of ethylene glycol during fomepizole therapy: implications for management. For the Methylpyrazole for Toxic Alcohols Study Group. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10918102/),%,25.5,269286,DB00898,Ethanol
,10918102,half-life,All patients with normal serum creatinine concentrations at the initiation of fomepizole treatment had rapid rates of renal elimination (half-life of 16.8+/-0.8 hours).,Toxicokinetics of ethylene glycol during fomepizole therapy: implications for management. For the Methylpyrazole for Toxic Alcohols Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10918102/),h,16.8,269287,DB00898,Ethanol
,9647353,maximum value,"The transdermal in vitro E2 flux rate out of a complete MCRS, claimed to deliver 25 microg/day, increased steadily, reaching a maximum value of 2.06 +/- 0.58 microg/h at 30 to 40 hours and decreased to a rate of about 0.5 microg/h from 60 to 90 hours.",Pharmacokinetics of the transdermal reservoir membrane system delivering beta-estradiol: in vitro/in vivo-correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9647353/),[μg] / [h],2.06,269387,DB00898,Ethanol
,2755281,flux,"The flux from water or alcoholic solution was 4.4 or 10 micrograms/cm2/h, and the tleg was 7.8 or 3.7 h, respectively.",Percutaneous absorption of rosmarinic acid in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),[μg] / [cm2·h],4.4,270400,DB00898,Ethanol
,2755281,flux,"The flux from water or alcoholic solution was 4.4 or 10 micrograms/cm2/h, and the tleg was 7.8 or 3.7 h, respectively.",Percutaneous absorption of rosmarinic acid in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),[μg] / [cm2·h],10,270401,DB00898,Ethanol
,2755281,tleg,"The flux from water or alcoholic solution was 4.4 or 10 micrograms/cm2/h, and the tleg was 7.8 or 3.7 h, respectively.",Percutaneous absorption of rosmarinic acid in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),h,7.8,270402,DB00898,Ethanol
,2755281,tleg,"The flux from water or alcoholic solution was 4.4 or 10 micrograms/cm2/h, and the tleg was 7.8 or 3.7 h, respectively.",Percutaneous absorption of rosmarinic acid in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),h,3.7,270403,DB00898,Ethanol
,2755281,t1/2,"After I.V. administration, RA is best described by a 2-compartment open model; t1/2 = 1.8 h, t1/2 alpha = 0.07 h, V tau = 2.3 L/kg, V beta = 15.3 L/kg.",Percutaneous absorption of rosmarinic acid in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),h,1.8,270404,DB00898,Ethanol
,2755281,t1/2 alpha,"After I.V. administration, RA is best described by a 2-compartment open model; t1/2 = 1.8 h, t1/2 alpha = 0.07 h, V tau = 2.3 L/kg, V beta = 15.3 L/kg.",Percutaneous absorption of rosmarinic acid in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),h,0.07,270405,DB00898,Ethanol
,2755281,V tau,"After I.V. administration, RA is best described by a 2-compartment open model; t1/2 = 1.8 h, t1/2 alpha = 0.07 h, V tau = 2.3 L/kg, V beta = 15.3 L/kg.",Percutaneous absorption of rosmarinic acid in the rat. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),[l] / [kg],2.3,270406,DB00898,Ethanol
,2755281,V beta,"After I.V. administration, RA is best described by a 2-compartment open model; t1/2 = 1.8 h, t1/2 alpha = 0.07 h, V tau = 2.3 L/kg, V beta = 15.3 L/kg.",Percutaneous absorption of rosmarinic acid in the rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),[l] / [kg],15.3,270407,DB00898,Ethanol
,2755281,absolute bioavailability,"Upon topical administration of RA in form of a W/O ointment (25 mg/kg, 50 cm2), the absolute bioavailability was 60%.",Percutaneous absorption of rosmarinic acid in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),%,60,270408,DB00898,Ethanol
,2755281,peak time,"4.5 hours (peak time) after topical administration of about 3 mg on the hind leg over 20 cm2, RA was measured in blood, skin, muscle and bone tissue.",Percutaneous absorption of rosmarinic acid in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2755281/),h,4.5,270409,DB00898,Ethanol
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,49-57,271663,DB00898,Ethanol
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,35,271664,DB00898,Ethanol
,1545348,Apparent systemic clearance (CL),"Apparent systemic clearance (CL) of methylprednisolone was 21 mL/min (low dose), approximately twice the liver blood flow.",Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),[ml] / [min],21,271665,DB00898,Ethanol
,22687893,maximum concentration (C(max)),"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],29,271667,DB00898,Ethanol
,22687893,maximum concentration (C(max)),"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],12,271668,DB00898,Ethanol
,22687893,plasma AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],119,271669,DB00898,Ethanol
,22687893,plasma AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],25,271670,DB00898,Ethanol
,22687893,C(max),"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],120,271671,DB00898,Ethanol
,22687893,C(max),"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],26,271672,DB00898,Ethanol
,22687893,AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],26,271673,DB00898,Ethanol
,22687893,AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],341,271674,DB00898,Ethanol
,22687893,AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],84,271675,DB00898,Ethanol
,22687893,C(max),"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],8737,271676,DB00898,Ethanol
,22687893,AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],6331,271677,DB00898,Ethanol
,22687893,AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],280 370,271678,DB00898,Ethanol
,22687893,AUC,"Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],124 381,271679,DB00898,Ethanol
,22687893,C(max),"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],28,271680,DB00898,Ethanol
,22687893,C(max),"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],11,271681,DB00898,Ethanol
,22687893,AUC,"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],123,271682,DB00898,Ethanol
,22687893,AUC,"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],34,271683,DB00898,Ethanol
,22687893,C(max),"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],107,271684,DB00898,Ethanol
,22687893,AUC,"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],59,271685,DB00898,Ethanol
,22687893,AUC,"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],364,271686,DB00898,Ethanol
,22687893,AUC,"Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01).",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],228,271687,DB00898,Ethanol
,22687893,C(max),"Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure.",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],8620,271688,DB00898,Ethanol
,22687893,C(max),"Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure.",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[ng] / [ml],4958,271689,DB00898,Ethanol
,22687893,AUC,"Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure.",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],66 329,271690,DB00898,Ethanol
,22687893,AUC,"Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure.",Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22687893/),[h·ng] / [ml],35 728,271691,DB00898,Ethanol
,6846783,elimination half-life,"In control rats treated with olive oil and water the elimination half-life for halothane amounted to 0,78 (0,69-0.88) h (confidence limits for p = 0.95).",[Metabolism of halothane in rats with CCl4-alcohol-induced liver fibrosis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846783/),h,"0,78",271730,DB00898,Ethanol
,6846783,elimination half-life,In rats with CCl4-ethanol-induced liver fibrosis and steatosis this elimination half-life was prolonged to 1.24 (1.07-1.41) h indicating an impaired metabolic degradation of halothane in these rats.,[Metabolism of halothane in rats with CCl4-alcohol-induced liver fibrosis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846783/),h,1.24,271731,DB00898,Ethanol
,21116612,steady blood alcohol concentrations (BAC),"In this study, 19 heavy cannabis users participated and received three alcohol dosing conditions that were calculated to achieve steady blood alcohol concentrations (BAC) of about 0, 0.5 and 0.7 g/l during a 5-h time window.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[g] / [l],0,272127,DB00898,Ethanol
,21116612,steady blood alcohol concentrations (BAC),"In this study, 19 heavy cannabis users participated and received three alcohol dosing conditions that were calculated to achieve steady blood alcohol concentrations (BAC) of about 0, 0.5 and 0.7 g/l during a 5-h time window.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[g] / [l],0.5,272128,DB00898,Ethanol
,21116612,steady blood alcohol concentrations (BAC),"In this study, 19 heavy cannabis users participated and received three alcohol dosing conditions that were calculated to achieve steady blood alcohol concentrations (BAC) of about 0, 0.5 and 0.7 g/l during a 5-h time window.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[g] / [l],0.7,272129,DB00898,Ethanol
,21116612,steady-state BACs,"Mean steady-state BACs reached 0, 0.36 and 0.5 g/l.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[g] / [l],0,272130,DB00898,Ethanol
,21116612,steady-state BACs,"Mean steady-state BACs reached 0, 0.36 and 0.5 g/l.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[g] / [l],0.36,272131,DB00898,Ethanol
,21116612,steady-state BACs,"Mean steady-state BACs reached 0, 0.36 and 0.5 g/l.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[g] / [l],0.5,272132,DB00898,Ethanol
,21116612,apparent elimination half-life,"The apparent elimination half-life of THC was slightly prolonged (1.59 vs. 1.93 h, p < 0.05) and the concentration 1 h after smoking was slightly lower (24 vs. 17 ng/ml, p < 0.05) with the higher ethanol dose.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),h,1.59,272133,DB00898,Ethanol
,21116612,apparent elimination half-life,"The apparent elimination half-life of THC was slightly prolonged (1.59 vs. 1.93 h, p < 0.05) and the concentration 1 h after smoking was slightly lower (24 vs. 17 ng/ml, p < 0.05) with the higher ethanol dose.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),h,1.93,272134,DB00898,Ethanol
,21116612,apparent elimination half-life,"The apparent elimination half-life of THC was slightly prolonged (1.59 vs. 1.93 h, p < 0.05) and the concentration 1 h after smoking was slightly lower (24 vs. 17 ng/ml, p < 0.05) with the higher ethanol dose.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[ng] / [ml],24,272135,DB00898,Ethanol
,21116612,apparent elimination half-life,"The apparent elimination half-life of THC was slightly prolonged (1.59 vs. 1.93 h, p < 0.05) and the concentration 1 h after smoking was slightly lower (24 vs. 17 ng/ml, p < 0.05) with the higher ethanol dose.",Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21116612/),[ng] / [ml],17,272136,DB00898,Ethanol
,3391105,MIC,"Clofoctol was extracted from samples using ethanol and the concentration of drug in the extracts was determined by the broth macrodilution method using as reference microorganisms S. aureus ATCC 29213 and B. cereus NCIB 8122, whose MIC values were 0.537 and 1.074 micrograms/ml respectively.",A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391105/),[μg] / [ml],0.537,272290,DB00898,Ethanol
,3391105,MIC,"Clofoctol was extracted from samples using ethanol and the concentration of drug in the extracts was determined by the broth macrodilution method using as reference microorganisms S. aureus ATCC 29213 and B. cereus NCIB 8122, whose MIC values were 0.537 and 1.074 micrograms/ml respectively.",A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391105/),[μg] / [ml],1.074,272291,DB00898,Ethanol
,3391105,AUC,"Results indicate that clofoctol is well absorbed after a single rectal dose of 1.5 g, with a plasma Cmax at the 30th min after administration and an average AUC value of 80.91 micrograms/ml/h.",A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391105/),[μg] / [h·ml],80.91,272292,DB00898,Ethanol
,3391105,AUC,"The Cmax of lung tissue (which was higher than the plasmatic one) occurred at the 90th min and the average AUC value was 229.65 micrograms/ml/h, indicating good penetration of clofoctol into human lung tissue and appreciable tissue storage of the drug.",A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391105/),[μg] / [h·ml],229.65,272293,DB00898,Ethanol
,24641773,percentage transmittance,Nanoemulsion was found to be clear and transparent in appearance with a percentage transmittance of 98.2.,Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24641773/),,98.2,272314,DB00898,Ethanol
,24641773,Refractive index,Refractive index of 1.32 of the nanoemulsion indicated the isotropic nature of the drug.,Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24641773/),,1.32,272315,DB00898,Ethanol
˜,24641773,oral bioavailability,In vivo oral bioavailability of the nanoemulsion formulation was found to be 2.6-fold higher than the plain drug (˜ 40%) as observed from pharmacokinetic studies.,Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of artemether. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24641773/),%,40,272316,DB00898,Ethanol
less,29641159,oral bioavailability,"Rebamipide (RBP) is a potent anti-ulcer and anti-oxidative agent, which is a BCS class IV drug with a low oral bioavailability of less than 10%.",Capmul MCM/Solutol HS15-Based Microemulsion for Enhanced Oral Bioavailability of Rebamipide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29641159/),%,10,272584,DB00898,Ethanol
,8568633,absolute bioavailability,The absolute bioavailability of propentofylline from gel preparations was almost 100%.,[Studies on development of pharmaceutical preparation with the purpose of improving controlled-release and bioavailability]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8568633/),%,100,273388,DB00898,Ethanol
,18253718,clearance,"The clearance of unchanged 1,2-DEB in the whole blood and in the blood cells was 6.4 and 3.9 ml min(-1), respectively.","Bio-distribution study of 1,2-diethylbenzene and its main metabolites by whole-body autoradiography and tissue homogenates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18253718/),[ml] / [min],6.4,273623,DB00898,Ethanol
,18253718,clearance,"The clearance of unchanged 1,2-DEB in the whole blood and in the blood cells was 6.4 and 3.9 ml min(-1), respectively.","Bio-distribution study of 1,2-diethylbenzene and its main metabolites by whole-body autoradiography and tissue homogenates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18253718/),[ml] / [min],3.9,273624,DB00898,Ethanol
,18253718,apparent half-life,"The apparent half-life of unchanged 1,2-DEB in plasma is very fast (5 min) which suggests a quick distribution and/or metabolism in liver and/or other tissues such as the lung.","Bio-distribution study of 1,2-diethylbenzene and its main metabolites by whole-body autoradiography and tissue homogenates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18253718/),min,5,273625,DB00898,Ethanol
,27455771,entrapment efficiency,"Novel long-circulating liposome was successfully prepared by ethanol injection method attaining a entrapment efficiency of 89.4%, exhibiting a homogeneous particle size of 245.2 nm and -24.3 mV zeta potential with smooth continuous surface.",Novel Long-Circulating Liposomes Consisting of PEG Modified β-Sitosterol for Gambogic Acid Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27455771/),%,89.4,273801,DB00898,Ethanol
,9063813,V(max),the V(max) value (0.41 +/- 0.05 mg/ml/hr) in the pyrazole-pretreated group was significantly lower than that (0.70 +/- 0.03 mg/ml/hr) in the control.,Role of alcohol dehydrogenase in rat ethanol elimination kinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9063813/),[mg] / [h·ml],0.41,273840,DB00898,Ethanol
,9063813,V(max),the V(max) value (0.41 +/- 0.05 mg/ml/hr) in the pyrazole-pretreated group was significantly lower than that (0.70 +/- 0.03 mg/ml/hr) in the control.,Role of alcohol dehydrogenase in rat ethanol elimination kinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9063813/),[mg] / [h·ml],0.70,273841,DB00898,Ethanol
,9063813,K(m),"The K(m) value (1.44 +/- 0.12 mg/ml) in the pyrazole-pretreated group was significantly higher than the control (0.07 +/- 0.01 mg/ml), similar to the in vitro value in hepatic alcohol dehydrogenase (ADH).",Role of alcohol dehydrogenase in rat ethanol elimination kinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9063813/),[mg] / [ml],1.44,273842,DB00898,Ethanol
,9063813,K(m),"The K(m) value (1.44 +/- 0.12 mg/ml) in the pyrazole-pretreated group was significantly higher than the control (0.07 +/- 0.01 mg/ml), similar to the in vitro value in hepatic alcohol dehydrogenase (ADH).",Role of alcohol dehydrogenase in rat ethanol elimination kinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9063813/),[mg] / [ml],0.07,273843,DB00898,Ethanol
,9063813,first-order elimination rate,"The first-order elimination rate from the two-compartment model with parallel first-order and Michaelis-Menten kinetics was a very low value of 10(-5)min(-1) ,which shows that a pathway with a higher K(m) than blood ethanol concentration does not contribute to in vivo ethanol elimination.",Role of alcohol dehydrogenase in rat ethanol elimination kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9063813/),1/[min],10(-5),273844,DB00898,Ethanol
,9063813,K(m),The K(m) value (0.02 mg/ml) from fitting the double Michaelis-Menten model is similar to that in vitro in ADH3.,Role of alcohol dehydrogenase in rat ethanol elimination kinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9063813/),[mg] / [ml],0.02,273845,DB00898,Ethanol
